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DIRECTOR'S
REPORT
We have now, as a great nation, set as a national objective the working out of the
human DNA sequence. Similar to the 1961 decision made by President Kennedy
to send a man to the moon, the United States has committed itself to a highly
visible and important goal. Although the final monies required to complete the
human DNA sequence of some 3 billion base pairs will be an order of magnitude
smaller than that needed to let Americans explore the moon, the implications of
the Human Genome Project for human life are likely to be far greater. A more
important set of instruction books will never be found by human beings. When
finally interpreted, the genetic messages encoded within our DNA molecules will
provide the ultimate answers to the chemical underpinnings of human existence.
They will not only explain how we function as healthy human beings, but also let
us understand at the chemical level the multitude of genetic diseases, such as
cancer Alzheimer's, and schizophrenia, that demean the individual lives of so
many millions of our citizens.
The possibility of knowing our complete set of genetic instructions seemed an
undreamable scientific objective in 1953 when Francis Crick and I found the
double helical structure of DNA. Then, there existed no way to sequence even
very short DNA molecules, nor did there exist any possibility of obtaining the
totality of human DNA as a collection of discrete pieces for eventual chemical
analysis. Only years later, with the 1973 birth of the recombinant DNA revolution,
was it possible to think of isolating individual genes. This breakthrough provided
the incentive for Walter Gilbert and Fred Sanger to develop their powerful
sequencing techniques that now make it almost routine to establish in a single
experiment the sequences of some 300-500 base pairs (bp) within a given DNA
molecule.
The first complete DNA sequences to be established by these procedures were
those of the smaller DNA viruses-the monkey virus SV40 and the phage +X174,
each of which contains some 5000 bp. These sequences became known by 1977,
and within the next five years the tenfold larger DNAs of the bacteriophages T7
and A were worked out. Today, the more than 100,000-bp DNAs of several plant
chloroplasts and of the herpesvirus EBV have been established. The largest DNA
now sequenced is that of cytomegalovirus (a herpesvirus), which contains almost a
quarter of a million base pairs and has just been completed by Bart Barrel's group
at the Laboratory of Molecular Biology in Cambridge.
Simultaneously, the sequences of a large number of individual genes have been
worked out, with the total number of base pairs approaching 25 million. The most
completely known organism to date is the intensively studied bacterium
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Escherichia coli, with over 800,000 by of its 4.8 x 106-bp genome already
established. There now exist in the United States and Japan a number of labs
geared up to complete the E. coli sequence in university-like environments, and
there are good reasons for believing that success will come within the next
decade. Today, DNA sequencing usually costs between three and five dollars per
base pair, and so at most, 25 million dollars would be required; a large, but not
unthinkable sum when spent over an extended interval. Most likely, as sequencing
efficiencies improve, the E. coli sequence will finally cost a sum less than half this
amount. Conceivably, we could know the complete sequences of one to several
bacteria without the creation of a major research program specially aimed at
working out complete genomes.
A completely different picture holds for the human genome, which is almost
1000 times larger and is distributed over 24 different chromosomes. Here, the
cottage industry approach involving small groups of individuals, each working at a
large number of different sites, seems very unlikely to succeed. The time involved
would more than exceed the lifetimes of those who would like to work this way. To
be truly exciting for both our best scientific minds and the average citizen, we
must aim to complete the job over a 15-year time interval. Those who start the
project should plan for themselves, not their scientific descendants, to complete it.
From the beginning, we have to design game plans where economies of scale are
sought and found. We shall, moreover, have to bring into existence sequencing
facilities far larger than any that exist today and that of necessity more resemble
industrial production lines than conventional university research laboratories.
The first serious proposal to start sequencing the human genome occurred at a
meeting held in early 1985. Robert Sinsheimer, then Chancellor of the University of
California at Santa Cruz, brought together a small group of scientists with the
hope that the project might be centered in the Santa Cruz environment. Renato
Dulbecco came away excited from that gathering, and when he flew to Cold
Spring Harbor later that year to speak at the dedication of our Joseph Sambrook
Laboratory, he spoke glowingly of the prospects for cancer research if we knew
the sequence of our own DNA. By this time, the Department of Energy was
seriously thinking about taking on the challenge. Toward this end, Charles DeLisi,
then head of the DOE's Division of Health and Environmental Research, brought
together in Santa Fe in February 1986 some 80 scientists with expertise in DNA
research and human genetics. Sensing the need for large dedicated labs, he and
his colleagues at the DOE proposed that their National Laboratories, particularly
those at Livermore and Los Alamos, should be the center of the American, if not
the worldwide, human genome effort.
Over the next several months, rumors that the DOE would soon commence a
large-scale human genome program began to spread through the general biologi-
cal community. The pros and cons for such a DOE-led project were first discussed
before a more general audience here at Cold Spring Harbor in 1986. During the
course of that June's Symposium on the "Molecular Biology of Homo sapiens': as
special afternoon session took up the question. Although several of the more-
senior scientists, like myself, Walter Gilbert, and Paul Berg, voiced the opinion that
now was the time to start the project, much less enthusiasm, if not downright
hostility, was voiced by many younger scientists. They feared that a megabillion
dollar project would of necessity divert money away from single-investigator-ini-
tiated research grants and slow down the pace at which our country does high-
quality biological and medical research. Also troubling to many was the thought
that the DOE had never been a major supporter of recombinant-DNA-based
research and possessed no strong set of administrators familiar with the world of
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genetics. The intellectual competence for managing the Human Genome Project
might never exist within a DOE whose leaders were invariably physical scientists
and where biology of necessity always occupied a low position on its totem pole
of priorities. Conceivably, strong managers could be brought in from the outside,
but lacking such assurances, the safe course then seemed to me for NIH itself to
take on the Human Genome Project, provided that new monies would be
appropriated by Congress to fund it.
Soon the controversy reached the attention of the Board of Basic Biology and
the Commission on Life Sciences of the National Academy of Sciences. After a
joint meeting in Woods Hole in August 1986, a decision was made to appoint a
special (National Research Council) committee to prepare a report as to what our
nation should do next. Chaired by Bruce Alberts, known for his distrust of big labs
for biology, the 15-member committee represented a diverse collection of
viewpoints, including that of past strong vocal opposition to the project. Its six-
month-long deliberations led to a unanimous report, "Mapping and Sequencing
the Human Genome," which urged that the United States should commence the
Human Genome Project, working cooperatively with those other nations who
wished jointly to pursue the common goal.
Soon after the NRC Committee began its deliberation, it became apparent that
within the meeting room the project itself was not really controversial-who could
be against obtaining the much higher molecular genetic and physical maps of
human DNA that would need to be on hand before the sequencing itself could
begin. Such maps would be invaluable allies in the finding of key human disease
genes. These mapping efforts would dominate the first five years of the project;
only then would the production-line sequencing efforts commence. What had
generated much of the initial opposition was fear that the project would be
divorced from the main currents of biological research, focusing exclusive concern
on human DNA sequences, most of which might prove uninterpretable unless
equal attention was paid to the genomes of much simpler model organisms such
as E. coli, the yeasts, the roundworm Caenorhabditis elegans, and the fruit fly
Drosophila, as well as to the much more closely related mouse. There was also
strong reservation about any project where the ultimate control of resources lay in
the hands of administrators, like those who rule the DOE, as opposed to control
by the scientific community itself. DOE's known propensity for overruling peer
review panels had created much unease at the thought that they might direct the
project.
In urging that the Human Genome Program start, the committee emphasized
the need for technological improvements that lead to five- to tenfold improvements
in the efficiency of current gene mapping, sequencing, and data analysis capabili-
ties. Only when the true cost of sequencing falls to no more than 50 cents a base
pair should extensive sequencing begin. With this proviso, the total costs of the
project should not exceed 3 billion inflation-adjusted dollars. Federal funding was
urged to rise quickly to 200 million dollars a year, with the project planned to be
completed in approximately 15 years. The sequencing of the model genomes was
urged to go hand in hand with, if not slightly ahead of, that of the human
genome. Knowledge of the simpler structures of the genes of bacteria and
budding yeasts should facilitate the task of distinguishing the amino acid coding
regions (exons) of the human genome from the much more prevalent noncoding
(intron) components.
In addressing the question of whose genome would be sequenced, the
committee pointed out that no two individuals (except for identical twins) contain
exactly the same DNA sequences because of mutations, particularly in noncoding
3
regions, that have occurred during the course of evolutionary time. The Human
Genome Program would be producing a prototype blueprint laying out the basic
organization and sequence of the genes of our 24 chromosomes. Most likely, it
will be a composite of regional sequences from the chromosomes of many
different individuals already being mapped in major laboratories. Later, the nature
and extent of the variation from one person to another can be ascertained when
large numbers of sequences from specific regions are compared.
To ensure that the project be scientist-directed, the formation of a strong human
genome advisory committee, chaired by a leading scientist, was deemed
indispensable. It should both participate in the planning process and provide
oversight on ongoing programs. A majority of the committee, furthermore, felt that
the Human Genome Program should be assigned to a single federal agency, but
it did not rule out dual management by both the DOE and NIH as long as there
existed a unified scientific advisory committee.
Parallel with the deliberations of the NRC panel, the Office of Technology
Assessment (OTA) of the U.S. Congress was commissioned by the House
Committee on Energy and Commerce to prepare a report that later was to be
entitled "Mapping Our Genes-The Genome Project: How Big, How Fast?" The
Congressional interests on which they focused centered on (1) assessing the
scientific and medical reasons for genome projects, (2) the potential funding-at
what level and through what mechanisms, (3) how to coordinate activities if several
federal agencies are involved, and (4) how to strike a proper balance between the
virtues of international scientific collaboration and the need to promote the United
States competitive position in biotechnology. Unlike the NRC report, the OTA
document did not offer specific recommendations, viewing as its purpose the
informing of Congress on the options for future action. Despite this aim for neutral-
ity, reading of the OTA report left the unmistakable message that some form of
human genome program was bound to proceed and that Congress had a real
role in seeing that it started off in the right direction.
In fact, in their 1988 Federal budget request the DOE had asked for 15 million
dollars, and later received 10 million dollars, to start their human genome effort.
There was no formal request from NIH for genome studies, but during the spring
1987 Congressional appropriation hearings, its director Jim Wyngaarden was
asked how much they would need to have a meaningful program. His reply was
50 million dollars. Later, in mid-May, David Baltimore and I visited key mentors of
the House and Senate Appropriation Committees on behalf of the Delegation for
Basic Medical Research, of which I was the official spokesman. We emphasized
the need for a multihundred-million-dollar increase in AIDS research monies as
well as indicated that a 30-million-dollar appropriation would let NIH start a serious
human genome effort. In the summer, when the respective appropriation
subcommittees marked up and then reconciled their NIH budgets, 18 million
dollars for genome studies was added to the NIGMS (National Institutes for
General Medical Studies) budget. By then, Ruth Kirschstein, the Director of
NIGMS, had sent out RFAs (requests for grant applications) on genome studies,
with the funds for the program hopefully to come from new monies added to the
NIGMS budget.
The HHS (Health and Human Services) appropriation, with its NIH component,
only became signed into law by President Reagan in early December, two months
along into the 1988 fiscal year. The 17.4 million dollars finally allocated for genome
studies allowed Jim Wyngaarden to convene quickly an 18-member Ad Hoc
Advisory Committee on Complex Genomes to propose priorities for the NIH
Genome Program. Meeting in Reston, Virginia, in late February, it was ably
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chaired by David Baltimore and broadly backed the main features of the prior
NRC report. In its final recommendations it strongly supported Jim Wyngaarden's
proposal to establish an Office of Human Genome Research to be headed by a
new Associate Director of NIH. A key feature of the Office was to be a permanent
expert Advisory Committee to work with the head of the genome effort to keep
the various genome efforts on target. Emphasis was also given to the need during
the early phases of the program for major training efforts that would prepare
prospective scientists with the new technologies needed to generate and then
assemble the massive amounts of new information that would flow out of the
genome programs.
At the Reston meeting, I strongly urged that the Associate Director position be
filled by an active scientist, as opposed to an administrator, arguing that one
person had to be visibly seen in charge and that only a prominent scientist was
likely to reassure simultaneously Congress, the general public, and the scientific
community that scientific reasoning, not the pork barrel, would be the dominant
theme in allocating the soon to be large genome monies. Then I did not realize
that I could be perceived as arguing for my own subsequent appointment. For
many years, my most visible role had been that of an administrator dominated by
the fund-raising activities needed to keep Cold Spring Harbor Laboratory at the
forefront of DNA-based science. Whether I was still a real scientist was not at all
clear.
So, I felt uneasy when I heard rumors that I was to be offered the position of
Associate Director of NIH. My job here as the Director was already more than full-
time, and if I ran the genome effort, I would hold simultaneously two demanding
positions. Yet, if I turned down the job, it was not clear that any prominent scientist
still active in the lab would take on the task. Lacking a real boss, the NIH program
might have the same severe drawbacks that had worried us about how the DOE
would run their genome studies. So, when in early May Jim Wyngaarden asked
me to come down to Building 1 to talk about working for NIH, I knew I would
accept. By then I had also realized that I would only once have the opportunity to
let my scientific life encompass a path from double helix to the three billion steps
of the human genome.
I soon also had the reassurance of very capable assistance in the running of
the Bethesda office. Because I would not be a full-time employee, the head of the
Office of the Human Genome was to be Elke Jordan, then on Ruth Kirschstein's
staff at NIGMS, in charge of its Genetics Program, as Deputy Director and later
Associate Director for Program Activities. I had first met Elke in the mid-1960's
when she worked on phage A in Matt Meselson's lab at Harvard. Assisting her was
to be Mark Guyer, also an experienced NIGMS administrator and a product of
Norman Davidson's lab at Caltech before spending several years in the biotechnol-
ogy industry. So, I would have no reason to feel apprehensive that I would have
no real role in the day-to-day operations of the Human Genome Program. My
major task clearly was to help formulate a workable strategy for establishing the
human genome sequence.
Officially, I started working for our government in early October, having secured
permission from my Trustees here at Cold Spring Harbor to begin a commuting
life where I would try to spend the beginning of each week at NIH. Already by
then, Jim Wyngaarden had sent suggestions to the HHS Secretary as to possible
members of the Program Advisory Committee on the Human Genome. The 12
members finally chosen were much to our liking and had Norton Zinder as their
Chairman. Its composition reflected a broad range of expertise, with strong
representation from the world of pure science that had initially reacted so
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negatively when the Human Genome Program was first discussed. Their presence
on the Advisory Board was a strong message to the world of biology that NIH
would not bring forth a narrowly construed effort catering exclusively to the
immediate needs of the human genetics community. And by having three
members from industry, we sought to reassure Congress that our nation's competi-
tive position in biotechnology would not be neglected.
Beginning with my opening press conference at NIH, and later through other
meetings with the press, I made clear my concern with the ethical implications of
an ever-increasing knowledge of human genes and of the respective genetic
diseases that result from imperfections in our genetic messages. This knowledge
undoubtably will lead to much deeper understanding of many of the worst
diseases that plague human existence. Thus, there are strong ethical reasons to
pursue this genetic knowledge as fast as possible and with all our might. On the
other hand, the knowledge that some of us as individuals have inherited disease-
causing genes is certain to bring unwanted grief unless appropriate therapies
have been developed. So, it is imperative that we begin to educate our nation's
people on the genetic options that they as individuals may have to choose
between.
I believe we should put real money behind these convictions and suggested
that at the start at least 3% of our genome-targeted funds should go to grants in
the ethics area. In doing so, we must be aware of the bad misuses of the then
very incomplete knowledge of human genetics that went under the name of
eugenics during the first part of this century. There exists real fear among many
individuals that genetic reasons will again be used to make the lives of our
underprivileged even more disadvantaged. So, we must work to ensure that the
right laws come into existence at both the federal and state levels to prevent
spying into the privacy of an individual's DNA by either prospective employers or
insurers, or government agencies. If we fail now to act, we are bound to witness
unwanted and unnecessary abuses that eventually will create a strong popular
backlash against the human genetics community. We only have to look at how the
Nazis used the German professors of human genetics to justify their genocide
programs, first against the mentally ill and then against the Jews and the Gypsies.
We need no more vivid reminders that science in the wrong hands can do
incalculable harm.
At its inception, the Office of the Human Genome had essentially only an
advisory function with the legal authority for the initial distribution of NIH genome
funds belonging to NIGMS. All the 1988 monies in fact were distributed by peer-
reviewed NIGMS grants before I went to Bethesda, and the 1989 appropriation of
27.6 million dollars will likewise be distributed by NIGMS. For both the 1988 and
1989 monies, special ad hoc genome study sections were convened, with several
specifically responding to requests for grants aimed at technology innovation.
Although the rumor is going around the biological world that our monies allow all
approved applications to be funded, this is not true. Only approximately 30% of
the grants so far approved will in fact be funded, a figure not that different from
that which used to hold for more regular study sections. Our funding level is,
however, above the disastrous 15-18% level now predicted for much of NIGMS.
So, we are bound to feel more than the occasional ill will from those less fortunate.
We must strive to see that the quality of funded genome research remains high
and that the larger sum of money to be available in fiscal 1990 is spent wisely.
It was clear from the first study section that I sat in as an observer that totally
distributing our funds through conventional research grants would work only
during our first several years of operation. Now we need to encourage many
6
different approaches to genome mapping, sequencing, and information storage
and retrieval. Over the next few years, as we begin to make real choices as to how
to proceed, we will need the legal authority to distribute our monies in much more
targeted ways, creating the peer review mechanisms for funding large groups to
completely map and then sequence chromosome-sized sections of DNA. Jim
Wyngaarden had told me when I first came to work with him that he wanted to
change our Office into a "Center," which would have the authority to make grants,
as soon as we had sufficient funds to start a targeted program. The inclusion in
President Reagan's 1990 budget of 100 million dollars for genome studies gave
him the go-ahead signal to request the HHS Secretary to authorize our upgrading
into a "Center" This request has just been approved by Secretary Louis Sullivan,
and in October we will become a "Center." Now we are busily recruiting
the new individuals that will let us have by early next year a staff of some
20 persons.
There still is uncertainty over how the plans we develop through our Program
Advisory Committee will be coordinated with the DOE program. Last summer, a
congressional bill was proposed authorizing a multi-agency coordinating
committee that would add to the number of meetings I would need to attend, but
which did not address the question whether NIH or DOE would play the role of
leader. To circumvent what we feared would be an unneeded further level of
bureaucracy, NIH and DOE signed in the fall of 1988 a memorandum of
understanding which created a unified NIH-DOE Genome Committee, with its
members drawn from a subset of our respective advisory bodies. I see as the
most important immediate task of the joint committee the drawing up of a joint
National Genome Plan to be submitted to Congress at the time it considers our
fiscal 1991 appropriation. We have already scheduled our first planning meeting to
be held here in Cold Spring Harbor the last days in August, with a smaller, follow-
up meeting planned for early October in San Diego. I most look forward to these
meetings where for the first time, the question before us is no longer whether to
start a targeted genome program, but how to best mount one.
By now I am convinced that labs must be created over the next five years large
enough to oversee over the subsequent decade the detailed physical mapping
and sequencing of individual chromosomes. Groups of about ten individuals are
probably the appropriate size for a cost-effective analysis of the typical bacterial
and yeast chromosomes, which tend to range in size from one to several
megabases (106). For the human chromosomes, which average in size over 100
megabase pairs, it may be necessary to put together groups of some 50 trained
personnel. Their collective output of finished sequences would need to be approxi-
mately a phage X equivalent of DNA (40 kilobases) per working day. The informa-
tional aspects of the genome program will, with time, become more important as
an ever-increasing set of new DNA sequences begin to be compared with the
sequences previously obtained. So, although the key talents needed to start a
successful genome program are likely to be those of the recombinant DNA
chemist, our effectiveness at the end of the program may depend more on the
computer skills that are applied.
The idea that the various human chromosomes will become divided up between
different labs is far from today's conventional wisdom. Seeming to argue against
this approach is the fact that most chromosomes are already being both
genetically and physically mapped in a large number of high-quality labs.
Deciding which one of these groups should be given the funds to complete the
maps of their respective chromosomes at first sight appears an impossible political
task. But closer inspection reveals that these gene mappers are primarily
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interested in locating their own specific disease genes. Once their gene is
mapped, they will want to go on to its subsequent cloning and are very likely to
discontinue mapping per se. To my knowledge, the number of individuals wanting
to make complete high-resolution physical maps of their respective chromosome is
less than the fingers on two hands. Badly duplicative efforts only exist for 21, the
smallest human chromosome, which has the added incentive of containing a gene
that leads to increased susceptibility to Alzheimer's disease. Here, we may witness
a truly competitive race to clone the overlapping sets of DNA fragments that are
needed to commence sequencing. Up till now, the only chromosomes where
serious efforts have been started to make complete sets of overlapping DNA
fragments are 21, 22, 19, 16, 11, and X. Our real problem will not be in deciding
between alternative proposals for total mapping and sequencing, but in actually
persuading intelligently led groups to focus on those chromosomes that still have
no champions.
The question must thus be asked whether we may all too painfully find that we
will have the money but not the talented brains to bring the Human Genome
Project home to completion within an acceptable time period. I think not, but in so
arguing I want to focus on the chief motivation that attracts talented scientists to
their goals. Contrary to popular misconception, it is seldom fame or financial
benefit. To be sure, when one makes a great discovery, it is frequently rewarded
by a major scientific prize and the prospect of a much better academic or
industrial position. But the more important reward is the satisfying of one's curiosity
about how nature operates, and for biologists this means deeper and deeper
understanding of the nature of living organisms. The working out of a bacterial
genome will let us know for the first time the total set of proteins needed for a
simple cell to grow and multiply. As soon as we have the E. coli genome, we shall
have in our possession the amino acid sequences of all those proteins that, for
example, control its gene expression or function as channels through which ion
and key molecules move. Then the E. coli cell will begin to be treated as an
object that we realistically can hope someday to comprehend in its entirety, as we
can today understand complex machines like the 747. A total understanding of E.
coli of course will not fall out immediately from the possession of its instruction
book, and hundreds of years are likely to pass before E. coli poses no further
scientific challenges. But the mere statement that how E. coli functions will one
day be completely known is an extraordinary scientific assertion.
Possession of the genomes of multicellular organisms like C. elegans (r\-,100
megabases) and Drosophila (r\-,150 megabases) will be equally important scientific
landmarks. Their much more complex genomes provide the instructions for the
extraordinarily complex set of events that allow fertilized eggs to develop into
functional adults. Until a decade ago, how multicellular organisms develop was
virtually a black box at the molecular level. Then a number of molecular embryolo-
gists began to clone the regulatory genes that control the passage from one
developmental stage to another. And now a number of the key development steps
in genetically well-characterized organisms are understood at the molecular level.
But if we are to understand all the events that lead, say, to the differentiation of a
nervous system, we will need to work from the whole set of genetic instructions.
So, both the C. elegans and Drosophila worlds are starting to make plans for
working out their respective DNA messages. The group farthest ahead is that of
C. elegans, where virtually all its genome is available as cloned sets of overlap-
ping DNA fragments.
The main mappers of C. elegans, John Sulston and Alan Coulson from
Cambridge and Bob Waterston from Washington University, now are'about to start
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pilot sequencing efforts that they hope will bring the cost quickly down to less
than a dollar a base pair. Optimally, production-line-type sequencing efforts will
begin both in the UK and in our country within three to four years, raising the
possibility of establishing the total C. elegans genome by the year 2000. This
project will probably motivate the Drosophila world to see whether they can work
to a similar timetable. Here again, I would hope that the final sequencing effort be
shared between Europe and the United States, with the total final costs for these
programs to be no more than 75 million dollars each. Inherent scientific interest in
the smaller model organisms, which may well be extended to the small-genome
plant Arabidopsis, could prove to be the key ingredient in attracting the appropri-
ate high-level scientific talents to develop the production-line sequencing capabili-
ties that we will need to tackle the human chromosomes.
The first serious efforts to clone overlapping fragments of human chromosomes
have just begun, with most of the American effort so far centered in our National
Laboratories. Both at Livermore and at Los Alamos, cell-sorting instruments have
been adapted to chromosome separation, with the resulting semipurified
chromosomes used to prepare "chromosome-specific libraries" of cloned DNA
fragments inserted into cosmid vectors. Ordering of these cloned human DNA
fragments (,,50 kilobase pairs in length) into the overlapping sets (contids)
presents a greater technical problem than present when working with either C.
elegans or Drosophila libraries. Over half of human DNA comprises highly
repetitive sequences that greatly hinder the detection of true overlaps between
DNA fragments. Recently, the assembly problem has begun to seem less
daunting due to the ability to clone much larger DNA fragments (> several
hundred kilobases) in yeast artificial chromosomes (YACs) using techniques
developed at Washington University by Maynard Olson. Also encouraging is the
ability to pinpoint at the megabase level of resolution the chromosomal location of
any DNA fragment through in situ hybridization to stretched out metaphase
chromosomes.
Assembly of almost complete sets of overlapping DNA fragments for the first
several chromosomes may well have to occur over the next two to three years if
we are to complete the human genome sequence within the next 15 years. The
option of letting the job spread out over, say, 10 years does not exist if we are to
keep costs under control. So, hopefully, the three main DOE groups at Berkeley,
Los Alamos, and Livermore will show they are up to the goals they have staked
out for themselves through assembling soon the overlapping DNAs of
chromosomes 21, 16, and 19 in forms ready for sequencing. There is no
assurance, however, that it will be the DOE labs that will put together the first
useful overlapping maps. Not only is chromosome 21 up for grabs, but the almost
equally small size of chromosome 22 has already made it a tempting target for
scientists at Caltech and Massachusetts General Hospital. Competition, at least ini-
tially, will also exist between the several groups in Italy, London, and Houston that
have all aimed to assemble the X chromosome map. In contrast, there is likely to
be cooperation from the start between the labs at the Salk Institute and in London
that aim to make the overlapping map of chromosome 11. How fast other groups
will come into existence for the overlap mapping of the remaining human
chromosomes is not obvious. We do know, however, that groups of two to four
scientists are not big enough to conquer the average-size chromosome within a
reasonable time. Instead, funds for groups of around ten may have to be
committed for a realistic chance of success. Even when we really know how to
succeed, sums of 2-5 million dollars are likely to be consumed for every
chromosome successfully mapped.
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These sums will thus be a modest entry fee for those nations who wish to be
real participants in the Human Genome Program. So far, only the United States,
the United Kingdom, and Italy have announced definite programs, but there are
good reasons for believing that France, the USSR, Japan, and possibly Canada
will join. Whether Germany will mount an effort is problematic because of the
negative connotations that human genetics research still brings to the German
psyche. How to ensure that we as nations work together instead of indulging in
costly competitive races for the same chromosomal objectives is not yet settled.
Although a number of prominent molecular biologists and human geneticists have
banded together to form "The Human Genome Organization" (HUGO), it is not yet
a free-standing organization capable of taking the steps that will make it a real, as
opposed to paper, organization. Although the decision was made to have three
regional offices, in the United States, Europe, and Japan, the funds have yet to be
found to attract a Secretary General who would be responsible for coordinating
the efforts of the regional offices. Now, I suspect, a truly effective Secretariat will
cost initially about 1.5 million dollars per year, with the sum rising to possibly 3
million dollars when the Human Genome Program is in full operation, say five
years from now. Initially, the HUGO founders hope to find private or foundation
donations for much of this sum, arguing that most governments will join in only
when a seasoned administrator is already in place.
HUGO's coming into existence will greatly facilitate the free and open
exchanges of data that we would all like to be features of the Human Genome
Program. Knowing the sequences of, say, half the human chromosomes without
having access to the other half would be unbearably frustrating. Optimally, soon
after new sequences are established, they will be added to a worldwide accessi-
ble database. Complicating this matter will be the fact that labs that are generating
the sequences, before passing them on to others, will naturally want to work out
the genes located within them and find clues for where they function or how they
are expressed. In putting real meaning into their DNA sequences, it is highly likely
that they will obtain the first indication of many, until then undiscovered, important
human proteins that will provide clues to the functioning of the human body.
Moreover, there are bound to be commercial implications from the first learning of
many of these new human proteins.
Thus, it would be naive to expect that any extensive human sequence data will
be released by a sequencing group until it had a reasonable time to explore its
implications. It would not be unreasonable for the scientists concerned to ask, say,
for a year delay before passing their results on to an openly accessible database.
This is already the custom followed in the several labs that already have
sequenced big DNA pieces (e.g., a viral genome). The 4 x 107-bp sequence of
bacteriophage T7 DNA worked out at Brookhaven National Laboratory by Bill
Studier and John Dunn only became available after the many months needed to
first interpret it and prepare it for publication in an established journal. With the
human genome, we could easily find that we are generating sequences faster
than they can be scientifically interpreted by their finders, leading to apparently
unacceptable delays in general release. So we as a nation may have difficulty in
setting the limits of time that DNA sequences can remain the private property of
those who find them. In trying to be fair to all sides, we must remember that the
chief reason many labs will take on production-level sequencing is not high
technology development but the desire to be the first to see the genetic messages
for a given chromosome and to have the opportunity to exploit the countless
surprises these sequences will present.
Clearly, it will be easier psychologically for a lab to release their own sequences
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if they can be exchanged for others of equal dimension. Sharing of the human
DNA database is much more likely to occur if large-scale mapping and sequenc-
ing efforts are undertaken by all those major industrial nations that will want to use
these data. Now it is too early to ask what we should do if we identify one or
more countries with the economic clout to join in but that apparently intend to
free-load on the traditions of scientific openness of other nations. I do not like even
contemplating such a possibility, since our Congress is bound to act outraged by
such one-sided behavior and want to move us toward a more nationalistic
approach to science. I would hate this alternative, since it is so counter to the
traditions that have allowed me to admire and enjoy the scientific life. But, if the
major nations in the world fail to see that the human genome belongs to the
world's people, as opposed to its nations, then we may be in for a fight that no
one of sense can want.
HIGHLIGHTS OF THE YEAR
DNA Learning Center Dedicated
The fantastic pace of discovery in the various fields of DNA science requires
extraordinary measures to keep the general public informed. The first large-scale
effort in the world was the dedication and formal opening of our DNA Learning
Center in the village of Cold Spring Harbor on September 18th. Dr. Robert E.
Pollack, former Cold Spring Harbor scientist and Dean of Columbia College at
Columbia University, delivered the keynote address, entitled "Reading DNA': to a
standing-room-only crowd in Grace Auditorium. He stressed the importance of
public education in DNA, because of the vast potential impact DNA technology
holds for the future.
Over 750 invited guests arrived that day to preview the Smithsonian Institution's
exhibit The Search for Life: Genetic Technology in the Twentieth Century. David
Mick los, Director of the Learning Center, and Jack Richards, Director of Building
and Grounds, along with their staffs, performed miracles to get the Learning
Center renovated and the exhibit installed in time for the opening. Since that date,
there has been steady progress and improvement with the installation of an office
suite in the basement and a one-of-a-kind bookstore. The bookstore and exhibit
have been ably run by a team of local volunteers, directed by Mrs. Anne Meier
and Mrs. Sandy Ordway. A new exhibit produced at the Learning Center, entitled
DNA Detective, had its debut in spring 1989. This exhibit highlights and
demonstrates the use of recent DNA technology for identification in various legal
suits and for diagnosis of genetic disease. Several museums have already
expressed serious interest in having their own DNA Detective exhibits.
Judging from the huge number of Learning Center visitors, from senior citizens
to elementary school students, who have performed experiments in the Bio2000
teaching laboratory and viewed the exhibit, I am convinced that we have set an
impressive example for other institutions to follow.
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Guest cabins under
construction
Upper Campus Development Moves Ahead
The Upper Campus is starting to show hints of what it will look like upon
completion. The first group of six guest cabins was finished in April of this year,
just in time for the first spring meeting. Each of the Adirondack-style winterized
cabins accommodates eight visiting scientists in four bedrooms and has a
common meeting room and two bathrooms. The six cabins are interconnected by
raised walkways that give them a small community feel. So far, scientists who have
stayed in the cabins have reacted positively to this new on-grounds housing-not
surprisingly, when compared to the alternative many-mile van trek to local motels.
Tentatively, we plan to start the construction at a nearby site of a new group of six
cabins in mid-1990.
Neuroscience Center Takes Shape
To make way for the 20 million dollar Neuroscience Center, we said goodbye to
the L-shaped Page Motel. Named for Arthur W. Page, its two unheated wings had
served us well for 32 and 35 summers, respectively, but in a mere 30 minutes, it
was all reduced to a pile of rubble by an earth mover. Thankfully, the Page name
lives on at the Laboratory in the Arthur W. and Walter H. Page Laboratory
dedicated last year and now a home for the plant genetics program.
In place of the Motel, there now stands the first giant leap on our way to
opening the Neuroscience Center. The 150-car two-level garage was completed
this spring and will now act as a staging area for construction of the Beckman
Neuroscience Laboratory and accompanying Dolan Hall. Presently an imposing
structure, the garage will be much less conspicuous when completed; from most
vantage points, the lower level will seem underground.
Major Gifts for the Neuroscience Center
Looking to complete the funding for the Neuroscience Center, we are elated to
acknowledge votes of confidence from both local and national sources. The Dolan
Family Foundation of Oyster Bay donated 2 million dollars for the Visitor Lodge,
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which will henceforth be known as Dolan Hall. This 60-room facility is anxiously
awaited, as the soaring meetings attendance is sending greater numbers to area
motels. The Dolan family is no stranger to the Laboratory. Mrs. Helen Dolan, a
member of the Board of Trustees, and Charles F. Dolan, Chairman and CEO of
Cablevision Systems, have both been dedicated friends of the Laboratory.
On the national scene, we were able to attract the attention of the highly
respected W.M. Keck Foundation of Los Angeles. Their two million dollar grant will
fund construction of the W.M. Keck Foundation Structural Biology Laboratory. This
facility, located on the lower level of the Beckman Neuroscience Laboratory, will
house the molecular structure analysis facilities. Using X-ray crystallography and
other methods, researchers here will study in detail the three-dimensional
structures of key protein and nucleic acid molecules.
I was particularly pleased to acknowledge the recent major gift from Mrs. Lita
Annenberg Hazen, our newest trustee. To honor her support, the tower at the focal
point of the Center's courtyard will be called Hazen Tower. No ordinary structure,
Hazen Tower will fit in well with the character of Cold Spring Harbor Laboratory,
with its open walls revealing a double-helical staircase at its core.
Cornerstones Dedicated
We heralded in the construction of the Beckman Neuroscience Laboratory and
Dolan Hall with the dedication of two cornerstones on May 12, 1989. With the help
of quickly installed ramps and walkways, we were able to hold the ceremony on
the just-completed parking garage. Representatives from most major contributors
were present, with the notable exception of Arnold and Mabel Beckman, who due
to Mrs. Beckman's illness were unable to attend. Arnold Beckman had the
foresight to realize the importance of the Center and made his critical contribution
early in the development stage. I was saddened to hear a few weeks later that
Mabel had passed away. My sincerest sympathies to Arnold.
Joseph Perpich of the Howard Hughes Medical Institute, Charles Dolan, and A.
Terry Anderson were among the speakers. Ms. Anderson represented the Nassau
County Executive's Office and the Nassau Industrial Development Agency, which
helped the Laboratory acquire 20 million dollars in industrial development bonds
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from Morgan Guaranty Trust Co. of New York to cover interim construction costs.
As a keynote speaker, Dr. Robert Horvitz of the Massachusetts Institute of Technol-
ogy, the only person ever to take three neurobiology courses at the Laboratory in
one summer, remarked, "I believe we are laying the cornerstone today not only for
a new building, but also for a new era in neuroscience and medicine':
Second Century Campaign Goes Public
Amidst the furious pace of construction, we also managed to embark on the first
large-scale public appeal for support in the Laboratory's history. As of April 1989,
we announced that 28 million of the 44 million dollar Second Century Campaign
goal had been raised from our trustees, private foundations, and a few corpora-
tions. To raise the remaining 16 million dollars, we knew it would be necessary to
expand our base of support.
On April 22, 1989, we kicked off this public phase of the campaign in grand
fashion. Over 100 campaign volunteers and guests-some long-time benefactors,
others new-gathered in Grace Auditorium to receive their task from David L. Luke
Ill, whom we are grateful to have as chairman of the campaign. I doubt the
Laboratory's fund-raising message has ever been put so simply and elegantly as
when David said, "I think we can recognize that if we want to find answers for
tomorrow for problems that cannot be solved today, there has to be commitment
to organizations who are dedicated to pushing back the frontiers of knowledge.
We are such an institution:'
To aid the campaign volunteers, the two newest campaign tools, both highlight-
ing the Laboratory's cancer research, were presented and well-received: "A Vision
of Hope," a 12-minute video produced by Zebra Productions, and "The Good
Fight': a full-color brochure written and designed by Daniel Schechter and Margot
Bennett of our Public Affairs Office. Together, these will serve as an easy introduc-
tion for those unfamiliar with our work. Following the presentation, volunteers
dined with some of the scientists in Bush Lecture Hall, which, thanks to clever
decorating, became an elegant dining hall.
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We Begin to Teach Courses in the Fall and Spring
Expanding our role as the world's largest center for postgraduate biology
education, we have added four courses-two in spring, two in fall-to our already
packed course and meetings schedule. Making possible these new offerings were
the funds given to us two years ago specifically designated for teaching by the
Howard Hughes Medical Institute. Our now seven-month respite from visitors will
dwindle to only 5 months as we develop a more year-round program. The first of
these new courses, "Macromolecular Crystallography," was offered last October
and co-organized by Laboratory scientist Jim Pflugrath. Another organizer was
Johann Diesenhofer, who just after the course ended learned he had been
awarded the 1988 Nobel Prize for chemistry in recognition of his role in the
elucidation of the three-dimensional structure of the photoreaction center responsi-
ble for photosynthesis. Taught largely in Bush, which proved a perfect spot for the
needed large number of graphic terminals, this course will again be offered this
year.
Two more courses were initiated early this spring, both of which also covered
the newest experimental techniques. They were "Cloning and Analysis of Large
DNA Molecules" and "Protein Purification and Characterization': the latter co-
organized by Dan Marshak. This coming fall, the fourth new course will focus on
Schizosaccharomyces pombe, an organism that has quickly jumped to the
forefront of research on the cell life cycle and its control. Entitled the "Molecular
Genetics of Fission Yeast': this course will be co-organized by David Beach.
Fifty-third Symposium Focuses on Cellular Signaling
The record-breaking attendance at the 1988 Symposium on the Molecular Biology
of Signal Transduction verified the words of summarizer H.R. Bourne, who said,
"The 53rd Cold Spring Harbor Symposium came at a perfect time." The more than
440 scientists who packed Grace Auditorium and spilled over into the closed-
circuit viewing room in Bush saw 119 speakers lecture on areas from learning and
memory, to signaling pathways, to cellular membranes,
to gene expression and
cell proliferation. Having been in attendance at the 26th Symposium on
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Mechanisms of Cellular Regulation in 1961, it gave me great pleasure to see how
far the world has come and also what lies just ahead. The fierce pace of lectures
was briefly interrupted by a wonderful Dorcas Cummings Lecture on learning and
memory by Eric Kandel, a Laboratory trustee and pioneer in the biology of
learning. Using his favorite lab subject, the large sea slug, Aplysia, as an example,
he gave the LIBA members and guests an overview of the chemical changes that
occur during learning. This was followed by 21 of the traditional dinner parties for
visiting scientists and friends at our neighbors' homes.
Timely and Exciting Banbury Conferences
In his first full year as Director of the Banbury Conference Center, Jan Witkowski
has firmly established that Banbury meetings will continue to be up-to-the-minute,
exciting, and, on occasion, controversial. As a result of a December 1988 meeting
on the Polymerase Chain Reaction, a technology in its relative infancy, a Current
Communications volume on PCR will be the first thorough treatment of this
extraordinary procedure. The November meeting on DNA Technology and
Forensic Science was attended by experts from all sides of the issues, including
Alex Jeffreys, inventor of "DNA fingerprinting." The resulting Banbury Report is sure
to be a seminal publication in the field. Early this year, our Congressional Aides'
meeting in January on The Ethos of Scientific Research offered a rare chance for
scientists and legislators to get together and speak their minds openly on fraud in
science. The sessions ranged from philosophical debate on the nature of scientific
research to the practicalities of dealing with misconduct. The discussions were
vigorous, but by the end of the meeting each side got to see the other's position,
if not sometimes agree with it.
Baring Brothers Co. conference at Banbury Center
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Baring Brothers & Co. Hosts Business Leaders at Banbury
We were very fortunate to have Baring Brothers & Co., Inc., co-sponsor a meeting
at our Banbury Center last October for senior executives. Douglas E. Rogers, a
director of Baring Brothers, and I organized the meeting, which proceeded to be
an overwhelming success for both the scientists and the corporate visitors. The
executives from companies in the pharmaceutical, biotechnology, and related
fields came not only to stay informed, but also to look for possible research
collaborations and new venture ideas. Seemingly a miniature rehearsal for the
upcoming 54th Symposium on immunology, nine of the world's leading immunolo-
gists gathered at Banbury to address some 30 company leaders. From allergies to
autoimmunity, the experts brought the guests up to date on all the latest research
findings. In addition, the executives "got their feet wet" in bench molecular biology,
performing a DNA restriction analysis experiment at the DNA Learning Center. A
similar meeting is already scheduled for this coming October.
Uplands Farm Purchased from Nature Conservancy
After several years of leasing the 12-acre Uplands Farm lot from the Long Island
Chapter of the Nature Conservancy, we closed on a contract in May to purchase
the land. Our Uplands Farm experimental station consists of a cytogenetics lab,
planting fields, a research greenhouse tall enough for a winter corn crop, two
residences, and fertile fields for growing maize. This, along with the dedication in
1987 of the Page laboratory, completes our several-year efforts to expand the plant
research program, which focuses on the genetic manipulation of corn.
Strengthening of Our Administrative Capabilities
The number of scientists here at Cold Spring Harbor Laboratory has been steadily
increasing as the new facilities provided by the Sambrook and Page Laboratories
become fully utilized. At this time, there are 130 persons doing full-time science, a
number that increased by a further 25 during this visitor-filled summer. The Lab's
administrative center, the George Lane Nichols Building, is correspondingly a
much busier site. Our Administrative Director Morgan Browne has recently
strengthened our ability to handle this onrush of new business by appointing two
senior administrators: Chuck Haibel, as Director of Purchasing, and Tony Napoli,
as Director of Personnel. Chuck has spent his entire career in the purchasing field,
most recently as the Purchasing and Facilities Manager for Praxis Biologics, Inc.,
a start-up biotechnology firm in Rochester, New York. Tony came from Gulf and
Western Industries, where he was Vice President of Human Resources for a
consumer products division.
By now there is no way we could have handled in Nichols the increasing tasks
of our Development Office. Thus, last fall, we renovated the until now largely
vacant basement floor of Wawepex for Konrad Matthaei and his staff of the
Development Office. Graced by a new porch that faces the harbor, the suite of
offices was finished just in time to make the final preparations to begin the Second
Century Campaign.
Undergraduate Research Program
Despite the lack of National Science Foundation funding this past year, the
Undergraduate Research Program (URP) continued to hold its own. We received
130 applications for a final 19 spots (the same as last year), two of which were
filled by students from Switzerland and England. Without NSF funding,
Winship
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Herr had a harder time keeping the program, begun in 1959, running smoothly.
But with help from the Alfred P Sloan Foundation, the Burroughs Wellcome Fund,
and the Robert Olney Fund, he was more than able to put together another
excellent group of URPs.
LIBA Garden Party a Throwback to Bygone Era
Thanks to the unending efforts of George W. Cutting, Jr., who can seemingly
always be seen giving a Laboratory tour to potential donors, membership in LIBA
has soared now to 725 members. Many of the new members come as a result of
a benefit garden party, held June 10th of this year on the Airs lie lawn in the
tradition of Marshall Field's benefit gala back in 1932. A warm summer evening
greeted the 350 new friends of the Laboratory, all of whom received LIBA
membership as part of their benefit donation. The party, organized by Mrs. Jane
Greenberg, was followed by 26 dinner parties at local residences for all the
guests.
At the LIBA annual meeting in January, Edward Pulling was elected as
Honorary Director, after serving 20 years as a LIBA director and 17 years as
chairman. His diligence and concern as chairman of our building committee can
be seen in the new buildings and the face lifts of old ones that have come into
existence over the past 20 years. I'm sure his work at Cold Spring Harbor is far
from finished.
Last year's more than 300,000 dollars in contributions to LIBA made possible
LIBA Fellowships for Joseph Colasanti, Bernard Ducommun, Ann Sutton, and
Peter Yaciuk. In addition, the new Investigator Start-Up Fund awarded grants to
Dave Frendewey and Tom Peterson. Remaining contributions went toward the
Unrestricted Fund, giving the Laboratory most-needed additional resources to
adapt to scientific progress.
Robertson Research Fund: A Key Endowment
It is exceedingly difficult for a young scientist to get government or other funding
when he or she has no prior results to put in a grant application. For this reason,
we created the CSHL Outstanding Junior Fellow Award with support from the
Robertson Research fund, our biggest endowment. The award provides salary
support for the Fellow, as well as a research technician. This past year, the awards
sponsored Adrian Krainer and Carol Greider, who study RNA splicing and the
enzyme telomerase, respectively.
Other major commitments of the fund were the full support of our Postdoctoral
Fellows, one Visiting Scientist, and two graduate students. The plant research
program and X-ray crystallography group also received funds while they were in
the process of securing independent research support. And Robert Franza
received invaluable assistance from the Fund to bridge the gap between his two
NIH awards. Robertson monies also helped keep the formal seminar program
running by providing backup honoraria and travel support for otherwise unfunded
speakers.
Michael Wig ler Elected to the National Academy of Sciences
Citing his "distinguished and continuing achievements in original research': Michael
H. Wig ler was elected this year into the prestigious National Academy of Sciences.
Although his scientific accomplishments are many, he is probably best known for
his co-isolation of the first human oncogene. In 1981, building on work he started
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at Columbia University, Mike and his associates at the Laboratory searched the
DNA of human cancer cells and found the RAS oncogene that had helped give
rise to a prostate cancer cell. Later they showed that this oncogene arose through
a single nucleotide change in the sequence of a normal RAS gene that codes for
a GTP-bound membrane protein involved in signal transduction. Since 1981, Mike's
research team in Demerec Lab has discovered several additional important
oncogenes and key clues to how these genes function. Today, they also intensively
study the functioning of the RNA gene equivalents in simple yeast cells.
1988 Changes in Our Scientific Staff
We keenly felt the loss of two Senior Staff Scientists, James Feramisco and Amar
Klar, both of whom served the Laboratory with distinction for ten years. In 1978,
Jim, who was working on his Ph.D. at the University of California, Davis, attended
a seminar given by me there on changes in cell architecture that occur with
malignancy. Soon after, he wrote me for a postdoctoral position in the cell biology
group and came the next year to McClintock Lab. Within three years of his
coming, he became head of the cell biology research group and, in 1984, a
senior scientist. Jim now is at the Cancer Center of the University of California
Medical School, San Diego, where he continues to do research on the biochemis-
try of oncogenic proteins.
Amar Klar also departed this year. Fresh from a postdoctoral period at Berkeley,
Amar joined Jim Hicks and Jeff Strathern in 1978 to form the yeast genetics
group, in the then Davenport Lab, that so revolutionized our ideas on how yeast
cells switch their sex. Their cassette model is increasingly realized as one of the
great achievements of 20th century genetics. Amar now continues his high-
powered genetics approach at the Frederick Cancer Research Facility in
Maryland.
Senior Staff Investigators William Welch and Mark Zoller both accepted new
positions in San Francisco, California. Bill, whose research at Cold Spring Harbor
focused on the response of mammalian cells to physiological stress, now is
Associate Professor of Medicine at the University of California, San Francisco. At
the Department of Cardiovascular Research, Genentech, Inc., Mark now works on
the development of second-generation tissue plasminogen activator (TPA) for
dissolving blood clots.
Leaving their positions as Staff Investigators were Ashok Bhagwat, from Rich
Robert's lab, who is now Assistant Professor of Chemistry at Wayne State
University in Detroit, Michigan, and Daniel Broek, from Mike Wigler's lab, who is
Assistant Professor at the Comprehensive Cancer Center, University of Southern
California, Los Angeles. Also leaving Mike's lab was Scott Powers, who is presently
Assistant Professor at the Robert Wood Johnson Medical School, Department of
Biochemistry, Piscataway, N.J. Margaret Sharma, who worked with Terri
Grodzicker, accepted an appointment as Assistant Professor at the University of
Tennessee Health Science Center in Memphis.
New Staff Members
Newly appointed to positions as Senior Staff Investigators are Arne Stenlund and
Kim Arndt. Arne, whose Ph.D. was awarded from Uppsala University in Sweden,
completed his postdoctoral work with Mike Botchan in the Department of
Molecular Biology at the University of California, Berkeley. He works in James Lab
and is particularly interested in the replication and transcription of bovine
papillomaviruses. In 1981, Kim received his Ph.D. in biochemistry from the
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University of Pennsylvania and then worked with Gerry Fink at the Whitehead
Institute at the Massachusetts Institute of Technology before joining us in the early
part of this year. He is studying the interactions of proteins with DNA at the
molecular level, combining his expertise as a biochemist with the techniques of
today's yeast genetics.
New Visiting Scientists
With the arrival of Nicholas Dyson, the joint program between Ed Harlow's
laboratory and Amersham International to produce monoclonal antibodies for
research purposes was ensured a smooth transition.
It seems most appropriate that in this year of "glasnost': we have four scientists
from that USSR visiting us. Konstantin Galactionov, a native of Leningrad, is on
leave from that city's Academy of Science, the Institute of Cytology. He is working
with David Helfman in McClintock Laboratory on cell biology and molecular
cytology. Valentin Shick and Grigory Yenikolopov come to us from the Institute of
Molecular Biology at MoscoWs Academy of Science, and Mart Ustav comes from
the Molecular Biology Institute of Estonia.
Departing Visiting Scientists
After completing their studies at the Lab, several visiting scientists departed for
new institutions or returned to former ones. Andre-Patrick Arrigo accepted a
position as Professor at the Institut National de la Sante et de la Recherche
Medicale (INSERM) at Montpelier, France. Barbara Knowles and Davor Solter, both
Professors at Wistar in Philadelphia, returned to that institute after spending their
sabbatical leaves here. A native of Lithuania, Donaldas-Jonas Citavicius returned
home after working in Michael Wigler's laboratory for six months. Margaret
Raybuck, who worked with Ed Harlow in the monoclonal antibody facility, went
back to Amersham International in England. After spending their sabbatical leaves
with us, Steve Munroe and Paul Young, both Associate Professors in biology,
moved on: Steve to Marquette University in Milwaukee and Paul to Queen's
University in Kingston, Ontario, Canada.
Staff Promotions
At the end of the year, the Laboratory's Trustees approved the promotions of David
Beach and Ed Harlow from Senior Staff Investigators to Senior Scientists, or
"Rolling-5" rank. A native of England and a graduate of Cambridge University,
David received his Ph.D. in 1977 from the University of Miami in Florida studying
developmental neurobiology. During the last five years at the Laboratory, he has
focused his studies on eukaryotic cell-cycle control in fission yeast. Recently, he
has expanded the scope of that work considerably to include research on the
molecular basis of cell-cycle control in mammalian cells. In 1982, Ed, coming from
the University of Oklahoma, completed his doctorate in biochemistry at the
Imperial Cancer Research Fund, London. Instrumental in setting up the new
monoclonal antibody facility in Sambrook Lab, he has developed a host of
antibodies to study adenovirus E1A proteins and the human p53 tumor antigen.
This year, Ed and his research team were the first to determine a physical link
between a viral oncogene and an anti-oncogene (a cancer-suppressing gene),
thereby providing a key piece of the cancer puzzle.
Guilio Draetta and Elizabeth (Betty) Moran, formerly Staff Investigators, have
accepted positions as Senior Staff Investigators. A native of Italy, Guilio completed
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his M.D. in 1981 at the University of Naples, and then stayed on to pursue
postdoctoral studies. In 1983, he went to the National Institutes of Health in
Bethesda, Maryland, where he worked at the National Cancer Institute prior to
accepting an appointment as Robertson Fellow at Cold Spring Harbor in 1986.
Since then, he has worked with David Beach in Demerec Lab on cell-cycle control
in yeast and vertebrates. Betty came to us in 1983 as a postdoctoral fellow in Mike
Mathews' lab, after completing her doctorate in microbiology at the New York
Medical College. She studies the role of adenovirus E1A protein in regulating
transformation and viral transcription.
Accepting a new position as Staff Investigator is Jeff Kuret, formerly a postdoc-
toral fellow working under Mark Zoller. In 1984, Jeff completed his Ph.D. in
pharmacology at Stanford University in California. After two and a half years of
postdoctoral studies with Phil Cohen at the University of Dundee in Scotland, Jeff
came to Cold Spring Harbor to continue work on protein kinases.
Newly designated Staff Associate Maureen McLeod joins only two other such
appointees at the Laboratory. Created last year, the position provides a transitional
stage between the postdoctoral period and an independent staff position. The
postdoctoral fellow's potential for technical proficiency, scientific creativity, and
independent thought is emphasized. Maureen, who received her Ph.D. in 1984
from SUNY, Stony Brook, works with David Beach on cell-cycle regulation.
Postdoctoral Fellows
Leaving the Laboratory after completion of their postdoctoral terms were: Susan
Alpert to the University of California Medical School, San Francisco; Thomas
Baumruker to Sandor Research Institute, Austria; Vicki Bautch to the University of
North Carolina, Chapel Hill, North Carolina; Robert Cafferkey to the Scripps Clinic,
La Jolla, California; Steven Cheley to the Worcester Foundation for Experimental
Biology, Shrewsbury, Massachusetts; Roger Cone to Tufts University School of
Medicine, Division of Molecular Medicine, Boston, Massachusetts.; Shimon Efrat to
the Department of Molecular Pharmacology, Albert Einstein College of Medicine,
Bronx, New York; Michaela Fairman to the Cancer Research Campaign (CRC),
Molecular Embryology Group, Department of Zoology, Cambridge, England; Joan
Harper to the Biological Sciences Department at Columbia University, New York;
Christine Jolicoeur to the University of California, San Francisco; Christa Lechelt to
the Max Planck Institute in Germany; Brenda Lowe to the U.S.D.A. Agricultural
Research Service, Albany, California; Lee Mizzen to the Lung Biological Center at
the University of California, San Francisco; Avudaiappan Maran to the Long Island
Jewish Medical Center, New Hyde Park, New York; Peter Whyte to the Fred
Hutchinson Cancer Research Center, Seattle, Washington; Gregory Prelich to the
Department of Genetics, Harvard Medical School, Cambridge, Massachusetts;
Shreenath Sharma to the University of Tennessee Health Science Center,
Memphis; Vijay Sharma to the Department of Civil Engineering, University of
Manitoba, Winnipeg, Canada; and Paul Walton to the University of California, San
Diego.
Graduate students Paul Chomet and Carmela Stephens completed their doctoral
dissertations; Paul went to the Department of Genetics at the University of
Berkeley in San Francisco and Carmela to the Children's Medical Hospital in
Boston. After receiving his doctoral dissertation with Mike Wig ler, Scott Cameron
entered the Massachusetts Institute of Technology-Harvard Medical School
Program in Cambridge.
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Employees Recognized for 15 or More Years of Service
In 1988, we were pleased to acknowledge the
contribution of valued employees
who have worked at the Laboratory with such great
dedication and enthusiasm. In
recognition of 15 or more years of service, momentos were
presented to the
following: Carol Caldarelli, housekeeper; Susan Cooper, Director
of Libraries and
Public Affairs; Barbara Cuff, buildings and grounds secretary
(now retired); Nancy
Ford, Director of Publications; Terri Grodzicker, Assistant
Director for Academic
Affairs; Doug Haskett, plumber; Laura Hyman, Assistant to
the Director of
Libraries; Jack Richards, Director of Buildings and Grounds;
William Keen,
Comptroller; John Maroney, Assistant Administrative Director;
Phyllis Myers, senior
laboratory technician; Richard Roberts, Assistant Director for Research; Madeline
Szadkowski, McClintock Laboratory secretary; Hans (Buck) Trede, grounds
foreman; and Barbara Ward, meetings and courses Registrar.
Awards will be given
each future year to staff members reaching 15 years of service.
Our Very Effective Board of Trustees
As our board members work with me in preparing for our 1990 Centennial Year I
realize how fortunate I and the Laboratory are in having the backing of such
distinguished men and women. They never cease to amaze me with their intelli-
gent, loving enthusiasm for our many diverse activities. Sadly, the conclusion of
two consecutive three-year terms as trustee made it necessary for Ralph Landau
to leave our board. Few individuals equal Ralph in his achievements as a creative
engineer, industrialist, and academic economist, and we are indeed fortunate that
we have had his penetrating mind and warm heart on our side. Happily, Ralph's
position on our board will be taken over by his talented daughter, Laurie, also a
resident of nearby Asharoken, who, after acquiring both veterinary and business
degrees at the University of Pennsylvania, has become an expert in aquatic
veterinary medicine and helps run a summer program in this area at the Marine
Biological Laboratory in Woods Hole. Leaving also at the conclusion of his most
recent two consecutive terms was Townsend Knight, who carries on the
distinguished legal career of his Jones' family forebears and whose seasoned
advice we increasingly count on in this age of litigation. And for the same
statutory reasons, we lost the invaluable services of Mary Jean Harris, who played
an important role in the founding of the DNA Learning Center. We have also lost
the dedicated help of Harvey Sampson, a trustee since 1984, who, because of the
change in his main residence from Cold Spring Harbor to St. Thomas in the Virgin
Islands, thought it appropriate to resign this past winter. We thank him for his
many contributions of time and support and hope he will somehow continue to
find other ways to improve our existence.
Joining the board last year was W. Maxwell Cowan, the Vice President for
Research at Howard Hughes Medical Institute. Max, a distinguished anatomist and
neurobiologist, has been involved with our neurobiology program since its
inception in the early 1970s and made an unforgettable presentation at our 1987
Shearson Conference on "The Brain" where he produced an intact human brain for
examination. Our newest trustee, elected this May, Lita Annenberg Hazen, has
also long been involved with neurobiology. She founded the Neurosciences
Institute at the Rockefeller University, as well as being the sponsor of a
distinguished series of yearly meetings on neurobiology that attract neuroscientists
of the highest distinction.
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Our Scientific and Administrative Staff Lets Me Shuttle Back and Forth
between My Two Jobs
I would have never dared accept the genome job at NIH was it not for the fact
that our Lab is essentially in very good scientific, physical, and financial health. So,
I go back and forth to NIH not fearing that my absence is seriously harming our
efforts. But others must work harder to compensate for my inability to be at my
desk. Rich Roberts has done a first-class job as our Assistant Director for Science,
keeping our scientific budget balanced and seeing that we continue to recruit the
new scientists that do not let us go stale. And Terri Grodzicker, our Assistant
Director for Academic Affairs, oversees most competently our ever-changing series
of meetings and courses, simultaneously acting as the main editor of our fast-
growing Genes and Development journal. Equally important, I continue to know
that Jack Richards, as Director of Buildings and Grounds, performs far beyond the
call of ordinary responsibilities, seeing that our buildings and grounds are
attractive and functional despite the great burden he bears in keeping our 20
million dollar neurobiology construction project almost invisible to all.
Equally important has been my reliance on Susan Cooper, who does an extraor-
dinarily good job in running our Public Affairs Office. Her vast experience and
competence let her present our activities to the outside world in ways that please
instead of embarrass. She has also put together the very competent staff that
makes her offices in Grace so reassuring to be in.
Likewise in tip-top shape are our administrative offices headed by Morgan
Browne, who over the past four years has most competently presided over our
transition from an institution that was beginning to aspire to be first-class into one
that now knows how to act like one. At this moment, Morgan, working with our
most effective comptroller, Bill Keen, handles more than 70 million dollars in our
various accounts-40 million dollars of which are endowment funds, an
unimaginable sum to all when I arrived as the Director 21 years ago. Then we had
an endowment of only 20,000 dollars, about all of which legally belonged to LIBA.
Enjoying the Beauty of Bungtown Road
A prime goal of mine for many years has been to restore the inherent beauty of
Bungtown Road, along which much of our Laboratory stretches. When I first came
here in the summer of 1948, this then sylvan path had a rural quality that reflected
what Long Island must have been like in the 19th century. Since then, our
immediate part of Long Island has lost its potato fields and all too many of its
parkland-like great estates. Our immediate environment along the inner harbor
fortunately remains unspoiled, and we have the potential for looking almost as
perfectly tranquil as we were during the whaling ship days. But increasingly
defacing our appearance has been the ever-increasing number of telephone
poles, which grew larger in size and number as we increased the pace of our
science and teaching. So, I have long dreamed of putting all of our communica-
tions and electrical wiring underground and then to repave Bungtown Road, most
of which had become a giant pothole. Happily, these jobs at last are done, and I
now can walk to and from my house thrilled by beauty similar to that which must
have existed when there were sheep on our fields to produce the fleece for the
woolen mill that once existed at the intersection of Bungtown Road and 25A.
I know there is talk that as I once commuted between Harvard and Long Island,
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only to eventually move full-time here, my days on the Pan Am
Shuttle portend my
going on full-time to Washington. But a Bungtown
Road restored and the new
pond beside it make my every return here a delight. No one need further imagine
that the corridors of real power will tempt me.
August 2, 1989 James D. Watson
Bungtown Road
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ADMINISTRATION
The past year was a good one financially for the Laboratory as revenues once
again comfortably exceeded expenses before depreciation. For the first time, four
NIH-supported Program Project Grants-for research on cancer, oncogenes, and
HIV and for core support-were in place for most of the year. The goal of fully
funding depreciation, however, remained elusive. This future cost of replacing
facilities and equipment will increase as the present capital programs are
completed and technological obsolescence of equipment continues to accelerate.
It is extremely important that we provide adequately for these requirements.
The overall financial position of the Laboratory is strong. The value of
endowment and similar funds rose from $31.3 million at year-end 1987, to about
$36 million at the end of 1988, and to nearly $40 million by mid-1989. The appreci-
ation has been the result of substantial reinvested income, good market
performance, and additional contributions. These funds reduce the Laboratory's
dependence on the "soft money" of short-term government grants. They contribute
greatly to our independence and ability to recruit and maintain a world-class
scientific staff.
In many respects, 1988 was an extraordinary year at the Laboratory. The
research was unusually productive even by past standards, and the education
programs, already unique in the world, continued their rapid growth. Construction
of the Neuroscience Center began, the DNA Learning Center opened, our first
ever capital campaign was launched, and Dr. Watson assumed leadership of the
national effort to sequence the human genome. The administrative departments
supported all this and should feel great pride and satisfaction in their
accomplishments.
Meetings and Food Service deserve special recognition for their handling of the
large increase of visitors attending the many functions here. This past spring,
attendance at meetings had to be limited because of capacity restrictions. This is
a period of transition when many of our infrastructure facilities, such as overnight
housing and kitchen and dining, have become seriously overtaxed. New or
refurbished facilities are just now becoming available, as is the case with our six
new guest houses providing overnight accommodations for 48 scientists. Other
facilities, such as Dolan Hall, are in the construction phase. Some are still being
planned, as is the expansion and refurbishment of Blackford Hall. Older facilities
such as the Page Motel have been demolished to make room for new construc-
tion. Barbara Ward, Maureen Berejka, Jim Hope, and their staffs now organize,
house, and feed more than 5000 visitors annually with good grace and a
minimum of inconvenience. But they look forward to the day when all of our
infrastructure facilities will be on a par with the comfort and convenience of Grace,
Auditorium.
One cannot speak of Cold Spring Harbor or Banbury Center meetings without
noting the superlative job Herb Parsons does with audiovisuals. There is no
service at the Laboratory that is performed better or more reliably or that is so
widely praised by the visiting scientists who depend on Herb for their
presentations.
Susan Cooper assumed the leadership of Public Affairs this past year, in
addition to being Director of the Library. The visibility and reputation of the
Laboratory were further enhanced in local and national print and television, always
with taste and sensitivity. Supporting the "Second Century" capital drive, Susan's
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staff produced the excellent Good Fight brochure, which describes cancer
research at the Laboratory. Collaborating with Zebra Productions,
they fashioned a
wonderful new video that highlights the Lab's scientists describing their own
feelings about doing science and living at Cold Spring Harbor. The Harbor
Transcript newsletter was given a new look, greater frequency, and a larger
circulation. The DNA Learning Center opening and the Neuroscience Center
cornerstone ceremony were great successes, and planning moved ahead for the
many forthcoming centennial events.
1988 was Tony Napoli's first year heading the Personnel department. Under his
direction, the personnel staff computerized and updated the personnel records
and brought order to salary administration. Management of on- and off-grounds
housing was also improved. Perhaps most importantly, they have enhanced the
sense of community and caring at the Laboratory. Chuck Haibel, also in his first
year at the Laboratory, brought new spirit and professionalism to the Purchasing
department and modernized and improved shipping and receiving. The new
Development department, under Konrad Matthaei, gave new impetus to both
annual and capital giving, as described elsewhere in this Report.
Bill Keen deftly managed the transition to a much faster MAI Basic Four
business computer with higher memory capacity. Already, management of the
operating budget has improved. The arrival of Barbara Wang permitted Bill to
spend more time managing cash and preparing the long-term forecasts and
planning documents needed for the Lab's expansion programs. This past spring, a
$20 million issue of tax-exempt Civic Facility Revenue Bonds was completed
through the Nassau County Industrial Development Agency. Secured by a letter of
credit from Morgan Guaranty Bank, the Bonds are rated AAA by Standard and
Poors and assure the Laboratory the lowest possible interest rate on borrowed
funds. They provide great flexibility in managing the cash flow and timing of our
large capital construction program.
In recent years, commercial relations have become increasingly important at the
Laboratory, and John Maroney has been most effective in supervising and
managing these activities. He has been particularly helpful in acting as liaison
between the scientific staff and our patent attorneys and in processing inquiries
from commercial interests regarding licensing and research support arrangements.
Recently, he shaped and drafted the Laboratory's new Professional Misconduct
Policy, now required by Federal Granting Agencies. Besides helping enormously
as my assistant, John has also pursued a law degree at Touro College, and we
congratulate him on his graduation in June.
Jack Richards, Art Brings, and Susan Schultz are others we could not do
without. Nor could the Board of Trustees and its 14 committees function without
the very careful and personal attention of Roberta Salant.
The expansion of the Laboratory is an exciting but considerable challenge.
Additional staff will soon be required for whom we have no physical space.
Additional funds will be needed, the sources of which are not yet identified. There
are programs and facilities to be designed which are now barely in the conceptual
stage. Nevertheless, I am sure that the administrative departments will get the job
done, and we should view the future with anticipation and not alarm.
G. Morgan Browne
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BUILDINGS AND GROUNDS
Maintaining the physical plant is becoming more challenging as the Laboratory
grows in both size and complexity. The Buildings and Grounds Department has
perservered to create a pastoral environment for research and to have a facility
that functions effectively on a daily basis. Each day, all of our trades respond to
many problems, including leaks, lack of heat or air conditioning, and telephone
repairs. Our workers strive to repair all of our systems so that the important work of
the Laboratory is not disrupted. The Department has also updated mechanical
systems in an effort to improve reliability.
Neuroscience Center
One of the several milestones achieved during 1988 was, most notably, the
groundbreaking for the Neuroscience Center. The project is divided into three
phases of construction: Phase 1, Excavation and Demolition; Phase 2, Parking
Garage and Site Work; and Phase 3, Laboratory and Lodge. Designs for the
complex were finalized and put into a construction documentation format so that
bids could be obtained. The contractor selected for Phases 1 and 2 is A.D.
Herman Construction Company, who was also contracted for the construction of
Grace Auditorium. Nasco Associates, Inc., an outside cost-consulting firm, has
been employed to keep track of all the expenses.
Another milestone was the demolition of the 33-year-old Page Motel, located on
the site of the Neuroscience Center. In preparation for the bulldozer, the primary
electrical loop from the Buildings and Grounds office to the Treatment Plant was
completed so that the loop that ran underneath the Page Motel could be
disconnected. In October, a 30-ton bulldozer was brought onsite and within 45
minutes, the motel met its demise. In the weeks to follow, the landscape was
changed into a barren crevasse, and by year's end, the back west retaining wall
for the parking garage and most of the columns were in place.
Log Cabins
On the hill overlooking the site of the future Neuroscience Center is the new
complex of six heated log cabins. Construction of the cabins was begun in March.
Each cabin will contain four double bedrooms, two baths, and a common day
room. With the help of an outside contractor, the exterior of the cabins, including
the roof, was completed. Our carpenters then began work on the interiors,
including the insulation, ceilings, trim, and cabinets. Coordinating with the
carpenters, our plumbers and electricians began to install piping and wiring, and
our painters began the staining and painting. While construction was going on,
the Grounds crew worked on the landscaping, and Wendy Hatch and the Building
Commission designed the interior blinds, curtains, bedspreads, and paint colors.
All six cabins will be completed for the 1989 Spring meetings.
Other Alterations and Renovations
Demerec: Because of badly deteriorating copper pipes, the Demerec well water
loop that heats and cools the building was completely repiped by our plumbers.
This massive project was completed in 10 weeks and has resulted in much less
time spent for repairs.
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Wawepex: The lower level of the Wawepex building
was completely reworked to
accommodate the new Development Office. The design
included a new porch on
the east side and a new stairway to the Blackford lawn
and the Buildings and
Grounds Office.
Grace Auditorium: Plans for the lower-level bookstore
and office conversions were
designed and executed. Some of the boiler room
equipment was relocated to
make room for the bookstore, and construction was
completed on schedule.
Delbruck: The DelbrOck Teaching Laboratory was completely
renovated. The
furnishings were removed and replaced with new benches, bookshelves, and
equipment. The walls were painted, and air-conditioning and heating systems were
installed.
Uplands Farm: The heating controls in the Uplands greenhouse have been
improved to provide for more accurate temperature control. In addition, a new
tractor, pickup truck, and farm implements were purchased for the Farm Research
Group.
DNA Learning Center: The auditorium area at the Center was redesigned and
renovated to accommodate the "Search for Life" exhibit from the Smithsonian
Institute. The project included the creation of a bookstore, a holding room,
basement offices, and laboratory and storage areas. In addition, a new heating
and cooling system was installed, the electrical system was rewired, and two new
control panels and a transformer were installed. The project was completed just in
time for the opening of the exhibit in September.
A Word of Thanks
Buck Trede deserves much praise for a job well done in keeping the grounds
looking attractive even though we keep digging holes and trenches in every
corner of the Lab grounds. The custodial department is performing better than
ever thanks to Danny Jusino, who took over as our Custodial Foreman.
We wish to extend our heartfelt thanks for the fine service of two of our
employees who left during the year: Barbara Cuff and Willie Gardner. Barbara,
who was our office secretary for more than 18 years, was replaced by Dottie
Smith, a most vivacious and well-organized person. What a lucky break for us!
Willie, who was our Custodial Foreman, departed from our doors after having
been at the Lab for over 6 years. We miss them, and we wish them much
happiness.
Jack Richards
DEVELOPMENT
To address the growing financial requirements of the Laboratory, the development
function, formerly operating as a part of the Public Affairs Department, was given
its own identity. Charged with increasing our support from the private sector,
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both by expanding annual contributions and by directing and coordinating the
Laboratory's first capital drive, the Development Department was established as a
separate entity early in 1988. By June, we had set up shop on the ground floor of
Wawepex, the building Mr. Jones built in 1850 to serve as a granary for his
whaling fleet.
Our Annual Giving Program is sponsored by the Long Island Biological
Association under the very able direction of Chairman George W. Cutting, Jr, and
its 28 directors. This organization of "Friends of the Laboratory" is responsible,
through its Associate Program and its membership, for the largest source of
unrestricted annual giving. (A complete report of their activities may be found in
Financial Support of the Laboratory, later in this Annual Report.) The Corporate
Sponsor Program is an important source of restricted funding for the Laboratory,
as we share the latest biotechnical information with some 30 leading corporations.
(A report of this Program also appears later in this Annual Report.) As our facilities
and staff expand, in order to maintain our position among the preeminent basic
research institutions in the world, it is imperative that we expand our base of
annual support by upgrading our own gifts and introducing many more friends to
this remarkable "village of science:'
In 1985, Dr. Watson and the trustees gave considerable thought as to what
would be needed to keep Cold Spring Harbor Laboratory in the forefront of basic
research and education in the field of molecular biology for the second century of
our existence. Because capital campaigns are pivotal points in the life of an institu-
tion, indicating the direction of future growth and vitality, the trustees decided to
embark on a capital campaign coinciding with the Laboratory's centennial. Capital
campaigns are quite distinct and apart from annual giving programs, in that they
are mounted to meet specific new needs of an institution that cannot be met
through its annual operating budget.
Trustee Treasurer, and Chairman of Westvaco, David L. Luke III was selected to
chair the first public capital campaign ever undertaken in the Laboratory's 100-year
life, the Second Century Campaign. Under his thoughtful and careful guidance,
planning continued throughout 1985, and in January of 1986, the private solicita-
tion of leadership gifts from trustees and foundations and from corporations
closest to us was begun. The Campaign goal is to raise $44,000,000 in gifts and
pledges by December 31, 1991: $31,500,000 for facility construction and
renovation, $10,500,000 for staff and student endowments, and $2,000,000 for
program and unrestricted endowment.
At year's end, through the prodigious efforts of Mr. Luke, Dr. Watson, Morgan
Browne, and the trustees, over $28,000,000 had been given or pledged to the
Second Century Campaign and plans were well along to bring the Campaign to
the public. (Campaign contributions are listed under Financial Support of the
Laboratory.)
We thank again and again all those who have given so generously to the
Campaign, and we urge those who have not yet made a commitment to consider
as handsome a gift as possible. (Methods of giving either outright or in trust or by
will are outlined under Financial Support of the Laboratory.) Your generous
support honors our distinguished reputation and ensures our vigorous future.
Konrad Matthaei
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LIBRARY SERVICES
Staff Changes
In February 1988, I was given responsibility for the Office of Public Affairs, and I
continue as Library Director, doing budgeting, personnel, and original cataloging.
Fortunately, I am blessed with a staff that has been willing to tighten the reins.
Genemary Falvey, head of library services, has taken on additional day-to-day
responsibilities. She is handling the frontline information needs in an exemplary
fashion. As Genemary absorbs more of the work, so must her highly motivated
staff. Wanda Stolen, a Laboratory veteran of 5 years, does all online interlibrary
loans and bindery preparation like a professional, while handling other public and
technical services. Jeannette Romano, who has been with us since August, is
responsible for acquisitions, claiming materials not received, and informational
references.
Celebrating more than 15 years of service, Laura Hyman continues to
demonstrate her ability to adapt to change. Working for two incredibly challenged
departments, Laura handles the finances for both departments, shares events
planning for Public Affairs, and coordinates archives and records management for
the library. She continues in the library, training, structuring special projects, and
helping as needed. Supporting Laura's expanding role, Lynn Kasso ably handles
all library correspondence. She is the key operator for the labwide mailing list
(CLAM) and organizes archives, fulfilling all requests for historical materials.
Archives Renovation
The library attic was completely renovated to house the Laboratory Archives,
which includes the Carnegie Collection of historic books and journals. In addition,
two major gifts to the Laboratory, the Harris and Fricke collections, have been
cataloged for the Archives. The Harris collection was recently augmented by
additional gifts from Mrs. Noelle Glenn, who purchased the Harris/De Tomasi
house. The gifts include sculpture, paintings, and prints by Jane Davenport Harris
De Tomasi. Jane Davenport's work will be exhibited during the Cold Spring
Harbor Laboratory Centennial.
Rearrangement of Library Collection and Offices
In September, our current book and reference collections were moved to the lower
level of the library, providing needed quiet study space on this level. A VCR and
monitor were installed in Reference Room I, thanks in part to a generous gift from
Mr. Henry Platt. A collection of videotapes, including some of the staff seminars,
has been assembled. To provide additional study space on the main level, the
offices of the Library Director were moved to the second floor. Genemary Falvey
and the library assistants remain on the first floor. The second floor now also
houses the Marketing and Journal Departments, the office of the Director of
Publications, and the library administrative offices. These new arrangements have
made operations more efficient for all of the departments involved.
Reference Services Thriving
Automated interlibrary loan service continues to provide rapid retrieval of
requested books and periodicals. The use of our computerized search service
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increased by 81% in 1988. The annual report collection was expanded this year to
include many more businesses and institutions to aid the Development Office in
their fund-raising effort.
Storage Facility
Our storage facility continues to function very well, with overnight retrieval of
requested volumes. In emergencies, same-day retrieval is possible. Although the
number of volumes requested increased by 148%, some titles have not been
accessed since we opened the storage facility in 1985. Accordingly, we are
withdrawing these titles from our collection to make room for other inactive titles
and to give us much needed shelf space in the main library. Space continues to
be the major drawback in library service. The future must bring a serious plan for
expansion.
Permanent Collection Remains Stable
In 1988, our monograph and journal collections increased by only 1%. This was
achieved by judicious trimming and updating of the current book collection.
Careful examination of the journal renewals and cancellation of some titles allow
the purchase of others to keep pace with the Laboratory's changing directions.
Susan Cooper
PUBLIC AFFAIRS
Public Affairs at Cold Spring Harbor Laboratory had its official inception in 1983
under the able direction of David Mick los. Initially the stepchild of the Library and
Publications departments and labeled "Information Services': it evolved over a
period of five years to encompass fund raising, media relations, audiovisual/
photographic services, and public relations materials. A new tone was set: A
forum for communication with the Laboratory's constituencies was established,
necessitating a wide range of expanded services.
Department Structure Changes
Structural and staff changes were numerous in 1988. In February, David assumed
full-time responsibility for the DNA Learning Center, while Susan Cooper coupled
her library and events-planning assignments with media relations and
public/community affairs. The Corporate Sponsor program was passed to Jan
Witkowski at the Banbury Center, and fund-raising activities were coordinated
under Konrad Matthaei, Director of Development.
A New Staff for Public Affairs
Since the written word is the focal point of public relations activities, we were
pleased to hire a talented science writer, Daniel Schechter, a graduate of MIT's
writing program. In 1988, he was responsible for most of the text of three Harbor
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Transcripts, Visitor's Guide to the Search for Life, The Good Fight, various
brochures for public affairs and development, as well as a dozen or
more press
releases. In addition to preparing copy, Dan has handled the editorial and design
functions necessary to present these materials. In June, Emily Eryou left the
Library to join us as public affairs assistant, replacing Ellen Skaggs. Emily is an
extremely capable editor, as well as a writer in her own right. Along with
managing the day-to-day activities of the department, she created the Lab-wide
calendar and wrote the 1988 Undergraduate Research Program report and
articles for the Harbor Transcript.
Sue Zehl, who joined the staff in 1985 and established a design concept to take
the Laboratory into its second century, resigned her position to pursue exhibit
design at the DNA Learning Center. However, during the year, several new pieces
were created: the first four-color poster for the 1989 Symposium on Immunological
Recognition; the first combined meetings and courses calendar poster; Walking
Tour: The History, Science, and Architecture of CSHL, written by Elizabeth
Watson; and the very handsome The First Hundred Years, a small history of the
Laboratory written by David Mick los. To replace Suds substantial skills, which
include photography, design, and layout, we were fortunate to hire Margot
Bennett, a graduate of Cooper Union and a former employee of Newsday.
Margot's design skills were immediately applied to planning the layout of The
Good Fight: Cancer Research at Cold Spring Harbor Laboratory, our newest
public relations tool. Rounding out the Public Affairs staff, Herb Parsons ably
directs the audiovisual services for both the Laboratory and Banbury Center.
Press Coverage
Press activity at the Laboratory has never been greater. The appointment of
James D. Watson to the NIH Office of Human Genome Research, the Laboratory's
continuing scientific discoveries, plans to establish a Neuroscience Center at the
beginning of our second century, and the opening of the DNA Learning Center
have resulted in a genuine desire to heighten public awareness. These events
have individually and collectively attracted coverage by major national news-
papers, several national news magazines, and the television networks. There has
also been a discernible increase in local coverage both in the press and on
television.
Special Events
In 1988, Public Affairs had responsibility for various events, both large and small.
In April, students and friends honored Jim Watson on the occasion of his 60th
birthday with a daylong meeting of reminiscences, a festschrift, a scrapbook, and
a banquet. The planning and coordination of the DNA Learning Center dedication
in September was a major media affair. We also hosted five Banbury seminars, a
program in conjunction with Lloyd Harbor and its five residing nonprofit organiza-
tions. Finally, the Public Affairs department established bimonthly guided walking
tours for the public, conducted numerous special tours, and gave talks to local
groups.
Along with these activities, planning got under way for the centennial celebra-
tion in 1990, including design and acquisition of appropriate commemorative
items, identification of special events to be held, and the commissioning of two
books to mark our century of achievement. The plan for the central event includes
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the re-creation of the first biology class, fireworks, tall ships, and an array of
whaling-era activities.
We look forward to the challenge presented by the plans for the centennial
celebration. The implementation of this multifaceted, two-year-long event will
require the entire staff to marshall its various skills to ensure that this milestone is
observed in grand fashion.
Susan Cooper
PUBLICATIONS
After the upheavals of 1987, 1988 was a year of consolidation for the Publications
staff. Eighteen new books were published, the largest annual total ever. Of these,
16 books arose from meetings held at the Banbury Center and in Grace
Auditorium, on subjects as diverse as cancer, aging, vaccines, parasites, and plant
genetics. Over 600 leading scientists contributed the papers included in these
volumes. Acquiring articles from these busy people for assembly into books that
are timely and attractive is a huge task demanding persistence and diplomacy
from the editorial and production staff. Their reward is the special value placed on
the proceedings of Cold Spring Harbor Laboratory meetings in the literature of
science. Book production was made faster and cheaper this year by the develop-
ment in-house of microcomputer-based typesetting systems, and as a result, the
purchase price of smaller books was reduced by as much as 20%.
A laboratory manual, Antibodies, by Ed Harlow and David Lane, and a
monograph on the nematode, Caenorhabditis elegans, edited by William Wood,
were also published. The first, a unique guide to immunological techniques,
became a best-seller even before publication. The second is a widely praised,
scholarly work of lasting value to the small but growing community of scientists
using the worm to study genetics, neuroscience, and cell biology. These are two
very different volumes, but each, like the conference proceedings, is an example
of the kind of book the Laboratory has a reputation for doing well.
That reputation was enhanced by the rise in stature of the journal, Genes &
Development. In its second year, it became known as a place for good, often
outstanding papers-remarkably rapid acceptance in a scientific community
generally skeptical about new journals. This success can be credited to Mike
Mathews' insistence, as Editor, on the highest standards for published papers and
the staffs commitment to rapid refereeing and publication. The journal's circulation
increased steadily throughout the year. In December, after almost 2 years as
Editor, Mike happily resumed full-time laboratory work and we welcomed Terri
Grodzicker as his successor.
A videotape, Transgenic Techniques in Mice, giving instruction on the genetic
manipulation of embryos, was released in December as the first in a planned
series of visual guides to complex laboratory methods. Created by Roger
Pedersen and Janet Rossant, the tape subsequently won a national educational
award
The 1987 Annual Report and 13 books of meetings abstracts were also
published on the Laboratory's behalf during the year. As our publications
increased and diversified and journal subscriptions grew, the Customer Service
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and Marketing Departments coped well with increasing work.
Following Susan
Cooper's departure for Public Affairs, Charlaine Apsel took charge of both
departments. The marketing effort was augmented by the opening
of a bookstore
in Grace Auditorium, for the supply of Laboratory publications and sundries to
employees and visitors.
In this year of consolidation, there was also building for the future. At the year's
end, several innovative books were in press and over 20 monographs and
laboratory manuals had entered the planning stage. Joe Sambrook, Ed Fritsch,
and Tom Maniatis continued intensive work, coordinated by
Nancy Ford, on the
second edition of their 1982 classic manual Molecular Cloning. Despite the many
competing books now available, orders for the manual flooded in from June to
December, in advance of publication in 1989. Plans were made for the launch in
1989 of a second journal, Cancer Cells: A Monthly Review, and an experienced
science editor, Paula Kiberstis, joined us to take charge of it. The journal will
review and comment on new findings in cancer biology and their significance for
the diagnosis and treatment of disease. To publish Genes & Development and
Cancer Cells, a Journal Department was founded, with Judy Cuddihy as
Managing Editor.
Publishing at the Laboratory began in 1933, when the proceedings of the
Annual Symposium first appeared. With his personal interest in books, Dr. Watson
established a first-class publishing program when he became Laboratory Director.
Many books originated in the meetings and courses held here and set a standard
for excellence in content and production. Our aim now is to build further and
diversify the program, increasing its revenues for the Laboratory, while retaining its
reputation for quality. In 1988, much investment was made in that future, and to
signal our intention, the decision was taken as the year ended to enter 1989 under
the new banner of "Cold Spring Harbor Laboratory Press'
John R. Inglis
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TUMOR VIRUSES
The DNA tumor viruses, adenovirus and simian virus 40 (SV40), have now been
studied at Cold Spring Harbor Laboratory for 20 years. These viruses interact with
cells in two ways. They replicate in the cells and tissues of their natural hosts,
releasing numerous progeny that can perpetuate the infectious cycle. Alternatively,
they may form a close liaison with the chromosomes of other cells, resulting in
subtle perturbations of cellular gene function that can lead to transformation and
tumorigenesis. Both the overt and covert activities of the viruses rest upon interac-
tions of viral products-DNA, RNA, and proteins-with the cellular machinery
responsible for synthesizing macromolecules and for regulating cell growth and
behavior. The libretto for such a large repertoire of activities is compressed into
the relatively small genomes of the two viruses, which are fully sequenced and
can readily be manipulated by recombinant DNA techniques. Consequently,
investigations of the viruses' activities continue to afford new insights, and not a
few surprises, into the operation of normal cell processes such as DNA replication,
transcription, and protein synthesis, as well as the mode of action of oncogenes
and the sequelae of transformation. The progress reports that follow summarize
recent developments in these areas.
With the arrival from Berkeley of Arne Stenlund, the Tumor Virus Group sustains
its links with two alumni-Ulf Pettersson and Mike Botchan, in whose labs Arne
was a graduate student and postdoctoral fellow, respectively-and also returns to
a project that lapsed 5 years ago with the departure of Louise Chow and Tom
Broker. Arne joined the Laboratory late in the year and will be continuing his
studies of bovine papillomavirus. This is another DNA tumor virus, distantly related
to SV40 but with some features that are all its own, and it promises a new dimension
to the investigations in future years.
DNA SYNTHESIS
B. Stillman E. White T. Melendy G. Prelich
S. Brill T. Tsurimoto S. Smith
J.F.X. Diffley F Bunz R. Cipriani
S. Din K. Fien S. Longinotti
M. Fairman Y. Marahrens S. Penzi
During the past year, we have continued to seek an
understanding of the mechanism and regulation of
DNA replication in eukaryotic cells. The DNA tumor
virus, SV40, continues to be our main focus, but
these studies increasingly lead toward an apprecia-
tion of the replication of cellular chromosomes. As
a consequence, our studies on the replication of DNA
in the yeast Saccharomyces cerevisiae are expanding,
since this biological system combines biochemistry
with the power of genetics.
SV40 DNA Replication
F. Bunz, K. Fien, S. Din, M. Fairman, T. Melendy,
G. Prelich, T. Tsurimoto, S. Longinotti, B. Stillman
A cell-free system from human 293 cells capable of
replicating plasmid DNAs containing the SV40
origin of DNA replication has been used as an
experimental system to identify cellular proteins
involved in DNA replication and to determine the
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mechanism of replication. This cell-free system
requires the SV40-encoded large tumor antigen (T
antigen), but for the most part, DNA replication
relies upon cellular proteins. To identify these cellular
proteins and understand the mechanism of DNA
replication and how it may be regulated throughout
the cell cycle, we have biochemically fractionated the
cellular extract into a number of essential compo-
nents and have purified several replication proteins.
The functions of these cellular proteins in DNA
replication have been determined, and studies have
begun to determine if they are growth-regulated or
if they play a role in the switch from the GI phase
to the S phase of the cell cycle.
INITIATION OF REPLICATION
SV40 T antigen binds to specific DNA sequences
within the origin of DNA replication, and correct
binding is essential for DNA replication. In addition
to this essential function, T antigen also has ATPase
and DNA helicase activities, both of which are
required for DNA replication in vitro (see collabora-
tive work with Y. Gluzman's laboratory, Molecular
Biology of SV40). It has also been shown by J.
Hurwitz's laboratory (Memorial Sloan-Kettering
Cancer Center) that T antigen, in the presence of
ATP, induces local unwinding of the SV40 origin
sequence upon binding to the core origin sequences.
A cellular protein called replication factor A
(RF-A) was purified and is essential for SV40 DNA
replication in vitro. This protein contains multiple
subunits of 70,000, 34,000 and 11,000 daltons and
binds preferentially to single-stranded DNA. Recent
work has demonstrated that RF-A functions in both
initiation and elongation of DNA replication.
Kinetic analyses of SV40 DNA replication and origin
unwinding in the absence of DNA replication have
lead to the identification of at least two distinct steps
during initiation: The first step is the formation of
a DNA-protein complex containing SV40 T antigen,
which, for reasons of analogy to the well-character-
ized Escherichia coli chromosome initiation reac-
tions, we have called the open complex. The second
stage of initiation at the SV40 origin is the formation
of an unwound complex that requires RF-A. This
intermediate probably represents the DNA-protein
complex that is recognized by the DNA polymerase
a/DNA primase holoenzyme for starting DNA syn-
thesis at the origin (see Fig. 1).
A series of monoclonal antibodies have been
produced that recognize the 70,000- and 34,000-
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dalton subunits of RF-A. These antibodies have been
useful in determining the function of RF-A in replica-
tion but have also proved to be invaluable reagents
for studying the cell biology of the protein. RF-A
is a nuclear protein, and its levels in the nucleus do
not change throughout the cell cycle in any signifi-
cant way. Recently, we have demonstrated that the
34,000-dalton subunit is phosphorylated at multiple
sites, and we are investigating the role that protein
phosphorylation may have in the function of RF-A.
ELONGATION OF SV40 DNA REPLICATION
We have previously described the purification of a
replication factor required for the complete replica-
tion of SV40 DNA in vitro and the identification
of this 36,000-dalton protein as the proliferating cell
nuclear antigen (PCNA). PCNA was shown to be
a cell-cycle-regulated protein (originally called cyclin)
and also to be equivalent to the polymerase 8
auxiliary protein. Polymerase 8 has recently been
recognized as a second replicative DNA polymerase
present in eukaryotic cells, the other being the well-
characterized DNA polymerase a. The role of PCNA
in DNA replication is discussed below.
Another replication factor, RF-C, has been puri-
fied as an essential replication protein and is required
for the elongation of DNA replication from the SV40
origin. RF-C is a multisubunit protein and appears
to contain a number of protein subunits. The puri-
fied factor contains protein subunits of 37,000 and
41,000 daltons, each of which migrates as a doublet
in acrylamide gels, but also associated with the
activity is a series of higher-molecular-mass proteins
in the range of 100,000-140,000 daltons. RF-C binds
to both single- and double-stranded DNAs, and
studies on its function during replication have re-
vealed a role with PCNA in chain elongation.
The roles of both PCNA and RFC in DNA
replication were investigated by analyzing the prod-
ucts of DNA replication in reconstituted reactions
either in the presence or in the absence of each factor.
Surprisingly, omission of each factor alone yielded
the same biochemical phenotype, namely, an interest-
ing defect in elongation of replication. In the absence
of either factor alone, initiation at the origin pro-
ceeded normally, but subsequent chain elongation
was abnormal. The leading-strand products (those
synthesized continuously in the 5' to 3' direction) were
absent, whereas the lagging-strand products (those
synthesized discontinuously as Okazaki fragments)
were shorter than normal and were displaced from
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FIGURE 1 Proposed scheme for initiation of DNA replication at the SV40 origin. Two
steps prior to priming of DNA synthesis at the origin are shown, based on kinetic analysis
of initiation. The unwound DNA in the open complex has been reported by Boroweic
and Hurwitz (EMBO J. 7: 3149 [1988]).
the template DNA. Furthermore, the replication tion origin. These results suggested that in the ab-
products that remained bound to the template DNA sence of PCNA, RF-C, or both, replication at the
were predominantly located at or near the replica- origin occurred normally, but subsequent elongation
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was defective. Therefore, it was concluded that under
normal circumstances, PCNA and RF-C are required
for a post-initiation step in replication, presumably
as part of a large complex of proteins that form the
replication machinery at a fork.
The discovery that PCNA is a processivity factor
for DNA polymerase 5 raised the possibility that this
DNA polymerase was involved in replicative DNA
synthesis. Since, in the absence of PCNA, DNA
synthesis only occurred on the lagging-strand tem-
plate and not on the leading-strand template, we
proposed that DNA polymerase 8 was the polymer-
ase required for synthesis of leading strands at a
replication fork and that PCNA is required for the
switch from DNA synthesis at the replication origin
to DNA-polymerase-8-dependent synthesis during
elongation. To extend this model further, we have
suggested that DNA polymerase a, with its asso-
ciated DNA primase activity, is responsible for syn-
thesizing the RNA-primed Okazaki fragments on the
lagging-strand template. A model of this mode of
synthesis, involving an asymmetric distribution of
the replicative DNA polymerases a and 8, is shown
in Figure 2. The replication protein, RF-C, is also
required for the switch from the initiation mode to
the elongation mode of DNA replication, and we
have suggested that it also functions at a replication
fork.
We have begun to test the dual polymerase model
for synthesis of leading and lagging strands at a
eukaryotic replication fork by testing replication by
purified polymerases on artificial replication tem-
plates. Initial results demonstrate that polymerase
a activity is stimulated by both RF-A and RF-C,
whereas polymerase 8 activity is stimulated by RF-A
and RF-C, but only in the presence of PCNA. These
results are consistent with the dual polymerase model
shown in Figure 2. We also note that RF-A, which
is required for origin unwinding by T antigen during
the initial stages of replication, also seems to play
a role at the replication fork and thus may be a bridge
between the two modes of replication.
5!
FIGURE 2 Proposed model for the asymmetric distribution of polymerases a and 8 at a eukaryotic replication
fork. The factors PCNA, RF-A, and RF-C were identified as essential components of the replication apparatus
based on studies with SV40 as a model system.
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Replication-dependent Chromatin
Assembly
S. Smith, B. Stillman
In addition to our studies on SV40 DNA replication,
we have previously described a cell-free system that
supports assembly of the replicating plasmid DNA
into a chromatin structure that resembles the
structure of mammalian cell chromosomes. The
chromatin assembly occurs concomitantly with
DNA replication and requires the addition of a
nuclear extract obtained from human cells to the
DNA replication reactions. Biochemical fraction-
ation of the nuclear extract has resulted in the
identification of a single component required for
replication-dependent chromatin assembly in vitro.
We have purified this component, chromatin assem-
bly factor I (CAF-I), as a multisubunit protein
complex that is required for chromatin assembly
during DNA replication. CAF-I is distinct from the
previously characterized chromatin assembly factors,
nucleoplasmin and Ni, that were identified in
Xenopus egg extracts. These factors act as histone
storage and carrier proteins, but CAF-I appears to
perform some other function in the assembly of
correctly spaced chromatin because the histones are
supplied in a soluble form. The minichromosomes
assembled de novo by CAF-I consist of correctly
spaced nucleosomes containing the four core
histones H2A, H2B, H3, and H4, and thus resemble
chromatin found in vivo. The focus of current efforts
is to understand the role of the CAF-I multisub-
unit protein in the replication-coupled chromatin
assembly process. In addition, we will use this in vitro
system to investigate the influence of site-specific
DNA-binding transcription factors on chromatin
assembly, replication, and structure.
Yeast DNA Replication
J.F.X. Diffley, S. Brill, Y. Marahrens, B. Stillman
As an approach to understanding chromosomal
DNA replication and its control, we have been
studying the yeast S. cerevisiae. Yeast has several
advantages for studying DNA replication, including
well-characterized genetics, the availability of a large
number of cell-cycle-arrested mutants, and the
availability of well-characterized origins of DNA
replication (ARSs). Our approach to understanding
the mechanism and control of yeast chromosomal
DNA replication has been threefold. First, we have
been characterizing proteins that interact specifically
with one ARS, ARS1. Second, we have been ana-
lyzing the sequences required for ARS1 function
both on plasmids and in their normal chromosomal
location. And finally, we have been using our
knowledge of the enzymology of SV40 replication
in vitro to identify analogous yeast factors that will
ultimately allow genetic analysis of the roles of these
proteins in cellular DNA replication.
Proteins that interact specifically with yeast ARSs
are likely to have important roles in controlling DNA
replication. Two proteins that interact specifically
with ARS1 have been identified, characterized, and
purified. These proteins are designated ARS binding
factors 1 and 2 (ABFI and ABF2). ABFI is a se-
quence-specific DNA-binding protein that binds to
a single site within a region of ARSI important but
nonessential for ARS function. ABFI binds at or
near many but not all ARSs, including ARS2, the
2µM origin, and three of the four ARSs associated
with transcriptional silencing of mating-type infor-
mation at the HML and HMR loci. In addition to
its potential role in initiation of DNA replication,
a role for ABF1 in transcriptional silencing has
clearly been indicated by deletion analysis of one of
these silencers (HMR E)
We have purified the protein to homogeneity,
raised polyclonal antiserum to the purified protein,
and used this antiserum to screen an expression
library. A single clone was obtained that contained
a full-length copy of the ABFI gene. The sequence
of the insert contained within this recombinant
phage revealed several interesting features of the
encoded ABF1 protein. First, ABF1 appears to be
similar to a growing number of transcription factors
with extremely high asparagine content, including
the Drosophila deformed gene product, the yeast
heat-shock transcription factor (HSTF), and RAP1,
another yeast protein involved in transcriptional
silencing. In fact, the similarity to RAP1 extends far
beyond amino acid composition. These two proteins
are 30% identical over 60% of the protein. The
possible significance of this with respect to transcrip-
tional silencing is discussed below. Finally, ABF1
appears to contain an interesting variation on the
zinc finger DNA-binding motif typified by that
found in the transcription factor TFIIIA. In the
TFIIIA-like zinc finger, a single molecule of zinc is
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coordinated by two cysteine and two histidine
residues each in short conserved structures that are
separated by a short linker. In ABF1, the cysteine
and histidine regions are conserved, although the
length of the linker between them is tenfold longer
than in TFIIIA. We have used chemical modifica-
tion to demonstrate that sequence-specific DNA
binding by ABF1 requires both unmodified cysteine
residues and the presence of zinc, arguing that this
putative zinc finger is an important functional
domain of ABF1. With the ABF1 gene in hand, the
role of ABF1 in initiation of DNA replication and
general cellular function can now be investigated.
ABF2 has a number of biochemical properties
which suggest that it may have an important role in
the initiation of DNA replication. The binding of
this protein to ARS DNA, in fact, is reminiscent of
the binding of several prokaryotic initiator proteins.
ABF2 binds to several (at least five) discrete sites
within ARS1 separated by A +T-rich sequences that
are essential for complete ARS function, similar to
the binding of the E. coli dnaA protein binding
adjacent to the A +T-rich 13-mer sequences. Our
current efforts are aimed at isolating the ABF2 gene
and further characterizing the interactions between
ABF2 and ARS DNA.
To better understand initiation of yeast replica-
tion, we have undertaken a systematic mutagenesis
of ARS1. Mutant ARSs are being tested both
indirectly by their ability to support the stable
propagation of episomes and directly using the
recently developed two-dimensional gel techniques
to quantify replication frequencies of mutant ARSs
when placed back at their normal chromosomal
locus. Initial deletion analysis of sequences flanking
the essential 11/11 ARS consensus sequence has
defined a critical sequence that contains a 9/11 match
to the ARS consensus sequence, consistent with the
view that ARSs are composed of multiple, properly
spaced and oriented ARS consensus sequences.
Interestingly, these correspond to the sequences
specifically located between ABF2-binding sites at
several ARSs tested. Further analysis of ARS1
coupled with more extensive ABF2 footprint analysis
should lead to insights into initiation of DNA
replication.
Finally, we have recently begun searching for yeast
proteins that can complement human 293 cell
fractions in various aspects of SV40 DNA replica-
tion in vitro. Initially, we have concentrated on
searching for the yeast homolog of the single-
stranded DNA-binding protein, RF-A, since we can
follow its activity with the relatively simple origin
unwinding assay. Following a purification protocol
similar to that used for the purification of human
RF-A, a structurally and functionally similar protein
has been purified to apparent homogeneity. The
yeast RF-A (yRF-A), like its human counterpart, is
composed of three subunits (70, 36, and 11 kD) and
also like human RF-A, single-stranded DNA-binding
activity resides in the largest subunit. Furthermore,
yRF-A substitutes completely for the human protein
in the unwinding assay. As with the ARS-binding
factors, the availability of purified yRF-A will allow
the isolation of the genes encoding these proteins.
Subsequent genetic analysis will determine the role
of yRF-A in yeast replication and, by inference, in
human replication.
The approaches outlined above should ultimately
lead to a more complete understanding of how
chromosomal DNA replication is accomplished.
Understanding how these proteins are regulated
throughout the cell cycle will lead to a deeper
understanding of how cell proliferation is controlled.
ABF1, Nuclear Lamins, and
Transcriptional Silencing
J.F.X. Diffley, B. Stillman
Wild-type yeast contain three cassettes of mating-
type information on chromosome III. Mating type
is determined by expression of the cassette at the
MAT locus, whereas the cassettes at HML and HMR
are transcriptionally inert. HML and HMR contain
the promoter elements required for active expression,
but they are maintained in an inactive state by the
concerted action of cis- and trans-acting elements.
Sequences known as E and I lying on either side of
each of the silent cassettes are required to maintain
the silent state. One of these, HMR E, has been
shown to function in a distance- and orientation-
independent manner and, by analogy to transcrip-
tional enhancers, they have been termed silencers.
ABF1 (see above) binds to three of the four silencers
(HML I, HMR E, and HMR I), and another DNA-
binding protein, RAP1, binds to two of the four
silencers (HML E and HMR E). In addition to being
transcriptional silencers, these sequences function
on plasmids as ARSs, and at least one, HMR E,
exhibits a mitotic partitioning function in addition
to its ARS activity. Transcriptional silencing also
requires the action of the four SIR genes. None of
the SIR genes are essential for viability nor do they
encode either ABF1 or RAP1, although evidence
points to action of the SIR genes through ABF1 and
RAP1.
The molecular mechanism of silencing is, at
present, obscure, although two observations that we
have made may help to elucidate this pathway. First,
as mentioned above, ABF1 and RAP1 exhibit
extensive homology with each other. Interestingly,
this homology does not include the putative zinc
finger of ABF1, suggesting that regions outside the
DNA-binding domains of these proteins may be con-
served. Since the ABF1 and RAP1 sites at HMR E
are functionally redundant, and since these proteins
act in silencing through the SIR genes, we suggest
that the conservation between ABF1 and RAP1
includes sequences involved in interaction with one
or more of the SIR gene products. The second
observation we have made involves the SIR4 gene.
SIR4 is a large protein with several genetically
defined subdomains. During the course of compar-
ing the predicted ABF1 protein sequence with other
proteins, we noticed that within a long region of
predicted a-helix in the carboxy-terminal subdomain
of SIR4 were 12 in-phase heptad repeats that typify
the central rod of the intermediate filament (IF)
proteins. If the amino acids of the heptad repeat are
designated (a-b-c-d-e-f-g), residues a and d are
generally hydrophobic, aliphatic amino acids and
form the basis for coiled-coil interactions between
IF protein monomers. Homology searches with this
sequence revealed that the strongest similarity was
with the central rod of the human nuclear lamins
A and C, which form a filamentous structure known
as the nuclear lamina subjacent to the nuclear
envelope. Although lamins A and C are highly ho-
mologous to other IF proteins, the 95-amino-acid
region of homology between SIR4 and the lamins
contains the 43-amino-acid region found only in
lamins A and C and not in other members of the
IF family.
These observations suggest a mechanism for
transcriptional silencing. Since SIR4 homology with
the lamins is within the heptad repeats that are clearly
implicated in IF dimerization and higher-order
multimerization, we propose that the carboxyl
terminus of SIR4 is inserted into the nuclear lamina
by direct interaction with as yet unidentified yeast
homologs of the human nuclear lamins. A complex
including SIR4 and some or all of the other SIR gene
products would then form and interact directly with
ABF1 and RAP1 bound at the E and I regions
through conserved amino acid sequences in these two
sequence-specific DNA-binding proteins. The pro-
posed interaction between ABF1/RAP1 and the
lamina-bound SIR complex would account for the
partitioning phenomena seen with HMR E-con-
taining plasmids, since in yeast, unlike higher eu-
karyotes, the integrity of the nuclear envelope is
maintained during a closed mitosis. How associa-
tion with the lamina would affect transcriptional
silencing is suggested by the results of Sedat and co-
workers, who showed that specific and almost
universally heterochromatic regions of Drosophila
salivary gland polytene chromosomes are associated
with the nuclear envelope. Thus, the lamina may
represent a transcriptionally inert region of the
nucleus. We are currently investigating the validity
of this model by looking at the subnuclear localiza-
tion of the SIR gene products and the silencer
sequences.
Biological Function of the 19-kD
Product of the Adenovirus E1B
Oncogene: Disruption of IFs and
the Nuclear Lamina
E. White, R. Cipriani
The adenovirus E1A and E1B genes cooperate to
transform primary rodent cells and are responsible
for regulating adenovirus gene expression during
productive infection. E1B encodes two major gene
products, the 19,000-dalton (19K) and 55,000-dalton
(55K) tumor antigens. We have been primarily
interested in determining the function of the 19K
protein in transformation and productive infection.
Initially, we approached the function of the 19K
protein by examining the effect of mutations in the
E1B 19K coding region on the virus life cycle. It was
found that 19K viral mutants were not defective for
virus replication but were defective for transforma-
tion, and possessed a multitude of phenotypes. These
phenotypes included the degradation of host-cell and
viral DNA (deg phenotype), enhanced and unusual
cytopathic effect (cyt phenotype), the formation of
large plaques (Ip phenotype), and a host-range (hr)
phenotype whereupon the mutant viruses replicate
more efficiently than the wild-type virus. Manifesta-
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tion of the 19K mutant phenotypes was E1A-depen-
dent, genetically defining an interaction between the
E1A proteins and the E1B 19K protein. The main
conclusions from this genetic analysis were, first, that
the 19K protein functioned to protect DNA from
degradation during infection and, second, that it
acted as a negative regulator of E1A- dependent viral
early gene transcription. As the 19K protein was
found in the cytoplasm and the nuclear envelope/
lamina, the effect of the 19K protein on gene expres-
sion and DNA stability was likely to be indirect,
possibly via an effect on mRNA metabolism, chro-
matin and nuclear structure, or on the E1A proteins.
Unfortunately, the pleiotropic nature of the mu-
tant phenotypes made it difficult to determine the
primary function of the 19K protein in infected cells.
Therefore, we decided to look for a biological
function of the 19K protein by using plasmid
expression vectors to produce the 19K protein in cells,
outside the realm of a productive infection.
CONSTRUCTION OF E1B PLASMID
EXPRESSION VECTORS
The E1B 19K protein is a fairly abundant protein in
adenovirus-infected and -transformed cells. Hence,
we chose to express the 19K protein under the control
of strong, heterologous promoters, as opposed to the
normal E1B promoter. The mouse metallothionein
and the cytomegalovirus promoter-enhancer were
used to drive expression from the 19K coding region,
flanked by SV40 small t intron and polyadenylation
sequences. The pMT19K and pCMV19K plasmids
contained an additional point mutation that
introduces a stop codon at the second position of
the overlapping E1B 55K reading frame, which did
not affect the amino acid sequence of the 19K pro-
tein. The E1B 19K protein should therefore be the
only E1B protein expressed from this plasmid, and
it is the only E1B protein product immunologically
detectable. These plasmids, when introduced into
He La and COS cells by calcium phosphate precipi-
tation, transiently express the E1B 19K protein to
levels comparable to those found in infected and
transformed cells. The 19K protein localized to the
cytoplasm and nuclear envelope of transfected cells,
closely resembling its localization in transformed
cells and in infected cells at early times postinfection.
Two other E1B plasmid expression vectors were
constructed that encode either all of E1B (pCMVE1B)
or just E1B 55K sequences (pCMV55K). pCMVE1B
expresses both the 19K protein and 55K and related
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proteins after transient transfection, whereas pCMV-
55K expresses only the 55K and related proteins. The
E1B 55K protein was detected by indirect immunoflu-
orescence with a 55K-specific monoclonal antibody
and was found to colocalize with p53 in a perinuclear
spot in the cytoplasm, resembling the localization
of E1B 55K and p53 proteins in transformed cells.
We have used these expression vectors for probing
the function of the individual E1B proteins in (1) the
cooperation with E1A in the transformation of
primary cells and (2) as a means for examining the
effect of E1B proteins on regulation of gene expres-
sion, cell growth, and architecture.
TRANSFORMATION OF PRIMARY RODENT CELLS
WITH E1A AND E1B
The ability of the E1B 19K protein to cooperate with
E1A to transform primary baby rat kidney (BRK)
cells was determined by DNA-mediated gene trans-
fer. BRK cells were transfected with plasmids en-
coding E1A alone (pE1A), E1A plus E1B (either pEl
or pE1A plus pE1B), and E1A (pE1A) plus the E1B
19K protein (pCMV19K). Transfection of BRK cells
with E1A alone resulted in the appearance of a few
small, not very dense, and often abortive foci that
were difficult to establish in long-term culture. These
cells grew slowly to low saturation density, and their
morphology was very flat and often resembled the
morphology of the primary BRK cells. Transfection
of BRK cells with pCMV19K alone did not result
in foci formation, nor did transfection of cells with
the T24 Ha-ras plasmid. Transfection of plasmids
encoding E1A plus E1B resulted in the appearance
of large numbers of dense foci with very transformed
morphologies that were easily established in culture.
Cotransfection of pE1A plus pCMV19K plasmids
greatly increased the frequency of focus formation
over transfection of pE1A alone, resulting in about
half the number obtained with E1A plus an intact
E1B gene. The morphology of the E1A-E1B 19K
transformants was different from that of cell lines
expressing only E1A, and they were readily estab-
lished into cell lines that grew to high density. There-
fore, the E1B 19K protein was responsible for pro-
moting focus formation, producing morphological
changes associated with the transformed phenotype,
and enabling cells to grow rapidly and to high den-
sity.
E1B 55K protein contributes to the transforma-
tion process as well by promoting the frequency of
transformation and further altering cell morphol-
ogy. Cotransfection of pE1A plus pCMV55K plas-
mids also resulted in the appearance of foci that can
be established in long-term culture. Therefore, both
E1B proteins contributed to the transformation pro-
cess, but expression of either one along with E1A
enabled the formation of foci and long-term growth
in culture.
TRANSIENT EXPRESSION OF THE E1B 19K PROTEIN
DISRUPTS IFs AND THE NUCLEAR LAMINA
Transfection of either He La or COS cells with the
pCMVE1B expression vector resulted in a subtle
alteration in cell morphology. We therefore tested
the possibility that expression of an E1B gene
product could affect cell architecture. He La cells were
transfected with pCMV19K or pCMVE1B, and at 48
hours posttransfection, the cells were fixed and
stained for double-label indirect immunofluores-
cence with a polyclonal antibody directed against the
ElB 19K protein, in conjunction with monoclonal
antibodies specific for the IF-related protein vimentin
or the nuclear lamins.
In normal He La cells or He La cells transfected
with carrier DNA, the IFs exist as long filaments that
extend from the vicinity of the nuclear envelope to
the cell periphery (Fig. 3). Drastic alterations in the
distribution of vimentin containing IFs were ob-
served in many of the cells that expressed the 19K
protein. Routinely, 10-5007o of cells transfected with
the pCMV19K plasmid expressed the 19K protein
and 12-50% of those had severe perturbations in the
IF system. The IFs became detached from the nuclear
envelope and the plasma membrane, formed large
clusters in the cytoplasm, and often appeared
fragmented (Fig. 3). The 19K protein was often
observed to colocalize with the disrupted IFs in the
cytoplasm (Fig. 3).
Vimentin shares extensive amino acid and
secondary structure homologies with the nuclear
lamin proteins. Furthermore, the 19K protein is
known to associate with the lamina physically. We
therefore investigated the possibility that the 19K
protein might also disturb nuclear lamina structure
as well as cytoplasmic IFs. pCMV19K-transfected
He La cells were stained by double-label indirect im-
munofluorescence with antibodies directed against
the E1B 19K protein and lamins A and C. Lamin
antibodies stain the nuclear envelope-lamina in a
uniform fashion, but in 7% of the cells that expressed
the 19K protein, small areas of the lamina were
devoid of lamin staining (Fig. 3). As in the case of
vimentin staining, the 19K staining of the lamina was
coincident with that of the lamins (Fig. 3).
The effect of the 19K protein is specific for IFs
and the lamina, since 19K expression did not disturb
the organization of microtubules or the actin
cytoskeleton. Furthermore, disruption of IFs and the
lamina also occurred in cells infected with wild-type
adenovirus but not in cells infected with an E1B 19K
gene deletion mutant. Therefore, 19K-dependent IF
and lamina disruption is specific for those cytoskele-
tal elements, it is a normal occurrence in productively
infected cells, it is the result of expression of the 19K
protein alone, and it is not a transfection artifact.
DISRUPTION OF IFs IN TRANSFORMED
BRK CELL LINES
The arrangement of IFs and the nuclear lamina was
investigated in BRK cell lines that were immortal-
ized by E1A alone or transformed by ElA plus E1B,
E1A plus pCMV19K, E1A plus pCMV55K, or E1A
plus ras. As expected, the cell lines that expressed
the E1B 19K protein displayed perturbations in the
arrangement of IFs, whereas in those lines that did
not express the 19K protein, the arrangement of IFs
appeared normal. What was surprising, however, was
the degree of IF disruption. In primary BRK cells,
BRKs immortalized by ElA, and BRKs transformed
by E1A plus pCMV55K or E1A plus ras, the IFs
appeared as continuous filaments radiating out from
the nuclear envelope to the cell perimeter. IF
disruption was observed in BRK cells transformed
by pE1A plus pCMV19K or pE1A plus pE1B
plasmids. In two of the pE1A-pE1 B cell lines, all of
the cells showed gross abnormalities in the arrange-
ments of IFs. The types of IF distributions in these
cell lines fell into three categories: cells in which the
IFs appeared short and very disorganized, with 19K
staining evident in areas of the most pronounced
disorganization; cells where vimentin appeared in
large perinuclear aggregates coincident with the
localization of the 19K protein; and cells that
appeared predominantly devoid of vimentin staining.
Whether this absence of vimentin staining represents
the total lack of vimentin IFs or is a consequence
of epitope masking is not yet known.
Finally, despite the disruption of the vimentin
network in E1A- and E1B-transformed BRK cell
lines, tubulin and actin distributions appeared
normal. Therefore, BRK cells transformed by ade-
novirus DNA sequences displayed gross perturba-
tions in the vimentin IF network, and this was di-
47
Ca rrier
CMV I9K
CMV I9K
Carrier
CMV 19K
Phase Vimentin EIB I9K
Phase Lamins EIB I9K
FIGURE 3 Disruption of IFs and the lamina by 19K expression in transient assays. HeLa cells were transfected
either with carrier DNA or with pCMV19K plasmid DNA, and at 48 hr posttransfection, cells were fixedin either paraformaldehyde (upper panels) or methanol (lower panels). Double-label indirect immunofluo-
rescence was performed with either anti-vimentin andanti-E1B 19K antibodies (upper panels) or anti-lamins
and anti-E1B 19K antibodies (lower panels). The phase-contrast and immunofluorescent staining for vimentinor lamins and the E1B 19K protein is shown for the same set of cells in each horizontal row.
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rectly correlated with expression of the E1B 19K
protein.
In conclusion, the 19K E1B- transforming protein
of adenovirus functions to specifically disrupt IFs
and the nuclear lamina of transfected, infected, and
transformed cells. This is likely to be the main, if
not the only, function of the 19K protein. Therefore,
the role of the 19K protein in the prevention of
abnormal cytopathic effect, DNA degradation, and
increased early gene transcription in productively
infected cells, and in transformation are likely
consequences of IF and lamina disorganization.
Once having determined a function of the E1B 19K
protein, we can now begin to address (1) how the 19K
protein disrupts IFs and the lamina and (2) why
disruption of these structures prevents the occurrence
of the pleiotropic phenotypes in El B mutant infected
cells and promotes oncogenic transformation.
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plays in SV40 DNA replication, evaluating the effect
of posttranslational modification, particularly phos-
phorylation, on the overall functioning of the pro-
tein, and analyzing the domain of the protein in-
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volved in the specific recognition of the SV40 origin
of replication.
Our previous studies on the origin-specific DNA-
binding domain of large T antigen utilized a series
of deletion mutants coding for amino-terminal
fragments of different lengths and allowed us to map
the carboxy-terminal boundary of this domain at
amino acid 246. To delineate this boundary, DNA-
binding activity was measured by immunoprecipi-
tating protein-DNA complexes and examining the
labeled DNA fragments coprecipitated from a
mixture of specific and nonspecific DNA. Truncated
T-antigen proteins containing the amino-terminal
272 or 266 amino acids bound origin-containing
DNA with a low efficiency compared to shorter
proteins. These proteins, beginning with an amino-
terminal fragment 259 amino acids in length and
culminating with a protein of 246 amino acids,
displayed a resurgence in specific DNA-binding
activity. We have since confirmed and further
quantitated these findings by means of a nitrocel-
lulose-filter-binding assay using individual gel-puri-
fied fragments containing the wild-type SV40 origin
of replication, site I or site II, and equimolar mix-
tures of them. The 246-amino-acid protein bound
to all fragments tested with an approximately two-
fold greater efficiency than the 259-amino-acid pro-
tein, and they both displayed efficient site I binding
at concentrations of protein lower than that required
to achieve efficient site II binding. This filter-binding
assay will be employed to determine precisely the
dissociation constants for T-antigen binding to the
various origin fragments under a variety of condi-
tions. Initial results indicate that the dissociation
constant is surprisingly high. Limited proteolysis of
T antigen in other laboratories has generated a frag-
ment that spans residues 131-371 which specifically
recognizes the SV40 origin of replication (Simmons,
J. Viro157: 776 [1986]). We have utilized this amino-
terminal boundary and produced a protein contain-
ing amino acids 132-246 that contains all of the
information necessary to recognize the SV40 origin
of replication.
Addition of the monoclonal antibody employed
in the immunoprecipitation assays (Pab419) to DNA-
binding reactions containing full-length T antigen
from He La cells resulted in an increased retention
of the site II fragment on nitrocellulose filters.
Preliminary results indicate that the DNA-binding
activity of the truncated proteins is unaffected by
the presence of antibody. Furthermore, Pab419 had
no effect on the ability of the protein to bind to
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single-stranded DNA. This raises the interesting
possibility that certain monoclonal antibodies may
stabilize particular conformations of T antigen and
thus influence the protein's activity in vitro. These
studies will be pursued by making use of the battery
of monoclonal antibodies we have at our disposal.
The 246- and 259-amino-acid proteins have been
purified from bacteria, He La cells have been infected
with an adenovirus vector, and insect cells have been
infected with a baculovirus vector. The truncated
proteins produced in insect cells and bacteria behave
similarly in a DNA-binding assay. Both proteins bind
first to the wild-type origin fragment, then to site
I, followed by the site II fragment. The mammalian
proteins, however, bind first to the wild-type
fragment, followed by the site II fragment. Binding
to the site I fragment is seen only at high protein
concentrations. DNA-binding studies comparing the
full-length proteins are currently in progress.
The helicase activity of large T antigen requires
the protein to interact with single-stranded DNA.
The 246-amino-acid truncated derivative that bound
efficiently to origin sequences was also able to
interact with a partial duplex helicase substrate. This
binding was competed by single-stranded DNA in
a 1:1 ratio. SV40 origin sequences contained within
a pBR322-based plasmid effectively competed for
binding, whereas pBR322 failed to compete at a mass
ratio of 100:1. Various RNAs (a globin, poly[A],
poly[U], poly[C]) only competed at mass ratios that
exceeded 100:1. Poly(G), however, competed more
efficiently than single-stranded DNA. This may be
due to the large amount of secondary structure
present in this polyribonucleotide. Full-length T
antigen from He La cells behaved similarly in these
competition experiments, with the exception that
pBR322 lacking origin sequences was an effective
competitor.
All of these truncated proteins lack the putative
metal-binding motif found between residues 302 and
320. It is therefore unlikely that this structure plays
a pivotal role in the recognition of specific or
nonspecific DNA sequences. We have observed that
micromolar concentrations of zinc efficiently pro-
mote the oligomerization of T-antigen monomers.
This oligomerization can be reversed with either
EDTA or DTT, both of which are capable of che-
lating metal ions. Furthermore, a truncated protein
that contains the amino-terminal 246 amino acids
and lacks the putative metal-binding motif behaves
predominately as a monomer. A protein containing
the amino-terminal 360 amino acids, however, also
behaves predominately as a monomer. Thus, the
mere presence of the putative metal-binding motif
is not sufficient to promote oligomerization. Atomic
absorption spectroscopy performed in collaboration
with D. Geidroc and J. Coleman (Dept. of Molecular
Biophysics and Biochemistry, Yale University) has
revealed 1 g atom of zinc that is resistant to removal
by dialysis associated with pure preparations of T an-
tigen. Further experiments are in progress to probe
the nature of this association and to address whether
or not T antigen is a zinc metalloprotein. It is worth
noting that the region of T antigen involved in spe-
cific DNA binding contains numerous cysteine and
histidine residues that may also be involved in co-
ordinating a metal ion. The 246-amino-acid protein
that lacks the metal-binding motif is currently being
analyzed for its zinc content and should further ad-
dress this question. Proteolysis studies will also be
performed on the full-length protein to determine
if a stable folded domain containing a coordinated
metal ion can be isolated. Finally, we will size-frac-
tionate T antigen in the presence of various concen-
trations of metal ions and assay individual fractions
for origin-specific DNA binding, single-stranded
DNA binding, helicase activity, and in vitro DNA
replication activity.
Last year, we described the use of a bacterial
expression system to produce T antigen that lacks
mammalian posttranslational modifications. Full-
length T antigen purified from E. coli directs levels
of in vitro DNA synthesis 10-1507o of those directed
by T antigen purified from a mammalian source. The
purified protein binds to fragments containing the
wild-type SV40 origin of replication or site I with
the same efficiency as mammalian T antigen. How-
ever, T antigen from bacteria fails to bind to frag-
ments containing only site II at protein concentra-
tions where its mammalian counterpart binds ef-
ficiently.
Further biochemical characterization of T antigen
from E. coli has revealed that its ability to function
in an origin-specific unwinding assay parallels its
apparent inability to bind specifically to site II. The
nature of these defects may thus account for the low
replication levels observed. The E. coli-produced
protein possesses levels of helicase activity compara-
ble to that of mammalian T antigen, providing
evidence that both efficient site II binding and
helicase activity are required to achieve origin-
specific unwinding. The aforementioned conditions,
however, are not sufficient for unwinding to occur.
This is supported by the existence of a mutant T
antigen containing a single lesion at amino acid 224.
This mutant retains wild-type levels of helicase
activity and binds to site II, yet it is still defective
in its ability to catalyze the unwinding of origin-
containing plasmids.
Our previous studies on phosphorylation of T
antigen have clearly implicated this posttranslational
modification with a role in regulating SV40 DNA
replication. Briefly, we demonstrated that T antigen
treated with calf intestinal alkaline phosphatase
(CIAP) displayed an increase in its ability to direct
SV40 origin-specific DNA synthesis in vitro. This
was accompanied by at least a fourfold increase in
binding to site II, an essential element within the
SV40 origin of replication, and a twofold increase
in binding to site I. The protein's intrinsic ATPase
activity remained unaltered (Mohr et al., EMBO J.
6: 153 [1987]). Interestingly, CIAP treatment of T
antigen successfully removed 80% of the 32P label
from the polypeptide. The remaining 20% remained
covalently attached to the protein following subse-
quent treatment with bacterial alkaline phosphatase
in 0.1% SDS (unpublished observations). Work in
other laboratories has established that whereas CIAP
removes phosphate from serine residues on T anti-
gen, the threonine residues resist the action of this
enzyme (Shaw and Tegtmeyer, Virology 115: 88 [1981];
Grasser et al., J. Virol. 61: 3373 [1987]; Klausing et
al. J. Virol. 62: 1258 [1988]). There are two phos-
phothreonine residues present on T antigen, Thr-124
and Thr-701. Proteins containing the conservative
substitution of alanine for threonine at residue 701
are indistinguishable from wild-type in plaque as-
says, in vivo replication assays, and DNA-binding
assays performed in crude extracts. Mutants at Thr-
124, however, fail to form plaques, do not replicate
SV40 DNA in vivo, and fail to bind to site II (Schnei-
der and Fanning, J. Virol. 62: 1598 [1988]). We have
obtained the coding sequences for these mutant T
antigens from Dr. Fanning and have overexpressed
these proteins in adenovirus vectors. The immuno-
affinity-purified mutant proteins will be tested in
several quantitative in vitro assays (replication, DNA
binding, helicase, unwinding). Pure protein will also
allow us to address the effect mutating this critical
threonine residue has on the interactions that occur
between T-antigen molecules in solution and those
that occur when the protein is bound to DNA.
Finally, it will also facilitate comparisons between
full-length T antigen produced in E. coli and the
mammalian Thr-124 mutant. The similarity between
these two proteins is striking, as they both replicate
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DNA poorly and bind to DNA fragments contain-
ing the wild-type origin or site I, yet fail to bind to
site II.
Recently, it has been demonstrated that ATP can
alter the DNA-binding pattern of T antigen. It has
been reported that efficient binding to site II at 37°C
is ATP-dependent, and the limits of protection as
assayed by DNase I footprinting are extended over
the AT-rich region of the origin (Deb and Tegtmeyer,
J. Virol. 61: 3649 [1987]; Boroweic and Hurwitz,
Proc. Natl. Acad. Sci. 85: 64 [1988]) in the presence
of this nucleotide. This phenomenon has also been
observed in electron micrographs of T antigen-DNA
nucleoprotein complexes (Dean et al., Proc. Natl.
Acad. Sci. 84: 8981 [1987]). We will initially examine
two replication-defective T antigens for their ability
to respond to ATP in this footprinting assay. One
mutation has wild-type levels of helicase activity and
binds to both origin sites, yet fails to unwind origin-
containing plasmids. The second mutant is defective
in ATP hydrolysis. Full-length T antigen from E. coli
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The adenovirus oncogene E1A (early region 1A) is
a multifunctional protein that affects many aspects
of cellular function, such as transcription and
induction of cellular DNA synthesis and prolifera-
tion. Expression of E1A can lead to immortaliza-
tion or transformation of different cell types. Several
E1A proteins are expressed as a result of alternative
splicing of the primary transcripts, and different
proteins may express some but not all of the E1A
functions. We have been interested in several aspects
of E1A function. First, we have been analyzing the
growth factors induced in primary epithelial cells by
E1A proteins. Second, we have been using E1A
mutants to define the role of growth factors in E1A-
induced cell proliferation. We have also continued
work using viral vectors that express E1A and SV40
T antigen to immortalize a variety of primary cell
types.
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will also be tested in this assay. It will be extremely
important to assess the effect of ATP on the ability
of this protein to bind to site II. The continued
analysis of these mutant T antigens will allow us to
pinpoint the defect in the initiation of replication
and will lend support to the biological significance
of these partial biochemical reactions. Furthermore,
the distribution of their phenotypes reinforces the
complex nature of the initiation reaction and the
multiplicity of functions provided by T antigens.
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Role of the Adenovirus E1A 12S Gene
Product in Stimulation of Epithelial
Cell Proliferation, Immortalization,
and Growth-factor Production
I Grodzicker, M. Cleary, P Hinton, M. Quinlan
In our pursuit of the identification of the 12S-
induced growth factor, we have been testing the
ability of known growth factors to stimulate
quiescent primary baby rat kidney (BRK) cells to
proliferate. These cells do not respond to TGF13,
PDGF, EGF, bradykinin, or bombesin. TGF13 also
does not inhibit the proliferative response of the
primary epithelial cells to the 12S-conditioned
medium. However, the BRK cells do proliferate in
the presence of bFGF or TGFa. Since we know that
our growth factor(s) does not bind to the EGF
receptor, we have eliminated the possibility that
TGFa is present in the conditioned medium. In addi-
tion, 12S-conditioned medium induces a morpholog-
ical alteration of NIH-3T3 cells that resembles that
which is produced by the conditioned medium from
cells transformed by the Kaposi sarcoma oncogene,
a member of the FGF family (provided by C. Basilico,
NYU School of Medicine). We have been pursuing
purification of the growth factor from conditioned
medium of 12S virus-infected immortalized epithelial
cells in collaboration with Dan Marshak (see Protein
Chemistry, this section).
The 12S protein encoded by the adenovirus ElA
region induces cellular DNA synthesis in and
proliferation and immortalization of primary rat
epithelial cells in the presence or absence of serum,
as well as the production of a growth factor(s) that
stimulates epithelial cell proliferation. We have
undertaken a mutational analysis of the 12S gene
to determine the sequences required for these
functions. We found that a region near the carboxyl
terminus of the 12S protein was required for growth
factor induction. No activities have been defined
previously for this region. Furthermore, we showed
that growth factor production was necessary for
epithelial cells to survive past their normal life span
in culture and to become immortalized. The ability
to induce growth factor production required prior
expression of E1A activities encoded by the amino
terminus of the 12S protein, including activation of
quiescent cells into the cell cycle, and an unknown
activity that required expression of the first 13 amino
acids of the gene. In addition, examination of the
subcellular localization of mutant 12S polypeptides
suggested new regions that affect the nuclear locali-
zation of ElA proteins.
Use of Retroviruses That
Carry Immortalizing or
Transforming Genes
L. Arrigoni, R. Cone
An epithelial-cell-transforming virus could be of
great use, both in the culture of epithelial cell lines
and in the study of carcinogenesis. Since the adenovi-
rus E1A gene has been shown to partially transform
some epithelial cells from primary rat cell cultures,
we constructed retrovirus vectors containing either
the 12S or 13S E1A cDNA sequences to facilitate the
transfer of these genes into a variety of primary cell
types. The 12S E1A virus induced proliferation and
immortalization of epithelial cells in rat kidney, liver,
heart, pancreas, and thyroid primary cultures. In the
two cases tested, heart and liver cultures, E1A-
immortalized cells were nontumorigenic, but they
could be completely transformed by subsequent
introduction of the ras oncogene. To our surprise,
the 13S virus had a greatly reduced immortalization
potential. This may be related to the fact that the
12S ElA protein is required for the complete induc-
tion of the cellular DNA replication machinery in
the quiescent human epithelial cells in which adeno-
viruses normally replicate.
We have utilized a retrovirus vector encoding the
adenovirus E1A oncogene and the neomycin phos-
photransferase gene to establish a differentiated hu-
man thyroid cell line capable of expressing HLA class
II antigens in collaboration with T. Davies (Mt. Sinai
Medical Center). Human fetal thyroid was collage-
nase-digested, cultured as a monolayer, and infected
directly with 12S or 13S E1A-containing retrovirus
constructs. Infected clones were selected in a hor-
mone-supplemented medium containing bovine TSH
(10 mU/m1), 10% fetal bovine serum, and 0.5 mg/ml
G418 antibiotic. A rapidly growing clone (designated
12S) was chosen for detailed analysis over 11 months
of continuous culture. The 12S clone was sensitive
to >10 µU /ml bovine TSH when assessed by extracel-
lular accumulation of cAMP, but bovine TSH had
no influence on [3H]thymidine incorporation over
a 72-hour period. One 12S ElA line, in particular,
has additionally retained the ability to inducibly ex-
press class II histocompatibility antigens, in response
to a-interferon, a property that makes the line useful
for the study of human thyroid autoimmune disease.
During this past year, in collaboration with D.
Williams (Children's Hospital, Boston), we have
continued to examine the use of oncogene-contain-
ing retrovirus vectors for the establishment of dif-
ferentiated cell lines. T.M. Dexter showed some time
ago that long-term bone marrow cultures provide an
in vitro environment capable of supporting prolifer-
ation of hematopoietic stem cells, analogous to the
role of bone marrow in vivo. These cultures are very
complex, containing a variety of adherent stromal
cells and nonadherent hematopoietic cells that are
dependent on the stromal cells for continued growth
in culture. To simplify the study of stromal cell-he-
matopoietic cell interactions, we have established a
number of murine bone marrow stromal cell lines
from long-term Dexter-type cultures by infection of
the adherent layer with retroviruses encoding ElA
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or SV40 T antigen. Three of five lines immortalized
with SV40 T antigen were able to support prolifera-
tion of the most primitive murine hematopoietic cell
known, the CFU-S cell (colony forming unit-spleen),
whereas none of the E1A-immortalized lines were
able to do so. Assays were performed by cocultivat-
ing fresh nonadherent bone marrow cells with feeder
layers of immortalized stromal cell lines and quan-
titating the number of CFU-S cells per culture at
1-week intervals for up to 5 weeks. CFU-S cells are
quantitated by virtue of their ability to home to the
spleen and form macroscopic hematopoietic colonies
there after intravenous injection into irradiated
recipient mice.
One clone, U2, supported CFU-S proliferation at
levels comparable to those of primary murine
adherent cells (200 per flask for up to 5 weeks).
Evidence from a number of laboratories suggests
that proteins on the surface of stromal cells may be
involved in the homing and proliferation of CFU-S
cells. Future efforts will be directed toward identify-
ing proteins on the surface of U2 cells that may be
involved in these processes.
Structure-Function Relationships in
the Adenovirus E1A Gene
E. Moran, P. Yaciuk, M. Corrigan
Our work continues to focus on how the structural
features of the E1A gene products determine their
biological activities, particularly their ability to
induce quiescent cells to enter the cell cycle. In past
years, we have shown that the E1A proteins contain
three highly conserved amino acid regions that are
important for biological activity. We have also found
that the first two of these are involved in the cell-
cycle regulating and transforming activities of the
E1A products. By last year, we had mapped the
boundaries and defined most of the essential amino
acids of domain 2. Our delineation of the minimal
essential sequence of domain 2 led us to the recogni-
tion that this domain represents a conserved amino
acid motif common to the transforming proteins of
several divergent classes of DNA tumor viruses. We
further demonstrated that the homologous domain
from the papovavirus SV40 T antigen can substitute
functionally for adenovirus E1A domain 2 and,
additionally, that either of these domains can as-
sociate specifically with a common cellular protein.
These results suggested strongly that the transform-
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ing proteins of different classes of DNA tumor
viruses act at least partly through a similar biochem-
ical mechanism. The identification of the common
cellular target as the product of the retinoblastoma
tumor suppressor gene (see E. Harlow, Protein
Immunochemistry, this section) verified the common
identity of the cellular target, and suggested a model
for the mechanism of DNA-tumor-virus-induced
release from normal cellular growth controls.
Although domain 2 plays an essential role in E1A-
transforming functions, we have found that it is not
sufficient for these functions. A large deletion (PSdI)
near the amino terminus, removing all of conserved
domain 1 and many of the surrounding sequences,
is also unable to participate in host-cell transforma-
tion. The defect in this mutant is not due to tertiary
disruption of domain-2 structure, because this
peptide is able to cooperate in trans with a domain-
2 deletion peptide (CXd1). This trans-cooperating
activity argues that each domain remains structur-
ally intact in its individual peptide and demonstrates
the extraordinary autonomy of each region.
Much of our work this year has focused on
defining the essential sequences in El A upstream of
domain 2, understanding the relationship between
this region and E1A domain 2, and probing the
structural relationships between E1A and other
DNA-tumor-virus-transforming proteins. Since at
least two separable regions of E1A can cooperate to
enact transforming functions, we considered whether
each region has a separate function or whether they
act in concert, perhaps in a single complex, to enact
a single function.
As stated above, sequences in domain 2 are
essential for detectable association with the retino-
blastoma tumor suppressor gene product. Deletion
of the intervening sequences between conserved
domains 1 and 2 does not disrupt this association.
Deletions extending further upstream, to within
conserved domain 1, do, however, disrupt or destabi-
lize this association, so that the association is not
detectable by coimmunoprecipitation. This raises the
possibility that the essential function contributed by
the upstream region is participation in binding the
retinoblastoma product. One could imagine that the
trans-cooperation effect is the result of an associa-
tion between the domain-1 peptide, the domain-2
peptide, and the retinoblastoma product.
Our attempts to demonstrate by coimmunopre-
cipitation the formation of a heterodimer or complex
between the ElA peptides expressing separate regions
have yielded only negative results, even under con-
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FIGURE 1 The first bar in the diagram above represents the 289R E1A protein product. The residues bordering the three highly
conserved regions are noted above the bar. The black regions in the smaller bars below represent deleted sequences. The table
to the right summarizes the phenotype of the deletion mutants. The first column indicates the ability of each mutant to cooperate
with an activated ras oncogene to transform primary cells. The second column indicates the ability of each mutant to cooperate
in this assay with an E1A domain-2 deletion mutant. Determination of domain-2-cooperating activity is not applicable (N.A.) in the
case of the domain-2 deletion mutant itself (CXdI) or in cases where the mutant product has a positive function on its own. The third
column indicates the ability of each mutant to bind the cellular retinoblastoma tumor suppressor gene product stably enough for
detection in a coimmunoprecipitation assay from infected cells.
ditions that do not disrupt the association between
the wild-type E1A products and host-cell proteins.
Although these experiments do not rule out the pos-
sibility that there is a necessary association that is
too transient or unstable to be detected in this assay,
the available evidence does not support a model pre-
dicting formation of a single active complex. It there-
fore remains possible that each region contributes
a relatively independent function.
To determine the actual active site in the upstream
E1A region, we have made systematic deletions
extending from the upstream boundary of domain
2 toward the amino terminus or from the extreme
amino terminus toward domain 2. We used similar
analyses in the past to show that the functional
boundaries of domains 2 and 3 correspond very
closely with the boundaries of the highly conserved
sequences. Surprisingly, though, the results of the
present analysis indicate that most of conserved
domain 1 is actually dispensable for at least part of
E1A-transforming function. The truly essential
sequences in this region appear to lie near or in the
relatively unconserved region preceding conserved
domain 1.
The upstream sequences essential for transforma-
tion do not appear to coincide with the upstream
sequences necessary for stable association with the
retinoblastoma product. We have characterized
mutants with deletions extending from the border
of domain 2 well upstream into conserved domain
1 (in fact, removing 30 of the 40 amino acids
recognized as comprising domain 1) that are not
severely defective for E1A-transforming function.
These mutants do not show detectable association
with the retinoblastoma gene product. Conversely,
deletions confined to the relatively unconserved
region preceding domain 1 abolish E1A-transforming
function but continue to bind the retinoblastoma
55
gene product indistinguishably from wild-type E1A.
These mutants also trans-cooperate with domain-2
deletion mutants. These results suggest that the
transforming function required from the ElA region
upstream of domain 2 is separate from the function
promoting association with the retinoblastoma
product.
It appears that the sequences upstream from
domain 2 constitute several different regions. The
nonconserved region (residues 80-120) between
conserved domains 1 and 2 is dispensable for retino-
blastoma product binding and essentially all other
known ElA activities. This region is highly variable
both in sequence and in length in the E1A gene
products of various adenovirus serotypes.
The highly conserved region that extends from
approximately residue 40 to residue 80 may play a
significant role in ElA transformation functions, but
it is not absolutely essential. Residues from at least
50 onward in domain 1 are not required for transfor-
mation, although this region appears to be required
for stable association with the retinoblastoma prod-
uct. Nevertheless, considering the known properties
of the retinoblastoma product, it is unlikely that the
association between the E1A and retinoblastoma
products is not required for ElA function. We
suggest that whereas the second domain constitutes
an essential active site for transformation and
retinoblastoma product association (consistent with
our demonstration that a single amino acid substitu-
tion in domain 2 abolishes transformation activity
and retinoblastoma product binding), the first
conserved region, at least from residues 50 to 80,
functions more as a stabilizer of this association, or
of ElA structure or function, than directly as an
active site.
Failure to detect retinoblastoma association with
domain-1 deletion mutants may not reflect lack of
functional association in vivo, since these mutants
retain appreciable transformation activity. This
would be consistent with the properties of the E7
transforming gene of the human papillomaviruses.
The E7 gene product has a transforming activity
similar to that of the E1A products, and a region
highly homologous to ElA domain 2. However, the
E7 protein shows only limited homology with E1A
conserved domain 1. Deletion of E1A residues 51-116
removes most of the sequences that are not homol-
ogous between E1A and E7, making the E1A deletion
product look very similar to the wild-type E7 prod-
uct. The transforming activity and lack of detect-
able retinoblastoma product association in the 51-116
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deletion mutant mimic the properties
of the E7 prod-
uct in that retinoblastoma
product association with
the E7 product has not been
detected by coimmuno-
precipitation of products expressed intracellularly,
but has been detected in vitro. We are currently as-
sessing the ability of the 51-116 product to associate
with the retinoblastoma product in vitro.
Although most of conserved domain 1 is not
essential for transforming activity, there does appear
to be an essential upstream region. It has been known
for several years that loss of the first 14 residues from
the E1A proteins does not destroy the E1A-trans-
forming function, but we have found that a deletion
from residues 15 to 35 abolishes this activity. The
boundaries of this deletion lie entirely upstream of
the recognized conserved boundaries of domain 1.
Although loss of function in a deletion mutant does
not mean necessarily that the deletion removes an
essential active site, the mutant peptide in this case
is as stable as the wild-type E1A proteins, and co-
operates efficiently in trans with a domain-2 dele-
tion product, so its defect is not due to disruption
of domain-2 structure. The deletion product associ-
ates very stably with the retinoblastoma product, so
this also is not the function lost by this deletion. This
mutant demonstrates clearly that association with
the retinoblastoma product is not sufficient for E1A-
transforming activity.
Since the E1A products associate with several
cellular products, it is possible that at least one other
association is required for E1A-transforming activity,
or there may be an alternative biochemical function
required. We are continuing work to determine the
biochemical nature of the activity required and to
understand the structural and functional relation-
ships between E1A active sites and those of the
transforming proteins of other classes of DNA tumor
viruses.
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The Protein Immunochemistry Laboratory is divided
into two units, one doing basic research and the other
serving as a central facility for the production of
monoclonal antibodies. The monoclonal antibody
facility is supervised by Carmelita Bautista and is
ably staffed by Margaret Falkowski and Susan Allan.
During the past year, this facility has produced over
700 hybridoma cell lines that secrete antibodies
specific for 15 different antigens. This work has been
done in close collaboration with many other groups
at Cold Spring Harbor Laboratory, and the resultant
antibodies are currently being used by many of the
Cold Spring Harbor research groups.
The research in the Protein Immunochemistry
Laboratory has focused on understanding the bio-
chemical activities of the adenovirus E1A proteins.
In particular, we have concentrated on understand-
ing the ability of E1A to transform cells in culture.
ElA has been studied intensely over the last several
years, mostly concentrating on two of its functions:
trans-activation and transformation. Studies from
a number of laboratories have shown that these two
activities map to different regions of the E1A pro-
teins, supporting the hypothesis that these activities
are distinct biochemical functions. Two regions of
the E1A protein sequence are required for transfor-
mation, and these regions correspond to amino acid
sequences that are highly conserved between E1A
proteins from various serotypes of adenoviruses.
These sequences are known as conserved regions 1
and 2, and studies from many laboratories have
shown that these regions are important for E1A-
mediated transformation (see, e.g., E. Moran in the
Adenovirus Genetics section).
Our studies and those of other laboratories have
shown that when the E1A proteins are introduced
into mammalian cells, they form stable protein/
protein complexes with cellular polypeptides. At
present, there are ten cellular proteins that are known
to bind either directly or indirectly to ElA. The pro-
teins are known by their relative molecular weights
of 300K, 130K, 107K, 105K, 90K, 80K, 60K, 50K,
40K, and 28K. Much of the work in the Protein
Immunochemistry Laboratory centers on under-
standing the function of these various E1A /cellular
protein complexes.
Cellular Proteins That Are Targets for
Transformation by Adenovirus E1A
P Whyte, N. Williamson, E. Harlow
At least ten cellular proteins are known to form
complexes with the adenovirus E1A proteins. The
three most abundant of these proteins have relative
molecular weights of 300K, 107K, and 105K (p105-
RB). To determine in which of the E1A activities
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these proteins complexes might participate, the bind-
ing sites for these proteins on E1A were determined.
The regions were mapped using a series of deletion
mutants and were found to include two evolution-
arily conserved regions encoded within the first exon
of E1A. Amino acids 1-76 contained the binding site
for the 300K protein and amino acids 121-127 con-
tained the binding site for the 107K protein. The third
cellular protein, p105-RB, appeared to interact with
sequences from two noncontiguous regions of the
E1A polypeptide chain. This interaction required the
presence of amino acids 30 to 60 and 121 to 127. The
location of the binding sites for these proteins
coincided with the regions of E1A that are required
for the transforming function of E1A. These results
suggest that these interactions may be important
elements of the transforming activity of E1A.
The 105K Protein That Binds to E1A Is
the Product of the Retinoblastoma
Anti-oncogene
P Whyte, K. Buchkovich, M. Raybuck, E. Harlow
[in collaboration with J. Horowitz, S. Friend,
and R. Weinberg, Whitehead Institute]
The E1A proteins of adenovirus are required for viral
transformation. These proteins form stable com-
plexes with several cellular proteins, and mutational
analysis has revealed that the binding sites for three
of these cellular proteins coincide with the regions
of E1A required for cellular transformation in col-
laboration with an activated ras gene. This correla-
tion has led us to hypothesize that these cellular
proteins are targets for E1A-mediated transformation.
We have demonstrated by peptide mapping and
immunochemical analyses that one of the E1A-
associated proteins, p105, is the product of the
retinoblastoma gene (RB-1). The RB-1 gene was first
identified as a locus responsible for predisposition
to retinoblastoma. The disruption of both copies of
this gene has been linked to the appearance of
retinoblastomas and other related tumors, suggest-
ing that the RB-1 gene product may be a component
of a regulatory pathway responsible for inhibiting
cellular proliferation. Since inactivation of genes
such as RB leads to tumor growth, these proteins
have been described as tumor suppressors or anti-
oncogenes. The product of the RB gene was first
identified by Lee et al. (Nature 329: 642 [1987]).
These authors showed that the RB gene product was
a nuclear phosphoprotein with a relative molecular
weight of approximately 110K. The similar size and
subcellular localization prompted us to compare the
RB protein with the E1A-associated 107K and 105K
polypeptides. These studies have shown that the RB
polypeptide and the 105K protein comigrate on one-
dimensional gels and yield identical patterns on
Cleveland partial proteolysis experiments. In ad-
dition, antibodies specific for the 105K E1A-associ-
ated protein will bind directly to the RB protein made
in vitro. Likewise, antibodies made to peptides whose
sequence was deduced from the RB-1 cDNA confirm
that the E1A proteins form a complex with the RB
gene product, now known as p105-RB. The demon-
stration of the p105-RB/E1A complex is the first
example of an association between an anti-oncogene
and an oncogene.
The RB Protein Is a Common
Target for Transformation
by DNA Tumor Viruses
N. Dyson, L. Duffy, E. Harlow [in collaboration
with K. MOnger, B. Werness, and P Howley,
National Cancer Institute]
The RB gene is the best-characterized example of
the tumor suppressor genes or anti-oncogenes. These
genes are thought to function in the negative
regulation of cellular proliferation. Recently, the RB
protein has been shown to form stable protein/
protein complexes with the transforming proteins of
two DNA tumor viruses, the adenovirus E1A protein
(see the previous report) and SV40 large T antigen
(DeCaprio et al., Cell 54: 263 [1988]). To investigate
the association between these and other proteins with
the RB anti-oncoprotein, we have used assays that
demonstrate complex formation in vitro. In these
experiments, retinoblastoma proteins are synthesized
in vitro in rabbit reticulocyte lysates. Radiolabeled
RB proteins are then mixed with lysates containing
a protein of interest. If complex formation occurs,
the radiolabeled RB protein can be detected after
immunoprecipitation using antibodies specific for
the protein of interest.
Using this assay, we have shown that large T
antigens from all of the commonly used polyo-
mavirus-type viruses will bind to the human RB
protein. These include the human BK and JC virus,
baboon SA12 virus, rhesus SV40, hamster lympho-
tropic virus, and the prototype mouse polyomavirus.
Similar experiments using the mouse RB protein
yielded analogous results. The observation that all
of these viral large T antigens are capable of binding
suggests that interactions with p105-RB are a com-
mon feature of these virus infections.
Neither the polyomaviruses nor the adenoviruses
are thought to be associated with human cancer, but
they can cause tumors in rodents. The assay de-
scribed above has been used to demonstrate that the
E7 oncoprotein of the human papillomavirus type
16 can form similar complexes with p105-RB. Human
papillomavirus type 16 is found associated with
approximately 50% of cervical carcinomas. These
results suggest that these three DNA viruses may
utilize similar mechanisms in transformation and
implicate RB binding as a possible step in human
papillomavirus-associated carcinogenesis.
Mapping the Regions of the
RB Protein Required for the
Interaction with Adenovirus
E1A and SV40 Large T Antigen
Q. Hu, N. Dyson, E. Harlow
The protein product of the RB gene is thought to
function in a pathway that restricts cell proliferation.
Recently, transforming proteins from three different
classes of DNA tumor viruses have been shown to
form complexes with the RB protein (p105-RB).
Genetic studies suggest that these interactions with
p105-RB are important steps in transformation by
these viruses. It is therefore possible that these viruses
modulate p105-RB function through these asso-
ciations.
To understand the function of the p105-RB/viral
oncoprotein complexes better, we have mapped the
regions of the RB protein that are necessary for
association. Using polymerase chain reaction (PCR)
technology, we have prepared and tested a series of
mutants for their ability to form complexes with
adenovirus E1A and SV40 large T antigen. Labeled
RB proteins, synthesized using an in vitro transla-
tion system, were incubated with E1A-containing
lysates or with purified T antigen, and complex
formation was demonstrated by coprecipitation us-
ing anti -E1A or anti-T-antigen monoclonal antibod-
ies. Two noncontiguous regions of RB were found
to be sufficient for complex formation with the viral
proteins. Similar portions of RB were required for
complex formation with E1A or large T antigen,
although we have observed slight differences in
patterns of RB coprecipitation by E1A or T antigen
with some of the mutants. At present, the two regions
needed for binding include a fragment of 205
residues (amino acids 385-590) and one of 132
residues (amino acids 640-772). This second region
contains the retinoblastoma deletion found in the
J82 bladder carcinoma cell line, previously shown
to be unable to bind to E1A.
Phosphorylation of the RB
Protein during Specific
Phases of the Cell Cycle
K. Buchkovich
The RB gene product (p105-RB) is a nuclear phos-
phoprotein found in a wide variety of tissues and
cells. It is referred to as the product of an anti-
oncogene or tumor-suppressor gene because of its
hypothesized role as an inhibitor of cellular prolifer-
ation. Two lines of evidence support the hypothesis
that p105-RB functions in the control of cell prolifer-
ation. First, extensive genetic studies of RB patients
have demonstrated a correlation between the absence
of the RB-1 gene and tumor formation (for review,
see Benedict, Adv. Viral Oncol. 7: 19 [1987]). Second,
the reintroduction of the RB-1 gene into cells lacking
a functional p105-RB protein reduces the growth rate
and tumorigenicity of these cells (Huang et al.,
Science 242: 1563 [1988]). The presence of p105-RB
in various cell types suggests that its role is not tissue-
specific but probably is performed throughout the
body and throughout development. The presence of
both the mRNA and protein in embryonic and
rapidly proliferating cells raises the possibility of
posttranslational control of the antiproliferative
activity of p105-RB. Our results show that p105-RB
exists in at least two forms generated by posttrans-
lational modification. During the cell cycle, p105-
RB is phosphorylated in a phase-specific manner.
In the GI phase of the cell cycle, p105-RB exists in
an unphosphorylated form. Beginning in the S phase,
p105-RB is phosphorylated. We hypothesize that
phosphorylation may be a reversible switch to ensure
that p105-RB signals are given at the proper time
during the cell cycle.
The 107K Cellular Protein That
Binds to Adenovirus E1A also
Binds to the Large T Antigens
of SV40 and JC Virus
N. Dyson, K. Buchkovich, P. Whyte, E. Harlow
The association between the RB protein (p105-RB)
and the large T antigen of SV40, the E1A proteins
of adenovirus, or the E7 protein of human papillo-
mavirus type 16 is thought to be an important step
in transformation by these viral oncogenes. All three
proteins share a small region of amino acid homology
that is necessary for high-affinity binding with p105-
RB. Mutations of this homology region have been
shown to reduce drastically the frequency of transfor-
mation mediated by the E1A or large T oncogene.
In addition to being required for high-affinity
interactions with p105-RB, for E1A this small region
is also sufficient for interaction with a second cellular
protein of 107,000 daltons (107K).
Recently, we have shown that in SV40- or JCV-
transformed human cells, immunoprecipitations of
the large T antigens contain a polypeptide that
comigrates with the cellular E1A-associated 107K
protein. Partial proteolysis studies have confirmed
that the 107K polypeptides coprecipitated with
monoclonal antibodies specific for all three viral pro-
teins are identical. Several experimental approaches
have confirmed that the 107K proteins found in the
large T antigen immunoprecipitations are detected
as a result of complex formation. First, on sucrose
gradients, the 107K protein copurifies with a portion
of the large T antigen. Second, six monoclonal
antibodies that recognize six different epitopes on
T antigen all coprecipitate the 107K protein, indicat-
ing that the 107K polypeptide must be either closely
related to T antigen or complexed with it. Third,
complexes between T antigen and the 107K protein
were formed following in vitro mixing. To distinguish
the 107K protein from p105-RB, cells carrying
homozygous deletions for the retinoblastoma locus
were infected with adenovirus, and lysates were
immunoprecipitated with anti -E1A antibodies. Full-
length 107K protein was present in these cells,
showing that the 107K and p105-RB proteins are
encoded by separate genes. Although p105-RB and
107K are encoded by different genes, these polypep-
tides have several characteristics in common and may
have similar or related structures at their binding sites
for E1A. The demonstration of complexes between
107K and the large T antigens of SV40 and JCV
60
suggests that these associations may represent
another component of a common mechanism for
transformation between adenoviruses and polyoma-
viruses.
Production of Monoclonal Antibodies
Specific for the E1A-associated
Cellular Proteins
L. Duffy, B. Faha, A. Giordano, P. Whyte, E. Harlow
Over the course of our studies with the E1A polypep-
tides, we have identified a number of cellular proteins
that bind to E1A. Genetic and physical studies have
shown that many of these interactions are likely to
be important for E1A-mediated activities. One of the
major methods used to study these interactions and
the cellular proteins themselves has been to use
immunochemical reagents. The production of anti-
bodies that recognize these proteins directly has been
an important part of our work. To prepare these re-
agents, E1A antibodies were purified and covalently
attached to appropriate solid supports. Large-scale
preparations were then used to immunoaffinity
purify E1A and its associated proteins from trans-
formed cells. The resulting proteins were injected into
mice for the production of monoclonal antibodies.
These studies have produced approximately 20 hy-
bridomas, 2 of which have been used extensively. C36
is specific for the p105-RB retinoblastoma protein,
and C160 recognizes the 60K cellular protein. These
antibody production experiments are continuing as
we attempt to prepare good reagents for all of the
cellular proteins that bind to E1A. Only one of these
cellular proteins has been studied in detail, the
retinoblastoma p105-RB protein. The cDNA for this
protein is available, and we have been attempting to
express this protein in bacteria to facilitate antibody
production.
Screening Human Tumor Cell
Lines for Loss of Potential
Anti-oncoproteins
W. Reece, P Whyte, E. Harlow
One of the hallmarks of tumor suppressor genes is
that both alleles of a candidate gene are mutated in
certain tumors. This feature is best demonstrated in
the case of the RB-1, where both copies of this gene
are mutated in all of the retinoblastoma tumors that
have been characterized to date. The mutations of
the RB-1 gene often lead to loss of the RB protein.
If this characteristic of the RB-1 gene is common
to other tumor suppressor genes, then candidate
tumor suppressors may be able to be identified by
the absence of a protein in tumor cell lines. All of
the proteins that bind to the adenovirus E1A
polypeptides are potential tumor suppressor genes;
therefore, we have been screening human tumor lines
for the absence of these proteins. Cell lines from
tumors with known chromosomal changes were
grown in tissue culture, infected with adenovirus, and
immunoprecipitated with antibodies specific for
E1A. One of the first cells that showed changes in
the E1A-associated proteins was a bladder carcinoma
cell line, known as J82. J82 cells produce a truncated
retinoblastoma protein. After the initial identifica-
tion of the mutated protein, the genetic lesion was
characterized by J. Horowitz and colleagues at the
Whitehead Institute. We have continued to screen
additional lines, and approximately 100 cell lines
have been analyzed using this technique. Several
other potential mutations in the retinoblastoma gene
have been identified, and we are currently studying
several cell lines that show changes in the 107K E1A-
associated protein.
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oncogene products can be deduced from the se-
quence of cDNA molecules on the basis of the
genetic code. However, the proteins that are made
from the oncogenes are modified enzymatically
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following translation. These modifications change
the nature of the protein, both in structure and in
function. Why does a cell use modifications to alter
the function of proteins when the genes themselves
can be turned on and off? Modification on proteins
provides very fine regulation of function and is often
reversible. Modifications are the fine tuning of the
systems in cellular physiology and are critical to
proper function. During the past year, our attention
has focused on one particular type of modification,
the phosphorylation of oncogene products by en-
zymes called protein kinases. In addition, we have
obtained a new instrument, the plasma-desorption
mass spectrometer, for the detailed analysis of pro-
teins and their modifications. We continue to use
state-of-the-art instruments to study the biochem-
istry of proteins.
Modification of Oncogene Products
D. Carroll, N. Santoro, M. Vandenberg, D. Marshak
The overall objective of our current research is to
elaborate upon our earlier observations that have
linked casein kinase II (CK-II) activity to the induc-
tion of cell growth and the phosphorylation of the
viral oncoprotein SV40 large T antigen (LTag) and
the adenovirus E1A-13S transcription product, as
well as the nuclear oncoproteins c-Myc and c-Fos.
To this end, we are taking advantage of several dif-
ferent biochemical strategies using purified E1A,
LTag, and Myc protein and derivatization of phos-
phoserine to S-ethylcysteine to identify CK-II phos-
phorylation sites.
Purified, LTag and Myc proteins maximally incor-
porate 5 and 7 moles of phosphate per mole of
protein, respectively, with Km values of 300 (LTag)
and 150 nm (Myc). The synthetic peptides E1A-001
and MYC-019, whose primary structure spans the
predicted CK-II phosphorylation domains within the
E1A and Myc proteins, respectively, can competi-
tively inhibit CK-II-dependent phosphorylation of
the full-length proteins with K1 values of around
500 nM.
In most of the nuclear oncoproteins we have
predicted as being substrates for CK-II, the primary
structure of the motif is characterized by clusters of
serine residues. This is particularly true for LTag and
Myc. Phosphorylation sites on LTag have been
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mapped last year in this lab and in other laborato-
ries. It is clear that CK-II phosphorylates Ser-107,
but there also is phosphorylation at Ser-111 and Ser-
112 that have not been well defined. Recent develop-
ments in microchemical analysis have allowed for
determination of specific phosphorylated serines. To
sequence phosphorylation sites on the peptides, we
have used 13-elimination of phosphoserine with bar-
ium hydroxide, followed by reaction of the product,
dehydroalanine, with ethanethiol. This results in the
stoichiometric conversion of phosphoserine to S-eth-
ylcysteine and the kinetics and extent of phosphory-
lation of serine can be quantitated accurately. This
approach is unique in its ability to permit the identifi-
cation of phosphorylated serines in regions charac-
terized by the presence of multiple serines. Using
synthetic peptides spanning the serine clusters found
in Myc and LTag, we have derivatized the phosphor-
ylated serines and determined the kinetics of CK-II-
dependent phosphorylation. This approach has
permitted the observation that the phosphorylation
of adjacent serines is likely to be cooperative, with
the negative charge contributed by the phosphate on
one serine making the neighboring unphosphory-
lated serine a more likely substrate for CK-II. Such
cooperativity could likely prove to be highly signifi-
cant in identifying the mechanisms underlying phos-
phorylation-dependent regulation of these protein
activities.
Further analysis of the kinetics of LTag phos-
phorylation demonstrated that the incorporation of
phosphate into the intact protein was nonlinear.
Increasing proportions of substrate (LTag) resulted
in an increasing velocity of the enzyme. These data
suggested that LTag was activating its own
phosphorylation by CK-II. To test this hypothesis,
we phosphorylated Myc protein at saturating levels
with CK-II and added catalytic amounts of LTag.
In the absence of LTag, the phosphorylation kinetics
of Myc were linear, and in the presence of LTag,
activation of CK-II phosphorylation of Myc was
observed. Analysis of the sequence of LTag has
allowed us to predict the domain of LTag that has
the activating property. We are currently studying
synthetic peptides from LTag as activators of the
enzyme. Preliminary studies of COS I cells that
overproduce LTag indicate that there is much greater
CK-II activity in these cells than in the parent line,
CV-1. Our observations may provide insight into the
mechanism of LTag transformation of cells and the
role of CK-II in viral oncogenesis.
Structure and Function of CK -II
D. Carroll, D. Marshak
We are continuing work in developing reagents and
purifications to analyze CK-II structurally. Using
purified CK-II from bovine liver, we have raised
polyclonal antibodies in rabbits to the enzyme. These
antibodies were quite difficult to elicit in rabbits, and
efforts to immunize mice for monoclonal antibod-
ies failed. The polyclonal antibodies react on dot-
blot experiments on nitrocellulose, but attempts to
do Western blots have been unsuccessful. This sug-
gests that the antigenic site for these antisera may
overlap two of the subunits of the protein, and gel
electrophoresis that separates the subunits destroys
the antigenicity. To develop more reagents for CK-II,
we are trying to sequence the regulatory subunits to
develop synthetic peptide antigens for immunization.
In addition, we plan to use oligonucleotide probes
to isolate cDNA clones of the regulatory and cata-
lytic subunits of the enzyme. Brain tissue is a very
rich source of CK-II, so we are purifying the enzyme
from bovine brain. Initial purification steps indicate
that the brain enzyme is similar but not identical to
that of liver or lung.
Protein Kinases in Cell Growth
D. Carroll, D. Marshak, S. Coleman
Last year, we began to study the function of CK-II
in cultured cells under various growth conditions.
Experiments were conducted to study CK-II induc-
tion during the cell cycle. WI-38 cells, a human lung
fibroblast cell line, were serum-starved to synchronize
in Go. After serum stimulation, CK-II levels and
cAMP-dependent protein kinase activities were
measured over a 48-hour time course. CK-II was
induced sixfold by 15-30 minutes, with a correspond-
ing eight- to tenfold decrease in cAMP-dependent
protein kinase activity. These changes in kinase ac-
tivities were independent of protein synthesis. At 16
hours, when thymidine incorporation into DNA
began, cAMP-dependent protein kinase levels re-
covered to near basal levels, whereas CK-II showed
a recovery followed by a second phase of induction.
These results suggest that there is an early phase of
CK-II induction by serum growth factors, coincident
with the transcriptional induction of the early ac-
tivatable genes, such as c-myc and c-fos. In addition,
there appears to be a second phase of induction
coincident with the S phase. We have followed up
on these observations and have noted that there is
an elevation in phosphate incorporated into the
endogenous c-myc coincident with the 0.5- and 12-
hour time points and that this increased phosphory-
lation can be blocked by the CK-II competitive
substrate MYC-019. This observation underscores
the likely role of CK-II in modifying growth-related
proteins such as c-Myc. Our future experiments on
CK-II in cell growth will focus on the cell cycle of
mammalian cells.
Further experiments were conducted to link CK-
II to other signal transduction pathways. Phorbol
esters stimulate CK-II levels, presumably through a
protein-kinase-C-mediated event. Preloading of cells
with dibutyryl cAMP (which activates the cAMP-
dependent protein kinase) blocks the phorbol ester
induction of CK-II. Our working hypothesis in this
area is that protein kinase C is a positive regulator
of CK-II and that cAMP-dependent protein kinase
is a negative regulator of CK-II. Protein tyrosine
kinases have been shown by other laboratories to
affect CK-II activities in growth-factor-stimulated
cells. These effects are relatively modest and are
indirect, probably involving other intermediate
protein kinases. Experiments are now under way to
evaluate the roles of raf kinase and cdc2 kinase in
the regulation of CK-II activity in signal transduc-
tion. During the coming year, we are hopeful that
a new chapter in the ever-expanding story of signal
transduction will be written linking CK-II to various
cellular processes.
Mass Spectrometry of Proteins
and Peptides
D. Marshak, G. Binns
During 1988, Cold Spring Harbor Laboratory
became one of the first sites for a new type of
instrument, a plasma desorption, time-of-flight mass
spectrometer. This instrument is unique in its ability
to measure the molecular weight (mass) of large
macromolecules, including proteins, very accurately.
Most laboratories would estimate the molecular
weight of a protein by its relative mobility in an
electric field, a process known as electrophoresis.
Even under ideal circumstances, these size estimates
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are only within about 1000 atomic mass units. With
our new mass spectrometer, molecular weight can
be measured to within 0.1 mass units for small
proteins and 1-10 mass units for larger proteins. This
capability becomes essential when searching for
modifications of proteins. For example, much of our
work involves phosphorylation of serine residues on
proteins. This modification adds 80 mass units to
a protein, a change that is easily demonstrated by
the mass spectrometer. However, phosphorylated
proteins often show anomalous mobility under
electrophoresis. Thus, the use of mass spectrometry
opens new doors to the analysis of modifications on
proteins.
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The mass spectrometer is especially helpful in the
analysis of synthetic peptides. We synthesize peptides
on a solid support, usually a modified polystyrene,
using symmetric anhydride activation of N-a-t-Boc
amino acids. This year, we have begun using a new
solvent, N-methyl-pyrrolidone, with an addition of
dimethylsulfoxide for the final coupling. This solvent
system causes increased swelling of the polystyrene
resin and more efficient coupling of the amino acid
derivatives. The peptides are cleaved from the sup-
port using hydrogen fluoride (HF) in the presence
of scavengers, such as anisole and thiocresol. Strong
acids such as HF can lead to several unwanted side
reactions including dehydration, oxidation, electro-
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philic aromatic substitution, alkylation, condensa-
tion, and various miscellaneous free radical addi-
tions. The mass spectrometer allows us to screen the
products of the synthesis and to eliminate the un-
desirable side products rapidly. The crude peptide
product is subjected to preparative HPLC at high
flow rates, 40-75 ml/min on columns that are 49-57
mm in diameter. Fractions that are collected from
this chromatography are analyzed by mass spectrom-
etry, and the desired fraction is identified in less than
1 hour. Thus, the purification of a synthetic peptide
is reduced from 1-2 weeks to 1-2 days.
During the course of our analyses of synthetic
peptides by mass spectrometry, we noticed that long
runs on the instrument resulted in a discrete pattern
of fragments from the peptide. Our lab and other
investigators have used the plasma-desorption mass
spectrometer to measure the mass of the whole mol-
ecule, but we now realize that the complete structure
of a peptide can be deciphered from its fragmenta-
tion pattern. Thus, we can obtain both molecular
weight and structural information from the mass
spectrometer. Figure 1 shows the mass spectrum of
an analog of angiotensin I, a peptide involved in the
control of blood pressure. The peak corresponding
to the intact molecule at a mass of 1283 is off scale
in order to show the smaller peaks of fragment ions
that describe the complete structure. We are very
enthusiastic about the potential for structural anal-
ysis by mass spectrometry.
PROTEIN SYNTHESIS
M.B. Mathews
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A. Maran R. Galasso P.A. Wendel
G.F. Morris H. Goodrich
The Protein Synthesis group continues to investigate
the control of gene expression at several levels. In
addition to the adenovirus system, which for many
years has been a mainstay of the group's work,
studies of the AIDS human immunodeficiency virus
type 1 (HIV-1) now form a substantial fraction of
our research effort. There have also been some
changes in personnel. Drs. M. Kessler and T. Pe'ery
joined the lab as postdoctoral fellows in the latter
part of the year, and Drs. A. Maran and E. Moran
moved on. Betty Moran is continuing her studies of
the transformation-related activities of the adenovi-
rus E1A gene in James Lab, and her research report
will be found in the Adenovirus Genetics section.
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Adenovirus VA RNA and
Translational Control
K.H. Mellits, L. Manche, P.A. Wendel, A. Maran,
M.B. Mathews
Unlike most adenovirus genes, which encode
proteins and are transcribed by RNA polymerase II,
the adenovirus VA RNAs are noncoding and are
transcribed by RNA polymerase III. Nevertheless,
they play an equally important role in protein
synthesis. These two RNAs, VA RNA, and VA
RNA'', are both about 160 nucleotides long, and
VA RNA1 in particular becomes very abundant at
late times of infection. As described in previous years'
reports, VA RNA, is required for the efficient
synthesis of proteins at late times of adenovirus
infection, so that cells infected with a mutant ade-
novirus (d1331) that fails to make VA RNA1 synthe-
size proteins at less than one tenth of the normal rate.
The mechanisms underlying this inhibitory process
have been worked out in considerable detail. In the
absence of VA RNA1, translation is blocked by the
action of a cellular protein kinase known as DAI,
the double-stranded (ds) RNA-activated inhibitor of
protein synthesis. In the presence of dsRNA, which
is probably transcribed from the viral genome itself,
this kinase phosphorylates the initiation factor eIF-2,
thereby sequestering the recycling factor (GEF or
eIF-2B) in a tight complex and blocking the initiation
step of protein synthesis. We have now purified the
DAI enzyme and are continuing our efforts to
ascertain the mechanism by which VA RNA prevents
the activation of DAI.
As a first step, we generated linker-scanning and
deletion mutants within the 3' half of the VA RNA'
molecule. The mutants were tested in a transient
expression assay for their ability to correct the protein
synthesis defect observed in d1331-infected cells.
Based on the knowledge that VA RNA possesses
short duplexed regions and that such short stretches
of dsRNA are unable to activate DAI, we had
speculated that the duplexed regions would play an
important role in the function of VA RNA. Surpris-
ingly, we found that activity was retained after
deletion of a region near the center of the gene,
nucleotides 72-85, which forms part of one of the
longer duplexes. On the other hand, activity was
drastically reduced by mutations located further to
the 3' side of this region. Analysis of the secondary
structure of wild-type VA RNA1 using the nuclease
sensitivity technique allowed us to derive a model
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for its secondary structure. Similar analysis of mu-
tant RNAs suggested that a complex stem and loop
structure located roughly in the center of the pro-
posed secondary structure model is important for
VA RNA's function. This central stem-loop structure
is flanked by duplex regions that seem to be necessary
for its stability. When the wild-type flanking se-
quences were replaced with foreign sequences, ac-
tivity was retained provided that the foreign se-
quences restored base pairing. These findings
emphasize that maintenance of duplex structure is
more important than sequence conservation in some
regions of the molecule, whereas in other regions,
more intricate structural features are required.
We have begun to examine the interactions be-
tween DAI, VA RNA, and dsRNA at the biochemi-
cal level. Wild-type VA RNA binds to DAI and
blocks the binding of dsRNA to DAI at concentra-
tions similar to those that are effective in vivo. This
result raises the possibility that VA RNA may func-
tion by competing, directly or indirectly, for the
binding of dsRNA to the enyzme. To test this idea
further, we are in the process of assaying the ability
of mutant VA RNAs to bind to DAI and to compete
with dsRNA for binding to DAI. Preliminary results
suggest that there is no simple relationship between
DAI binding and functional activity, but current data
are limited by the difficulty of producing the mutant
RNAs in adequate quantities. To alleviate this
problem, we have cloned the VA RNA, gene into a
vector containing the T7 RNA polymerase promoter
so that copious quantities of the RNA can be
synthesized in vitro. Wild-type VA RNA made in this
manner is fully functional, and we are now transfer-
ring the mutant VA RNA genes into the same vector
so that suitably large quantities of these RNAs can
be synthesized. In principle, the T7 system also offers
the possibility of producing the wild-type transcript
on a scale sufficient to attempt a determination of
its tertiary structure using X-ray crystallographic
methods, and we have initiated experiments toward
this end.
Regulation of Gene Expression
by ElB
C. Herrmann, M.B. Mathews
We have been studying the regulation of gene
expression by a product of the adenovirus early
region 1B. This region, together with ElA, is re-
sponsible for the ability of adenoviruses to transform
cells. The E1B region encodes two major protein
products of 55,000 and 19,000 daltons, which have
both been implicated in the regulation of viral gene
expression and in the complete transformation of
primary rodent cells. Our attention has been focused
on the smaller of these proteins, the 19K tumor
antigen, and its role in increasing the expression of
other genes. In the initial stages of this work, we
employed infection and transient expression tech-
niques to introduce the gene for the 19K protein into
cells. We found that the 19K protein increased
expression from several adenovirus promoters and
from a cellular promoter in a sequence-independent
manner. This increase occurred at or before the level
of mRNA accumulation in the cytoplasm, consistent
with elevated transcription from the various pro-
moters. To facilitate further study, we have now
constructed human cell lines that produce the 19K
protein under the control of the inducible metallo-
thionein promoter, allowing a high level of expres-
sion of the 19K protein. The 19K-expressing cell lines
were characterized for 19K DNA, mRNA, and pro-
tein levels and were shown to complement 19K
mutant viruses for their cyt (enhanced cytopathic
effect) and deg (DNA degradation) phenotypes,
indicating that the stably introduced gene is func-
tional.
To examine the effect of the 19K protein on the
expression of heterologous genes, a test promoter
fused to the chloramphenicol acetyltransferase (CAT)
gene was transfected into a 19K-expressing cell line
or a control cell line, and expression from each
promoter was assayed by measuring CAT activity.
The promoters tested were the adenovirus early (E1A,
E1B, E2e, E3, and E4) and late (MLP, IX, IVa2, and
E2L) promoters, the SV40 early promoter linked to
its enhancer, the human immunodeficiency virus
type 1 (HIV-1) long terminal repeat (LTR), and the
promoter for the cellular 70-kD heat-shock protein
(hsp70). Without exception, these promoters showed
greatly increased activity in the 19K-expressing cell
line compared to the control line. Furthermore, we
found that the 19K protein increased expression of
the VA RNA, gene which is transcribed by RNA
polymerase III. These results indicate that the 19K
protein acts in a nonspecific manner. The effect of
the 19K protein appears to be limited to transfected
genes, however, since we could not detect an increase
in the synthesis of the endogenous hsp70 protein.
We are currently examining the levels of other cellular
proteins in the 19K-expressing and control cell lines
by two-dimensional gel analysis.
We have been interested in determining the level
of control at which the 19K protein acts to increase
the level of expression of transfected genes. Our
results show that one role of the 19K protein is to
stabilize transfected plasmid DNA. In the absence
of the 19K protein, the majority of the input DNA
is degraded, especially at late times posttransfection.
In 19K-expressing cells, however, a higher level of
DNA is retained (approximately eightfold greater),
suggesting that the increase in gene expression is due,
at least partly, to an increase in plasmid DNA levels.
The stabilization of plasmid DNA is not dependent
on the transcriptional activity of the plasmid, since
plasmids lacking promoters were stabilized to the
same extent as plasmids containing actively tran-
scribed promoters. Although we cannot rule out
subsidiary effects at the transcriptional level, ex-
periments using virus-infected cells indicate that the
19K protein does not have a direct effect on transcrip-
tional activity as measured by a nuclear runoff assay;
so it seems likely that the primary effect of the 19K
protein in transfected cells is to increase the level of
DNA, which in turn leads to a higher rate of
transcription. Further experiments are under way to
assay directly for a possible transcriptional action
of the 19K protein in transfected cells.
Stabilization of plasmid DNA explains the non-
specific action of the 19K protein and is consistent
with its role during viral infection, where it prevents
the degradation of viral and cellular DNAs. We are
in the process of testing other viral proteins that
increase gene expression in a nonspecific fashion, to
determine if stabilization of DNA is a general mech-
anism whereby gene expression can be regulated.
Regulation of PCNA
G.F. Morris, M.B. Mathews
The proliferating cell nuclear antigen (PCNA), also
known as cyclin and DNA polymerase-8 auxiliary
factor, is present in reduced amounts in nongrow-
ing cells and is synthesized at a greater rate in the
S phase of growing cells. (Its alias notwithstanding,
PCNA is unrelated to the cyclins first discovered in
sea urchins and clams and now detected in frogs and
yeast; see Genetics Section.) This pattern of expres-
sion, coupled with the demonstration that PCNA
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plays a role in DNA replication, suggested that the
availability of PCNA may regulate DNA synthesis.
To test this idea, we conducted an investigation of
the synthesis, stability, and accumulation of PCNA
throughout the cell cycle. He La cells were fraction-
ated by centrifugal elutriation, a technique that
separates cycling cells into nearly synchronous pop-
ulations of cells at various positions in the cell cycle
without the physiological stresses imposed by other
methods of achieving cell synchrony. We found that
there is an increase in the rate of PCNA synthesis,
with a peak early in the DNA synthetic, or S, phase
of the cell cycle, but the magnitude of the increase
is only two- to threefold (Fig. 1, top). This change
reflects similar changes in the amount of PCNA
mRNA. The fluctuating synthesis of PCNA main-
tains this protein at a roughly constant proportion
of the total cell protein and ensures that its cellular
concentration doubles in the cell cycle as required
for preservation of a steady state. Consistent with
these findings, the stability of PCNA does not differ
significantly from that of total cellular protein in the
synchronized He La cells.
On the basis of these observations, we conclude
that the synthesis of PCNA in cycling He La cells
maintains PCNA in excess of the amount involved
directly in DNA replication and that the amount of
the protein neither fluctuates significantly with the
cell cycle nor is limiting for DNA synthesis. It
remains possible, however, that cells exhibiting more
tightly controlled growth properties than He La cells
regulate the synthesis of PCNA differently during
the cell cycle. Nevertheless, consistent with its role
in DNA replication, we found that a variable
proportion of PCNA is tightly associated with the
nucleus (Fig. 1, bottom). This fraction reaches a
maximum value of about 35°7o of the total at the
peak of S phase and presumably represents those
molecules involved in replication complexes. We
believe that the recruitment of PCNA into replica-
tion complexes can account for the large fluctuations
in the immunofluorescent staining intensity pre-
viously reported for PCNA during the cell cycle.
To pursue our analysis of the expression of this
protein at the molecular level, we have cloned the
promoter for the PCNA gene. The cloned promoter
directs the synthesis of RNA with the correct size
for a properly initiated PCNA transcript in He La
nuclear extracts, and it potentiates the synthesis of
a reporter mRNA in transfected He La and 293 cells.
We are presently working to define the cis-acting
elements required for transcription of PCNA mRNA
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in both systems with a view to exploring the mecha-
nisms whereby PCNA synthesis is increased by serum
factors and by adenovirus infection.
Structure and Function of HIV-1 tat
A.P. Rice, H. Goodrich, M. Sullivan, R. Packer
Human immunodeficiency virus type 1 (HIV-1), the
causative agent of acquired immune deficiency
syndrome (AIDS), is a retrovirus with an unusually
complex genetic structure. Besides encoding the
usual structural proteins common to all nondefec-
tive retroviruses (gag, pol, env), HIV-1 contains at
least six additional genes known as yip, vpr, vpu, tat,
rev, and nef. The tat, rev, and nef genes specify
regulatory proteins that work in trans to control HIV-
1 gene expression. The nef protein acts to down-
regulate HIV-1 replication. The rev protein controls
the relative abundance of spliced and unspliced
RNAs. The tat protein functions to increase the
amount of HIV-1 gene expression. We are examining
the mechanism of action of the tat protein in the
regulation of HIV-1 gene expression.
The HIV-1 tat protein trans-activates gene expres-
sion by interacting with the so-called TAR element
located within the viral long terminal repeat (LTR)
sequence. The molecular mechanisms by which tat
acts upon the TAR element are unclear, but as
discussed in last years' report, they include increased
transcription of mRNA from the LTR as a major
(and possibly sole) component. This transcriptional
regulation by tat has been proposed to involve
antitermination. The tat protein from HIV-1 strain
HXB2 consists of 86 amino acids encoded in two
exons. The first exon encodes the first 72 amino acids
and the second exon encodes the remaining 14. To
gain further insight into structural features of the
tat protein involved in trans-activation, we have
carried out a mutational analysis of the HIV-1 tat
gene. A tat cDNA was introduced into a SV40 late
promoter-based expression vector, and site-directed
mutagenesis was used to make a collection of 24
mutant proteins. The trans-activation activities of
the mutant proteins were assayed in plasmid DNA
cotransfection experiments.
We found that a deletion mutant containing only
the first 57 amino acids retains approximately 3007o
activity, but further deletion to amino acid 48 abol-
ishes all activity. We also have found that a mutation
near the amino terminus of the protein, the deletion
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FIGURE 1 Regulation of PCNA. (Top) PCNA synthesis during the cell cycle determined
by two-dimensional gel electrophoresis. Cells were fractionated by elutriation and pulse
labeled with [35S]methionine. Equal amounts of radioactive protein from each fraction were
separated by two-dimensional gel electrophoresis in the Cold Spring Harbor Laboratory
Quest facility. Separation in the first dimension was by isoelectric focusing from high pH
to low pH (right to left). Separation in the second dimension was by SDS-polyacrylamide
gel electrophoresis (top to bottom). Only the portion of interest of each autoradiogram
is shown. The arrowhead denotes PCNA. Quantitation of PCNA synthesis by computer-
aided densitometric scanning indicated that PCNA synthesis varied about twofold during
the cell cycle, with a peak of synthesis at the beginning of S phase (Fractions 4 and 5).
(Bottom) Chromatin-bound PCNA in cycling HeLa cells. Nuclei prepared from elutriated
HeLa cell fractions were washed with saline solution to remove loosely bound PCNA.
The tightly bound PCNA was released by incubation with DNase, resolved in an SDS-
polyacrylamide gel, and electrophoretically transferred to a nitrocellulose membrane. PCNA
was detected in each fraction by reaction with mouse monoclonal antibody to PCNA and
1251-labeled rabbit anti-mouse antibody, followed by autoradiography. The chromatin-
bound PCNA in unfractionated HeLa cells is shown in lane T Lanes 1 through 10 show
the bound PCNA observed as the cell progresses from G1 (lane 1) through S (peak in
lane 6) into the G2 phase of the cell cycle (lane 10).
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of residues 3 through 6, greatly reduces activity. Our
results with mutations at the amino and carboxyl
termini agree with those of other workers in the field.
There are two regions located within the central
region of the tat protein with notable sequence
features; a cysteine-rich region and a region rich in
basic residues. The cysteine-rich region contains
seven cysteine residues between amino acids 22 and
37; the basic region contains eight lysine and arginine
residues between amino acids 49 and 57. The basic
region of the tat protein constitutes a nuclear locali-
zation signal, reminiscent of a similar sequence first
identified in SV40 large T antigen. tat expressed and
purified from Escherichia coli has been shown to
bind two metal ions, either cadmium or zinc, per
molecule and to form a homodimer, and it has been
proposed that cysteine residues play an important
role in these two processes. Several research groups,
including our own, have shown that six of the seven
cysteines are important for function, the exception
being Cys-31. Mutation of any of the remaining six
cysteine residues individually to either glycine or
serine abolishes activity of the tat protein, consistent
with the notion that these residues coordinate metal
binding and dimerization and that this is a crucial
property for function.
We have concentrated our mutagenesis on the
noncysteine residues between amino acids 18 and 47,
in most cases changing a single wild-type amino acid
to alanine. Proteins with mutations at residues 23,
24, 46, and 47 were found to be as active as wild-
type tat protein, but mutations between residues 26
and 41 greatly reduced the activity of the tat protein.
The data suggest that the precise structure of this
region of the tat protein, from residue 26 to 41, is
crucial for function. We are currently conducting
studies on wild-type and mutant tat proteins to cor-
relate biochemical properties such as metal binding
and dimer formation with functional properties.
Mechanism of trans-Activation by
HIV-1 tat Protein
M.F. Laspia, M. Kessler, M.B. Mathews, A.P. Rice
Expression of the genes of the human immunodefi-
ciency virus type 1 (HIV-1) is greatly stimulated by
the trans-activator encoded by the viral tat gene. tat
appears to interact with a sequence in the long
terminal repeat (LTR) that lies downstream from the
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site of transcriptional initiation, to increase the levels
of RNA. The tat-responsive element is called TAR,
an acronym for the trans-activation response ele-
ment. Although the detailed mechanism of trans-
activation of HIV-1 gene expression by tat is unclear,
and regulation has been suggested to occur at sev-
eral levels, we and other investigators find the pre-
dominant mode of regulation by tat to be tran-
scriptional. The 5'-untranslated region of HIV-1
mRNA, transcribed from the TAR region, is capable
of forming a secondary structure, and mutations that
alter this structure abolish trans-activation by tat.
A model for the action of tat has been proposed
which suggests that tat acts as an antiterminator,
relieving a block to transcription elongation that
occurs within the LTR.
We have made use of a recombinant adenovirus
system, containing the HIV-1 LTR fused to the
reporter gene chloramphenicol acetyltransferase
(CAT) to study HIV-1 gene expression. As described
last year, an advantage of this system is that infection
with the recombinant adenovirus provides an
efficient, controllable means to deliver an HIV-1
LTR/reporter gene fusion into human cells. Further-
more, recombinant adenoviruses can be used for
large-scale infections, providing the opportunity to
perform biochemical analysis. To determine the
sequences required for trans-activation by tat, we
introduced a number of deletions from the 5' end
of the LTR and several TAR region mutations into
the HIV/adenovirus recombinant. He La cells
expressing tat were infected with these viruses, and
CAT expression and mRNA levels were measured.
For comparative purposes, we also analyzed trans-
activation of the HIV-1 LTR by the adenovirus ElA
13S gene product. This protein, which acts to increase
transcriptional initiation, was introduced by coinfec-
tion with a wild-type adenovirus.
We found that tat increases the level of correctly
initiated mRNA by more than 50-fold (Fig. 2). E1A
also increased the level of HIV-1 RNA, presumably
by increasing the rate of transcriptional initiation.
A mutant containing a large deletion within the TAR
region lacked the ability to respond to tat but was
still trans-activated by E1A, indicating that the HIV-1
promoter does not absolutely require TAR to func-
tion. In addition to authentic full-length RNAs, a
number of short transcripts were detected that ini-
tiated correctly at nucleotide +1 and appeared to
terminate at + 55 and + 59. Physical characteriza-
tion of the short transcripts indicated that they are
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FIGURE 2 Analysis of RNA transcribed from the HIV -1 promoter in cells infected with the HIV-1 recombinant adenovirus. (A) A
riboprobe-RNase protection assay of cytoplasmic RNA isolated from HIVCATad-infected HeLa cells (HeLa), HeLa cells expressing
tat (+tat), and HeLa cells coinfected with HIVCATad and wild-type adenovirus (+adenovirus). (8) A schematic of the transcripts
and probes. Transcripts are depicted as wavy lines, initiating from nucleotide +1 on the template DNA and transcribed in a rightward
direction. U3 and R are regions of the HIV-1 LTR. The CAT gene begins at nucleotide +80. The probe was radiolabeled antisense
RNA extending from nucleotide +80 to -117. Probe fragments protected by correctly initiated full-length mRNA and short transcripts
are shown as thickened lines. An 80-nucleotide fragment is protected by full-length transcripts, whereas fragments of 55 and 59
nucleotides are protected by short transcripts.
not polyadenylated and are not produced by splicing,
consistent with the idea that they result from pre-
mature termination. The level of full-length tran-
scripts was increased in the presence of tat or of E1A.
ElA also increased the level of short transcripts by
severalfold, but tat did not. In neither case could the
level of full-length transcripts be accounted for
simply by extending the short RNAs observed in their
absence. These results are consistent with a model
that tat acts to increase the level of transcriptional
initiation as well as the efficiency of reading through
a proximal termination site. Interestingly, no short
transcripts were detected with the TAR deletion
mutant, nor was the basal level of gene expression
increased. These observations provide no support for
the idea that the TAR region acts as a terminator
of transcription.
To determine the relative contributions of in-
creased initiation and antitermination to the regu-
lation of HIV-1 gene expression, we have used nuclear
runon transcription assays to measure the distribu-
tion of RNA polymerase molecules engaged in
transcription of the HIV-1 LTR. We find that tat
causes a tenfold increase in the frequency of RNA
polymerases engaged in transcription between nu-
cleotides +1 and + 80, suggesting that tat acts to
increase the level of transcriptional initiation. We are
currently examining the effect of tat on RNA
polymerase distribution in promoter distal regions
to assess the degree to which antitermination contrib-
utes to the regulation of HIV-1 gene expression.
We have also analyzed nested deletions of the LTR
cloned into the recombinant adenovirus and found
that nucleotides upstream of -104 are dispensable
for trans-activation by both tat and ElA. Deletion
of sequences upstream of nucleotide - 48, removing
both the core enhancer elements and the Spl sites,
greatly reduced gene expression but still permitted
some trans-activation by both tat and ElA. Thus,
sequences lying downstream from - 48 seem to be
required for trans-activation by both tat and ElA.
We will now use site-directed mutagenesis to identify
promoter elements that are required for trans-
activation by both E1A and tat.
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J. Harper S. Munroe
C. Marcincuk M. Wallace
Isolation of the Spliceosome
G.C. Conway
The process of RNA splicing requires multiple
factors that bind stably to pre-mRNA, forming a
macromolecular complex called the spliceosome. My
research goal is to isolate splicing factors and na-
tive spliceosomes. Density gradient and native gel
analyses of in vitro splicing reactions can provide
fractions enriched in splicing complexes. However,
these fractions are still contaminated with endog-
enous particles that pre-exist in splicing extracts; in
the case of native gel analysis, the splicing complexes
have undergone some dissociation due to the elec-
trophoretic conditions. My approach to the isolation
of the spliceosome is to remove contaminating par-
72
In Press, Submitted, and In Preparation
Herrmann, C.H. and M.B. Mathews. 1989. Cell lines containing
the adenovirus E1B 19K protein display increased expression
of foreign genes and stabilization of transfected DNA.
(Submitted.)
Kostura, M. and M.B. Mathews. 1989. Purification and activation
of the double-stranded RNA-dependent elF-2 kinase DAI. Moi,
Cell Biol. 9: 1576-1586.
Laspia, M.F., M.B. Mathews, and A.P Rice. 1989. The tat-1 protein
increases initiation of HIV-1 transcription. (In preparation.)
Mathews, M.B. 1989. The proliferating cell nuclear antigen, PCNA,
a cell-cycle regulated DNA replication factor. In Growth control
during cell aging (ed. E. Wang and H.R. Warner). CRC Press,
Boca Raton, Florida. (In press.)
Morris, G.F. and M.B. Mathews. 1989. Regulation of proliferating
cell nuclear antigen (PCNA/cyclin) during the cell cycle. J. Biol.
Chem. (in press).
O'Malley, R.P., R.F. Duncan, J.W.B. Hershey, and M.B. Mathews.
1989. Modification of protein synthesis initiation factors and
shut-off of host protein synthesis in adenovirus-infected cells.
Virology 168: 112-118.
Rice, A.R., M. Kostura, and M.B. Mathews. 1989. Identification
of a 90 kD polypeptide which associates with adenovirus VA
RNA, and is phosphorylated by the double-stranded RNA
dependent protein kinase. (Submitted.)
Rice, A.R., F. Carlotti, and H. Goodrich. 1989. Mutational analysis
of HIV-1 tat protein. (In preparation.)
tides from nuclear extracts by density gradient frac-
tionation prior to reconstituting an in vitro splicing
reaction.
Nuclear splicing extracts have been layered onto
sucrose gradients and material fractionated by
sedimentation. There are three peaks of OD2 ab-
sorbing material: one sedimenting less than 30S, a
45S peak, and one sedimenting faster than 50S. The
material that sediments faster than 30S contaminates
spliceosome preparations isolated by density gradi-
ents and by native gels. It was hoped that fractions
less than 30S would splice exogenously added RNA,
thus providing a cleared splicing extract devoid of
large particles. Unfortunately, neither of these frac-
tions splices exogenously added pre-mRNA. How-
ever, fractions greater than 30S will complement
fractions that are less than 30S in RNA splicing.
Interestingly, if nuclear extracts are incubated with
ATP prior to gradient fractionation, fractions less
than 30S will now splice RNA, and the 45S peak of
material is reduced to one third of the original OD260
absorbance. This suggests that RNA and/or protein
components are released or degraded from fast-
sedimenting endogenous complexes. Likely splicing
factors with a large OD260 value that might shift to
upper gradient fractions are snRNPs (small nuclear
ribonucleoprotein particles). The snRNPs are known
to be involved in RNA splicing. Examination of the
RNA species in gradient fractions indicates that the
Ul and U2 snRNAs do in fact shift to upper gradient
fractions after ATP incubation. The gradient distri-
bution of two other splicing factors, SF2 and the
heat-labile factor, has also been examined. These
protein factors are present in fast-sedimenting frac-
tions in unincubated extracts but shift to upper gra-
dient fractions upon ATP incubation. Thus, it ap-
pears that splicing extracts contain fast-sedimenting
complexes that possess splicing factors. Under splic-
ing conditions, splicing factors are released from
these complexes and remain at the top of density
gradients. These top fractions constitute a cleared
extract.
I have investigated splicing complex formation
using cleared extracts and have found that spliceo-
somes formed in cleared extracts possess many
properties different from those formed in standard
nuclear extracts. These differences are apparently due
to factors not necessary for splicing that bind to pre-
mRNA in standard extracts but are missing from the
splicing complexes formed in cleared extracts. For
example, the spliceosome in cleared extracts sedi-
ments at 45S as opposed to the 50S to 60S complex
formed in standard extracts. The kinetics of spliceo-
some formation in cleared extracts is also acceler-
ated compared to those in standard extracts. These
accelerated kinetics may be due to the prior release
of splicing factors from endogenous complexes as
well as reduced competition with endogenous heter-
ogeneous nuclear RNA (hnRNA), which is missing
in cleared extracts. Finally, the cleared splicing extract
should be a powerful tool in the isolation of highly
enriched spliceosomes.
Splicing reactions using cleared extracts should
contain only one large complex, the spliceosome
formed on exogenously added pre-mRNA. A
splicing reaction with a cleared extract analyzed by
density gradient sedimentation reveals that the
snRNA species remains at the top of gradients if pre-
mRNA is not added. However, if the reaction is
performed with the addition of pre-mRNA, the pre-
mRNA and snRNAs now cosediment into the
gradient. This shift of the snRNAs would never be
visible with standard extracts, because lower-gradient
fractions have too much background. Using this
approach, I have begun to analyze the proteins that
shift into lower-gradient fractions in response to the
addition of pre-mRNA. The use of RNA mutants
with defective 5' and 3' splice sites will hopefully allow
the correlation of cis- and trans-acting elements. This
approach to spliceosome isolation should also be of
value in the ultrastructural characterization of the
spliceosome.
Alternative Splicing of the
Adenovirus E1A Gene
J. Harper, S. Miceli
We have continued our experiments to identify
factors that may affect alternative splicing patterns
of pre-mRNAs from complex transcription units.
Our work has focused on the adenovirus ElA
transcription unit, which has three 5' splice sites and
two 3' splice sites that are used to generate at least
five different mRNAs in infected cells. We have
previously reported that although the splicing of E1A
pre-mRNA appears to be regulated temporally
during the course of adenovirus infection, all of these
RNAs can be produced during in vitro splicing
reactions using extracts prepared from uninfected
He La cells, indicating loss of regulation under these
conditions. This may be due to our inability to extract
active regulatory factors by our current methods or
may indicate that E1A splicing is regulated in vivo
by alteration of the substrate pre-mRNA, rather than
solely by changes in trans-acting factors.
Despite this disappointing result, we have success-
fully used E1A pre-mRNA splicing as a model for
5' splice site selection in vitro to identify an activity
that affects competition between alternative 5' splice
sites but has no effect on splicing in the absence of
competition. We consistently observe that the ratio
of different E1A products varies dramatically
between different in vitro reactions, depending on
the particular extract used. The reasons for these
extract-dependent differences are not yet clear, but
we have ruled out such obvious possibilities as
differences in salt concentration during extraction
or dialysis or differences in total protein concentra-
tion. The most useful comparison for evaluating
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extract differences is the ratio of 13S to 12S RNA.
These RNAs are generated by splicing between two
different 5' splice sites and a common 3' splice site.
In some extracts, splicing wild-type ElA substrate
RNA produces predominantly 13S RNA, whereas
splicing the same substrate under identical conditions
in other extracts produces large amounts of 12S RNA
in addition to 13S RNA. These examples represent
the extremes of activity observed in a survey of
numerous extracts, of which approximately 30%
produce high levels of 12S RNA, 10% produce
extremely low levels of 12S RNA, and the remaining
60% produce intermediate levels of 12S RNA from
the wild-type El A substrate.
When a mutant substrate, d11500 RNA, that is
missing the 13S 5' splice site is used, high levels of
12S RNA are produced by all extracts. This
demonstrates that all extracts contain the necessary
factors for 12S splicing; therefore, the inability of
some extracts to produce 12S RNA from the wild-
type substrate must result from competition between
the 12S and 13S reactions. Inhibition of 12S splicing
by this competition is not due to depletion of a
common splicing factor required for both 12S and
13S splicing under the conditions used. When a
mixture of d/1500 RNA and another mutant
substrate, pm975 RNA, that carries a mutation at
the 12S 5' splice site are spliced in the same reaction,
high levels of 12S RNA and 13S RNA are produced
by all extracts. This demonstrates that all extracts
have sufficient splicing factors needed to produce
12S and 13S RNAs in the same reaction, as long as
the reactions occur on separate molecules, and
suggests that the variation between extracts is due
to a factor that modulates the competition between
the 12S and 13S reactions on the same substrate
molecule.
The activity that stimulates 12S splicing from the
wild-type substrate can be separated from common
splicing factors by fractionation of a nuclear extract
on a DEAE-cellulose column. The extract is loaded
on the column in buffer containing 0.1 M KC1, and
the flowthrough fractions are pooled to make
fraction I. After the column is washed, bound
material is eluted with 0.6 M KCl to make fraction
II. Both fractions are dialyzed and concentrated.
Fraction I alone does not contain splicing activity;
however, fraction II is quite efficient in splicing 13S
RNA from the wild-type substrate and 12S RNA
from the d11500 substrate. Fraction II by itself makes
very low levels of 12S RNA from the wild-type
substrate, but addition of fraction I restores the 12S
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splicing. The amount of 12S RNA synthesized varies
proportionately with the concentration of fraction
I in reactions
supplemented with dilutions of fraction
I, although the efficiency of 13S splicing is un-
affected. The result is that fraction I contains a
soluble factor that affects 5' splice site selection. Such
a factor may participate in regulating correct 5' splice
site selection during splicing of RNAs that are not
normally alternatively spliced, as well as affecting
alternative splicing patterns. We are continuing to
fractionate extracts to purify this factor further and
are examining the effect of this factor on the splicing
of a variety of substrate RNAs.
Inhibition of Pre-mRNA Splicing
by Antisense RNA
S. Munroe
We have previously demonstrated that antisense
RNA specifically and efficiently inhibits pre-mRNA
splicing in vitro. Subsequent work, described below,
has been directed at determining the mechanism of
this inhibition and characterizing factors that medi-
ate inhibition by promoting the rapid annealing of
complementary RNA molecules.
Antisense RNAs complementary to either the 5'
or 3' exons inhibit splicing of a pre-mRNA transcript
consisting of the first two exons and first intron of
human [3-globin pre-mRNA. Particularly interest-
ing is the observation that antisense RNAs annealing
to regions of the exon some distance from the nearest
splice site also inhibit splicing efficiently. For ex-
ample, a 70-nucleotide antisense RNA, designated
E2-70, that is complementary to sequences in the 3'
exon more than 130 nucleotides from the nearest
splice site blocks splicing as efficiently as antisense
RNAs annealing closer to the 3' splice site. These
results were unexpected since it has been shown that
most of the 5' and 3' exons can be deleted from this
transcript without severely inhibiting splicing. Our
results suggest the presence of direct or indirect
interactions between exon and splice site sequences.
Such interactions may be important for determin-
ing the specificity of splicing.
Antisense RNAs annealed to the 3' exon block,
splicing at an early stage, prior to cleavage at the 5'
splice site. In the presence of antisense RNA, E2-70
pre-mRNA accumulates in a 40S RNP complex. This
complex cosediments with the 40S presplicing
complex formed in an uninhibited reaction that is
known to contain a single small nuclear ribonucleo-
protein (snRNP) complex, U2 snRNP. The snRNP
components of complexes formed upon inhibition
with antisense RNAs are presently being examined
to establish more precisely the stage at which spliceo-
some assembly is blocked.
In contrast to the high level of inhibition observed
with antisense RNAs complementary to globin
exons, antisense RNAs complementary to regions
immediately adjacent to the 3' splice site of globin
pre-mRNA are poor inhibitors. This appears to
reflect the inability of antisense RNAs to anneal
efficiently near the 3' splice site. Analysis of anneal-
ing by nuclease protection assay shows that E2-130,
which spans the 3' splice site, anneals inefficiently
to pre-mRNA. Splicing factors binding at this site
may block or displace antisense RNAs. Annealing
of a second antisense RNA (E2-70) to a nonover-
lapping downstream site substantially enhances an-
nealing of E2-130. This result suggests that antisense
RNAs annealed to the 3' exon block or destabilize
binding of factors at the 3' splice site.
When antisense RNAs are added to in vitro
splicing reactions 5 minutes or more after initiation
of pre-mRNA splicing, annealing and inhibition are
greatly reduced. However, we have found that pre-
annealing of E2-70 facilitates annealing of antisense
RNA E2-80B added 10 minutes later to an adjacent
site on the 3' exon. These results are consistent with
a model in which antisense RNA bound to the exon
blocks assembly of the functional splicing complex
at a stage where pre-mRNA is extended in an "open"
configuration, in which it can readily base pair to
antisense RNAs. In the absence of antisense RNA,
this open complex is rapidly converted to a closed
complex in which pre-mRNA is sequestered and
unable to anneal to late-added antisense RNAs. The
addition of antisense RNA at the beginning of
splicing may lock in the open complex and inhibits
splicing by blocking the transition to a closed
complex during spliceosome assembly. Since the
transition from the open to closed complex may be
mediated by proteins binding along exons, one
possible mechanism for inhibition by antisense RNA
bound to the exon is that it may perturb the binding
of heterogeneous nuclear RNP (hnRNP) proteins to
the pre-mRNA. This hypothesis will be tested by
examining the binding of proteins to exon sequences
in a series of overlapping pre-mRNAs in the presence
and absence of bound antisense RNAs.
Inhibition of splicing by antisense RNAs appears
to be mediated by several different activities in a
He La cell nuclear extract that promote, block, or
destabilize the annealing of complementary RNAs.
We have further characterized requirements for
annealing in vitro and have started to purify factors
that facilitate annealing of complementary RNAs.
Optimal annealing takes place in 15-20 mm MgC12,
40-60 mm KC1 at 37°C in the absence of ATP. These
conditions differ from those required for splicing.
Annealing of complementary RNA molecules does
not require the presence of splice site sequences.
Predigestion of nuclear extracts with protease elim-
inates annealing activity, suggesting that annealing
factors include one or more protein components.
Several chromatographic procedures have been used
to partially purify annealing factors. Annealing
activity is bound to DEAE-cellulose at 50 mm KC1,
but elutes in a broad peak between 0.1 and 0.3 M salt.
Material collected from the front half of this peak
was further fractionated on a phosphocellulose
column. Most of the activity elutes in a step between
0.15 and 0.3 M KC1. Further activity elutes in the
0.3-0.5 M step. Material collected from these two
steps was subjected to further fractionation by
Cibacron blue affinity chromatography. The fraction
eluting from phosphocellulose with 0.5 M KC1 binds
tightly to this affinity column, and the fraction elut-
ing with 0.3 M salt binds loosely. This result suggests
that at least two independently eluting factors are
capable of promoting RNA/RNA annealing. Addi-
tional procedures are being tested to purify these
annealing factors further.
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Studies of regulation of transcription in mammalian
cells have shown that transcriptional control is
manifested by a complex network of cis-acting
promoter elements and transcription factors. We use
the small DNA tumor virus SV40 as a model system
with which to probe transcriptional control in
mammalian cells. This virus contains a relatively
small regulatory region of about 400 by that includes
the bidirectional early and late promoters and the
origin of replication. The early promoter relies
entirely on host-cell trans-acting factors to initiate
transcription. Transcription of the early region
results in expression of the large T antigen protein,
which, in turn, initiates DNA replication and late
transcription. We have focused our studies on the
SV40 early promoter and particularly on the
structure and function of the enhancer region.
Enhancers were first discovered in SV40 and have
the ability to activate transcription over very large
distances (up to 10 kb) from a position either
upstream or downstream from the transcriptional
start site. Our past studies showed that the SV40
enhancer is a composite of many subunits that
cooperate with one another at different organiza-
tional levels to activate transcription. The individual
subunits frequently represent sequence motifs found
in other enhancers. We refer to these subunits as
"enhansons" for the indivisible units of enhancer
structure. Enhansons probably represent individual
binding sites for transcription factors, although, in
certain cases, such as the jun and fos proto-oncogene
products, the factors may represent homodimers or
heterodimers.
We have continued our analysis of cis-acting
elements within the SV40 enhancer, but we are also
shifting our emphasis to molecular analysis of the
cellular factors responsible for transcriptional
regulation. These latter studies have led us to a
detailed analysis of the 8-bp octamer motif
ATGCAAAT that is found in the promoter of a
number of lymphoid-specific and ubiquitously
expressed genes. The ubiquitously expressed genes
include those encoding the Ul to U6 small nuclear
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RNAs (snRNAs) and the histone H2B. In collabo-
ration with the laboratory of N. Hernandez (Mo-
lecular Genetics of Eukaryotic Cells Section), we
have investigated the activity of the SV40 octamer
motif in the context of the P-globin promoter, which
represents a prototypical mRNA promoter, and in
the U2 snRNA promoter. These studies showed that
the octamer motif has different functions (ubiq-
uitous or cell-specific), depending on the promoter
context in which it is located. In the U2 snRNA
promoter, the octamer motif is active ubiquitously,
but in the 13-globin promoter, it is lymphoid-specific.
Unlike the octamer motif, none of the SV40 en-
hancer elements that activate the 13-globin promoter
in HeLa cells can activate the U2 snRNA promoter;
thus, the octamer motif defines a new class of en-
hancer elements that are specific for snRNA genes.
The characterization of the octamer motif has
been paralleled by the purification of the ubiqui-
tously expressed octamer-motif-binding protein Oct-
1 and isolation of a cDNA clone encoding this
protein. The gene encoding the related lymphoid-
specific octamer-binding protein Oct-2 has been
cloned in three other laboratories (P. Sharp and D.
Baltimore, Massachusetts Institute of Technology;
P. Matthias and W. Schaffner, University of Zurich;
and R. Roeder, Rockefeller University). These two
proteins are probably responsible for the ubiquitous
and lymphoid-specific activity of the octamer motif
in the snRNA and immunoglobulin promoters,
respectively. They thus serve as a model system to
examine how two transcription factors that recognize
the same DNA sequence can differentially activate
transcription. One explanation is that these two
factors share related DNA-binding domains but
differ in the activation domains. The cloning of the
genes encoding Oct-1 and Oct-2 go a long way toward
answering these questions. For example, these two
proteins do indeed share very similar DNA-binding
domains. This DNA-binding domain is also shared
by a pituitary-specific factor, called Pit-1 (or GHF-1),
and a nematode cell lineage gene, called unc-86. This
new 160-amino-acid domain (called POU, pro-
nounced "pow", for Pit, Oct, Unc) contains two
subdomains, a homeo domain and POU-specific
domain. Future efforts will focus on the structure
of this new type of DNA-binding domain and on
the characterization of the activation domains that
differentiate the Oct -1 and Oct-2 factors.
In a new effort initiated this year with other
members of the laboratory, we are studying
transcriptional regulation of the human immunode-
ficiency virus (HIV), the etiological agent of AIDS.
In this effort, we are concentrating our efforts on
adapting the strategies we have used to study the
SV40 enhancer to the HIV regulatory region. This
year, these studies have allowed us to identify
elements that are shared by these two promoters. In
the future, we plan to identify the transcriptional
control elements that are responsible for T-cell-
specific expression of this virus.
Structure and Function of
the SV40 Enhancer
A. Aurora, J. Clarke, W. Herr, B. Ondek,
S. Stern, M. Tanaka
Figure 1 shows our current understanding of the
structure of the SV40 enhancer, with individual
enhanson units shown above the sequence and the
three A, B, and C enhancer elements initially
identified by viral revertant analysis shown below the
sequence. The A, B, and C enhancer elements have
the property that simple duplication of these
elements can create an enhancer. For this reason,
P. Chambon and colleagues (Strassbourg) have sug-
gested they be referred to as proto-enhancers. Last
year, we showed that the A and B elements, or proto-
enhancers, are composed of subunits that must be
located in close proximity to each other in order to
be functional. These subunits correlated with pro-
tein-binding sites and therefore seemed likely to be
the indivisible units of enhancer structure. We
therefore coined the term "enhansons" to define these
units of enhancer structure. Much of our effort on
the structure and function of the SV40 enhancer
during the past year has focused on characterizing
the properties of enhansons and how they cooperate
with one another.
Our studies of the SV40 enhancer in the murine
embryonal carcinoma cell line F9 were completed this
year. We studied the activity of the SV40 enhancer
elements in this cell line by using a polyomavirus
enhancer replacement vector and also by testing the
activity of multimerized synthetic enhancers. These
studies clarified the structure of the A element. In
our previous studies, we had not identified the
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FIGURE 1 Structure of the SV40 enhancer. A diagram of the SV40 early promoter is shown above the nucleotide sequence of the
SV40 enhancer region. The diagram shows the early transcriptional start sites to the right (wavy arrow), TATA box region (A/T), perfect
(21 bp) and imperfect ("21 bp") 21-bp repeated sequences that contain Sp1-binding sites, and the 72-bp element that is repeated
in wild-type SV40. The stippled boxes show the location of the A, B, and C elements originally defined by SV40 revertant analysis
in CV-1 cells. Above the sequence of the SV40 enhancer are shown sequence motifs and enhansons discussed in the text. Below
the sequence are double point mutations (dpm) used in SV40 revertant analyses and the position of the A, B, and C elements. The
extended A element results from experiments in murine embryonal carcinoma F9 cells discussed in the text.
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second A element enhanson that cooperates with the
coreA enhanson (also referred to as GTIIC, see Fig.
1). In undifferentiated F9 cells, the C element is
inactive, and this allowed us to determine that the
A element extends further downstream than pre-
viously recognized and actually overlaps the C ele-
ment. This became evident because the dpm6 muta-
tions, which inactivate the C element, also inactivate
the A element. Thus, the second A element enhanson
is apparently the CACA/GTI motif. Unlike the
coreA enhanson, however, a duplication of the GTI
motif that arose in the polyomavirus/SV40 enhancer
revertants from F9 cells does not create a proto-
enhancer. Thus, some enhansons can cooperate with
duplicates of themselves, whereas others apparently
do not.
A detailed analysis of the SV40 B element has
shown that some enhansons can also function
independently as proto-enhancers without an en-
hanson partner. This conclusion arose from our
studies of the SV40 octamer motif that overlaps the
sph enhansons I and II. In studies performed in
collaboration with N. Hernandez' laboratory (Mo-
lecular Genetics of Eukaryotic Cells Section) and
described elsewhere in this report, we showed that
the octamer motif itself functions as a lymphoid-
specific proto-enhancer for activation of the13-globin
promoter. Multiple mutations within sequences
flanking both sides of the octamer motif did not
affect the enhancer activity of the multimerized SV40
octamer motif, but all mutations within the motif
inactivated function. This result contrasts with the
activity of the sph enhansons in which neither
enhanson is sufficient for activity. Therefore, en-
hansons can be classified into different groups. Sim-
ilar conclusions have been described by Fromental
et al. (Cell 54: 943 [1988]), in which the enhansons
were classified as class-A enhansons, which cannot
cooperate with another enhanson of the same class
(e.g., CACA/GTI motif), class-B enhansons, which
cooperate with themselves or with class-A enhansons
to create proto-enhancers (e.g., coreA or sphll
motifs), and class-C enhansons, which are proto-
enhancers themselves (e.g., the octamer motif).
This classification of enhansons can explain the
unexpected results we obtained from a new series of
SV40 revertant isolations. We initially identified
enhansons by the structure of revertants of the triple
mutant dpm1.2.6, in which each of the A, B, and
C elements was mutated (see Fig. 1). Some of these
revertants contained 9-bp duplications of the coreA
or sphl enhansons. To
identify new enhansons, we
isolated revertants from a different triple enhancer
mutant called dptn8.9.10, in which the opposite
"half" of each element was mutated (see Fig. 1). As
tested with synthetic enhancers, these three sets of
double point mutations, dpm8, dpm9, and dpm10,
inactivate the B, A, and C elements, respectively.
Surprisingly, in the dpm8.9.10 revertants, no new
combination of enhanson duplications was observed.
Instead, most revertants contained duplications of
the region upstream within which W. Schaffner and
colleagues (University of Zurich) have identified
other proto-enhancers. This result can now be ex-
plained if the GTI motif in the A element and the
sphl motif in the B element are class-A enhansons
that cannot cooperate with themselves to create a
proto-enhancer. Because mutations in neither "half"
of the C element resulted in identification of C
element subunits, we suspect it is a class-C enhanson
or indivisible proto-enhancer. Consistent with this
hypothesis, the C element is recognized by a nuclear
factor called NF-KB that may act like the lymphoid
octamer-motif-binding factor Oct-2 and not require
a flanking factor to activate transcription.
To study the protein-protein interactions involved
in enhanson function, we have concentrated on two
motifs: the coreA enhanson, which cooperates with
itself to generate a very active proto-enhancer in
HeLa cells, and the AP-1 motif, which binds to the
known transcription factors and proto-oncogenes
jun and fos. Screening of a HeLa cell nuclear extract
fractionated by heparin agarose chromatography
with a coreA motif probe identified a coreA-motif-
binding factor. When a probe containing the duplica-
tion of the coreA enhanson that is very active in vivo
is used in a gel-retardation assay, two different
DNA/protein complexes are observed: a more
abundant slow-migrating complex II and a less
abundant fast-migrating complex I. When one or the
other coreA motif is mutated by a single point
mutation, only complex I is evident, and both
complexes disappear when both coreA motifs are
mutated. We interpret these findings to suggest that
complex I contains a single site bound by the coreA
factor, whereas in the slower-migrating complex II,
two coreA motifs are occupied. The overabundance
of the slower-migrating complex II suggests a
cooperative interaction between bound coreA
factors. Consistent with such a cooperation, when
the spacing between coreA motifs is altered, the
relative abundance of complex II decreases in
approximate proportion to the decrease in enhancer
function in vivo. These results suggest that some of
the cooperativity between class B enhansons is the
result of cooperative DNA binding. This is unlikely
to be the whole story, however, because isolated
coreA motifs can still bind to this coreA motif factor,
but they are nevertheless inactive in vivo.
The analysis of the AP-1 (or P) motif (see Fig. 1)
has the advantage that both genes encoding proteins
known to bind to this motif, jun and fos, are cloned
and have been extensively characterized. The SV40
AP-1 motif does not have the properties of a proto-
enhancer in CV-1 cells, because in neither the
dpm1.2.6 nor the dpm8.9.10 triple mutants was the
AP-1 motif duplicated to restore enhancer function.
In one revertant of the mutant dpm2, isolated a
number of years ago, we observed a 9-bp duplica-
tion of the AP-1 motif. Such 9-bp duplications are
a hallmark of class-B enhansons that can cooperate
with themselves. We therefore tested the enhancer
potential of the duplicated AP-1 motif and found
that it was indeed considerably more active than
when one or the other of the two motifs is inactivated
by point mutation or when they are separated by 5
bp. We now plan to study the interaction of fos and
jun with the duplicated AP-1 enhansons to under-
stand how the enhansons cooperate to enhance tran-
scription.
We have also taken a foray into yeast to test its
suitability as a host to study the SV40 enhancer.
Studies of yeast transcription factors during the past
few years have shown that some are very similar to
mammalian factors. For example, two factors
isolated from yeast, GCN4 and yAP-1, are very
similar in structure and DNA-binding properties to
the mammalian AP-1 family of factors such as fos
and jun. Therefore, we tested the activity of different
wild-type and mutant multimerized SV40 enhancer
element constructs in the budding yeast Saccharo-
myces cerevisiae. Restriction fragments containing
the multimerized enhancers were cloned into a yeast
expression vector containing the TATA box from the
yeast His4 promoter fused to 13-galactosidase. After
transformation of yeast, cells were grown and tested
for 13-galactosidase activity. We expected two kinds
of potentially useful results. In the first, certain
families of wild-type and mutant multimerized en-
hancers could exhibit the same pattern of activity
in yeast as in mammalian cells. This result would
suggest a yeast homolog of a mammalian transcrip-
tion factor. Alternatively, a motif may be inactive
in yeast; in which case, yeast may prove to be an ideal
system in which to study the activity of the mam-
malian factor. The results of the experiment failed
to identify SV40 enhancer elements that fit in the
first class of active elements that faithfully reproduce
the activity found in mammalian cells. For example,
certain C element constructs were active in S. cere-
visiae, but this did not apparently reflect the activity
of the KB site (see Fig. 1) because other constructs
that still contained a wild-type -KB site were inactive.
There were members of the second class, however,
because none of the B element constructs were active,
suggesting that there is no octamer-motif-binding
factors like Oct-1 or Oct-2 in yeast. We may therefore
be able in the future to study Oct-1 and Oct-2
function in yeast.
Oct-1 (OBP100), a Homeo Domain
Protein, Binds to Remarkably
Degenerate Octamer Motifs
through Specific Interactions
with Flanking Sequences
T. Baumruker, R. Sturm, W. Herr
During the past 3 years, we have pursued the char-
acterization of the ubiquitous octamer-motif-binding
factor from HeLa cells. This factor binds to two sites,
I and II (see Fig. 2), within the SV40 enhancer: Site
I contains a 7/8 match to the canonical octamer
motif ATGCAAAT, whereas the downstream site II
contains two sequences with only six (Octa2) or five
(Octa3) matches to the octamer motif. We originally
referred to this protein as OBP100 because it is a 100-
kD octamer-binding protein. In agreement with D.
Baltimore, P. Sharp, and their colleagues (Massa-
chusetts Institute of Technology), we now refer to
the ubiquitous octamer-binding protein as Oct-1 and
the lymphoid-specific factor as Oct-2. Oct-1 is
probably the same as OTF-1, which R. Roeder and
colleagues (Rockefeller University) showed activates
histone H2B gene expression in vitro, and NFIII, a
factor that activates adenovirus DNA replication (P.
van der Vliet [University of Utrecht] and T. Kelly
[Johns Hopkins] and their colleagues). The pattern
of Oct-1 binding to the SV40 enhancer has led us
to use the Oct-1 protein as a model system to under-
stand how sequence-specific DNA-binding proteins
can bind to families of very degenerate sequences.
The studies described last year showed that Oct-1
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FIGURE 2 Structure of the two SV40 enhancer
binding sites for the octamer-binding protein Oct-1
(referred to as OBP100 in the figure). The SV40 early promoter is as described in Fig.
1. The sequence
shows the region encompassing the two Oct-1-binding sites.
Octamer-related motifs are identified above
the sequence, and the limits of the binding sites are shown by
the solid lines below the sequence. The
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binding sites by chemical modifica-
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can bind to two adjacent sites within the SV40
enhancer, of which only site I contains the previously
recognized octamer motif (see dashed lines in Fig.
2). The second site was shown by chemical modifica-
tion interference to extend over a 13-bp sequence con-
taining the overlapping Octa2 and Octa3 sequences.
To extend these earlier studies, we combined the use
of mutagenesis and chemical modification interfer-
ence with electrophoretic mobility-shift analysis to
examine the precise sequence requirements for Oct-1
binding to sites I and II. These studies showed that
the size of these two binding sites differ: Binding site
I is 11 by long, whereas binding site II is 14 by long
(shown by solid bars in Fig. 2). Furthermore, the
octamer-related sequence recognized by Oct-1 in site
II is not the 6/8 Octa2 sequence but the 5/8 Octa3
sequence. The mutational studies showed that Oct-1
can recognize the very degenerate Octa3 octamer
motif because it makes important sequence-specific
contacts with the DNA flanking the degenerate oc-
tamer motif. Thus, sequences that are not normally
conserved because they are not essential for binding
to a perfect octamer motif become essential for bind-
ing to a degenerate motif. These results have impor-
tant ramifications because they stress the context
dependence of any mutational analysis of a cis-acting
element; thus, although a particular point mutation
may have a drastic deleterious effect in a particular
promoter element, the same mutant sequence may
be functional in a different context.
80
Once the exact nature of the interaction between
Oct-1 and SV40 binding site II became evident, we
realized that there is considerable sequence similar-
ity (7 out of 9 match) between binding site II and
the TAATGARAT (R = purine) motif found in the
immediate-early (IE) promoters of herpes simplex
virus (HSV). The TAATGARAT motif is the target
for transcriptional activation of the HSV IE genes
by the late HSV gene product VP16 (also called
Vmw65). VP16 is a structural component of the HSV
virion, and upon infection, it is released into the cell
where it binds to the DNA indirectly through interac-
tions with one or more cellular factors present in
uninfected cells. The HSV TAATGARAT motifs can
be divided into two different classes that differ from
one another by the sequences flanking the motif. In
the first class, the flanking sequences ATGCTAAT-
GARAT create a 7/8 octamer motif (ATGCTAAT')
that overlaps the TAATGARAT motif. In the second
class, there is no such overlapping motif. Therefore,
to test the ability of Oct-1 to bind directly to the
TAATGARAT motif, we selected a class II motif
from the HSV ICP4 promoter. Gel-retardation
studies, chemical modification interference, and
DNA affinity precipitation studies showed that
indeed the Oct-1 protein can bind directly to the
TAATGARAT motif, thereby extending the range of
Oct-1 binding sites to include sites that have at best
a 4 out of 8 match to the octamer motif.
Figure 3A shows a compilation of different Oct-1
binding sites that we have studied, ordered to
generate the maximum sequence relationship be-
tween any two adjacent sequences in the figure. This
organization shows that a progression of DNA-bind-
ing sites from the SV40 site I motif to the TAAT-
GARAT motif can be made in which any two sites
are at least 6007o similar (9 out of 14 positions). Nev-
ertheless, when SV40 site I and the TAATGARAT
motif are directly compared, they bear little resem-
blance (4 out of 14 matches, Fig. 3B). Thus, the
relationship between two very dissimilar binding sites
can be established by the progression. These results
offer an explanation for how a DNA-binding protein
can bind to very dissimilar sequences: Flexible DNA
sequence recognition arises because there are few,
if any, obligatory contact sites for DNA binding, but,
rather, specific binding reflects the sum of many
independent interactions.
The Oct-1 Protein Contains a
Bipartite POU DNA-binding Domain
with a Homeo Subdomain
R. Sturm, W. Herr, G. Das, M. Cleary
To understand how the Oct-1 protein binds to
consensus and degenerate octamer motifs and how
it displays a different trans-activation potential from
the lymphoid-specific Oct-2 protein, it became
imperative to obtain a cDNA clone of the gene
encoding Oct-1. We were successful in this endeavor,
and it led us to the discovery of a new conserved
domain called POU (pronounced "pow") within
transcription factors.
The first cDNA clone for the gene encoding Oct-1,
referred to as oct-/, was identified by screening a
kgt11 recombinant phage library in situ with an oc-
tamer motif DNA probe. We screened a human 4111
cDNA library prepared from the teratocarcinoma cell
line NTERA2D1 (P. Andrews, Wistar) constructed
by J. Skowronski (Molecular Genetics of Eukaryotic
Cells Section). Of 4 x 10' phage screened, we
obtained one positive phage that produced a 190-
kDO-galactosidase fusion protein that bound specifi-
cally to the octamer motif. To test stringently the
DNA-binding specificity of this recombinant protein
compared to He La-cell-derived Oct-1 protein, we
compared their DNA-binding affinity for SV40 site
I and the TAATGARAT motif, which differ greatly
in sequence (see Fig. 3B). We were encouraged to find
that these two proteins showed the same relative
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FIGURE 3 Sequence comparison of different Oct-1-binding
sites. In A, the sequences are ordered to achieve the highest
degree of similarity between sites. The numbers to the right
between sequences indicate the number of sequence matches
(out of 14) between each pair of sites. (H2B) Histone H2B
promoter; (IgH) immunoglobulin heavy-chain enhancer; (U2) U2
small nuclear RNA enhancer; (Perf. site II) SV40 site II converted
to a perfect octamer motif; (Clone 12) an artificial SV40 site II mutant
that binds Oct-1; TAAT, TAATGARAT motif. (8) Direct comparison
of the SV40 site I and TAATGARAT motif.
affinity for these two very different sites. The au-
thenticity of the cloned oct-/ gene was further es-
tablished by showing that, as expected for a ubiq-
uitously expressed gene, oct-/ mRNA could be de-
tected in all seven cell lines tested with the cDNA
clone. Furthermore, rabbit antibodies raised against
the recombinant 3- galactosidase fusion protein re-
acted with the He La-cell-derived Oct-1 protein.
The Oct-1 antibodies and the RNA hybridizations
also showed that there is a relationship between the
Oct-1 and Oct-2 proteins, because Oct-1 probes cross-
reacted with the Oct-2 protein and mRNA from
lymphoid cells. The similarity between the Oct-1 and
Oct-2 proteins was established by comparing the
amino acid sequences predicted for the two proteins
from DNA sequence analysis. The nucleotide se-
quence of the Oct-1 cDNA clone revealed an open
reading frame fused to 13-galactosidase extending for
760 amino acid residues. The amino-terminal third
of this reading frame is very rich in glutamine (25010),
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the central portion contains a high concentration
of
acidic and basic residues, and the carboxy-terminal
region is rich in serines and threonines. When the
Oct-1 sequence is compared to the sequence
de-
termined for Oct-2 by R. Clerc, L. Corcoran, D.
Baltimore, and P.A. Sharp (Massachusetts Institute
of Technology), the central 160-amino-acid charged
region shows a striking 90% similarity between the
two proteins. The carboxy-terminal 60 amino acids
within this region are distantly related to the homeo
domain first identified in proteins involved in
Drosophila development. The homeo domain con-
tains an a-helix-turn-a-helix motif that is similar to
the DNA-binding domains of prokaryotic DNA-
binding proteins. Consistent with this similarity,
deletion analysis of the Oct-1 protein showed that
the homeo domain is essential for DNA binding.
Twenty-five residues amino-terminal to the homeo
domain begins a stretch of 75 residues that is
identical at 74 positions in Oct-1 and Oct-2. Surpris-
ingly, comparison of the sequences of the Oct
proteins and two other homeo domain proteins,
which were identified concurrently with the Oct-1
and Oct-2 proteins, showed that the homeo domains
of these four proteins are much more related to one
another than to other homeo domain proteins.
Furthermore, these new proteins are also very similar
in the amino-terminal segment that is nearly identical
in the two Oct proteins. Figure 4 shows a schematic
representation of the four proteins. The two non-
Oct proteins are the pituitary-specific factor Pit-1,
characterized by H. Ingraham, M.G. Rosenfeld, and
colleagues (University of California, San Diego)
(also referred to as GHF-1 by M. Karin and
colleagues [UCSD]), and the product of a cell-lineage
gene in the nematode Caenorhabditis elegans called
unc-86 (M. Finney, G. Ruvkun, and H.R. Horvitz,
MIT and Harvard). The extended region of similar-
ity has been called the POU domain, and it contains
two subdomains, the POU-specific domain and the
POU homeo domain. These two subdomains are
linked by a short 15-27-amino-acid-long noncon-
served region of dissimilarity between the two proteins.
These sequence comparisons drew together a new
class of homeo-domain-containing proteins. None
of these four proteins were originally isolated by
virtue of being a homeo-domain-containing protein,
and they thus form a diverse group of functionally
characterized proteins. Three of them are mam-
malian transcription factors, two of which bind to
identical sequences, and the fourth is a developmen-
tal gene in worms. Although the other three are ex-
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FIGURE 4 Position of the bipartite
POU domain within the four
POU proteins Oct-1, Oct-2, unc-86, and Pit-1/GHF-1 ordered
according to size from largest to smallest (top to bottom). They
are aligned according to the position of the POU domain. The
POU-specific subdomain is hatched, the POU homeo domain
is stippled, and the nonconserved sequences in between are
blackened as indicated by the expanded and labeled POU
domain shown below.
pressed only in specific cells, the Oct-1 protein is
unusual because it is the first clearly ubiquitously
expressed homeo domain protein.
Why should the POU proteins, unlike the large
majority of homeo domain proteins, contain another
highly conserved subdomain within the POU do-
main? Deletion analysis of the Oct-1 protein showed
that the POU domain is sufficient for sequence-
specific binding to DNA. Figure 5 shows a schematic
of the Oct-1 POU domain. The sequence compari-
son between the POU proteins revealed that the
POU-specific subdomain can be subdivided into two
highly conserved regions called the A and B boxes.
The POU homeo domain contains the helix-turn-
helix (H-T-H) motif that contacts DNA. This particu-
lar region is very closely related among the four POU
proteins and may suggest that they contact DNA in
a similar manner. Because the two Oct proteins bind
to identical sequences, it seemed plausible that the
nearly identical Oct-1 and Oct-2 POU-specific
domains might be involved in binding to DNA.
To test whether the POU-specific domain is
required for DNA binding, we created amino-
terminal deletions of Oct-1 extending into the POU-
specific sequences and showed that deletion of the
POU A box already results in loss of binding in a
gel-retardation assay. To make more subtle muta-
tions, we created three amino acid substitutions with-
in the POU A, B, and homeo domains in sequences
that are conserved between all four POU proteins.
In addition, to test the flexibility of the "linker"
region between the two POU subdomains, we in-
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FIGURE 5 Mutations within the POU-specific and POU-homeo domains are deleteri-
ous to DNA binding, but an insertion between the two domains does not affect binding.
(Top) Position of the triple alanine substitutions within the POU A, B, and homeo regions
and the six alanine insertion between the two POU subdomains. The amino acid sequence
surrounding each set of mutations is shown; the amino acids shown by large letters are
identical among all four POU proteins. The relative DNA-binding activity of each mutant
is shown at the bottom. (Bottom) Gel-retardation analysis of the POU domain point mutants.
Three probes, SV40 site I (lanes 1, 4, 7, 10, 13), nonbinding SV40 site I mutant dpm8
(lanes 2, 5, 8, 11, 14), and the TAATGARAT motif (lanes 3, 6, 9, 12, 15) (see Figs. 1 and
3), were tested with proteins of wild-type Oct-1 (WT), the POU A (A-AAA), B (B-AAA), and
homeo (H-AAA) substitution mutants, and the six alanine insertion (P6XAH) mutant as
indicated. The free probe migrates at the bottom of the gel and the complex with Oct-1
migrates near the top.
serted six alanine residues in this region (see Fig. 5).
As shown in the gel-retardation assay in Figure 5,
the amino acid substitutions all had a severe effect
on DNA binding to the very different SV40 site I
octamer motif and TAATGARAT motif. The inser-
tion of six alanines, however, had no obvious effect
on DNA binding. These results suggest that the POU
domain is a new type of bipartite DNA-binding
structure in which the homeo subdomain is insuffi-
cient for effective DNA binding. We are currently
extending the structural studies of the POU domain
to determine whether the POU-specific sequences
actually contact the DNA or are instead involved in
stabilizing the homeo domain.
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HIV Enhancer: Common Elements
between HIV and SV40 Promoters
W. Phares, J. Clarke, W. Herr,.
Figure 6 shows a comparison of the SV40 early
promoter and the HIV promoter. There are a number
of striking similarities between these two promoters:
They both contain TATA box motifs (A/T), multiple
binding sites for the transcription factor Spl (hatched
boxes), and either one or two copies of a 10-bp
sequence motif, GGAAAGTCCC (in SV40) or
GGGACTTTCC (in HIV). This latter motif is
recognized by the nuclear factor NF-x13. It was first
shown to be functionally important by its central
location in the SV40 enhancer C element. In the HIV
promoter, this motif is referred to as the enhancer
core (EC).
To dissect the HIV promoter, we are focusing our
attention on the sequences upstream of the Spl-
binding sites, which by analogy to the SV40 early
promoter, probably contain multiple enhancer
elements. In our first efforts, we have asked whether
HIV enhancer elements can functionally replace the
SV40 enhancer and, if so, whether we could identify
those elements by SV40 revertant analysis. Of
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particular interest was determining whether the
enhancer core of HIV, which by sequence is very
similar to the SV40 C element, can functionally
replace the SV40 enhancer in the SV40 permissive
African green monkey kidney cell line CV-1.
We have used the SV40 enhancer replacement
vector pSVER, in which the SV40 enhancer is deleted
and can be replaced by heterologous enhancers, as
a functional assay to identify HIV enhancer ele-
ments. Three HaeIII-resistant fragments of the HIV-
1 long terminal repeat (Fig. 6) were individually
cloned into the pSVER vector, and DNAs were
transfected into CV-1 cells to recover viable virus.
All the SV40-HIV recombinant viruses were unable
to form plaques on CV-1 cells upon direct transfec-
don of cells, indicating a defective function in the
initial recovered viruses. With continued propaga-
tion, however, growth revertants arose from recom-
binants containing the 91-bp HaeIII fragment that
spans the enhancer cores but not from recombinants
carrying the upstream 76-bp and 117-bp HaeIII frag-
ments.
Sequence analysis of the enhancer region of
revertants from virus carrying the 91-bp fragment
in either orientation revealed tandem duplications
that always spanned at least one of the HIV enhancer
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FIGURE 6 Comparison between the SV40 early promoter and HIV promoter. Shown
from right to left are transcription start sites (wavy arrow), TATA boxes (A/T), and Sp1-binding
sites (hatched boxes). Upstream of the regions are shown the 72-bp element with the
position and sequence of the A, B, and C elements for SV40 and the enhancer core elements
(EC), homologies to the interferon-y (IFN-y) and IL-2 (IL-2) genes, and the approximate
position of the negative regulatory element (NRE) for the HIV promoter. The sequence
of the 10-bp NF-KB-binding site similarity is shown above the enhancer cores and is
bracketed in the C element sequence. The base changes in mutants spm5 and dpm10
are as indicated.
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core sequences that are similar to the SV40 enhancer
C element. This analysis therefore indicates that
duplication of the HIV enhancer core sequences is
sufficient to restore SV40 replication in CV -1 cells.
To extend this finding further, we have compared the
activities of reiterated copies of the SV40 C element
and the HIV ECI and ECII elements, in transient
expression assays of transfected DNA. The results
show that multiple copies of each of these elements
can independently enhance transcription in CV-1
cells to equivalent levels, whereas the point mutants
spm5 and dpm10 (see Fig. 6) abolish activity. Taken
together with the SV40 revertant analysis, these
results indicate that in CV-I cells, a nonlymphoid cell
line, the enhancer core elements of HIV are function-
ally equivalent to the SV40 C element. Thus, if NF-
KB is responsible for the activity of the C element,
its activity is unlikely to be lymphoid-specific.
Future studies will extend the viral revertant
analysis of the HIV promoter to T cells, the replica-
tion permissive host for HIV, and macrophages, a
restrictive host, by utilizing a polyomavirus vector
that will grow in mouse cells. In addition, we will
examine the promoter sequences in different isolates
of HIV from AIDS patients. These future studies
may indicate which promoter elements are most
relevant to pathogenicity of the virus.
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MOLECULAR GENETICS OF EUKARYOTIC CELLS
This section encompasses a very broad range of biological problems, utilizing a
wide range of methodological approaches. The two distinct but interweaving
themes that repeatedly arise in the individual efforts are the control of gene
expression and the molecular basis of normal and abnormal physiology, particu-
larly relating to cancer. The sections led by Drs. Hanahan, Field, and Skowronski
utilize the powerful methods of germ line gene transfer to create transgenic mice
that model diseases such as cancer, diabetes, hypertension and AIDS, the
acquired immune deficiency disease associated with infection by the human
immunodeficiency virus type 1 (HIV-1). Dr. Wigler's lab focuses on the function of
oncogenes, particularly the RAS, ROS, and MAS oncogenes. Dr. Bar-Sagi's lab
also studies the function of the RAS oncogenes, and the role of phospholipid
metabolism in signal transduction. Dr. Gilman's group studies the mechanisms of
signal transduction that result in changes in nuclear transcription. Dr. Hernandez's
lab studies the mechanisms of gene transcription in two systems: the genes
encoding small nuclear RNAs (snRNAs), and the HIV-1 genome. Dr. Spector's
group utilizes high-resolution electron microscopy and image analysis techniques
to study the structural and functional organization of the cell nucleus. Dr. Franza's
lab studies cellular proteins involved in the control of transcription. He has
identified the products of two cellular proto-oncogenes that interact with specific
transcription control elements. He also studies cellular proteins that control
transcription of the HIV provirus. Dr. Helfman's lab studies the genes encoding the
various isoforms of tropomyosins and how different oncogenes act to alter
expression of the tropomyosin genes. Dr. Welch's lab continues its studies of the
proteins associated with cellular responses to stress. The 2D-Quest facility of Dr.
Garrels and co-workers continues to build up its various protein databases and to
improve upon methodology for processing two-dimensional gel information.
TRANSGENIC MICE
D. Hanahan J. Alexander S. Efrat M. Steinhelper
J. Skowronski J. Almeida S. Grant S. Teplin
L. Field S. Alpert J. Hager L. Usher
V. Bautch C. Jolicoeur P. Weinberg
Gene transfer into the mouse germ line provides an
ideal model system in which to study complex
biological problems at the organismal level. In the
past, a major focus of the Transgenic Mouse Group
at Cold Spring Harbor Laboratory has been models
of targeted oncogenesis. More recently, our experi-
ments have addressed a broader spectrum of issues,
as, for example, tumor angiogenesis, autoimmunity,
human immunodeficiency virus long terminal repeat
(HIV LTR) tissue specificity, cardiocyte regeneration,
and hypertension. These studies illustrate the strengths
of the transgenic approach, especially with regard
to the ability to characterize genetic and epigenetic
events that profoundly influence normal develop-
ment as well as complex disease processes.
Induction of Angiogenesis
during Tumorigenesis
D. Hanahan, J. Alexander [in collaboration with J. Folkman,
K. Watson, and D. lngber, Childrens Hospital Medical
Center, Harvard Medical School, Boston]
During the last several years, we have extensively
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characterized several lines of transgenic mice that
develop tumors of the pancreatic 13 cells as a result
of inheriting an oncogene. Although tumor develop-
ment is an inevitable consequence of carrying
this
particular oncogene, there is considerable evidence
that the oncogene itself is necessary but not sufficient
for the process and that other changes are required
as well. This conclusion is based on studies on
oncogene expression and its relationship to 13-cell
proliferation and tumor development, which have
been described in previous annual reports (see
especially the 1987 Annual Report).
The insulin-producing [3 cells are localized in
approximately 400 focal nodules of cells that are
called the islets of Langerhans. The islets are
scattered throughout the exocrine pancreas and
themselves comprise the endocrine pancreas. Their
transformation has been accomplished with a hybrid
oncogene composed of the rat insulin gene promoter/
enhancer region aligned to transcribe the protein-
coding region for SV4O large T antigen. In several
lines of mice, large T is expressed in virtually all of
the 13 cells in every pancreatic islet. This expression
ensues in the developing endocrine pancreas (and the
nervous system) beginning at embryonic day 10 in
the 19-day gestation of a mouse and persists in the
insulin-producing 13 cells thereafter. This potent
oncoprotein, which binds both the retinoblastoma
tumor supressor protein (see E. Harlow, Tumor
Viruses Section) and the p53 oncoprotein (itself a
putative tumor suppressor), does not immediately
elicit a tumor or even abnormal proliferation. Rather,
one can discern a progression from normality to
hyperplasia to neoplasia.
In one particularly well-characterized line (RIP-
Tag2), the islets are histologically normal at birth,
but a few begin to evidence hyperplasia by 4-6 weeks
(both histologically and by 13-cell proliferation). By
9.5 weeks, 50% of the islets are hyperplastic, and by
12 weeks, 70% are hyperplastic. However, only about
2% of the islets progress into histologically distinct
solid tumors, which are evident by 12 weeks of age,
and kill the animal by 13-14 weeks. Thus, following
activation of oncogene expression (the first step), we
can discern two additional steps: the development
of hyperplasia (the second step) and the progression
to neoplasia (the third step). The reproducibility of
this multistep tumorigenesis is providing a new
approach to study mechanisms of conversion of a
normal cell into a cancer cell.
With regard to the progression from hyperplasia
to neoplasia, we now have evidence that implicates
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the induction of angiogenesis
as an important event
in this process. It is clear
from the work of Judah
Folkman and his
colleagues that virtually every
established tumor has the capability to elicit neo-
vascularization, i.e., the formation
of new blood
vessels. Moreover,
the ability to induce capillary
ingrowth to a tumor following transplantation can
be seen to be crucial to its expansion, since if neo-
vascularization is inhibited, so too is tumor growth.
However, it is not clear from this previous work when
the ability to induce capillary ingrowth appears dur-
ing the primary development of a tumor.
Histological analyses of the pancreases of RIP
Tag2 mice at different stages of tumorigenesis have
revealed that normal islets are quiescent with regard
to the vasculature, whereas every solid tumor (and
a small subset of the hyperplastic islets) shows evi-
dence of neovascularization, as assessed by [3H] thy
midine autoradiography to detect proliferating cap-
illary endothelial cells, and immunostaining with
laminin, which visualizes new capillary sprouts.
It is possible that every islet composed of prolifer-
ating cells expressing the large T oncogene is inher-
ently angiogenic, but that its surrounding environ-
ment suppresses neovascularization, or that upon
reaching a size threshold, an islet automatically be-
comes angiogenic. Alternatively, individual hyper-
plastic islets could switch on angiogenic activity in
a manner unrelated to size or surrounding environ-
ment. To distinguish between these possible mecha-
nisms, an in vitro bioassay for angiogenesis was
developed. Normal and hyperplastic islets were phys-
ically separated from the pancreas, as were solid
tumors. Individual islets or tumors were placed in
a microwell containing a collection of capillary en-
dothelial cells dispersed in a collagen gel. The islets
from normal mice or from young RIP-Tag2 mice did
not influence the endothelial cells. In contrast, every
solid tumor elicited a dramatic response. The endo-
thelial cells radially align, begin migrating toward
the tumor, form capillary sprouts and then tubes,
and finally degrade the basement membrane sur-
rounding the tumor. This recapitulates the known
stages of neovascularization of tumors in vivo. Thus,
this bioassay distinguishes between normal islets and
the tumors that arise out of them.
Hyperplastic islets were then analyzed through-
out the reproducible time course of tumor develop-
ment in the RIP-Tag2 family. In 4-5-week-old mice,
none of the islets were angiogenic in vitro. At 6-7
weeks, 0.57% of the islets were angiogenic in vitro;
this frequency increased to 2.8% during the 8-10-
week period and was 3.8% at 12 weeks, when 2%
of the islets were represented as solid tumors, which
were all angiogenic as well.
This statistical analysis of islets throughout the
preneoplastic period has revealed that a small
fraction are angiogenic in vitro. (Over 1200 isolated
islets have been individually isolated and analyzed,
which allows this conclusion.) Since more than 50%
of the islets are hyperplastic by 9.5 weeks, one can
conclude that hyperplasia does not obligate angio-
genic activity, since only 2.8% of the islets are an-
giogenic in vitro. Nor does oncogene expression,
since 100% express the large T oncoprotein. More-
over, the in vitro bioassay also demonstrated no strict
correlation between islet size and angiogenic activity.
Thus, the data support the conclusion that angio-
genic activity is induced in a small fraction (r\-,3%)
of the islets during the hyperplastic stage. The frac-
tion of angiogenic islets correlates very well with the
incidence of solid tumors (2%), whereas neither cor-
relates with the frequency of hyperplasia (50-70%).
This suggests that the induction of angiogenesis is
a localized, secondary event necessary for the pro-
gression from hyperplasia to neoplasia. Future stud-
ies will address the mechanism of the switch to an
angiogenic state and the causality of that change in
mediating tumor progression.
Influences of Nerve Growth Factor
on the Development of the
Peripheral Nervous System
in Transgenic Mice
D. Hanahan, J. Alexander [in collaboration with
R.H. Edwards and W.J. Rutter, Hormone Research
Institute and Departments of Neurology and Biochemistry
and Biophysics, University of California, San Francisco]
Nerve growth factor (NGF) is expressed in tissues
that become innervated during neuronal develop-
ment. In vivo, NGF is known to support the survival
and differentiation of both sympathetic and sensory
neurons. This conclusion comes from studies in
which antibodies to NGF are administered during
development, which causes whole populations of
neurons to die, and by the complementary approach,
addition of exogenous NGF, which increases the
number of these same neurons by two- to fourfold.
These observations suggest that NGF is involved
in directing the ingrowth of neurites to cells or tissues
destined to become innervated and that it does so
by being expressed in the target tissue. However, this
possibility has been difficult to directly address
experimentally. Transgenic mice present a new
approach to questions on the roles of growth and
differentiation factors in development, and we have
now applied this system to studies on the role of NGF
in the development of innervation in a peripheral
tissue, the endocrine pancreas.
We chose to overexpress NGF in the islet cells of
the pancreas for three reasons: (1) The pancreas is
innervated by sympathetic, parasympathetic, and
sensory neurons, so the response of a variety of
neurons can be observed; (2) there is no indication
that the pancreatic innervations are so profoundly
influential that perturbations of it would be lethal;
and (3) we have established that gene expression can
be reliably targeted to the pancreatic 13 cells in
transgenic mice through the use of the insulin gene
regulatory region.
A hybrid gene composed of the insulin gene
promoter/enhancer linked to the protein-coding
information for mouse NGF was established in two
lines of transgenic mice (RIP-NGF1 and RIP-NGF2).
Both express NGF in their pancreatic [3 cells, as
evidenced by immunostaining with antibodies spe-
cific for NGF. Nontransgenic mice show no expres-
sion. Each transgenic line has a distinct pattern of
NGF expression. Line 1 shows heterogeneous, high-
level expression, in that only a fraction of the islets
express NGF, and only a fraction of the 13 cells within
an islet show expression, albeit at a high level. In
contrast, mice in line 2 show evidence of uniform,
low-level expression of NGF in virtually every 13 cell
in every islet.
The expression of NGF in the 13 cells of the islets
results in the selective hyperinnervation of those islets
by sympathetic neurons. Neither the sensory nor
parasympathetic innervation is influenced by over-
expression of NGF. There are two major subclasses
of sympathic neurons, which are visualized by their
expression of somatostatin or neuropeptide Y. Syn-
thesis of NGF in 13 cells only affects the neuropep-
tide Y subset, which normally innervates the pan-
creas, and not the somatostatin-positive class, which
projects to different targets.
The innervation of the islets induced by NGF is
highly selective not only for the type of neuron it
affects, but also for the density and location of the
nerve processes. In both lines, the mice show selective
hyperinnervation of the islets and not of the sur-
rounding exocrine pancreas. In line 2, which is uni-
formly expressing NGF in the islets, every islet is
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similarly hyperinnervated. In line 1, which is char-
acterized by sporadic islets expressing high levels of
NGF, the pattern of hyperinnervation is similarly
sporadic, and those islets that are affected have very
dense neural processes. Thus, NGF acts in a localized
fashion to influence the innervation of the collection
of cells expressing it, in a manner that appears semi-
quantitative.
These studies show that NGF can directly influ-
ence the extent of innervation of a target tissue by
the levels of its expression in that tissue. NGF can
apparently only influence neurons that normally
project to that tissue, since the neuropeptide Y-posi-
tive neurons do respond, whereas the somatostatin-
positive neurons do not. The former innervate the
pancreas and the latter do not. A surprise, however,
is that the sensory neurons that project into the pan-
creas are not affected. Sensory neurons are known
to be responsive to NGF in vitro and canbe affected
by anti-NGF antibodies during their development.
It is possible that NGF requires a cofactor in order
to influence sensory neuron development, and this
cofactor may not be available in the islet cells. Al-
ternatively, the sympathetic neurons may compete
more effectively for the available NGF. The current
studies motivate both further investigation into these
possibilities and similar approaches that seek to
assess the influence of targeted expression of NGF
on central nervous system development in transgenic
mice.
Diabetes Induced in Transgenic Mice
by Expression of Human Ha-ras
in Pancreatic 13 Cells
S. Efrat, C. Jolicoeur, D. Hanahan
Our work has focused in recent years on the study
of targeted oncogenesis in 13 cells in transgenic mice,
by introducing hybrid insulin-promoted oncogenes
into the mouse germ line. As part of this study, we
have generated transgenic mice expressing the
activated human Ha-ras oncoprotein in 13 cells. As
with several other hybrid insulin oncogenes expressed
in the 13 cells, expression of ras does not cause any
abnormal cell proliferation. However, unlike mice
harboring other hybrid oncogenes, the insulin-ras
mice develop diabetes several months after the onset
of oncogene expression in [3 cells. The disease results
from dysfunction and degeneration of p cells, with-
out an obvious autoimmune response.
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The onset of transgene expression occurs in 13 cells
during embryonic development, with no discernible
consequences. Young adult mice
also do not show
any abnormalities. Beginning at 5 months of age,
male mice develop hyperglycemia (>400 mg /dl) and
glucosuria and die prematurely within a short time
thereafter. Histological analysis reveals holes in the
majority of the large islets (Fig. 1). In the insulin-
ras females, no hyperglycemia or premature death
has been observed (the oldest female analyzed so far
was 13 months old), but holes do occur in a small
number of the islets, beginning at about 10 months
of age.
The destruction of the islets is not associated with
an obvious inflammatory activity. Leukocytes have
not been observed to infiltrate the islets of the
insulin-ras mice, as judged from histological analysis
and by immunostaining for surface markers of
lymphocytes and macrophages. Immunostaining for
the MHC class I and class II antigens does not reveal
any abnormal expression on the surfaces of the 13
cells. In addition, sections of pancreas from diabetic
animals have been stained with autologous sera,
which did not reveal autoantibodies directed against
the islets. These results suggest that the death of 13
cells in the insulin-ras mice does not involve an
autoimmune response, although this be con-
firmed by classic immunosuppression experiments.
Immunohistochemical analysis with monoclonal
antibodies directed against the human ras protein
(Y13-238 and -259) detects high levels of ras in the
13 cells of both male and female transgenic mice.
Control C57BL/6 mouse islets do not stain for ras,
in contrast to normal human islets (Furth et al.,
Oncogene 1: 47 [1987]). This difference is probably
not due to lack of cross-reactivity between the human
and the mouse proteins (human and mouse ras
proteins are identical in the first 94 amino acids,
where Y13-259 binds). RNA analysis of mouse 13
cells, obtained from tumors arising in insulin-SV40
T antigen transgenic mice, also fails to detect any
ras transcripts (S. Efrat, unpubl.; M. Perucho, pers.
comm.).
In human type I diabetes, hyperglycemia appears
only when the number of 13 cells falls below 10% of
their normal value. In the insulin-ras diabetic males,
although the islets are damaged, they contain 13 cells
staining for insulin in numbers well above the critical
level (Fig. 1). This suggests that insulin processing
or secretion may be impaired in the remaining 13 cells.
Insulin radioimmunoassay reveals very low levels of
circulating hormone in the serum of the diabetic
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FIGURE 1 Immunohistochemical analysis of islet hormones in the pancreas of insulin-ras mice. Thin sections
of paraffin-embedded pancreas were immunostained with antisera specific for the indicated hormones
and visualized with horseradish-peroxidase-conjugated second antibody. M indicates month. Magnifica-
tion, 194 x .
mice, suggesting that the impairment is at the level
of secretion. Immunostaining for the other islet
hormones does not reveal any abnormality (Fig. 1).
Electron microscopy analysis of islets isolated from
diabetic males is in progress to identify any cell
lesions that may precede the stage of cell death.
It therefore appears that high levels of activated
ras protein are toxic to 13 cells, possibly by causing
an impairment in the secretion pathway from the
Golgi to the cell membrane. It is possible that ras
itself, or another G protein, is involved in the
regulation of secretory granule traffic in the 13 cells
and that overexpression of ras interferes with the
normal regulation. The long latency period between
the appearance of ras in the cells and the observed
cell death remains difficult to explain. Interestingly,
the same activated human ras protein has been
overexpressed in several other secretory cell types in
transgenic mice, such as the pancreatic acinar cells
(Quaife et al., Cell 48: 1023 [1987]), where it causes
development of neonatal hyperplasia, and in mam-
mary epithelial cells (Andres et al., Proc. Natl. Acad.
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Sci. 84: 1299 [1987]), where dedifferentiation, tumor
formation, and reduced synthesis of milk proteins
have been observed in rare cases. However, expres-
sion of ras in these secretory cells does not lead to
cell degeneration, as is observed in 13 cells.
A second unresolved issue is the strong suscepti-
bility of males to the effect of ras. Male mice are
known to be more susceptible to diabetes induced
either by obesity mutations, such as db, or by
treatment with streptozotocin, a drug toxic to 13 cells
(Leiter et al., Immunogenetics 26: 6 [1987]). The
reasons for these gender differences are not
understood, although sexual dimorphism in glucose
metabolism has been suggested to be involved.
Estrogens have been shown to act synergistically with
insulin to increase glucose uptake, whereas andro-
gens reduce it, possibly by indirectly antagonizing
the action of insulin on cells (Bailey et al. Diabetolo-
gia 19: 475 [1980]). In the case of the db/db mice,
it has been suggested that sex steroids can determine
the penetrance of the diabetogenic stress imposed
by the obesity mutation (Leiter, Metabolism 37: 689
[1988]). Experiments are in progress to address these
questions in the insulin-ras lineage described here,
as well as in additional lineages harboring hybrid
insulin-ras transgenes, employing either the activated
or the normal human Ha-ras genes. These studies
may contribute to our understanding of13-cell func-
tion and of possible involvement of sex hormones
in 13-cell physiology.
Studies of Transgene Integration
Using Plasmid Rescue
S. Grant, J. Alexander, D. Hanahan [in collaboration with
J. Jesse and F Bloom, Bethesda Research Laboratories]
For the generation of transgenic mice, linear DNA
molecules are microinjected into the pronuclei of
fertilized mouse embryos, whereupon the DNA
becomes integrated into the mouse chromosome. The
typical structure of the integration includes multiple
copies of the injected DNA in a head-to-tail tandem
array. This integration frequently results in rearrange-
ments and deletions of the injected DNA as well as
the chromosomal DNA at the locus of integration.
Disruption of the chromosomal DNA may result in
an insertional mutation, most frequently manifest-
ing as a recessive embryonic-lethal phenotype. To
understand further the process of integration of
microinjected DNA and to analyze the transgene-
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flanking cellular sequences, we have utilized the
plasmid-rescue procedure (Hanahan et al., Cell
21 127 [1980]).
We have examined transgenic mice carrying insulin
promoter-S V40 T antigen hybrid gene constructs
within a pBR-based plasmid. To "rescue" the
transgenes, the high-molecular-weight transgenic
mouse spleen DNA is digested to completion with
a restriction enzyme that cuts once within the
construct and in the flanking cellular DNA. This
linearized DNA is then ligated at low concentration,
to favor circularization, and then transformed into
competent Escherichia coli and selected for anti-
biotic resistance encoded by the rescued plasmid
sequences.
Although the method of plasmid rescue is highly
efficient for yeast, it has been quantitatively ineffi-
cient from mammalian DNA (including transgenic
mouse DNA) (Hanahan, in E. coli and S. typhi-
murium: Cellular and molecular biology, American
Society of Microbiology, Washington D.C. [1986]).
These observations and reconstruction experiments
suggest that plasmid DNA grown in mammalian cells
is modified and subsequently restricted by the com-
mon E. coli strains used for transformation, such
as DH5a. In-vitro-methylated plasmid DNAs are
restricted and have been used to select strains of
E. coli that contain mutations in site-specific
methylation-sensitive restriction systems, including
the McrA and McrB (modified cytosine restriction)
(Raleigh and Wilson, Proc. Natl. Acad. Sci. 83: 9070
[1986]) and Mrr (N6methyladenine modification)
(Heitman and Model [1987]) loci. We have made
derivatives of DH5a and MC1061, by introducing
mutations in the Mcr and Mrr loci, and tested these
mutant strains for the restriction-like phenotype
observed with plasmid rescue from transgenic mouse
DNA.
We have used four lineages of transgenic mice
carrying insulin promoter-SV40 T antigen hybrid
gene constructs, of which two lineages (RIP-Tag2 and
RIR-Tag2) express T antigen in 13 cells from embry-
onic day-e10 and develop (3-cell tumors "fast" at
16-24 weeks of age, and two "slow" lineages (RIP-
Tag3 and RIP-Tag4) that first express T antigen at
10 weeks of age and develop tumors at 30-60 weeks.
The fast and slow tumor phenotypes are heritable
upon continuous backcrossing and thus represent
transgene position effects. Our first observation
using the E. coli strains with Mcr and Mrr mutations
was an increase in efficiency of plasmid rescue
compared to the parental strains, suggesting that
these mutations released the inhibition to transfor-
mation seen in the parental E. coli strains. Interest-
ingly, the number of plasmids rescued in different
mutant strains of E. coli correlated with the
phenotype of tumor formation of these transgenic
mice, in that fast lineage DNA rescued well in E. coli
McrA- McrB- Mrr+, whereas slow lineage DNA
rescued only in E. coli strains McrA- A(McrB- Mrr-).
This requirement of a deletion encompassing McrB
to Mrr for plasmid rescue from slow lineages implies
that these deleted loci detect and restrict a modifica-
tion that distinguishes the slow and fast lineages and
therefore may play a role in the different timing of
transgene expression.
These methylation-restriction mutant strains have
facilitated the recovery of large numbers of plasmids
from the four lineages of transgenic mice. We have
systematically identified clones that represent junc-
tions between adjacent transgenes in the head-to-tail
tandem array, between transgenes and flanking cel-
lular DNA, as well as rearranged and deleted trans-
genes. We are currently analyzing the structure of
these plasmids in detail. In conclusion, our results
demonstrate that plasmid rescue using E. coli strains
deficient in methylation-restriction loci is a rapid and
efficient method for retrieving integrated transgenes
and their flanking cellular sequences. The require-
ment for mutations in these E. coli restriction systems
may, in addition, enable us to investigate the nature
of stable position effects that influence tumor for-
mation.
Genetic Control of Autoimmunity
toward the Insulin-producing
13 Cells in Transgenic Mice
J. Skowronski, C. Jolicoeur, S. Alpert, D. Hanahan
Transgenic mice expressing new proteins provide an
approach to study self-tolerance and autoimmunity,
a disease characterized by a failure to establish or
maintain recognition of self. Direct'ag expression of
novel antigens to specific cell types, which are known
to be susceptible to autoimmune phenomena, such
as the pancreatic-insulin-producing 13 cells, may
perturb their recognition as self. If so, the precise
knowledge of the transgenic antigen would allow
examination of initial events in which an autoanti-
gen and the cell that expresses it become targets for
an autoimmune response.
One example of such a system is provided in
transgenic mice harboring hybrid genes composed
of the rat insulin gene transcription control region
fused to the coding information of the SV40 early
region (RIP-TAG mice) (Hanahan, Nature 325: 155
[1985]). Mice of all lines harboring the hybrid
insulin-T antigen genes express large T antigen in
the insulin-producing 13 cells of the pancreatic islets
of Langerhans, which, as a consequence, eventually
undergo neoplastic transformation. Individual lines
of insulin-T antigen transgenic mice reproducibly
show distinct patterns of developmental expression
of the transgene, which could be classified into one
of the two groups, early and late. In lines character-
ized by the early onset of expression, T antigen is
detectable immunohistochemically in the develop-
ing pancreas through the second half of prenatal life
(Alpert et al., Cell 53: 295 [1988]). Expression
continues thereafter in most, if not all, of the 13 cells.
In lines showing the late onset, T antigen is not
detectable prenatally; it can be first visualized
immunohistochemically in a subset of insulin-
producing cells of adult mice at 10-12 weeks of age.
The immunological response to T antigen appears
to depend on the developmental timing of its
presentation. Mice of RIP-TAG lines showing early
onset of expression of the transgene (RIP-1 Tag2 and
RIR Tag2) are immunologically tolerant to the large
T antigen, whereas those characterized by the
developmentally delayed expression (RIP-1 Tag3 and
RIP-1 Tag4 lines) are not (Adams et al., Nature
325: 223 [1982]). Interestingly, mice of nontolerant
lines spontaneously develop serum antibodies that
react with the SV40 large T antigen. The humoral
response to T antigen is accompanied by lymphocyte
infiltrations of the islets of Langerhans (insulitis) and
their destruction. This suggests that the spontane-
ous immune response is targeted against the T-anti-
gen-expressing 13 cells. Interestingly, the penetrance
of this phenotype is not complete; it was observed
to be 60Wo and 35 Wo when mice of transgenic RIP-1
Tag3 and RIP-1 Tag4 lines, respectively, were random-
ly sampled from the breeding colony. Thus, delayed
expression of the SV40 T antigen is necessary for
the heritable predisposition to develop autoimmu-
nity, but it is not sufficient to elicit the autoimmune
phenotype.
All the transgenic founder mice generated with the
insulin promoter-SV40 early region hybrid gene were
constructed in the F2 hybrids between C57BL/6J
(B6) and DBA/2J (D2) inbred strains of mice. The
transgenic founder mice were propagated by back-
crosses to B6 mice or by intercrosses among trans-
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genic mice. Thus, individual mice of the RIP-1 Tag3
and Tag4 mice are not genetically identical, as they
have different genetic contributions from the two
parental strains. It is therefore possible that there is
a genetic component to the autoimmune response.
To test this hypothesis, RIP-1 Tag3 male mice were
crossed to females of several different inbred strains,
including the parental B6, and D2, strains and B6D2/
F, hybrid mice. The development of autoimmune
phenotype was followed in transgenic progeny until
30 weeks of age. Differences were observed in both
the incidence and the dynamics of the development
of serum IgG antibodies reacting with SV40 large
T antigen. Virtually all of the RIP-1 Tag3 progeny
derived from the D2 backcross developed high levels
of circulating anti-T-antigen antibodies by 20-25
weeks of age. In contrast, only a minor fraction
(17%) of RIP-1 Tag3/B6 mice developed humoral
responses against T antigen by 30 weeks. RIP-1 Tag3
progeny derived from the B6D2/F, displayed an
intermediate frequency of the autoimmune pheno-
type (55%). Interestingly, in these two last crosses,
the dynamics was different from that observed in
RIP Tag3/D2 mice, since the incidence of autoim-
mune mice was increasing more slowly and gradually
up to 30 weeks. These observations are consistent
with the assumption that a single locus present on
the DBA/2J background acts dominantly to pro-
mote autoimmune responses. However, altered dy-
namics of the phenotype suggests that additional loci
are involved in genetic control (or modulation) of
autoimmunity in RIP-1 Tag3 mice.
To test whether the immunoregulatory loci of the
MHC (H-2 in mice) are controlling the autoimmune
phenotype in RIP-1 Tag3 mice, the H-2 haplotypes
of transgenic progeny derived from the B6D2/F,
cross were examined. The H-2 haplotypes were dis-
tinguished by a restriction-fragment-length polymor-
phism (RFLP) between the H-2b (B6) and H-2d
(D2), which is detected by an Ars cDNA probe. By
30 weeks of age, 90% of mice carrying the hybrid
H-2b/H-2d haplotypes had high titers of circulating
anti-T-antigen antibodies. In contrast, only 30% of
the H-2b/H-2b mice had high titers. Thus, loci linked
to the MHC are associated with the development of
autoimmunity in RIP-1 Tag3 mice, and it is tempt-
ing to speculate that MHC itself might be involved.
The MHC-linked locus (loci) is not strictly required
for the development of T-antigen-primed autoimmu-
nity, since a fraction of H-2b/H-2b mice also devel-
ops spontaneous autoimmunity.
RIP-1 Tag3 transgenic mice are heritably predis-
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posed to develop autoimmune response targeting
pancreatic 13 cells by the virtue of the developmen-
tally delayed expression of the transgene. This pre-
disposition results in overt autoimmune phenotype
when combined with additional, proper genetic ele-
ments. There are several components to the auto-
immune phenotype. Developmentally delayed ex-
pression of the SV40 large T protein, which precludes
establishment of the self-tolerance to this novel f3-cell
antigen, is the crucial event, since neither predispo-
sition to develop autoimmunity (specifically target-
ing (3 cells) nor immunoregulatory defects have ever
been observed in the mouse strains used in our trans-
genic experiments. Penetrance of the autoimmune
phenotype is under additional genetic control to
which both the H-2 and non-H-2 loci contribute. H-2
seems to be the major determinant of susceptibility
(or resistance). However, our results suggest that
effects of H-2 can be modulated by other loci. Com-
plex genetic control of autoimmune phenotype in
RIP-1 Tag3 mice and, in particular, its association
with the loci of the MHC are reminiscent of human
autoimmune diseases and, specifically, human-in-
sulin-dependent diabetes mellitus and its animal
models, where (3-cell autoimmunity has been found
correlated with particular class II loci of the MHC.
It is not clear whether class I or class II loci, or both,
are the susceptibility loci in RIP-1 Tag3 mice, and
further studies are necessary to define them.
Latency and Activation of the HIV-1
Transcription Regulatory Region
in Transgenic Mice
J. Skowronski, L. Usher
Human immunodeficiency virus (HIV) is the etiolog-
ical agent of AIDS, the acquired immunodeficiency
syndrome. The major target in HIV infections is the
CD4 subset of T lymphocytes, where the CD4 anti-
gen acts as a receptor for the virus. Cell types other
than CD4 T lymphocytes can also be productively
infected with HIV. These additional cell types include
endothelial cells, monocytes, glial cells, and possibly
others.
Infections of humans with HIV are characterized
by a prolonged absence of detectable virus produc-
tion, as well as an absence of any clinical manifesta-
tions of the disease after the primary infection. The
latency of viral infection in humans has been mim-
icked in experiments with in-vitro-infected human
T cell lines. Here, the dormant state of the provirus
has been found to correlate with the transcriptional
inactivity of the viral promoter, which, subsequently,
can be activated by a variety of stimuli that also
activate T cells. In addition, the trans-acting proteins
of several viruses, including herpesviruses, adeno-
viruses, and some lymphotropic viruses, are capable
of activating transcription of the HIV promoter. The
implications of these results are twofold. First, they
indicate that transcriptional activation of the HIV
promoter elements is critical for transition of HIV
to the active state. Second, they implicate antigenic
stimulation and opportunistic infections as potential
in vivo routes to activate the transcriptionally dor-
mant HIV promoter and consequently elicit virus
production in latently infected individuals.
We have recently initiated experiments directed
toward the development of transgenic mouse models
to study the transcriptional regulation of the HIV-1
promoter in vivo in various tissues and cell types,
under a variety of physiological and experimental
conditions. This approach, where the introduced
gene is heritably present in every cell of the transgenic
animal, should allow us to overcome the limitations
of experiments performed directly on human sub-
jects and provide small animal models that are
amenable to genetic and biochemical studies. To
define tissue specificity of the HIV transcriptional
control elements, two reporter genes were placed
under the transcriptional control of the HIV-1 long
terminal repeat (LTR) and introduced into the germ
line of the inbred C3HeB/FeJ mice. E. coli P-galac-
tosidase (P-Gal) and SV40 large T antigen (TAG)
have been used as the two reporter proteins. A com-
mon advantage to both of these reporter proteins
is that immunological and histochemical reagents
exist, which allow sensitive detection of these proteins
in situ. In addition, T antigen is a potent oncoprotein
capable of altering growth characteristics of a broad
variety of different cell types, including lymphoid
cells, when expressed in transgenic mice. Advantages
of constructing transgenics in inbred lines of mice
are twofold. First, all of the progeny originated from
the same transgenic founder could be considered ge-
netically identical; thus, any alterations of the
phenotype in individual mice of a transgenic line,
if observed, will result from epigenetic factors, rather
than from genetic factors. Second, inbred background
should allow transfers of selected populations of cells
between transgenic and wild-type animals of the
same inbred strain (e.g., adoptive transfers of the
immune system), which may facilitate our analyses.
Multiple lines of transgenic mice were established
with each of the two hybrid genes (HIV LTR /(3 -Gal
lines 1 through 6 and HIV LTR/TAG lines 1 and 2)
and we have initiated their analysis. Autopsies
performed on a limited number of the HIV LTR/
TAG transgenic animals at different ages revealed
that HIV LTR/Tagl mice reproducibly develop hy-
perplasias of the thymus. Thymuses are overtly en-
larged at 2 months of age (two- to fivefold) and by
6-9 months, occupy the major part of thoracic cavity,
which probably results in respiratory and circulatory
insufficiency leading to premature death of animals.
In contrast, mice of the HIV LTR/Tag2 line do not
exibit any overt phenotype. Expression of the LTR
T-antigen transgenes was analyzed by RNase pro-
tection of an antisense probe after hybridization to
RNAs isolated from numerous tissues and organs
of these mice. Two transcripts of sizes predicted for
the correctly initiated (within the HIV LTR) and
spliced mRNAs encoding the SV40 large T and small
T-antigens were detected in RNA isolated from all
major lymphoid organs, including thymus, spleen,
and lymph nodes of mice of both transgenic lines.
Transgenes were also expressed in skin and small
intestines both in transgenic lines and in the bone
marrow of HIV LTR/Tag2 mice. Transcripts from
the transgenes have not been detected in several other
tissues such as brain, kidney, testis, muscle, or heart
in either of the transgenic lines. Such patterns of
expression of the transgenes, observed reproducibly
in mice of two independently derived transgenic
lines, indicate that the HIV promoter is lymphoid-
specific. This conclusion is not contradicted by the
relatively high level of expression of the transgenes
in skin and intestine, because both of these tissues
perform immune functions and contain major popu-
lations of T and/or B lymphocytes, respectively. We
have also initiated analysis of all six lines of the HIV
LTR /(3 -Gal mice using an extremely sensitive fluores-
cent assay of the P-galactosidases in live cells (in
collaboration with S. Fiering and L.A. Herzenberg,
Stanford University). Suprisingly, no expression of
n -Gal transgenes has been detected in the lymphoid
compartment of mice of any of the transgenic lines.
There are many possible explanations of so dras-
tically different behavior of T antigen and 1i -Gal
reporter genes. One possibility is that SV40 large T
and small T antigens, once expressed, may freeze the
target cell in a condition permissive for transcrip-
tional activity of the HIV LTR. Alternatively, the
LacZ protein-coding region may contain dominant,
cis-acting signals that silence the HIV LTR upon
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transmission through the mouse germ line. These and
other possibilities are currently under investigation.
We are now defining the exact specificity of the
HIV promoter for different cell types within the
lymphoid compartment of the HIV LTR/TAG mice,
which is composed of different functionally distinct
populations of B and T lymphocytes. We have
developed an assay using the polymerase chain
reaction (PCR) that allows detection of specific tran-
scripts in a small number of cells. When combined
with cell-sorting techniques, this procedure will allow
us to analyze expression of the transgenes in func-
tional subsets of transgenic lymphocytes. Solid tis-
sues, such as skin and intestine, are also amenable
to this type of analysis. The identity of cells residing
in skin and capable of supporting expression of the
HIV LTR is of a special interest, since these cells have
been implicated in pathogenesis of Kaposi's sarcoma,
a proliferative disorder of skin frequently associated
with AIDS.
In summary, through these transgenic experi-
ments, we hope to identify cell types and in vivo
conditions that are permissive for expression of the
HIV promoter. This knowledge should provide a
stage to define tissue-specific trans-acting factors
critical for transcriptional activation of HIV from
the latent state.
Transgenic Models of Myocardiocyte
Proliferation
M. Steinhelper, P. Weinberg, S. Teplin, L. Field
The regulation of cell division has been a major focus
of research at Cold Spring Harbor Laboratory for
many years. We are specifically interested in the
control of myocardiocyte proliferation. Cardiac
tissue has long been viewed as incapable of regener-
ation. Unlike their skeletal muscle counterpart,
cardiac muscle lacks precursor stem-cell populations
(the so-called satellite cells). Thus, physical or
chemical trauma, which induces skeletal muscle
regeneration via satellite cell proliferation, fails to
elicit a similar response in the heart. The unfortunate
consequence of this is that cardiac tissue cannot be
replaced after destructive trauma, as, for example,
damage resulting from an infarct. Previously, we
generated transgenic mice that carry fusion genes
composed of the atrial natriuretic factor (ANF)
promoter linked to sequences encoding the SV40
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large tumor antigen (TAG). These animals, desig-
nated ANF-TAG, develop unilateral atrial tumors;
although both atria express T antigen, only the right
atrium exhibits a hyperplastic response to the onco-
protein. Given the pronounced hyperplasia observed
in ANF-TAG atria, much of our efforts have involved
further characterization of these animals with the
hope of identifying molecular controls that regulate
myocardiocyte proliferation. Furthermore, we have
initiated studies to determine if ventricular myocytes
can be induced to proliferate in a manner analogous
to that observed in atrial cells. The results that we
have obtained with respect to these issues are con-
sidered separately below.
GENETIC LOCI AFFECTING ATRIAL HYPERPLASIA
IN ANF-TAG MICE
The ANF-TAG transgenic mice were produced in
(C57BL/6J x DBA/2J)/F2 embryos (abbreviated
(B6 x D2)/F2). Consequently, subsequent breeding
of the transgenic animals must result in segregation
of alleles arising from one or the other progenitor
strains (namely, B6 alleles or D2 alleles). Given this
segregation, there is a distinct possibility that
polymorphic alleles that differentially affect atrial
tumorigenesis in ANF-TAG mice may be identified.
To address this issue systematically, we have gener-
ated sublines by repeatedly backcrossing ANF-TAG
mice to either the B6 or D2 progenitor animals. After
four generations of D2 backcrossing, right atrial
hyperplasia is apparent in neonatal pups by 6 days
of age. Moreover, these mice die on average at 8
weeks of age, with severe right atrial hyperplasia. In
contrast, mice derived from four successive back-
crosses to the B6 progenitor exhibit no atrial tumori-
genesis prior to 1 year of age, and a significant num-
ber of these mice die of presumed old age without
displaying any overt cardiac pathology at necropsy.
More intriguing are the distinct differences in atrial
tumor morphology observed in the two sublines.
Mice from the D2 subline show a gross hyperplasia
involving essentially all cells of the right atrium.
Moreover, unilateral left atrial involvement is never
observed. In contrast, tumors developing in atria of
the B6 subline appear (based on histological exam-
ination) to arise from a focal event (i.e., only a
portion of the atrial cells are involved). The latency
and focal nature of pathology in the C57BL/6J
subline invite consideration of a cooperative genetic
event. Were this the case, one might expect that this
putative cooperative event could occur at finite
frequency in the left atrium and consequently give
rise to left atrial tumors. Indeed, such events do occur
as illustrated by three mice (all animals from the B6
subline) that had left atrial tumors in the absence
of right atrial involvement. It should be noted that
the influence of genetic background on atrial tumor-
igenesis has been observed in two independent ANF-
TAG lineages, which essentially rules out trivial
explanations related to the effect of transgene inte-
gration site on the phenotype.
Crossing mice from the ANF-TAG D2 subline with
B6D2/F, mice results in a segregating pattern of
cardiac pathology and death (40-60% D2-like),
supporting the involvement of one or possibly two
genetic loci. Interestingly, the steady-state level of
T antigen also appears to segregate into two discrete
classes among transgenic siblings generated in these
crosses. The D2 and B6 sublines have been estab-
lished as a true breeding genetic resource. Using these
animals, we will attempt to map genetically the loci
responsible for the segregating phenotype by utilizing
standard linkage analyses as well as recombinant
inbred lines of mice. In so doing, we hope to deter-
mine the number of loci that influence the observed
differences in atrial tumorigenesis as well as the
position of these genes on the mouse linkage map.
Moreover, it will be of interest to determine if segre-
gation of T antigen steady-state levels is related (or
causal) to the pattern of atrial tumorigenesis.
Last year, we initiated a series of experiments in
which the ANF-TAG transgene was introduced into
the inverted viscera (iv) background. iv influences
the spatial development of the internal viscera;
animals that are + /+ or + /iv have normal viscera,
whereas animals that are iv/iv have viscera that
develop as a mirror image compared to that of
unaffected mice. Our goal was to cross the ANF-TAG
transgene into this background and assess the
sidedness of the ensuing atrial tumorigenesis.
Animals that exhibited the iv phenotype were
identified by simple ECG analyses. Characterization
of several (iv/iv, + /ANF-TAG) animals has indicated
that atrial pathology follows the viscera; i.e.,
hyperplasia develops in the functional right atria.
However, in performing control analyses on ANF-
TAG animals that failed to show the iv phenotype
(genetic intermediates in this experiment), we
discovered several mice that exhibit bilateral atrial
hyperplasia. This change in atrial pathology may be
attributable to several causes. For example, the
genetic background of the iv mice may be sufficiently
different from that of the ANF-TAG progenitors so
as to cause bilateral hyperplasia. Indeed, the results
above clearly indicate that genetic background can
exert profound influence on atrial tumorigenesis.
Alternatively, a mutation capable of altering the
pathology may have arisen during generation of the
iv/ANF-TAG hybrids. The new phenotype may have
evolved as a consequence of changes in steady-state
oncogene expression, induction of requisite progres-
sion factors, or repression of anti-oncogenes. To
address directly the nature of the bilateral phenotype
will first necessitate the generation of true breeding
populations of mice. Once these animals are avail-
able, we will initiate linkage analyses to map geneti-
cally the locus (loci) responsible for the phenotype.
In conclusion, traditional genetic backcross ex-
periments have revealed at least one (and more likely
two) genetic locus that regulates both the temporal
pattern and eventual end-stage morphology of T-an-
tigen-induced cardiac pathology. We hope to identify
these loci genetically over the next year by utilizing
traditional linkage studies as well as recombinant
inbred lines of mice. In addition, the iv experiments
have identified an additional trait that bestows a
bilateral hyperplastic phenotype.
PROPAGATION OF SUBCUTANEOUS TUMOR
TRANSPLANTS DERIVED FROM ANF-TAG ATRIA
The unilateral atrial hyperplasia in ANF-TAG mice
may arise as a consequence of physiological differ-
ences between the left and right portions of the heart.
For example, differential chamber pressure, oxygena-
tion, or sympathetic innervation could exert a pro-
found influence, which is ultimately manifested as
unilateral atrial tumorigenesis. To address this issue
directly, we evaluated the growth potential of left and
right transgenic atria at a physiologically neutral site.
Nude mice, which lack the capacity to mount an im-
mune response against foreign tissues, received both
left and right transgenic atria from neonatal mice.
Transplantation of neonatal right atria resulted
in the proliferation of myocytes (four out of four
transplants), which continued to express the ANF-
TAG transgene. In contrast, transplanted left atria
did not proliferate to any detectable extent in four
attempts. These results imply that an intrinsic dif-
ferential capacity to respond to an intracellular
mitogenic signal (i.e., SV40 T antigen) exists between
right and left atrial cells. Moreover, these results rule
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out the possibility that unilateral hyperplasia is a sole
consequence of physiological differences within the
context of the heart.
The tumorigenic capacity of hyperplastic right
atria was also assessed in syngeneic animals. Injec-
tion of minced hyperplastic ANF-TAG atria subcu-
taneously into numerous mice gave rise to a single
tumor (TSP.A) palpable after a 9-month latency.
Subsequent passage of the TSP.A tumor resulted in
enhanced growth typified by an increase in the fre-
quency of transplants yielding tumors (>90%) and
by a markedly decreased average latency (2.5 months)
upon passage. The TSP tumors were encapsulated
by a thin layer of connective tissue and were nour-
ished by several prominent blood vessels arising
predominantly from the dorsal scapular fat pad of
the host mouse. The ANF-TAG fusion gene and T
antigen were detected in TSP tumor tissue by
Southern and Western blots, respectively. These
results confirm an atrial origin of the TSP tumor.
ECG leads placed across the TSP tumors revealed
an abnormal arrhythmic electrical activity indepen-
dent of the host's cardiac activity; that this electri-
cal activity originated from the TSP tumor was
confirmed by ECG analysis of explanted tumors in
vitro.
Both the TSP tumors and the original hyperplas-
tic ANF-TAG atria have surprisingly retained a
phenotype characteristic of highly differentiated
cardiac tissue, at the level of gross structural organi-
zation and at the level of molecular expression. This
observation is striking in view of the fact that car-
diocytes from the TSP tumors have been propagating
outside of the context of a heart for a period greater
than 18 months. It is of interest to note that there
is no detectable a-actin isoform switching in either
the TSP tumors or the hyperplastic atria, suggesting
that these myocytes retain a differentiated state
similar to that of normal adult tissue. In this regard,
T-antigen-induced proliferation differs markedly
from other forms of myocyte growth, where a-actin
switching has been shown to be a biochemical hall-
mark. The absence of induction of contractile pro-
tein fetal isoforms in the presence of cell prolifera-
tion is an important consideration with regard to the
potential of cardiocyte regeneration. Finally, promi-
nent vascularization accompanies cardiocyte prolif-
eration in the TSP tumors. Moreover, the ectopic
cardiac tissue is no longer a "vital" host organ, and
the subcutaneous localization of the transplant
renders it experimentally accessible. These properties
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suggest that the TSP transplants will provide an
attractive model system for the study of cardiac -
specific angiogenesis.
TRANSGENIC MODELS OF VENTRICULAR
MYOCYTE PROLIFERATION
The highly differentiated state displayed by the TSP
tumors, and in particular by the hyperplastic atria,
generates renewed interest in the potential of
inducing cardiocyte regeneration in vivo. Clearly, T
antigen is capable of reversing the events that arrest
atrial myocardiocyte division in transgenic model
systems. Indeed, recent observations that document
an association between viral oncogenes and the
retinoblastoma protein, a putative tumor suppres-
sor protein (see E. Harlow and E. Moran, Tumor
Viruses Section), suggests a possible molecular
mechanism for this reversal. The ability to effect a
controlled proliferation of differentiated cardiocytes,
particularly ventricular myocytes, by transient
exposure to T antigen (or a T-antigen derivative) may
be of considerable therapeutic value.
Given this, it is imperative to establish the respon-
siveness of ventricular myocytes to T antigen. In
generating the ANF-TAG mice, three transgenic ani-
mals were obtained that died at 1-3 weeks of age.
Histological analysis of the hearts from these animals
indicated gross atrial hyperplasia. In addition, there
was significant hyperplasia of the ventricular septum,
as well as the right and left ventricle walls. Immu-
nohistological analyses revealed that the hyperplas-
tic ventricular myocytes were expressing T antigen.
Ventricular expression of the endogenous ANF gene
is observed during late embryological development.
We postulate that the ANF-TAG animals exhibiting
ventricular oncoprotein expression carried trans-
genes that integrated in a chromosomal site compati-
ble with normal developmental expression. In sup-
port of this notion, none of the established ANF-TAG
lineages exhibit T-antigen expression during embryo-
logical development, in either the atrium or ventricle.
Thus, it would appear that ventricular myocytes are
responsive to T antigen, at least at late stages of
embryological development. To address the issue of
ventricular responsiveness further, we have generated
fusion genes comprising ventricle-specific promoters
fused to T-antigen sequences. The promoters were
isolated from the human cardiac actin gene and the
rat a-myosin heavy chain. We have initiated microin-
jections with these fusion genes and hope to have
transgenic animals shortly. Such animals will provide
a powerful model system with which to assess the
proliferative potential of ventricular myocytes.
Electrophysiology of Hyperplastic
ANF-TAG Atria
M. Steinhelper, L. Field [in collaboration with
K. Dresdner and A. Wit, Columbia University]
Atrial hyperplasia in the ANF-TAG mice is accompa-
nied by a progressive increase in both the frequency
and severity of cardiac conduction abnormalities,
as assessed by electrocardiographic analysis. These
conduction abnormalities are manifest as ventricu-
lar contractile arrhythmias and can eventually be
lethal to the animal. Generally, disturbances in car-
diac conduction reflect changes in cellular electro-
physiological parameters, such as resting membrane
potential, action potential waveform, and automatic-
ity, and in the patterns of intercellular conduction.
Reductions in the transmembrane potential would
result in action potentials with slower upstroke
depolarization rates, as well as depressing atrial
impulse conduction leading to conduction block.
The combination of slower conduction, conduction
block, and depressed action potentials are factors
that contribute to reentrant arrythmias (which ac-
company a significant number of human myocardial
infarctions) and may explain the rapid and fraction-
ated ECG of transgenic mice with atrial hyperpla-
sia. Studies were therefore initiated to determine if
the ANF-TAG mice might serve as a useful model
for conduction abnormalities.
In the initial experiments, intracellular recordings
were performed on myocytes from three nontrans-
genic control atria and four ANF-TAG transgenic
atria. The preliminary results indicate that expression
of T antigen in cardiac tissue elicits several perturba-
tions of cellular electrophysiology. Spontaneous and
stimulated muscular contractions were evident in
normal atria; however, most regions of hyperplastic
atria did not contract spontaneously and were paced
ineffectively by a stimulating bipolar electrode. The
most striking difference between hyperplastic and
normal atrial tissue was the diminished mean
diastolic potential (MDP), which decreased from a
normal value of - 78 ± 4 mV (n =17) to - 63 ± 1 mV
(n = 46) in the hyperplastic atria (p <0.0001). To assess
action potential waveforms, atria were paced by a
50-V square-wave pulse lasting 2-5 msec. Normal
atrial cells had action potentials characterized by a
rapid initial upstroke, a brief or negligible plateau
phase, and a gradual repolarization smoothly return-
ing to the MDP. In contrast, hyperplastic atrial cells
had action potential waveforms with markedly re-
duced upstroke amplitudes and velocities. Action
potential durations were not altered when cells fired
spontaneously with near-normal upstrokes. Several
cells in the hyperplastic tissue spontaneously fired
rapid bursts of rhythmic and arrhythmic activities,
whereas other cells were quiescent. Quiescent cells
were generally unresponsive to stimulation either by
neighboring cells firing spontaneously or by a
bipolar electrode. A nodule at the expected site of
the sinoatrial node was found in one hyperplastic
atrium. Cells in this region exhibited spontaneous
rates of 11-13 beats/second, which is similar to the
normal heart rate in mice.
We have identified several cellular electrophysio-
logical perturbations resulting from the expression
of T-antigen oncoprotein in cardiac atria. It is of
interest to note that the hyperplastic atria have
regions that are electrically quiescent. Similarly,
histochemical studies have shown a heterogeneous
pattern of TCA cycle activity, as evidenced by a
succinate dehydrogenase assay. Given the fact that
both TCA cycle and electrical activity are dependent
on adequate perfusion, it will be of interest to
determine the spatial relationship between these two
physiological markers. Moreover, further character-
ization of these electrophysiological perturbations
during the development of atrial hyperplasia should
enhance our understanding of the molecular mecha-
nisms by which cardiac arrhythmias arise and develop.
Transgenic Models That Aberrantly
Express Peptide Hormones Regulating
Cardiovascular Homeostasis
M. Steinhelper, P Weinberg, S. Teplin, L. Field
[in collaboration with K.L. Cochrane, University of Virginia]
The maintenance of blood pressure and electrolyte
homeostasis in mammals is regulated in large
measure by the action of peptide hormone systems
operating both in the peripheral circulation and in
the central nervous system. Disruption of the regu-
latory systems comprising these hormones often
results in profound pathophysiological consequences.
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The acute role of vasoactive compounds may be
readily assessed by bolus administration. However,
the chronic effects of these compounds are less
amenable to study largely because of limitations in
existing delivery systems. We are using the transgenic
approach to introduce into the mouse germ line
fusion genes that may circumvent these limitations
and provide lineages of mice with heritable defects
in cardiovascular regulation. Our initial experiments
will focus on atrial natriuretic factor (ANF), a pep-
tide hormone that is synthesized in the cardiac atria.
ANF is secreted from the atrium in response to in-
creases in blood pressure. Once in the circulation,
ANF elicits a natriuretic and diuretic effect by al-
tering glomerular filtration rate and renal collect-
ing duct transport.
To study the effects of chronically elevated levels
of ANF, we have designed fusion genes that should
lead to peripheral overexpression of the hormone.
Thus, we have combined the sequences coding for
ANF with the 5' regulatory sequences of the mouse
albumin gene, the mouse transthyretin gene, or the
rat cytosolic phosphoenolpyruvate carboxykinase
gene. Expression of these fusion genes should result
in secretion of ANF from hepatocytes (in addition,
the transthyretin construct should be active in the
choroid plexus). Multiple founder mice carrying
albumin-ANF (ALB-ANF, seven mice), transthy-
retin-ANF (TTR-ANF, ten mice), and phosphoenol-
pyruvate carboxykinase-ANF (PEPCK-ANF, seven
mice) have been generated. For the ALB-ANF mice,
transgenic lineages have been established and fusion
gene expression has been examined. One lineage has
been shown to have approximately two- to threefold
elevated levels of serum immunoreactive ANF. Al-
though this represents a clear elevation in circulat-
ing hormone, the net increase in steady-state levels
is somewhat disappointing. Nevertheless, this lineage
will be used to assess the consequences of moderately
elevated ANF levels. The TTR-ANF and PEPCK-
ANF founders are presently establishing lineages,
and fusion gene expression will be evaluated as the
animals become available. Given the number of in-
dependent transgenic animals in hand, as well as the
different promoters that were used, we anticipate
obtaining animals expressing a broad spectrum of
circulating ANF concentrations. Such a distribution
of animals would provide a formidable model system
in which to assess the consequences of chronic hor-
mone overexpression.
Finally, investigation of hormones that regulate
blood pressure requires a quantitative means of
assessing changes in this parameter.
Blood pressure
measurements in small rodents
such as mice may be
obtained using pneumatic pulse transducers and
occluding cuffs that are quite similar to those
familiar instruments used by our own physicians.
However, indirect blood-pressure measurements of
rodents are less reliable compared with those of
humans, owing to the requirement for either gentle
restraint of conscious rodents or the use of anesthe-
sia. Highly reliable blood-pressure measurements in
rodents thus require a more experimentally complex
method. To this end, we have established methodol-
ogy to obtain direct blood-pressure measurements
on conscious mice. A cannula fashioned from PE-
10 tubing, inserted via the femoral artery into the
inferior aorta, was positioned a few millimeters distal
to the renal artery. Mice were conscious and freely
moving about their cage within 1 hour after surgery,
and pulsatile arterial pressure was detected using a
pressure transducer coupled to a physiograph. One-
hour recordings of pulsatile arterial pressure with
pulse pressures of 20-50 mm Hg have been obtained
from nontransgenic mice as long as 1 week after
surgery, demonstrating the amenability of the murine
cardiovascular system to rigorous analysis. This type
of analysis will thus provide a reliable means with
which to assess the physiological perturbations
resulting from transgene expression.
PUBLICATIONS
DyCaico, M., S.G.N. Grant, K. Felts, W.S. Nichols, S.A. Geller,
J. Hager, A. Pollard, S.W. Kohler, H.P. Short, F.R. Jirik, D.
Hanahan, and J. Sorge. 1988. Neonatal hepatitis induced
by al antitrypsin: A transgenic mouse model. Science 242:
1409-1412.
Efrat, S., S. Linde, H. Kofod, D. Spector, M. Delannoy, S. Grant,
D. Hanahan, and S. Baekkeskov. 1988. fl-cell lines derived
from transgenic mice expressing a hybrid insulin gene-
oncogene. Proc. Natl. Acad. Sci. 85: 9037-9041.
Field, L.F. 1988. Atrial natriuretic factor-SV40 T antigen transgenes
produce tumors and cardiac arrhythmias in mice. Science
239: 1029-1033.
Singer M.F., J. Skowronski, TG. Fanning, and S. Mongkolsuk.
1988. The functional potential of the human LINE-1 family of
interspersed repeats. Banbury Rep. 30: 71-78.
Skowronski, J., S. Alpert, and D. Hanahan. 1988. The use of
transgenic mice to study interactions of a novel l3 cell antigen
with the immune system. In Lessons from animal diabetes
// (ed. A. Shafrir and A.E. Renold), pp. 158-164. John Libbey
& Co.
Skowronski, J., T.G. Fanning, and M.F. Singer 1988. Unit length
LINE-1 transcripts in human teratocarcinoma cells. Mol. Cell.
Biol. 8: 1385-1397.
In Press, Submitted, and In Preparation
Fabian, J., L.J. Field, J. Mullins, and K.W. Gross. 1989. Differen-
tial expression of the mouse Ren 1 alleles. (In preparation.)
Grant, S.G.N., I. Seidman, D. Hanahan, and V. Bautch. 1989.
Intestinal and pancreatic neuroendocrine tumors in transgenic
mice: Influence of transgenes on tumor progression.
(Submitted.)
Grant, S.G.N., J. Jesse, F Bloom, J. Alexander, and D. Hanahan.
1989. Mutations in E. coli methylase restriction systems allow
efficient plasmid rescue of integrated transgenes and reveal
DNA modifications associated with transgene position effects.
(In preparation.)
Hicks, B.A., R. Stein, S. Efrat, S. Grant, D. Hanahan, D. Wahoff,
and A.A. Demetriou. 1989. Glucose-regulated pancreatic p
cells correct hyperglycemia when transplanted into nude
athymic diabetic rats. (Submitted.)
Lindgren, V., M. Sippola-Thiele, J. Skowronski, E. Wetzel, PM.
Howley, and D. Hanahan. 1989. Specific chromosomal
abnormalities characterize fibrosarcomas of bovine papil-
lomavirus-1 transgenic mice. Proc. Natl. Acad. Sci. (in press).
Mbikay, M., S.G.N. Grant, F. Sirois, H. Tadros, J. Skowronski, C.
Lazure, N. Seidah, D. Hanahan, and M. Cretian. 1989. cDNA
sequence of neuroendocrine protein 7B2 expressed in p cell
tumors of transgenic mice. Int. J. Pept. Protein Res. 33: 39-45.
Rindi, G., S. Grant, V. Bautch, Y. Yiangou, M.A. Ghatei, S.R. Bloom,
D. Hanahan, and J.M. Polak. 1989. Intestinal neuroendocrine
tumors arising from S cells express secretin and evidence
neuroendocrine plasticity. (Submitted.)
Skowronski, J., C. Jolicoeur, and D. Hanahan. 1989. Modulation
of tolerance and autoimmunity in transgenic mice. In Current
communications in molecular biology: Perspectives on the
molecular biology and immunology of the pancreatic 13 cell
(ed. D. Hanahan et al.). Cold Spring Harbor Laboratory, Cold
Spring Harbor, New York.
Skowronski, J., C. Jolicoeur, S.A. Alpert, and D. Hanahan. 1989.
Both H-2 and non H-2 alleles modulate autoimmunity in RIP-1
Tag #3 mice. (In preparation.)
Steinhelper, M.E. and L.J. Field. 1989. Cardiocyte proliferation
in transgenic mice. In The development and regenerative
potential of cardiac muscle (ed. J. Oberpriller and A. Mauro).
Harwood Academic Press. (In preparation.)
Steinhelper, M.E. and L.J. Field. 1989. Influence of genetic
background on atrial tumorigenesis in transgenic mice. (In
preparation.)
Steinhelper, M.E. and L.J. Field. 1989. Proliferation in vivo of
differentiated cardiomyocytes in tumor transplants derived
from transgenic atria. (Submitted.)
GENETICS OF CELL PROLIFERATION
Michael Wig ler C. Birchmeier
D. Broek
J. Field
S. Powers
D. Young
R. Ballester
G. Bolger
J. Colicelli
K. Ferguson
J. Gerst K. O'Neill
T. Michaeli M. Riggs
S. Sharma L. Rodgers
A. Vojtek G. Asouline
I. Wieland J. Brodsky
S. Cameron R. Elsin
H.-P. Xu D. Klein
C. Nicolette B. Shenko
Our laboratory studies the relationship among
oncogenes, signal transduction, and malignant trans-
formation, with particular emphasis on RAS genes.
Three mammalian RAS genes, Ha-ras, Ki-ras, and
N-ras, are capable of the malignant transformation
of cultured animal cells. Mutations in these genes
have been linked to a large number of human can-
cers. Perhaps as much as 2507o of human tumors
contain mutant RAS genes, pointing to a common
metabolic defect in a large fraction of human ma-
lignancy. It is therefore imperative that we under-
stand the biochemical function of RAS proteins.
The RAS genes encode closely related proteins that
bind guanine nucleotides (Scolnick et al., Proc. Natl.
Acad. Sci. 76: 5355 [1979]; Shih et al., Nature 287:
686 [1980]); Ellis et al., Nature 292: 506 [1981]) and
are localized to the inner surface of the plasma mem-
brane (Willingham et al., Cell 19: 1005 [1980]; Papa-
george et al., J. Virol. 44: 509 [1982]). Normal RAS
proteins also slowly hydrolyze GTP (Gibbs et al.,
Proc. Natl. Acad. Sci. 81: 5704 [1984]; McGrath et
al., Nature 310: 644 [1984]; Sweet et al., Nature
311: 273 [1984]). These properties are similar to those
of the G proteins, which has led to the widespread
101
expectation that RAS proteins, like G proteins, are
involved in the transduction of membrane signals
that are linked to cellular proliferation or differen-
tiation. Many of the mutations that activate the RAS
genes result in the production of proteins with
impaired GTP hydrolysis (Gibbs et al., Proc. Natl.
Acad. Sci. 81: 5704 [1984]; McGrath et al., Nature
310. 644 [1984]; Sweet et al., Nature 311: 273 [1984]).
This has suggested that, like G proteins, RAS
proteins are active when bound to GTP but inactive
when bound to GDP. The biochemical function of
the mammalian ras proteins is unknown.
We have been studying the function of the yeast
RAS genes in the expectation that such study will
lead to insights into the functioning of the mam-
malian RAS genes. Saccharomyces cerevisiae have
two genes, RAS1 and RAS2, that are structurally
homologous to the mammalian RAS genes (DeFeo-
Jones et al., Nature 306: 707 [1983]; Dhar et al.,
Nucleic Acids Res. 12: 3611 [1984]; Powers et al., Cell
36: 607 [1984]). The yeast and mammalian RAS
genes are functionally related as well, since mam-
malian RAS genes can complement yeast lacking
their endogenous RAS genes (Kataoka et al., Cell
40: 19 [1985]), and yeast RAS genes canmalignantly
transform cultured animal cells (DeFeo-Jones et al.,
Science 228: 179 [1985]). In the yeast S. cerevisiae,
RAS proteins appear to control events related to
growth arrest. The RAS2 gene can be activated by
a point mutation analogous to the point mutation
of Ha-ras, which activates its oncogenic potential
(Kataoka et al., Cell 37: 437 [1984]). Cells carrying
the activated RAS2' '9 gene fail to arrest in GI when
starved, remain heat-shock-sensitive when they reach
stationary phase, and fail to accumulate storage
carbohydrates (Kataoka et al., Cell 3 7: 437 [1984];
Sass et al., Proc. Natl. Acad. Sci. 83: 9303 [1986]).
These same sets of phenotypes are observed when
the adenylyl cyclase pathway is activated (Uno et al.,
J. Biol. Chem. 257: 14110 [1982]) and first led us to
suspect an interaction between RAS proteins and
adenylyl cyclase.
Our laboratory is also continuing investigations
into two mammalian oncogenes. The MAS oncogene
encodes a potential hormone or neurotransmitter
receptor with seven transmembrane domains. The
overexpression of MAS leads to a minimally trans-
formed phenotype. The ROS oncogene encodes a
large transmembrane tyrosine kinase, which also is
a potential receptor for an unknown ligand. The ROS
gene is expressed and rearranged in some glioblas-
tomas.
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Interaction between RAS Proteins
and Yeast Adenylyl Cyclase
J. Field, J. Colleen', R. Ballester,
T Michael
In yeast, RAS proteins are required for the proper
functioning of adenylyl cyclase (Toda et al., Cell
40: 27 [1985]). This is readily seen both from studies
in vivo with mutant yeast strains (Toda et al., Cell
40. 27 [1985]; Nikawa et al., Genes Dev. 1: 931 [1987])
and from studies in vitro (Broek et al., Cell 41: 763
[1985]; Field et al., Mol. Cell. Biol. 72: 2128 [1987];
Field et al., Mol. Cell. Biol. 8: 2159 [1988]). Our in
vitro systems use RAS proteins purified from an
Escherichia coli expression system ( Broek et al., Cell
41: 763 [1985]; Gross et al., Mol. Cell. Biol. 5 1015
[1985]) and an adenylyl cyclase complex purified
from S. cerevisiae (Field et al., Mot Cell. Biol. 8: 2159
[1988]). Our method of purification of adenylyl
cyclase is novel. It involves making in yeast a fusion
protein of adenylyl cyclase with a small amino-
terminal peptide epitope. Extracts of yeast are passed
over an affinity column containing monoclonal
antibodies directed against the peptide epitope.
Adenylyl cyclase is then eluted with synthetic peptide,
resulting in a greater than 100-fold purification. The
resulting complex contains a 70-kD component that
copurifies with adenylyl cyclase activity in glycerol
sedimentation gradients.
We conclude from our in vitro studies that RAS
proteins interact directly with the adenylyl cyclase
complex. The addition of either yeast RAS2 protein
or mammalian Ha-ras protein can result in a greater
than 20-fold stimulation of activity. We can also
conclude from in vitro work that RAS proteins
bound to GTP stimulate adenylyl cyclase, but RAS
proteins bound to GDP do not (Field et al., Mol.
Cell. Biol. 8: 2159 [1988]). Thus, the activity of RAS
proteins is controlled by the guanine nucleotide they
bind, consistent with the model of oncogenesis
proposed for mutant, activated RAS. We have also
concluded from our work that the stimulation of
adenylyl cyclase requires the continued presence of
RAS proteins.
We cannot conclude from our work that RAS
proteins act directly on adenylyl cyclase itself, since
the adenylyl cyclase complex copurifies with a 70-
kD protein (Field et al., Mol. Cell. Biol. 8: 2159
[1988]). We are currently investigating the role of the
70-kD protein in the RAS responsiveness of adenylyl
cyclase (1) by attempting the purification of the 70-
kD protein and cloning the gene that encodes it and
(2) by performing deletion analysis of adenylyl
cyclase.
Control of RAS Protein Activity
S. Powers, D. Broek, S. Cameron, K. Ferguson,
K. O'Neill
In S. cerevisiae, the CDC25 protein appears to
control RAS protein activity. cdc25" alleles were
first discovered as cell-cycle GI arrest mutants (Hart-
well et al., Genetics 74: 267 [1973]; Hartwell, Bac-
teriol. Rev. 38: 164 [1974]). Cells lacking cdc25 are
deficient in cAMP and have aberrant adenylyl cyclase
activity (Martegani et al., EMBO J. 5: 375 [1986];
Broek et al., Cell 48: 789 [1987]; Camonis et al.,
EMBO J. 5: 375 [1986]; Nikawa et al., Genes Dev.
1: 931 [1987]). Cells that contain the activated,
mutant RAS2va119 gene do not require the CDC25
product (Broek et al., Cell 48: 789 [1987]; Robinson
et al., Science 235 1218 [1987]). These data are
consistent with a model in which the CDC25 product
acts upstream of RAS and causes its activation,
possibly by catalyzing nucleotide exchange.
Further evidence in favor of this model has come
from our discovery of mutant RAS proteins that be-
have as though they interfere with CDC25 activity
(Powers et al., Mol. Cell. Biol. 9: 390 [1989]). These
mutant RAS genes were found in the course of a ge-
netic screen for temperature-sensitive RAS mutants.
We found in this screen dominant temperature-sensi-
tive lethal RAS2 alleles. Significantly, lethality can
be overcome by the presence of the CDC25 gene on
a high-copy plasmid but only if a wild-type RAS2
or RASI gene is also present. Lethality can also be
overcome if cells contain the mutationally activated
RA S2va"9 gene. Thus, the mutant RAS proteins ap-
pear to interfere with the activation of wild-type RAS
proteins, perhaps by forming a complex with CDC25
proteins. The mutations in interfering RAS genes lo-
calize to the region that encodes part of a consensus
nucleotide-binding site common to many GTP-bind-
ing proteins (Powers et al., Mol. Cell. Biol. 9: 390
[1989]).
To explain our results with CDC25 and RAS, we
propose that RAS proteins and CDC25 proteins
normally undergo a transient and direct interaction,
similar to models that have been proposed to explain
the interaction of receptors with G proteins (Gilman,
Ann. Rev. Biochem. 56: 615 [1987]; Stryer, Ann. Rev.
Neurosci. 9: 87 [1986]). As in those models, CDC25
proteins interact with the GDP-bound form of RAS
proteins and, by virtue of stabilizing the transitional
state of nucleotide-free RAS protein, catalyze
nucleotide exchange. We propose that the dominant
temperature-sensitive RAS proteins remain bound
to CDC25 protein because alterations in the consen-
sus nucleotide-binding site alter nucleotide affinity
and stabilize a nucleotide-free RAS-CDC25 protein
complex.
Interfering Mutants in Signal
Transduction Pathways
S. Powers, T. Michaeli, J. Field, J. Colicelli, R. Ballester
The discovery that there exist mutant forms of RAS
that interfere with activation of normal RAS led us
to think about interfering mutants in a more general
sense. In the broadest possible terms, if there is a
signal transduction pathway wherein protein X
interacts with protein Y, which then interacts with
protein Z in a cascade of information flow, one can
expect at least four types of dominant interfering
mutant proteins: mutants of X that complex ineffec-
tively with Y; mutants of Y that complex ineffectively
with X; mutants of Y that complex ineffectively with
Z; and mutants of Z that complex ineffectively with
Y. Genetic screens can be designed to search for
mutations that produce these kinds of proteins, and
such mutants may be valuable tools in the analysis
of complex signaling pathways.
We have applied this approach to the RAS /ade-
nylyl cyclase pathway of S. cerevisiae. We randomly
mutagenized Ha-ras genes by passage of plasmids
carrying Ha-ras through a mutator strain of E. coli
(Silhavy et al., in Experiments with gene fusions,
Cold Spring Harbor Laboratory, Cold Spring Har-
bor, New York [1984]), and screened the mutagenized
plasmids for their ability to suppress the heat-shock
sensitivity of strains of yeast carrying the RAS2va119
gene. One such mutant was found, and sequence
analysis revealed that it contained an arginine for
cysteine substitution at codon 186 (T. Michaeli, sub-
mitted). This disrupts the Cys-A-A-X (where A is any
aliphatic amino acid and X is the terminal amino
acid) consensus sequence of RAS proteins (Taparow-
sky et al., Cell 34: 581 [1983]; Powers et al., Ce1136:
607 [1984]) that functions as a target for the fatty
acid addition which causes membrane localization
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of RAS (Willumsen et al., Nature 310: 583 [1984];
Powers et al., Cell 47: 413 [1986]). We found that
other mutations in this region which destroy the
consensus sequence also result in Ha-ras genes that
interfere with the phenotype of RAS2-19.
Our analysis of the mutant Ha-ras proteins with
a disrupted Cys-A-A-X consensus sequence indicates
an unexpected complexity of RAS interactions. The
mutant proteins remain cytosolic, in keeping with
the findings of other investigators that the Cys-A-
A-X sequence is required for membrane localization
(Willumsen et al., Nature 310: 583 [1984]). The Ha-
ras mutants do not block RAS2a1' protein from
localizing to the membrane. Their effect is therefore
not likely to be due to dominant effects on RAS
protein processing. Competition experiments indi-
cate that the effects of the Ha-ras mutants are com-
peted by overexpression of RAS2-19 but not by
overexpression of CYR1, the gene that encodes
adenylyl cyclase. From this, we conclude that these
Ha-ras mutant proteins interfere with a cytosolic
factor which may facilitate the interaction of RAS2
with adenylyl cyclase. Alternatively, the mutant Ha-
ras may interfere with a second function of RAS.
Evidence for multiple functions of RAS in yeast is
given below.
We have also found mutant CYR1 genes that
interfere with the phenotypes of RASIa19. We used
a strategy similar to the one described above. We
passaged a plasmid carrying CYR1 through a
mutator strain of E. coli and readily found clones
of CYR1 that blocked the heat-shock sensitivity of
RAS2a119 strains. The ease with which this screen
yielded interfering mutations in CYR1 led us to
suspect that virtually any mutation that disrupted
the enzymatic function of adenylyl cyclase could
result in an interfering protein. Direct tests proved
this hypothesis to be correct. The region encoding
the catalytic portion of the adenylyl cyclase is located
at the 3' end of CYR1 (Kataoka et al., Cell 43: 493
[1985]). Frameshift or deletion mutations in this
region result in the production of interfering forms
of the CYR1 product. Competition assays suggest
that the effects of defective CYR1 genes can be
suppressed by overexpression of RAS proteins. It is
likely, we think, that the mutant CYR1 genes encode
proteins that form ineffective complexes with RAS
proteins. More generally, it may be true that proteins
which are the targets of RAS action can interfere
with RAS function when they are functionally in-
competent.
Feedback Regulation of
RAS Activity
S. Cameron
In the course of screens for genes that, when
overexpressed, can suppress the phenotypes induced
by RAS2-", we cloned two genes of S. cerevisiae
that encode cAMP phosphodiesterases PDE1 and
PDE2 (Sass et al., Proc. Natl. Acad. Sci. 83: 9303
[1986]; Nikawa et al., MoL Cell. Biol. 7: 3629 [1987]).
Together, these genes appear to encode the totality
of cAMP phosphodiesterase activity measurable in
yeast cell extracts (Nikawa et al., MoL Cell. Biol.
7 3629 [1987]). Surprisingly, we found that cells
which lacked these genes, but that were otherwise
normal, did not accumulate enormous levels of
cAMP (Nikawa et al., GenesDev. 1: 931 [1987]). One
explanation for this result is that elevated levels of
cAMP directly or indirectly feedback to turn off the
further production of cAMP. Confirmation of this
theory comes from examining cAMP levels in cells
that lack the PDE genes but contain the RAS2a"
gene (Nikawa et al., Genes Dev. I: 931 [1987]). Such
cells have enormously elevated levels (over 1000 -
fold!) of cAMP. In addition to confirming the exis-
tence of feedback, these studies indicate that the
RAS2-w) protein is unresponsive to feedback
controls.
Feedback requires the activity of the cAMP-
dependent protein kinases (cAPK). The catalytic
subunits of these genes are named TPK1, TPK2, and
TPK3 (Toda et al., Cell 50: 277 [1987]). Cells with
attenuated TPK genes have enormously elevated
cAMP levels when they are grown in rich medium
containing glucose (Nikawa et al., Genes Dev. 1: 931
[1987]). This result is consistent with the idea that,
through homeostasis, the activity of the cAPK regu-
lates cAMP levels. A dramatic demonstration of this
is seen upon feeding glucose to cells with an attenu-
ated cAPK system. Wild-type cells show a biphasic
response to glucose when fed: A tenfold elevation
of cAMP ensues within minutes and diminishes to
basal levels within 10 minutes (Beullens et al., Eur.
J. Biochem. 172: 227 [1988]). In cells with an attenu-
ated cAPK system, glucose feeding does not induce
a biphasic response in cAMP levels. Rather, there
is a sharp, perhaps 100-fold, elevation of cAMP levels
that remain elevated as long as glucose is present
(Wigler et al., Cold Spring Harbor Symp. Quant.
Biol. 53: 649 [1988]). This result indicates that (1) the
cAPK system participates in the physiologic feedback
regulation of the cAMP response to glucose and (2)
glucose is a stimulant of the system, and the system
remains stimulated as long as glucose is present.
These results on feedback of cAMP production also
suggest the possibility that the levels of cAMP in a
cell may oscillate in response to cycles of stimula-
tion and feedback.
RAS-independent Pathways
for Growth Control
S. Cameron, J. Colicelli, A. Vojtek, K. Ferguson, H. Xu
The yeast S. cerevisiae undergoes marked changes
in response to nutrient limitation. Diploid cells will
sporulate under appropriate starvation conditions.
Haploid cells respond by becoming heat-shock-
resistant and by accumulating storage carbohydrates.
Since these responses can be mimicked by mutations
that lower the activity of the cAMP-dependent pro-
tein kinase (cAPK) and can be blocked by mutations
that raise the activity of the cAPK, it is natural to
assume that physiologic modulation of cAMP ac-
tivity by cAMP regulates these responses. However,
the cAPK system may not be the only signaling sys-
tem that generally regulates growth and responses
to nutrition. We have used the genetics available in
yeast to examine this question more directly.
The yeast S. cerevisiae contains a cAMP-responsive
kinase activity. Genes encoding a regulatory subunit,
BCYI (Toda et al., MoL Cell. Biol. 7 1371 [1987]),
and three catalytic subunits, TPKI, TPK2, and TPK3
(Toda et al., Cell 50: 277 [1987]), have been isolated.
Disruption of the BCYI gene results in a very severe
phenotype (Toda et al., MoL Cell. Biol. 7 1371
[1987]). We have characterized the role of the cAPK
catalytic subunit genes in producing the bcyl-
phenotype, and in the process, we have generated
mutant cAPK catalytic subunit genes (TPK) that
suppress the bcyl- defects (Cameron et al., Cell
53: 555 [1988]). The mutant TPK genes appear to
encode functionally attenuated catalytic subunits of
the cAPK. bcyl- yeast strains containing the mutant
TPK genes respond appropriately to nutrient con-
ditions, even in the absence of CDC25, both RAS
genes, or CYRI. Together, these latter genes encode
the known components of the cAMP-generating
machinery. The results indicate that cAMP-indepen-
dent mechanisms must exist for regulating glycogen
accumulation, sporulation, and the acquisition of
thermotolerance in S. cerevisiae. In particular, RAS-
independent signaling systems must exist. Indeed,
we have isolated many genes that can modulate the
phenotype of the activated RA S/cAMP signaling
system but that do not appear to belong to that
signaling system.
Evidence for Additional
Functions of RAS
S. Powers, T. Michaeli, A. Vojtek
Most of the effects of RAS on yeast cells can be
explained by their action on adenylyl cyclase. The
phenotype of cells containing RAS2- "9 can readily
be understood as a consequence of the perturbation
of cAMP production: cAMP levels are elevated in
cells containing RAS2-19; activation of the cAMP-
dependent protein kinases leads to a phenotype that
closely resembles that due to RAS2 "9; and elevated
expression of cAMP phosphodiesterases reverses the
RAS2-119 phenotype (Sass et al., Proc. Natl. Acad.
Sci. 83: 9303 [1986]; Nikawa et al., MoL Cell. Biol.
7: 3629 [1987]). Moreover, the lethality that otherwise
results from disruption of both RAS genes can be
overcome by disruption of the gene, BCYI, that
encodes the cAMP-dependent protein kinase
regulatory subunit (Toda et al., Ce1150: 277 [1987]).
The resulting unbridled protein kinase activity is
sufficient to complement the loss of RAS function.
However, there are subtle effects of disruption of
both the RAS] and RAS2 genes that do not appear
to be identical to the effects of disrupting the
adenylyl cyclase gene, and mutations in RAS act in
ways that cannot be explained readily by effects upon
adenylyl cyclase.
There are two major differences between cells
lacking RAS and cells lacking CYRI. First, haploid
spores that lack the CYRI gene are often viable,
although they give rise to very slow growing colonies,
whereas haploid spores that lack both RASI and
RAS2 genes are almost never viable (Toda et al., in
Oncogenes and cancer, Japan Sci. Soc. Press,
Tokyo/VNU Sci Press [1987]). Second, overexpress-
ing the TPK genes can readily suppress the growth
defect resulting from lack of CYRI, but cannot so
readily suppress the growth defects resulting from
lack of RAS genes (Wigler et al., Cold Spring Harbor
Symp. Quant. Biol. 53: 649 [1988]). Indeed, such
RAS-deficient strains suppressed by TPK genes are
often temperature-sensitive. Thus, it appears that
RAS may have additional functions besides the
stimulation of adenylyl cyclase.
The results described above can each be explained
in many ways. For example, one may propose that
there is a second gene encoding adenylyl cyclase. We
have rigorously eliminated this possibility. If such
a second adenylyl cyclase existed, it would have to
produce 1000-fold lower cAMP levels than the CYR1
gene. Alternatively, one can propose that it is better
to have no cAMP (cyrl-) than a little (rasl- ras2-).
However, there is one telling piece of evidence that
rules out this possibility. We have shown that many
strains that lack both CYR1 and RAS, but that are
viable because TPK genes are highly expressed, are
temperature-sensitive. This temperature sensitivity
is cured by expressing RAS in such cells. Thus, RAS
can act even in the absence of adenylyl cyclase. Lack
of CDC25 function produces the same defects as lack
of RAS function even in the absence of CYR1.
Hence, we conclude that RAS has additional
functions besides stimulating adenylyl cyclase and
that these functions are also shared by CDC25
(Wig ler et al., Cold Spring Harbor Symp. Quant.
Biol. 53: 649 [1988]).
Comparison of
and Yeast RAS
S. Powers, J. Field, K.
T. Michaeli, J. Colicelli
Mammalian
Ferguson, R. Ballester,
The similarities of the mammalian and yeast RAS
genes are striking. The mammalian Ha-ras can
complement yeast lacking their own RAS genes.
Purified Ha-ras protein can stimulate purified yeast
adenylyl cyclase (Broek et al., Cell 41: 763 [1985]).
Genetic experiments demonstrate that Ha-ras can
provide the additional functions of RAS in yeast,
complementing the loss of RAS even in strains that
lack adenylyl cyclase (Wig ler et al., Cold Spring
Harbor Symp. Quant. Biol. 53: 649 [1988]).
There are other similarities between mammalian
and yeast RAS. Mammalian Ha-ras protein, like
yeast RAS, is probably subject to feedback inhibition
(Bar-Sagi and Feramisco, Science 233: 1061 [1986]).
We have evidence, too, that Ha-ras can interact with
CDC25. The analogous mutations can be introduced
into Ha-ras, which cause the dominant interfering
mutants of RAS2. When these mutant Ha-ras genes
are expressed in yeast, they also appear to block
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CDC25 activity (Powers et al., MoL Cell.Biol. 9 390
[1988]). Similar mutants are also interfering in animal
cells (Feig and Cooper, Mol. Cell. Biol. 8 3235
[1988]), suggesting that there is a mammalian protein
that catalyzes nucleotide exchange in mammalian
RAS proteins. Perhaps there is a CDC25 homolog
in mammals.
Two other questions of similarity are raised by our
studies of yeast. First, in yeast, RAS absolutely
controls its effector pathway. It is not clear if this
is so in mammals, although we suspect it is so.
Second, in yeast, it is likely that RAS has more than
one function. It is quite possible that RAS proteins
also have more than one function in mammalian
cells. This might explain some of the difficulty of
assigning a function to mammalian RAS.
There are obvious differences between mammalian
and yeast RAS proteins. The most glaring difference
appears to be in the immediate biochemical function
of the RAS proteins in their respective hosts. It is
unlikely that mammalian RAS functions to stimulate
adenylyl cyclase in vertebrates (Birchmeier et al., Cell
43: 615 [1985]). Indeed, a fundamentally different
model of RAS action has been proposed in
mammalian cells. Our model of RAS action is rather
like the model of action for G proteins and transdu-
cin (Gilman, Ann. Rev. Biochem. 56: 615 [1987]).
This model is strongly supported by experiments in
yeast. A radically different model, emerging from
the discovery of a Cil Pase-activating protein (GAP),
and speculative analogies between RAS proteins and
bacterial elongation factor EF-Tu, has been proposed
(Adari et al., Science 240: 518 [1988]; Ca les et al.,
Nature 332: 548 [1988]). Our own opinion is that the
latter model is wrong. There are too many similari-
ties between yeast and mammalian RAS to cause us
to abandon the yeast model. Our own studies point
to the complexity of RAS interactions with its
effectors, and although the identities of the individ-
ual effectors may have evolved during speciation, we
feel that the patterns of RAS interactions may have
changed little in evolution.
The Search for the Mammalian
RAS Target
J. Collicelli, T. Michaeli, C. Birchmeier, J. Field
Our discoveries of interfering mutants in the RAS
signaling pathway have led to a strategy for searching
for the target of RAS protein action in mammalian
cells. We have postulated that the function of RAS
in yeast would be inhibited by the expression, in
yeast, of the mammalian target for RAS action. We
have therefore constructed rat brain cDNA libraries
in yeast expression vectors to test this idea. In a pilot
experiment, we transformed yeast containing the
activated RAS2va"9 gene and screened for heat-
shock-resistant colonies among the transformants.
One colony was identified that contained a vector
that reproducibly induced heat-shock resistance in
yeast strains carrying RAS2va"9. Analysis revealed
that this vector contained a cDNA insert with the
potential to encode a protein highly homologous to
the Drosophila dunce product (Chen et al., Proc.
Natl. Acad. Sci. 83: 9313 [1986]), and we tentatively
call our gene DNC (Colicelli et al., Proc. Natl. Acad.
Sci. [1989] in press).
The dunce locus was identified in mutant flies with
defects in learning (Chen et al., Proc. Natl. Acad.
Sci. 83: 9313 [1986]). dunce encodes a cAMP
phosphodiesterase, leading us to suspect that the
mammalian gene we cloned also encoded a cAMP
phosphodiesterase. To test this idea, we transformed
a yeast strain that lacks the two genes which encode
cAMP phosphodiesterases, PDE1 (Nikawa et al.,
Mol. Cell. Biol. 7 3629 [1987]) and PDE2 (Sass et
al., Proc. Natl. Acad. Sci. 83: 9303 [1986]). pdel-
pde2- yeast carrying the rat DNC express a high-
affinity cAMP phosphodiesterase (Colicelli et al.,
Proc. Natl. Acad. Sci. [1988] in press). We do not
believe DNC encodes the mammalian RAS target.
Rather, it is likely that DNC suppresses RAS2va" by
lowering cAMP levels. As precedent, overexpression
of either PDE gene suppresses RAS2va19 (Sass et al.,
Proc. Natl. Acad. Sci. 83: 9303 [1986]; Nikawa et al.,
Mol. Cell. Biol. 7: 3629 [1987]).
These results have import for the study of cAMP
phosphodiesterase activity in mammals. First, we
have now identified a strategy useful for cloning
mammalian cAMP phosphodiesterases. This may
lead to the discovery of a wide family of enzymes
of great physiological importance. Second, once
cloned, the biochemical and pharmacological prop-
erties of mammalian phosphodiesterases may be
studied after their expression in yeast lacking their
own endogenous phosphodiesterases.
The ROS Oncogene
C. Birchmeier, S. Sharma, K. O'Neill, L. Rodgers
As reported previously, we have identified oncogenic
forms of the human ROS gene (Fasano et al., Mol.
Cell. Biol. 4 1695 [1984]; Birchmeier et al., Mol. Cell.
Biol. 6: 3109 [1986]). This gene has the potential to
encode a transmembrane tyrosine kinase (Necka-
meyer and Wang, J. Virol. 53: 879 [1985]; Birchmeier
et al., Mol. Cell. Biol. 6: 3109 [1986]). Like other
oncogenes in this family, ROS probably encodes a
membrane receptor/kinase. We have noted a high
frequency of expression of ROS in malignant glio-
blastomas (Birchmeier et al., Proc. Natl. Acad. Sci.
84: 9270 [1987]), and as such, ROS may encode a
surface antigen useful for diagnosis and possibly
therapeutic intervention.
We have continued our study of ROS in three
veins: First, we have developed polyclonal antibod-
ies to the ROS product. These recognize a 270-kD
glycoprotein in most cells that express ROS. As such,
ROS would encode one of the largest known mem-
brane receptor/kinases. In collaboration with Tom
Jessel at Columbia University, these antibodies have
been used to study the expression of ROS in develop-
ing rat embryos. Our data suggest that ROS is
normally expressed on radial glial cells in the devel-
oping spinal cord.
Second, we have cloned most and perhaps all of
the cDNA of the large 8.3-kb ROS transcript found
in glioblastoma cells. DNA sequencing is not yet
complete, but it is apparent that ROS encodes a pro-
tein that is most similar to the Drosophila sevenless
product (Hafen et al., Science 236: 55 [1987]; Basler
and Hafen, Cell 54: 299 [1988]; Bowtell et al., Genes
Dev. 2: 260 [1988]). sevenless encodes a protein re-
quired for the proper development of fly retinal cells.
One interesting possibility is that ROS encodes a mem-
brane receptor important in cell-cell recognition.
Third, we have begun to characterize abnormal
ROS expression in one glioblastoma cell line, U-118
MG. In this cell, the ROS locus has fused with a
second locus, and a chimeric transcript and protein
result. Analysis of the cDNA for this transcript
indicates that the loss of the extracellular and trans-
membrane domains of ROS has occurred, leaving
the tyrosine kinase domain intact. Just such a rear-
rangement has been seen in the MET oncogene
(Dean et al., Nature 318: 385 [1985]) and suggests
that the rearrangement has activated the oncogenic
potential of ROS. One other peculiar feature of the
rearranged ROS in U-118 MG is that the normal ROS
allele is absent. This and other data suggest that the
ROS rearrangement has resulted from an intrachro-
mosomal deletion of chromosome 6 and a loss of
the normal chromosome 6. We will further character-
ize the nature of this event.
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The MAS Oncogene
D. Young, L. Rodgers
The human MAS oncogene was discovered by us
using the cotransfection and tumorigenicity assay
(Young et al., Cell 45: 711 [1985]). It encodes a protein
with seven transmembrane domains and probably
belongs to the family of genes encoding hormone
receptors that couple to G proteins. Cells trans-
formed by MAS grow to high cell density and form
tumors in nude mice but do not appear morpholog-
ically transformed and do not grow in suspension
in soft agar. Recently, we cloned the rat homolog
of MAS (Young et al., Proc. Natl. Acad. Sci. 85: 5339
[1988]). It encodes a protein very similar to the hu-
man protein. In rats, the expression of MAS appears
to be restricted to the brain, particularly the cerebral
cortex and hippocampus, suggesting that MAS en-
codes a receptor for a neurotransmitter (Young et
al., Proc. Natl. Acad. Sci. 85: 5339 [1988]). Most
recently, Hanley and co-workers in England have
reported evidence that angiotensin II is a ligand for
the MAS protein (Jackson et al., Nature 335: 437
[1988]). In collaboration with Richard Axel and Tom
Jessel at Columbia University, we are attempting to
confirm these results (so far unsuccessfully).
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RAS ONCOGENES AND SIGNAL TRANSDUCTION
D. Bar-Sagi N. Gale A. Samatar
L. Graziadei J. Suhan
S. Kaplan
During the past year, we have continued to investigate
the role of ras proteins in growth control. Our goal
is to define the mechanisms by which ras oncogenes
disrupt the normal proliferative program of eukary-
otic cells. A critical step toward understanding the
effects of ras proteins on cell growth is the identifi-
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cation of biochemical targets of these proteins. On
the basis of their structural and biochemical char-
acteristics, the ras proteins are considered to have
function(s) analogous to those of the G proteins
involved in intracellular signal transduction systems.
Recent studies from several laboratories, including
our own, have indicated that ras proteins may func-
tion as regulatory components of the phospholipid
metabolism signaling pathway. Therefore, the focus
of our work has been the analysis of the biochemical
link between ras proteins and phospholipid metabo-
lism. In addition, we have continued our studies on
the effects of ras proteins on membrane turnover and
the functional significance of these effects for the
growth-promoting activity of ras proteins.
RAS Proteins Can Activate
Phospholipase C in HL-60
Membranes
D. Bar-Sagi [in collaboration with S. Cockcroft,
University College, London]
We have established a cell-free membrane system to
investigate whether ras proteins may affect the
activity of the enzyme phospholipase C (PLC). The
plasma membranes were isolated from the human
leukemic (HL-60) cells prelabeled with [31-1]inositol.
Purified preparations of proto-oncogenic and onco-
genic forms of the human Ha-ras proteins were ob-
tained from the Escherichia coli expression system
(Fig. 1). Incubation of membranes with various
amounts of purified Ha-ras proteins had no effect
on PLC activity as measured by the formation of
the hydrolytic products [3H]inositol bis (IP2) and
tris (IP3) phosphates. However, when coupled to
the nonhydrolyzable analogs of GTP (GTPyS or
Gpp[NH]p), both the proto-oncogene and oncogene
ras proteins stimulated the formation of IP2 and
1P3 in a time- and dose-dependent manner. It has
been shown previously that GTPyS by itself (as well
as other nonhydrolyzable GTP-analogs) can stimu-
late 1P2 and IP3 production in a dose-dependent
manner. The possibility that the stimulatory effect
of Ha-ras proteins on PLC activity resulted from the
dissociation of GTPyS from the Ha-ras proteins was
controlled by measuring the amount of GTPyS that
dissociates from the ras protein during the incubation
period. We have found that the amount of free
GTPyS present in the incubation mixture could not
account quantitatively for the effects observed with
ras proteins coupled to GTPyS. The specificity of
the effect of Ha-ras proteins on PLC activity was
established by testing the effects of other purified
preparations of G proteins (a-subunits of G G,,
and GO on PLC. Even when coupled to GTPyS,
these proteins had no effect on IP2 and 1P3 produc-
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FIGURE 1 SDS-PAGE patterns at different stages of purifica-
tion of the oncogenic (T24) Ha-ras protein. The DE-52 fractions
containing T24 (panel a) were precipitated by 60% ammonium
sulfate. The precipitate was dissolved and applied to a Sephadex
G-75 column. The T24-containing fractions from the Sephadex
G-75 column (panel b) contained few detectable impurities that
could be totally eliminated by hydrophobic chromatography on
phenyl-Sepharose column (panel c).
tion at all concentrations tested. We conclude that
purified Ha-ras proteins can exert a stimulatory
effect on PLC activity in a cell-free system. Using
various mutant ras proteins (in particular "effector
domain" mutants), we are currently investigating the
mechanisms underlying the effects of ras proteins
on PLC activity.
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Phospholipase A2 in ras-transformed
Cells
D. Bar-Sagi, J. Suhan, S. Kaplan
We have made several observations consistent
with
the possibility that the activation ofphospholipase
A2 (PLA2) is associated with the acquisition and/or
maintenance of the transformed phenotype. First,
we have found that normal rat kidney (NRK) cells
transformed by the v-Ki-ras (KNRK) show approxi-
mately twofold enhancement of PLA2 activity
compared to normal NRK cells (Fig. 2b,c). Moreover,
we have observed that the addition of serum to
membrane preparations of NRK
cells resulted in a
fourfold stimulation of PLA2 activity, whereas in
KNRK cells, serum had no apparent effect on
PLA2 activity (Fig. 2d). Second, in a recent study,
we have found that microinjection of the ras
oncogene protein into quiescent fibroblasts induced
a rapid (^,30 min after injection) and time-dependent
stimulation of PLA2 activity. Third, analysis of the
spatial relationship between PLA2 and the Ki-ras
oncogene protein, carried out at a high level of res-
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PLA2 activity in normal (NRK) and ras-transformed (KNRK) cells. Cellular phospholipids were labeled with
32PO4 or with [3H]arachidonic acid. (b) 32P-labeled phospholipids were extracted and analyzed by TLC.
(c) [3H]Arachidonic acid released to the medium was extracted and analyzed by TLC. (1) NRK cells; (2)
KNRK cells. (0) Origin of TLC plate; (AA) arachidonic acid; (LPE) lysophosphatidylethanolamine; (LPC)
cells.
lysophosphatidocholine. (d) Activation of PLA2 by serum in membrane preparations of NRK and KNRK
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olution by the use of the double immunogold label-
ing method, revealed a close proximity (,,100-500
A) between PLA2 and the ras oncogene protein in
the ruffles of Ki-ras-transformed cells. Similar ob-
servations were made in normal cells. To investigate
the specificity of the double-immunogold-staining
pattern of ras protein and PLA2, we have used the
same labeling technique to examine the relationship
between the distribution of the ras oncogene protein
and another membrane protein, Na-K ATPase. We
have found no spatial proximity between the Na-K
ATPase staining and ras staining. Therefore, the
coincident subcellular location of the ras protein and
PLA2 could not be attributed solely to the occur-
rence of the two proteins in the same subcellular
compartment (i.e., the cell membrane). Finally, we
have found that microinjection of an inhibitory anti-
PLA2 antibody into ras-transformed cells resulted
in the transient reversion of the transformed phe-
notype. Taken together, our findings to date may
indicate some functional relationship between ras
protein and PLA2.
Molecular Cloning of
Phospholipase
N. Gale, L. Graziadei, A. Samatar, D. Bar-Sagi
To clone cDNAs encoding cellular form(s) of
PLA2, we have used two approaches: First, using
the oligonucleotide hybridization procedure, we
screened a rat pancreatic 2 gt1 1 cDNA library. The
sequence of the oligonucleotide was derived from
the published cDNA sequence of the rat pancreatic
PLA2. In our primary screening, we have identified
15 positive plaques. These plaques were isolated,
purified, and rescreened with two oligonucleotide
probes corresponding to the amino- and carboxy-
terminal regions of the pancreatic PLA2. The phage
DNAs from the clones that were positive for both
probes were isolated, and the size of the cDNA
inserts was found to be approximately 500-600 bp.
Preliminary characterization of the clones by restric-
tion analysis and immunological screening strongly
suggests that they are the full-length cDNAs that
encode the rat pancreatic PLA2. Studies are now
under way to determine the sequence of these cDNAs
and to establish whether these clones were derived
from the same template mRNA. We will utilize these
cDNAs to determine the expression of rat pancreatic
PLA2 in other rat tissues and as probes for the
screening of other expression libraries to identify
homologous sequences corresponding to other
form(s) of PLA2.
In the second approach, we used rabbit polyclonal
anti-PLA2 antibody and a monoclonal anti-PLA2
antibody to screen rat pancreatic and rat brain Xgtll
cDNA libraries. We generated the antibodies against
porcine pancreatic PLA2 and showed that they
recognize cellular form(s) of PLA2 in rat cells. To
date, the immunological screening of the cDNA
expression libraries yielded two independent clones:
(1) a rat pancreatic cDNA clone that appears to be
different from the pancreatic clones identified by the
oligonucleotide screening method and (2) a rat brain
cDNA clone that expresses an immunoreactive
polypeptide and is a probable candidate for a cDNA
encoding some form of cellular PLA2. The cDNA
inserts from these clones are currently being char-
acterized.
Effect of ras Proteins on
Phospholipid Methylation
S. Kaplan, D. Bar-Sagi
Phospholipid methylation involves the stepwise
methylation of phosphatidylethanolamine (PE) to
form phosphatidylcholine (PC) by apparently two
methyltransferases. On the basis of earlier studies,
phospholipid methylation has been postulated to
play an important role in receptor-mediated events
in several systems, including oocyte maturation,
NGF-induced PC12 differentiation, and histamine
secretion in mast cells. Because all of these cellular
responses can be triggered by ras proteins, we con-
sidered the possibility that phospholipid methylation
may be the common determinant mediating the di-
verse effect of ras proteins. We have begun to examine
this possibility by studying methylation of phos-
pholipids in membrane preparations. Phospholipid
methylation can be assayed by measuring the in-
corporation of radioactive methyl group of S-ade-
nosyl-Omethy/-311}methionine (3H-SAM), a methyl
donor, into a lipid fraction. The identity and relative
abundance of the methylated phospholipids can then
be determined by thin-layer chromatography (TLC)
(Fig. 3). For the purpose of characterizing the effect
of ras proteins on phospholipid methylation, we have
initially investigated the effect of guanine nucleotide
on phospholipid methylation. We have observed that
the addition of GTPyS (10 p,m) to the incubation
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FIGURE 3 Effect of ras proteins on phospholipid methylation. (a) Scheme for the conversion of phosphatidylethanolamine to
phosphatidylcholine. (PMT I) Phospholipid methyltransferase I; (PMT II) phospholipid methyltransferase II; (SAM) S-adenosylmethionine.
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+ Ha-rasva12 (1 IM). Quantitation of 3H-methyl-incorporated phospholipids was determined by scraping the labeled phospholipids
off the plates and liquid scintillation counting.
mixture in the presence of Mg" (5 mm) resulted in
significant inhibition of the methylation response.
These observations may suggest the involvement of
an inhibitory guanine-nucleotide-binding protein in
the regulation of phospholipid methylation. More
recently, we have examined the effects of ras proteins
on phospholipid methylation. We have found that
in the absence of GTPyS, addition of ras proteins
(both proto-oncogenic and oncogenic forms, 1 LM)
had no effect on phospholipid methylation. How-
ever, in the presence of GTPyS, the Ha-ras oncogene
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protein prevented the inhibitory effect induced by
GTPyS.
Regulation of Membrane
Turnover by ras Proteins
D. Bar-Sagi [in collaboration with B. Gomperts,
University College, London]
We have previously demonstrated that microinjec-
tion of the Ha-ras oncogene protein into quiescent
fibroblasts results in a rapid and dose-dependent
stimulation of membrane ruffling and pinocytosis.
Furthermore, microinjection of anti-ras antibodies
inhibited these membrane activities in both normal
and v-Ki-ras-transformed cells. These findings
suggest that ras proteins participate in the regulation
of membrane turnover. To identify the function of
ras proteins in membrane turnover, we have used rat
peritoneal mast cells that, upon exposure to appro-
priate ligands, undergo exocytotic degranulation. Rat
mast cells were found to express low levels of the
normal ras protein, as detected by immunoblotting.
Microinjection of the oncogenic Ha-ras protein in-
duced exocytotic degranulation. This effect was pro-
duced in the absence of external ligands and was
dependent on extracellular calcium. In contrast,
microinjection of the same amount of the proto-
oncogenic Ha-ras protein had no apparent effect.
The ultrastructural features of exocytotic degranu-
lation in mast cells injected with the ras oncogene
protein are similar to those seen when mast cells are
activated by soluble ligand (Fig. 4). Taken together
with the stimulatory effect of the ras proteins on
pinocytotic activity previously shown in fibroblasts,
FIGURE 4 Ultrastructural analysis of mast cells. (a) Resting mast cell; (b) mast cell 2
min after stimulation with compound 48/80 (2 4g/m1); (c) mast cell injected with buffer
alone; (d) mast cell injected with the ras oncogene protein. The injected cells were fixed
and processed for transmission electron microscopy at 4 hr postinjection. In the resting
cell (a) or cell injected with buffer alone (c), the granules are dense, andthere is no evidence
of exocytosis. The cells stimulated with compound 48/80 (b) or injected with the ras
oncogene protein (cf) show an exocytotic response as indicated by the conversion of most
of the granules to less-dense granules and the occurrence of exocytotic pits.
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our present findings suggest a role for ras proteins
in the signaling process that controls membrane
recycling via an exocytotic-endocytotic shuttle.
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NUCLEAR ONCOGENES AND SIGNAL TRANSDUCTION
M. Gilman L. Berkowitz K. Riabowol
R. Graham W. Ryan
Development, differentiation, and cellular
ation are largely coordinated by extracellular signals.
These signals, usually in the form of polypeptide
growth factors and hormones, carry complex instruc-
tions to cells that specify dramatic changes in cellular
behavior. These changes in behavior are effected by
stable changes in the pattern of gene expression in
the cell. How are these signals transmitted to the
nucleus to generate changes in the pattern of cellular
gene expression? Recent evidence suggests that this
is essentially a two-step process.
First, the immediate signals triggered at the cell
surface in the first few seconds and minutes are
transmitted directly to a group of immediate-early
genes, some of which are activated within 5 minutes
of exposure to the signal.
Second, products of these genes act to activate or
repress a second class of genes that includes genes
directly involved in the cellular response.
Our work concerns the c-fos proto-oncogene,
which occupies a critical focus for this signaling
cascade. The c-fos gene is an immediate-early gene
that is a direct target for the first events triggered
by extracellular signals. Transcription of the c-fos
gene is activated within 5 minutes of exposure to
signals and is subsequently shut down approximately
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30 minutes later. Activation of transcription is
independent of new protein synthesis in the cells. Our
primary effort is aimed at understanding how
signaling information travels from the cell surface
to the c-fos gene and how c-fos transcription is
activated in response to this information. Our
strategy is to work backward from the gene toward
the cell surface by (1) identifying the DNA sequences
within the c-fos gene that are the targets for different
intracellular signaling pathways, (2) identifying
cellular proteins that interact with these sequences,
and (3) using these proteins to identify the next
agents up the signaling cascade. Figure 1 summarizes
our current picture of the signaling network.
A second focus for our efforts is to understand
how the products of the c-fos gene and related genes
function to control the expression of the second wave
of genes involved in the cellular response to signals.
In particular, we want to understand the biological
specificity of these signals -how different signals
elicit different responses in cells. Here, our strategy
is to examine at a molecular level the proteins
induced in cells in response to distinct signals to
understand (1) the basis for the specificity of induc-
tion and (2) the functional differences among pro-
teins induced by different signals.
c-fos Sequences in Communication
with Distinct Intracellular Signal
Transduction Pathways
M. Gilman, R. Graham
The c-fos gene is activated by several distinct
intracellular signal transduction pathways. We wish
to determine which sequences within the c-fos gene
are in communication with each of these pathways.
Previous work by ourselves and several other groups
has established that a 20-bp sequence element, the
serum response element (SRE), located 300 by
upstream of the start site for c-fos transcription, is
required for the response of transfected c-fos genes
to whole serum. Serum, however, is a complex
mixture of growth factors that activate multiple
signal transduction pathways. Therefore, we have
asked which individual pathways act on c-fos via
the SRE and which pathways act through other
sequences.
Our results show that at least two distinct intra-
cellular signal transduction pathways converge on the
SRE (see Fig. 1). One pathway acts through the cel-
lular enzyme protein kinase C. Induction of trans-
fected c-fos genes in mouse fibroblasts by activators
FIGURE 1 Summary of signaling pathways and
intracellular mediators involved in the induction of
c-fos transcription. Shown are the several distinct
signal transduction pathways known to trigger c-fos
transcription (see text). The ovals represent known
or potential cytoplasmic mediators of these signals.
Arrows from these ovals connect the pathways to the
c-fos cis-acting elements required for their action on
c-fos transcription. For the cAMP pathway, arrows
with solid lines represent the strongest element,
whereas arrows with dashed lines represent weaker
elements. Circles represent nuclear DNA-binding
proteins identified or inferred from DNA-binding
studies discussed in the text. Rectangles along the
representation of the c-fos gene are identified
regulatory elements.
of protein kinase C is completely dependent on the
SRE, and an oligonucleotide comprising the SRE
at least partially restores response to these agents to
a c-fos promoter deleted for sequences upstream of
-151. Growth factors also trigger signals indepen-
dent of protein kinase C, although their precise bio-
chemical nature is not understood. These signals,
too, are dependent on the SRE, and response to
protein-kinase-C-independent signals is also restored
to deleted c-fos promoters by an SRE oligonucleo-
tide. Thus, at least two (and perhaps more) intracel-
lular signaling pathways act on the c-fos gene via
the SRE.
In contrast, at least two other pathways are
independent of the SRE. One pathway, involving the
intracellular second messenger cAMP, acts through
several other sequence elements in the gene (see
below). In addition, another pathway that uses
intracellular calcium as a second messenger is also
independent of the SRE. Like cAMP, calcium
induction of the c-fos gene is not impaired by SRE
mutations; however, the calcium-responsive sequences
in the gene have not yet been indentified.
Although most of our work in this area has
involved fibroblasts, we are now beginning to study
c-fos induction in T cells. In the body, most T cells
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remain in a resting state until they
encounter their
cognate antigen, at which
time they initiate a defined
program of gene expression that
results in prolifer-
ation and secretion of a
variety of lymphokines. The
c-fos gene is induced as part
of this cascade. Because
signal transduction in T cells
is not as well under-
stood as in fibroblasts, we are
using our bank of c-fos
promoter mutants to study the different
pathways
that communicate T-cell activation
signals to the
nucleus.
Finally, we are investigating the
role played by the
SRE in the transcriptional shutoff
of the c-fos gene
that follows induction. Shutoff
requires new protein
synthesis, suggesting that c-fos
transcription is ac-
tively repressed by a protein synthesized
in response
to the primary signal. An obvious
candidate for such
a protein is the Fos protein itself. This became an
especially attractive hypothesis with the demonstra-
tion that complexes of the Fos and Jun
proteins bind
to specific DNA sequences. We have shown
that a
sequence located immediately adjacent to the SRE
is a binding site for the Fos/Jun complex in vitro.
However, mutations in this site that abolish binding
of the complex do not affect transcriptional shutoff,
nor do mutations in the cAMP response elements
(CRE) in the c-fos gene, which also bind the Fos/Jun
complex in vitro. Therefore, we are now testing
whether it is the SRE itself that controls both acti-
vation and repression. We have used site-directed
mutagenesis to generate a large collection of muta-
tions in the SRE, and we have begun to test whether
any of these mutant SREs are defective in induction
and/or repression. Our preliminary data suggest that
in fact certain SRE mutations result in an element
that confers stable, rather than transient, serum
induction on a deleted c-fos promoter. Thus, it is
likely that the SRE is a target for both positive and
negative signals.
c-fos DNA Sequences Responsive
to cAMP
L. Berkowitz, K. Riabowol, M. Gilman
Expression of the c-fos gene is rapidly and transiently
induced in BALB/c 3T3 fibroblasts by agents that
elevate the intracellular concentration of cAMP. Like
induction by serum, induction of c-fos expression
by cAMP does not require new protein synthesis,
suggesting that the c-fos gene is a direct target of
this signaling pathway. Unlike induction by serum,
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response to CAMP does not require the SRE. using
gene transfer, DNA binding, and microinjection
assays, we have localized the sequences in the mouse
c fos promoter that mediate the response to CAMP
We find that there are several elements within the
promoter that mediate the response to CAMP (see
Fig. 1). All elements share a match to the consensus
core sequence established for CREs: TGACG. The
major CRE in the c-fos promoter as established by
transient expression assays is an element located
at
iposition - 65 that was previously identified as a basal
promoter element and a protein-binding site. We have
shown that this sequence acts as a CRE in its natural
context in the c-fos promoter. However, it is not the
only CRE in the promoter, because mutation of this
site, although it abolished cAMP response of a -71
deletion, did not abolish response of a c-fos pro-
moter carrying sequences through -356. Using site-
directed mutagenesis, we localized these additional
CREs to positions - 290 and - 340 in the c-fos
promoter. The results of the transient expression
assays permitted us to establish the order of potency
of these sites as - 65 > - 290 > -340. This heirarchy
corresponded precisely with the avidity with which
these elements bind cellular CRE-binding factors in
vitro.
To determine whether the elements we have
mapped using the transient expression assay actually
function as CREs for the endogenous c-fos gene in
its natural chromatin configuration, we developed
a microinjection competition assay. In this assay, we
microinjected double-strand oligonucleotides cor-
responding to the c-fos CRE at - 65 into fibroblasts,
treated the injected cells with agents that elevate
cAMP concentrations, and assayed for expression
of the endogenous c-fos gene by indirect immunoflu-
orescence using affinity-purified antibodies against
Fos. The CRE oligonucleotide constitutes an in vitro
binding site for cellular CRE-binding proteins. If
interaction of these proteins with CREs in the en-
dogenous c-fos gene is required for response to
cAMP, we predicted that microinjection of this
oligonucleotide would block c-fos induction. We
observed (Fig. 2) that the CRE oligonucleotide
blocked c-fos induction by cAMP but not by serum.
In contrast, an oligonucleotide encoding the SRE
blocked induction by serum, but not by cAMP. A
mutant CRE oligonucleotide had no effect on c-fos
expression under any conditions. Thus, sequence
elements related to the CREs mapped using the
transient expression assay are functionally required
for induction of the endogenous c-fos gene by cAMP.
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FIGURE 2 Injection of CRE oligonucleotides blocks cAMP-induced endogenous c-fos expression. Quiescent BALB/c 3T3 fibroblasts
(C) or cells stimulated for 90 min with 10% calf serum (A,D,F,G) or with IBMX and forskolin (B,E,H) were processed to detect c-fos
immunofluorescence. One hour prior to stimulation, cells were microinjected with double-strand oligonucleotides as described in
text. (A,B,C) Cells received no oligonucleotide; (D,E) cells received the wild-type CRE oligonucleotide; (F) cells received the mutant
(pm3) CRE oligonucleotide; (G,H) cells received the wild-type SRE oligonucleotide. Fields of cells were photographed and processed
identically to allow direct comparison between panels.
These experiments also establish that these elements
are positive activators of transcription and that there
are no unrelated elements in the c-fos gene that are
also capable of mediating response to cAMP.
Currently, our efforts are aimed at studying the
cellular proteins that interact with the c-fos CREs
to determine how transcription is activated in
response to cAMP. Using the polymerase chain
reaction technique, we have isolated cDNAs encod-
ing full-length CREB proteins. We plan to raise
antibodies to these proteins for in vitro transcrip-
tion and microinjection assays. In addition, given
the role for the catalytic subunit of cAMP-dependent
protein kinase in c-fos induction by cAMP (see
below), we will study the effect of phosphorylation
on the function of these proteins.
The Catalytic Subunit of cAMP-
dependent Protein Kinase
Induces Expression of Genes
Containing cAMP-responsive
Enhancer Elements
K. Riabowol, M. Gilman [in collaboration with J.S. Fink,
D.A. Walsh, R.H. Goodman, and J.R. Feramisco]
The mechanism by which cAMP exerts its cellular
effects is largely through the cAMP-dependent
protein kinase (A-kinase). However, the way that
cAMP affects eukaryotic gene expression is less clear.
In Escherichia coli, cAMP regulates the expression
of genes involved in sugar catabolism by binding to
catabolite gene activator protein (CAP). Subsequent
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binding of the cAMP-CAP complex to specific DNA
sequences directly activates transcription of cAMP-
regulated genes, including those involved in sugar
catabolism. The holoenzyme of A-kinase exists as
an enzymatically inactive tetramer, composed of two
catalytic (C) and two regulatory (R) subunits. When
levels of cAMP are elevated, cAMP binds to the R
subunits and the holoenzyme dissociates, yielding
an R subunit dimer and two active C subunits. Both
the C and R subunits of A-kinase have been sug-
gested to mediate the transcriptional regulation of
cAMP-responsive genes. The R subunits could func-
tion in a manner similar to that of bacterial CAP
and, upon binding cAMP, act directly upon a target
DNA site in cAMP-responsive genes. Alternatively,
the C subunit of A-kinase could phosphorylate
chromosomal or other nuclear proteins, which could
then induce gene expression.
To distinguish between these two models, we
microinjected purified C and R subunits, separately
and together, and determined their effects on the
expression of cAMP-regulated genes. Two different
assays were used to measure cAMP-responsive gene
expression. First, a C6 glioma cell line containing
a stably integrated fusion gene consisting of the
human vasoactive intestinal peptide (VIP) gene
promoter/enhancer region joined to the E. coli lacZ
gene was tested. Expression of the fusion gene in
individual cells was detected by staining using the
chromogenic 13-galactosidase substrate X-gal. Treat-
ment with 5µM forskolin and 0.5 mm isobutyl me-
thylxanthine (IBMX) for 6 hours, which increases
intracellular levels of cAMP, induced 13-galactosidase
expression as detected by the appearance of cells that
stained blue with X-gal. We found that injection of
purified C subunit also resulted in the expression of
13-galactosidase in the injected cells, whereas injection
of R1 or R subunits, or of C subunit plus varying
amounts of R11 subunit, did not induce expression
of the fusion gene. As a second assay, we examined
the regulation of an endogenous gene within the
context of its native chromatin configuration. Thus,
we measured the appearance of fos protein in the
nuclei of cells microinjected with the different
subunits of A-kinase. Expression of fos protein was
monitored by indirect immunofluorescence using
affinity-purified antibodies raised against v-fos
protein. Figure 3 shows that by 90 minutes, expres-
sion of fos protein was markedly induced in cells
injected with C subunit (panel A), and by 3 hours,
very high levels of nuclear fos staining were observed
(panel B). Panel D shows that a mixture of equal
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amounts of C and R11 subunits failed to induce fos
expression in these cells. Injection of ras protein,
which is also known to induce fos expression in fi-
broblasts, was included as a positive control and is
shown in panel C.
These experiments show that the C subunit of
A-kinase is sufficient to induce the expression of at
least two genes that are regulated by cAMP and sug-
gest that protein phosphorylation plays a role in this
process. The experiments in which a mixture of C
and R subunits were injected indicate that R can
inactivate the C subunit, most likely by forming a
catalytically inactive tetramer. Furthermore, the fact
that Ri or R were unable to induce transcription
by themselves implies that these R subunits do not
play a crucial role in the expression of these genes.
Since these microinjection experiments were carried
out in the absence of agents that increase intracellu-
lar levels of cAMP, they also suggest that activation
of cellular proteins by binding cAMP is not required
for expression of the genes tested.
Cellular Proteins That Interact
with the c-fos SRE
W. Ryan, R. Graham, M. Gilman [in collaboration with
R. Franza, Cold Spring Harbor Laboratory]
The c-fos SRE is clearly a multifunctional element.
It is a target for activation by at least two distinct
intracellular signaling pathways, and it confers
constitutive activity on the c-fos promoter. In
addition, preliminary data suggest that it is also a
target for repression of c-fos transcription following
serum stimulation. Despite these multiple activities,
until recently only a single cellular protein that binds
to this element has been identified. This protein,
serum response factor (SRF), is a 67-kD phospho-
protein that binds in a symmetrical fashion to the
SRE. Its DNA-binding activity does not appear to
be modified in response to signals that induce c-fos
transcription, so its precise role in the control of c-fos
transcription in response to extracellular signals is
not clear; it is reasonable to expect that other cel-
lular proteins may be involved in the complex regu-
latory events that occur at the SRE.
We have recently identified two new cellular
proteins that interact with the SRE. One binds
directly to the SRE, and the second appears to
recognize the SRE-SRF complex. To identify any
additional cellular proteins that bind to the SRE, we
FIGURE 3 Microinjection of the C subunit of cAMP-dependent protein kinase induces expression of c-fos.
Logarithmically growing rat 208F fibroblasts were made quiescent by incubation in medium containing
0.1% FCS for 24 hr prior to injection. Purified C subunit of A-kinase was injected, and the cells were incubated
for 90 min (A) or 3 hr (B) prior to fixation and staining for the fos protein. Ras protein (C) and a mixture
of equal amounts of C and Rif subunits (D) were also injected, and the cells were fixed and processed
for immunocytochemistry with fos antibody following 3 hr (ras) or 6 hr (C + RH) of incubation at 37°C.
No nuclear fluorescence was observed in cells injected with the mixture R11 when cells were fixed
and processed for immunofluorescence 1, 2, or 4 hr following injection (not shown). Insets in panels B
and C show higher magnification micrographs of the nuclei of C subunit and ras injected cells, respectively.
fractionated a nuclear extract prepared from human
T cells by heparin-agarose chromatography (Fig. 4).
We assayed column fractions using two assays for
sequence-specific DNA-binding proteins. One assay,
the commonly employed mobility-shift assay, orig-
inally detected only a single, specific SRE-binding
protein, which turned out to be SRF. The second
assay, a DNA-affinity precipitation assay, detected
a second specific SRE-binding protein. This protein
was distinct from SRF in several features, including
its size (62 kD), its biochemical and chromatographic
properties, and its DNA-binding specificity. In
particular, it makes quite distinct contacts with SRE
DNA. Unlike SRF, which binds symmetrically to
both sides of the SRE dyad, the 62-kD protein binds
only to the 5' half of the SRE, a surprising observa-
tion in view of the similarity of the two halves of
the SRE dyad.
The second new protein has the unusual property
that it does not bind directly to the SRE as do SRF
and the new 62-kD protein, but instead binds to the
complex of SRF and SRE DNA. We detected this
activity following fractionation of nuclear extracts
by heparin-agarose chromatography, when we ob-
served that the mobility of the SRF-SRE complex
in mobility-shift gels increased following chromatog-
raphy. We found that by adding flowthrough frac-
tions from the heparin-agarose column to heparin-
agarose fractions containing partially purified SRF,
we could reconstitute the lower mobility complex
observed in crude nuclear extracts. These observa-
tions suggested that the complex formed in crude
extracts was in fact a ternary complex consisting of
SRE DNA, SRF, and an unknown additional protein
separable from SRF by heparin-agarose chromatog-
raphy. We have partially purified this activity and
identified it as a polypeptide of 62 kD. Although it
is fully separable on heparin-agarose from the 62-
kD protein described above that directly binds the
SRE, it is possible that these activities represent al-
ternate forms of the same polypeptide.
Formation of the ternary complex requires more
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FIGURE 4 Heparin-agarose chromatography of H9 cell nuclear extract. (A) Column profile. () Protein concentrations in the correspond-
ing fractions; (0) estimated KCI concentrations in the fractions as determined by conductivity measurements. (B) Mobility-shift assay
of peak fractions. The assay was carried out without a preincubation step, using Tris-glycine electrophoresis buffer. The probe was
the wild-type SRE. The arrowhead indicates the specific complex that formed in these assays. The other bands formed equally well
in a parallel assay using a mutant SRE probe (data not shown). (C) DNA-affinity precipitation assay of selected fractions from the
heparin-agarose column. The indicated fractions were incubated with either ligated wild-type SRE oligonucleotide (W, lanes 2,4,6,8,10,12)
or mutant SRE (M, lanes 3,5,7,9,11,13). The arrowheads indicate proteins specifically recovered with the wild-type oligonucleotide.
Lane 1 contains H9 whole-cell extract. The indicated markers are hsp90 (93 kD), hsp70 (73 kD), and actin (43 kD). Protein bands
were visualized by silver staining. (0) Mobility-shift assay performed using the preincubation protocol and Tris-borate electrophoresis
buffer. The probe was the wild-type SRE. The arrowheads indicate specific complexes that did not form in a parallel assay using
the mutant SRE probe (data not shown).
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FIGURE 5 High-resolution two-dimensional gels of c-fos immunoprecipitation products.
Lymphoid (top panel, human H9) or fibroblast (bottom panel, rat 208F) cells previously labeled with
[35Sjrnethionine were harvested under nondenaturing conditions. Cell lysates were immunopre-
cipitated using affinity-purified antibodies raised against bacterially produced fos protein. Washed
pellets were boiled in Laemmli sample buffer and subjected to two-dimensional gel electropho-
resis and fluorography. Light arrows indicate polypeptides unique to fibroblasts. Bold arrows
indicate H9-specific immunoprecipitation products. Actin is labeled Ac on both autoradiograms.
SRE DNA sequence than does binding of SRF alone,
suggesting that this new activity may recognize
DNA.
This idea is supported by two observations. First,
using methylation interference assays, we find that
methylation of guanine residues that do not interfere
with SRF binding block formation of the ternary
complex. Furthermore, we have identified single
point mutations in the SRE that bind SRF but fail
to form the ternary complex, suggesting that this new
factor specifically recognizes SRE DNA sequences.
Preliminary analysis of these SRE mutants in vivo
suggests that this new complex acts to repress c-fos
transcription.
Stimulus-specific and Cell-type-specific
fos-associated Proteins
K. Riabowol, M. Gilman [in collaboration with
R. Franza, Cold Spring Harbor Laboratory]
Several lines of evidence suggest that the c-fos protein
may play a role in gene transcription. c-fos is known
to bind specific DNA sequences implicated in
transcriptional control, in a synergistic manner with
the product of the c-jun proto-oncogene. Overexpres-
sion of c-fos can also induce expression of cotrans-
fected reporter plasmids whose transcription is
directed by several heterologous promoter/enhancer
sequences. Immunoprecipitation of c-fos protein
under nondenaturing conditions reveals the presence
of several fos-associated and fos-related proteins.
Some of these proteins have been identified as the
products of the c-jun proto-oncogene (Fos-associ-
ated) and of the FRA1 (Fos-related antigen 1) gene.
In addition to these associated and related proteins,
we have observed a variety of other proteins that are
specifically immunoprecipitated using our polyclonal
rabbit affinity-purified fos antibodies. Several of the
immunoprecipitated polypeptides that are cell-type-
specific are indicated in Figure 5. Thus, it appears
that subsets of proteins associate with c-fos, only
some of which are common to markedly different
cell types. In addition, we have observed the associa-
tion of c-fos with proteins of distinct relative
molecular weights when quiescent fibroblasts are
stimulated with different agents. Figure 6 shows im-
munoprecipitations from rat 208F fibroblasts that
were stimulated with serum or with agents that in-
crease intracellular levels of cAMP (IBMX and for-
skolin). Although most protein bands are found in
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FIGURE 6 Stimulus-specific fos-associated proteins. Quiescent
rat 208F fibroblasts were stimulated with 10% fetal calf serum
(lanes Si and S2), the phorbol ester PMA (lane P), or with IBMX
plus forskolin (lane IF) for 90 min in the presence of 250 RCi /ml
of [35S]methionine. Cell lysates were prepared and immunopre-
cipitated as described in Fig. 1. Immunoprecipitates were ana-
lyzed by one-dimensional SDS-PAGE and fluorography. The bold
arrow identifies the fos-associated c-jun protein and the light
arrows indicate serum-specific or IF-specific fos-associated pro-
teins.
immunoprecipitations of cells stimulated with both
agents, some bands are unique. To better character-
ize and identify such cell-type-specific and stimulus-
specific proteins associated with c-fos, we are now
beginning to raise polyclonal and monoclonal anti-
bodies specific for individual proteins present in the
c-fos immunoprecipitation complex.
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TRANSCRIPTION INITIATION AND TERMINATION IN sNRNA
GENES AND HUMAN IMMUNODEFICIENCY VIRUS
N. Hernandez U. Grossniklaus R. Lucito
S. (fill P. Reinagel
S. Lobo M. Sheldon
We are interested in the mechanisms that govern ini-
tiation and termination of transcription, and we are
studying these mechanisms in two types of transcrip-
tion units: the human small nuclear RNA (snRNA)
genes Ul, U2, and U6 and the human immunodefi-
ciency virus type 1 (HIV-1).
SMALL NUCLEAR RNA GENES
The snRNA genes Ul to U7 encode snRNAs that
are packaged with a set of proteins to form small
nuclear ribonucleoprotein particles (snRNPs). The
snRNPs Ul, U2, U4, U5, and U6 are all involved
in the splicing of pre-mRNAs, whereas the U7
snRNP is involved in the 3' processing of histone pre-
mRNAs. All of the snRNA genes characterized to
date are transcribed by RNA polymerase II (pol II)
except for the U6 gene, which is transcribed by RNA
polymerase III (pol III). However, the pol II and pol
III snRNA genes have very similar promoters and
seem to be more related to each other than to mRNA
pol II transcription units or to the well-characterized
pol III transcription units, such as the 5S and tRNA
genes.
The promoters of the human pol II snRNA genes
are essentially bipartite and consist of an "snRNA
proximal element" (snPE) located around position
- 50 upstream of the cap site, and an enhancer
located around - 220. The snPE is unique to snRNA
genes and is functionally equivalent to the TATA box
of mRNA promoters; it is essential for efficient
transcription and localizes the start site of transcrip-
tion. The enhancer consists of two adjacent motifs:
the octamer motif ATGCAAAT, also found in the
immunoglobulin promoters and enhancers, and an
Spl-binding site. The enhancer stimulates transcrip-
tion from the promoter relatively independently of
distance and orientation.
The formation of the pol II snRNA 3' ends occurs
by an unusual mechanism, which most probably
involves termination of transcription. The cis-acting
elements required include a short sequence located
downstream from the last coding nucleotide of the
genes called the "3' box," as well as sequences in the
5'-flanking region of the genes. Indeed, when the Ul
or U2 promoters are replaced by mRNA promoters,
the 3' box is ignored and RNAs extend to a polyaden-
ylation site inserted downstream. We have recently
completed a detailed mutational analysis of the hu-
man U2 5'-flanking region, which showed that the
5' elements required for 3'-end formation coincide
with promoter elements. In this analysis, replacement
of the U2 enhancer by SV40-derived synthetic en-
hancers inhibited RNA 3'-end formation at the 3'
box. Moreover, the synthetic enhancers did not
stimulate transcription from the U2 promoter, al-
though they efficiently activate mRNA promoters.
This suggested that the pol II snRNA genes are
transcribed by a specialized transcription complex
that recognizes the 3' box as a termination signal and
does not contain the same type of enhancer-binding
factors as mRNA transcription complexes.
The U6 gene is transcribed by pol III and tran-
scription ends in a run of T residues, the 3' signal
characteristic for termination of transcription by pol
III. However, the structure of the U6 promoter
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suggests that the gene belongs to a new family of
pol III transcription units, of which the human
7SK
gene is another member. Indeed, the U6- and 7SK-
coding regions are not required for transcription,
even though they contain a homology with the A
box, a promoter element required for transcription
of several pol III genes. Instead, the 5'-flanking
sequences of the genes are sufficient to direct tran-
scription and contain sequences that are very similar
to promoter elements of the pol II snRNA genes.
The U6 and 7SK promoters contain an enhancer
region with one or more octamer motifs, and the U6
and U2 enhancers can functionally replace each
other. The U6 and 7SK promoters also contain an
snPE around position - 55, as well as a motif not
found in the pol II snRNA promoters: a T/A-rich
region located around -25 and reminiscent of the
TATA box of mRNA genes. Because the U2 and U6
promoters are very similar but yet are recognized by
different RNA polymerases, they constitute an ideal
system to study the determinants of RNA polymer-
ase specificity.
HUMAN IMMUNODEFICIENCY VIRUS
HIV-1 causes AIDS. Infection of T cells by the virus
leads to a latency period of variable length. The
transition to productive infection is thought to be
triggered by immunological activation of the infected
T cells. Initially, immunological activation may
induce cellular trans-acting factors, which in turn
stimulate transcription from the promoter contained
within the viral long terminal repeat (LTR). The virus
is then able to synthesize its own trans-activator, tat-1,
which further stimulates transcription from the HIV
LTR by several hundredfold, leading to virus replica-
tion and cell death. Interestingly, the target sequence
(TAR) for trans-activation by the tat protein lies
downstream from the transcriptional start site. The
mechanisms of tat trans-activation are poorly under-
stood and may include stimulation of transcription
initiation, stimulation of transcription elongation
(antitermination), and posttranscriptional effects.
That tat may act as an antiterminator is suggested
by the observation that in the absence of tat, short
transcripts ending just downstream from the TAR
region are generated. In the presence of tat, these
short transcripts disappear, and transcripts reading
through the putative premature termination site are
detected. Thus, tat may act as a specific antitermi-
nator that relieves termination downstream from the
TAR region.
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The pal II snRNA Promoters Are
Activated by a New Class of
Enhancer Elements
U. Grossniklaus, N. Hernandez [in collaboration with
M. Tanaka and W. Herr, Cold
Spring Harbor Laboratory]
Recent experiments with yeast and mammalian
trans-activators, such as GAL4, GCN4, and steroid
receptors, have revealed a general mechanism for
activation of pol II transcription. These trans-
activators consist of a DNA -binding domain and an
activation domain characterized by a high concentra-
tion of negative charges. Surprisingly, the activation
domains of different trans-activators are interchange_
able. For example, the activating domain of GAL4,
when fused to the DNA-binding domain of the hu-
man estrogen receptor, can stimulate transcription
from the vitellogenin A2 promoter in HeLa cells.
Moreover, hybrid mammalian promoters in which
DNA-binding sites for GAL4 have been inserted
upstream of the TATA box can be stimulated by
GAL4 supplied in trans. From these observations,
a model emerges in which the activating domains of
different transcription factors are equivalent, and the
specificity of transcription activation is solely con-
ferred by the specificity of the DNA-protein inter-
actions.
In this context, the octamer motif presents a
paradox. This motif is found in the promoter region
of heavy- and light-chain immunoglobulin genes, in
the heavy-chain (IgH) enhancer, and in the SV40
enhancer. In these contexts, and when inserted
upstream or downstream from other mRNA pro-
moters, the octamer motif displays lymphoid-specific
activity. But the octamer motif also plays a role in
non-B cells as an enhancer of snRNA transcription
and as a cell-cycle-regulated proximal element in the
histone H2B gene. These different patterns of
lymphoid-specific and ubiquitous transcriptional
regulation parallel the expression of two proteins that
bind indistinguishably to the octamer motif. The
protein Oct-2 is expressed only in B cells, whereas
Oct-1 is ubiquitously expressed (see R. Sturm and
W. Herr, Tumor Virus Section). This observation,
however, is not sufficient to explain the different
patterns of expression of snRNA and immunoglob-
ulin genes. Indeed, if the activation domains of
different transcription factors are interchangeable
and the specificity of activation is conferred solely
by the specificity of DNA binding, why are immuno-
globulin genes not expressed in HeLa cells?
To resolve the paradox, we have studied the
abilities of different versions of the SV40 B element
to enhance expression of the human 3- globin and
U2 snRNA promoters in He La cells and in B cells.
As shown in Figure 1, the B element contains a
tandemly repeated Sph motif (indicated by arrows)
and a seven out of eight match to the octamer
consensus ATGCAAAT (bracketed). In He La cells,
the ability of the B element to enhance 13-globin
expression is dependent on the Sph motifs, whereas
the octamer motif is inactive. We introduced a set
of double point mutations into the B element, as
indicated in Figure 1. dpm2 modifies the second Sph
motif and obliterates Sph motif activity. dpm7
modifies the octamer motif and strongly reduces its
activity, but it has no effect on Sph motif activity.
dpm8 destroys both Sph and octamer motif ac-
tivities. These different versions of the B element
were polymerized to generate synthetic enhancers
containing six copies of the element, and the ability
of these synthetic enhancers to stimulate the 33-globin
and the U2 promoters was tested in B cells and in
He La cells. The results are summarized in Figure 2.
In the context of the 13-globin promoter, enhancer
activity in B cells was dependent on a functional
octamer motif, whereas in He La cells, enhancer
activity was dependent on functional Sph motifs.
The enhancement pattern of read-through transcripts
derived from cryptic promoters within the U2 vector
(labeled "read-through" in Fig. 2) was identical to
that observed with the 3-globin promoter. These
read-through transcripts are of the mRNA type as
opposed to the snRNA type, because they are not
terminated at the 3' box but extend to a polyadenyl-
ation further downstream. In contrast to the 13-globin
promoter and the cryptic promoters within the U2
vector, activation of transcription from the U2 pro-
moter was always dependent on a functional octamer
motif. These results suggested that (1) the Sph-motif-
binding proteins that can activate transcription from
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FIGURE 1 Sequence of the wild-type and mutant B20 synthetic
enhancer repeats. The Sph motifs are underlined and the octamer
motif at the junction of the two Sph motifs is bracketed. The
changes introduced by the double point mutations dpm2, dpm7,
and dpm8 are indicated.
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FIGURE 2 Summary of the activities of the B20 wild-type and
mutant synthetic enhancers in the context of the p-globin and
U2 promoter in B cells and HeLa cells.
the 13-globin promoter in HeLa cells cannot activate
transcription from the U2 promoter and (2) the ubiq-
uitous octamer-binding protein present in HeLa cells
is an enhancer-binding protein that stimulates only
snRNA promoters. This, in turn, suggests that the
ubiquitous octamer-binding protein is not a tran-
scriptional activator of the GAL4 class. To test this
hypothesis directly, we inserted GAL4-binding sites
in the U2 and 0-globin promoters and determined
the ability of each hybrid promoter to be trans-ac-
tivated by GAL4. Although the 13-globin promoter
was efficiently stimulated by GAL4, the U2 promoter
was not, confirming that the U2 promoter is stimu-
lated by a special class of trans-activator.
Although the 6XB20 dpm2 P-globin promoter was
inactive in HeLa cells, it could be activated by co-
expression of the herpes simplex virus trans-activator
VP16 (VMW65). This protein normally trans-
activates the viral immediate-early genes, although
it does not bind DNA. VP16 seems, then, to convert
the ubiquitous octamer-binding protein into a trans-
activator of the GAL4 class.
Figure 3 shows a series of cartoons depicting
hypothetical transcription complexes that form in
B cells or HeLa cells, on either the 13-globin or U2
promoter carrying the SV40 B element. For simplic-
ity, only one copy of the B element is shown, and
pol II is not represented. Figure 3A shows the
transcription complex formed on the 13-globin
promoter in B cells. A TATA box complex is bound
close to the cap site, and the B-cell-specific octamer-
binding protein Oct-2 is bound to the octamer motif
of the B element. This factor activates transcription
from mRNA promoters and is therefore depicted as
a protein of the GAL4 class containing an acidic
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FIGURE 3 Model for activation of the p-globin and U2 promoters
by the octamer and Sph motifs. Hypothetical complexes formed
on the P-globin and U2 promoters in B cells and in HeLa cells
are shown. The DNA is represented by a thin line, the Sph motifs
are indicated by arrows, and the octamer motif is indicated by
an open box. For simplicity, only one wild-type B20 repeat of
the synthetic enhancer is shown. (In D, B20 wild type is replaced
by B20/dpm2, i.e., there are no functional Sph motifs.) The start
site of transcription is depicted by a wavy arrow. The DNA is
looped and shown binding a proximal promoter complex (TATA
complex or snRNA proximal complex) and a distal trans -activator.
Successful protein-protein interactions between the trans-activator
and the proximal complex result in an increased rate of transcrip-
tion initiation. The octamer motif DNA-binding domains are
stippled and the Sph motif DNA-binding domain is shown striped.
The trans-activation domains of the GAL4-type trans-activators
are shown as acidic domains. Oct-1 and Oct-2 are likely candidates
for the trans-activation factors binding to the octamer motif (for
further details, see text).
activation domain. This domain can interact pro-
ductively with the TATA box complex, and this
results in efficient initiation of transcription. Figure
3B shows the transcription complex found on the
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ii_giobin promoter in I Iel .a cells. In this case, Oct
is replaced by the Sph-binding factors,
productively interact with the I ATA box complex
through acidic domains, consistent with the idea that
the activation domains of the GALA type
activators are interchangeable. In the U2 promoter,
however, the TATA complex is replaced by an snpE
complex, which interacts productively only with
Oct-1 (Fig. 3C). Because Oct-1 does not stimulate
transcription from mR NA promoters, it does not
belong to the GAL4 class of trans-activators and
therefore is not represented with an acidic activation
domain. The activation domain is of another nature
and is specific for the snPE. In Figure 3D, VP16 is
shown serving as an adaptor between the Oct-I
protein and a TATA box complex, essentially
providing Oct-1 with the necessary acidic domain.
This model is consistent with all of our results and
explains why the ubiquitous octamer-binding pro-
tein, although able to bind the octamer motif, will
not stimulate transcription from an immunoglobulin
promoter. It also emphasizes that not all trans-
activation domains are interchangeable and that the
specificity of trans-activation is conferred not only
by DNA-binding specificity, but also by protein-
protein interactions between proximal transcription
complexes and distal enhancer-binding proteins.
cis-Acting Elements Involved in
U2 and U6 Transcription
S. Lobo, N. Hernandez
A U6 promoter truncated at position -70 and thus
missing the enhancer region is still recognized by pol
III in vitro. In the pol II U2 promoter, the cor-
responding region contains only one element es-
sential for efficient transcription, the proximal
element. To determine which cis-acting elements in
the U6 promoter define it as a pol III promoter, we
introduced a series of clustered point mutations
between positions - 70 and +1 and analyzed their
effect in vivo and in vitro. Mutations that modified
the snPE strongly reduced transcription both in vivo
and in vitro. Mutations that affected the T/A-rich
region reduced transcription in vitro severely and
generated novel start sites in vivo. a-Amanitin
experiments in whole cells demonstrated that these
new start sites were used by pol II. Thus, mutation
of the T/A-rich region converts the U6 promoter into
a pol II promoter, which, like the U2 promoter, is
PROXIMAL ELEMENT T/A ELEMENT
U6: pol III CTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCG
U2: pol II GGCTGGGGCTCTCACCGCGACTTGAATGTGGATGAGAGTGGGACGGTGACGGCGGGCGCGAAGGCCCCTCGAGTACCTAG
U2/TA: pol III t t tatat
FIGURE 4 Clustered point mutations that convert the U2 promoter into an RNA pol III promoter. (Line 1) U6 5'-flanking sequences
from -76 to +1. The proximal element and the T/A-rich element are overlined. The start site of transcription is indicated by a star.(Line 2) 5'-flanking sequences of the pU2/-247/RA.2 construct, which are identical to natural U2 5'-flanking sequences from
-71
to -4. The region around the U2 cap site has thus been replaced by other sequences, and transcription from the U2 promoter
starts mainly at the nucleotide indicated by a star. Four mismatches between the U2 and U6 proximal elements are indicated in
bold letters. (Line 3) Mutations that convert the U2 promoter into an RNA pol III promoter. The location of the start site used by RNA
pol III is indicated by a star.
inactive in vitro. We showed that, indeed, this pol
II activity was dependent on the snPE, like in the
U2 promoter.
Interestingly, the site of transcription termination
changed depending on which RNA polymerase was
transcribing the gene. pol III transcription from the
U6 promoter read through a 3' box inserted down-
stream and terminated at a run of Ts. When the T/A-
rich region was mutated, however, transcription ended
at the 3' box. This suggests that in pol II snRNA
genes, the polymerase itself or an associated factor
is involved in recognition of the 3' box. Since tran-
scription from mRNA promoters ignores the 3' box,
it also suggests that the U1 -U5 snRNA genes are
transcribed by pol II transcription complexes dif-
ferent from those that transcribe mRNA genes.
The observation that mutation of the T/A-rich
region converted the U6 promoter into a pol II
promoter suggested that this region constitutes a
dominant signal for pol III specificity. To test this
directly, we created a T/A-rich element in the U2
promoter by mutating 7 by as shown in Figure 4.
Indeed, this mutation converted the U2 promoter
into a pol III promoter, active in vitro. Thus, in the
human U6 snRNA gene, pol III specificity is
conferred by a single, short cis-acting element, which
may be binding a single trans-acting factor. We are
now focusing on the identification and character-
ization of this factor as well as the factors that bind
to the snPE.
Function of Mammalian RNA 3'-end
Formation Signals in the Fission
Yeast Schizosaccharomyces pombe
P. Reinagel, N. Hernandez [in collaboration with
D. Frendewey, Cold Spring Harbor Laboratory]
snRNA transcripts end at a position determined by
a 3'-flanking signal, the 3' box. This signal can only
be recognized by RNA pol II transcription complexes
that initiate at snRNA promoters. Little is known
about the mechanism by which the 3' box is recog-
nized, so it is of interest to determine whether this
signal can function in fission yeast where genetic
dissection of function is possible. Weak homology
with the vertebrate 3'-box consensus can be found
at variable distances downstream from the cloned
Schizosaccharomyces pombe snRNA genes.
We have tested the ability of S. pombe to recognize
a human snRNA promoter and 3' box. For this
purpose, a construct containing the human U2
promoter followed by (1) spacer sequences, (2) a 3'
box, and (3) the Ad2 L3 polyadenylation site was
introduced into S. pombe, and transcription from
the human U2 promoter was monitored by RNase
T1 protection analysis. No correctly initiated RNA
could be detected, suggesting that the human U2
promoter was not utilized by the S. pombe transcrip-
tion machinery. To determine whether the human
3' box could be utilized, we replaced the human U2
promoter by the 5'-flanking sequence of the S. pombe
U4 snRNA gene (obtained from D. Tollervey). This
chimeric gene is expressed in S. pombe and gives rise
to transcripts that ignore the 3' box signal. Thus, if
snRNA 3'-end formation in fission yeast occurs by
a mechanism analogous to that in vertebrates, the
3'-flanking signal must be significantly diverged from
the 3' box of the human genes. We are now determin-
ing whether the L3 polyadenylation signal is func-
tional in S. pombe.
Premature Termination in the
HIV-1 LTR in Soluble Extracts
from HeLa Cells
M. Sheldon, S. 'fill, N. Hernandez
When a plasmid carrying the HIV-1 LTR is trans-
fected into COS cells, short transcripts terminated
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50-60 nucleotides downstream from
the cap site are
observed. Cotransfection of an expression
vector
carrying the viral trans-activator tat suppresses these
short transcripts and activates HIV expression
several
hundredfold.
To determine whether the short transcripts are
generated by premature termination of transcription
and whether tat acts as an antiterminator, we set out
to reproduce HIV premature termination of tran-
scription in vitro. In some extracts from He La cells,
we observe short transcripts of the expected length
when a plasmid carrying the HIV -1 LTR is used as
a template. These short transcripts are not observed
with a template carrying the Ad2 E4 promoter and
are sensitive to low concentrations of a-amanitin,
indicating that they are synthesized by RNA pol II.
We are now determining whether these extracts also
produce short transcripts when programmed by the
CELL BIOLOGY OF THE NUCLEUS
D.L. Spector W.-K. Chan J.R. Suhan
M. R. Delannoy
During the past year, our research program has
continued to focus on two areas: (1) biochemical
studies on the myc oncoprotein and (2) the structural
and functional organization of the cell nucleus. Our
structural studies have been greatly facilitated by the
use of image analysis and three-dimensional recon-
struction techniques at the electron microscopic level.
In addition, the use of the electron microscopy core
facility has continued to expand, and a large number
of collaborations are under way, with the excellent
technical expertise of Joe Suhan.
Three-dimensional Organization of
Small Nuclear Ribonucleoproteins
D.L. Spector, M.R. Delannoy
Using antibodies directed against small nuclear
ribonucleoproteins (snRNPs), we have shown that
these particles are concentrated within particular
regions of the cell nucleus. These regions have been
referred to as "nuclear speckles." Recently, our
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HIV-2 LTR. Our goal is to obtain antitermination
by tat or by extracts derived from tat-expressing cells
in vitro so that we can analyze the reaction bio-
chemically.
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studies on this nuclear region have been aided by the
use of image analysis and three-dimensional
reconstruction techniques. Images of cell sections
observed in the electron microscope (Fig. la) can be
directly transmitted to the image analysis system,
where a variety of operations can be performed on
the images. One such operation includes the
formation of a binary image of immunoreaction
product (Fig. lb). From such an image, measure-
ments and statistical analyses can be performed.
Using this technique, we have determined that cell
sections immunostained with anti-Sm monoclonal
antibodies contain approximately 20-30 snRNP
clusters that occupy approximately 14% of the
nuclear area of interphase cell sections. We are
currently evaluating cells at various stages of the cell
cycle in order to determine if the number and/or
nuclear area containing snRNPs is constant or
changes through the cell cycle.
Our previous studies on the distribution of
snRNPs in the cell nucleus have used immunofluo-
rescence microscopy or immunoelectron microscopy.
Both of these techniques resulted in the acquisition
II.
FIGURE 1 Distribution and quantitation of snRNP clusters. (A) 0.5 µm section of a CHOC 400 cell showing the distribution
of snRNPs via immunoperoxidase staining. Arrowheads point to the snRNP clusters. The nucleoli (No) and cytoplasm (C)
do not stain. This section has not been poststained. (B) Computer-generated binary image of the immunoreactive regions
of A showing the snRNP clusters in white. Using such a binary image, it has been determined that there are 27 snRNP
clusters in this cell section and that these clusters occupy approximately 14% of the nuclear area in this section.
of two-dimensional images that represent a small
sample of the distribution of snRNPs within the
whole nucleus. To gain a more complete understand-
ing of the distribution of snRNPs within the cell
nucleus, we have begun to evaluate three-dimensional
reconstructions of serial sections through complete
nuclei. CHOC 400 cells were grown in monolayer
culture and were incubated for 16 hours with 3-j.tm
mean diameter lectin-coated polystyrene spheres.
These spheres are taken up by the cells and serve as
fiduciary markers in aligning serial sections. Figure
2 (A-D) is a three-dimensional model of a recon-
struction from 17 100-nm serial sections. The snRNPs
are shown in white, nucleoli are shown in grey, and
the nuclear envelope is shown as a line surrounding
each section. Stereopair A and B provides a view
from the top surface of the cell looking down into
the nucleus. Stereopair C and D provides a view from
the bottom surface of the cell, which was attached
to the petri dish, looking up toward the cell surface.
The distribution of snRNPs appears to extend be-
tween the nucleolar surface and the nuclear envelope,
forming a reticular network. The nucleoli appear to
lie closer to the upper surface of the nucleus. Using
the three-dimensional reconstruction program, we
can rotate or tilt this model and cut in the X, Y, and
Z axes. Using these criteria, we are in the process
of determining whether a reproducible three-dimen-
sional pattern of snRNPs exists and whether this
pattern is cell-cycle-regulated.
Breakup and Morphogenesis
of snRNP-enriched Nuclear
Speckles
D. L. Spector, J. P. Suhan
As a means of trying to establish the functional sig-
nificance of the nuclear regions enriched in snRNPs,
we have evaluated several approaches that have al-
tered cellular metabolism in order to determine their
effects on the snRNP clusters. We have previously
shown that these clusters break up during mitosis
and alter their organization after the inhibition of
heterogeneous nuclear RNA (hnRNA) synthesis by
the adenosine analog 5,6-dichloro-1-P-D-ribofura-
nosylbenzimidazole (DRB). In addition, we have
shown that the in situ sites of DNA replication,
as measured by [3H]thymidine incorporation, and
the in situ sites of transcription, as measured by
[31-1Juridine incorporation, are not coincident with
the nuclear regions enriched in snRNPs. These data
raise the possibility that functions other than DNA
replication and transcription are associated with this
nuclear region; one such function may be pre-mRNA
processing.
In light of the findings of Yost and Lindquist (Cell
45: 185 [1986]), who demonstrated that the splicing
of pre-mRNA precursors (which do not code for
heat-shock proteins in Drosophila cells) were blocked
by heat shock, we were interested in determining if
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FIGURE 2 Model of a three-dimensional reconstruction of a CHOC 400 cell nucleus, showing the distribution
of snRNPs (region in white), nucleoli (region in grey), and the nuclear envelope (grey line around each
section). A-B and C-D represent stereopairs. Stereopair A-B provides a view from the top surface of the
cell looking down into the nucleus. Stereopair C-D provides a view from the bottom surface of the cell looking
up toward the cell surface.
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heat shock altered the organization of the snRNP-
enriched nuclear speckles. To address this question,
we heat-shocked CHOC 400 cells for 15 minutes at
45°C and fixed them for immunofluorescence
microscopy or allowed them to recover at 37°C for
various periods of time prior to fixation and
immunolabeling. The snRNPs were detected by
FITC-labeled monoclonal anti-Sm antibodies, and
hsp70 was detected by rhodamine-conjugated anti-
hsp70 polyclonal antibodies. Control cells grown at
37°C showed a typical speckled snRNP staining
pattern (Fig. 3b) and no detectable hsp70 (Fig. 3c).
After a 15-minute heat shock at 45°C, the speckled
staining pattern was disrupted, and snRNPs appeared
to be diffusely distributed throughout the nucleo-
plasm, excluding the nucleoli (Fig. 3e). After a 15-
minute recovery at 37°C, two to three speckles began
to reappear (Fig. 3h). Initial speckle formation was
almost always adjacent to the nucleoli. Several ex-
citing possibilities come to mind as to why the initial
speckles appear to be adjacent to nucleoli. Perhaps
the speckled pattern is anchored in the nucleoplasm
to the surface of the nucleoli. Alternatively, the
nucleolar organizer region (NOR) may more broadly
serve as a nuclear organizer, or perhaps the nucleus
contains other organizing centers that have yet to be
identified. Since heat shock causes a change and not
a loss of the snRNP immunofluorescence pattern,
it is unlikely that these initial snRNP clusters rep-
resent the sites of snRNA transcription. Further-
more, the snRNP proteins that are recognized by
anti-Sm antibodies are complexed with newly syn-
thesized snRNAs in the cytoplasm before they return
to the nucleus. These interesting observations are
currently being pursued by immunoelectron micros-
copy. After 30 minutes (Fig. 3k) and 60 minutes (Fig.
3n) of recovery, the number of speckles continued
to increase for 2 hours, when the typical speckled
staining pattern was reformed (Fig. 3q). By 2 hours
of recovery, hsp70 appeared in the nucleoli (Fig. 3r),
indicating that we had stimulated the heat-shock
response. In summary, we have shown a breakup of
snRNP-enriched nuclear speckles after heat shock
and a time-dependent recovery of the speckled
staining pattern after cells are returned to their nor-
mal growing temperature. Experiments using North-
ern blot analysis are currently under way to deter-
mine if the morphological changes of the speckled
staining pattern can be directly correlated with the
levels of dihydrofolate reductase (DHFR) pre-mRNA
processing. Since the DHFR message in CHOC 400
cells represents approximately 1007o of the cellular
message, we may be able to identify differences in
the amounts of precursor and spliced product over
time.
Structural and Functional Domains
of the c-myc Oncoprotein
W.-K. Chan, D.L. Spector [in collaboration with E. Chang
and J. Anderson, Cold Spring Harbor Laboratory]
Our studies are aimed at dissecting the structural and
functional domains of the c-myc oncoprotein as a
means of understanding its role in the cell nucleus.
We have expressed the recombinant human c-myc
protein using the PL-AR expression system, followed
by purification using a scheme developed by Watt
et al. (Mol. Cell. Biol. 5: 448 [1985]). Several
problems were encountered during purification due
to the cross-linking of the c-myc protein with
disulfide bonds forming insoluble inclusion bodies
in Escherichia coll. To circumvent these problems,
we expressed the c-myc protein in the T7 polymer-
ase system and developed a new purification protocol
that resulted in at least 95070 pure c-myc protein (Fig.
4, lane 1) devoid of cross-linking by disulfide bonds
(Fig. 4, lane 2).
We next attempted to illustrate the structural
domains of the c-myc protein by limited proteoly-
sis. When purified protein was digested with trypsin,
four protease-resistant fragments of 44K, 34K(trip-
let), 22K, and 18K were observed (Fig. 5, lanes 3-9).
These fragments were also seen when proteinase K
or V8 protease was used (data not shown). This result
suggested that there might be several domains in the
c-myc protein molecule that fold in a manner that
renders them relatively insensitive to protease
digestion. To verify whether the authentic c-myc
protein possesses similar domains, we performed
similar experiments on in-vitro-translated protein
and on the c-myc protein from Colo 320 cells. Similar
protease-resistant bands were observed when the
protein was labeled with [35S]cysteine. Interestingly
enough, when the protein was labeled with [35S]meth-
ionine, only the 44K and 34K bands were observed.
Since the methionine residues of the protein cluster
in the amino terminus of the protein (positions 1, 101,
120, and 134) and the ten cysteine residues are widely
scattered in the molecule (positions 25, 70, 116, 133,
171, 188, 208, 299, 342, and 438), the result suggested
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FIGURE 3 Breakup and morphogenesis of snRNP-enriched nuclear speckles. See text for a detailed description.
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FIGURE 4 Characterization of the c-myc oncoprotein expressed
in the T7 polymerase system. (A) SDS-PAGE of purified c-myc
oncoprotein. Purified protein runs around 65 kD (lane 1), although
it contains only 439 amino acids. This protein is devoid of
nonspecific cross-linking by disulfide bonds as it enters the gel
even without the addition of 0-mercaptoethanol (lane 2). (8)
Immunoblot of the purified c-myc protein. To show the correct
identity of the purified protein, a well-characterized monoclonal
antibody, B3 (from R. Watt), was used to probe the protein and
the same single protein band reacted with the antibodies (lanes
1 and 2). Lane 2 is loaded with five times more protein than lane
1. Lane M contains the molecular-weight markers.
that the 44K and 34K bands may be from the amino
terminus of the protein, whereas the 22K and 18K
bands may be from the carboxyl terminus of the
protein. To confirm this, we are in the process of
purifying and determining both the amino- and
carboxy-terminal sequences of the proteolytic frag-
ments (in collaboration with Dan Marshak, Tumor
Virus Section). Nevertheless, the above data suggest
that the E. coll-synthesized c-myc protein is folded in
a fashion similar to that of the in-vitro-translated and
cellular c-myc proteins.
After the establishment of an efficient purification
scheme for each individual fragment, we will determine
the domain that is important for oligomerization
and/or nucleic acid binding. The purified intact c-myc
protein and its proteolytic fragments will be used for
crystallization to determine the three-dimensional
structure of the protein. It is hoped that an understand-
ing of the structure of the protein will help to elucidate
its precise function in the cell nucleus.
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FIGURE 5 Partial proteolysis of the recombinant c-myc
oncoprotein. The purified protein was digested with trypsin at
a substrate-to-enzyme ratio equal to 2000:1 (w/w) at room tempera-
ture. After different times, an aliquot of the protein was taken out
and analyzed in SDS-PAGE. (1,2) Without protease digestion;
(3-9) Digested with trypsin. The time shown at the bottom of each
lane is the time of incubation of the mixture at room temperature.
The highlighted bands are the 44K, 34K, 22K, and 18K proteolytic
fragments.
Nuclear Association of the
c-myc Oncoprotein
W.-K. Chan, D L Spector
As an approach to understand the function of the
c-myc oncoprotein in the cell nucleus, we would like
to identify nuclear proteins that interact with c-myc
in the nucleus by coimmunoprecipitation experi-
ments. During the past year, we have generated
several polyclonal antibodies against the purified
recombinant c-myc protein from E. coli (Fig. 6A,
lane 2), and we recently generated a battery of
monoclonal antibodies (assisted by Ed Harlow's
group [Tumor Virus Section]; Fig. 6A, lanes 3, 5,
and 6) that recognize different epitopes on the c-myc
protein (Fig. 6B, contrast lanes 3 and 5). These
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FIGURE 6 Characterization of the polyclonal and monoclonal antibodies
(MAbs) against the c-myc oncoprotein. (A)
Immunoprecipitation of the c-myc protein from Colo 320 cells using
polyclonal or monoclonal antibodies. Colo 320 cells
were labeled with [35S]methionine, lysed, and immunoprecipitated
with polyclonal or monoclonal antibodies. The immu-
noprecipitates were analyzed in SDS-PAGE. (1) Immunoprecipitate from
normal rabbit serum; (2) from rabbit 138, which
was immunized with recombinant c-myc protein; (3) from MAb KC8; (4)
from MAb KC14; (5) from MAb KC26; (6) from MAb
KC33. (8) Characterization of the reactivities of some of the MAbs against c-myc
protein by immunoblotting. The purified
c-myc protein was either digested with trypsin (substrate to enzyme =
2000:1) or was undigested and run in SDS-PAGE
and transferred onto nitrocellulose. Lanes 1,3,5,7, and 9 were loaded with
trypsinized c-myc, whereas lanes 2,4,6,8, and
10 were loaded with intact c-myc. Lanes 1 and 2 were probed with serum from
rabbit 138; lanes 3,4 with KC8; lanes 5,6
with KC26; lanes 7,8 with KC33; and lanes 9,10 with B3. Note that KC26 recognizes
different proteolytic fragments as compared
with other MAbs. Lane M represents the molecular-weight markers.
antibodies will be useful reagents for coimmuno-
precipitation experiments to investigate the possible
c-myc-associated and/or related protein(s). Different
conditions of immunoprecipitation including the use
of different detergents, ionic strength, and pH of the
buffer will be tested to reveal the possible c-myc
complex in the nucleus. The identification and char-
acterization of the c-myc-associated protein(s) may
shed some light on the function of the c-myc protein
in the nucleus.
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CELLULAR TRANS-ACTIVATORS OF GENE EXPRESSION
B.R. Franza J. Ross
We study the cellular proteins involved in the control
of growth of mammalian cells. A focus for these
studies has been the identification and characteriza-
tion of cellular proteins that interact either directly
or indirectly with specific nucleic acid structures. For
some time, it has been known that certain DNA
sequence elements direct the expression of genes by
modulating transcription. We have identified several
proteins that interact with different sequence
structures and have learned some interesting things
about them: (1) The protein products of several
cellular proto-oncogenes cooperatively interact with
at least two specific sequence elements. (2) Certain
combinations of these proteins interact with single-
stranded DNA containing specific sequences. (3)
Several cellular proteins interact with the direct repeat
sequence elements in the human immunodeficiency
virus type-1 long terminal repeat (HIV-1 LTR). (4)
These same proteins interact with control elements
in T-cell-specific genes, including the interleukin-2
receptor a gene (IL-2Ra). (5) Induction of binding
of certain of these proteins is independent of de novo
protein synthesis. (6) Expression of the trans-
activator gene of the human T-lymphotrophic virus
type I (HTLV-I) results in activation of binding of
at least one of these proteins. Some details of these
studies are discussed below.
FOS-ASSOCIATED PROTEIN P39 IS THE PRODUCT
OF THE JUN PROTO-ONCOGENE
Proto-oncogenes, the cellular homologs of retroviral
oncogenes, play key roles in the regulation of normal
cell growth and development. An understanding of
the role of the products of proto-oncogenes in
normal cellular processes is a necessary prelude to
determining the molecular basis of oncogenesis.
Several proto-oncogene products have been shown
to function in one or another aspect of intra- or
intercellular communication (signal transduction) as
extracellular growth factors, cell-surface receptors,
G proteins, kinases, or transcription factors. I have
pursued studies for several years (in collaboration
with Tom Curran and his colleagues at the Roche
Institute of Molecular Biology) aimed at elucidat-
ing the function of the fos proto-oncogene and
related genes. This has led to the characterization
of Fos as a member of a set of cellular proteins that
recognize specific DNA elements involved in tran-
scriptional control. Included in this set is another
proto-oncogene product (Jun). We have suggested
that the proteins encoded by the fos and jun gene
families function as transcriptional regulators in
coupling short-term signals elicited by cell-surface
stimulation to long-term responses by regulating
patterns of gene expression through control elements
such as AP-1 (activator protein-1 binding site) and
CRE (cAMP-response element binding site). We are
attempting to determine the mechanism(s) whereby
Fos and Jun bring about such effects. Eventually,
we hope to correlate these observations with studies
of the physiological variables that alter the function
of Fos and Jun (as well as Fra-1 and JunB) during
normal cell growth, during the cell-division cycle, and
in transformed cells.
The fos oncogene is encoded by two murine (FBJ-
MSV, FBR-MSV) retroviruses and one chicken
(NK24) retrovirus that cause bone tumors. The fos
proto-oncogene, c-fos, is expressed at low levels in
the majority of cell types; however, it is induced
rapidly and transiently by a bewildering array of
extracellular stimuli. These stimuli may be associated
with mitogenesis, differentiation, or neuronal ex-
citation. These observations led to the classification
of c-fos as a cellular immediate-early gene that might
participate in a signaling process in several cell types.
It is our contention that the protein product of c-fos
regulates expression of specific target genes contain-
ing AP-1 and/or CRE sites in these many situations.
The protein product of c-fos (Fos) is a 62-kD
nuclear phosphoprotein that participates in protein
complexes with a 39-kD cellular protein (p39).
Antibodies raised against a synthetic peptide
corresponding to Fos amino acids 127-152 precipi-
tate a complex array of proteins from serum-
stimulated cells. The collaboration between the
Franza and Curran laboratories was first initiated
to analyze the many proteins present in these
immunoprecipitates using the high-resolution two-
dimensional gel system and computer-accessible
protein database developed by Garrels and Franza.
These studies revealed several important features: (1)
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Fos undergoes complex posttranslational
modifica-
tion, resulting in more than 20 distinct
forms that
can be resolved on two-dimensional gels.
(2) Fos
associates with at least three distinct proteins, one
of which exhibited cell-type specificity
(it was
identified in PC12 cells treated with nerve growth
factor [NGF] but not in serum-stimulated fibro-
blasts). These proteins were referred to as Fos-
associated proteins (Fap). (3) Several proteins,
antigenically related to Fos, were induced by serum
in fibroblasts and by NGF in PC12 cells. Thus,
extracellular stimuli led to the appearance of several
protein complexes containing Fos and the synthesis
of several Fos-related proteins.
Previous studies demonstrated that the Fos protein
complex and related proteins exhibited nonspecific
DNA-binding activity and were associated with
chromatin in isolated nuclei. These data suggested
that Fos might function as a DNA-binding transcrip-
tional regulator. A clue to a specific DNA-binding
activity was obtained from studies performed by
Bruce Spigelman and colleagues at Harvard, in
which a gel-retardation complex composed of DNA
and protein was inhibited by anti-Fos antibodies. We
noted that the DNA (derived from a control region
of an adipocyte differentiation-sensitive gene [aP2])
contained a sequence very similar to the AP-1 site
present in the hMTIIA and SV40 enhancer ele-
ments. To study this interaction, we employed the
microscale DNA-affinity precipitation (DNAP)
assay (see the 1987 Annual Report) in which several
oligonucleotides containing normal and mutated AP-
1-binding sites were evaluated. We found that many
control regions containing AP-1 sites interacted
specifically with the Fos complex, several Fos-related
antigens (FRAs), and other cellular proteins. It was
clear from these studies that a number of cellular
proteins interacted with AP-1 sites, although pre-
viously, other investigators had identified a single
47-kD protein and designated it the activator protein-
1 (AP-1). Pursuing these studies led to the identifi-
cation of the Fos-associated protein, p39, as the
product of the c-jun proto-oncogene (see Fig. 1).
COOPERATIVE INTERACTION OF NUCLEAR
PROTO-ONCOGENE PRODUCTS WITH
SPECIFIC NUCLEIC ACID ELEMENTS
To investigate further the nature of the Fos and Jun
interaction with the AP-1 and CRE sites and to
determine the role of protein complex formation in
DNA binding, we reconstructed the protein-protein
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FIGURE 1 Comigration of proteins immunoprecipated by anti-
Jun and p39 isolated in DNAP assays with oligonucleotides
containing AP-1 binding sites. H9 cells (1 x 108) were stimulated
by the addition of Ca- ionophore A23187 to a final concentra-
tion of 10-6m for 20 min, and [35S]methionine (2.0 mCi) was then
added. Cells were harvested 30 min later; extracts were prepared
and examined by immunoprecipitation (A) or by DNAP assays
(B,C). Recovered proteins were separated on two-dimensional
gels. Only the portion of the gel in which p39 migrates is present.
(A) H9 cells were treated with A23187 labeled with [35Slmethi-
onine as described above, and the cells were then harvested and
prepared for immunoprecipitation. Cell extracts were incubated
with anti-PEP-1. DNAP analysis with the HIV ( -357 to -316)
oligonucleotide. DNAP analysis was carried out with biotinylated
DFSE2 oligonucleotide. Both oligonucleotides contain AP -1-
binding sites, and in DNAP assays, they bind Fos, Fos-related
antigens, and p39. The hash marks on each panel indicate the
number of forms of p39 that were resolved on the two-dimensional
gels.
and protein-DNA interactions in vitro using Fos and
Jun synthesized in reticulocyte lysates. The Fos-Jun
complex formed extremely rapidly in vitro and
possessed similar, although not identical, hydro-
dynamic properties to the complex present in cell
extracts. Although Jun exhibited some AP-1 binding,
Fos acted with Jun to give enhanced, specific DNA-
binding activity. The increased affinity of the Fos-
Jun complex for DNA resulted from a stabilization
of the protein-DNA complex. These experiments
demonstrated a cooperative interaction of the protein
products of two proto-oncogenes with DNA ele-
ments (AP-1 and CRE) involved in transcriptional
regulation. In addition, we have demonstrated co-
operative interactions at the AP-1 and CRE sites
using in-vitro-translated Fra-1 and Jun. Similarly, we
have shown that the product of the jun-related gene,
JunB (first identified by Daniel Nathans and
colleagues at the Johns Hopkins Medical School)
associates with either Fos or Fra-1 at AP-1 and CRE
sites using the DNAP assay and DNA-mobility shift
A. B.
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assay. Therefore, the products of several distinct
nuclear proto-oncogenes contribute to stable, spe-
cific interactions with nucleic acid structures that
mediate transcriptional control.
SEQUENCE-SPECIFIC SINGLE-STRANDED
DNA RECOGNITION BY THE FOS/JUN
PROTEIN COMPLEX
We have demonstrated that in-vitro-translated Fos
and Jun proteins interact with single-strand sequence
structures containing the AP-1-binding site (see Fig.
2). Additionally, we have demonstrated that the Fra-1
C.
I 2 3 4 5 6 7
Fos
Jun
Jun partial
/product
Fra I
Jun partial
product
FIGURE 2 Fos+Jun and Fra1 +Jun interact with the AP-1 structure in single-stranded DNA. The
DNA sequences of oligonucleotides used in these studies are
DAP-1ss 5' TCGACGTGACTCAGCGCGCATCGTGACTCAGCGCGC3'
aDAP-1ss 5'GCGCGCTGAGTCACGATGCGCGCTGAGTCACGTCGA3'
The bold letters designate the two bases in each AP-1 motif that were altered to generate mutant
oligonucleotides (T to A and A to T respectively, for each strand). The annealed duplexed oligonu-
cleotide is referred to as DAP-1. Each oligonucleotide is a two-time iterated sequence of the AP-1
structure in the human metallothionein IIA gene. (A) Each lane represents the translation products
of mRNA for c-jun, c-fos, and c-fra1. Visualization of protein is the result of incorporation of
[35S]methionine during the in-vitro-translation reactions. (B) Mixture of Fos and Jun and resultant
DNAP assays: (1) Reaction mixture containing all components except for biotinylated (b-) oligonu-
cleotide; (2) reaction containing b-DAP-1 double-strand probe; (3) reaction containing b-mutant DAP-1
double-strand probe; (4) reaction containing b-DAP-1ss probe; (5) reaction containing b-a DAP-1ss
probe; (6) reaction containing b-mutant DAP-1ss probe; (7) reaction containing b-mutant aDAP-1ss
probe. (C) Mixture of Fra1 and Jun and resultant DNAP assays. All lanes are the same as the Fos
+ Jun DNAP assays.
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Through evolutionary time, such retroviruses have 
condensed a set o f regulatory elements into a small 
piece of genetic material. It is clear that these 
elements provide the virus with the ability to be 
silenced (i.e., nonexpressed, latent state), to be 
activatable when the growth status of the cell in 
which they reside changes, and to be highly expressed 
when the intracellular setting is appropriate. We have 
learned to take advantage of the virus in that we use 
its small control region to detect the cellular proteins 
needed to regulate its expression, and we have used 
this information to probe the regulation of com- 
plicated human cellular genes.
One result o f these investigations has been the 
identification of several cellular proteins that interact 
with the HIV-1 enhancer and with a control element 
essential for inducible expression of IL-2Ra. Investi- 
gations of the IL-2Ra promoter have been done in 
collaboration with Warner Greene and colleagues 
at Duke University Medical School. The IL-2Ra 
element is structurally similar to the 10-bp sequence 
that is repeated in the HIV-1 enhancer. Figure 3 shows 
a region of a two-dimensional gel in which several 
of the proteins that interact with either o f these 
control elements are represented. The cells used in 
this study are a human T-lymphoblast line called 
Jurkat. In Figure 3A, the proteins expressed in 
unstimulated Jurkat cells that interact specifically 
with the 10-bp sequence are shown. Stimulation of 
the cells with the tumor promoter, phorbol 12-myri- 
state 13-acetate (PMA), results in quantitative and 
qualitative changes in the interacting proteins. Pro- 
teins designated KP are members of the set o f pro- 
teins that we have previously designated HIVEN86A. 
The alphanumeric system that we now use to map 
and keep track of these complicated interactions is 
consistent with the QUEST database system. Each 
spot has a unique designator, and in all subsequent 
investigations, we will use this designator to link the 
protein spots from different images in which they 
appear. Our suspicion, several years ago, that more 
than one protein would be found to interact with 
transcription control elements has proven to be the 
case. It is fortunate that we have the database system 
to monitor these numerous interactions. It should 
also be evident that even when the precise biochem- 
ical function of each of these proteins is known, we 
will still require the database system to discern how 
the cell regulates them through processes such as 
differentiation or the cell division cycle.
gene product also cooperatively associates with the 
same single-strand nucleic acid structures (see Fig. 
2). The product of the Jun-related gene, JunB, also 
associates with Fos or Fra-1 at AP-1 single-strand 
sites. Little is known of specific interactions of 
mammalian cellular proteins with single-stranded 
DNA. It is tempting to speculate that a functional 
role of these various complexes might involve either 
the induction of deformation of duplexed DNA or 
stabilization of a nonduplexed structure. In any 
event, models for eukaryotic transcription, and 
possibly replication, can now be considered in which 
the appearance of an AP-1 motif within DNA could 
either positively or negatively affect such syntheses 
of nucleic acid. It is unlikely that the AP-1 single- 
strand sequence structure will remain unique in this 
regard.
MULTIPLE CELLULAR PROTEINS INTERACT WITH 
THE HIV-1 ENHANCER ELEMENT
The strategy of combining the microscale DNA- 
affinity precipitation assay with high-resolution two- 
dimensional gels has proven itself useful to the study 
of the control of human retroviral gene expression. 
Viruses like the HIV-1 require cellular proteins for 
their replication. Specifically, cellular proteins that 
control the expression (transcription) of cellular 
genes are also required to generate mRNA from the 
integrated retroviral DNA. HIV-1 actually contains 
DNA sequences that are identical to regulatory 
sequences attached to normal cellular genes. Cellular 
proteins recognize these sequences just as they do 
when they are linked to cellular genes. In this way, 
the virus utilizes cellular systems to activate and 
maintain transcription. mRNA is the genetic 
material of these types of viruses and therefore the 
cell actually provides the means for the virus to 
propagate itself. Any hope of understanding how the 
AIDS virus remains dormant in the cell and then is 
activated to express its mRNA rests on understand- 
ing how these normal cellular proteins function. The 
process of latency itself is interesting because its 
maintenance may involve cellular proteins that 
silence specific cellular genes as a normal conse- 
quence of differentiation.
Since HIV-1 is a small genetic unit compared to 
the entire human cellular genome, it actually provides 
us with a very powerful tool for understanding both 
its regulation and the regulation of cellular genes.
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FIGURE 3 Multiple T-cell proteins specifically interact at either the HIV-1 enhancer or the IL-2Ra promoter.
Jurkat T cells were prelabeled with [35S]methionine for 3.5 hr, washed, and then incubated in the presence
(B) or absence (A) of PMA for 30 min. 35S-labeled extracts were mixed with biotinylated dimers of the wild-
type (A, B) IL-2Ra (or HIV-1 enhancer) oligonucleotide probes. Nucleoprotein complexes were precipitated
with avidin agarose and associated proteins were subjected to two-dimensional gel electrophoresis.
PROTEIN SYNTHESIS IS NOT REQUIRED FOR
THE MODULATION OF INTERACTIVE EVENTS
AT THE HIV-1 ENHANCER
One issue in determining the mechanisms control-
ling the transcription status of a gene is determin-
ing if the proteins required to effect the change must
themselves be synthesized as part of the modulatory
event. A convention that has been adopted by nu-
merous investigators is the use of protein synthesis
inhibitors that act on living cells to prevent de novo
synthesis consequent to the addition of an activat-
ing agent. PMA, mitogenic lectins, serum, and
growth factors comprise some of the agents that
activate transcription of specific cellular genes. To
discern whether any of the proteins we already had
identified to interact with the HIV-1 enhancer would
show a quantitative change even in the presence of
a protein synthesis inhibitor, we devised the following
approach. The Jurkat cells (or any other growing cell)
are first metabolically labeled with a radioactive
amino acid. The cells are then removed from the
labeling environment, and a protein synthesis inhib-
itor is added to their growth media. Then, either
nothing else is added or different activating agents
are added to the growth media. After specified
intervals, the cells are harvested and lysed, and
DNAP assays are performed. Subsequent two-dimen-
sional gel analysis of the DNA-protein complexes
provides results such as those shown in Figure 4.
It is clear that the protein synthesis inhibitor
cycloheximide is capable of inducing quantitative
and qualitative alterations in the proteins that
interact with the HIV-1 enhancer even in the absence
of an activating agent. This is not unprecedented.
The time of exposure critically affects the results.
In this experiment, the cycloheximide and PMA were
incubated with the cells for 90 minutes prior to
harvesting the cells. If the interval were 30 minutes,
one would see much less of a cycloheximide effect
and much more of a PMA effect. This suggests that
the one thing cycloheximide is doing is preventing
the production of sufficient protease to digest these
proteins and therefore they accumulate. It also
suggests that PMA may not only recruit already
synthesized proteins, but induce their production as
well when an inhibitor of protein synthesis is not
present in the growth media. The proteins represented
in these panels are not the only ones we have
identified whose interactions with the HIV-1 en-
hancer can be induced by cycloheximide. It is there-
fore likely that the cell at any time is prepared to alter
the expression of at least some subset of genes in-
dependent of de novo synthesis of protein. Irrespec-
tive of how many biological reasons there may be
for such a mechanism, it implies that evolutionary
selection has required some cellular responses to be
very quick.
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FIGURE 4 Induction of specific DNA-protein interactions by protein synthesis inhibitors. Jurkat T lymphoblasts
were incubated with [35S]methionine for 3.5 hr. The cells were then placed in normal growth media to which
either nothing (A), PMA (8), cycloheximide (C), or PMA + cycloheximide (D) was added. After 90 min,
the cells were harvested and lysed, and DNAP assays were performed. The oligonucleotide probe used
for these studies represents the region in the HIV-1 LTR between -106 and -80 (direct repeat region).
A HUMAN RETROVIRAL TRANS-ACTIVATOR ALTERS
THE INTERACTION OF HIVEN86A (KP SERIES)
WITH DIFFERENT CONTROL ELEMENTS
In collaboration with Warner Greene and colleagues
at Duke University Medical School, we have
investigated the effect constitutive production of
HTLV-I Tax protein has on gene expression. Using
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Jurkat T cell lines that express the 40-kD Tax protein,
Greene et al. demonstrated deregulated expression
of the IL-2Ra receptor gene. The sequence element
required for this effect was demonstrated to be
structurally similar to the 10-bp direct repeat element
in the HIV-1 enhancer. As shown in Figure 5, the
binding of HIVEN86A to this region of the IL-2Ra
J U R KAT anti-sense fax
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-r\ 4f\
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HS73K HS72K
FIGURE 5 Microscale DNA-affinity precipitation assay of Tax-induced cellular DNA-binding proteins that interact
with the promoter. Biotinylated IL-2Ra oligonucleotide DNA representing bases +291 to +245 of the IL-2Ra
promoter was incubated with [35S]methionine-labeled nuclear proteins isolated from J-anti-tax-10 (A) or J-tax-
9 (8), followed by DNA-protein complex precipitation with avidin-agarose and two-dimensional gel electropho-
resis. The different isoelectric forms of the HIVEN86A protein and two heat-shock proteins (HS72K and HS73K)
are identified by arrows. HS73K is coprecipitated in these assays independent of Tax expression and DNA
probe sequence; HS72K represents a Tax-inducible protein with apparently nonspecific DNA-binding properties.
promoter is quantitatively greater in the Tax-
expressing Jurkat cells compared to similar numbers
of Jurkat cells that contain an antisense tax gene
construct. A similar increase is detected when an
oligonucleotide representing the HIV-1 enhancer is
used as the probe in the DNAP assay. It may be that
the deregulated expression of IL-2Ra gene expression
encountered in HTLV-I leukemias is to some extent
the result of Tax alteration in the availability of
proteins like HIVEN86A for interaction with control
elements in certain genes.
The systematic application of the microscale
DNA-affinity precipitation assay and immunopre-
cipitation assays in conjunction with high-resolution
two-dimensional gels has permitted rapid, compre-
hensive assessment of protein-DNA interactions and
the identification of specific members of the protein
complexes that associate with transcriptional control
elements. It is expected that sustained application
of this strategy will expand our knowledge of the
proteins involved in the control of cellular gene
expression.
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MOLECULAR BIOLOGY OF THE CYTOSKELETON
D.M. Helfman S. Cheley
S. Erster
K.I. Galactionov
L. Goodwin
J.P. Lees-Miller
L.A. Finn
W.M. Ricci
R.F. Roscigno
Our research has continued to focus on the structure,
expression, regulation, and function of the genes
encoding tropomyosin in muscle and nonmuscle
cells. Tropomyosins are important elements of the
contractile systems of skeletal, cardiac, and smooth
muscle cells and nonmuscle cells. Although they are
expressed in all cells, different isoforms of the protein
are characteristic of specific cell types. The gen-
eration of tropomyosin isoform diversity involves the
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expression of multiple genes, some of which encode
multiple isoforms via tissue-specific alternative RNA
processing. During the past year, we have completed
much of the structural analysis of the genes that
express muscle and nonmuscle tropomyosins. This
work has demonstrated that the rat genome contains
three functional genes that express at least 12 distinct
tropomyosin isoforms. One gene encodes rat
fibroblast tropomyosin-1 (TM-1) and skeletal muscle
V A
13-tropomyosin. A second gene encodes skeletal
muscle and smooth muscle a-tropomyosins and at
least seven other distinct tropomyosin isoforms,
including four isoforms expressed in fibroblasts
(TM-2, TM-3, TM-5a, and TM-5b) and three
isoforms unique to brain tissue. Interestingly, this
gene was also found to contain two alternative
promoters that contribute to the multiplicity of
isoforms expressed from this gene. The third gene
that we have characterized appears to be somewhat
unique in that it expresses only a single isoform,
namely, rat fibroblast TM-4. The molecular basis for
the generation of tropomyosin isoform diversity by
alternative RNA processing is not known and
constitutes one major area of our research. Another
interest of our laboratory has been to study the
function and expression of tropomyosin in normal
and transformed fibroblasts. Below is a summary
of our present studies.
Studies of Alternative Splicing of
Tropomyosin Pre-mRNAs
D.M. Helfman, L.A. Finn, W.M. Ricci,
R.F. Roscigno, K.S. Weber
The generation of protein isoform diversity by
alternative RNA splicing is a fundamental mech-
anism of eukaryotic gene expression, which contrib-
utes to tissue-specific and developmentally regulated
patterns of gene expression. Alternative RNA
splicing pathways have also been demonstrated for
a number of viral genes. At present, little is known
about the mechanisms that determine alternative
RNA splicing of complex transcription units. In
particular, it is not known how alternative splice sites
are selected and whether the splicing signals in
complex transcription units differ from those in
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simple transcription units. The identified sequence
elements required for pre-mRNA splicing include the
consensus sequences found at the 5' and 3' splice sites
and lariat branchpoints. Sequence comparisons
between splice junctions of alternative and constitu-
tive exons have failed to identify any significant
differences, suggesting that these sequences alone do
not account for the choice between alternative splice
sites. It seems likely that regulation of splice-site
selection in transcripts containing alternative 5' or
3' splice sites will involve other cis-acting elements.
In addition, a number of studies have suggested the
existence of trans-acting factors that interact with
sequence elements in the pre-mRNA to promote
differential splice-site selection. However, the identity
of the trans-acting factors and the signals they
recognize remain unknown.
We have been using the rat TM-1 gene as a model
to investigate the mechanism of a type of develop-
mental and tissue-specific alternative splicing. This
gene is composed of 11 exons (Fig. 1). Exons 1
through 5 and 8 and 9 are common to all mRNAs
expressed from this gene. Exons 6 and 11 are used
in fibroblasts as well as smooth muscle, whereas
exons 7 and 10 are used exclusively in skeletal muscle.
In the present studies, we have focused on the
mutually exclusive internal alternative splice choice
involving exon 6 (fibroblast-type splice) and exon 7
(skeletal-muscle-type splice). Our previous studies
of tropomyosin pre-mRNA splicing revealed an
ordered pathway of splicing in which either internal
alternatively spliced exon must first be joined to the
downstream common exon before it can be spliced
to the upstream common exon (Helfman et al.,
Genes and Dev. 2: 1627 [1988]). These studies
demonstrated that splicing of exon 5 to exon 6
(fibroblast-type splice) and exon 5 to exon 7 (skeletal-
muscle-type splice) was dependent on precursors in
which exon 6 or exon 7 was first joined to exon 8.
189 - 213 258 - 284
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FIGURE 1 Schematic diagram of the gene and model for the generation of rat fibroblast TM-1 and skeletal muscle p-tropomyosin
mRNAs by alternative RNA splicing. Open boxes represent common exons, hatched boxes represent
fibroblast or smooth muscle
exons, closed boxes represent skeletal muscle exons, and horizontal lines
represent introns; they are not drawn to scale. The amino
acids encoded by each exon are indicated. The cap site and polyadenylation signal AATAAA are also indicated.
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The data are consistent with a model in which the
critical event in alternative splicing occurs during the
joining of exon 6 to exon 8 (fibroblast-type splice)
or exon 7 to exon 8 (skeletal-muscle-type splice).
To study further the mechanism and regulation
of alternative splice-site selection, we have character-
ized the branchpoints used in processing tropomyo-
sin pre-mRNAs in vitro using nuclear extracts
obtained from He La cells. Splicing of exon 5 to exon
6 (fibroblast-type splice) involves the use of three
branchpoints located 25, 29, and 36 nucleotides
upstream of the 3' splice site of exon 6. Splicing of
exon 6 (fibroblast-type splice) or exon 7 (skeletal-
muscle-type splice) to exon 8 involves the use of the
same branchpoint located 24 nucleotides upstream
of this shared 3' splice site. In contrast, the splicing
of exon 5 to exon 7 (skeletal-muscle-type splice)
involves the use of three branchpoints located 144,
147, and 153 nucleotides upstream of the 3' splice
site of exon 7. These results are in contrast to the
majority of introns that have been studied in which
only a single adenosine residue, located within 18-40
nucleotides from the 3' splice site, is utilized during
lariat formation. These studies raise the possibility
that the use of branchpoints located a long distance
from a 3' splice site may be an essential feature of
some alternatively spliced exons.
We have begun to study the role of these unusual
branchpoints located upstream of exon 7. Deletion
analysis of sequences between these branchpoints
and the 3' splice site of exon 7 revealed that these
intron sequences were not necessary for utilization
of this 3' splice site in vitro. However, these sequences
were found to play an important role in alternative
splice-site selection. Transfection of a wild-type
minigene into He La cells containing exons 5 through
9 results in spliced RNA containing only exons
5 +6+8 + 9 (fibroblast-type splice). Interestingly,
deletion of sequences between the 3' splice site of
exon 7 and the upstream branchpoints resulted
predominantly in spliced RNA containing exons
5 +7 + 8+ 9 (skeletal-muscle-type splice). Thus, in-
tron sequences upstream of exon 7 contain an
important cis-acting element involved in alternative
splice-site selection. Computer analysis of these
regions revealed that intron sequences upstream and
downstream from exon 7 can form stable secondary
structures that would sequester this exon and prevent
its utilization. Thus, a simple mechanism may
account for the fact that exon 7 is not used in
nonmuscle cells (e.g., HeLa and rat fibroblasts),
because it is sequestered and unable to interact with
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the splicing machinery due to. RNA folding. t
more, specific sequences within introns could interact
with tissue-specific factors that stabilize or destabi-
lize (e.g., an RNA helicase) the formation of RNA
secondary structures, leading to alternative splice-
site selection. In addition, alternative splicing may
not be the result of tissue-specific splicing factors
that recognize specific 5' and /or 3' splice sites directly,
but rather through tissue-specific factors that control
the interaction of a general splicing factor(s) with
the alternative splice sites. It is interesting to note
that we have demonstrated efficient splicing of exon
5 to exon 7 and exon 7 to exon 8 (skeletal-muscle-
type splices) in HeLa cell nuclear extracts using
precursors that lacked downstream and upstream
intron sequences, respectively. Thus, utilization of
the 5' and 3' splice sites of exon 7 does not have an
absolute requirement for skeletal-muscle-specific
factors. In addition, the mechanism by which splicing
of exon 5 to exon 6 or exon 7 is dependent on these
exons being joined to exon 8 is not yet known. One
possibility is that joining together two exons and
thereby removing a flanking intron may prevent the
formation of RNA structures that interfere with the
interaction of a given 5' or 3' splice site with the
splicing machinery. Work is currently under way to
explore further the role of specific intron sequences
in alternative splice-site selection and to identify
tissue-specific factors that may interact with specific
regions of the pre-mRNA to generate alternative
RNA splicing.
Sequence Analysis of the
Rat TM-1
S. Erster, L.A. Finn, D.M. Helfman
We have determined the sequence of the entire rat
TM-I gene. Our sequence data extend from approxi-
mately 600 by upstream of the cap site to approxi-
mately 600 by downstream from the polyadenyla-
tion signal of exon 11. Characterization of the
fibroblast TM-1 and skeletal muscle 13-tropomyosin
cDNAs derived from this gene, as well as the
promoter region and the intron/exon borders, has
been described previously (Helfman et al., Mol. Cell.
Biol. 6: 3582 [1986]). The sequence analysis con-
firmed our previous observations, based on nuclease
protection and Northern analyses, that only two
mRNAs are expressed from the TM-1 gene. This gene
is far less complex than the gene that encodes the
rat skeletal muscle a-tropomyosin, as the latter gene
contains two alternate exons encoding amino acids
39-80 and four alternate exons encoding the car-
boxy-terminal region (compare Figs. 1 and 2). By
comparison, it has recently been determined that the
chicken gene that encodes chick fibroblast TM-1 and
skeletal muscle I3-tropomyosin also encodes a low-
molecular-weight tropomyosin iso form via an alter-
nate internal promoter. Thus far, we have found no
evidence of such a promoter in the rat TM-1 gene.
Our current hypothesis is that in rat, unlike chicken,
the low-molecular-weight 13-type tropomyosin is the
product of a separate gene, which encodes rat
fibroblast TM-4 (see below).
Another feature of the rat TM-1 gene is the
presence of long AC dinucleotide repeats in introns
1 and 9. Repeats consisting of alternating purines
and pyrimidines (RY), are abundant in eukaryotic
genomes. These sequences have the potential to
assume a left-handed Z-DNA conformation and
have been shown to have positive and negative effects
on transcription. The presence of these repeats is also
associated with increased recombination frequencies.
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FIGURE 2 Schematic diagram of the a-tropomyosin gene and model for the generation of muscle (skeletal and smooth)
and nonmuscle isoforms. Boxes represent exons and horizontal lines represent introns; they are not drawn to scale. The
different polyadenylation signals are also indicated (A). For an explanation, see text.
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Sequence analysis of several gene families, such as
globin and the immunoglobulins, has demonstrated
that these repeats are often the endpoints of substitu-
tion and insertion/deletion events, which may play
a role in gene conversion. This observation is of note
because the alternating purine and pyrimidine
repeats that are located in introns 1 and 9 in the TM-1
gene correspond to positions in the rat a-tropomyo-
sin gene, where there are additional promoters and
exons that are missing from the TM-1 gene (compare
Figs. 1 and 2).
The DNA sequence information is being used to
search for potential regulatory elements involved in
tissue-specific RNA processing. For example, using
computer programs, we are searching for possible
RNA secondary structures in defined regions of the
pre-mRNA that may be involved in splice-site selec-
tion. We have examined the nucleotide sequences in
the region of the alternative 3' splice sites and poly-
adenylation sites and have determined that the more
distal fibroblast-specific exon, which is utilized in
all smooth muscle and nonmuscle cells, is more ho-
mologous to the consensus splice-site sequences than
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those derived for the skeletal muscle 3' splice site.
We have also detected purine-rich and pyrimidine-
rich regions immediately upstream of the skeletal-
muscle-specific exon, which may interfere with uti-
lization of this exon by the formation of stable
secondary structures (see below).
In Vivo Analysis of Tropomyosin
Pre-mRNA 3'-end Processing
S. Erster, L.A. Finn, D.M. Helfman
Tropomyosin pre-mRNA 3'-end processing requires
alternative exon selection and utilization of the
appropriate poly(A) site (Fig. 1). At present, it is not
known if the 3'-end processing involves tissue-specific
splice-site selection and/or tissue-specific polyade-
nylation. We have studied these events by transient
expression of 3'-end minigenes in cultured cells,
followed by nuclease protection and primer extension
analyses. In COS cells, we detect splicing of the
constitutive exon 9 to both alternate exons 10 and
11, along with cleavage at both poly(A) sites, with
a preference for the fibroblast-specific pathway.
Mouse 3T3 fibroblasts appear to utilize the fibro-
blast-specific exon 11, and mouse C2 myotubes use
the skeletal-muscle-specific exon 10, suggesting that
these minigenes are processed in a tissue-specific
fashion in these cell lines. To identify cis-acting
elements involved in splice-site selection, we have
constructed a number of minigenes containing
mutations in defined regions. We have found a region
in intron 9 that when deleted results in the use of
the skeletal-muscle-specific exon 10 in 3T3 fibro-
blasts. Thus, intron sequences upstream of exon 10
appear to contain an important cis-acting element
involved in splice-site selection. It is possible that in
fibroblasts, the tropomyosin pre-mRNA assumes a
secondary structure in which the skeletal-muscle-
specific exon is inaccessible to the splicing machinery
and that our deletions have disrupted this structure
such that the skeletal-muscle-specific exon can now
be utilized. As mentioned above, the region just
upstream of the skeletal-muscle-specific exon con-
tains a purine-rich region followed by a pyrimidine-
rich region. Interestingly, this region is extremely
homologous in sequence and putative secondary
structure to the same region of the chicken TM-1
gene. Deletions and mutations in this and other re-
gions will hopefully allow us to define further the
cis-acting sequences involved in the regulation of
tropomyosin pre-mRNA alternative processing.
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Structural Analysis of
the Gene Encoding Rat
Fibroblast TM-4
JP. Lees-Miller, A. Yan, D.M. Helfman
We have determined the complete nucleotide se-
quence of the gene encoding rat fibroblast TM..4.
The 18-kb sequence included 1600 by of the 5'..
untranslated region and 200 by 3' to the poly(A)
cleavage site. The gene was found to contain eight
exons. Thus far, we have been unable to obtain any
evidence that this gene expresses more than a single
form of tropomyosin. For example, we did not find
any sequences within the introns of the TM-4 gene
encoding potential novel exons that would indicate
a potential alternative splice. Further experiments
using labeled intron sequences as Northern probes,
or RNase protection analysis with a full-length TM-4
antisense message, were also negative with RNAs
from a wide variety of tissue sources, including slow-
twitch and fast-twitch skeletal muscle and cardiac
muscle. It is therefore unlikely that the rat TM-4 gene
is alternatively spliced. Preliminary primer-extension
experiments aimed at localizing the TM-4 gene
transcription initiation site indicate that it is 120 by
upstream of the translation initiation site. This result
will be confirmed with RNase protection. Future
work on the TM-4 gene will be focused on determin-
ing what promoter and enhancer elements are
responsible for its transcriptional regulation.
Structural Analysis of the
a-Tropomyosin Gene and
the mRNAs Expressed from
It in the Brain
J.P. Lees-Miller, L. Goodwin, D.M. Helfman
The ot-tropomyosin gene consists of 15 exons, 5 of
which are common to all known mRNAs that are
expressed from it (Fig. 2). The remaining exons
include two exons (exons la and lb) that are
transcribed from separate promoters, two alterna-
tively spliced internal cassettes (exons 2a or 2b and
exons 6a or 6b), and four exons encoding different
carboxy-terminal amino acids (exons 9a, 9b, 9c, and
9d). The various splice choices allow for the possible
production of 24 proteins from the a-tropomyosin
gene. At present, we are reasonably certain that at
least nine of the possible isoforms are made (Fig.
2). These isoforms are distributed in a specific
manner among tissues such as striated muscle,
smooth muscle, kidney, liver, and brain. In addition,
four fibroblast isoforms are expressed from this gene
(see below).
We are particularly interested in three products
that are expressed in brain. Three a-tropomyosin
cDNAs (0k4, 1.2 kb; Ok15, 1.1 kb; and Ok10, 2.8
kb) were isolated from a rat brain library. Ok4 and
Ok10 possess a novel carboxy-terminal coding region
that is specific to brain and correspond to TMBr-1
mRNA and TMBr-3 mRNA, respectively (Fig. 2).
Multiple polyadenylation sites are associated with
the use of this exon (exon 9c), resulting in the length
difference of Ok4 and Ok10. The third cDNA clone
we isolated (0k15) contains a novel 5' end that is
encoded by a second a-tropomyosin gene promoter
and a novel 3' end, resulting from exon skipping of
the striated muscle carboxy-terminal coding region,
corresponding to TMBr-2 mRNA (Fig. 2). The exon
skip causes a frameshift that bypasses the normal
stop codon and radically alters the amino acid
sequence, so that it is in no way similar to the known
tropomyosin repeat pattern. Making use of a number
of restriction sites, we have engineered Ok154, which
contains the 5'-coding sequence of Ok15 (TMBr-2)
and the 3'-coding sequence of Ok4 (TMBr-1). RNase
protection experiments with antisense RNAs derived
from each of Ok4, 15, and 154 demonstrated that
they are all expressed specifically in brain.
We have also made full-length sense RNAs for
each brain-specific cDNA and translated them in
vitro with a rabbit reticulocyte lysate. We are in the
process of characterizing the mobility of the resulting
proteins by two-dimensional gel electrophoresis. We
have also mapped and sequenced the exon/intron
borders in the a-tropomyosin gene corresponding to
the novel 5'- and 3'-coding regions that are found in
Ok15 and Ok4, respectively (Fig. 2). This work
includes the sequencing of 1400 by upstream of the
novel promoter and 2000 by downstream from the
3'-coding region of Ok4 and Ok10. RNase protection
and S1 analyses of the novel promoter indicate the
presence of multiple transcription initiation sites
from 140 to 230 bases upstream of the translation
initiation site. This work will be confirmed with
primer-extension analysis. In the future, we hope to
determine the cell-type specificity of each tropomyo-
sin isoform in the developing rat brain and in
cultured nervous system cell lines. We also hope to
elucidate some of the factors required for brain -cell-
specific expression of the a-tropomyosin gene.
Four Rat Fibroblast Tropomyosins
Are Expressed from a Single Gene
via Alternative Splicing and
Utilization of Two Promoters
L. Goodwin, S. Cheley, D.M. Helfman
Multiple forms of tropomyosins have been detected
in many cultures of nonmuscle cells. For example,
on the basis of two-dimensional gel analysis, it was
reported previously that rat embryonic fibroblasts
contain at least five tropomyosin isoforms: three
major tropomyosins termed TM-1, TM-2, and TM-4,
with apparent molecular weights of 40,000, 36,500,
and 32,400, respectively, and two relatively minor
tropomyosins, termed TM-3 and TM-5, with ap-
parent molecular weights of 35,000 and 32,000,
respectively (Matsumura et al., J. Biol. Chem.
258: 954 [1983]). Each isoform can be identified in
cell-free translation products of fibroblast mRNA,
indicating the existence of multiple mRNAs. We have
previously described the isolation and characteriza-
tion of full-length cDNA clones encoding rat
fibroblast TM-1 and TM-4 (Yamawaki-Kataoka and
Helfman, J. Biol. Chem. 269: 14,440 [1985]; Yama-
waki-Kataoka and Helfman, J. Biol. Chem. 262:
10,791 [1986]). These studies revealed that these two
isoforms are the products of two separate genes. The
derived amino acid sequence of these cDNA clones
revealed TM-1 contains 284 amino acids, whereas
TM-4 contains 248 amino acids. In addition, we
demonstrated that the same gene that encodes rat
fibroblast TM-1 also encodes skeletal muscle 13-tro-
pomyosin via alternative RNA splicing and polyade-
nylation (Helfman et al., Mol. Cell. Biol. 6: 3582
[1986]).
As described above, we have characterized the gene
encoding rat fibroblast TM-4 and have not found
any evidence for the generation of additional
isoforms from this gene via alternative RNA process-
ing. During the past year, we have isolated and
characterized full-length cDNA clones to four
additional tropomyosin isoforms expressed in rat
fibroblasts, termed TM-2, TM-3, TM-5a, and TM-
5b. We have determined that these four isoforms are
expressed from a single gene by alternative splicing
and utilization of two alternate promoters (Fig. 2).
TM-2 and TM-3 are expressed from the upstream
promoter, and TM-5a and TM-5b are transcribed
from an internal promoter. TM-2 and TM-3 both
contain 284 amino acids and differ at an internal
region of the protein from amino acid 189 to 213,
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due to alternative splicing of exons 6a and 6b (Fig.
2). TM-5a and TM-5b both contain 248 amino acids
and differ at an internal region due to alternative
splicing of exons 6a and 6b (Fig. 2). The functional
significance of these four related isoforms is
unknown and is currently under study (see below).
The generation of these four isoforms from a single
gene raises a number of interesting questions
concerning the expression of these isoforms. For
example, two-dimensional gel analysis of the
tropomyosins expressed in cell lines transformed with
Kirsten virus (NRK 1569 cells) and Rous sarcoma
virus (NRK 4/435) demonstrated that these cells do
not express TM-2 and TM-3 but do express TM-5a
and TM-5b. Using probes derived from the full-
length cDNA clones, we have established that the
absence of TM-2 and TM-3 proteins in these
transformed cells correlates with a corresponding
lack of mRNA for these isoforms. At present, we
do not know if the lack of detectable mRNA
encoding TM-2 and TM-3 in these transformed cells
is due to inhibition of transcription from the
upstream promoter of this gene or by another
mechanism, e.g., changes in nuclear transport,
splicing, or mRNA stability. In the future, we will
examine the effect of various nuclear and cytoplas-
mic oncogenes on tropomyosin expression to
determine if there are alterations in transcription,
processing, and translation of tropomyosin mRNAs
in transformed cells.
Expression and Function of
Tropomyosin in Normal and
Transformed Cells
L. Goodwin, D.M. Helfman
Comparative two-dimensional protein gel analysis
of normal and transformed cells has revealed that,
of the numerous cytoskeletal proteins, tropomyosin
expression is selectively altered in transformed cells.
In general, these studies demonstrate that in trans-
formed cells, the levels of one or more of the major
tropomyosin isoforms of higher molecular weight
are decreased or missing, whereas the levels of one
or more of the lower-molecular-weight tropomyosin
isoforms are increased. The alterations in tropomyo-
sin synthesis have been reported to occur in cells
transformed by a variety of agents, including chemi-
cal carcinogens, UV radiation, and DNA and RNA
tumor viruses. Moreover, the changes in tropomyo-
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sin expression following transformation occur in cells
of all species examined, including chicken, rodents
(mouse and rat), and humans. Collectively, these
i
results indicate that alterations in tropomyosin ex-
pression are common features of the transformed
phenotype and that tropomyosin genes may represent
a target for oncogene action.
As described above, rat fibroblasts transformed
by Rous sarcoma virus or Kirsten virus (analyzed by
two-dimensional protein gel) show a complete loss
of expression of TM-2 and TM-3 concomitant with
an increase in the levels of TM-5a and TM -5b
expression. In addition, these alterations in tropo-
myosin expression appear to correlate well with the
rearrangement of microfilament bundles and the
morphological alterations observed in transformed
cells. To determine the functional significance of the
altered pattern of tropomyosin isoform expression
in transformed cells, tropomyosin isoforms (i.e.,
TM-2 and TM-3) will be introduced into living cells
by microinjection of RNA or protein and via expres-
sion of cloned cDNAs using eukaryotic expression
vectors. In this manner, we hope to address several
questions. For example, will forced expression of
specific tropomyosin isoforms in transformed cells
result in the reorganization of the microfilament
system and changes in morphology?
To synthesize biologically active mRNAs encoding
specific tropomyosin isoforms, the full-length
cDNAs encoding TM-I, TM-2, TM-3, TM-4, TM-
5a, and TM-5b were subcloned into SP6 plasmids.
Direct purification of individual tropomyosin iso-
forms from rat fibroblasts has been difficult using
conventional purification methods, which is likely
due to the fact that the different protein isoforms
have such similar physiochemical properties. To
prepare each of the fibroblast tropomyosin isoforms
(TM-I, TM-2, TM-3, TM-4, TM-5a, and TM-5b),
we have utilized a plasmid-cloning system that allows
for the production of the protein in Escherichia coll.
Using this system, we will prepare homogeneous
preparations of each of the isoforms. We have
already prepared large quantities of TM-2 from
E. coli for these studies. We are also interested in
examining the localization of the various tropomyo-
sin isoforms in normal cells. To this end, we will inject
the individually fluorochrome-labeled protein spe-
cies into living cells and follow the dynamic sub-
cellular distribution and incorporation into the mi-
crofilaments. In conjunction, we plan to prepare
isoform- specific antibodies to determine the patterns
of localization of each iso form. The distribution of
various tropomyosin isoforms in the normal cell may
allow insight into the role of tropomyosin in the
cytoskeleton and thus how perturbations in the
regulation of tropomyosin isoform synthesis contrib-
utes to the transformed phenotype.
Analysis of Tropomyosin Function in
Adenovirus-transformed Rat Cells
K.I. Galactionov, D.M.Helfman
We have used an established rat fibroblast cell line
(REF52 cells) and its adenovirus-transformed coun-
terpart (Ad5D.4A) to examine the role of a major
tropomyosin isoform in cytoskeleton organization
and cell shape. Normal rat fibroblasts (e.g., REF52
cells) contain six different isoforms of tropomyosin.
In the adenovirus-transformed cells (Ad5D.4A), only
TM-1 is absent. It was previously shown that re-
pression of TM-1 synthesis likely occurs at the tran-
scriptional level (Yamawaki-Kataoka and Helfman,
J. Biol. Chem. 262: 10791 [1987]). Neither the mech-
anism(s) responsible for repression of TM-1 synthesis
in the adenovirus-transformed cells nor the specific
function of TM-1 in normal cells is known. The
absence of TM-1 protein in the Ad5D.4A cell line
has been suggested to be responsible for the absence
of microfilament bundles and the accompanying
changes in cell morphology observed in these cells.
In addition, transformation of REF52 cells with
other oncogenic viruses (Kirsten, SV40, etc.) also
decreases the level of TM-1 protein, but to still de-
tectable levels. We wish to determine if the absence
of the TM-1 isoform in the adenovirus-transformed
cells is directly responsible for the changes in actin
filament assembly and cell morphology character-
istic of these cells.
The first goal of this study was to obtain stable
adenovirus-transformed cells expressing TM-1
protein. To express the TM-1 isoform, we have used
cDNA and genomic clones encoding this isoform
and a number of eukaryotic expression plasmids. For
transfection experiments, three types of constructs
were made; two of them contain the Drosophila and
human heat-shock promoters, respectively, and the
third contains the SV40 early promoter. Tropomyo-
sin cDNA containing sequences corresponding to the
first nine exons was subcloned adjacent to the
genomic 3' end in order to obtain correct processing
of the TM-1 transcript. These chimeric cDNA/ge-
nomic sequences were subcloned into plasmids con-
taining the inducible (heat-shock) or constitutive
(SV40) promoter regions. We have obtained stable
transformants using cotransfection of TM-1 con-
structions and pKOneo, followed by selection with
G418. Work is now under way to study the phenotype
of transformants. We also wish to study the function
of TM-1 in normal cells. In this case, transfection
of REF52 cells with the TM-1 sequences in the anti-
sense orientation was done using the same inducible
and constitutive promoters. Studies are under way
to determine the changes in TM-1 expression in these
cells and possible changes in the microfilament struc-
tures and cell shape. Finally, we plan to study the
function of TM-1 in different cell types by microin-
jection of fluorescently tagged TM-1 molecules and
determine its localization and possible rearrange-
ments during the cell cycle and following serum
stimulation. For this purpose, we are using a plasmid-
cloning system that allows for the production of
TM-1 protein in E. coli.
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MAMMALIAN STRESS RESPONSE
W.J. Welch A.P. Arrigo
R. Beckmann L.A. Mizzen
N.J.C. Lamb K.T. Riabowol
J.P. Suhan
L. Cipp
In addition to our studies on the physiology of the
stressed cell and the biochemistry of the individual
stress proteins, we are beginning to pursue new areas
of research regarding the mammalian stress response.
Specifically, it has become quite evident that the
stress response is associated with a number of
diseases in animals and may prove to have valuable
diagnostic potential. For example, it is now well
established that a stress response accompanies many
viral infections as well as a variety of tissue and organ
traumas such as stroke and heart attack. Finally,
autoantibodies to certain stress proteins may underlie
the severe pathological abnormalities seen in some
patients with autoimmune diseases. Moreover,
immunologists are now beginning to observe that one
or more of the stress proteins may be directly involved
in the immune response and that the febrile response,
in general, may serve to augment the activities of the
immune system.
At the cellular level, new data continue to impli-
cate a role for stress proteins in a number of cellular
processes including the regulation of steroid recep-
tors, various protein kinases, and finally mechanisms
by which proteins are assembled into larger macro-
molecular complexes. Considerable excitement con-
tinues to grow concerning the role for many of the
stress patterns in the pathways by which proteins are
translocated across intracellular membranes and
properly targeted to their final destination within the
cell. Consequently, we have experienced a tremen-
dous increase in the number of laboratories and
investigators who are beginning to focus their atten-
tion on the physiology of the stressed cell, the bio-
chemistry of the individual stress proteins, and the
medical applications of the stress response in terms
of both diagnostic and therapeutic routes.
Identification and Characterization
of Two Stress Proteins Present
within the Mitochondria
L.A. Mizzen, W.J. Welch [in collaboration with W.C. Chang
and J. Garrels, Cold Spring Harbor Laboratory]
During the past year, we have identified, character-
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ized, and purified two previously unrecognized stress
proteins that are components of the mitochondria.
The first, heat-shock protein (hsp) 58-k D, increases
in cells subjected to heat shock or a number of other
agents, such as heavy metals that similarly induce
a heat-shock-like response. The second, glucose-
regulated protein (grp) 75-k D, is a member of the
so-called glucose-regulated stress protein family. This
family of proteins (grp 75-kD, grp 80-k D, and grp
100-kD) exhibits increased synthesis in cells deprived
of glucose, calcium, or oxygen or in response to
agents that perturb the ability of the cell to maintain
homeostatic calcium levels. We have observed that
hsp58 and grp75, like most mitochondrial proteins,
are synthesized initially as precursors containing an
amino-terminal extension that apparently serves as
a "signal sequence," directing their import into the
mitochondria. Biochemical studies, in particular
exposure of purified mitochondria to various pro-
teolytic enzymes, indicate that both hsp58 and grp75
are present within the mitochondria and not exposed
to the cytosolic compartment. Both immunological
and biochemical data have demonstrated that the
grp75 protein represents yet another member of the
hsp70 family of stress proteins. The other members
of this family appear to be involved in the ATP-
dependent and transient interaction with a number
of other cellular proteins, presumably facilitating
their final three-dimensional confirmation. Con-
sequently, we suspect that grp75 similarly serves
a role in the folding and unfolding of target pro-
teins but within its own compartment, the mito-
chondria.
The hsp58 protein appears to be homologous to
the previously described bacterial and plant proteins
referred to as "chaperonins." The chaperonins have
been shown to facilitate the assembly of monomeric
proteins into larger macromolecular complexes.
Thus, again by analogy, we are examining whether
hsp58 similarly serves in a catalytic manner to
assemble proteins with its own compartment, the
mitochondria. After induction of the stress response,
we suspect that the cell, in the process of replacing
mitochondrial proteins that have become denatured,
expresses higher levels of these two mitochondri-
al proteins to facilitate the assembly of new pro-
tein complexes in the mitochondria and thereby pro-
vide for the restoration of proper mitochondrial
function.
70-kD Stress Proteins Participate in a
Variety of Cellular Processes
W.J. Welch [in collaboration with E. White and D. Spector,
Cold Spring Harbor Laboratory; W. Farrar, National
Institutes of Health; D. Toft, Mayo Clinic; K. Milarski
and R. Morimoto, Northwestern University; and
N. Spector, Dana Farber Cancer Institute]
As we examine the structure and function of the
hsp70 stress proteins, we are continuing to find new
aspects concerning the role of these proteins in a
diverse number of different biological systems. As
was discussed in last year's Annual Report, many
viral infections often result in the increased expres-
sion of the 70-kD stress proteins. Moreover, in many
cases, a number of virus-encoded proteins involved
in the transformation process interact with the hsp70
proteins. In a collaborative study with E. White and
D. Spector (see Cell Biology of the Nucleus, this
section), we found an increased expression of the 70-
kD stress proteins in cells infected with adenovirus.
Other laboratories have demonstrated that such in-
creased expression is due to activation of the 70-kD
gene by the adenovirus EIA protein. In addition,
using a combination of immunological and bio-
chemical methods, we found that the EIA protein
and 72-kD stress protein are co-localized in the
infected cell. At the present time, the significance
of this finding with respect to the activity of the EIA
protein remains unclear. Further studies are aimed
at determining whether the association with the 72-
kD stress protein serves in any way to stabilize and
regulate the biochemical activity of the EIA protein
(White et al., J. Virol. 62: 4153 [1988]).
Recent studies, in collaboration with David Toft
at the Mayo Clinic, have demonstrated that many
steroid receptors also appear to associate with two
of the major stress proteins. Most steroid receptors
exist as soluble moities within the cytoplasm and/or
nucleus. Steroids diffuse across the plasma mem-
brane, bind to their receptor, and thereby result in
a change in receptor confirmation. The receptor, now
in its "transformed" or activated state, will bind to
its target genes and promote gene transcription. Our
studies have shown that the steroid receptor, in its
"nontransformed" or inactivated state, forms a com-
plex with both the 90-kD and 70-kD stress proteins.
Through its interaction with the 90-kD protein, it
is thought that the steroid receptor protein is unable
to bind to its target gene. Following binding of the
steroid to its receptor, the 90-kD stress protein exits
the complex, and the receptor, still in association
with the 70-kD stress protein, subsequently binds to
DNA and activates transcription. Studies are there-
fore in progress to dissect the role of both the 90-kD
and 70-kD stress proteins in regulating and facilitat-
ing the action of the steroid receptor. The current
hypothesis is that although the 90-kD protein pre-
vents binding of the receptor to DNA in the absence
of hormone, the 70-kD protein somehow facilitates
a confirmational change in the activated receptor and
thereby promotes or facilitates the binding of its
receptor to its target gene (Kost et al., MoL Cell Biol.
[1989] submitted).
Yet another emerging area concerning a role for
the 70-kD stress proteins involves mitogenesis and
the cell cycle. In the case of human cells, one of the
70-kD stress proteins is synthesized at the GI/S
boundary in the normal unstressed cell. After its
synthesis, the 70-kD protein again becomes com-
plexed with a number of cellular proteins; the exact
identity of such proteins is currently under investi-
gation. Interestingly, the cellular complexes contain-
ing the 70-kD protein are observed to vary as a func-
tion of the cell cycle. Similar differences in complex
formation are seen at different points of the cell cycle
following heat shock. Consequently, we are trying
to determine the exact identity of those proteins
interacting with the 70-kD protein and the relevance
of such interactions (Milarski et al. J. Cell Biol.
[1989] in press).
Finally, in collaboration with a number of
laboratories, we are beginning to see a role for the
70-kD stress proteins in immune cell function.
Although too extensive to list here, one of our
collaborative studies has shown that both mitogen
and lymphokine stimulations of T lymphocytes
result in the increased synthesis of both the 70-kD
and 90-kD stress proteins (Ferris et al., Proc. Natl.
Acad. Sci. 11: 3850 [1988]). Moreover, these treat-
ments also result in a rapid and significant increased
phosphorylation of the low-molecular-mass 28-kD
stress protein. The activation of B lymphocytes by
bacterial endotoxins similarly results in the increased
expression of the 70-kD and 90-kD stress proteins
(in collaboration with N. Spector and L. Adler, Dana
Farber Cancer Institute). Interestingly, once acti-
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vated, the B cells now appear to be more resistant
to thermal stress than do their resting counterparts.
Role of the Heat Shock or Stress
Response in Human Disease
and Medicine
W.J. Welch [in collaboration with J. Winfield, University
of North Carolina, Chapel Hill; M. Tytell, Wake Forest
University; T. Nowak, National Institutes of Health]
Because the heat shock or stress response appears
to serve in the defense of cells to changes in its
environmental circumstance, it is not entirely surpris-
ing that the response may be implicated in a number
of important diseases. Indeed, a number of recent
studies have demonstrated that tissue and organ
traumas are accompanied by induction of the stress
response and that the stress proteins themselves may
play a central role in the repair of lesions incurred
due to the trauma. For example, we have found that
transient ischemic episodes in the brain (the basis
of stroke) result in the activation of the stress re-
sponse in some but not all areas of the brain. More
interesting is the fact that those areas within the brain
that survive the trauma exhibit the highest induction
of the stress proteins, whereas those areas that are
unable to survive show little or no induction of the
stress response. Therefore, using our battery of
antibodies to the stress proteins in immunocytochem-
ical studies, a number of investigators are examining
which regions within the brain show an induction
of the stress response and whether such induction
(or lack thereof) is associated with the survival
(nonsurvival) of the cells following trauma (Vass et
al., Acta Neuropathol. 77: 128 [1988]).
In a collaborative effort with M. Tytell's laboratory
at Wake Forest University, a similar study examining
light damage in the rat retina has revealed some
exciting results concerning the potential therapeu-
tic use of the stress response. During the past 15 years,
it has been well established that cells in tissue culture
can be made resistant to thermal killing simply by
a prior exposure of the cells to a nonlethal heat-shock
treatment. This phenomenon, referred to as thermo-
tolerance, is transient with the decay of the tolerant
state correlated with the turnover of the major stress-
induced protein, 72 kD. Tytell's laboratory has now
demonstrated an exciting potential use of thermo-
tolerance in the whole animal. Specifically, their
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laboratory has been examining ,photoreeeptor de-
generation in the retina of rats following exposure
to bright light. After exposure to intense light, rats
are sacrificed 2 weeks later, and the degree of pho-
toreceptor cell damage is ascertained. Normally, after
an intense light exposure, greater than 90% of the
photoreceptor cells are observed to die. 1 f, however,
the animals are first made thei motolerant (by prior
iexposure in a warm chamber in which body tempera-
ture is increased to 41-42°C), photoreceptor damage
due to the same light exposure is significantly re-
duced. Moreover, by examining the levels of the 70-
kD stress protein that accumulate in the retina of
animals made thermotolerant, a direct correlation
was observed with respect to the levels of the protein
and the light protection observed. These studies then
indicate that our ability to manipulate the levels of
the stress proteins in the animal may prove useful
in protecting tissues and organs after physical injury,
disease, and/or exposure to environmental insults
(Barbe et al., Science 241: 1817 [1988]).
Finally, in the area of infectious diseases, a number
of reports have demonstrated that certain immuno-
dominant proteins of infectious microorganisms
(Plasmodium falciparum, trypanosomes, mycobac-
terium tuberculosis, Leishmania) are homologs of
the stress proteins of eukaryotes. Often, the indi-
vidual so infected mounts an immune response
against the parasite forms of the stress proteins, and
later in life, the individual develops a severe auto-
immune disease. Consequently, it has been proposed
that the basis of this autoimmunity is due to the
production of autoantibodies against the individu-
al's own stress proteins. That this may indeed be the
case is indicated by recent studies by John Winfield
at the University of North Carolina in collaboration
with our research group. Specifically, in individuals
with systemic lupus erythematosus (SLE), autoanti-
bodies to both the 70-kD and 90-kD stress proteins
have been observed. Similarly, autoantibodies to the
70-kD stress protein have been found in sera from
rheumatoid arthritis patients, another autoimmume
disease (Minota et al., J. Exp. Med. 168: 1475 [1988]).
Keeping in mind that such individuals also produce
autoantibodies to other self-proteins, we still do not
know whether those autoantibodies directed against
the stress proteins are in fact the causative agent of
the disease. Nor do we know how and why such
autoantibodies to the stress protein arise. However,
these and other results have generated considerable
excitement among many immunologists, and we can
in the future expect new and exciting findings con-
cerning the role of the stress response and stress
proteins in the immune response.
PUBLICATIONS
Arrigo, A.-P, J.P. Suhan, and W.J. Welch. 1988. Dynamic changes
in the structure and intracellular locale of the mammalian low-
molecular-weight heat shock protein (28 kDa). Mo/. Cell. Biol.
8: 5059-5071.
Arrigo, A.-P., K. Tanaka, A. Goldberg, and W.J. Welch. 1988.
Identity of the 19S "prosomd' particle with the large multifunc-
tional protease complex of mammalian cells (the protosome).
Nature 331: 192-194.
Barbe, M.F., M. Tytell, D.J. Gower, and W.J. Welch. 1988. Hyper-
thermia protects against light damage in the rat retina. Science
241: 1817-1820.
Ferris, D.K., A. Harel-Bellan, R.I. Morimoto, W.J. Welch, and W.L.
Farrar 1988. Mitogen and lymphokine stimulation of heat
shock protein in T lymphocytes. Proc. Natl. Acad. Sci.
11: 3850-3854.
Lamb, N.J.C., A. Fernandez, M.A. Conti, R. Adelstein, D.B. Glass,
W.J. Welch, and J.R. Feramisco. 1988. Regulation of actin
microfilament integrity in living nonmuscle cells by the cAMP-
dependent protein kinase and the myosin light chain kinase.
J. Cell Biol. 106: 1955-1971.
Minota, S., B. Cameron, W.J. Welch, and J.B. Winfield. 1988.
Autoantibodies to the constitutive 73-kd member of the HSP70
family of heat-shock proteins in systemic lupus-erythematosus.
J. Exp. Med. 168: 1475-1480.
Mizzen, L.A. and W.J. Welch. 1988. Characterization of the
thermotolerant cell. I. Effects on protein synthesis activity and
the regulation of heat-shock protein 70 expression. J. Cell Biol.
106: 1105-1116.
Nishimura, R.N., B.E. Dwyer, W.J. Welch, R. Cole, J. DeVellis, and
K. Liotta. 1988. The induction of the major heat-stress protein
in purified rat glial cells. J. Neurosci. Res. 20: 12-18.
Riabowol, K., L.A. Mizzen, and W.J. Welch. 1988. Heat shock
is lethal to fibroblasts microinjected with antibodies against
hsp 70. Science 242: 433-436.
Vass, K., W.J. Welch, and T.S. Nowak. 1988. Localization of 70
kDa stress protein induction in gerbil brain after ischemia.
Acta Neuropathol. 77: 128-135.
Welch, W.J. 1988. The mammalian heat shock (or stress) response:
A cellular defense mechanism. Fourth International
Symposium on the Immunobiology Proteins and Peptides
(ed. M.Z. Atassi), pp. 287-304. Plenum Press, New York.
Welch, W.J. and L.A. Mizzen. 1988. Characterization of the
thermotolerant cell. II. Effects on the intracellular distribution
of heat-shock protein 70, intermediate filaments, and small
nuclear ribonucleoprotein complexes. J. Cell Biol.
106: 1117-1130.
Welch, W.J., L.A. Mizzen, and A.-P. Arrigo. 1988. Structure and
function of mammalian stress proteins. In Stress induced
proteins. U.C. L.A. Winter Symposium.
White, E., D. Spector, and W.J. Welch. 1988. Differential distribu-
tion of the adenovirus E1A proteins and colocalization of E1A
with the 70-kilodalton cellular heat shock protein in infected
cells. J. Virol. 62: 4153-4166.
In Press, Submitted, and In Preparation
Kost, S.L., D. Smith, W. Sullivan, W.J. Welch, and D.O. Toft. 1989.
The binding of heat shock proteins to the avian progester-
one receptor. Mo/. Cell. Biol. (in press).
Lamb, N.J.C., A. Ferandez, J.R. Feramisco, and W.J. Welch. 1989.
Modulation of vimentin containing intermediate filament
distribution in living fibroblasts by the cAMP dependent protein
kinase. J. Cell. Biol. (in press).
Milarski, K.L., W.J. Welch, and R.I. Morimoto. 1989. Cell-cycle-
dependent association of HSP70 with specific cellular proteins.
J. Cell Biol. (in press).
Mizzen, L.A., C. Chang, J.I. Garrels, and W.J. Welch. 1989. Identifi-
cation, characterization, and purification of two mammalian
stress proteins present within mitochondria: One related to
hsp70 and the other to the bacterial GroEL protein. Mot Cell
Biol. (Submitted.)
Mobbs, C., G. Fing, M. Johnson, W.J. Welch, and D. Pfatt. 1989.
Similarity of an estrogen-induced protein and an LHRH-
induced protein. (Submitted.)
Rose, D.W., W.J. Welch, G. Kramer, and B. Hardesty. 1989. Involve-
ment of the 90 kDa heat shock protein in the regulation of
protein synthesis. J. Biol. Chem. (in press).
QUEST LABORATORY/TWO-DIMENSIONAL GEL
BIOTECHNOLOGY RESOURCE
J.I. Garrels
B.R. Franza
C. Chang
H. Sacco
J. Kos
M. Hannaford
P. Myers
G. Mak
A. Rudman
S.-U. Din
T Husain
The QUEST laboratory has completed a major
phase of its development with the publication of the
REF52 database as a series of three papers in the
Journal of Biological Chemistry. The first paper
describes in detail our methods of image analysis and
provides important studies of the accuracy and
completeness of our analysis. The second paper
describes our methods of database construction and
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images has an average error per pixel of only 13%,
presents the "core" of the REF52 database. In the w
third paper of the series, we present the results of
hereas the integrated spot intensities are in error
by less than 4% on average. Since every Gaussian
our studies of growth-related protein changes in curve that models a spot has a positive error over
normal and virally transformed REF52 cells using
the full power of the database. Highlights of this
some pixels and a negative error over others, the
errors of the integrated intensity are much less than
work are presented below.
We have entered a transitional phase during which
the average pixel error.
we seek to upgrade our technologies. The limitations
More than 2000 spots were routinely detected in
of the present system are in the speed of the computer
the gels analyzed for the REF52 database. Of these,
analysis, the large amount of manual work that is
more than 97% were matched between typical gels,
% error. The greatest amount of
still required, and most importantly, in the long-term
with less than 1
a
standardization of the two-dimensional gel patterns.
analysis time, and the greatest source of ambiguity,
An upgrade to modern workstations will give us a is in making
the decisions about how to split
misshapen spots and spot clusters. At present, most
10- to 15-fold increase in computing speed, and
straightforward software enhancements can elimi- of this work is done
manually, but in the future, we
plan to use methods of automatic editing. The spot-
nate several of the manual steps of image analysis.
The problem of two-dimensional gel standardi- splitting decisions for
each new gel will be guided
zation is an engineering problem beyond our scope by the previous
decisions made for gels already in
at Cold Spring Harbor Laboratory, but several the database.
companies are now vigorously working in this area. To construct databases
for the quantitative
We hope soon to replace our 10-year-old Gel Lab- analysis of more than 2000
proteins per cell, we must
oratory with a new laboratory based on standardized realize that many important proteins are still missing
commercial equipment. The patterns obtained using from the analysis. The intensities of the proteins
such equipment should be obtainable in many other detected on a typical gel range from 4 parts per
laboratories, making our databases much more million (ppm) of the applied sample radioactivity
valuable to the scientific community. To further this to more than 20,000 ppm. To examine the numbers
aim, Jim Garrels is spending a sabbatical period with of proteins detected versus protein intensity, we
the Millipore Corporation near Boston. From Oc- constructed the histogram shown in Figure 1A. The
tober 1988 through September 1989, he will be work- distribution has a peak near 16 ppm, with a sharp
ing 2 days per week on average at Millipore helping drop in the number of proteins detected near the limit
them to test and evaluate equipment and methods of sensitivity.
for standardized two-dimensional gel electrophore- In Figure 1A, the numbers of low-intensity
sis. The remainder of his time during the sabbatical proteins are underestimated because many are
period is devoted to the development of software for obscured beneath larger proteins on the gel. To
Sun workstations, to continuing development of estimate the number of hidden proteins at each level
databases, and to the planning of the QUEST facility of protein intensity, test patterns were created within
of 1990. the computer. For each class of protein intensities,
100 spots were added at random locations to a typical
gel image, and after reanalysis of the image by the
Methods and Accuracy of background subtraction and spot detection pro-
Two-dimensional Gel Analysis grams, the number of added spots that were detected
was scored. The probability of spot detection for
J.I. Garrels spots of each size class is shown in Figure 1B, and
a corrected distribution of protein intensities is
The methods of computer analysis currently used shown in Figure 1C. As many as 1400 proteins (with
in the QUEST facility have now been published in intensities above the limit of sensitivity) might be
great detail (Garrels, J. Biol. Chem. 264: 5269 obscured beneath the 2000 most abundant proteins.
[1989]). Within this publication, analyses are Most importantly, the corrected distribution suggests
reported that test the accuracy and reproducibility that as we gain the ability to resolve and detect
of the system. The method of fitting two-dimensional proteins of lower intensity, the number of detected
Gaussian curves to the spots of two-dimensional gel proteins will continue to rise rapidly.
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FIGURE 1 Number of protein spots detected versus spot size
on a typical two-dimensional gel. (A) Number of spots versus spot
size, before correction for hidden spots. (8) Probability of detection
for spots in each size class, determined as described in text. (C)
Estimated number of spots in each spot size class after correction
for hidden spots. The hidden spots would have been visible had
they not been obscured beneath other spots and background
noise.
The Network Database
Structure
J.I. Garrels, B.R. Franza
The methods for relating data from many quantita-
tive two-dimensional gel experiments into a protein
database, and the application of these methods to
the REF52 protein database, have been fully de-
scribed (Garrels and Franza, J. Biol. Chem. 264: 5283
[1989]). Gels from each experiment are matched as
a group called a matchset. Within each matchset,
every gel is matched to every other gel. Spots not
detected in all gels are "added" to the gels from which
they are missing, so that the coordinate positions
of all spots are marked in all gels. (After repeated
Gaussian fitting, some of the added spots are found
to represent minor spots that were missed, and
others are scored as undetected spots.) In this
scheme, no particular gel need be designated as
a standard.
Linker gels are used to connect the various
experiments of the database. Any gel can become
a linker gel simply by being included in more than
one matchset, and the database grows as a network
of linked matchsets. The system can find paths of
gel-to-gel matches and linkers from one gel (such as
one that a user might be viewing at a workstation
screen) to any other gel in the database. Using the
shortest available paths, and checking alternate path-
ways if available, the system can retrieve quantita-
tive and annotative data for any gel of the database,
relative to the spots of any other gel in the database.
Examples of using the network database to recall
spot names, standard spot numbers, and other in-
formation are shown in Figure 2.
One advantage of the network structure is that it
allows each new matchset to be added to the database
by linking to whatever previous gel pattern it is most
closely related. Such a network structure can support
quite large databases (eventually hundreds or thou-
sands of gels) while keeping the average path length
between any two gels relatively small. Moreover, the
linker concept can be extended to the linking of
databases developed for different gel systems or for
different biological species. By choosing represen-
tative gels as linkers and by carefully matching as
many of the spots as possible (given the full experi-
ence of the database developer), independent data-
bases can be linked with respect to a substantial
number of their proteins.
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FIGURE 2 Examples of data from the REF52 network database.
The gel images taken from the workstation screen represent proteins
from REF52 cells at two different stages of growth. (Right) Highlighted spots are the nuclear proteins; (left) the highlighted spots
are the proteins with PCNA-like regulation. It can be seen that many of the latter are
nuclear. The names of proteins with PCNA-like
regulation are shown at the left. For Lamin-B, the isoelectric point and apparent molecular weight are displayed at the bottom of
the screen. Using the network database, quantitative and annotative data (including names, standard spot numbers, isoelectric point,
molecular weight, and other annotations) can be entered relative to any gel and retrieved relative to any other gel in the database,
The REF52 Database
J.I. Garrels, B.R. Franza [and the entire QUEST laboratory]
Many results of the analysis of REF52 cells have been
reported previously; however, the most important
result has come only with the analysis of the com-
plete database of normal and transformed REF52
cells using the latest tools we have developed for
database analysis (Garrels and Franza, J. Biol. Chem.
264: 5299 [1989]). The proliferation- and transforma-
tion-sensitive nuclear protein PCNA was used as a
model to search for other proteins that are altered
in rate of synthesis both by proliferative stimuli and
by transformation. The major properties of PCNA-
like regulation, illustrated graphically in Figure 3A,
are (1) enhanced rate of synthesis in SV40- and ad-
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enovirus-transformed cells at all cell densities, (2)
decreased synthesis in normal REF52 cells at
confluence, (3) sharply elevated synthesis after con-
fluent REF52 cells are refed, (4) elevated synthesis
at 24 hours, but not at 3 hours, after serum-deprived
REF52 cells are fed with fresh serum, and (5) no
suppression of synthesis in serum-deprived SV40-
and adenovirus-transformed cells.
A new program was used to assign a score to each
protein according to its degree of PCNA-like regula-
tion, and a set of 26 proteins that meet all criteria
were selected. Of these proteins, 14 are nuclear and
1 has been identified as the nuclear matrix protein
lamin-B. The high percentage of nuclear proteins is
a significant property of this set, since only 10% of
all proteins on the REF52 protein map are nuclear.
The most important property of this set is that nearly
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FIGURE 3 Patterns of regulation for PCNA and a set of coregulated proteins. (Top) Bar graphs for PCNA;
(bottom) bar graphs showing the average quantitative behavior for a set of 26 proteins with PCNA-like
regulation. Each bar represents data from one gel; the same gels are plotted on the top and bottom rows.
(Graph 1, Day 2) Cells in log phase growth: REF52, six SV40 transformants, one Ki-MSV transformant,
and two adenovirus transformants, respectively. (Graph 2, Day 6) Cells at confluence: REF52, six SV40
transformants, one Ki-MSV transformant, and two adenovirus transformants, respectively. (Graph 3, REF52)
REF52 cells grown to confluence and refed. Cells were labeled at days 2, 3, 4, and 6 after plating (bars
1-4). Another culture of REF52 cells was labeled 15 hr after refeeding on day 6 (bar 5). Finally, three cultures
of REF52 cells were grown for 12 days and were labeled with no refeeding (bar 6), at 5 hr after refeeding
(bar 7), and at 15 hr after refeeding (bar 8). (Graph 4, Serum Stim) Response to feeding in serum-deprived
cells. REF52 cells were deprived of serum for 60 hr and labeled without fresh serum (bar 1) or at 3 hr
(bar 2) or at 21 hr (bar 3) after refeeding with fresh serum. SV40-transformed REF52 cells (bars 4-6) and
adenovirus-transformed cells (bars 7-9) were similarly deprived of serum and refed. PCNA and the coregulated
proteins are responsive to serum only in normal REF52 cells.
all members share a sixth property that was not used
in their selection. In Kirsten murine sarcoma virus
(Ki-MSV)-transformed REF52 cells, PCNA and the
set of coregulated proteins are markedly repressed
at confluence, just as in normal REF52 cells. This
behavior is illustrated in Figure 3B, which depicts
the average quantitative behavior for the set as a
whole. It therefore appears that PCNA and a set of
coregulated proteins are synthesized at high levels,
uncoupled from the rate of proliferation, in cells
transformed by DNA tumor viruses but that the
coupling of synthesis to growth rate is normal in
retrovirus-transformed cells. These results show that
thorough analysis of a protein database can reveal
sets of coordinately regulated proteins that (1) are
involved in cell proliferation and (2) may have altered
regulation in transformed cells.
The He La Database
C. Chang, H. Sacco, G. Mak, P Myers, J.I. Garrels
[in collaboration with G. Morris and M. Mathews and
L. Mizzen and W. Welch, Cold Spring Harbor Laboratory]
A He La cell database has been targeted because it
is a popular human cell line in which many biochem-
ical studies have been carried out and because it is
in use in several other laboratories at Cold Spring
Harbor. The present HeLa cell database contains
basic characterizations of protein turnover, phos-
phorylation and glycosylation, and subcellular frac-
tionation. In particular, HeLa cells have been used
for studies of the cell cycle, of heat shock, and of
mitochondrial function.
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A group of 85 proteins that show elevated syn-
thesis in response to heat shock have been identified
using the QUEST system. Another group of proteins
have been identified as mitochondrial by the criterion
that their processing into mature forms is blocked
by the mitochondrial inhibitor nonactin. In pulse-
chase experiments, these proteins fail to appear in
the first 5 minutes, but they do appear during sub-
sequent chase periods. In nonactin-treated cells,
precursor forms with extra basic charge accumulate
in the cytoplasm. One protein, hsp58, is both a heat-
shock protein and a mitochondrial protein. In col-
laboration with L. Mizzen and W. Welch (now at the
University of California, San Francisco), it was
shown that this protein can be localized to mitochon-
dria by immunofluorescence. Antibodies to the
hsp58 protein cross-react with a Tetrahymena pro-
tein, which in turn is homologous to the bacterial
heat-shock protein groEL. This information adds
relevance to the HeLa database by identifying a mi-
tochondrial protein thought to function as a "mo-
lecular chaperone."
The cell-cycle analysis of HeLa cells was performed
in collaboration with G. Morris and M. Mathews.
Examination of cells sorted by centrifugal elutria-
tion showed remarkably few cell-cycle-specific dif-
ferences. Of over 1500 proteins examined, only 6 were
elevated at G1 phase, 8 at S phase, and 6 at G2 phase.
PCNA was the most prominent among the proteins
induced at S phase.
Experiments with Human HOS Cells
J.I. Garrels, C. Chang [in collaboration with
C.C. Kumar, Schering Research]
HOS cells are human osteosarcoma-derived fibro-
blast cells. They provide a human cell culture that
is analogous in several ways to our REF52 cell sys-
tem. Normal HOS cells are flat and nontumorigenic.
Transformed HOS cells have been derived using
tumor viruses (Ki-MSV) and chemical carcinogens
(MNNG). Revertants of the virus-transformed cells
are also available.
The work of Dr. Kumar has shown that a gene
for a smooth-muscle-specific myosin light chain is
expressed in HOS cells and that the mRNA synthesis
of this gene is turned off in transformed HOS cells.
On two-dimensional gel patterns, the spots corres-
ponding to myosin light chains have been identified
with specific antibodies, and the disappearance of
the smooth muscle form has been confirmed.
Interestingly, in a revertant of the K-HOS cells, the
smooth-muscle-specific form is again synthesized.
Other parallels exist with the REF52 database.
Transformation-specific changes of tropomyosins
and actins have been detected. The PCNA protein
is elevated in the transformed cells and expressed at
lower levels in the revertant. In the future, we plan
to build a database for HOS cells so that these
changes can be more fully explored. In particular,
we would like to try to locate in human cells more
of the proteins that were found to have PCNA-like
regulation in REF52 cells.
Proteins from Transgenic Mouse Cells
J.I. Garrels, C. Chang, P Myers [in collaboration with
D. Hanahan, S. Baekkeskov, Hagedorn Research
Laboratory, Gentofte, Denmark, and S. Grant and
S. Efrat, Cold Spring Harbor Laboratory]
D. Hanahan's laboratory has used the QUEST
facility extensively to analyze pancreatic islet cells
from transgenic mice. By putting SV40 T antigen
under control of the insulin or glucagon promoters,
they have achieved cell-type-specific transformation
of cells in vivo. Cell lines have also been derived from
some of these tumor lines. We have helped these
investigators to analyze their material on two-
dimensional gels and to interpret their data in the
light of our experience with normal and transformed
rat cells.
The samples analyzed have been used to analyze
both the developmental progress of pancreatic islet
tissue and the progression of transformation in the
islets. Of the proteins identified so far, two proteins
identified as growth- and transformation-sensitive
in rat REF52 cells (PCNA and a coregulated protein
at 85 kD) were also found to be regulated by growth
and transformation in mouse pancreatic islet cells.
We plan to develop the database much further after
our upgrade to new equipment is complete. The
transgenic mouse database not only allows our
collaborators to more fully investigate the effects of
specific genes on development and transformation,
but also gives us the opportunity to compare many
of the changes already observed in SV40-trans-
formed mammalian cell lines with the changes
brought on by SV40 transformation in vivo.
Yeast Database
J.I. Garrels, C. Chang, P. Myers [in collaboration with
C. McLaughlin, University of California, Irvine and
J. Warner, Albert Einstein College of Medicine]
As described in our previous report, we aim to make
the yeast database into a resource that can
complement the genetic map and the DNA and
protein sequence databases as a basic tool for the
yeast community. We have already shown that we
can compare experiments carried out with different
laboratory strains, and a matchset containing gels
from six common strains has been constructed as
a linker. The commercial strains, on the other hand,
have been found to be much less related, and it is
not clear whether they can be linked in detail into
the database of laboratory strains. If so, the results
could be useful in the identification and character-
ization of commercial strains, which are resistant to
conventional genetic analysis.
We have in the past year analyzed many of the key
yeast experiments on three gel types. Although this
entails extra effort (relative to the single gel type used
for the REF52 database), it provides additional
information (>3300 proteins scored). We have used
a broad (pH 3.5-10, LKB ampholytes) pH range on
10% slab gels to resolve most proteins with a
molecular weight above 20,000 and a narrow pH
range (pH 4-8, BDH ampholytes) on 10% slab gels
to resolve acidic proteins better. Additional basic and
low-molecular-weight proteins are resolved on
nonequilibrium gels run on 15% slab gels.
In an experiment to identify proteins coded from
genes with introns, the rna2 mutant was used at the
permissive and nonpermissive temperatures. Of the
well-resolved proteins on the gels (>1500 scored),
only 45 were missing in rna2 cells at the elevated
temperature. A simultaneous study to score the
effects of elevated temperature on normal yeast cells
has revealed 62 proteins induced by threefold or more
(heat shock) and 97 proteins inhibited by threefold
or more (heat stroke). The knowledge of the heat-
shock and heat-stroke responses was necessary to
score the rna2 experiment. In another experiment,
all detectable proteins were examined by kinetics of
labeling for protein processing and turnover rate.
These results will be compared to the heat-shock
results to determine if any relationship exists between
protein processing or turnover and the responses to
elevated temperature.
Services and Training Offered
by the QUEST Facility
C. Chang, H. Sacco, P. Myers, J.I. Garrels
Two-dimensional gel electrophoresis and analysis
have been carried out for a number of other investi-
gators. Small projects are analyzed by the QUEST
staff and the results are reported to the investigator.
For larger service projects, where we are not directly
engaged in the science or in the interpretation of the
gels, we train the investigators to perform their own
analysis. Cecile Chang has developed a three-part
training course that has been given to a total of ten
people. In addition, she gives individual training to
each investigator who uses a workstation. Users who
have had training and who have spent substantial
time using the QUEST facility are Steve Briggs and
Beth Elliot (CSHL plant group), Jeri Higginbotham
(Pioneer Hi-Bred and CSHL plant group), Peter
Hornbeck (NIH), and Steinunn Baekkeskov (Hage-
dorn Research Laboratory, Gentofte, Denmark).
Our future plans include much more extensive
training, including a 2-week summer course in the
principles and applications of two-dimensional gel
protein databases.
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GENETICS
With the ever increasing use of recombinant DNA in biological research, it might
have been supposed that classical genetic methods would have become
redundant. However, exactly the opposite has proved to be the case, and an
increased premium is now placed on study of organisms that are amenable to
both classical and molecular genetic approachs. At Cold Spring Harbor
Laboratory, we have continued to use the two yeasts, Schizosaccharomyces
pombe and Saccharomyces cerevisiae, and maize for genetic studies. An
account of the recent work of the Genetics Group follows. During the last year,
Amar Klar left to take up a position at The National Cancer Institute in Frederick,
Maryland.
EUKARYOTIC CELL-CYCLE CONTROL
D. Beach R. Booher G. Draetta
L. Brizuela B. Ducommun
L. Christy M. McLeod
S. Dembski L. Molz
Our research on the cell cycle of eukaryotic cells ini-
tially focused almost exclusively on the fission yeast.
This organism is particularly well suited to genetic
and molecular approaches to the problem of cell-
cycle regulation. Taking advantage of the insights and
reagents the laboratory has developed working with
yeast, our research on the cell cycle of higher
vertebrates has now matured into a major area of
activity that complements the primarily genetic
approaches provided by ascomycete genetics. During
the last year, we were joined by Paul Young (a visiting
scientist from Queens University, Ontario) and a new
postdoctoral fellow, Bernard Ducommun.
Cell Cycle of Fission yeast
R. Booher, L. Mo lz, B. Ducommun, D. Beach
The main focus of our work on the fission yeast cell
cycle during the last year has been the cdc13+ gene
and its relationship to cdc2+. cdc2+ encodes the
catalytic subunit of a protein kinase that acts in the
regulation of both DNA synthesis and the initiation
of mitosis. We previously identified an allele of cdc2+
that is defective in mitosis but not DNA replication.
As an extragenic suppressor of this mutation, we
isolated a new allele of cdc13+, a gene that is only
required for the initiation of mitosis. We determined
the nucleotide sequence of cdc13+ and found that it
encodes a protein homologous to mitotic cyclins. The
distinguishing feature of this class of proteins is their
gradual accumulation during interphase, but abrupt
proteolytic degradation at each cell division.
Immunofluorescence and immunoblotting experi-
ments revealed that the cdc13+ product is a nuclear
protein that behaves in exactly this manner (Fig. 1).
Furthermore, we showed that the cdc13+-encoded
cyclin acts as a regulatory subunit of the cdcr protein
kinase. The cyclin appears to target cdcr to the cell
nucleus and also to control its catalytic activity. We
believe that degradation of the cyclin at the meta-
phase/anaphase transition of mitosis is responsible
for inactivating cdc2+ and thus allowing cells to
return to interphase.
Further studies on the fission yeast cell cycle
include investigation of a new class of genes (mcs)
that were isolated as suppressors of a particular cdc2
mutant and also the cdc25+ gene, which appears to
function as a posttranslational activator of cdc2+.
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FIGURE 1 Immunofluorescence staining of the cdc13*-encoded
cyclin of fission yeast. Expressed either quantitatively as a function
of cell length (A) or as micrographs (B). The lower panel of 8
shows cell nuclei stained with DAPI.
Vertebrate Cell-cycle Control
L. Brizuela, L. Christy, G. Draetta, D. Beach
The last year has seen dramatic changes in our
understanding of the cell cycle of vertebrate cells,
including those of man. Following our identifica-
tion of cdc2 homologs in cells of diverse evolution-
ary origin, we were able to show (in collaboration
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with W. Dunphy and J. Newport, University of
California, San Diego) that the cdc2 2 protein kinase
is one component of the long elusive inducer of
mitosis, known as M-phase-promotin g factor
(MPF). We further showed, in collaboration with the
laboratory of J. Ruderman (Duke University), that
the mitotic cyclins of the surf clam are further
components of MPF. With the assistance of L.
Meijer (Marine Laboratory, Roscoff, France), we
found that both cdc2 and cyclins are components
of the M-phase-associated histone H I kinase, which
in its most active form now appears to be the same
entity as MPF.
These findings contribute to a remarkable unifica-
tion of eukaryotic cell-cycle research, as a result of
which it is now clear that the cdc2 protein kinase
and also cyclins play a fundamental role in the cell
cycle of all eukaryotes. Furthermore, it transpires that
geneticists, classic biochemists, and cell biologists
have each converged upon these same two molecular
entities, but from a quite different original perspec-
tive (Fig. 2).
A further wholly unexpected finding, developed
in collaboration with the laboratory of T. Roberts
(Dana Farber), was that the cdc2 protein kinase of
human HeLa cells is the most heavily tyrosine-
phosphorylated protein of the cell. This also turns
out to be the case in mouse 3T3 cells and a variety
of others (Fig. 3). The exact tyrosine kinase responsi-
ble for this phosphorylation is not presently clear,
but c-src is a good candidate. The biological role of
cdc2 tyrosine phosphorylation is under active
investigation.
Regulation of Meiosis
M. McLeod, M. Dembski, D. Beach
Fission yeast is an excellent model system in which
to investigate the molecular basis of commitment to
meiosis due to the ease of genetic investigation and
the ability to obtain large amounts of synchronized
meiotic cells. During the last year, considerable
progress has been made in identifying and isolating
genes regulating this process.
In Schizosaccharomyces pombe, entry into mei-
osis is regulated by both the mating-type genes and
environmental signals. Only diploids expressing all
four of the mating-type genes are able to undergo
meiosis, and full expression of the mating-type genes
requires conditions of nutritional limitation. We have
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FIGURE 2 Different perpectives of the eukaryotic mitotic oscillator. (MPF) M-phase-promoting factor; (H1K)
M-phase-associated histone H1 kinase.
shown that the primary role of the mat genes in
meiosis is to regulate transcription of the mei3+ gene.
The product of the mei3+ gene is a 21-kD protein that
acts as an inhibitor of the rani+ protein kinase. The
rani+ protein kinase is required during vegetative
growth and acts as a critical negative regulator of
meiosis. Thus, loss of rani+ kinase activity, either
through mutation or through expression of mei3+
causes cells to undergo meiosis.
Mutations at several genetic loci have been
identified that are able to suppress the phenotypes
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associated with loss of rani+. We have characterized
one of these, cgs1+, and have physically isolated the
gene. Cells containing a lesion in cgsl rapidly lose
viability as they become limited for nutrients and
approach stationary phase. Examination of the
morphology of these cells reveals that they become
aberrently elongated in response to nutrient deple-
tion. In addition, the cells are severely meiotically
defective.
Sequence analysis of cgs1+ shows that the gene
encodes the regulatory subunit of cAMP-dependent
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Antiphosphotyrosine immunoblot of whole-cell protein from 3T3 cells at different
times after mitogenic activation by serum. The triplet
bands at 34 kD are the cdc2 protein
kinase. (From A. Morla et al., in press).
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protein kinase. The product of the cgs1+ gene is a
spliced mRNA and the predicted protein product
shares 60% homology both with the regulatory
protein from Saccharomyces cerevisiae and with that
from other eukaryotes. cAMP-independent kinase
activity is observed in fractionated extracts from cells
containing a disrupted allele of cgsl. We propose that
loss of the regulatory subunit causes unregulated
cyclic A kinase activity that prevents cells from
entering meiosis. All of the observable phenotypes
associated with loss of cgs1+ are also seen when cells
are forced to express high amounts of rani+ protein
kinase. We thus propose that both kinases may share
a subset of substrates. Future studies will be directed
toward devising genetic screens that will enable us
to identify possible substrates of both cAMP-
dependent protein kinase and rani+ kinase.
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PRE-MRNA SPLICING IN SCHIZOSACCHAROMYCES POMBE
D. Frendewey J. Potashkin R. Li
A. Serrano C. Leptac
We are investigating the posttranscriptional processes
that are responsible for producing mature mRNAs
from their initial transcript precursors (pre-mRNAs).
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These pre-mRNA processing reactions include
attachment of a 7-methylguanosine "cap" structure
to the 5' end, addition of a polyadenylic acid "tail"
to the 3' end, and removal of introns. This last
process, pre-mRNA splicing, is the primary focus
of our research.
The splicing of pre-mRNAs occurs in the nucleus
in large ribonucleoprotein (RNP) complexes called
spliceosomes. The most conspicuous spliceosomal
components are the small nuclear RNAs (snRNAs)
Ul, U2, U4, U5, and U6, which reside in RNP
particles known as snRNPs. Each snRNP consists
of a single snRNA (with the exception of the U4/6
particle) and several common and RNA-specific
proteins. The spliceosome is an assembly of these
snRNPs, bound to the pre-mRNA substrate, and
probably ancillary proteins, which either contact the
pre-mRNA or are transiently or loosely bound to the
snRNPs. To understand how pre-mRNA splicing is
achieved, the constituents of the spliceosome must
be identified and characterized. Our approach to this
problem has been to use the molecular genetic ad-
vantages of yeast (in our case Schizosaccharomyces
pombe) to identify genes that are required for pre-
mRNA splicing. We expect that many of these genes
will encode products that function in the splice-
osome.
Search for New Pre-mRNA
Processing Mutants
J. Potashkin, D. Frendewey
Last year, we reported that we had produced a bank
of temperature-sensitive (ts) mutant strains of S.
pombe and had isolated three recessive pre-mRNA
splicing mutants from a screen of the first 100
members of this collection. Following a convention
agreed to by the yeast RNA-processing community,
these mutants have been named prpl, prp2, and prp3
to indicate defects in pre-RNA processing. During
the past year, we have continued our genetic investi-
gation of mRNA synthesis in S. pombe by extending
the screen for pre-mRNA splicing mutants to include
the complete is bank. Several new candidates for
prp- mutants have been identified.
Three classes of mutant phenotypes that indicate
aberrations in mRNA processing were revealed by
our search. The first class is represented by prpl and
prp2. These mutants accumulate unspliced pre-
mRNA and U6 pre-RNA (see below) and stop
making mature 13-tubulin mRNA (our test RNA)
very soon after being shifted to the nonpermissive
temperature (37°C). Thus, the mutants in this class
are completely blocked for pre-mRNA splicing. This
RNA-processing defect is always associated with a
"tight" is phenotype; these strains do not grow at
37°C. The second mutant mRNA processing
phenotype is similar to that expressed by prpl and
prp2, except that some mature 13-tubulin mRNA is
detected at the nonpermissive temperature. The
amount of spliced mRNA observed at 37°C in these
mutants is usually less than that seen at 23°C but
depends on the severity of the defect. The prp3
mutant is an example of this class. These mutants
are "leaky" is strains in that they grow slowly at the
nonpermissive temperature. We have also observed
a few mutants that exhibit a third phenotype that
may not reflect a defect in pre-mRNA splicing. This
class of is mutants does not accumulate unspliced
13-tubulin pre-mRNA; instead, an RNA is produced
that is larger than the unspliced pre-mRNA
accumulated by prpl, prp2, and prp3. The larger
RNA could be the result of aberrant 3'-end forma-
tion, alternative splicing, or a new transcription ini-
tiation site. We have recently begun to analyze the
defect in these unusual mutants.
Unspliced U6 RNA Precursor
Accumulates in the prp- Mutants
J. Potashkin, D. Frendewey
One of the analyses that we routinely perform on
the prp- mutants is a visualization of their snRNAs
by Northern blotting. The snRNAs are the only
known pre-mRNA splicing factors that we can
readily investigate in S. pombe. The Northern
analysis allows us to detect unusual changes in the
amount or size of a particular snRNA that might
correlate with the mutant phenotype. A check of the
snRNAs in prpl, prp2, and prp3 indicated normal
amounts and sizes for Ul, U2, U4, and U5 RNAs.
However, we observed a slight but reproducibly lower
level of U6 RNA in the mutants compared to that
in the wild type grown under identical conditions.
At the time, we did not know the meaning of this
observation, but the surprising results of Ohshima
and Tani (Nature 337: 87 [1989]) soon suggested an
explanation. They found that the gene for the U6
RNA of S. pombe contains an intron. This is the
only example of an intron in an snRNA gene from
any source. In addition, the U6 intron has several
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structural features -a length of 50 nucleotides and
consensus sequences at the 5' and 3' splice sites and
the presumptive branch point - that are typical of
introns found in S. pombe pre-mRNAs. Thus, we
thought that the reduction in U6 RNA in the prp-
mutants might be caused by a defect in the splicing
of the intron from the U6 RNA precursor.
We wanted to test this hypothesis and, at the same
time, use the prp- mutants to address two unresolved
questions concerning U6 RNA processing. First,
Ohshima and Tani were unable to demonstrate the
existence of an unspliced U6 RNA precursor, prob-
ably because they analyzed RNA from normal,
rapidly growing cells, where a high splicing efficiency
results in a low steady-state level of pre-RNAs. The
block in splicing in the prp- mutants might allow
easier detection of the U6 precursor. Second, since
the U6 intron resembles the introns of pre-mRNAs,
an interesting question is whether this intron, which
is part of a suspected RNA polymerase III transcript,
is spliced by the same apparatus that works on pre-
mRNAs, which are transcribed by RNA polymer-
ase II. If this is the case, then the splicing of the U6
RNA precursor would require the same genes that
are required for pre-mRNA splicing, and therefore
it should behave like a pre-mRNA in the prp-
mutants.
Our initial experiments aimed at answering these
questions were made by Northern blot analysis using
an antisense RNA probe complementary to the
human U6 RNA sequence, which we had previously
shown recognizes an RNA of the expected size in
S. pombe. At 23°C, the amounts of mature U6 RNA
in the prp- mutants are not different from that in
the wild type (Fig. la). After a 2-hour shift to 37°C,
the amount of mature U6 transcript is reduced
slightly in the mutants compared to the wild type,
and there is accumulation of a longer transcript
(about 150 nucleotides in length) in both the wild-
type and mutant strains. This is the size expected for
the unspliced precursor. After 6 hours at 37°C, the
accumulation of the longer transcript persists in prpl,
prp2, and prp3 but not in the wild type.
To determine whether or not the longer RNA was
an unspliced precursor, we used an oligonucleotide
that specifically recognizes the fission yeast U6 intron
as a probe on RNA blots. No precursor signal was
detected at 23°C (Fig. lb). The bands that are less
than 80 nucleotides are background signals that are
not observed when the blot is probed with another
intron-specific probe. After the cells are shifted to
37°C for 2 hours, an intron-containing transcript of
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FIGURE 1 Northern blot analysis of U6 RNA in the prp- mutants.
Total RNA from the wild type or prpl, prp2, and prp3 grown to
mid-log at 23 °C and then shifted to 37°C for either 2 or 6 hr was
fractionated by electrophoresis on a polyacrylamide/urea gel. The
RNA was then blotted onto a nylon membrane and hybridized
to the following probes: (a) An antisense RNA derived from the
human U6 gene; (b) an oligodeoxynucleotide complementary
to the intron of the S. pombe U6 gene; (c) an oligodeoxynucleo-
tide complementary to the second exon of the S. pombe U6 RNA.
P marks the position of the U6 RNA precursor, and M indicates
the position of the mature U6 RNA.
150 nucleotides appears in both the wild-type and
mutant strains. This RNA is seen exclusively in the
prp- mutants after 6 hours at 37°C. When the
autoradiograms from the intron oligonucleotide (Fig.
lb) and anti-U6 RNA probings (Fig. la) of the same
blot are aligned, the longer transcript detected with
the anti-U6 RNA probe corresponds exactly with
that of the intron-containing precursor.
The intron-specific oligonucleotide was stripped
from the membrane, and the blot was reprobed with
an oligonucleotide specific for the second exon of
the U6 pre-RNA. The same pattern of precursor and
mature transcripts is observed with the exon 2 probe
as with the anti-U6 RNA probe (compare Fig. 1, a
and c). There is an accumulation of precursor in prpl,
prp2, and prp3 after both a 2- and 6-hour shift to
37°C and a concomitant decrease in the mature
transcript compared to the wild type. The accumula-
tion of the U6 RNA precursor in the wild-type strain
after a 2-hour shift to the elevated temperature may
be the result of a transient decrease in the efficiency
of splicing associated with a mild heat shock caused
by the temperature shift. These observations were
confirmed in a series of primer-extension experi-
ments with total RNA prepared from the wild type
and the mutants as template.
A comparison of the amounts of precursor and
mature U6 RNAs in the mutants at 23°C and 37°C
clearly indicated that there is a significant accumula-
tion of unspliced U6 RNA in response to a shift to
the nonpermissive temperature. The pattern of
precursor accumulation in the mutants is the same
as that exhibited by a- and 13-tubulin pre-mRNAs;
prpl and prp2 accumulate more precursor and
produce less spliced product than prp3 at the
nonpermissive temperature. This strongly suggests
that some of the same trans-acting factors that are
required for the processing of pre-mRNAs are also
needed for the processing of the U6 precursor and
is consistent with the structural identity of the U6
intron with the introns of fission yeast pre-mRNAs.
prp4: A Pre-mRNA Splicing
Mutant with Reduced
snRNA Content
J. Potashkin, R. Li, A. Serrano, D. Frendewey
Much of our effort during the last year has been
devoted to the analysis of an interesting mutant that
we have recently named prp4. As with the other prp-
mutants, prp4 accumulates unspliced pre-mRNAs
and U6 pre-RNA at 37°C compared to the wild type
grown under identical conditions. This mutant is a
member of the phenotypic class represented by prp3;
it grows slowly at 37°C and produces mature P-tu-
bulin mRNA. However, the pre-mRNA splicing
defect in prp4 is much less severe than in prp3. In
fact, prp4 was not identified as a prp- mutant in our
original Northern blot screening of the is bank. We
discovered the pre-mRNA accumulation in prp4 only
when we used a more sensitive RNase protection
assay.
We began studying prp4 because it appeared to
have a defect in U2 RNA synthesis. As we reported
last year, this mutant was identified from a screen
of the first 70 is strains in our collection. It was
shown to have a reduced amount of U2 RNA com-
pared to the wild type and to produce two aberrant
U2 transcripts whose sizes are about 110 nucleotides
and 400 nucleotides. (The normal S. pombe U2 RNA
is 186 nucleotides.) We now know that all of the
nucleoplasmic snRNAs that we have been able to
analyze are affected in prp4.
The prp4 strain was backcrossed to the wild type
several times. Sporulation and tetrad analysis re-
vealed that the mild is growth phenotype segregated
2:2, with the defect in snRNA synthesis. Figure 2
shows that there is a two- to fivefold reduction in
the amounts of Ul, U2, U4, and U5 RNAs, as a
proportion of whole-cell RNA mass, in the progeny
from the is spores ( -) compared to the wild-type
spores ( + ). There is also a slight reduction in U6
RNA levels that is not evident in the exposure of the
U6 probing shown in Figure 2. In addition to de-
creased snRNA content, larger transcripts are pro-
duced for U2 (not seen in Fig. 2), U4, and U6 RNAs
in prp4 at the nonpermissive temperature. The larger
U6 RNA is unspliced U6 pre-RNA, which accumu-
lates in prp4 as in the other prp mutants. The longer
U2 and U4 transcripts, however, are extended at their
3' ends. Utilizing a variety of assays, we have not
detected the extended U2 and U4 RNAs in the wild
type at either 23°C, 30°C, or 37°C. We therefore
believe that these RNAs are not normal precursors
that are accumulating in the mutant at 37°C but are
aberrant transcripts peculiar to prp4. Less-abundant
larger RNAs are also detected by the Ul and U5
probes in the wild-type RNA samples (Fig. 2). These
RNAs, as with the major transcripts, are reduced in
the mutant. We are currently investigating whether
S. pombe expresses multiple forms of the Ul and
U5 RNAs.
Figure 2 also shows that K RNA, the RNA subunit
of the tRNA-processing enzyme RNase P, is dramati-
cally reduced in prp4. K RNA is presumed to be
nucleoplasmic and is found in a simple RNP. The
reduction in K RNA in prp4 indicates that it is related
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FIGURE 2 Northern blot analysis of snRNA from the progeny
of a cross between prp4 and the wild type. prp4 was mated to
a wild-type strain and allowed to undergo meiosis. Tetrads (contain-
ing four haploid spores) were dissected, and the spores were
grown at 23°C and then shifted to 37°C for 5 hr. Total RNA was
prepared from the progeny of each of the four spores (1, 2, 3,
and 4), fractionated, and blotted as in Fig. 1. The blot was
sequentially probed with antisense RNAs or oligodeoxynucleo-
tides that recognize K RNA and U1, U2, U4, U5, and U6 RNAs.
A plus (+) indicates a wild type, and a minus (-) indicates a
ts- spore. The results of two tetrads are shown.
to the other snRNAs with respect to its synthesis or
maintenance. Consistent with its considerably lower
levels of K RNA, prp4 accumulates pre-tRNAs at
37°C that are not processed at their 5' ends. Thus,
prp4 exhibits defects in pre-mRNA, U6 pre-RNA,
and pre-tRNA processing.
The one snRNA that we have tested whose
quantity in prp4 is similar to the wild type is U3
RNA. This snRNA is thought to reside in the
nucleolus and be required for rR NA processing. We
also compared the amounts of 7SL, RNA (a small
cytoplasmic RNA found in an RNP), the large and
small rRNAs, and tRNA between prp4 and the wild
type. As with U3 RNA, no
differences were observed.
All of the results we have described here were
obtained from experiments in which equal mass
amounts of wild-type and prp4 RNAs were corn_
pared. However, essentially identical results are
obtained when the snRNA content is analyzed on
the basis of cell equivalents. We have also examined
the mRNA transcribed from the alcohol dehydro-
genase (adh) gene, which contains no introns. The
results indicate that the mass proportion of the adh
mRNA in prp4 is identical to that of the wild type.
Therefore, RNAs that reside in the cytoplasm are not
affected in prp4. We have investigated the steady -
state mass proportions of all classes of cellular RNAs
encoded by the nuclear genome and have found that
only RNAs that are presumed to reside as snRNPs
in the nucleoplasm (as opposed to the nucleolus) are
reduced in prp4 compared to the wild type.
In summary, the prp4 mutant exhibits an interest-
ing but somewhat perplexing molecular phenotype.
Compared to the wild type, prp4 maintains a signifi-
cantly lower level of spliceosomal snRNAs, yet it is
not severely impaired for pre-mRNA splicing. The
best explanation for this result might be that the
snRNA requirement for splicing is dependent on
growth rate, and prp4 produces sufficient quantities
of snRNA to achieve a near-normal pre-mRNA
splicing efficiency at its low growth rate. In contrast
to is stains, the wild type increases its growth rate
when shifted from 23°C to 37°C. We have evidence
that along with the increase in growth rate, the steady-
state level of the snRNAs increases. In fact, we were
able to detect the difference in snRNA content
between the wild type and prp4 primarily because
prp4 fails to increase its snRNA accumulation in
response to temperature shift. A decreased snRNA
level is not an obligatory consequence of a low ts-
growth rate at 37°C, since all of the other is mutants
that we have investigated, including the pre-mRNA
splicing mutants prpl, prp2, and prp3, appear to have
normal quantities of snRNA. The is growth defect
in prp4 may be caused by an inability to increase
snRNA synthesis in response to the higher growth
temperature. Alternatively, the low snRNA concen-
tration in prp4 could be a secondary symptom of
a defect in another cellular process. We are currently
attempting to determine if the cause of the prp4
phenotype is a defect in transcription initiation or
termination, 3'-end processing, or instability of the
snRNPs.
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Characterization of Extrachromosomal
Forms of Mu
V Sundaresan, M. Papazian
During the past year, we have continued our investi-
gations into the mechanism and regulation of
transposition of the maize transposable element
system, Robertson's Mutator (Mu). This system is
characterized by an exceptionally high mutation rate
due to the transposition of a family of elements
called the Mu transposons.
An extrachromosomal circular form of the Mu
transposons has been described previously (Sundare-
san and Free ling, Proc. Natl. Acad. Sci. 84: 4924
[1987]). These extrachromosomal Mu elements are
correlated with Mu transposition activity and are
presumptive real or abortive transposition intermedi-
ates. Initially, only the Mul and Mul. 7 elements were
identified as extrachromosomal circles. During the
past year, screening of libraries constructed from
fractions of purified extrachromosomal DNA
revealed that several other Mu elements also generate
this extrachromosomal DNA species. Some of these
were found to be homologous to elements Mu4,
Mu6, and Mu 7 cloned independently by V. Chandler
(University of Oregon) by utilizing their homology
with Mul termini (Fig. 1). Our results suggest that
these elements are also transposable, confirming the
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idea that the 200-bp Mu inverted repeat termini are
sufficient for an element to transpose in an active
Mu background. We have been attempting to define
the nature of the junctions between these termini by
studying the cloned Mu circles. However, these
junctions appear to be extremely unstable, presum-
ably because of their ability to form cruciform struc-
tures. As a result, all of our clones to date have
deletions of variable lengths that include the junction
sequences. Other approaches including the polymer-
ase chain reaction (PCR) are being attempted to
circumvent this problem.
Maize Nuclear Proteins That Bind to
the Terminal Inverted Repeat
of the Mu-1 Transposable Element
Z.Y. Zhao, V. Sundaresan
At present, little is known about the protein factors
that catalyze Mu transposition or the genes encoding
them. The search for the transposase of the Mu
elements is of the utmost importance if we are to
understand the mechanism of Mu transposition. We
initiated our search for the Mu transposase by using
the Mu -1 terminal inverted repeat (TIR) sequence
as a probe, for two reasons: (1) All the members of
the Mu family share the same TIRs as Mu-/, but with
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different internal sequences. Therefore, we assume
that TIRs play an important role if the Mu elements
share the same mechanism of transposition. (2) For
many transposons found in bacteria and yeast, the
ends of these transposons play an important role in
transposition. For some transposons found in
bacteria, such as Tn3 (Ichikawa et al., Proc. Natl.
Acad. Sci. 84: 8220 [1987]) and bacteriophage Mu
(Craigie et al., Cell 39: 387 [1984]), the transposase
binds specifically to their TIR sequences.
Crude nuclear proteins were isolated from Mu-
active, Mu-inactive, and normal maize plants at the
Labeled fragment/PUC 119 ng
Labeled/unlabeled fragment ng
Poly(dI-dC):poly(dI-dC) ug
DS SS
FIGURE 1 Structure of the Mu elements that have
been cloned, showing that they share the same
200-bp termini but nonhomologous internal
regions, with the exception of Mul and Mul.7,
which are closely related.
seven-leaf stage. The right TIR DNA sequence (200
bp) of the Mu -1 element was 3'-end-labeled and used
as the probe in mobility-shift ("gel-retardation")
experiments. The mobility of the labeled fragment,
after incubation with or without the nuclear proteins,
on a polyacrylamide gel showed that nuclear
protein(s) from either Mu-active or Mu-inactive
plants did bind to the Mu -1 TIR sequence (Fig. 2)
The binding is specific for the Mu -1 TIR sequence
because it can be competed out by the unlabeled
Mu -1 TIR fragment (Fig. 2, lanes 6 and 11), but not
by linear pUC119 DNA fragments (pUC119 DNA cut
Mu-active line Mu-inactive line
1/10 1/100 1/10 1/100
1/10 1/100 1/10 1/100
0 0 0 1 1
oi
FIGURE 2 Gel retardation assays with Mu -1 TIR probe. (Lanes 1 and 2) Free double-
stranded and single-stranded probes, respectively. (Lanes 3-7) Probes incubated with
proteins from the Mu-active line and poly(dl-dC) (no poly[dl-dC] in lane 3 and 1µg in
other lanes); specific competition with unlabeled Mu TIR (lanes 5 and 6) and nonspecific
competition with pUC119 (lanes 7 and 8). (Lanes 9-14) Probes incubated with proteins
from the Mu-inactive line and the other factors; same as the Mu-active line (specific competi-
tion, lanes 11 and 12, and nonspecific competition, lanes 13 and 14).
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FIGURE 3 DNase I footprinting of the Mu -1 TIR fragment. (Lane
1) DMS-"G" track; (lanes 2 and 3) no protein; (lanes 4 and 5)
incubation with nuclear protein from the Mu-active line; (lanes
6 and 7) incubation with nuclear protein from the Mu-inactive line.
with HaeIII to generate linear DNA fragments as
a nonspecific competitor; Fig. 2, lanes 8 and 14).
When the 200-bp TIR was cut into four smaller
fragments (i.e., 22, 62, 43, and 95 bp), the binding
assay indicated that the nuclear protein(s) binds only
to the 62-bp fragment but not to the other fragments
(data not shown).
To determine whether the binding proteins from
Mu-active and Mu-inactive lines are the same or
AGACGCCG
TCTGCGGC
different, and to localize the protein binding site(s)
on the Mu -1 TIR DNA sequence, DNase I footprint-
ing was performed. The footprinting revealed that
the proteins from Mu-active lines bound to the TIR
at two different sites such that a 13-bp fragment and
another 8-bp fragment were protected. The two sites
are 5 by apart (Fig. 3, lanes 4 and 5). However, the
protein from Mu-inactive lines only revealed one of
these binding sites (the 13-bp site) on the TIR (Fig.
3, lanes 6 and 7). The two binding sites (13 by and
8 bp) were located within the 62-bp region of the TIR
(Fig. 4). These data are consistent with the gel-
retardation results. In addition, there appears to be
a third factor that binds specifically to the outside
end of the Mu inverted repeat; however, we have not
yet characterized this site in detail. The nuclear
protein(s) from normal maize plants, B73 and W22,
showed the same binding activity for the Mu -1 TIR
as the Mu-inactive lines.
Our current working model is as follows: The
transposition process involves two or more protein
factors, which may be encoded by the host genome
or by as yet undiscovered Mu elements. At least one
of the factors is present only in active Mu stocks and
is a good candidate for a transposase. The other two
factors appear to be ubiquitous and may also be
necessary for transposition. In this regard, it is useful
to note that analogous situations exist in bacteria;
e.g., transposition of the bacterial transposon TniO
requires IHF and HU5 in addition to IS/0 trans-
posase (Morisato and Kleckner, Cell 101 [1987]).
Furthermore, in the case of the P element of Dro-
sophila melanogaster, a protein that binds specifi-
cally to the 31-bp inverted repeat of the P element
has been found in both P and M strains (Rio and
Rubin, Proc. Natl. Acad. Sci. 85: 8929 [1988]). Since
the P-element-encoded transposase does not show
a specific affinity for this sequence, it is assumed
161bp 27
*P.
Internal seq.
CGGCGTCT
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161bp
CGGGAACGGTAAA
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TIR-R 212bp
FIGURE 4 Localization of the two protein-binding
sites I and II on the Mu -1 TIR sequence.
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that both proteins (one host-encoded and oneP-ele-
ment-encoded) are required for transposition.
Our future work on Mu will involve purification
of the proteins and cloning the genes encoding them,
in order to elucidate their roles in catalyzing or
regulating Mu transposition.
Regulation of Mu Activity
J. Brown, V. Sundaresan
Mu transposons are present in multiple copies in the
maize genome and can be either actively transpos-
ing ("on") or inactive ("off"). We have been studying
the regulation of Mu activity, using bzMum-9 as a
reporter. The bzMum-9 allele resulted from an
insertion of Mu at the Bz gene. In plants that contain
inactive Mu transposons (Mu-off), bzMum-9 acts
as a null, giving a bronze color to the kernel, whereas
in plants that contain active Mu (Mu-on), bzMum-9
becomes mutable, giving bronze kernels with purple
spots.
In a low percentage of the progeny of self-
pollinated and outcrossed plants, all or most of the
Mu transposons in a genome change from active to
inactive. It has been reported that the Mu -off state
is irreversible in the case of self-pollinated Plants,
but reversible in outcrossed plants, by plants crossing
"off" to "on" plants (Bennetzen, Mol. Gen. Genet.
208: 45 [1987]). In these crosses, the inactive state
was found to be "female-dominant" - the state of
activity of the female parent determined the outcome
(Walbot, Genetics 114 1293 [1986]). In contrast, our
recent results indicate that Mu-off plants from self-
pollinators (bronze) can readily be reactivated
(purple-spotted), regardless of sex, by crossing to or
by Mu-on plants (see Fig. 5). The terminal inverted
repeats of Mu transposons contain Hinfl sites. in
Mu-on plants, Mu sequences are digested to corn_
pletion by Hinfl, but in Mu-off plants, they are
resistant to Hinfl digestion. Since Hinfl activity is
inhibited by methylation of DNA, it is thought that
Mu sequences are methylated in the Mu-off state.
Genomic Southern analyses of Hinfl-digested DNAs
from our reactivation crosses, when probed with Mu,
show that in each case Mu methylation is associated
with inactivation and loss of methylation is
associated with reactivation. That inactive Mu-offs
derived from self-pollinators can be reactivated
suggests that inactive Mu derived by selfing does not
FIGURE 5 Reactivation of bzMum-9 stables: (Left) Female Mu-off bzMum-9 plants crossed to standard (non-Mu) bz males remain
Mu-off (bronze). (Right) Female Mu-off bzMum-9 crossed to Mu-on bz males reactivate to the Mu-on state (spotted).
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behave differently from inactive Mu derived by
outcrossing. In addition, the female dominance of
the Mu state previously reported is not a general
property of Mu.
Our observation can be reconciled with the earlier
reports aS follows: In separate studies using active
bzMum-9 stocks, we have found that Mu activity is
lost at a higher rate through the male than through
the female. Furthermore, in a plant in which Mu
activity is turning off, there appears to be a gradient
of inactivation going up the plant so that the pollen
gives more inactive Mu progeny than the ear (R.
Martienssen, pers. comm.). This behavior has been
observed in cycling Spm stocks as well (Federoff, Cell
56: 181 [1989]). Therefore, the outcome of a reactiva-
tion cross would depend on the active parent used.
In our crosses, the active Mu stock used for reactiva-
tion exhibits a very low rate of loss of activity (<207o)
both through the pollen and through the ear. If the
active Mu stock used is "cycling" to an inactive state
of Mu, then the loss would be significantly higher
through the pollen. In that case, it would fail to
reactivate efficiently when crossed to an inactive Mu
female, which would lead to the apparent "female
dominance" reported by the workers cited earlier.
Intragenic Recombination at Al
J. Brown
Since Al function is required for production of red
and purple anthocyanin pigments in the maize plant
and kernel, intragenic recombination events between
mutant alleles of Al restoring Al expression can be
scored easily. alMum2, a Mu-induced mutable allele
that contains a Mul transposon at nucleotide -100
(relative to the Al transcription start site) (O'Reilly
et al., EMBO J. 4: 877 [1985]), and al, aDt-induced
mutable allele that contains an rDt transposon at
+1077 (Brown et al., Mol. Gen. Genet. 215: 239
[1989]), were tested for recombination. Neither
alMum2 nor al give Al progeny when either allele
is homozygous. From crosses of alMum2/al plants
with al/al plants, 11 of 23,477 kernels that had
restored Al were found. The ratio of genetic to
molecular distance is 0.1 cM/kb in this case.
McClintock had previously reported a similar genetic
result using al-m2, which contains an Spm insertion
at -100 (Masson et al., Genetics 117 117 [1987]), and
also al. Of 70,039 kernels from test crossed alm-2/al
plants, 17 were restored for Al (McClintock, Maize
Genet. Coop. Newsl. 39: 42 [1965]). Since the
distance between insertions is 1.2 kb, this gives a
recombinational distance of 0.05 cM/kb.
When 0.05-0.1 cM/kb at Al is compared to the
overall genome correlation of 3.0 x 10-4 cM/kb
(1200 cM per genome, Coe et al., in Genetic maps,
Cold Spring Harbor Laboratory [1984], and 3 x
109 bp, Galbraith et al. Science 220: 1049 [1983]), it
seems that recombination rates at Al can be high.
This supports the idea that the larger genomes
contain highly recombinogenic regions (perhaps the
structural genes) interspersed with nonrecombino-
genic regions (Thuriaux, Nature 268: 460 [1977]).
Genetic Imprinting of the
R-Iocus in Maize
J. Colasanti, A. Klar, V. Sundaresan
Epigenetic signals are differentially inherited by cells
of identical genetic background during the develop-
ment of multicellular organisms. In this way, gene
expression required for the development of specific
structures and organs is possible while genetic
totipotency is maintained. Imprinting of genetic in-
formation in plants is believed to play a major role
in development of the whole organism. We are study-
ing a case of genetic imprinting in maize where a gene
is expressed differentially depending on whether it
is transmitted through the male or female gametes.
The R locus of maize is involved in the regulation
of anthocyanin pigment production in the seed and
plant. A functional R allele allows the expression of
purple pigmentation in the outer seed tissue
(aleurone). In the R-mottling phenomenon, the
expression of R in seeds of R/r heterozygotes
depends on the direction of the cross. Certain alleles
of R (such as R-r) exhibit normal seed pigmentation
when transmitted through the female gametophyte;
however, when transmitted through the male
gametophyte, R is expressed incompletely and the
aleurone pigmentation is mottled (Fig. 6). Kermicle
(Genetics 66: 69 [1970]) has shown, using B-A
chromosome translocations, that the absence of
mottling when R is transmitted through the female
is not due to an extra dose of the R allele in the
triploid endosperm of the kernel. This suggests that
during the development of the male gametophyte,
the R-locus is imprinted or altered in an epigenetic
fashion such that its expression is suppressed in the
next generation.
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FIGURE 6 Normal ears of corn segregating the R-r and r-g alleles. Full-colored kernels on the left ear
and the mottled kernels on the right ear are both heterozygous for the R allele. Full-colored kernels have
received the R-r allele from the female gametophyte, whereas the same allele was transmitted through
the male gametophyte in the mottled kernels.
We have used a developmental mutant of maize
(Ts6) to determine whether R-allele imprinting in the
pollen occurs as a result of the position of the tassel
in the plant or whether imprinting is gametophyte-
specific. Ts6 is a dominant mutation that results in
the formation of a female flower at the position
where the male flower would normally form. The
tassel seed ear is a large, multispike tassel-like
structure with extensive silks; the ear produces no
pollen, but it can be cross-pollinated to yield mature
kernels capable of expressing full color.
The question we asked was, Do kernels of a tassel
seed ear carrying the R-r allele exhibit the R-mottling
phenotype? That is, will R-r be imprinted in the
female gametophytes derived from what is normally
the cell lineage leading to male gametophytes? A Ts6
stock carrying the recessive r-g allele was crossed to
an R-r stock, and the progeny that inherited Ts6 were
crossed to pollen from r-g and R-g testers. Both the
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tassel seed ear and the normal ear of the Ts6 plants
were pollinated. From several such crosses, it was
apparent that the tassel seed ear behaved much like
a normal ear in this respect (see Table 1); i.e., when
the R-r allele is transmitted through kernels of the
tassel seed ear, they express full color, and mottling
occurs when R-r pollen is crossed to a tassel seed ear
with an r-g genotype (Fig. 7). From this experiment,
we conclude that the position of the flower has no
effect on imprinting and that R-imprinting is male-
TABLE 1 Effect on R Expression in the Kernel following
Transmission through the Tassel-seed Ear
Cross Ear Phenotype
Ts6/+, R-r/r-g x +/+, r-g/r-g tassel seed full color:colorless, 1:1
Ts6/+, R-r/r-g x +/+, r-g/r-g normal full color:colorless, 1:1
Ts6/+, R-r/r-g x +/+, R-g/R-g tassel seed full color:mottled, 1:1
Ts6/+, R-r/r-g x +/+, R-g/R-g normal full color:mottled, 1:1
gametophyte-specific, probably occurring late in the
development of the tassel.
The molecular basis for imprinting at this allele
is unknown, although methylation of the gene is a
possible explanation. Other experiments in progress
are designed to determine the point in pollen de-
velopment in which imprinting occurs.
Transposon Tagging of the
Maize dwarfl Gene
J. Colasanti, V. Sundaresan
The gibberellins represent a class of phyto-hormones
that are important in the growth and development
of plants. In maize, the recessive mutation dwarf]
(dl) has been biochemically characterized as being
deficient in an enzyme neccesary for the conversion
of a precursor gibberellin (GA20) to the active form,
GA1. A new allele of the dl gene has been isolated
from the F1 progeny resulting from the cross of a
Mu line to a normal inbred line. If the mutation is
a result of the insertion of a Mu element into the
wild-type gene (Dl), it should be possible to detect
a band cosegregating with the dwarf phenotype, as
detected by Southern blotting with Mu-specific
probes. This method of gene tagging is complicated
in Mu lines by the high copy number of elements
and their high frequency of transposition. To
FIGURE 7 A mature tassel seed ear exhibiting full-colored and mottled kernels (arrow).
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alleviate these difficulties, a dwarf line was selected
in which Mu transposition had switched "off."
In
this way, these lines can be out-crossed with lines
containing few or no Mu elements to dilute the
number of elements and facilitate identification of
a band that segregates with the dwarf phenotype.
In initial experiments, a Mul- specific probe was
used in an attempt to detect dwarf-segregating Mul
elements, as this element has been shown to be the
most active in terms of transposition (Lillis and
Free ling, Trends Genet. 2: 183 [1986]). However,
although a number of these elements have been
reduced to between 5 and 10 copies in most lines,
there are no cosegregating bands. The Mu elements
exist as a family of elements that share terminal
inverted repeat sequences but have considerably
different internal sequences. At least some and
perhaps all of the other elements may be transpos-
ing in Mu lines and causing insertional mutations.
Six other Mu elements have been cloned and partially
characterized (Mu3, Mu4, Mu5, Mu6, Mu7, and
Mu8). These were also used as probes in an attempt
to detect bands cosegregating with the dwarf
phenotype. Although none of these have shown
evidence of cosegregation with the dwarf phenotype
as of yet, other Mu elements may be characterized
in the future and used as probes.
To approach this problem from another angle, we
are also attempting to tag the dl gene using the Spm
transposable element. This element has been used
successfully to tag other genes (Cone et al., in Plant
transposable elements. Plenum Press, New York
[1987]) and offers some advantages over Mu; i.e.,
although the mutation rate is lower in an Spm stock,
the number of active Spm-like elements is also small,
so that the segregation analysis is simplified. Crosses
of Spm-active lines with dwarf lines were performed
this winter in Florida, and approximately 200,000
Fi progeny were obtained. These are now being
screened for potential new dwarf mutants, and so far,
two new dl mutants have been identified out of
38,000 progeny screened.
Transposon Tagging of a Quantitative
Trait Locus in Maize
V. Sundaresan
Quantitative traits in field crops (height, yield,
moisture) have been believed to be controlled by a
large number of independent loci. However, recent
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work using restriction-fragment-length polymor_
phisms (RFLPs) to study genetic linkage has shown
that in many cases, a few genetic loci appear to
account for much of the observed variation in the
F2 progeny of heterotic crosses. In particular, a
locus linked to an RFLP on chromosome 9 of maize
appears to account for about 25% of the variation
in height observed (T. Helentjaris, Trends Genet.
3: 217 [1987]). This RFLP maps very close to the
locus dwarf3 (d3) required for the synthesis of the
plant growth regulator gibberellin, and it has been
hypothesized that the observed variation in height
linked to this locus is due to different alleles of d3.
We have therefore begun an attempt to isolate this
gene using the maize transposable element Spm
(Suppressor-mutator) as a transposon tag. In the
summer of 1988, large-scale crosses were performed
between d3 testers and the Spm stock cl-m5
which carries an Spm and a dSpm element on
chromosome 9. Over 250,000 progeny were obtained,
and these will be screened in summer 1989.
Molecular Analysis of the
Maize P Locus
T. Peterson, C. Lechelt
Although a number of plant genes have been
isolated, in few cases do we have a thorough under-
standing of the mechanisms by which the genes are
expressed in specific tissues during development of
the plant. The maize P gene, which controls pig-
mentation of certain floral tissues, has several impor-
tant properties that are useful for studies of plant
gene structure and expression. First, P is expressed
in at least five distinct floral tissues, including the
pericarp, glumes of the cob, glumes of the tassel,
husks, and silks. Moreover, P can be expressed in-
dependently in these tissues; e.g., the alleles P-RR,
P-RW, P-WR, and P-WW specify red pericarp/red
cob, red pericarp/white cob, white pericarp/red cob,
and white pericarp/white cob, respectively. Second,
the P-controlled pigments are conspicuous but non-
vital, so mutants can be easily isolated and studied.
Third, mutations that occur during development of
the ear result in sectors of mutant pericarp, and the
mutant alleles can be recovered and propagated in
the progeny of kernels within the sectors. Finally,
the P locus is accessible to molecular dissection, since
it is "tagged" with the maize transposable element Ac.
Using the Ac element as a hybridization probe,
we have isolated 27 kb of genomic DNA from the
P locus. With an overlapping genomic BamHI clone
of 10 kb (kindly provided by Jychian Chen and
Stephen Dellaporta), the entire cloned region
comprises 34 kb. The cloned DNA contains two 5.8-
kb homologous regions, in direct orientation,
separated by 6.6 kb. The Ac element in the original
P-VV allele is inserted in the 6.6 kb of DNA between
the 5.8-kb direct repeats.
We knew from previous experiments that the Ac
insertion in P-VV is correlated with a change in
transcriptional pattern around the Ac insertion site.
For a complete transcriptional analysis of the cloned
P-locus DNA, restriction fragment probes spanning
the 34-kb region were hybridized to Northern blots
of RNA from plants carrying the mutant P-VV and
functional P-RR alleles. The results allowed a coarse
determination of transcribed regions that are most
probably specific for the P gene.
We found that probes from a region of 7.3 kb
around the Ac insertion site detect five transcripts
of 7, 6.5, 2, 1.4, and 1 kb in RNA of P-RR and P-RR
revertants derived from P-VV. The multiple RNA
molecules may be formed by alternative splicing.
None of these transcripts are found in RNA from
the P-VV allele. Instead, a transcript of 9.5 kb in size
is detected in P-VV RNA by probes located 5' of Ac
and by Ac-specific probes. The 9.5-kb RNA is a
chimeric transcript containing P- and Ac-specific
sequences that most likely terminates within the Ac
element, since it is not detected by probes 3' of Ac.
Hybridization with single-strand-specific M13 probes
demonstrated that the direction of transcription of
the P gene is identical to that of the Ac gene in the
cloned P-VV allele. Thus, the transcriptional start
site(s) of the P gene is located 5' of the Ac element
in the P-VV allele used for these studies.
Probes made from DNA fragments outside the
7.3-kb region around the Ac insertion site do not
detect differences in RNA from the P-VV and P-RR
alleles. Some probes do not hybridize at all to RNA
of the two alleles; these sequences might represent
introns or nontranscribed DNA. Other probes detect
a similar pattern of transcripts in P-VV and P-RR
RNA. These transcripts do not seem to be specific
for the P gene, since they do not correlate with the
phenotype, but we cannot exclude the possibility that
they are somehow involved in P gene expression.
Although the 7.3-kb region around the Ac in-
sertion site is able to code for the largest transcript
of 7 kb, we do not yet know whether the promoter
of the P gene is also located in this region or whether
RNA synthesis starts further 5'. At present, it is also
unknown which of the five transcripts (or all of
them) are important for the expression of the P gene.
Short-range Transposition of Ac
from the P-OVOV Allele
T Peterson, S. Allan
Last year, we reported the isolation and preliminary
characterization of an allele termed P-OVOV (orange
variegated pericarp and cob) derived as a change in
state of P-VV. P-VV specifies colorless pericarp with
red sectors, whereas P-OVOV specifies orange peri-
carp with many dark red sectors, and some colorless
sectors. Southern analysis showed that the Ac
transposable element is in the opposite orientation
in P-OVOV relative to P-VV.
Cloning and sequencing show that inversion of Ac
occurred by short-range transposition and reinser-
tion in an inverted orientation. The Ac element has
transposed 160 by toward the 5' end of the P locus.
Although the Ac element in P-VV is not bordered
by host direct repeats, the Ac element in the P-OVOV
allele is flanked by 8-bp direct repeats of a sequence
that is present once in the progenitor P-VV allele.
The orange variegated pericarp phenotype specified
by P-OVOV may be considered as a mosaic of three
phenotypes:
1. The orange background color may be due to a
dilution of the red phlobaphene pigments,
resulting from a reduced level of expression of
P. Although we do not yet know why P-OVOV
allows a moderate level of P expression, an
orientation-dependent splicing mechanism simi-
lar to that proposed by Wessler et al. (Science
237: 916 [1987]) seems plausible; i.e., in P-VV,
transcripts from P terminate within the Ac
element, whereas in P-OVOV, the orientation of
Ac may allow splicing out of element sequences
during RNA processing.
2. The numerous red sectors may be due to excision
of Ac from P-OVOV, thereby restoring a P-RR
allele. We know that this is the case for one
germinal P-RR revertant from P-OVOV.
3. The occasional light sectors may result from a
variety of mutations at P, including deletions (see
below) and short-range transpositions. We have
characterized two germinal P-VV* mutants that
have variegated pericarp and cob resembling the
progenitor P-VV allele. Both cases were derived
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from kernels with variegated pericarp on other-
wise orange variegated ears. In one case (P-VV*-
4177), Ac has transposed from the site in P-OVOV
and inserted at a site approximately 700 by toward
the 3' end of the P locus, in the opposite orienta-
tion as in P-OVOV (i.e., in the same orientation
as the P-VV "grandparent" allele). In the second
case (P-VV*-4189), Ac has transposed from the
site in P-OVOV and inserted at a site approxi-
mately 4 kb toward the 5' end of the P locus. The
orientation of Ac in P-VV*-4189 is not yet known.
In these experiments, we have not detected a strict
polarity of transposition as might be predicted
from Greenblatt's results showing a 4-map-unit
region proximal to P that contained no Ac
insertions following transposition from P-VV
(Greenblatt, Genetics 108: 471 [19841). Rather, our
results indicate that Ac can transpose in either
direction from the site in P-OVOV to other sites
within the P locus.
P-OVOV Mutates to P-WW
by Deletion
P Athma, T. Peterson
As mentioned above, the P-OVOV allele carries an
Ac element in the inverted orientation with respect
to P-VV. The P-OVOVallele shows both sporophytic
instability (pericarp sectoring; see above) and
germinal instability, as evidenced by the progeny of
the cross:
P-OVOV/ P-OVOV x P-WW/P-WW
(both directions)
Among 10,820 progeny ears, 697 (6.4%) had red
pericarp and cob (P-RR) and 89 (0.8%) had white
pericarp and cob (P-WW). These frequencies can be
compared to those previously reported by Brink
(Genetics 43: 435 [19581): Among 4575 offspring of
the mating of P-VV/ P-VV x P-WW/ P-WW, 125
(2.7%) had red pericarp and cob and 8 (.17%) had
white pericarp and cob. Thus, both P-OVOV and
P -VV mutate to P-WW at low but detectable frequen-
cies. It is not known whether the different frequen-
cies arise from background effects, direction of the
cross, or actual differences in mutation frequency
of P-VV and P-OVOV.
We have investigated the molecular basis of seven
P-WWalleles derived from P-OVOV. Each allele was
obtained independently from kernels with mutant
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pericarp sectors from separate orange variegated
ears. Southern analyses indicate that six of the seven
P WW mutants have a large deletion at the P locus;
the seventh mutant has a more complex structure and
will not be considered further here. To map the
deletion endpoints, restriction fragments to the right
and left of the Ac insertion site in P-OVOV were used
as probes. Southern analysis with probes spanning
a 3-kb region to the right of Ac showed that this
region was deleted in the mutants. Similarly, the
probes to the left of Ac representing a 9.5-kb region
were also deleted.
Molecular analysis shows that the P locus contains
two direct repeats of 5.8 kb, separated by 6.6 kb (see
above). The Ac element in the P-OVOV allele is
situated in the 6.6 kb of DNA between the two 5.8
-kb
repeats. In the P-WW mutants, the deletion end-
points lie within the two 5.8-kb homologous direct
repeats, on either side of Ac. We suspect that the
deletions may have occurred by homologous recom-
bination between the two direct repeats such that the
17 kb of intervening DNA, including Ac and part
or all of the P gene, is deleted.
The possible involvement of the Ac element in the
occurrence of deletions is suggested by the apparent
stability of the P-RR allele. Although P-RR contains
the 5.8-kb direct repeats, mutations to P-WWare rare.
On the other hand, the P-WW-1112 allele, obtained
directly from P-VV, has a deletion of the same type
as the six P-WW mutants derived from P-OVOV. We
do not know whether the deletions are somehow
induced by the presence of an active Ac element or
the increased length of DNA between the direct
repeats.
We thank Rob Fincher and Ruth Meier of Pioneer
Hi-Bred for overseeing the maize crosses and
isolation fields.
Isolation of the Hml gene
by Transposon Tagging
G. Johal, S. Briggs
The Hml locus of maize confers resistance to the
fungal pathogen Helminthosporium carbonum (race
1). The pathogen causes a severe leaf spot disease,
and under ideal conditions, it can cause complete
rotting and subsequent blackening of the cob.
Nothing is known about the gene product of the
Hml locus, which has been characterized phenotyp-
ically and by classic linkage analysis. Since know-
ledge of a gene's mRNA or protein product is es-
sential for most widely used cloning procedures,
there has been little progress to date in cloning these
valuable genes.
An alternative gene-cloning strategy has been
proposed that is based on gene tagging using mobile
genetic elements. Three different transposable
element systems have been used to tag the Hml locus.
These will be discussed separately, since they differ
from each other in technology and strategy for
creating mutations and subsequent handling of
mutant material to isolate the target gene.
The major advantage of Robertson's Mutator
system (Mu) is its high rate of mutation. This is
perhaps due to the high copy number of Mul
elements (about 30) in mutator stocks. However, this
high copy number of transposing Mu elements
makes it difficult to correlate a specific restriction
fragment with a mutant allele.
Cloning with Mu was initiated by crossing a Mu
Hml line with an hml line. Several susceptible
mutants were isolated from the cross. These mutants
were crossed with a resistant inbred (Hml/Hml).
Two different strategies have been used to identify
Mu insertions at the Hml locus.
From the outcross progeny of one of the mutants,
a plant carrying the mutant allele was identified using
restriction-fragment-length polymorphisms (RFLPs).
Hybridization to Mu (a Mu 1.4 internal fragment)
revealed 17 insertions. A bacteriophage X library of
1.3 x 106 phage was constructed from a partial
Sau3AI digest of genomic DNA. Sixty three Mu-
homologous clones were recovered, out of which 39
seem to be unique.
The overall objective of this first strategy is to map
each Mu insertion to its precise chromosome loca-
tion. This will be done using recombinant inbreds.
Each probe from the flanking DNA is hybridized
to recombinant inbred parents cut with different
enzymes to identify RFLPs. The recombinant inbred
DNAs are then cut with the appropriate enzymes and
probed with each clone. The pattern of RFLPs in
the recombinant inbreds is sent to Brookhaven Na-
tional Laboratory for entry into the database and
placement on the genetic map. Clones that map to
the proximal region of chromosome 1L will be tested
for linkage with the Hml locus as well as polymor-
phism between near isogenic inbreds that differ only
at the Hml locus. The clones that show tight linkage
and/or polymorphism will be considered for further
analysis to identify Hml transcripts.
Another objective of this approach is to determine
the genomic distribution of Mu elements and the
pattern of transposition. By hybridizing each probe
to siblings of the mutant, we can distinguish which
Mu insertions were inherited by the mutant and
which occurred de novo. This may provide insight
into the mechanism of transposition of Mu.
During characterization of Mu-homologous
clones, we have identified other size classes and types
of Mu elements. One element is 1.2 kb in size and
another is about 1.7 kb in size but differs from the
previously described 1.7 Mu. Another Mu element
appears to lack the terminal inverted repeats. We are
in the process of subcloning these new Mu elements
for sequencing purposes.
Another interesting observation is the presence of
two copies of Mu in the same clone. There are at
least 3 such clones out of 39. We are presently trying
to identify the DNA fragment between the Mu
elements to determine if it is common to all of the
clones containing two copies of Mu.
The second strategy is to identify Mu restriction
fragments that cosegregate with the mutant Hml*
allele. Progeny from each of several mutants were
grown and self-fertilized. The progeny that bear the
Hml* allele, as opposed to the hml tester allele, are
being distinguished using RFLP probes. Among the
progeny from the self-fertilization, Hml* homo-
zygotes will be identified by inoculation. Hybridiza-
tion of DNA from several progeny should reveal one
or more bands present in all of the susceptible
progeny but segregating in the resistant progeny.
The Ac/Ds transposable element system has also
been used to mutagenize Hml. A series of 2046
families have been generated, each of which is
segregating for a different transposed Ac. These
families were generated as part of a collaboration
with Marc Albertson at Pioneer Hi-Bred Interna-
tional, Inc., and Stephen Dellaporta and Jychian
Chen at Yale University. One of the families has been
found to segregate for susceptibility to H. carbonum.
Further tests are being done to clarify the relation-
ship between the transposed Ac and the mutation.
The transposable element, Spm, is the third
mutagenic agent we have used. Plants of the
genotype c-m5, Hml were crossed with c, hm plants.
The c-m5 allele was isolated by Barbara McClintock
as an insertion of Spm at the C locus.
Purple kernels (C germinal revertant) were picked
to enrich for transposed Spm elements. These kernels
were planted in the greenhouse and inoculated as
seedlings to score for susceptible mutants. From the
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cross where the Spm parent was male, we
recovered
5 mutants out of 6000 revertant kernels. Another
3
mutants were recovered from the cross
where the Spm
plant was the female parent. Tests are
under way to
determine whether any of these mutations
are
associated with transposition of Spm to the
Hml
locus.
Genetic Characterization of
Transposed Ac Elements in
Rpl and Rpp9 Mutant Lines
S. Briggs, B. Bergen
Resistance to infection by the common rust (Puccinia
sorghi) and southern rust (Puccinia polysora) patho-
gens is conferred by Rpl and Rpp9, respectively. In
collaboration with D. Wilkinson and D. Christian-
sen at Pioneer Hi-Bred International, Inc., several
Rpl and Rpp9 mutants have been identified. Dur-
ing the past year, genetic and molecular studies have
been done to determine which, if any, of the muta-
tions have been caused by insertion of an Ac ele-
ment.
Plants of the constitution r:nj:ml/r, Rpp9 were
pollinated by an r, rpp tester. The r-njml allele was
derived by Irwin Greenblatt as an insertion of Ac
at R-nj. Excision of Ac from r-nj:ml can restore the
R-nj phenotype. R-nj revertant kernels (5300) were
selected from 71 ears (families). Approximately 5000
seedlings were inoculated and scored for suscepti-
bility in the greenhouse. Six susceptible progeny were
observed from four different families. Seed was
obtained from four of the plants, representing three
of the families, by crossing to an r-m3, rpp tester.
Jerry Kermicle derived the r-m3 allele as a Ds
insertion at the R locus. All four plants transmitted
a transposed Ac to their offspring according to their
ability to destabilize r-m3. By counting the members
in each progeny class, it was possible to determine
the linkage between the transposed Ac and R-nj. The
target locus, Rpp9, and the donor locus, R-nj, lie on
the same chromosome, 61 cM apart. Transposition
of Ac from r-nj:ml to Rpp9 would result in a
transposed Ac unlinked to R-nj. In two cases, Ac was
tightly linked to the donor locus R-nj, but in the other
two cases, the transposed Ac was unlinked to R-nj.
To ascertain whether or not Ac was linked to the
target locus, Rpp9, in the latter two cases, closely
linked RFLP probes were hybridized to blots of
siblings that were segregating for transposed /lc. In
one case, the RFLP probe NPI 285 (a gift from Npi,
Inc.), which is tightly linked to Rpp9, was found to
be unlinked to transposed Ac. In the other case,
the fragment corresponding to the mutant-bear-
ing chromosome was not observed, suggesting that
this region of the chromosome may have been de-
leted.
A similar study has been done with Rpl, w hich
is tightly linked to Rpp9. Plants of the constitution
r-nj:ml/r, Rpl-d were pollinated by an r, rp tester.
R-nj revertant kernels (1500) were selected and
planted. These kernels came from 47 ears (families).
Approximately 1300 plants grew and were screened
for susceptibility. A total of 68 susceptible plants
from 6 different families were identified. Seed was
recovered from 35 of the plants, representing 5
families, either as self or outcross progeny.
Fifteen plants from each of the 35 putative mutant
families were crossed with the tester, r-m3, rp.
Thirteen of the families contained a transposed Ac.
Seven of the 13 transposed Acs are unlinked to R-nj.
We are now determining whether any of the 7 un-
linked transposed Acs are located at the Rpl locus.
Our first tests for cosegregation of each transposed
Ac with the mutant Rpl alleles utilized RFLP probes
for the chromosome region of Rpl. However, poly-
morphisms between the disjoining chromosomes
have not been found. We are continuing to search
for polymorphisms, and, in the meantime, we have
begun isolating the transposed Acs as restriction
fragments; these can be used for cloning or for
generating probes of the flanking DNA with an
inverse polymerase chain reaction. In either case,
unique probes from the flanking DNAs will be
generated for mapping the genetic location of each
transposed Ac with a highly polymorphic recom-
binant inbred family.
The transposed Acs are being isolated by taking
advantage of the propensity of active Acs to be
flanked by hypomethylated DNA. For example, in
one family, Pstl generated a 9-kb Ac-homologous
restriction fragment only from siblings that inherited
an active Ac. Cryptic (homologous but inactive)
elements form a high-molecular-weight smear on the
blot. Such digests are fractionated on glycerol
gradients to isolate the fragment bearing the active
Ac. We have identified at least one enzyme for
isolating the transposed Ac from four of the seven
cases where Ac is unlinked to the donor (R-nj) locus.
Quantitative Protein Changes
in Response to HC Toxin
B. Elliott, S. Briggs
Resistant (Hml) and susceptible (hml) inbreds were
crossed, and the progeny were selfed to generate F2
immature embryos. The immature embryos were
used to initiate embryogenic tissue cultures by Jon
Duvick and Joyce Maddox at Pioneer Hi-Bred
International, Inc. Each culture line was character-
ized with regard to HC toxin sensitivity, which
segregates with hml.
We have used these culture lines to study changes
in protein synthesis or modification following
exposure to HC toxin. Proteins were labeled using
[35S]methionine. Gels were run and digitized by
members of the Quest facility. Sensitive and insensi-
tive lines were compared to control for any non-
specific effects. Samples were taken at different times
following exposure to HC toxin. A comparison of
three different sensitive and three different resistant
lines after 1 hour of treatment revealed a single spot,
which decreased approximately 5007o in the resistant
lines, but increased, remained stable, or decreased
slightly in the susceptible lines. After 1 hour of
treatment, seven other proteins had increased in only
the susceptible line(s). This change peaked between
1 and 5 hours after exposure with a 5- to 20-fold
increase, followed by a return toward the control level
by 11 hours after exposure. The cultures turn brown
18 hours after exposure, but it is not clear at what
time cell death occurs.
Either tunicamycin or cycloheximide will protect
sensitive lines from HC-toxin damage. Removal of
inhibitor restores toxin sensitivity. [31-1]Mannose
labeling revealed that one of the proteins that
increased dramatically in susceptible cells upon
exposure to toxin is a glycoprotein. None of the
proteins described appear to be phosphoproteins.
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CELL-CYCLE CONTROL IN SACCHAROMYCES CEREVISIAE
B. Futcher R. Nash K. Erickson
G. Tokiwa
This is our first year at Cold Spring Harbor Labor-
atory, and a very productive year it has been. We were
able to clone the WHIP gene, which had eluded us
for several years, and found that it was a cyclin
homolog. A year ago, we thought we were alone
working on a potentially interesting but overlooked
gene; now we find ourselves (and others!) working
on a protein that may be the cell-cycle timer in yeast,
echinoderms, amphibians, mammals, and probably
eukaryotes in general.
Cloning and Partial Characterization
of WHI1
G. Tokiwa, R. Nash, K. Erickson, B. Futcher
WHI1-1 is a dominant mutation that produces small-
size cells ("wee" cells) with very short GI phases
(Figs. 1 and 2). Mutant cells are small because they
commit themselves to cell division prematurely; we
interpret this to mean that the cellular measuring
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FIGURE 1 Coulter channelyzer plots of cell volume distributions. (A) Tetrad BF328-4 segregating 2:2 for WHI1-1:
(B) tetrad BF334-2. (C) Wild-type and a mutant strain growing in a medium containing the relatively poor carbon
source glycerol. td is the culture doubling time. The modes of the peaks are indicated in C.
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device that determines the proper time for division
is abnormal. We mapped the mutation, and from
the map position, we were able to clone the wild-
type and mutant genes. Dosage studies were done
with the cloned genes. Zero doses (i.e., a deletion of
the gene) produced large cells with long GI
phases - the opposite of the WHI1-1 phenotype.
Increasing the dosage of the wild-type gene ( WHIP)
decreased cell size and decreased the length of GI.
Increasing the dosage of the mutant gene reduced
cell size to about 50% of wild type, and decreased
G1 to nearly 0% of the cycle (Table 1; Fig. 2). Thus,
in some sense, the mutant gene is hyperactive, since
it behaves like many doses of the wild-type gene. The
fact that WHIP dosage affects the time of com-
mitment generally supports the idea that the WHI1
protein is part of a cellular measuring device.
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The wild-type and mutant genes were sequenced,
and this gave three important pieces of information.
First, the newly installed Fast A program found that
WHIP- was a cyclin homolog (Fig. 3), a result
confirmed by statistical analysis done by G. Otto.
Cyclins (not to be confused with proliferating cell
nuclear antigen [PCNA], formerly called cyclin) were
first discovered in clams and sea urchins. They are
proteins that accumulate with time in newly fertilized
oocytes and then are suddenly destroyed at mitosis.
This pattern of accumulation and sudden degrada-
tion occurs in each cell cycle. Microinjection ex-
periments have shown that quiescent oocytes could
be forced through meiosis I by cyclin mRNA
(Swenson, Farrell, and Ruderman; Pines and Hunt),
and this is consistent with the observation that
WHI1-1 promotes premature division.
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FIGURE 2 Flow cytometry. Cellular DNA was stained with
propidium iodide, and the fluorescence per cell was measured.
The y axis is the number of cells; the x axis is the intensity of
fluorescence. Peaks due to cells in G1 and G2 are indicated. The
G2 peak actually includes cells in 02, M, and cytokinesis. (A)
Deletion allele; (8) wild-type allele; (C) WHI1-1 mutant allele. (D)
Haploid containing two copies of the mutant gene; this strain
seems to lack G1 entirely; (F) haploid strain containing one wild-
type gene and one mutant gene; the short-G1 phenotype
indicates that WHI1-1 is dominant, as expected for a hyperac-
tive allele.
Second, the WHI1-1 mutation is a stop codon two
thirds of the way through the gene. Thus, the lack
of the wild-type carboxyl terminus apparently
hyperactivates the protein. Third, this carboxy-
terminal third has an unusual amino acid composi-
tion. It is very rich in proline, serine, and threonine.
Regions of similar composition have been called
PEST (Proline, Glutamate, Serine, Threonine) re-
gions by Rogers, Wells, and Rechsteiner; such regions
are found in nearly all proteins with short half-lives
and may be signals for degradation. PEST regions
TABLE 1 Effect of WHI1 Alleles on Cell Volume and G1
Phase
Cell
volume Normalized % of Cycle
Genotype (PIO) volume spent in Gi
whi1-310 (A) 55 ± 5 1.2 37
WHI1 + 44 ± 3 1.0 27
2 x WHI1+ 35 ± 3 0.80 n.t.
WHI1-1 27 ± 2 0.61 19
WHI1 + WHI1-1 27 0.61 15
2 x WHI1-1 25 0.57 0-10
n.t. indicates not tested. ± represents the range over at least
eight measurements. Where ± is not indicated, less than eight
measurements were done. For most constructions, each transfor-
mant behaved similarly, but for 2 x WHI1-1 strains, some transfor-
mants repeatably had a Gi of about zero, whereas others had
a Gi of about 10%.
are found in the other sequenced cyclins as well as
in WHIP (Fig. 3).
These observations led to the hypothesis that (1)
the PEST regions of WHIP and other cyclins have
something to do with the sudden degradation of
these proteins at a certain point in the cell cycle and
(2) the hyperactivity of the mutant WHI1-1 protein
is due to the loss of this PEST region, so that it can
no longer be degraded. We will be testing this
hypothesis in the current year.
The whi3 Mutation
R. Nash, B. Futcher
One of our chief difficulties in working with WHI1-1
was that it was not deleterious to the cell, and so it
could not be cloned by selecting for a complement-
ing plasmid. We wished to find new Whi mutants
in a way that would make cloning easy even if no
selection could be applied for the wild-type gene. To
do this, we used the technique of transposon tagging.
A Ty transposon marked with G418 resistance, and
carrying a galactose-inducible transposase, was
obtained from J. Boeke. Yeast were transformed with
this construct, and transposition was induced. An
apparently new whi mutation was obtained, which
we named whi3. The mutation was genetically
inseparable from G418 resistance, as expected if it
were caused by a Ty insertion. The G418-marked Ty
element has been cloned out of the mutant strain
along with flanking DNA. This flanking DNA has
been used as a probe to obtain clones from a library
of wild-type DNA. These clones may include the
intact WHI3 gene.
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Urchin
cdc13
Clam A
MalgtrnmN
mttrrltrqhllantlgnndenhpsnhiaraksslhssenslvnmsqpgkkatvsstnVpKKrhaLddvsnFhNfalhhdgenqMqRRgkmntrsngLsg
mailkdtiir
WHI1
Urchin mnlhgeskhTfNneNvsArLggKsiavQKpa
rAalgNisnvvRtaqaGskkvVkkdtrQkamtktkatsq
cdc13 kegvpLaskntNVrHttAsVstRrAleEK_SiipaLDDepasKKRrqp
svfnsSVpS1pqH1stkshsyst
Clam A qkraaLgviTnqVnQqvriqpsRaAkpksSefniqDENaftKKnaktfGqqpSqfSvfvDptpaapvqka
WHI1 yanaryatas tstataasysaasc
nl 111qkrraiasakskNpNlVkrElqAHhsaiSEYnnDqLdh
Urchin slhaVvglPvedLPtEMRsts
DvLdamEVdqaieafSQqliaLQvEDIdkDDgdNPqLcSEYakDIY1Y
cdc13 hgvdafhkdqAtIPkkLKkdvDErVvskDIpk1hrdsvEspesqDwDDLiiEDwADPLMVSEYvvDIFeY
Clam A ptshVtdiPaAlttlQrvpltEvpqspdiIsledsmeSpmildLpeEEkplDreAviLtVpEYeeDIYnY
WHI1 yfrLshterplynitNfnsQpqvnpKMRfLIfDfIMycHtRLNLstsTLFLtftILDKYsSrfiIksyny
Urchin LRrLEVEmMvpanYLDROetqiTg-RMR1ILVDWLVQVH1RFHLLgETLFLtVgLIDRFLaeHSVSKGKL
cdc13 LneLEIEtMpsPtYMERQkELaw--KMRgILtDWLIEVHsRFRLLpETLFLaVNIIDRFLS1RvcSlnKL
Clam A LRqaEMknrakPgYMkRQtDItTs--MRcILVDWLVEVseedKLhrETLFLgVNyIDRFLSkiSV1RGKL
WHI1 QLLsLtALwIsSKFwDsknrmatlkVlqnLccNqYsikQfttMEmhLFKsLdwsIcqsatFDsyidiflf
Urchin QLVGVtAMFIASKYEEMYPPEInDFV--YITDNaYTkaQIrOMEiaMLKgLkYkLgkPlcLHFLRRnSKA
cdc13 QLVGIAALFIASKYEEVmcPsVqNFV--YMaDggYdeEEILQaERyILRVLeFNLAyPnpMNFLRRiSKA
Clam A QLVGaAsMFLAaKYEEIYPPDVkEFa--YITDDtYTsQQVLrMEH1ILKVItFDVAvPttnwFcedflKs
lnnaagtainkssssqgpslnineiklgaimlcelasfnlelsf
WHIZ qstsplspgVvlsapleaFIQqkLaLkYdrSliAlgAInLiK1sLnyynsnlWe-NInlaleencqDLdi
Urchin agvDaQkHTLAKYLMEITLPEYsM-VqYsPSEiAAAAIYLsmtLLdpEthssWcpkWHYSmYsEdHLrp
cdc13 dfyDiQtRTVAKYLVEIgLLDhkL-LpYpPSQqcAAAMYLARe.MLGrgP---WnrNLVHYSGYEEyQLis
Clam A cdaDdklKsLtmFLtELTLIDmdayLkYlPSitAAAALcLARysLGiEP---WpqNLVKktGYEigHFvd
WHI1 kLseIsntLLdiamdQnsfpssfksKYlnsnkts/aksi/dalqnyciqlkleeFyRscieletmyntiFa
Urchin IVqKIVqiLLRdDSasQky-sAVktKYgSsK FM:KiSgiaqLdsslLk
cdc13 VVICKMInyLqKpvqHE AffkKYaSkK FMKaSLfvrdwIkkns
Clam A cLKdLhktsLgaESHQQq---AVqeKYkqdKyhqvsd FsKnpVphnLaLlaL
STOP
WHI1 gsfdsdsltcvysnattpksatvssaatdyFsdhtHLrRltKDsisppfaftptssssspspfnspykts
Urchin qiaggsnE
cdc13 iplgddaD edytFhkqkRIqHdmKDeew
WHI1 ssmttpdsashhshsgsfsstqnsfkrslsipqnssifwpspltpttpslmsnrkllqnlsvrskrlfpv
WHI1 rpmatahpcsaptqlkkrstssvdcdfndssnlkktr
FIGURE 3 Alignment of WHI1+ with three cyclins. The complete sequences of WHI1`, sea urchin cyclin, clam
cyclin A, and S. pombe cdc13 are shown. Uppercase letters represent conserved residues; bold uppercase letters
represent conserved residues with a high Mutation Data Matrix weighting. Possible PEST regions are underlined.
Basic residues associated with PEST regions are italicized. Also italicized is the WHO` sequence nktslakslld, which
is similar to a sequence found 95 residues more amino-terminal in the other cyclins. The position of the stop codon
in WHI1-1 is shown.
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TRANSCRIPTION AND CELL-CYCLE REGULATION IN YEAST
K.T. Arndt A. Sutton
K. Tice
In almost all aspects of basic cellular processes, the
yeast Saccharomyces cerevisiae has been found to
be very similar to higher eukaryotic cells. For this
reason, and the ease of manipulation and the
powerful genetic approaches available with yeast, we
are using yeast in our lab to study transcriptional
regulation and cell-cycle control.
Transcriptional Regulation
of the HIS4 Gene
K. Tice
Our ultimate goal is to understand completely the
regulation of the yeast HIS4 gene and use HIS4
regulation as a model for the transcriptional regu-
lation of other systems. The HIS4 gene is under
complex transcriptional control. Two independent
systems activate HIS4 transcription: basal control
and general amino acid control. In general amino
acid control, starvation for any one or more amino
acids causes an increase in the levels of the GCN4
protein. The GCN4 protein binds to the sequence
TGACTC, repeated five times in the HIS4 promoter,
to activate HIS4 transcription. GCN4 binds one of
these HIS4 elements, repeat sequence C, much more
tightly than the others, and most (approximately
8007o) of the GCN4-dependent activation of HIS4
transcription is due to repeat sequence C. We are
using defective GCN4 derivatives to obtain muta-
tions in the general transcription machinery (see
below).
The basal level control activates HIS4 transcrip-
tion in the absence of amino acid starvation. In
addition, either phosphate or adenine starvation will
cause a further increase in the already high basal
levels of HIS4 transcription. Activation of the basal
level transcription of HIS4 requires two trans-acting
proteins, encoded by the BAS1 and BAS2 genes.
Mutations in BAS2 cause a phosphate requirement
(BAS2 is the same gene as PHO2) and mutations
in either BAST or BAS2 cause an adenine require-
ment. Thus, in yeast, the phosphate, purine, and
histidine pathways are coregulated. Analysis of the
metabolites in these pathways shows the biological
rational for the coregulation. In addition, we have
very recently found that BAS1, but not BAS2,
regulates pyrimidine biosynthesis. The particular
genes under BAS1 and BAS2 regulation in some of
these pathways have yet to be determined.
In vitro, BAS2 present in yeast extracts binds to
the HIS4 promoter (at a site different from GCN4)
in the presence or absence of BAS1. In vivo, however,
both BAS1 and BAS2 are required in order to activate
HIS4 transcription. In contrast, the BAS1 protein
is not required for BAS2 to activate PHO5 transcrip-
tion. Under conditions where HIS4 has high basal
level transcription, the transcription of the PHO5
gene is extremely low. PHO5 transcription dere-
presses only under conditions of phosphate starva-
tion. This differential activation by BAS2 is very
interesting, since the BAS2 protein is homologous
to homeobox proteins of Drosophila and is most
homologous to the engrailed protein. DNase I foot-
print analysis shows that the engrailed protein binds
to the HIS4 promoter with an affinity equal to or
greater than the presently defined engrailed binding
sites in Drosophila. In addition, the engrailed protein
and BAS2 protect identical nucleotides of the HIS4
promoter from DNase I digestion. We have expressed
engrailed in yeast under control of the GAL] pro-
moter and are determining whether engrailed can
substitute for BAS2 for activation of HIS4 transcrip-
tion and if this activation requires BAS1. These ex-
periments are directly relevant for Drosophila de-
velopment, since results in Pat O'Farrell's laboratory
show that engrailed by itself binds to the promoter
of a reporter gene but does not activate transcrip-
tion of this reporter gene in Drosophila cell culture.
Thus, engrailed (like BAS2) may require a pro-
tein similar to BAS1 in order to activate transcrip-
tion. Such a protein is already known to exist in
Drosophila.
We have sequenced the BAS] gene and found that
it is homologous to the myb oncogene that was
originally isolated from a chicken virus and later
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shown to have cellular homologs in chickens, mice,
humans, and Drosophila. The expression of the
Drosophila myb gene is very high in the embryo but
very low in the adult, suggesting that the Myb protein
has a role in embryogenesis. We have overproduced
the BAS1 protein and various derivatives in bacteria
using both APL and T7 promoters (BAS1-binding
activity is undetectable in extracts prepared from
wild-type yeast). We have found that (1) the amino-
terminal domain of BAS1, which contains the myb
repeat motif, binds specifically to the HIS4 promot-
er; (2) BAS1 protects a region of 26 bases on the HIS4
promoter that overlaps with the BAS2-binding site;
(3) even though BAS1- and BAS2-binding sites over-
lap by eight to ten bases, they can bind simultane-
ously to the promoter; (4) the BAS1 protein and the
engrailed protein can also bind simultaneously; and
(5) BAS1 and BAS2 do not bind cooperatively to the
HIS4 promoter. Thus, the adjacent binding of BAS1
and BAS2 is required to activate HIS4 basal tran-
scription. Overproduction in yeast of either protein
in the absence of the other only weakly activates
HIS4 transcription. We are currently investigating
if the BAS1/BAS2 system is homologous to a Myb/
engrailed system. That BAS1 cannot activate HIS4
transcription without BAS2 suggests why the v-myb
oncogene myeloid and erythroid hema-
topoietic cells in culture but cannot transform fi-
broblasts or other cell lines. Perhaps only a few adult
tissues contain the BAS2-like protein necessary for
myb to cooperatively activate transcription. Present-
ly, we are investigating the details of the BAS1/BAS2
transcriptional activation system.
Another protein present in yeast nuclear extracts,
YNF1, binds to a single site in the HIS4 promoter.
When YNF1 binds to this site, it displaces both
GCN4 (from its highest-affinity binding site) and
BAS2 from their binding sites. In the absence of
BAS1, BAS2, and GCN4, YNF1 does not activate
HIS4 transcription. Since YNF1 displaces two acti-
vators of transcription (competition determined by
in vitro DNase I footprinting), our working model
is that YNF1 functions as a repressor of HIS4
transcription. We have screened 500,000 plaques
from a yeast ?.gtl1 expression library using a labeled
DNA fragment containing four tandem YNF1-
binding sites. However, although positive controls
have worked, the YNF1 gene has not been found
among the Xgtll plaques. We are switching to a
genetic approach for the isolation of the YNF1 gene.
The type of regulation imposed on HIS4 transcrip-
tion by YNF1 will then be determined.
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General Transcription
Factors in Yeast
A. Sutton
When the levels of HIS4 transcription are quan-
titated by assaying the levels of 13-galactosidase from
a HIS4-lacZ fusion, a wild-type strain gives about
400 units of activity, whereas a strain containing
deletions of the GCN4, BAS], and BAS2 genes gives
less than a unit of activity. As a result, a strain deleted
for the three activators of HIS4 transcription is His-.
We have reverted this strain to His with the
assumption that mutations in genes encoding general
transcriptional factors could result in increased HIS4
transcription. This reversion analysis has identified
four suppressor genes that permit HIS4 transcrip-
tion in the absence of GCN4, BAS1, and BAS2. We
have termed these suppressors sit genes for suppres-
sors of initiation of transcription. These suppressor
genes encode factors that affect the transcription of
many diverse genes.
Two of the suppressors, SIT1 and SIT2, are
encoded by RPB1 and RPB2, the genes for the two
largest subunits of RNA polymerase II. All strains
containing suppressor mutations in RPB1 and RPB2
have reduced transcription of the INO1 gene and an
inositol requirement.
Mutations in SIT3 or high-copy-number SIT3
increase HIS4 transcription in the absence of GCN4,
BAS1, and BAS2. SIT3 is the only suppressor that
suppresses when the wild-type gene is present in high
copy number. The increase in HIS4 transcription by
high-copy-number SIT3 or by sit3 alleles is largely
independent of the HIS4 TATA sequence. Another
effect of high-copy-number SIT3 is suppression of
the lack of a TATA sequence. In a wild-type cell, both
GAL4 protein and GCN4 protein require a TATA
sequence to activate transcription. However, high-
copy-number SIT3 is able to increase transcription
by GAL4 or GCN4 from promoters containing no
TATA sequence. We sequenced the SIT3 gene and
found that it is identical to GCR1, a gene previously
identified as being required for high-level transcrip-
tion of almost all glycolytic enzymes (whose com-
bined mRNAs constitute over 50% of the mRNA
in a yeast cell). Presently, we are not sure exactly how
SIT3 functions. SIT3 is a protein that if altered (sit3
mutants) or if overexpressed (high-copy-number
SIT3) can recognize transcriptional activation
proteins at almost any promoter to stimulate TATA-
independent transcription. We are presently using
two approaches to examine if SIT3 is one of a set
of similar general transcription factors that recognize
bound transcriptional activation proteins and in turn
interact with RNA polymerase II. The first approach
is to find other genes that, when mutated, are lethal
in combination with a deletion of the SIT3 gene. A
strain with a deletion of the SIT3 gene is extremely
sick but viable. The second approach we are taking
is to find other genes in high copy number that can
stimulate transcription from defective GCN4 deriva-
tives that bind DNA normally but have very weak
acidic activation domains. We will subsequently use
direct biochemical analysis to determine if SIT3 and
any other factor interact with the acidic domain of
the activation proteins and the acidic heptapeptide
repeat at the carboxyl terminus of RPB1.
The SIT4 protein is over 5007o identical to the
catalytic subunit of bovine type-2A protein phospha-
tase. In the haploid, sit3 in any pairwise combina-
tion with sitl, sit2, or sit4 is viable, consistent with
the view that SIT3 encodes a factor that functions
as an accessory role to the RNA polymerase II
holoenzyme. In contrast, all pairwise combinations
between sitl, sit2, and sit4 are inviable. The inviabil-
ity of sit 1 sit2 double mutants is easily understood
as an interaction between altered versions of the
largest subunits of RNA polymerase II that leads to
a more severe phenotype than either of the single
mutants. One interpretation of the gene interactions
between sit4 and the sit/ and sit2 RNA polymerase
II mutations is that SIT4 encodes a factor that
interacts with RNA polymerase II. We are currently
testing this model by Western and immunoprecipi-
tation analyses to determine the phosphorylation
state of RPB1 in strains containing wild-type SIT4,
sit4 mutations, and overexpression of SIT4.
The SIT4 Protein Phosphatase
Is Required for Progression
through G,
A. Sutton
Regulation of the cell cycle, most importantly the
decision of whether or not to initiate a new cycle,
is a major determinant of cell proliferation. For the
yeast Saccharomyces, cells that are nutritionally
starved (such as by limiting an essential nutrient in
the growth medium) or cells in a saturated culture
arrest in GI . Cells that have arrested at this point
in G, are in a physiological state distinct from GI
cells in actively growing cultures. In general, cells ini-
tiate a new cycle only when they will be able to
complete the entire cycle.
Much of what is known about regulation of the
cell cycle comes from strains containing conditional
mutations that arrest in GI at the nonpermissive
temperature. Strains containing cdc19, cdc25, or
cdc35 (adenylate cyclase) arrest in G, at what seems
to be close to the nutritional arrest point (unbudded
uninucleate GI cells with no spindle pole satellites).
Conditional mutations in the CDC28 gene, which
encodes a protein kinase, cause arrest in G, as
unbudded uninucleate GI cells with spindle pole
satellites. These cells continue some growth and
become misshapen "shmoos." This G, arrest point
in cdc28 mutants has been operationally defined as
START. Supposedly, if a normal cell passes this
point, it is committed to completion of the cycle. The
execution point or the time of action of the CDC28
kinase is probably at some point before START.
Throughout the cell cycle, the amounts of the CDC28
protein are constant, but its kinase activity occurs
almost exclusively during G, (and possibly only
during early GI) when CDC28 is associated with
p40 in a higher-molecular-weight complex. Within
this higher-molecular-weight complex, p40 itself is
phosphorylated, presumably by the CDC28 kinase.
Fission yeast and human cells also contain a kinase
(cdc2) that is similar to CDC28, but in these
organisms, this kinase is also required for the
G2/mitosis transition. In this additional role, the
Cdc2 protein homolog functions in a complex that
was previously identified as MPF (maturation-
promoting factor) and histone H1 kinase. The
existence of a cdc2 homolog in human cells implies
that certain aspects of cell-cycle control are the same
in yeasts and vertebrate organisms. If so, vertebrate
cells are likely to have a GI decision/commitment
point for entry into the cell cycle analogous to the
yeast START (and a second control acting at the
G2/mitosis transition).
Most cell-cycle control models include kinases
(such as the Cdc2 and CDC28 kinases) that add
phosphate groups to their substrate proteins. What
is not usually included in these discussions is the
involvement of protein phosphatases, which remove
phosphate groups from proteins. The only known
way to remove phosphates from a protein, other than
protein degradation, is via protein phosphatases. The
involvement of protein phosphorylation/dephos-
phorylation in controlling a protein's activity has
been recognized for many years.
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As stated above, we originally identified the SIT4
gene as a suppressor of a HIS4 transcriptional defect.
All sit4 strains are temperature sensitive for growth.
We have found that at the nonpermissive tempera-
ture, sit4 strains (and mutations in sit4 created solely
with a temperature criterion) have a cell-cycle-arrest
phenotype and arrest as large nonbudded uninuclear
G, cells. These sit4-arrested cells have a diameter
about 1.5 times as large as the diameter of cdc25 or
cdc35 cells at the nonpermissive temperature. In
addition, sit4-arrested cells contain a single organiz-
ing center for microtubules on the surface of their
larger than normal single nucleus. Since the spindle
pole body is the organizing center for the microtu-
bules, this result probably indicates that spindle pole
migration has not occurred. We currently do not
know whether or not the spindle pole body has
duplicated.
Since sit4 cells arrest in GI, we have investigated
genetic interactions between sit4 alleles and cdc25
or cdc28 alleles. In crosses of sit4 with cdc25, the
expected number (25%) of double mutant progeny
were obtained and the haploid double mutants had
normal mitotic growth. However, in crosses of sit4
alleles with cdc28, the expected number of double
mutant progeny were not obtained. Haploid strains
containing a chromosomal sit4 allele, a chromosomal
cdc28 allele, and the wild-type SIT4 gene on a URA3
centromere plasmid have normal mitotic growth.
However, this strain cannot grow at all on growth
medium that selects against the plasmid URA3 gene.
Thus, the sit4 cdc28 double mutation is mitotically
lethal.
We are currently investigating the role of SIT4 in
G, progression by both genetic and biochemical
approaches. We have taken two genetic approaches.
The first approach is to obtain high-copy-number
suppressors of the slow growth of sit4 strains. Using
this approach, we have obtained five different genes.
One of these genes, which gives weak suppression
is another protein phosphatase (which we cal;
PPH2). We have sequenced about half of the PpH2
gene and found that it is about 90% identical to type_
2A protein phosphatases. We are now investigating
if PPH2 is essential and if it is a cell-cycle gene. The
second genetic approach, which is in progress, is to
obtain second-site suppressors of the temperature-
sensitive arrest defect of the pphl-102 allele. This
PPHI allele was isolated solely for near-normal
growth at permissive temperatures but a temperature-
sensitive growth defect at 38 °C. At the nonpermis-
sive temperature, this strain arrests in GI identically
as sit4 strains. Hopefully, some of the suppressors
of the temperature-sensitive arrest phenotype of
pphl-102 strains will be substrates of the phosphatase.
We are also using immunological and biochemi-
cal analyses to understand the function of PPM
(= SIT4). We have prepared antibodies to the amino
terminus of PPHI and have also tagged PPH1 with
an epitope that is recognized by a monoclonal
antibody. These will serve as tools for immunofluo-
rescence (to determine the localization of PPH1) and
immunoprecipitation analyses. In particular, we are
looking for interactions of PPHI with the CDC28
kinase and possibly BCY1 (regulatory subunit of
cAMP-dependent protein kinases). Hopefully, our
combined genetic and biochemical approach will
elucidate the role of the PPHI phosphatase in GI
progression.
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YEAST GENETICS
A.J.S. Klar J. Wood
The Developmental Fate of Fission
Yeast Cells Is Determined by the
Patterns of Inheritance of Parental
and Grandparental DNA Strands
A.J.S. Klar
Discovering the mechanism by which sister cells gain
different developmental fates is central to an under-
standing of eukaryotic cell differentiation. This issue
can be addressed in molecular terms by investigat-
ing the pattern of cell fate determination in the
fission yeast Schizosaccharomyces pombe. Mitoti-
cally dividing cells of this ascomycetes fungus exist
as one of the two alternate cell types, called P (for
Plus) and M (for Minus). However, the P and M
mating types are unstable and the cell types inter-
change spontaneously nearly every other generation.
When the phenotype of individual cells is monitored,
a remarkable pattern of cell-type switching is ob-
served. Miyata and Miyata (J. Gen. Appl. Microbiol.
27: 365 [1981]) found that among a pair of sister cells,
one will divide to produce one changed cell and one
unchanged cell in about 72-9407o of cell divisions,
whereas the other sister always produces an un-
changed pair of cells. In other words, according to
this so-called "one-in-four rule," only one grandchild
acquires the switched mating type among the four
grandchildren of a cell obtained after two genera-
tions.
The P and M cell types are controlled, respectively,
by the alternate mail -P and matl-M alleles of the
mating-type locus (mail). Mating-type interchange
involves a gene conversion event in which a copy of
unexpressed mating-type information residing at the
mat2-P or the mat3-M "donor" locus is transposed
to matl, resulting in a switch of cell type. Previous
studies have argued that the recombination event
required for matl switching is initiated by a site-
specific double-stranded DNA break (DSB) found
in the matl gene. By assuming that the cut DNA at
the receptor site is a necessary precondition for
switching by gene conversion, it then follows that
the one-in-four switching rule must be a consequence
of the observed level of in vivo DSB.
The switching of one in four related cells must be
the result of unequal distribution of developmental
potential to daughter cells in each of two consecu-
tive apparently asymmetrical cell divisions. A strand
segregation model was proposed (Klar, Nature
326: 466 [1987]) to explain the developmental
asymmetry in which a hypothetical site- and strand-
specific "imprinting" of the specific matl DNA
strand (say "Watson strand") is assumed to occur in
the cell. That cell could generate developmentally
specific unequivalent daughter cells, since one
daughter inherits the imprinted Watson strand while
the other daughter inherits the unimprintable Crick
strand.
The strand segregation model makes two specific
predictions: one molecular and the other genetic. In
an earlier observation (Klar, Nature 326: 466 [1987]),
it was found by DNA analysis that strains construct-
ed to contain the matl inverted duplication exhibit
the DSB in vivo in one cassette or in the other, but
never simultaneously in both cassettes in a given
chromosome. In addition, compared to wild-type
strains, twice as many chromosomes contain the
DSB, thus satisfying the molecular prediction.
Another key genetic prediction of the strand segrega-
tion model is that two-in-four related cells should
switch in strains containing an inverted tandem
duplication of matl. This is predicted because, in a
given cell, both strands can be imprinted: one strand
in one cassette and the other strand in the second
cassette. Their segregation will generate two develop-
mentally equivalent sister chromatids, and their
inheritance should produce equivalent sister cells.
Each of the equivalent sister cells may generate one
switched and one unswitched progeny. The essence
of the second critical prediction is that two "cousin"
cells should switch.
A particularly satisfying result obtained by em-
ploying a single-cell assay testing the pattern of
switching is that two (cousins)-in-four related cells
indeed switch in strains containing an inverted
tandem duplication of matl. Thus, both parents of
those four cells have become developmentally
equivalent. I therefore conclude that the pattern of
switching in the fission yeast cell lineage is dictated
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by the pattern of inheritance of DNA strands and
not because of unequal distribution or expression
of factors in sister cells.
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STRUCTURE
This section includes four laboratories interested in the detailed structure
properties of proteins. The Structure Program is relatively new and was
organized when Jim Pflugrath and John Anderson joined Cold Spring Harbor
Laboratory to set up a new X-ray crystallography laboratory. The other two
groups that are associated with this program are those of Mark Zoller, whose
laboratory is interested in the structure-function relationships of protein kinases,
and Rich Roberts, whose laboratory has had a long-standing interest in
restriction enzymes and their associated methylases.
Advances in recombinant DNA technology now allow the ready cloning and
overexpression of proteins of interest. This, combined with new methods for
purification, offers the possibility that many proteins important for our work can
be obtained in quantities sufficient to permit their crystallization. The time is right
to capitalize both on the new technology and on the possibilities for analysis and
understanding that can be afforded by X-ray crystallography. Over the next few
years, we anticipate growing interactions between the members of the Structure
Program and all other members of Cold Spring Harbor Laboratory.
NUCLEIC ACID CHEMISTRY
R.J. Roberts L. Hamablet J. Meyertons
C. Marcincuk S. Miceli
J. Mart ling G. Otto
J. Posfai
D. Roberts
M. Wallace
Cytosine Methylase Domains
J. Meyertons
My research has focused on identifying the protein
domains of Hhal (recognition sequence: 5'
GmeCGC 3') and Hpall (recognition sequence: 5'
CmeCGG 3') methylases that are responsible for
sequence-specific recognition of DNA. The initial
step involved constructing a pBR322-based plasmid
able to express both methylase genes. The plasmid
was constructed with the two methylase genes in
tandem and arranged in the same orientation relative
to transcription. In one construct, the Hhal
methylase was upstream of the Hpall methylase; in
the second construct, the Hpall methylase was
upstream of the Hhal methylase. Unique restriction
sites between the methylases can be used to linearize
the plasmid and allow nuclease BAL-31 digestion.
After nuclease BAL-31 digestion, the deleted
plasmids can be religated and transformed into
Escherichia coli. Among the products of these
manipulations, there should be hybrid methylases
that have the amino-terminal region of the Hhal
methylase fused to the carboxy-terminal region of
the Hpall methylase, and vice versa. In this way, I
hope to swap the recognition domains of the two
proteins and then to characterize that domain both
genetically and biochemically.
Because the hybrid proteins may be less efficient
as methylases than their parents, I am setting up an
assay system able to detect very low level expression
of cytosine methylases. This assay depends on the
Mcr system of E. coli. This is a sequence-specific,
modification-dependent restriction system that
cleaves DNA at 5-methylcytosine residues. Transfor-
mation of a methylase plasmid into an E. coli strain
with an active Mcr system prevents the survival of
the methylase because the methylated DNA is
cleaved. To detect the hybrid methylases, I am
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constructing strains with temperature-sensitive mu-
tations in the Mcr genes. Two main Mcr systems are
known, A and B. The A system is known to restrict
DNA methylated by the HpaII methylase, whereas
both systems restrict DNA methylated by the Hhal
methylase. Appropriate Mcr A+ and Mcr B+ strains
were mutagenzied to produce temperature-sensitive
or cold-sensitive mutations in the Mcr genes. The
presence of the Mcr mutations was confirmed by
cross-streaking with T-even phages and with bac-
teriophage methylated by Hhal or HpaII and com-
plementation tests.
To aid in the identification of an active hybrid
methylase further, an SOS-inducible promoter fused
to the lacZ gene has been transduced into each of
the Mcr temperature-sensitive strains. In these
strains, 13-galactosidase is made in response to any
DNA damage, such as cleavage of methylated DNA.
The intensity of the blue color can be used as an
indicator of the levels of methylase activity. A light-
blue colony could represent weak methylation
activity that was not strong enough to cause lethality
at the nonpermissive temperature. The temperature-
sensitive alleles in the Mcr genes along with the
colony color indicator in the strain will provide two
complementary methods to look for methylase
activity. The Mcr temperature-sensitive genes will be
further characterized because these temperature-
sensitive strains will have future value in studying
other methylases including eukaryotes, such as
mammals and plants.
Structure and Function of
Integration Host Factor, a
Site-specific DNA-binding
Protein in Escherichia coli
D. Roberts
Integration host factor (IHF) is a site-specific DNA-
binding protein that has been shown to play a role
both in the regulation of gene expression and in site-
specific recombination (for recent review, see
Friedman, Cell 55: 545 [1988]). IHF was first
identified as an E. coil factor necessary for bacterio-
phage ), integration in vitro. IHF binds specifically
to DNA, recognizing a 13-nucleotide nonpalin-
dromic consensus sequence. IHF binding causes the
DNA to bend at the site of binding.
In vivo, a variety of cellular processes are affected
192
(p80, and Mu
in IHF mutants. In addition to decreased 2, integra_
tion, there is decreased growth, packaging,
lysogmenuiztaantitosnaoref ubnacatbeireiotpohsaugpcpso2rIt
replication
ofIHF
21,
the plasmid pSCI01, and they exhibit decreased
excision or transposition of transposable elements.
Finally, expression of several genes is altered,
including the i/v operon, IHF itself, Xel I, Mu early
genes, Tn/O transposase, and the tra genes of the F
plasmid.
The primary goal of this work is to analyze the
structure and function of IHF. To do this, I Plan to
generate an extensive set of IHF mutants. These
mutants will be used to identify the essential
structural domains for DNA binding, DNA bending,
DNA site recognition, and dimer formation. Of
particular interest would be mutants that can bind
to DNA but fail to bend it; these mutants should
help define the role of DNA bending in the recombi-
nation reactions in which IHF is involved. Also of
interest would be mutants with altered sequence
specificity; these should define the regions of the
protein that recognize and interact with DNA. This
structural and functional analysis of IHF should
provide new information about how a protein can
recognize a specific DNA sequence, as IHF is likely
to be structurally different from other known se-
quence-specific DNA-binding proteins.
Measures of Sequence Similarity
G. Otto
In a general sense, taxonomy is the classification of
comparable objects into related sets. Although tax-
onomic analysis is prominent at the organismic level,
it is conspicuously underdeveloped in molecular bi-
ology. The rising flood of sequence data only empha-
sizes the need for general methods of analysis that
group similar sequences into sets that share and are
predictive of given functions. Beyond these predictive
goals are questions about the origins of DNA and
protein diversity, such as whether existing sequences
are descendents of a small set of progenitor domains.
Taxonomic analysis of sequences differs from that
of organisms in two important respects: (1) The sim-
plicity of sequences allows for measures of similar-
ity that are more rigorous than those available for
complex morphological traits and (2) the results of
sequence analysis make testable predictions. The goal
of my research is to write a set of programs that
systematically analyzes a given database of sequences
and returns the taxonomic structure of the database
as its output.
The measure of similarity is the critical issue for
developing a taxonomy of sequences. Past work has
not emphasized probability theory, yet this approach
provides a natural and convenient measure of
similarity. A probability value can be calculated for
every alignment of two sequences; the optimal
alignment is the one whose P value is smaller than
all the others. Similarity is then defined as this
smallest P value and represents the probability that
the optimal alignment of two sequences is due to
chance. Probabilistic measures can be derived for any
criteria of sequence matching. The matching of
identical residues is the simplest of these matching
criteria. In this case, the calculation of P values
reduces to a simple iteration of the binomial formula.
Measures for other matching criteria, such as those
that allow conservative substitutions, will require
more sophisticated techniques. However, this sim-
plest measure of similarity illustrates the main points
of the analysis.
Every pairwise comparison is characterized by the
P value of its optimal alignment; these values vary
between 0 and 1. The closer a P value is to zero, the
greater the confidence that two sequences are similar.
The distribution of P values expected from the
comparison of unrelated sequences will be important
to this discussion. If a sequence is randomly gen-
erated and compared with a set of unrelated
sequences, the resulting P values are expected to be
uniformly distributed over the unit interval (0-1). The
methods for calculating these probabilistic measures
of similarity are tested by comparing large sets of
unrelated sequences and asking whether the resulting
distributions of P values are uniform. Given a proper
measure of similarity, deviations from uniformity
provide a basis for doing groupwise comparisons.
The first step is to partition the database into sets
of sequences sharing common functions, such as the
binding of ATP or NAD or proteolytic activity. The
test sequence is then compared with the sequences
of each functional set. If the test sequence is
unrelated, then we expect to observe a uniform
distribution of P values within that set. However,
a distribution significantly skewed toward zero
suggests that the test sequence is similar to the set
even though it may not be especially similar to any
member of the set. The subset of similar sequences
is then examined to see if they share a common region
of alignment that might correspond with the ligand-
binding site. Although the majority of sequences in
the database may not be obviously similar to any
other sequence, there is reason to suspect that
relationships will exist between proteins sharing a
function. For example, most ATP-binding proteins
are not obviously homologous, yet one third of the
known sequences share a definite pattern. Moreover,
this pattern corresponds to a portion of the ATP-
binding site. Conservation of ligand-contacting
residues is consistently observed when diverging
series of homologous proteins of known structure
are compared. In contrast, noncontact residues show
very little conservation. Consequently, similarities
between isofunctional proteins are expected to
involve only the relatively small number of residues
that are essential for function. One goal of a
systematic analysis is to detect weak similarities that
are nevertheless shared by a class of proteins and that
may be predictive of function.
Nothing prevents the comparison of a set of
sequences with itself or with another set. Given a
database partitioned into isofunctional sets, a natural
move is to do all pairwise comparisons within these
sets. After frankly homologous sequences are
identified, the test of similarity is, again, whether
the distribution of P values for each comparison is
uniform. If a similar subset is identified, a multiple
alignment of the sequences is examined for a
common region of similarity that may correspond
to the ligand-binding site. A consensus pattern of
residues that are especially conserved is then sought
within this region. Sequences remaining in the
original set are searched for matches to this pattern
as a test of distant relationships. The final result is
a pattern that is predictive of a particular function.
Analyzing the database in this way will produce a
dictionary of predictive patterns.
The method described above does not require the
presence of gross homologies; these would actually
hinder the definition of sequence patterns corre-
sponding to ligand-contacting residues. However, the
limits of sensitivity have not been exhausted. So far,
the focus has been on the optimal alignments from
each comparison, yet these are just the best of the
ranked lists of alignments. These lesser alignments
can also be examined in rank order for consensus
patterns. Measures of significance must be developed
for this process, since proceeding far enough in these
ranked lists would make even random sets appear
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to have a common pattern. However, this procedure
approximates explicit simultaneous searches of mul-
tiple sequences, which is a notoriously intractable
problem. Structural data can also be used to increase
the sensitivity of these methods. There are additional
ways to increase the sensitivity of comparative meth-
ods for protein sequences in particular. These include
probabilistic measures that allow for conservative
substitutions and measures that favor patterns of
matching that reflect the natural periodicities of
secondary structure.
After isofunctional sets have been compared with
themselves, the next step is to compare each set with
all the others. Again, if a set is unrelated to another,
then the P values from all of the pairwise compari-
sons should be uniformly distributed. The question
is whether similarities between isofunctional sets
would reflect similarities between the ligands bound.
Similarities between the structures of nucleotide-
binding proteins at both the primary and tertiary
levels argue for such relationships. It is then rea-
sonable to ask whether some portion of the evolu-
tionary history of intermediary metabolism can be
deduced from existing sequences. There is a comple-
mentary method that should be carried out in
parallel to the comparison of functionally defined
groups. This approach ignores all additional biologi-
cal knowledge and compares every sequence with all
other sequences in the database. Based only on
sequence, this program would attempt to find all
clusters of mutually similar sequences. The groups
defined by this independent method can then be
compared with those defined by the previous
approach. There should be substantial agreement
between them. The aim of both these approaches
is to reduce the apparent diversity of sequences into
a taxonomic structure that is both explanatory and
predictive.
Algorithms and Computer Programs
for the Identification of Functional
and Structural Motifs in Protein
Sequences
J. Posfai
Common patterns (motifs) in the sequences of
functionally related proteins are expected to char-
acterize common functional and/or structural do-
mains of those proteins. If these motifs can be iden-
tified, they might be used to localize functional
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domains in sequences and also to predict possible
functions for newly identified proteins. Recently, I
have developed different algorithms and computer
programs for the semi-automatic generation of such
motifs. Beginning with a set of sequences of func-
tionally related proteins, a global alignment of these
sequences is performed. Consensus-type patterns are
generated from the conserved regions of the
alignment. Patterns that discriminate all the proteins
with the common function from all other proteins
in the PIR database are used as motifs, characteris-
tic of the common function. The main principles
behind the algorithms are described below. The use
of the programs based on these algorithms is
demonstrated by an analysis of the sequences of
bacterial methylase enzymes.
GLOBAL SEQUENCE SIMILARITY
A set of related sequences with low-level global
similarity is identified using an approach based on
graph theory. Sequences are represented as vertices
(dots) of a graph, and high (higher than a preset
limit) similarity scores from pairwise comparisons
of two sequences are represented by edges (lines)
connecting the corresponding vertices in the graph.
Highly (higher than a second preset limit) connected
subgraphs establish subsets of proteins with global
sequence similarity. A very low similarity score
threshold can be applied if the connectivity threshold
is set high. In this way, a set of 13 5C cytosine
methylase sequences shows global sequence similar-
ity, since each member of the set has a relatively high
score with respect to all other members of the set.
In contrast, endonuclease sequences belonging to the
same type of restriction-modification system, or
having the same DNA recognition specificity, show
no sequence similarity.
GLOBAL ALIGNMENT
Unlike other multiple alignment programs, which
optimize some abstract similarity score function, our
alignment procedure is based on finding common
patterns within the sequences being compared. The
program scans the sequences to be aligned for
identical patterns of three amino acids in a span of
9-11 residues. Segments found to be similar by this
criterion are aligned and used as anchor points, or
boundaries, for the subsequent alignments. Then,
the segments within these boundaries are searched
for identical patterns of relaxed specificity (two
amino acids and one or two nucleotides, two amino
acids, one amino acid and two nucleotides, etc.).
These patterns can then provide further anchor
points for the alignment.
This method has identified and aligned ten
conserved blocks in the 13 5C cytosine methylase
sequences (Fig. 1). Five of these blocks are highly
conserved, since each block contains at least three
invariant positions. The five other conserved blocks
show greater variability. Most likely, the conserved
blocks play a role in those enzymatic functions that
are common to all methylases such as interaction
with S-adenosylmethionine. The highly variable
region between conserved blocks VIII and IX is
believed to be responsible for specific DNA recog-
nition.
MOTIF DEFINITION AND SEARCH
Similarity in the conserved blocks is described by a
consensus-type pattern of specific and nonspecific
positions. A position in the conserved block is
regarded as specific if the variance at that position
is limited either to invariant positions or to positions
where no more than four different amino acid
residues occur. At nonspecific positions, any amino
acid can occur, whereas at specific positions, only
residues that are present in at least one of the
sequences of the alignment are allowed. A program
Phi3T
Rhol 1 s
SPR
Hhal
Noel!
Haelll
EcoRII
Dcm
Mspl
Ddel
Sinl
BsuRI
BspRI
FIGURE 1
based on a Depth-First-Search algorithm is used to
locate those sequences that contain any of the search
patterns. If these patterns do not occur in other
sequences, they are regarded as predictive motifs,
characteristic of the common function of the related
sequences from which they were built.
It has been possible to build characteristic patterns
from each of the five highly conserved blocks of the
5C cytosine methylases. The predictive power of the
motifs was verified by locating them in the sequences
of three newly determined 5C cytosine methylases.
Interestingly, with slightly decreased specificity
searches, the bacterial motifs can be discovered in
the sequence of the murine methylase that is
responsible for methylation of the CG dinucleotide.
Unidentified open reading frames (ORFs) in two
GenBank entries were also found to contain strong
matches to the motifs typical of the carboxy-terminal
regions of methylases. Unfortunately, the amino-
terminal sequences of these ORFs had not been
determined. The motifs were also useful in pinpoint-
ing sequencing errors in these two GenBank se-
quences, since reading frame changes were required
to accommodate all the detected motifs in the ORFs.
These sequencing errors had been noted by the
authors in a recent publication.
We are planning to automate these procedures and
use them in the construction of a database of
predictive functional motifs of protein sequences.
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Schematic diagram of the alignment of 13 methyltransferase sequences.
Each line represents one sequence. Gaps were
introduced in the alignment where the lines are interrupted. Boxes indicate where the ten
blocks of conserved residues occur. ()
Five highly conserved blocks; (0) five less-conserved blocks. The variable region that is probablythe sequence recognition domain
lies between blocks VIII and IX.
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Restriction Endonucleases
L. Hamablet, J. Mart ling, J. Meyertons,
S. Miceli, R.J. Roberts
The collection of restriction endonucleases continues
to grow, and more than 1100 enzymes have now been
characterized; 147 different specificities are known.
During the last year, 39 new enzymes have been
isolated and characterized as part of a collaborative
program with I. Schildkraut and D. Comb (New
England Bio-Labs). Among these are six valuable
new specificities. Having just received support under
the Human Genome Initiative, our screening pro-
gram is being expanded, and we are focusing our
efforts to identify more restriction enzymes like Notl
and Sfil that recognize octanucleotide sequences.
Such enzymes are especially valuable for generating
large fragments of DNA that are necessary for the
initial physical mapping of large genomes. Recently,
we have discovered an enzyme, Fsel, from a Frankia
species that cleaves most of our test DNAs relatively
infrequently and has the properties to be expected
of an octanucleotide-recognizing enzyme. Further
characterization is currently under way.
The restriction enzyme database has undergone
a major transition during the last year as we have
switched database management systems from
INFORMIX to the relational system ORACLE. This
has involved a great deal of new codes and extensive
checking to ensure that the transfer maintained the
integrity of the data, much of which has been
collected over a span of 16 years. Now that this
transition is complete, the job of data management
and distribution will be considerably easier. Our
immediate goals are to automate as much as possible
the generation of reports from the database and the
dissemination of restriction enzyme information to
interested individuals. In particular, the data required
by computer programs to search DNA sequences for
restriction enzyme recognition sites are now available
in electronic form. Within a few hours of entry into
the database, information about a new enzyme can
be sent to any individual with access to a co mputer
network.
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MACROMOLECULAR CRYSTALLOGRAPHY
J.E. Anderson A. Caleca L. Gloss M. Ulman
J.W. Pflugrath E. Chang D. Greif J. Walter
J. Kuret C.K. Cheung M. Macias K. Zachmann
J. Fu D. Sterner
The objective of the Macromolecular Crystallogra-
phy Group is to determine the structures of a number
of biologically important proteins to atomic reso-
lution in order to better understand their functions
in cell processes such as signal transduction, growth
control, and development. Our studies are designed
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to benefit from and to complement the genetic and
biochemical experiments performed in our own
laboratory and by our collaborators. Together with
these data, crystallographic models of protein
kinases, proto-oncogene products, and trans-acting
factors will help us to comprehend the roles of these
macromolecules in cell growth and differentiation,
in cell transformation, and, ultimately, in diseases
such as cancer and AIDS.
Our crystallographic experiments require well-
formed crystals of the macromolecule being investi-
gated. To grow crystals of a useful size (>0.3 mm
on a side), we must have available several milligrams
of the highly purified macromolecule. Although this
does not guarantee that crystals can be produced,
it is the minimal prerequisite before attempting to
crystallize the molecule. To this end, a major part
of our laboratory and time is devoted to expressing
and purifying to crystallographic homogeneity the
proteins we are studying.
Overexpression of Nuclear
Proto-oncogene Proteins
in Bacteria
E. Chang, A. Caleca, L. Gloss, D. Greif, J. Walter
[in collaboration with T Curran, Roche Institute of
Molecular Biology, Nutley, New Jersey, and
W.-K. Chan, Cold Spring Harbor Laboratory]
A major goal of our group is to determine the
structures of the protein products of the nuclear
proto-oncogenes c-fos, c-jun, and c-myc. All of these
proteins are present at very low levels in the
eukaryotic cells where they naturally occur. To obtain
the large amount of material required for crystalli-
zation, we overexpressed the proteins in Escherichia
coli using the bacteriophage T7 expression system.
In addition to providing enough of the proteins,
bacterial expression eliminates the heterogeneity
resulting from posttranslational modifications, such
as phosphorylation, that the proteins are subject to
in eukaryotic cells.
We obtained rat cDNA encoding c-fos, c-jun, and
the Fos-related antigen fral from T. Curran. SDS-
PAGE of lysates of cells containing the c-jun or fral
expression plasmids and induced with isopropyl-132
D-thiogalactopyranoside (IPTG) shows Coomas-
sie-stained bands that are the size expected for intact
Jun or Fral protein, respectively. In Western blotting
experiments, these proteins react with antibodies
made against a Jun peptide (obtained from P. Vogt,
University of Southern California) and with anti-
serum raised against a bacterial trpE-v-fos fusion
protein (obtained from K. Riabowol, Cold Spring
Harbor Laboratory), respectively. Fractionation of
the sonicated whole-cell lysate by low-speed centrifu-
gation indicates that the Fral protein occurs exclu-
sively in the soluble fraction. The Jun protein, how-
ever, is produced as insoluble aggregates called in-
clusion bodies, which often occurs when eukaryotic
proteins are overexpressed in bacteria. Purification
of inclusion body proteins usually involves solubili-
zation of the insoluble aggregate with denaturants
such as urea or guanidine hydrochloride. Since we
prefer to avoid these rather harsh treatments, we
looked for ways to increase the amount of soluble
Jun protein. We found that reducing the growth tem-
perature from 37°C to 30°C increased the proportion
of Jun found in the soluble fraction. Furthermore,
we found that it is the post-induction temperature
and not the pre-induction temperature that matters;
this allows us to avoid reduced yields due to lower
cell density at lower pre-induction growth tempera-
ture. When cells are grown at 37°C and then shifted
to 30°C upon addition of IPTG, about half of the
total Jun protein is soluble, with a negligible decrease
in total (soluble + insoluble) yield.
We have not yet successfully overexpressed intact
Fos protein. In Western blotting experiments using
induced whole-cell lysates of cells carrying the c-fos
expression plasmid, a band of the appropriate
molecular weight reacts with Fos antiserum, but no
corresponding band is visible on Coomassie-stained
gels. A number of additional lower-molecular-weight
bands also react with the antiserum, suggesting that
intact Fos is degraded by endogenous proteases. We
are currently investigating whether expression in
protease-deficient strains of E. coli will increase the
level of intact Fos.
We obtained the human c-myc-coding sequence
from the plasmid pOTS-myc (from W.-K. Chan),
which encodes a full-length Myc polypeptide with
four additional amino acids on its amino terminus.
We used this DNA to construct the T7 expression
vector pEC-mycl.2. Cells carrying pEC-mycl.2 make
a protein that reacts with anti-Myc monoclonal
antibody B3 in Western blots and has the appropri-
ate apparent molecular weight for intact Myc protein.
This protein is present in approximately equal
amounts in both the soluble and the insoluble
fractions of whole-cell lysates. Amino-terminal
amino acid sequencing of the protein after purifica-
tion from cultures carrying pEC-mycl.2 indicates
that its amino-terminal sequence is the same as that
of the "authentic" c-Myc protein, without the four
additional amino acids encoded by the original
construct pOTS-myc. We are currently devising
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protocols to purify Jun, Fral, and Myc to homo-
geneity. When we obtain the homogeneous protein,
crystallization trials will begin.
Bacterial HIV-1 Tat Protein
C.K. Cheung, J.E. Anderson [in collaboration
with C. Rosen, Roche Institute of Molecular Biology,
Nutley, New Jersey]
Human immunodeficiency virus type 1 (HIV-1)
causes AIDS. HIV-1 usually lies dormant for a
variable period of time after infection and then, for
reasons that are not entirely clear, begins to multiply
and kill T4 lymphocytes, leading to full-blown AIDS.
The HIV-1 Tat protein is required for the virus to
grow. Therefore, understanding the structure and
function of Tat could lead to the development of
drugs that inhibit it and thus delay or prevent the
onset of AIDS.
HisTat is the bacterially expressed first exon of tat
(66 of 86 residues) from HIV-1 strain HXB2, with
15 residues (MRGSHHHHHHGSVDE) added onto
the amino terminus. This "histidine leader" facilitates
purification Ni" ions when a crude
lysate of cells expressing HisTat is passed over a
nickel-affinity column. Most of the other proteins
pass through the column, and when HisTat is eluted
with decreased pH, it is about 90% pure. We
obtained HisTat from C. Rosen, after passage over
the nickel-affinity column. The histidine leader is
removed by treating HisTat with Staphylococcus
aureus V8 protease at pH 4.0. Under these condi-
tions, V8 protease cleaves only after glutamic acid
(E) and does so efficiently only if the following
amino acid is not proline. Fortuitously, the two
glutamic acid residues that occur in the Tat-specific
part of HisTat are both followed by proline, and so
the major site of cleavage is between the last residue
of the leader and the first residue of Tatl -66. Using
V8 digestion, we can generate a good yield of Tatl-
66 and are currently devising ways to purify Tat1-66
to homogeneity. Tat has a cysteine-rich region in
which 7 out of 16 residues are cysteine, and these
residues tend to oxidize readily to intermolecular
disulfide bonds, producing a collection of Tat oligo-
mers and complicating the purification and handling
of the protein. Once we have purified a single oligo-
meric species, we will attempt to crystallize it and
determine its three-dimensional structure.
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Restriction-Modification Enzymes
J. Fu, A. Caleca, J.E. Anderson [in collaboration
with I. Schildkraut, New England Bio-Labs, and
R.M. Blumenthal, Medical College of Ohio]
Restriction endonucleases and modification meth-
ylases recognize specific DNA sequences and then
cleave or methylate the DNA, respectively. Meth
ylation by a particular methylase protects the site
from cleavage by the corresponding endonuclease.
Our goal is to solve the structures of some of these
enzymes both as free proteins and in complexeswith
oligonucleotides carrying their recognition sites.
These structures will help us to understand how spe-
cific DNA sequences are recognized by these pro-
teins, and they will also help us to understand their
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HindIII endonuclease (from I. Schildkraut) from
a
solution of 2.3 M ammonium sulfate and 20 um
glycine (pH 9.60) at 21°C. The crystals are unusually
fragile and difficult to mount for diffraction analysis.
They do not diffract beyond 5 A. We are looking for
conditions that will improve their order, e.g., the
addition of metal ions to help strengthen intermo-
lecular contacts in the crystal.
Small crystals (0.05 x 0.02 x 0.01 mm) of PaeR7
endonuclease (from I. Schildkraut) appear in a
solution of 1.3 M phosphate (pH 6.40) at 21°C. We
are searching for conditions that will produce crystals
large enough for diffraction analysis.
We have purified Pvull methylase (from R.M.
Blumenthal) to greater than 90% homogeneity. The
purification involves cation-exchange/affinity chro-
matography on phosphocellulose, followed by hy-
drophobic interaction chromatography on a TSK
phenyl -5PW FPLC column and cation-exchange
chromatography on a Pharmacia Mono S FPLC
column. Once we obtain homogeneous methylase,
we will begin crystallization experiments.
Cell Cycle of Fission Yeast
J. W. Pflugrath, M. Macias, D. Sterner [in collaboration
with D. Beach, Cold Spring Harbor Laboratory]
The gene product of cdc2+ plays an important role
in cell-cycle regulation of the fission yeast Schizosac-
charomyces pombe. Beach and co-workers (Genetics
Section) have demonstrated that another gene
product, pl3suc', forms a stable complex with the
cdc2+ protein kinase. Although p13su1' is necessary
for cell-cycle progression, the exact character of its
interaction with the kinase is unknown. It is not a
substrate of the kinase. To probe and understand this
interaction at the molecular level, we have purified
with new procedures the yeast pl3suc' from an
engineered strain of Escherichia coli (kindly provided
by G. Draetta, L. Brizuela, and D. Beach) and ini-
tiated crystallization trials.
Area Detector Software
J. W. Pflugrath, M. Ulman [in collaboration with the EEC
Cooperative Workshop on Position-sensitive Detectors]
In the area of computational crystallography, we
continue to develop and improve the device-indepen-
dent area detector software system MADNES. This
work is part of an international effort to create soft-
ware that can be used on any area detector hardware,
whether designed privately or commercially. This
software is now used by over a dozen laboratories
worldwide on several different kinds of area de-
tectors.
Our group coordinates the maintenance and
debugging of MADNES. To this end, we edit and
distribute a digest about the software to all users via
a computer network. Among improvements incorpo-
rated into MADNES in the last year are three-
dimensional profile analysis, better background
estimation, and easier offline processing.
Yeast cAMP-dependent Protein Kinase
J. Kuret
Protein kinases are key regulatory molecules that
modulate many cellular processes, including cell
growth, differentiation, and proliferation. Nearly 100
protein kinases have been identified thus far, each
of which is capable of integrating input signals and
coordinating physiological responses by phosphor-
ylating a specific range of substrate proteins. I am
interested in the structural basis of this "substrate
specificity" and wish to identify the amino acid
residues responsible for imparting selectivity to the
interaction of kinases and their substrates. To achieve
this goal, I have initiated a structural study of the
cAMP-dependent protein kinase from Saccharomy-
ces cerevisiae. This enzyme exists as a heterotetramer
of two catalytic and two regulatory subunits (mo-
lecular mass = 195,000 daltons). In collaboration
with M. Zoller's laboratory, I have designed a yeast-
based expression system capable of accumulating the
cAMP-dependent protein kinase up to 4% of the
total soluble protein. The enzyme produced by this
system is fully active, soluble, and responsive to
cAMP. To simplify purification and crystallization
of the cAMP-dependent protein kinase, I truncated
both subunits to produce a fully active heterodimer
of 72,000 daltons. The kinase dimer is much smaller,
less flexible, and less heterogeneous than the native
cAMP-dependent protein kinase tetramer, yet retains
nearly identical catalytic properties. Purification of
the catalytic subunit has proved to be relatively
simple, and my attention is now turned toward ob-
taining highly purified dimer. Once sufficiently pure
kinase is obtained, I will crystallize the protein and
determine its three-dimensional structure in collabo-
ration with J. Pflugrath. In addition to elucidating
the structural basis of substrate recognition, the
three-dimensional structure of the kinase will help
us to identify amino acid residues involved in ca-
talysis and cAMP-mediated allosteric regulation.
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STRUCTURE-FUNCTION OF CAMP
-DEPENDENT PROTEIN KINASE
M.J. Zoller L.R. Levin
K.E. Johnson
J. Kuret
Protein kinases are a family of proteins that play an
important role in the regulation of cellular processes
such as signal transduction, progression through
the
cell cycle, and metabolism. These enzymes transfer
the terminal phosphate from ATP onto serine,
threonine, or tyrosine residues of substrate proteins.
Phosphorylation/dePhosphorylation of proteins is
clearly a major cellular mechanism to alter and
reversibly control protein function, activity, associa-
tion, localization, and stability. The important
biological questions regarding protein kinases are the
identification of the signals that regulate their
activities and the identification and localization of
the substrate targets. The important structural
questions for this class of enzymes concern enzy-
matic mechanism, regulation of activity, and sub-
strate specificity.
Comparisons between the primary sequences of
all known eukaryotic protein kinases have shown that
they belong to a superfamily that can be broken
down functionally into a group of enzymes that
phosphorylate serine and threonine residues and
another group of enzymes that phosphorylate
tyrosine. Despite the large number of proteins kinases
with known primary structures, the functional role
for each of these conserved amino acids remains
largely unknown. Thus, a large effort is currently
aimed at determining the three-dimensional structure
for a protein kinase. A detailed structure will begin
to address the structural questions outlined above.
The best-understood protein kinase in terms of
structure and biochemistry is the cAMP-dependent
protein kinase (cAdPK). The protein has been
purified from a number of eukaryotic sources,
including bovine heart, porcine heart, skeletal
muscle, and yeast. Crystallographic studies on the
isolated subunits are now in progress and will define
more precisely the residues that comprise each
functional domain.
In the yeast Saccharomyces cerevisiae, three genes,
TPKI, TPK2, and TPK3, encode distinct catalytic
subunits of cAdPK, C1, C2, and C3, respectively.
The three proteins exhibit approximately 75% amino
acid identity with each other. Toda et al. (Cell S0: 277
[1987D demonstrated genetically that the three C
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subunits were functionally similar and that at least
one gene was necessary for viability. The cDNAs and
genes encoding mammalian C subunits from a
number of sources have also been isolated and
characterized. This has identified at least two distinct
but nearly identical mammalian C subunits termed
Ca and CO. The level of sequence conservation
between the yeast and mammalian C subunits is only
53%. With the isolation of cDNAs and genes for
the various subunits, the structure/function of
cAdPK can now be approached by isolation of
mutants through genetic screens and by use of the
techniques of molecular biology and systems for
expression of heterologous genes. The first section
(Levin and Zoller) involves identification of residues
important for R-C interaction. The second section
(Johnson and Zoller) demonstrates the use of yeast
as a heterologous expression system for studying the
mammalian cAdPK.
Association of Catalytic
and Regulatory
Subunits of cAdPK
L.R. Levin, M.J. Zoller
We have previously reported the isolation and
characterization of a mutation in the C subunit of
yeast cAdPK that disrupts the tight R-C interaction
required to maintain the inactive holoenzyme (Levin
et al., Science 240: 68 [1988]). In the yeast S. cere-
visiae, a single gene encoding the R subunit (BCYI)
and three genes encoding the C subunits (TPKJ,
TPK2, and TPK3) have been isolated. The C subunit
mutation responsible for the unregulated phenotype
is a single nucleotide change in TPK1, resulting in
the substitution of an alanine for the threonine at
position 241 in C1. The mutant, CI(Ala-241), has a
decreased affinity for the R subunit without an ap-
preciable loss in affinity for its substrates. These data
suggest that Thr-241 participates in the interaction
with the R subunit.
The three yeast C subunits are homologous to the
mammalian C subunits, with each exhibiting
approximately 5007o amino acid sequence identity
with bovine Ca. There are two known sites of
phosphorylation in the mammalian C subunit: Ser-
338 and Thr-197. The phosphoserine residue is in the
carboxyl terminus of the mammalian C subunit and
is not conserved in any of the yeast isozymes. The
phosphothreonine residue exists in a region that
displays 72 Wo amino acid identity and is analogous
to Thr-241 of yeast CI. The yeast and mammalian
C subunits are conserved functionally as well as
structurally. The mouse Ca can replace the yeast C
subunits in vivo and support growth of yeast cells
(see below). The mouse C subunit is capable of
forming a complex with the yeast R subunit, indicat-
ing that the specific contacts responsible for the R-C
interaction are conserved between the two species.
The phosphorylation of the mammalian analog of
Thr-241 and the similarity in the interaction between
the subunits in these two species suggest to us that
Thr-241 is phosphorylated in yeast C1. To confirm
that this residue is phosphorylated in yeast, we
compared the phosphorylation states of wild-type
C, and the mutant CI(Ala-241). Two-dimensional
gel electrophoresis of 32P-labeled C, reveals multiple
isoforms, confirming that there are numerous
modifications to the protein. CI(Ala-241) also
contains multiple isoforms, but it is missing one of
the prominent 32P-labeled forms of CI, consistent
with it having one less-phosphorylated species.
Phosphoamino acid analysis of immunoprecipi-
tated, 32P-labeled C, and C,(Ala-241) revealed a
consistent decrease in the amount of phosphothreo-
nine in the mutant protein. Both mutant and wild-type
proteins contain phosphothreonine and phospho-
serine but no detectable phosphotyrosine. Densi-
tometry revealed that wild-type CI contains approx-
imately three times more phosphothreonine than the
mutant CI(Ala-241). Since the only difference be-
tween C, and CI(Ala-241) is the substitution of Thr-
241 by alanine, we conclude that the loss of phospho-
threonine is the direct result of that substitution.
We suspected that the phenotype of CI(Ala-241)
could be due to the loss of the negatively charged
phosphothreonine. Using site-directed mutagenesis,
we attempted to mimic the acidic moiety by substitut-
ing either aspartate or glutamate for Thr-241. Glycine
was substituted at this site to investigate the effect
of replacement by another small, uncharged amino
acid. All three substitutions were made with the use
of a single, degenerate oligonucleotide and con-
firmed by nucleotide sequencing.
To determine the in-vivo-regulated state of each
of the C subunits, they were expressed in yeast in
the absence of any wild-type C subunit. When nu-
trient-limited, wild-type yeast cells become resistant
to heat shock. Starved cells stop proliferating and
enter a cell-cycle state termed Go, which enables
them to survive a period of time at elevated tempera-
tures. Yeast cells containing an activated cAdPK,
through mutations that either increase the cellular
level of cAMP or decrease the level of functional R
subunit, do not enter Go and are sensitive to heat
shock. We have previously shown that the Thr-241
to alanine substitution results in increased catalytic
activity in the absence of cAMP regulation. We tested
the heat-shock phenotype of cells that express wild-
type C, or mutant CI(Ala-241) as their only C
subunits. As expected, nutrient-limited yeast cells
expressing C,(Ala-241) are very sensitive to heat
shock. They lose viability after just 10 minutes at
the elevated temperature, whereas cells expressing
wild-type C, are able to withstand 40 minutes at
55°C. We then tested the heat-shock sensitivity of
the strains expressing the other mutant C subunits.
The strain containing CI(Gly-241) was approxi-
mately as sensitive to heat shock as the strain express-
ing C,(Ala-241). In contrast, cells expressing either
CI(Asp-241) or CI(Glu-241) are resistant to heat
shock. Both strains retain viability when left at 55°C
for up to 40 minutes. These two altered C subunits
could be reverting the heat-shock sensitivity by
decreasing their catalytic activity or by increasing
their affinity for the R subunit. To understand the
biochemical effect of each substitution, we purified
each of the mutant C subunits and characterized
their in vitro affinity for the R subunit and their
catalytic activity.
Each of the substituted C subunits was purified
from overexpressing strains of yeast. The in vitro
kinase activity of each of the purified C subunits
was measured using the peptide substrate, Kemptide.
Each altered C subunit was preincubated with
increasing amounts of the wild-type R subunit to
determine the amount required to inhibit catalytic
activity. The concentration of R that reduces the
activity by 50137o is termed the IC50. The IC50 of
CI(Ala-241) is 27 times greater than the IC50 of
wild-type CI. The IC50 of CI(Asp-241) is increased
7-fold over wild type, and the IC50 of CI(Glu-241)
is increased 14-fold over wild type. CI(Gly-241) was
not characterized in vitro. It was not able to be
purified by anti-R subunit immunoaffinity chroma-
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tography because the holoenzyme was unstable.
There is a correlation between decreased
affinity for
the R subunit and increased heat-shock sensitivity.
The kinetic constants were
determined for each
C subunit. The Km for ATP is approximately
twofold higher than that for wild type in
all of the
altered C, subunits, whereas the Km for Kemptide
is between three- and fourfold higher than that for
wild type in the mutants. The predominant effect
of each of the C, subunit mutations is the change
in affinity for the R subunit and not their catalytic
activity.
The substitution of alanine for threonine in
C,(Ala-241) causes a 27-fold reduction in R subunit
affinity in vitro and the disruption of cAMP
regulation in vivo. We believe that the affected
residue, Thr-241, is normally phosphorylated and
that it is the acidic threonine-phosphate which is
responsible for the tight interaction between the
subunits. Figure 1 depicts our model for the
inhibition and activation ofcAdPK. The negatively
charged group in C would be opposed by a positively
charged group in R. The positively charged element
could exist anywhere within the minimally required
region of the R subunit as defined by deletion studies
(M.J. Zoller and K.E. Johnson). This positively
charged element would be absent from substrates,
but could exist in the heat-stable protein kinase
WILD TYPE
C R
THR 241 --ALA
THR 241
inhibitor (PKI). Binding of the effector, cAMP
'would stabilize an altered conformation of R, Which
displaces this positively charged element and Would
cause R to behave like a substrate. R dissociates from
C, leaving C active to phosphorylate other substrates
When Thr-241 is replaced with 1-1alanine, there is ,:
innegatively charged side chain n C to contact the
positively charged element in R, resulting in unreg.
ulated C subunit. Replacing Thr-241 with aspartate
supplies a negatively charged side chain that would
mimic the threonine-phosphate and contact the
positively charged element in R. This holoenzyme
would be stable and require cAMP for C subunit
activation.
Mammalian Catalytic Subunit
Functionally Replaces Its
Yeast Homolog
K.E. Johnson, M.J. Zoller [in collaboration with W. Yonemoto
and S. Taylor, University of California, San Diego]
The expression of eukaryotic protein kinases in
E. coli has proven to be difficult and unpredictable.
Although the abl protein kinase was successfully
expressed in E. coli, our experiments on expression
of yeast C subunits in E. coli produced large amounts
ALA
FIGURE 1 Model for the inhibition and activation of cAMP-dependent protein kinase.
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of predominantly insoluble and inactive protein. The
mouse Ca cDNA expressed in E. coli is partially
soluble, and the enzyme in the soluble fraction is
active (W. Yonemoto and S. Taylor, unpubl.). How-
ever, certain mutant forms have proven to be unstable
and/or insoluble. In addition, the E. coli system
cannot be used to study the role of posttranslational
modifications specific to eukaryotic systems. Ca and
Cr3 were also overexpressed in NIH-3T3 cells pro-
ducing only a tenfold increase in C subunit protein.
This approach is not an ideal system for studying
mutant proteins, since wild-type C subunits are
expressed from the chromosomal copies in the ge-
netic background. Several cell lines with altered
subunits of cAdPK have been identified, but a strain
completely devoid of the C subunit has not been
adequately characterized for protein structure studies.
Yeast provides an ideal experimental system for
the study of protein structure and function. By
manipulation of chromosomal sequences, mutant
proteins can be expressed in yeast and studied in the
absence of wild-type proteins. Mutant proteins with
desired properties can be obtained using genetic
screens. In addition, a number of posttranslational
modifications are conserved between yeast and
mammalian cells. Recently, we purified one of the
three C subunits of yeast and demonstrated
that in vitro, it was functionally similar to the
mammalian catalytic subunit (Zoller et al., J. Biol.
Chem. 263: 9142 [1988]). We also developed a yeast
expression system to produce mutant C subunits in
the absence of the wild-type C subunit (Zoller et al.
[1989] in prep.). We have extended this yeast expres-
sion system to provide a means to study the structure
and function of the mammalian C subunit. In the
present study, we demonstrate that the mammalian
C subunit can functionally replace its yeast homolog
and that sufficient amounts of protein can be ob-
tained for enzymatic and structural analyses of
mutants we intend to make in the future.
In experiments conducted previously, we demon-
strated that the kinetic properties of the two enzymes
were similar with respect to kcal and affinity for
ATP but were different with respect to affinity for
the peptide substrate Kemptide. The yeast enzyme
exhibited about a 10-fold higher Km for this peptide
substrate. In addition, the yeast C subunit exhibited
a 100-fold lower affinity for a derivative of the heat-
stable PKI. These data suggested that the two en-
zymes exhibit subtle differences in protein substrate
specificities.
Since yeast require at least one functional TPK
gene for viable growth, our strategy was to examine
whether yeast cells containing the mammalian C
subunit as the sole source of cAdPK were viable. The
Ca cDNA was cloned into two different yeast
expression vectors: one that expresses Ca using the
promoter and terminator from the yeast C subunit
gene, TPKI, and the other that expresses Ca from
the ADO promoter, a strong, constitutive promoter
from the gene encoding yeast alcohol dehydrogenase
I. These vectors are multicopy episomal plasmids
that are maintained by prototrophic selection for
leucine. The plasmids were constructed to express
the natural Ca protein.
Substitution of the yeast TPKI gene with the Ca
cDNA was accomplished using a plasmid swap
procedure. The starting strain, LL8, contains
chromosomal disruptions of all three yeast C subunit
(TPK) genes. The strain is kept alive by maintenance
of a plasmid that contains the wild-type TPKI gene.
This vector is distinguished by the presence of the
ADE8 gene, which confers adenine prototrophy. LL8
was transformed with the Ca expression vectors,
LEU-F,ADE± transformants were selected, and the
cells were then grown without selection to induce loss
of one or the other plasmid. The plasmid present
in a particular colony can be identified by its
prototrophic markers. Since at least one C subunit
gene is required for viability, viable cells must
maintain at least one of the two plasmids. Thus, we
predicted that following nonselective growth,
ade-,LEU+ cells would express on the mammalian
Ca. Viable cells were obtained that contained the
expression vector using the natural TPKI promoter.
In contrast, no transformants were obtained using
the ADH expression vector. We suspected that
expression using the ADO promoter resulted in a
level of C subunit that was lethal. This was observed
with the yeast C subunit using a similar high-level
expression vector (unpublished).
Chromatographic analysis of extracts from yeast
cells demonstrated that the mammalian C and yeast
R subunits associate in vivo to form a tetrameric
(R2C2) holoenzyme. We then purified mammalian
C from an overexpression strain using the strong
constitutive ADH promoter. Overexpression was
achieved by coexpression of the ADH-Ca with over-
expression of the yeast R subunit, BCY1. Purifica-
tion was accomplished using the two-step immuno-
affinity chromatography procedure that we developed
for purification of the yeast C subunit. The major
protein observed on an SDS-polyacrylamide gel was
Ca, which was about 8507o pure by Coomassie stain-
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ing. The mammalian protein purified
from yeast
comigrated with the Ca produced in E. coll. Recently,
we obtained polyclonal antibodies
raised against
mouse Ca expressed in E. coil (W. Yonemoto, un-
publ.). The Ca isolated from yeast reacts with the
anti-Ca antibodies and not with anti-yeast C anti-
bodies. Biochemical and structural characteristics
of
yeast-expressed Ca showed that the properties of the
yeast-produced C subunit are similar to the published
properties of the bovine heart C subunit. The most
notable difference between the two enzymes is their
affinity for the heat-stable PKI.
Studies on the bovine heart C subunit showed that
it contained an amino-terminal myristoyl moiety that
was linked to the protein through the glycine that
immediately followed the initiator methionine. The
enzyme that catalyzes this modification is present
in yeast as well. Since we produced the amino acid
sequence of the natural mammalian protein, we
predicted that the mammalian C subunit expressed
in yeast would contain this modification if the ini-
tiator methionine was removed posttranslationally.
To test this, exponentially growing cells were labeled
with [31-1]myristic acid, the cells were lysed, and the
Ca was then immunoprecipitated from soluble cell
extracts and subjected to SDS-PAGE. The labeled
proteins were visualized by autoradiography. A 31-1-
labeled protein with a relative molecular weight of
43,000 was selectively immunoprecipitated using the
anti-Ca sera but not using preimmune sera. This
radioactive protein comigrated with the purified Ca
protein marker.
In summary, we have described an ideal system
in which to study the structure and function of the
cAdPK. We can now begin to make mutants using
yeast genetics or site-directed mutagenesis. Our
biocherapproach exploits the techniques of protein
istry, molecular and cellular biology, and yeast ge-
netics. Information from studying mutant proteins
will be integrated into the model derived from the
crystal structure that is soon to emerge. Conversely
,
hypotheses concerning the structure or enz ymatic
mechanism of the protein that stem from the three-
dimensional structure can be tested by expression
of
mutants in this system. Finally, the expression of the
mammalian cAdPK in yeast provides a genetic sys-
tem to study interactions with mammalian substrates
such as the CRE transcription factor.
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NEUROSCIENCE
The efforts in neuroscience research have focused on the mechanism of
neurotrophic factors of the central nervous system. We have been particularly
interested in proteins that cause the initiation of neurite outgrowth from the
embryonic cell of the cerebral cortex. This brain region is the seat of higher brain
functions, such as learning and memory, and is the target of debilitating diseases,
such as Alzheimer's and epilepsy. Our goals are to identify the role of these neural
growth factors in the development of the brain and their potential involvement in
degenerative processes. In pursuing these objectives, we adopt a molecular
approach, employing biochemistry, cell biology, and molecular genetics.
GROWTH AND DIFFERENTIATION OF NEURAL CELLS
D. Marshak J. Figueiredo M. Schmiedeskamp
S. Pesce R. Tonner
Purification and Characterization
of Neurotrophic Factors
J. Figueiredo, B. Tanner, S. Pesce, D. Marshak
The differentiation of neurons of the central nervous
system includes the extension of neuritic processes,
or neurites, from the cell body of a postmitotic
neuroblast. These neurites become the axons and
dendrites of the mature neuron, receiving and send-
ing signals within a neuronal circuit. We have been
purifying proteins from bovine brain extracts that
cause neurite outgrowth in model systems of neu-
ronal differentiation. We have used primary cultures
of neurons from 7-day-old chicken embryo cerebral
cortex, maintained in a serum-free defined medium.
At this stage, the cultures are nearly all neurons, with
little glial cell contamination. The neurons are post-
mitotic, and in culture, they attach to poly-L-lysine-
coated plates and are flat and phase dark. Upon
stimulation with a neurotrophic substance, the cells
become rounded and bright, and they send out
neurites within 24 hours.
We have fractionated bovine brain extracts to
purify substances that cause neurite extension in this
assay. One neurotrophic substance is a disulfide form
of a calcium and zinc ion-binding protein, known
as S10013. This protein is 10.5 kD and forms dimers
of 21 kD. Under certain conditions, particularly in
acid, the protein can polymerize to higher-molecular-
weight forms. The dimer form appears to be the
active species in neurite extension. Reduction and
alkylation of the cysteine residues result in loss of
activity. When protein is purified under nonreduc-
ing conditions, there is a significant yield of dimer,
as shown on the polyacrylamide gel in Figure 1. This
disulfide dimer is predominantly a parallel form,
diagramed schematically in Figure 2. Our working
model is that the dimer represents a small population
of the molecules that are secreted during develop-
ment and, possibly, at later times in the adult nervous
system.
Further fractionation of a heat-stable protein
fraction from bovine brain yielded another factor
that causes neurite outgrowth at high specific
activity. Preliminary characterization of this factor
indicates that it has an apparent molecular weight
on gel filtration of 97,000 and binds to heparin-
Sepharose conjugates. The assay system utilized does
not respond to any of the known, soluble neuro-
trophic proteins, such as nerve growth factor (NGF)
and acidic or basic fibroblast growth factors (aFGF,
bFGF). Thus, the molecules identified in the chick
embryo cortical cell assay are unique among neuro-
trophic factors.
To confirm the observations in this system, we have
used the mouse neuroblastoma cell line, neuro-2a,
as a model system for neurite outgrowth. These cells
205
FIGURE 1 Polyacrylamide gel electrophoresis of S10013 isolated
from bovine brain in the absence of reducing agents, showing
the presence of the disulfide dimer. Molecular-weight standards
are shown in the right hand lane.
proliferate in culture when grown in media supple-
mented with serum. However, at low density in
serum-free media, they differentiate by sending out
neurites in 6-8 hours. Although the mechanism of
neurite outgrowth in these cells may be different from
that of primary cells, they remain a useful and rapid
assay system for neurotrophic factors.
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FIGURE 2 A schematic diagram of the disulfide dimer (parallel
form) of S10013 from brain.
Role of S1000 In Vivo
D. Marshak, S. Pesce, M. Schmiedeskamp
During the past year, the role of the S1000 protein
in vivo has become an important issue, because the
gene for this neurotrophic factor has been localized
to human chromosome 21 in band 21q22.3 by ge-
netics groups in other laboratories. This is signifi-
cant because this region of chromosome 21 is in-
volved in Down's syndrome. Our demonstration of
a neurotrophic activity for the protein, combined
10 100 1000
picograms S100/3
10000 100000
FIGURE 3 Radioimmunoassay of S10013. The vertical axis shows the percentage of radioiodinated
S10013 bound in the absence of competing antigen. The horizontal axis shows the amount, in
picograms, of unlabeled S10013 added to the reactions. Each point is an average of duplicate assays
with standard errors shown by the bars.
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with the abnormal neurological development seen
in Down's patients, has led us to investigate the action
of sloop in vivo. We raised antibodies in rabbits
against native and denatured S10013. These antisera
were titered, and the most reactive antiserum can
detect the antigen at 1:1000 dilution. Using a
competitive inhibition radioimmunoassay, we can
detect picogram amounts of S10013, as shown in
Figure 3.
In the developing chick embryo, there appears to
be a small amount (<20 pg/mg) of S10013 at early
stages (embryonic day 5-7). Between days 7 and 18,
there is an increase in S100I3 of three- to fivefold,
as shown in Figure 4. This increase correlates with
the proliferation of astrocytes in the cortex. We are
currently extending these observations to examine
the developmental pattern in the mouse and in mouse
models of Down's syndrome. The availability of a
bioassay, a sensitive radioimmunoassay, and a cDNA
probe for quantitating mRNA levels allows us to
study the changes in S10013 at several levels.
Expression of S10013
in Mammalian Cells
D. Marshak, S. Pesce
The cDNA probe for S10013 has been characterized
in some detail. One clone was selected for further
study, and it contains a 1.5-kb insert in an Okayama-
Berg expression vector, pcD2. Restriction enzyme
mapping of the insert indicates a full-length coding
region, with extensive 5' and 3' noncoding regions.
We have transfected this plasmid into COS I cells,
a monkey cell line that contains large amounts of
T antigen from SV40. These cells express proteins
at high levels from plasmids containing the SV40
early promoter, as in pcD2. The transfected cells
express sloop that can be detected in immunopre-
cipitation experiments. Extracts of transfected cells
show neurotrophic activity in the chick embryo assay,
whereas mock-transfected and control cell extracts
show no activity.
Immunocytochemical localization of sloop in
transfected cells resembles that in the astrocytoma
cell line, C6, which expresses large amounts of the
protein. These experiments demonstrate that neu-
rotrophic activity resides in S1001. Further studies
are under way to express the protein in constructs
using different tissue-specific promoters. These
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FIGURE 4 Changes in S10013 in the developing chicken embryo
brain. The vertical axis shows the amount of immunoreactive
material in picograms per milligram wet weight of brain tissue.
The horizontal axis shows the number of days of embryonic
development. Hatching occurs on day 21, and neurotrophic
activity is tested on cells from day-7 embryos.
constructs also provide the basis for construction of
transgenic mice that express S100f3 in overabundance
in either neurons or glia. Such animals may provide
a new model for the study of developmental and
degenerative neurological diseases.
Structural Analysis of a
Glial Antigen
D. Marshak [in collaboration with C. Dulac
and N. LeDouarin, Nogent-sur-Marne, France]
During an exciting period of 3 months in the spring,
Dr. C. Dulac purified and characterized a glycopro-
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tein antigen from quail nerves. This protein appears
to be a very early developmental marker for glio-
blasts that are destined to become oligodendrocytes
in the central nervous system and Schwann cells of
the periphery, both myelin-producing cells. Using a
monoclonal antibody produced by Du lac and
colleagues at Nogent, we made an immunoaffinity
chromatography column and purified sufficient
quantities of protein for structural analysis. Amino-
terminal sequence analysis yielded information use-
ful for constructing oligonucleotide probes as well
as synthetic peptides for production of a site-directed
antibody. In addition, sites of N-linked and 0-linked
oligosaccharides were tentatively identified. This
project demonstrated the power of a multidisciplin-
ary approach to protein structural analysis, given the
modern tools of protein biochemistry and neurobi-
ology available in our laboratory.
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CSH LABORATORY JUNIOR FELLOWS
In 1986, Cold Spring Harbor Laboratory began a new program to encourage
independent research by outstanding young scientists who, during their graduate
studies, displayed exceptional promise of becoming leading scientists of the future.
The purpose of this program is to provide an opportunity for one fellow each year
to work independently at the Laboratory for a period of up to 3 years on projects
of their choice. Each fellow is provided with a salary, research support, and
technical assistance so that they can accomplish their goals free from other
distractions. The interaction among research groups at the Laboratory and the
program of courses and meetings on diverse topics in molecular biology contrib-
ute to a research environment that is ideal for innovative science by these fellows.
The first Cold Spring Harbor Fellow (1987) was Adrian Krainer, a former
graduate student with Tom Maniatis at Harvard University. The 1988 Fellow was
Carol Greider from Elizabeth Blackburn's laboratory at the University of California,
Berkeley. We have recently awarded the 1989 Fellowship to Eric Richards from
Fred Ausubel's laboratory at the Massachusetts General Hospital, who will join the
laboratory in the summer of 1989 to begin work on the molecular biology of
Arabidopsis.
A.R. Krainer
C. Greider
Biochemistry of Mammalian
Pre-mRNA Splicing
A.R. Krainer, D. Kozak, E. Chan
The aim of our research is to obtain a detailed
understanding of the mechanism of pre-mRNA
splicing in mammalian cells. In particular, we are
interested in determining how the RNA cleavage-
ligation reactions are catalyzed, and how the specific-
ity of splice-site selection is achieved. As part of this
effort, we are purifying several factors necessary for
cleavage of the pre-mRNA at the 5' splice site and
for lariat formation. Our general strategy is to
develop complementation assays for individual
activities, such that one or both cleavage-ligation
reactions are strictly dependent on the presence of
the active component in question. The factors
responsible for these activities are purified and then
characterized to determine their mode of action. The
identification and detailed characterization of
splicing factors should provide crucial insights into
the mechanism of pre-mRNA splicing, the specific-
ity of splice-site selection, and the origin and
evolution of the splicing machinery and of pre-
mRNA introns.
ISOLATION OF ACTIVE SMALL NUCLEAR
RIBONUCLEOPROTEINS
We have continued our efforts to isolate active small
nuclear ribonucleoproteins (snRNPs), which are the
only components of known identity that have been
clearly shown to be essential splicing factors. For this
purpose, we generated a monoclonal antibody that
recognizes the distinctive trimethylguanosine (TMG)
portion of the snRNA 5' caps. Because the snRNA
trimethylated cap is conserved in all eukaryotes, the
anti-TMG monoclonal antibody we generated has
also proven useful to other laboratories that are
studying snRNPs and snRNAs and other trimethyl
capped RNAs from a variety of species, including
vertebrates, insects, trypanosomes, nematodes, and
yeasts. To carry out immunoaffinity experiments
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under optimal conditions, we recently switched the
isotype of this monoclonal antibody from IgG1 to
IgG2a, by screening for spontaneous heavy-chain
switch variants, followed by sequential sublining.
The new monoclonal antibody retains its specificity
for TMG and can now be efficiently bound to
immobilized protein A. The resulting high-efficiency
immunoadsorbents are used for preparative purifica-
tion of all the snRNPs from He La cell nuclear
extracts in a single step (Fig. 1). The bound snRNPs
are eluted under gentle conditions by competition
with free nucleoside.
The purified snRNPs retain activity, as demon-
strated by their ability to complement a micrococcus-
nuclease-treated nuclear extract (Fig. 2). This assay
was employed because for unknown reasons, it was
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FIGURE 1 RNA composition of anti TMG column fractions. HeLa
snRNPs were purified as described in the text, and the RNAs
from 5 x 106 cell equivalents of each fraction were extracted
and analyzed by PAGE/urea and ethidium bromide staining. (1)
Crude splicing extract; (2) column flowthrough; (3) bound fraction
eluted by competition with an excess of free nucleoside. The
identities of the small RNAs are indicated at the left.
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not possible to deplete fully the extracts of snRNPs
by immunoaffinity chromatography (Fig. 1)./. Al-
though the nuclease treatment may give rise to
snRNP cores or free polypeptides with residual
activities, the successful complementation test dem-
onstrates that the purified snRNPs constitute struc-
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FIGURE 2 Protein composition of purified snRNPs. The
indicated fractions were analyzed by SDS-PAGE and Coomassie
blue R-250 staining according to the method of Giulian et al. (A)
or on a 12% gel according to the method of Laemmli (8). (A)
(Lane 1) Molecular-weight markers, 14.4K-97K; (2) 10 41 (2 x
106 cell equivalents) of splicing extract; (3) 50 RI (2.5 x 108 cell
equivalents) of concentrated snRNPs; (4) markers, 1.7K-17.2K.
(B) (Lane 1) Markers, 43K-200K; (2) 50 pl of snRNPs; (3) 10 41
of splicing extract; (4) markers, 14.4K-97K. The identities of the
known snRNP polypeptides are indicated at the right of each
panel.
tural units with complementable activity. SDS-PAGE
analysis of the active snRNPs demonstrates the pres-
ence of all known snRNP polypeptides, as well as
several minor ones (Fig. 3). Silver staining and two-
dimensional gel analysis revealed no additional con-
taminants. The relative abundances of the character-
istic polypeptides suggest heterogeneity in the protein
composition of individual snRNPs. Thus, the U1-
specific polypeptide C appears to be underrepre-
sented relative to the 70K and A polypeptides, which
are also U1- specific (Fig. 3A). Whether this apparent
heterogeneity reflects the in vivo stoichiometry, or
whether it reflects different stages of assembly, or
loss of polypeptide C upon isolation, remains to be
determined. Among the previously unidentified
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FIGURE 3 (A) Assay of snRNP splicing activity. Human P-globin pre-mRNA was incubated under splicing
conditions with 15 p,I nuclear extract (lane 1), 15 pl of micrococcus-nuclease-treated nuclear extract (NEMN)
(lane 2), 10 p.I NEMN + 1 pl purified snRNPs + 4 pl buffer (lane 3), and 10 pl NEMN + 5 pl purified
snRNPs (lane 4). The structures and electrophoretic mobilities of the precursor, intermediates, and products
of the reaction are shown at the right of the autoradiogram. (B) Micrococcal nuclease digestion of snRNAs
in the splicing extract. (Lane 1) 30 pi splicing extract; (lane 2) 30 RI NEMN.
polypeptides are four very large polypeptides that
are present in small quantities (Fig. 3B). These
polypeptides are also obtained by immunoprecipi-
tation of HeLa snRNPs with anti-Sm antibodies.
One of these could be the homolog of a U5-asso-
ciated 260K polypeptide in Saccharomyces cerevisiae
that is essential for splicing in vivo. Further fraction-
ation of the snRNPs should allow us to determine
whether these polypeptides are associated with an
individual snRNP and whether they play a role in
splicing.
We are fractionating the snRNPs into individual
particles, in order to assay the activities of each major
particle directly by complementation. This is es-
pecially important in the case of U5 snRNP, for
B
200
- 70K 11697 -
68 -
-A
1-\' BI 43
B,
-C
D
E
- F
-G
31 -
21.5 -
z
CC
C
CD
r0
M E z M
1 2 3 4
- 70 K
-A
- A:
-B
B,
-C
211
which a direct involvement in splicing has not been
demonstrated. Such fractionation studies may also
reveal the involvement in splicing of minor snRNPs.
So far, we have obtained highly enriched Ul snRNP
by Mono Q chromatography, although this snRNP
appears to be very heterogeneous in its polypeptide
composition. It may be possible to exploit this
heterogeneity to find out which Ul snRNP polypep-
tides are necessary for its activity.
STUDIES OF sNRNP FUNCTION
The functions of Ul and U2 snRNPs are understood
at present primarily in terms of specific base pairing
between the snRNAs and conserved complementary
sequences in the pre-mRNA. The roles of the snRNP
polypeptide subunits and of the remaining snRNAs
are not understood. One or more of the snRNP
polypeptides may have enzymatic activities that are
relevant to the overall splicing reaction. In addition,
one or more snRNAs may act as a ribozyme to cata-
lyze part of the splicing reaction. We are characteriz-
ing the purified particles to uncover such potential
activities.
Complementation studies have previously defined
four nuclease-resistant activities: Two are necessary
for the first cleavage-ligation reaction of splicing and
two are necessary for the second cleavage-ligation
reaction of splicing. Two of these activities, arbitrar-
ily named SF4A and SF4B, could be chromato-
graphically separated from snRNPs that retained
activity and all the known polypeptides, suggesting
that these activities are not intrinsic to the snRNPs.
In contrast, the activities termed SF2 and SF3 could
not be separated from the snRNPs by ion-exchange
or gel-filtration chromatography without loss of
activity. This raised the possibility that SF2 and SF3
represent known snRNP polypeptides or perhaps
factors that are loosely associated with one or more
snRNPs. To address this possibility, the purified
snRNPs were tested for SF2 and SF3 activities, but
neither activity could be detected. Splicing activity
could be obtained by providing the snRNPs in one
fraction and SF2 and SF3 activities in a separate
fraction. We conclude that SF2 and SF3 activities
are not encoded by known snRNP polypeptides. If
interactions among these factors are necessary for
splicing, they can occur during the reaction.
The RNA-binding properties of the purified
snRNPs were investigated by incubation with im-
mobilized polynucleotides. All of the snRNPs bind
efficiently to poly(G), but not to poly(A) or poly(c),
and only Ul snRNP binds to poly(U). The snRNPs
can also bind to pre-mRNA splicing substrates, and
we are now trying to determine whether purified
snRNPs have specific binding sites on pre -mRNA
in the absence of other components. There is reason
to believe that such binding will be modulated by
additional protein factors. Auxiliary activities that
enhance specific binding of Ul, U2, and U5 snRNPs
in crude extracts have been described. One of these
is an RNA-binding protein, termed IBP, which has
apparent specificity for intron sequences, and has
been reported to associate with U5 snRNP under
certain conditions. RNA-binding experiments with
the purified snRNPs indicate that IBP is not ef-
ficiently retained in the immunoaffinity-purified
particles. If this factor is necessary for splicing, it
may function independently or it may associate with
U5 snRNP during the course of the reaction. Ad-
ditional experiments are required to understand the
interactions between IBP and U5 snRNP and their
potential significance to splicing.
Since pre-mRNA splicing requires ATP, for rea-
sons that are still unclear, and since at least the U1-
specific 70K polypeptide is a phosphoprotein, we
assayed the purified snRNPs for ATPase and auto-
phosphorylation activities. Neither activity could be
detected in pure, active snRNPs in the absence of
additional factors, under splicing conditions. We
found that Ul snRNP can bind to immobilized ATP,
and we are investigating the specificity of this bind-
ing.
Treatment of the snRNPs with N-ethylmaleimide,
under conditions that inactivate the splicing extract,
did not inactivate the snRNPs as assayed by com-
plementation. This observation suggests that snRNP
polypeptides present in intact particles do not con-
tribute essential sulfhydryl groups to splicing. Anal-
ogous conclusions have been reached in the case of
ribosomal protein sulfhydryl groups. In contrast,
another RNP particle, the SRP, is inactivated by sulf-
hydryl modification of its polypeptide constituents.
STUDIES OF PROTEIN SPLICING FACTORS
We have continued our efforts to fractionate several
of the protein components that are necessary for the
two cleavage-ligation steps of splicing. SF2 is an
activity originally defined in a biochemical com-
plementation assay as one of a minimum of two
protein components necessary for 5' splice site
cleavage and lariat formation during pre-mRNA
splicing in vitro. The S100 fraction generated during
the preparation of splicing extracts is inactive in
splicing, even though it contains other components
necessary for splicing, such as U snRNPs, SF3,
SF4A, SF4B, and creatine phosphokinase. Whereas
other splicing factors leak out from the nucleus, SF2
is preferentially retained, suggesting that it may be
associated with large RNP complexes or with nuclear
structures in vivo. We have extensively purified SF2
from He La nuclear extracts, by complementing the
S100 fraction for splicing. The most purified, active
preparations contain four major polypeptides, which
have now been separated to allow determination of
their amino-terminal amino acid sequences. We are
currently attempting to purify active SF2 to homo-
geneity. The ongoing physical and biochemical
characterization of SF2 includes a comparison with
activities characterized in other laboratories, and
with major and minor snRNP and hnRNP polypep-
tides. In addition, purified SF2 is being analyzed to
determine its putative enzymatic activities, RNA-
binding properties, and specific interactions with pre-
mRNA and with purified, active snRNPs, as well as
to examine its role in the spliceosome assembly
pathway.
Identification and Cloning of
the Tetrahymena Telomerase
RNA Component
C. Greider, L. Sellati
Telomeres have been known to be essential for
chromosome stability since the work of Muller, B.
McClintock, and others in the 1930s. Chromosomes
broken in any of a number of ways undergo
rearrangement and fusion events that normal
chromosomes do not. In addition to providing stable
ends, telomeres must allow the complete replication
of linear chromosomes. Since all known DNA
polymerases function in the 5' to 3' direction and
require a primer, one would predict that lagging
strand synthesis would result in a region at the end
of each chromosome that has not been fully
replicated. After a number of rounds of replication,
chromosomes would be expected to shorten from
their ends. A number of models have been proposed
to account for how telomeres overcome this
incomplete replication problem. Molecular charac-
terization of the structure and dynamics of telomeres
in vivo led to the proposal that de novo addition of
telomeric sequences onto the ends of chromosomes
balances the loss of sequences from the ends.
Telomeres from all eukaryotes studied, including
those as distantly related as Tetrahymena yeast,
Arabidopsis, and humans, consist of tandem repeats
of simple C + G-rich sequences, where one strand is
very G-rich. In all cases examined, the G-rich strand
is oriented toward the end of the chromosome.
The Tetrahymena telomere terminal transferase, or
telomerase for short, recognizes the 3' end of telo-
meric G-strand sequences and adds tandem repeats
of the Tel telomeric sequence, TTGGGG,
in an apparently template-independent manner.
Thus, this enzyme may play a role in establishing
a length equilibrium at the ends of chromosomes.
The Tel telomerase exhibits two distinct
kinds of primer specificities. Telomere sequence oli-
gonucleotides corresponding to the telomeres from
five different organisms are all efficiently elongated
by telomerase in vitro. Nontelomeric oligonucleo-
tides and C-rich telomere-strand oligonucleotides are
not elongated. In all cases, the sequence added onto
the primers is the Tetrahymena telomeric TTGGGG
sequence. Since the oligonucleotides that are elon-
gated have different primary sequences, some other
feature such as the structure, or G-richness, of these
oligonucleotides must be specifically recognized by
telomerase. The oligonucleotide d(TTGGGG)4 forms
a novel intramolecular structure involving G-G Hoog-
steen base pairs (Henderson et al., Cell 51: 899 [1987]).
This unusual structure may be involved both in telo-
merase recognition and in telomere stability in vivo.
In addition to elongating telomeric primers specifi-
cally, telomerase specifically recognizes the sequence
at the 3' end of the primer oligonucleotides. When
the 3' end of the primer has the sequence ...TTGGGG,
then the sequence TTGGGG is first added; however,
when the primer ends in the sequence ...TTGGG, the
sequence that is first added is GTTGGGG. If
...GGGG'TT is the primer, GGGGTTGGGG is added.
In all cases, after the completion of the first TTGGGG
sequence, hundreds of tandem TTGGGG repeats are
added.
Biochemical characterization indicated that telo-
merase is a ribonucleoprotein (RNP) complex and
that a specific RNA is required for telomerase activity.
To identify the required RNA, telomerase extracts
were fractionated using several different chromato-
graphic steps, and the RNAs that copurified were
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identified. One small 159-base RNA reproducibly
copurified with telomerase over several different five-
column series. This RNA was gel-purified and se-
quenced using enzymatic RNA sequencing techniques.
Since coming to Cold Spring Harbor Laboratory,
I have focused on cloning the gene for this RNA and
on demonstrating that this RNA is essential for
telomerase activity. DNA oligonucleotides comple-
mentary to the sequence of the 159-base RNA were
synthesized. Southern blot analysis using these
oligonucleotides showed that there was a single gene
for the 159-base RNA in Tetrahymena. A 2-kb
HindIII fragment of macronuclear genomic DNA
was cloned, and the sequence of the entire RNA-
coding region, as well as some 5'- and 3'-flanking
sequences, was obtained. The most notable feature
of the RNA sequence was the presence of
CAACCCCAA within the coding region for the
RNA. This sequence could provide a template for
the TTGGGG repeats that are synthesized in vitro.
Oligonucleotides complementary to the 159-base
RNA were synthesized that span the entire length
of the RNA (Fig. 4). When telomerase was prein-
cubated with these antisense oligonucleotides be-
fore the addition of the d(TTGGGG)4 primer and
reaction buffer, oligonucleotide 3 and oligonucleo-
tide 8, which hybridized across and near the CAAC-
CCCAA sequence, both dramatically affected telo-
merase activity. Oligonucleotide 3 inhibited elon-
gation by telomerase, whereas oligonucleotide 8 was
itself efficiently elongated. Since oligonucleotide 8
was the only nontelomeric sequence oligonucleotide
out of 14 tested that was elongated in vitro, its utiliza-
tion as a primer may be due to the ability of oligonu-
cleotide 8 to hybridize just 3' of the CAACCCCAA
sequence in the 159-base RNA. This result, along
with the inhibition by oligonucleotide 3, suggested
that the CAACCCCAA sequence serves as a tern_
plate for the synthesis of TTGGGG repeats.
As a further test for the involvement of the 159_
base RNA in telomerase activity, complementary
oligonucleotides were preincubated with telomerase
in the presence or absence of RNase H, and the
elongation activity was measured. RNase H will
cleave the RNA of a DNA/RNA duplex. The corn_
petitive inhibition of oligonucleotide 3 was relieved
by pelleting telomerase in an ultracentrifuge after
preincubation with oligonucleotide 3. Preincubation
in the presence of both oligonucleotide 3 and RNase
H resulted in cleavage of the telomerase RNA with
the CAACCCCAA sequence and concomitant in-
activation of the telomerase activity. Preincubation
of telomerase with RNase H and most of the other
oligonucleotides shown in Figure 1 did not result in
cleavage of the 159-base RNA or inactivation of the
enzyme activity. The inactivation of telomerase by
RNase H and oligonucleotide 3 directly demon-
strated that the 159-base RNA is required for telo-
merase activity.
Preliminary results suggest that TTGGGG repeat
addition is processive. A model consistent with this
processivity and other telomerase characteristics is
presented in Figure 5. The natural ends of chromo-
somes have a single-strand overhang on the TTGGGG
strand. The model suggests that after specific primer
recognition (1) the sequence TTGGGG is hybridized
to the CAACCCCAA sequence in the RNA; (2) the
sequence TTG is then added one nucleotide at a time;
(3) translocation then repositions the 3' end of the
TTGGGG strand such that the 3'-most TTG nucleo-
Oligo 7
AUACCCGCUUAAUUCAUUCAGAUCUGUAAUAGAACUGUCAUU
Oligo 3 Oligo 8
CAACCCCAAAAAUCUAGUGCUGAUAUAACCUUCACCAAUUAG
Oligo 6
GUUCAAAUAAGUGGUAAUGCGGGACAAAAGACUAUCGACAUU
Oligo 10
UGAUACACUAUUUAUCAAUGGAUGUCUUAUUUUU
FIGURE 4 Sequence of the Tetrahymena telomerase RNA shown along with the DNA
oligonucleotides used in cloning and RNase H experiments. The region that may provide
a template for synthesis of TTGGGG is underlined.
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CCCCAACCCCAA
GGGGTTGGGGTTG
Elongation
CCCCAACCCCAA
GGGGTTGGGGTTG
Trans location
CC AACCCCAAC
GTTGGGG TTGGGG T TG
CCCCAACCCCAACCC
GGGGTTGGGGTTGGGGTTGG
Elongation
CCCCAACCCCAACCC
GGGGTTGGGGTTGGGGTTGG
FIGURE 5 Model for processive elongation of telomeres by telomerase. After specific primer recognition,
the sequence TTGGGG is hybridized to the CAACCCCAA sequence in the RNA. The sequence TTG is
then added one nucleotide at a time. Translocation then repositions the 3' end of the TTGGGG strand such
that the 3'-most TTG nucleotides are hybridized to the RNA component of telomerase. Now elongation
can occur again, copying the template sequence to complete the TTGGGGTTG sequence.
tides are hybridized to the RNA component of telo-
merase; and (4) elongation occurs again, copying the
template sequence to complete the TTGGGGTTG
sequence.
To test this model, we are currently looking for
conditions in which telomerase activity can be
reconstituted from isolated protein and synthetic
RNA transcripts. In addition, experiments are under
way to express the Tetrahymena telomerase RNA in
yeast cells to determine whether this RNA can
compete with a putative yeast telomerase RNA.
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COLD SPRING HARBOR
MEETINGS

53rd COLD SPRING HARBOR SYMPOSIUM
ON QUANTITATIVE BIOLOGY
The Molecular Biology of Signal Transduction
May 25-June 3
430 participants
For many decades, it has been clear that cells have a multitude of ways of
sensing their environment and converting a plethora of external signals into
measured intracellular responses. Already by 1965 Earl Sutherland had made the
distinction between the "first-messenger" role of hormone-like signals and the
"second-messenger" role of cyclic AMP, whose concentration was somehow
influenced by signals from first messengers. In Sutherland's scheme, the first
messenger binds to cellular receptors, with such binding events somehow
leading to control of the concentration of the second messenger. Now we realize
that many first messengers do not act directly through second messengers, but
instead work at the genetic level by binding to cytoplasmically located receptors,
which can then bind to DNA and turn on or off the functioning of specific genes.
Today, we refer to the way that external signals are passed through various
cellular components as signal transduction processes, with receptors and their
associated molecules known as biological transducers. Because most transducer
molecules are present in very limited amounts, their study at the biochemical
level until recently was at best difficult, and hypotheses as to how they functioned
were almost impossible to test rigorously.
P. Chambon, J.D. Watson
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Today, recombinant DNA techniques have dramatically changed
the picture.
Even very rare receptors are now open to analysis if their respective
genes can
be cloned, and virtually every month, the amino acid sequence of a new
key
biological transducer is established. The time was thus appropriate last June
to
hold a Cold Spring Harbor Symposium on the Molecular Biology of Signal
Tranduction.
The final program consisted of 119 speakers, who spoke before an audience
of 439, the largest ever yet to attend a Cold Spring Harbor Symposium. The
meeting opened with a series of five virtually electric presentations by Howard
Berg. Alfred Gilman, Mark Ptashne, Lubert Stryer, and Keith Yamamoto. A mode
of high excitement prevailed throughout the subsequent 14 long sessions, which
were concluded by a graciously thoughtful summary by Henry Bourne.
This meeting was supported in part by the National Cancer Institute, a division
of the National Institutes of Health; the U.S. Department of Energy; the Lucille P.
Markey Charitable Trust; and the National Science Foundation.
Welcoming Remarks: J.D. Watson
SESSION 1 OPENING REMARKS
Berg, N.C., Dept. of Cellular and Developmental Biology,
Harvard University and Rowland Institute of Science,
Cambridge, Massachusetts: Bacterial chemotaxis.
Gilman, A., Dept. of Pharmacology, University of Texas
Southwestern Medical Center, Dallas: Role of G proteins
in transmembrane signaling.
Stryer, L., Dept. of Cell Biology, Stanford University School
of Medicine, California: Molecular mechanism of visual
excitation.
SESSION 2 BACTERIAL CHEMOTAXIS
Chairman: D. Koshland, University of California, Berkeley
Koshland, D.E., Jr., Bollag, G.E., Milligan, D.L., Sanders,
D.A., Dept. of Biochemistry, University of California,
Berkeley: Sensory transduction in bacterial chemotaxis.
Adler, J., Boileau, A.J., Buechner, M., Delcour, A.H., Li, C.,
Sager, B.M., Shi, W., University of Wisconsin, Madison:
New kinds of behavior of E. coli.
Stewart, R., Russell, C.B., Dahlquist, F.W., Institute of
Molecular Biology, University of Oregon, Eugene: Feed-
back events during sensory adaptation by E. coli.
Hess, J., Oosawa, K., Simon, M., Division of Biology,
California Institute of Technology, Pasadena: Protein
phosphorylation and signal transduction in bacteria.
SESSION 3 SIGNAL TRANSDUCTION IN YEAST
Yamamoto, K.R., Godowski, P.J., Picard, D., Sakai, D.D,,
Dept. of Biochemistry, University of California, San
Francisco: Signal transduction and transcriptional regula-
tion by the glucocorticoid receptor.
Ptashne, M., Dept. of Biochemistry and Molecular Biology,
Harvard University, Cambridge, Massachusetts: A
universal (perhaps) activator of gene expression.
Stock, J., Mottonen, J., Stock, A., Schutt, C., Depts. of
Biology and Chemistry, Princeton University, New
Jersey: Three-dimensional structure of the chemotaxis
response regulator.
Ames, P., Chen, J., Wolff, C., Parkinson, J.S., Dept. of
Biology, University of Utah, Salt Lake City: Structure-
function studies of bacterial chemosensors.
Macnab, R.M., Dept. of Molecular Biophysics and
Biochemistry, Yale University, New Haven, Connecticut:
The end of the line in bacterial sensing-The flagellar
motor.
Chairman: I. Herskowitz, University of California, San Francisco
Marsh, L., Herskowitz, I., Dept. of Biochemistry and
Biophysics, University of California, San Francisco: Sites
that determine ligand selectivity in the yeast a-factor
receptor (STE2 protein).
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Matsumoto, K.,1 Nakafuku, M.,2 Nakayama, N.,1 Miyajima, I.,1
Kaibuchi, K.,1 Brenner, C.,1 Miyajima, A.,1 Arai,
K.,1 Kaziro, Y.,2 1Dept. of Molecular Biology, DNAX
Research Institute, Palo Alto, California; 2lnstitute of
D. Koshland, I. Herskowitz, G. Rubin
Medical Science, University of Tokyo, Japan: Role of G
proteins in yeast signal transduction systems.
Dietzel, C., Kurjan, J., Dept. of Biological Sciences,
Columbia University, New York, New York: Implication of
the SCG/-encoded G-protein homolog in pheromone
response in yeast.
Reneke, J.E., Blumer, K.J., Courchesne, W.E., Thorner, J.,
Dept. of Biochemistry, University of California, Berkeley:
Receptor desensitization in yeast involves three discrete
mechanisms.
Blinder, D., Spatrick, S., Bouvier, S., Sullivan, C., Jenness, D.,
Dept. of Molecular Genetics Microbiology, University of
Massachusetts Medical School, Worcester: Signals
controlling a-factor adaptation and receptor
internalization.
Clark, K., Davis, N., Wiest, D., Sprague, G., Jr., Institute of
Molecular Biology, University of Oregon, Eugene: Activity
and structure of yeast a-factor receptor.
Reed, S., de Barros Lopes, M., Ferguson, J., Jahng, K.-Y.,
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Inositol lipid phototransduction pathway in fly
photoreceptor.
SESSION 5 SECOND MESSENGER SYSTEMS. I
Chairman: M. Wig ler, Cold Spring Harbor Laboratory
Wig ler, M.,1 Cameron, 5.,1 Powers, S.,1 Field, J.,1 Toda, T.,2
M. Wig ler, H. Hanafusa, S. Numa
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Struhl, K., Dept. of Biological Chemistry, Harvard Medical
School, Boston, Massachusetts: Transcriptional enhance-
ment by the yeast GCN4 activator protein and the
related jun oncoprotein.
Harshman, K.D., Moye-Rowley, W.S., Parker, C.S., Division
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Ishikawa, Japan; 3Howard Hughes Medical Institute
Research Laboratories, Dept. of Neurobiology and
Behavior, State University of New York, Stony Brook;
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anti-oncogene.
McCormick, F.,1 Adari, H.,1 Trahey, M.,1 Wong, G.,1
Rubinfeld, B.,1 Willumsen, B.,2 Lowy, D.R.,3 1Cetus
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Genomic response factors.
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Almendral, J., Zerial, M., European Molecular Biology
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Mayer, B.J., Hamaguchi, M., Hanafusa, H., Rockefeller
University, New York, New York: Modulation of tyrosine
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Bristol, A., Hall, S., Sultzman, L., Knopf, J., Genetics
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tant PLC phospholipase C.
Berkeley: The oncogene jun-A transcriptional regulator
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Treisman, R., Norman, C., Runswick, M., Wilson, T., MRC
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Proteins involved in serum-regulated c-fos gene
transcription.
Ziff, E., Gizang-Ginsberg, E., Gorham, J., Greenberg, M.E.,
Kouzarides, T., Metz, R., Siegfried, Z., Thompson, M.A.,
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regulation by growth factors.
Prywes, R., Fisch, T.M., Roeder, R.G., Laboratory of Bio-
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Atwater, J., Sisson, J., Sassone-Corsi, P., Salk Institute,
San Diego, California: Regulation of fos gene-Role as a
trans-regulator of transcription.
Gilman, M., Berkowitz, L., Graham, G., Riabowol, K.,
Ryan, W., Jr., Franza, B.R., Jr., Cold Spring Harbor
Laboratory, New York: Intracellular mediators of c-fos
induction.
Curran, T.,1 Rauscher, F.J. 111,1 Cohen, D.R.,1
Ferreira, P.C.P.,1 Franza, B.R., Jr.,2 1Dept. of Molecular
Oncology, Roche Institute of Molecular Biology, Nutley,
New Jersey; 2Cold Spring Harbor Laboratory, New York:
fos-A nuclear messenger in signal transduction.
Franza, B.R., Jr., Cold Spring Harbor Laboratory, New
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proteins that interact with genetically defined transcription
control elements.
Baeuerle, P., Baltimore, D., Whitehead Institute, Massachusetts
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NF-KB transcription factor is controled by an inhibitory
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Chairman: R. Tsien, University of California, Berkeley
Harootunian, A.T., Tsien, R.Y., Dept. of Molecular and Cell
Biology, University of California, Berkeley: Sustained
calcium oscillations in fibroblasts are produced by a
combination of mitogen
Rozengurt, E., Nanberg, E., Erusalimsky, J., Morris, C.,
Mehmet, H., Woll, P., Millar, J., Sinnett-Smith, J.,
Imperial Cancer Research Fund, London, England: Early
signals in the mitogenic response.
Hanley, M.,1 Goedert, M.,2 Carpenter, D.,3 Cheung, P.,1
Dreher, M.,1 Gatti, A.,1 Hawkins, P.,1 Jackson, T.,1
Patterson, 5.,1 Vallejo, M.,1 1MRC Molecular
Neurobiology Unit, 2Laboratory of Molecular Biology,
Medical School, Cambridge, 3AFRC Institute for Animal
Disease Research, Huntingdon, England: Molecular
mechanisms and genetic manipulation of phospholipid
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SESSION 16 SECOND MESSENGER SYSTEMS. III
K Yamamoto
Saltiel, A.R., Rockefeller University, New York, New York:
Function of glycosyl-phosphoinositides in hormone
action.
Larner, J.,1 Huang, L.,1 Tang, G.,1 Suzuki, S.,1 Shen, T.Y.,2
Oswald, A.S.,2 Schwartz, C.F.W.,1 Romero,
G.,1 Roulidis, Z.,2 Zeller, K.,1 Leef, J.W.,1 Depts. of
1Pharmacology, 2Chemistry, University of Virginia School
of Medicine, Charlottesville: Insulin mediators-Structure
and formation.
Low, M.G., Dept. of Physiology and Cellular Biophysics,
Columbia University College of Physicians & Surgeons,
New York, New York: Functions of the glycosyl-
phosphatidylinositol anchor of cell-surface proteins.
Raetz, C.R.H., Dept. of Biochemistry, University of
Wisconsin, Madison: Gram-negative endotoxin-A
biologically active lipid.
Chairman: M. Berridge, Agricultural and Food Research Council
Berridge, M.J., Taylor, C.W., Dept. of Zoology, Agricultural
and Food Research Council, Cambridge, England:
Inositol trisphosphate and calcium signaling.
Gomperts, B.D., University College, London, England:
Phosphorylation/de-phosphorylation, Ca++ and G protein
(GE), in the control of exocytosis.
Garbers, D.L.,1 Lowe, D.G.,2 Dangott, L.J.,1 Chinkers, M.,1
Thorpe, D.S.,1 Bentley, K.,1 Ramarao, C.S.,1
Goeddel, D.V.,2 Singh, 5.,1 1Vanderbilt University
Medical Center, Nashville, Tennessee; 2Genentech, Inc.,
South San Francisco, California: Regulation of the
membrane form of guanylate cyclase.
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Sardet, C., Franchi, A., Pouyssegur, J., Centre de
Biochimie, CNRS, Nice, France: Molecular cloning of the
growth-factor-activatable Na+/H+ antiporter.
Summary: H. Bourne, University of California,
San Francisco
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221 participants
The last few years have seen the gradual development of a variety of tools that
make the possibility of mapping and sequencing whole genomes a realistic
possibility. Although many small workshops and meetings have been held to
discuss the possibility of sequencing the human genome, most have been
politically oriented. In contrast, this year's meeting at Cold Spring Harbor
Laboratory on Genome Mapping and Sequencing was the first to focus entirely
on science. A full gamut of techniques in this area were described and their use
for preparing maps of small and large genomes was presented. A significant
highlight was the announcement of the cloning of a stretch of DNA that
hybridizes to all human telomeres. By providing a probe for the ends of human
chromosomes, this development should greatly aid physical mapping of the
human genome. An informal session within the meeting saw the birth of HUGO,
the HUman Genome Organization.
M. Olson, J. Watson, F. Rudd le, V. McKusick
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SESSION 1 MAPPING. I: Cutting and Separation of Large
DNA Fragments
Chairman: R. Roberts, Cold Spring Harbor Laboratory
Cantor, C.R., Doggett, N., Abad, P., Mathew, M.K., Fan, J.B.,
Smith, C.L., Depts. of Microbiology, Psychiatry, and
Genetics and Development, Columbia University College
of Physicians & Surgeons, New York, New York:
Progress in large DNA methods and their application to
megabase restriction mapping.
Lai, E.,1 Woolf, T.,1 Kronenberg, M.,2 Hood, L.,1 1Division
of Biology, California Institute of Technology, Pasadena;
2Dept. of Microbiology and Immunology, University of
California, Los Angeles: Mapping genomic organi-
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electrophoresis-Application to the murine T-cell receptor
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Marchuk, D.,1 Cole, J.,1 Cantor, C.,2 Weissman, S.,3
Collins, F.,1 1University of Michigan, Ann Arbor;
2Columbia University, New York, New York; 3Yale
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California, Los Angeles: Macrorestriction mapping of
prokaryote genomes.
Helene, C., Laboratoire de Biophysique, INSERM, Museum
National d'Histoire Naturelle, Paris, France: Sequence-
specific recognition and cleavage of double-stranded
DNA by oligonucleotides covalently linked to photo-
sensitizers or phenanthroline-copper complexes.
SESSION 2 MAPPING. II: Linked Libraries and Large Clones
S. Weissman
Sigman, D.S. Dept. of Biological Chemistry, University of
California School of Medicine, Los Angeles: Targeting
the nuclease activity of 1,10-phenanthroline-copper.
Chairman: Maynard Olson, Washington University School of Medicine
Burke, D.T., Carle, G.F., Olson, M.V., Washington University
School of Medicine, St. Louis, Missouri: Construction of
libraries from eukaryotic genomes as yeast artificial
chromosomes.
Little, R.D.,1 Carle, G.,2 Olson, M.V.,2 Schlessinger, D.,1
Depts. of 1Microbiology, 2Genetics, Washington
University School of Medicine, St. Louis, Missouri:
Screening of YAC libraries containing human DNA
inserts.
Hieter, P., Shero, J. McCormick, M., Connelly, C., Vollrath, D.,
Dept. of Molecular Biology and Genetics, Johns Hopkins
School of Medicine, Baltimore, Maryland: Physical
mapping of large DNA by chromosome fragmentation in
S. cerevisiae.
Sternberg, N., Sauer, B., Central Research and Develop-
SESSION 3 POSTER SESSION
Avdalovic, N., Burns, J., Beckman Instruments, Palo Alto,
California: Automation of Sanger's protocols for high
thruput DNA sequencing.
Birren, B.W., Lai, E., Clark, S.M., Hood, L., Simon, M.I.,
Division of Biology, California Institute of Technology,
Pasadena: A new gel electrophoresis apparatus with
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ment Dept., E.I. du Pont de Nemours and Company,
Inc., Wilmington, Delaware: A new cloning system that
permits the efficient cloning, isolation, amplification, and
recovery of big DNA inserts.
Lehrach, H.,1 Zelietner, G.,1 Nicetic, D.,1 Craig, A.,1
Michiels, F.,2 1 Imperial Cancer Research Fund, London,
England; 2Plant Genetic Systems, Gent, Belgium:
Oligonucleotide fingerprinting, a parallel approach to
establish ordered clone libraries.
Livak, K.J.,1 Korolkoff, P.N.,1 Brenner, 5.,2 1Central
Research and Development Dept., E.I. du Pont de
Nemours and Co., Wilmington, Delaware; 2Molecular
Genetics Unit, Medical Research Council, Cambridge,
England: Use of fluorescent DNA terminators to map
overlapping DNA fragments.
versatile applications for DNA separation.
Bowcock, A.,1 Farrer, L.,2 Hebert, J.,1 Sternlieb, I.,3
Scheinberg, I.,3 Frydman, M.,4 Bonne-Tamir, B.,4
Cavalli-Sforza, L.,1 1Stanford University School of
Medicine, California; 2Boston University Medical Center,
Massachusetts; 3Albert Einstein College of Medicine,
Bronx, New York; 4Tel-Aviv University, Ramat-Aviv,
Israel: DNA markers closely linked to Wilson's disease.
Braaten, D.C., Little, R.D., Schlessinger, D., Dept. of
Microbiology, Washington University School of Medicine,
St. Louis, Missouri: Human 5S rDNA repeat-Sequence
and genomic clusters.
Branscomb, E.W., Slezak, T.R., Pae, R., Carrano, A.V.,
Biomedical Sciences Division, Lawrence Livermore Na-
tional Laboratory, California: Optimal overlap detection in
genomic ordering.
Canard, B., Cole, S.T., Institut Pasteur, Paris, France: Long-
range restriction mapping of the C. perfringens genome.
Carle, G.F., Little, R., Olson, M.V., Washington University
School of Medicine, St. Louis, Missouri: Analysis of a
YAC clone possessing homology with a member of the
class I HLA gene family.
Carle, G.F., Olson, M.V., Washington University School of
Medicine, St. Louis, Missouri: Physical characterization of
a 3-Mb yeast chromosome (XII) containing the rDNA
cluster from S. cerevisiae.
Chai, J., Institute of Genetics, Fudan University, Shanghai,
People's Republic of China: Creating a linear physical
map of human chromosome X.
Chandrasekharappa, S.C.1 Westbrook, C.,1 McClelland, M.,2
Depts. of 1Medicine, 2Biochemistry and Molecular
Biology, University of Chicago, Illinois: Production of
partial Not I enzyme digests by methylation competition.
Chimini, G.,1 Marguet, D.,2 Djabali, M.,1 Jordon, B.,1
Lauquin, G.,2 1Centre d'Immunologie INSERM-CNRS,
2Physiologie Cellulaire, Faculte des Sciences, Marseille,
France: Human genomic library in yeast artificial
chromosomes.
de Jong, P.J., Pederson, L., Summers, L., Biomedical
Sciences Division, Lawrence Livermore National
Laboratory, California: Long-range restriction mapping of
human chromosome 19 using Not /-linking probes.
Dulbecco, R., Salk Institute, La Jolla, California: A mapping
and sequencing project of a consortium of Italian
universities.
Evans, G.A., Lewis, K., Rothenberg, B.E., Evans, K.C., Salk
Institute, La Jolla, California: Genomic mapping by
cosmid multiplex analysis.
Fields, C.A., Coombs, M.J., Hartley, R.T., Knowledge
Systems Group, CRL, NMSU, Las Cruces, New Mexico:
Automated construction of functional models of multi-
kilobase regions of genomic DNA sequence.
Ganguly, S., Chaganti, R.S.K., Memorial Sloan-Kettering
Cancer Center, New York, New York: Nucleotide
sequence of an unusual t(14;18) translocation junction in
follicular lymphoma.
Grant, S.G., Mullins, L.J. Stephenson, D.A., Chapman, V.M.
Dept. of Molecular and Cellular Biology, Roswell
Memorial Institute, Buffalo, New York: Cumulative
molecular mapping of the mouse X chromosome-
Implications for the human genome.
Hochgeschwender, U., Sutcliffe, J.G., Brennan, M.B., Dept.
of Molecular Biology, Research Institute of Scripps Clinic,
La Jolla, California: An essentially complete library of
mouse chromosome 16-A systematic method for
production and linking of chromosome-specific libraries.
Hozier, J.,1.2 Hall, B., 2 Marzluff, W.,1 1Florida State
University, Tallahassee; 2Applied Genetics Labs, Inc.,
Melbourne, Florida: Mapping of histone genes in man
and mouse-A model for comparative mapping of
complex gene families.
Lander, E.S.,1'2 Botstein, D., 3'4 1Whitehead Institute for
Biomedical Research, 2Harvard University, Cambridge,
Massachusetts, 3Massachusetts Institute of Technology,
Cambridge, Massachusetts; 4Genentech, South San
Francisco, California: Methods for mapping the genes
involved in polygenic traits in mammalian genomes by
using a complete RFLP linkage map.
Lench, N.J.,1 Estivill, X.,2 Scambler, P.J.,1 Williamson, R.,1
1Cystic Fibrosis Genetics Research Group, St. Mary's
Hospital Medical School, London, England; 2Hospital de
la Santa Creu I Sant Pau, Barcelona, Spain: Identification
of rare cutter restriction sites using short synthetic
oligonucleotide probes.
Litt, M.1 Kondoleon, S.,1 Luty, J.,1 Carrero-Valenzuela, R.,1
Buder, A.,1 Ramsay, A.,1 Vissing, H.,2 vanTuinen, P.,3
Ledbetter, D.H.,3 1Oregon Health Sciences University,
Portland; 2State University of New York Downstate
Medical Center, Brooklyn; 3Baylor College of Medicine,
Houston, Texas: Three cosmids from a chromosome-17
library identify compound polymorphic loci on the long
arm of this chromosome.
Martin, R.K., Barker, P.E., Laboratory of Medical Genetics
and UAB Cystic Fibrosis Research Center, University of
Alabama, Birmingham: Deletion mapping with a series of
human chromosome-7 DNA markers.
McKusick, V.A., Dept. of Medicine, Johns Hopkins University
School of Medicine, Baltimore, Maryland: Morbid
anatomy of the human genome-Current status of the
human gene map.
Mead, D., Promega Corporation, Madison, Wisconsin: A
unique A vector engineered for high-resolution restriction
mapping of genomic inserts.
Nadeau, J.,1 Carlson, G.,1 Figueroa, F.,2 Henson, V.,1
Kasahara, M.,3 Klein, J.,2'3 1Jackson Laboratory, Bar
Harbor, Maine; 2Max Planck Institut fur Biologie
Abteilung Immungenetik, Tubingen, Federal Republic of
Germany; 3Dept. of Microbiology and Immunology,
University of Miami School of Medicine, Florida: Meiotic
and mitotic linkage maps of mouse chromosome 17.
Ott, J., Sandkuyl, L.A., Depts. of Genetics and Development
and Psychiatry, Columbia University, New York, New
York: Computer simulation methods for mapping human
disease loci by genetic linkage analysis.
Pearson, P.L.,1 Kidd, K.K.,2 Willard, H.F.,3 1Dept. of
Human Genetics, University of Leiden, The Netherlands;
2Dept. of Human Genetics, Yale University, New Haven,
Connecticut; 3Dept. of Medical Genetics, University of
Toronto, Ontario, Canada: ARPmap-A proposed
hierarchical information system for physical mapping of
the human genome.
Poustka, A.,1 Lehrach, H.,2 1Max Planck Institut fur
medizinische Forschung, Heidelberg, Federal Republic
of Germany; 2lmperial Cancer Research Fund
Laboratories, London, England: Rare cutter chromosome
jumping-A long-range cloning technique.
Ragsdale, C., Chu, D., Freeby, S., Zoller, P., Garfin, D.,
Bio-Rad Laboratories, Richmond, California: Genome
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mapping and sequencing conference.
Richterich, P. Pohl, F.M., Faculty of Biology, University of
Constance, Federal Republic of Germany: Direct blotting
electrophoresis-Recent improvements for colorimetric
DNA sequencing.
Sikela, J.M.,1 Law, M.L.,2 Kao, F.T.,2 Hartz, J.H.,2 Wei, Q.,2
Hahn, W.E.,1 1University of Colorado School of
Medicine, Boulder; 1 Eleanor Roosevelt Institute for
Cancer Research, Denver, Colorado: The gene en-
coding CaM kinase IV, a new brain Ca+ +/calmodulin-
dependent protein kinase, maps to human chromosome
5q21-q23.
Siniscalco, M., Memorial Sloan-Kettering Cancer Center,
New York, New York: A population approach to human
genome sequencing.
Sirotkin, K., Goad, W., Los Alamos National Laboratory,
New Mexico: Computer simulation of genomic mapping.
Smith, G.P., Division of Biological Sciences, Tucker Hall,
University of Missouri, Columbia: The Lehrach probe
hybridization map-Algebra of consistency and statistics
of inconsistencies.
Stewart, G.D., Kurachi, S., Kang, H., Baldori, N., Kahl, T.,
Kurnit, D.M., Howard Hughes Medical Institute,
University of Michigan, Ann Arbor: Rapid identification
and isolation of transcribed sequences.
Stormo, G.D., Dept. of Biology, University of Colorado,
Boulder: Determining the sequence specificity of
DNA-binding proteins.
Testa, J.R.,1 Park, M.,1 Blair, D.,2 Vande Woude, G.,1
1BRI-Basic Research Program, 2Laboratory of Molecular
SESSION 4 COMPLETE MAPS AND MODEL SYSTEMS
Chairman: J. Sulston, MRC Laboratory, Cambridge
Kohara, Y.,1 Akiyama, K.,1 Isono, K.,2 1Dept. of Molecular
Biology, Nagoya University, Japan; 2Dept. of Biology,
Oncology, Frederick, Maryland: FIGE analysis of two
rearranged met proto-oncogene alleles in a chemically
treated human osteosarcoma cell line, MNNG-HOS, and
use of a derivative chromosome 7 to map DNA markers
linked to the cystic fibrosis locus.
Toneguzzo, F.,1 Danby, P.,1 McKenny, K.,2 1EG&G
Biomeolecular, Natick, Massachusetts; 2National Bureau
of Standards, Gaithersburg, Maryland: An automated
system for detection of radiolabeled nucleic acids-DNA
sequencing and other applications.
Waye, J.S., Greig, G.M., Willard, H.F., Dept. of Medical
Genetics, University of Toronto, Canada: Molecular
organization of the human /3 satellite DNA family.
Weber, J.L., May, P.S., Marshfield Medical Research
Foundation, Wisconsin: A new type of polymorphic
human DNA marker.
Wenzel, R., Herrmann, R., Dept. of Microbiology, University
of Heidelberg, Federal Republic of Germany: Construc-
tion of a physical map of the Mycop/asma pneumoniae
genome.
Westbrook, C., Le Beau, M.M., Chandrasekharappa, S.C.,
Firak, T., Dept. of Medicine, University of Chicago,
Illinois: Physical mapping of the long arm of human
chromosome 5.
Zhao, Y.,2 Chai, J.,1 Wang, X.,1 Weng, X., Xou, Q.,2
Shen, G.,2 Tang, S.,2; lInstitute of Genetics, Fudan
University, Shanghai, 2Dept. of Biology, Hangzhou
University, People's Republic of China: Construction of
cosmid library and detailed physical map of rice
chloroplast genome.
Kobe University, Japan: Physical map of the whole E.
cofi chromosome.
Coulson, A.,1 Sulston, J.,1 Waterston, R.,2 1MRC Laboratory
of Molecular Biology, Cambridge, England; 2Washington
University Medical School, St. Louis, Missouri: The
genome of Caenorhabditis.
Link, A., Dutchik, J.E., Riles, L., Olson, M.V., Dept. of
Geneticks, Washington University School of Medicine, St.
Louis, Missouri: Physical mapping of the yeast genome.
Hauge, B.M., Yett, D., Fritze, C., Nam, H.-G., den Boer, B.,
Goodman, H.M., Dept. of Genetics, Harvard Medical
School, and Dept. of Molecular Biology, Massachusetts
General Hospital, Boston: Progress toward a physical
map of the Arabidopsis thaliana genome.
Smith, C.L., Condemine, G., Ringquist, S., Yu, M.T., Abad, P.,
Fan, J.B., Cantor, C.R., Depts. of Microbiology,
Psychiatry, and Genetics and Development, Columbia
University College of Physicians & Surgeons, New York,
New York: Molecular biological studies of whole
chromosomes.
Chikashige, Y., Matsumoto, T., Niwa, 0., Yanagida, M.,
Dept. of Biophysics, Faculty of Science, Kyoto
University, Japan: Creation of new Not I restriction sites
on S. pombe chromosome for genome mapping and ar-
tificial chromosome.
Weil, M.D., Patel, Y., Nelson, M., McClelland, M., Dept. of
Biochemistry and Molecular Biology, University of
Chicago, Illinois: Cleavage methods for megabase
mapping.
SESSION 5 MAMMALIAN MAPS OF WHOLE CHROMOSOMES
Chairman: E. Lander, Massachusetts Institute of Technology
Shimizu, N., Minoshima, S., Kudoh, J., Kawasaki, K.,
Fukuyama, R., Maekawa, M., Dept. of Molecular
Biology, Keio University School of Medicine, Tokyo,
Japan: Sorting of single homologs of human
chromosomes 21 and 22 to use for physical mapping.
Gardiner, K.,1 Watkins, P.,2 Patterson, D.,1 1Eleanor
Roosevelt Institute for Cancer Research, Denver,
Colorado; 2Integrated Genetics, Framingham,
Massachusetts: Mapping human chromosome 21.
Carrano, A.V., Branscomb, E.W., de Jong, P.J., Watkins, B.E.,
Mohrenweiser, H.W., Slezak, T., Biomedical Sciences
Division, Lawrence Livermore National Laboratory,
California: Creating an ordered cosmid set for
chromosome 19.
Hildebrand, C.E.,1 Stallings, R.L.,1 Deaven, L.L.,1
Longmire, J.L.,1 Cram, L.S.,1 Meyne, J.,1 Moyzis,
R.K.,1 Callen, D.,2 1Los Alamos National Laboratory,
New Mexico; 2Adelaide Childrens Hospital, Australia:
Physical maps of human chromosome 16-Status and
perspectives.
Gusella, J.F..1 Haines, J.,1 Tanzi, R.E.,1 Rouleau, G.,1
SESSION 6 MAMMALIAN MAPS-LARGE REGIONS
Chairman: C. Cantor, Columbia University
Barlow, D.P.,1 Lehrach, H.,2 lInstitute of Molecular
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Pulsed-field gel mapping of the mouse t-complex.
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of the human MHC.
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Frederick, Maryland; 4University of South Alabama,
Mobile; 5Columbia University, New York, New York;
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Green, P., Helms, C., Cartinhour, S., Weiffenbach, B.,
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Dracopoli, N.C., Rose, E., Stanger, B.Z., Ito, C.Y., Glaser, T.,
Whitfield, G.K., Guidon, P.T., Kourides, I.A., Housman,
D.E., Center for Cancer Research, Massachusetts
Institute of Technology, Cambridge: A genetic linkage
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analysis of a thyroid-hormone-regulated gene cluster in
1p22.
231
Sawada, 1.,1 Chorney, M.,1 Gillespie, G.,1 Kandpal, R.,1
Swaroop, A.,1 Shukla, H.,1 Weissman, S.M.,1 Tam, A.,2
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Davis, L.M., Nowak, N.J., Shows, T.B., Dept. of Human
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Willard, H.F., Dept. of Medical Genetics, University of
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and Population Cytogenetics Unit, Western General
Hospital, Edinburgh, 2Dept. of Zoology, University of
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Church, G.M., Gryan, G., Juang, G.J., Kieffer-Higgins, S.,
Mintz, L., Rubenfield, M.J., Temple, M., Wang, M.X.,
Dept. of Genetics, Harvard Medical School, Boston,
Massachusetts: Multiplex DNA sequencing.
Schwager, C.,1 Sproat, B.,1 Stegemann, J.,1 Voss, H.,1
Kristensen, T.,2 Ansorge, W.,1 1European Molecular
Biology Laboratory, Heidelberg, Federal Republic of
Germany; 2Research Institute for Internal Medicine,
University of Oslo, Norway: Development of DNA
sequencing techniques at the European Molecular
Biology Laboratory.
Weiss, R., Wills, N., Velick, S., Dunn, D., Geste land, R.,
Howard Hughes Medical Institute, Dept. of Human
Genetics, University of Utah Medical Center, Salt Lake
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Trainor, G.L.,1 Prober, J.M.,2 Dam, R.J.,2 Jensen, M.A.,3
Depts. of 1Central Research and Development,
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Nemours and Co., Inc., Experimental Station,
Wilmington, Delaware: An automated system for
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Cell and Molecular Biology of Chlamydomonas
May 4-May 8
ARRANGED BY
Robert Bloodgood, University of Virginia
Ursula Goodenough, Washington University
Joel L. Rosenbaum, Yale University
126 participants
Although yeast is in many respects a superb model organism for the analysis of
eukaryotic cells, it is not useful for the study of such important eukaryotic
activities as photosynthesis, phototaxis, ciliary motility and assembly, centriole
and basal-body function, and membrane-mediated cell-cell interactions. All of
these functions are under intensive study using the unicellular green alga
Chlamydomonas, which, like yeast, is readily manipulated in the laboratory and
has well-characterized genetics. The Third International Chlamydomonas meeting
took place at Cold Spring Harbor Laboratory in May, 1988, and was attended by
125 researchers from the United States and many foreign countries.
Students of Chlamydomonas have been frustrated by the lack of a reliable
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transformation system to analyze its many identified genes.
Since standard
transformation vectors fail to be expressed in Chlamydomonas,
many laboratories
have been working to develop systems using homologous
selectable genes.
Reports of successful chloroplast DNA transformation
(Boynton, Gillham, Harris,
Sanford, and colleagues, Duke and Cornell) and nuclear gene transformation
(Mayfield, Scripps Institute) using this approach were most encouraging, and
several other laboratories either have cloned selectable genes
or are close to that
goal. There were also two reports of endogenous transposable elements
in
Chlamydomonas, one a retrotransposon (Rochaix, Geneva) and one an Ac-like
element (Ferris, Washington University); such elements may prove useful in
developing a general vector system.
The remaining sessions were devoted to numerous research reports on the
topics listed above, and significant progress was repeatedly documented:
For
example, several flagellar genes have been cloned, RFLP maps have been
constructed, the chloroplast genome has been exhaustively mapped and
physically characterized, roles for cyclic AMP, rhodopsin, calcium, and other
interesting effectors are being found. There was considerable optimism the
Chlamydomonas is indeed coming into its own.
This meeting was supported in part by funds by Amoco Technology
Company, the National Science Foundation, the Department of Energy, the
Foundation for Microbiology, the International Society for Plant Molecular Biology,
Monsanto Company, Nippon Zeon Company, Ltd., and Zoecon Research
Institute.
SESSION 1 KEYNOTE ADDRESS -
J. -D. Rochaix, University of Geneva
Rochaix, J.-D., Kuchka, M., Choquet, Y., Goldschmidt-
Clermont, M., Day, A., Mayfield, S., Erickson, J., Girard-
Bascou, J., Bennoun, P., Depts. of Molecular and Plant
Biology, University of Geneva, Switzerland and Institut
de Biologiei physico-chimique, Paris, France: Photo-
synthetic mutants of C. reinhardtii-Tools for studying the
interactions between the chloroplast and
nucleocytoplasmic genetic systems.
SESSION 2 FLAGELLAR APPARATUS AND
CYTOSKELETON
Chairman: G. Witman, Worcester Foundation for
Experimental Biology
Kamiya, R., Kurimoto, E., Sakakibara, H., Dept. of
Molecular Biology, Nagoya University, Japan: Mutants
deficient in inner and outer dynein arms.
Piperno, G., Rockefeller University, New York, New York:
Molecular complexity and regulatory function of
axonemal dyneins located in the inner row of arms.
King, S.M., Witman, G.B., Worcester Foundation for
Experimental Biology, Shrewsbury, Massachusetts:
Molecular structure of outer-arm dynein from
Chlamydomonas flagella.
Mitchell, D., Dept. of Anatomy and Cell Biology, State
University of New York Health Science Center, Syracuse:
Characterization of the outer-arm dynein a and /3 heavy-
chain genes.
J.- D. Rochaix, J. Boynton
Wilkerson, C., Piperno, G., Luck, D., Rockefeller University,
New York, New York: Isolation and characterization of
an outer-arm dynein heavy-chain subunit.
Williams, B.D., Velleca, M.A., Curry, A.M., Rosenbaum, J.L.,
Yale University, New Haven, Connecticut: Cloning and
sequence analysis of the Chlamydomonas pf-14 gene
reveals a nonsense mutation.
Salisbury, J.L., Laboratory for Cell Biology, Dept. of
SESSION 3 FLAGELLAR DEVELOPMENT
Chairman: P. Lefebvre, University of Minnesota
James, S.W., Lefebvre, P.A., Silflow, C.D., Dept. of Genetics
and Cell Biology, University of Minnesota, St. Paul:
C. reinhardtii mutants resistant to antimicrotubule drugs.
Peet, R.C.,1 Beck, C.,2 West, J.,1 Opp, L.,1 Kuker, K.,1
Weeks, D.P.,1 1Zoecon Research Institute, Sandoz Crop
Protection Corp., Palo Alto, California; 2Albert-Ludwigs
Universitat, Freiberg, Federal Republic of Germany:
Characterization of oryzalin-resistant mutants of C.
reinhardtii.
Jarvik, J., Wright, R., Allen, J., Bruckner, M., Dept. of
Biological Sciences, Carnegie Mellon University,
Pittsburgh, Pennsylvania: Analysis of the basal body
cycle in C. reinhardtii.
Lee, V.D., Schibler, M.J., Huang, B., Dept. of Molecular
Biology, Research Institute of Scripps Clinic, La Jolla,
California: Colchicine-resistant /3- tubulin mutants in
C. reinhardtii.
SESSION 4 TRANSFORMATION
Chairman: D. Weeks, Zoecon Research Institute
Transformation and Transformation Techniques
Boynton, J.E.,1 Gillham, N.W.,1 Harris, E.H.,1 Hosier, J.P.,1
Johnson, A.M.,1 Jones, A.R.,1 Randolph-Anderson, B.L.,1
Robertson, D.,1 Klein, T.M.,2 Shark, K.B.,2 Sanford, J.C.,2
1Depts. of Botany and Zoology, Duke University,
Durham, North Carolina; 2New York Agricultural Experi-
ment Station, Cornell University, Geneva: Chloroplast
transformation in Chlamydomonas.
Mayfield, S., Research Institute of Scripps Clinic, La Jolla,
California: Approaches to nuclear genome
transformation.
Ferris, P., Dept. of Biology, Washington University,
St. Louis, Missouri: Characterization of a
Chlamydomonas transposon.
Leung, W.-C., Depts. of Medicine, Medical Microbiology,
and Infectious Diseases, University of Alberta,
Edmonton, Canada: Expression of HSV thymidine kinase
gene in recombinant C. reinhardtii.
Homologous Selectable Marker Genes
Fernandez, E., Ranum, L.P.W., Silflow, C.D., Lefebvre, P.A.,
Dept. of Genetics and Cell Biology, Bioscience Center,
University of Minnesota, St. Paul: Cloning of the
Developmental Genetics and Anatomy, Case Western
Reserve University, Cleveland, Ohio: Chlamydomonas
centrin-A calcium-sensitive cytoskeletal system that links
the flagellar apparatus to the nucleus.
Huang, B., Mengersen, S., Dept. of Molecular Biology,
Research Institute of Scripps Clinic, La Jolla, California:
Further characterization of a Chlamydomonas basal-
body-associated 20/kD CA+ +-binding protein.
Dutcher, S.K., Dehmer, K., Gibbons, W., Dept. of
Molecular, Cellular, and Developmental Biology, Univer-
sity of Colorado, Boulder: Isolation of dominant selec-
table mutations in Chlamydomonas.
Diener, D.R.,1 Baker, E.J.,2 Rosenbaum, J.L.,1 1Dept. of
Biology, Yale University, New Haven, Connecticut:
Differential translation of al- and a2-tubulin mRNAs in
Chlamydomonas.
Baker, E.,1 Rosenbaum, J.,2 1Dept. of Biology, University
of Nevada, Reno; 2Dept. of Biology, Yale University,
New Haven, Connecticut: Role of poly(A) in tubulin
mRNA stability.
Lefebvre, P., Barsel, S., Larkin, J., Silflow, C., Wexler, D.,
Dept. of Genetics and Cell Biology, University of
Minnesota, St. Paul: Flagellar regeneration mutants-
Defects in flagellar protein synthesis and length control.
P. Lefebvre
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structural gene for nitrate reductase in C. reinhardtii.
Beaumont, M.,1 Hodson, R.,2 1Dept. of Food Service,
2School of Life and Health Sciences, University of
Delaware, Newark: Isolation of acetamidase from C.
reinhardtii.
de Hostos, E.L.,12 Grossman, A.,1 1Dept. of Biological
Sciences, Stanford University, California; 2Dept. of Plant
Biology, Carnegie Institution, Stanford, California:
Structure and expression of the C. reinhardtii
arylsulfatase gene.
Dutcher, S.K., Dehmer, K., Gibbons, W., Molecular Cellular,
and Developmental Biology, University of Colorado,
Boulder: Isolation of dominant selectable mutations in
Chlamydomonas.
Thiry-Blaise, L.M., Dept. of Biology, University of Liege,
Belgium: Selection of Chlamydomonas DNA sequence
with promoter activity.
SESSION 5 CELL AND MOLECULAR BIOLOGY OF MITOCHONDRIA
AND CHLOROPLASTS
Chairman: J. Boynton, Duke University
Lee, R.W.,1 Lemieux, C.,2 Turmel, M.,2 1Dept. of Biology,
Dalhousie University, Halifax, 2Dept. de biochinie,
Faculte des sciences et genie, Universite Laval, Quebec,
Canada: Physical characterization of the mitochondrial
genome in C. moewusii and C. eugametos and its
transmission in high-viability backcrosses.
Matagne, R.F., Bovie, C., Rongvaux, D.,
Michel-Wolwertz, M.-R., Loppes, R., Genetics of
Microorganisms, Dept. of Botany, University of Liege,
Belgium: Mitochondrial DNA inheritance in
Chlamydomonas.
Wu, M., Chang, C.H., Wang, Z.F., Dept. of Biological
Sciences, University of Maryland-Baltimore County:
Regulation of the initiation of chloroplast DNA replication
in C. reinhardtii.
Thompson, R.J., Davies, J.P., Mosig, G., Dept. of Molecular
Biology Vanderbilt University, Nashville, Tennessee:
Torsional stress in the chloroplast DNA of C. reinhardtii
SESSION 6 TECHNIQUES IN CHLAMYDOMONAS RESEARCH
Chairman: E. Harris, Duke University
Togasaki, R., Indiana University, Bloomington: Isolation of
cloroplasts.
Kindle, K., Cornell University, Ithaca, New York: Particle gun
technology for transformation.
Harris, E., Duke University, Durham, North Carolina:
Traditional genetic analysis.
Ranum, L.P.W., Lefebvre, P.A., Silflow, C.D., Dept. of
Genetics and Cell Biology, University of Minnesota,
St. Paul: Mapping genes in Chlamydomonas using
RFLPs.
SESSION 7 CHLOROPLASTS AND PHOTOSYNTHESIS
Chairman: R. Togasaki, Indiana University
Spreitzer, R.J., Chen, C., Chastain, C.J., Chol let, R.,
Al-Abed, S.R., Zhang, D., Huether, M.J., Dept. of
Biochemistry, University of Nebraska, Lincoln: Chloroplast
mutations alter the substrate specificity of RuBisCO.
Beasley, E.M., Mets, L.J., Dept. of Molecular Genetics and Cell
Biology, University of Chicago, Illinois: Nuclear mutations
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differentially affects promoter activity in vivo.
Erickson, J.M., Dept. of Biology, University of California, Los
Angeles: Molecular and genetic analysis of photosystem
II polypeptides and genes.
Lemieux, C., Gauthier, A., Mercier, J.-P., Turmel, M., Dept.
of Biochemistry, Universite Laval, Quebec, Canada:
Evidence for the spreading of group I introns in the
chloroplast rRNA operon of Chlamydomonas.
Boynton, J.E., Gil lham, N.W., Harris, E.H., Liu, X.-Q., Dept.
of Botany and Zoology, Duke University, Durham, North
Carolina: Involvement of chloroplast genes in biogenesis
of chloroplast ribosomes in C. reinhardtii.
Roitgrund, C., Mets, L.J., Dept. of Molecular Genetics and
Cell Biology, University of Chicago, Illinois: Deletion and
linkage analysis define a 5-kb region of C. reinhardtii
chloroplast DNA necessary both for the trans-splicing of
ps1A1 transcripts and for the light-independent synthesis
of chlorophyll.
Johnson, D.W., Mueh, K.E., Dutcher, S.K., Dept. of
Molecular, Cellular, and Developmental Biology,
University of Colorado, Boulder: Use of repetitive DNA
probes to construct a molecular map of Chlamydomonas
rapidly.
Bloodgood, R.A., University of Virginia, Charlottesville:
Fluorescent antibody techniques and other fluorescent
staining methods.
affecting RuBisCO assembly in C. reinhardtii.
Kuchka, M.R.,1 Mayfield, S.P.,2 Rochaix, J.-D.,1 1Dept. of
Molecular Biology, University of Geneva, Switzerland; 2Dept.
of Molecular Biology, Scripps Clinic and Research Institute,
La Jolla, California: Nuclear mutations specifically affect the
synthesis of D2, a chloroplast-encoded polypeptide of the
G. Piperno, U. Goodenough, D.Luck
photosystem II complex.
Wang, W.-y, Chang, T.-E., Wegmann, B., Dept. of Botany,
University of Iowa, Iowa City: First two enzymes of the
chlorophyll biosynthetic pathway.
Merchant, S., Dept. of Chemistry and Biochemistry, University
SESSION 8 CELL SURFACE AND MATING
Chairman: U. Goodenough, Washington University
Pasquale, S.M., Goodenough, U.W., Dept. of Biology,
Washington University, St. Louis, Missouri: Sexual signaling
in C. reinhardtii gametes.
Snell, W.J.,1 Imam, S.H.,2 Buchanan, M.J.,1 Eskue, W.A.,'
'University of Texas Southwestern, Dallas; 2Plant Polymer
Research, Agricultural Research Service, Peoria, Illinois: Lysin
release and wall degradation during the mating reaction in
Chiamydomonas.
Matsuda, Y., Dept. of Biology, Faculty of Science, Kobe
University, Japan: Agglutinin and cell-wall lytic enzyme; key
molecules to investigate the sexual differentiation in
C. reinhardtii.
Musgrave, A., Kooijman, Dept. of Molecular Cell Biology,
SESSION 9 POSTER SESSION
Bingham, S.E., Strem, M.D., Martek Corporation, Columbia,
Maryland: Studies on oritidine-5'-phosphate decarbox-
ylase as a selectable marker in C. reinhardtii.
of California, Los Angeles: Transcriptional regulation gene
expression by Cu.
Herrin, D.L., Battey, J.F., Greer, K., Schmidt, G.W., Dept. of
Botany, University of Georgia, Athens: Pigment control of
photosynthetic gene expression in C. reinhardtii.
University of Amsterdam, The Netherlands: Agglutinin
complexes in C. eugametos flagellar membranes.
Goodenough, U., Dept. of Biology, Washington University,
St. Louis, Missouri: Effects of elevated cAMP levels on
flagellar agglutinability of Chiamydomonas gametes.
Woessner, J.P., Goodenough, U.W., Dept. of Biology,
Washington University, St. Louis, Missouri: Characterization
of zygote wall proteins in C. reinhardtii.
Bloodgood, R.A., Dept. of Anatomy and Cell Biology,
University of Virginia School of Medicine, Charlottesville:
Flagellar glycoprotein dynamics as the basis for gliding
motility in C. reinhardtii.
Coleman, A.W., Moore, L.J., Division of Biology and
Medicine, Brown University, Providence, Rhode Island:
Mitochondrial variation within a species.
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S. Bingham, T. Osafune
Dutcher, S.K., Lux, F.G., Dept. of Molecular, Cellular, and
Developmental Biology, University of Colorado, Boulder:
Inhibition of nuclear fusion to analyze diploid
Chlamydomonas.
Forest, C., Dept. of Biology, Brooklyn College of the City
University of New York, Brooklyn: Freeze-fracture of wild-
type and fusion-defective C. reinhardtii.
Graves, D.A., Greenbaum, E., Chemical Technology
Division, Oak Ridge National Laboratory, Tennessee:
Method for measuring in situ absolute photosynthetic
rates of individual colonies of Chlamydomonas.
Hasnain, S.E., vanWinkle Swift, K., Dept. of Biology, Texas
A&M University, College Station: Derivation of a
C. reinhardtii prototrophic strain from an arginine aux-
otroph by second-site chromosomal integration of wild-
type transforming DNA.
Herrin, D.L., Schmidt, G.W., Dept. of Botany, University of
Georgia, Athens: RNA splicing of chloroplasts-Evidence
of involvement of nuclear and chloroplast gene products.
Kamiya, R., Hasegawa, E., Dept. of Molecular Biology,
Nagoya University, Japan: Intrinsic difference in beat
frequency between the two flagella.
Kindle, K.L., Section of Biochemistry, Molecular, and Cell
Biology, Cornell University, Ithaca, New York: Expression
of a nuclear gene for a thylakoid membrane chlorophyll-
a/b-binding protein-Different mechanisms in the dark
and light.
Klein, U., Fischer, P., Botanical Institute, University of Bonn
Federal Republic of Germany: Compartmentation of
nitrogen-assimilating enzymes in C. reinhardtii.
Leu, S., Michaels, A., Dept. of Biology, Ben-Gurion
University of the Negev, Beer Sheva, Israel: Influence
of
membranes on translation of chloroplast mRNAs.
Loppes, R.,1 Dumont, F.,1 Peers, B.,1 Piette, J.,2
1Laboratory of Molecular Genetics, Dept. of Botany,
2Laboratory of Microbiology, Institute of Pathology,
University of Liege, Belgium: Characterization of new
Chlamydomonas DNA sequences conferring
autonomous replication in S. cerevisiae.
Manuel, L.J., Mason, C.B., Moroney, J.V., Dept. of Botany,
Louisiana State University, Baton Rouge: Inorganic car-
bon uptake by C. reinhardtii-New proteins are made
during adaptation to low CO2.
Marcus, Y., Dept. of Plant Biology, Carnegie Institute of
Washington, Stanford, California: Adaptation of low CO,
concentration during the cell cycle in C. reinhardtii.
Matters, G.L., Woessnew, J.P., Dept. of Biology, Washington
University, St. Louis, Missouri: Characterization of
zygote-specific genes in C. reinhardtii.
Melkonian, M.,1 Schulze, D.,1 McFadden, G.l.,2 Robenek, H.,3
1Botanisches Institut, Munster, Federal Republic of
Germany; 2Plant Cell Biology Centre, Melbourne,
Australia; 3Arbeitsgruppe Zellbiologie, Munster, Federal
Republic of Germany: Localization and possible function
of centrin, a calcium-modulated contractile protein, in the
flagellar apparatus of green algae.
Mergenhagen, D., Mergenhagen, E., Institut kir Allgemeine
Botanik, Hamburg, Federal Republic of Germany:
Physiological clock of C. reinhardtii in a microgravity
environment.
Orr, E., Dept. of Biology, Washington University, St. Louis,
Missouri: Evaluation of a Chlamydomonas transposon as
a transformation vector.
Park, P., Ford, C., Dept. of Genetics, Iowa State University,
Ames: Isolation and characterization of histone genes
from C. reinhardtii.
Schmitt, R.,1 Kirk, D.,2 1 Universitat Regensberg, Federal
Republic of Germany; 2Dept. of Biology, Washington
University, St. Louis, Missouri: Molecular analysis of the
relationship of C. reinhardtii and Volvox carteri to each
other and to other organisms.
Spreitzer, R.J., Zhang, D., Chen, C., Dept. of Biochemistry,
University of Nebraska, Lincoln: Heteroplasmic suppres-
sion of a missense mutation in the chloroplast gene that
encodes the RuBisCO large subunit.
Su, X., Kaska, D., Gibor, A., Dept. of Biological Sciences,
University of California, Santa Barbara: Characterization
of mRNA isolated during wall regeneration in
Chlamydomonas.
Surzycki, S.J., Fong, S., Hong, T-H., Opperman, T., Dept.
of Biology, Indiana University, Bloomington: Identification
and analysis of expression of chloroplast genes involved
in transcription, DNA replication, and DNA repair.
Van Winkle-Swift, K.,1 Burrascano, C.,2 Maddock, J.,2
Slack, 5.,1 Yoas, K.,1 Salinger, A.,1 1Dept. of Biology,
Texas A&M University, College Station; 2Dept. of
Biology, San Diego State University, California: Genetic
dissection of zygosporulation in Chlamydomonas.
Voigt, J., Vogeler, H.-P., Institut fur allgemeine Botanik,
Universitat Hamburg, Federal Republic of Germany:
Structure, biosynthesis, and turnover of the cell wall of
the unicellular green alga C. reinhardtii.
Waffenschmidt, S., Kuhne, W., Spessert, R., Jaenicke, L.,
SESSION 10 CELL CYCLE AND CIRCADIAN CLOCKS
Chairman: P.C.L. John, Australian National University
John, P.C.L., Research School of Biological Sciences,
Australian National University, Canberra City:
Chlamydomonas and controls in plant cell division.
Michaels, A., Leu, S., White, D., Dept. of Biology,
Ben-Gurion University of the Negev, Beer Sheva, Israel:
Chloroplast mRNA abundance and transcription in the
cell cycle of Chlamydomonas.
Ehara, T.,1 Osafune, T.,1 Hase, E.,2 1Dept. of Microbiology,
Tokyo Medical College, 2Chemistry Laboratory, Faculty
of Medicine, Teikyo University, Japan: Formation of giant
mitochondrion in an early phase of the cell cycle of C.
reinhardtii in synchronized culture.
Mergenhagen, D., Institut fur Allgemeine Botanik, Hamburg,
Federal Republic of Germany: Physiological and genetic
characterization of the circadian clock in a metabolic mu-
tant of C. reinhardtii.
Voigt, J., Munzner, P., Institut fOr Allgemeine Botanik,
Universitat Hamburg, Federal Republic of Germany: An
extranuclear gene regulates cell division in C. reinhardtii.
Mihara, S.1 , Hase, E.,2 1 Institute of Applied Microbiology,
University of Tokyo, 2Chemistry Laboratory, Faculty of
Medicine, Teikyo University, Japan: Regulation of cell-
cycle revolution in C. reinhardtii-A circadian timing
mechanism and a sequence of adenine-involving
reactions related to initiation of nuclear division.
RNA Processing
Institut fur Biochemie, Universitat Köln, Federal Republic
of Germany: Autolysins in C. reinhardtii.
Wakarchuk, W.W., Gromoff, E.D.v., Beck, C.F., Institut fOr
Biologie III, University of Freiburg, Federal Republic of
Germany: Identification of v-myc homologous genes in
C. reinhardtii.
Yu, L., Selman, B., Dept. of Biochemistry, College of
Agricultural and Life Sciences, University of Wisconsin,
Madison: Nucleotide sequence of the cDNA of the y
subunit from the ATP synthase of C. reinhardtii.
Kondo, R.,1 Johnson, C.,2 Hastings, J.W.,3 1National
Institute for Basic Biology, Okazaki, Japan; 2Vanderbilt
University, Nashville, Tennessee; 3Harvard University,
Cambridge, Massachusetts: Photoreceptor systems for
the circadian clock of Chlamydomonas.
Hegemann, P.,1 Foster, K.W.,2 1Max-Planck-Institut fur
Biochemie, Martinsried, Federal Republic of Germany;
2Dept. of Physics, Syracuse University, New York:
Preparation of eyespots and identification of a rhodopsin-
like protein.
Foster, K.W.,1 Saranak, J.,1 Derguini, F.,2 Nakanishi, K.,2
1Dept. of Physics, Syracuse University, 2Dept. of
Chemistry, Columbia University, New York, New York:
cis-trans-lsomerization is not required for activation of
Chlamydomonas rhodopsin.
Wegener, D., Gromoff, E.D.v., Muller, F., Fuchs, S., Treier, U.,
Beck, C.F., Institut far Biologie III , University of Freiburg,
Federal Republic of Germany: The sexual cycle, light,
and heat stress control the expression of defined C.
reinhardtii genes.
Wegener, D., Muller, F., Treier, U., Beck, C.F., Institut fur
Biologie III , University of Freiburg, Federal Republic of
Germany: Light-induced germination of C. reinhardtii
zygotes-Physiology and changes in gene expression.
Summary: D. Kirk, Washington University
May 11-May 15
ARRANGED BY
Michael Green, Harvard University
Christine Guthrie, University of California, San Francisco
Alan Lambowitz, Ohio State University
375 participants
The 1988 RNA Processing meeting processed a record number of abstracts in
its seventh year at Cold Spring Harbor Laboratory. The spotlight was again
focused on the catalytic possibilities of RNA. This year, new examples of self-
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cleaving RNAs were introduced, including the provocative
hepatitis delta agent,
and the possibility was raised that catalysis can be mediated by
structural motifs
more diverse than the simple "hammerhead." Although the RNA from
"telomerase" has not yet been shown to be the catalytically active partner
of the
RNP enzyme, its sequence analysis revealed the potential for templating
the
telomeric DNA sequence. Further inroads in mRNA splicing derived substantially
from mounting evidence that the yeast and mammalian splicing pathways are
fundamentally the same, thus allowing data from each system to inform the other.
In particular, despite earlier emphasis on the differences in branchpoint
recognition, it is now clear that mammalian introns obey the same sequence
preferences as yeast and that yeast U2 (which is known to base pair with the
TACTAAC box), although six times larger than human, can be deleted to the
same size with no ill effects. On the other hand, there is as yet no yeast analog
for a specific factor (U2AF) that mediates assembly at the 3' splice site in
mammalian cells. Especially encouraging was the observation that antibodies to a
yeast U5-specific snRNP protein cross-react with a similarly sized (>200 kD)
protein in He La extracts. A most exciting breakthrough in alternative splicing was
provided by the case of sex determination in flies, where decades of genetics
can now be brought to bear on a biochemical solution. trans-splicing in worms
and trypanosomes appears to utilize an snRNA linked in cis to the 5' exon; this
surprising finding suggests an interesting evolutionary link to self-splicing introns.
Finally, the audience was stunned by the announcement that the central dogma
is once again under attack-this time by the observation that trypanosome
transcripts undergo extensive posttranscriptional "editing" at the RNA level.
This meeting was supported in part by funds from the National Science
Foundation and the National Institute of General Medical Sciences, a division of
the National Institutes of Health.
J. Beggs, M. Rosbash
SESSION 1 CATALYTIC RNA AND TRNA PROCESSING
Chairman: N. Pace, Indiana University
Guerrier-Takeda, C.,1 van Belkum, A.,2 Pleij, C.W.A.,2
Altman, S.,1 'Dept. of Biology, Yale University, New
Haven, Connecticut; 2Dept. of Biochemistry, University of
Leiden, The Netherlands: Novel reactions of RNase P.
Waugh, D.S.,1 Green, C.J.,2 James, B.D.,1 Olsen, G.J.,1
Vold, B.S.,2 Pace, N.R.,1 'Dept. of Biology, Indiana
University, Bloomington; 2SRI International, Menlo Park,
California: Design and catalytic properties of an
abbreviated ribonuclease P RNA.
Wang, M.J., Li, X.-Q., Gegenheimer, P., Depts. of
Biochemistry and Botany and Molecular Genetics
Program, University of Kansas, Lawrence: Chloroplast
RNase P does not have a catalytic RNA subunit.
Winey, M., Culbertson, M.R., Laboratories of Genetics and
Molecular Biology, University of Wisconsin, Madison:
Mutations affecting the tRNA-splicing endonuclease ac-
tivity of S. cerevisiae.
Thompson, L.D., Daniels, C.J., Dept. of Microbiology, Ohio
State University, Columbus: Unique substrate recognition
properties of an archaebacterial tRNA intron
endonuclease.
Forster, A.C., Davies, C., Sheldon, C.C., Jeffries, A.C.,
Symons, R.H., Dept. of Biochemistry, University of
Adelaide, Australia: A structural model for the active sites
of self-cleaving viroid and newt RNAs.
Ruffner, D.E., Uhlenbeck, 0.C., Dept. of Chemistry, and
Biochemistry, University of Boulder, Colorado:
Nucleotide sequence requirements for a self-cleaving
RNA.
Feldstein, P.A., Buzayan, J.M., Bruening, G., Dept. of Plant
Pathology, University of California, Davis: A ribonuclease
activity derived from autolytic processing sequences of
satellite tobacco ringspot virus RNA.
Shareem, L.,1 Kuo, M.,1 Dinter-Gottlieb, G.,2 Taylor, J.,1
'Fox Chase Cancer Center, 2Drexel University,
Philadelphia, Pennsylvania: Self-processing of human
HDV RNAs.
Dreyfus, D.H., Emmons, S.W., Dept. of Molecular Biology
and Genetics, Albert Einstein College of Medicine,
Bronx, New York: A repetitive element in C. elegans with
similarity to both transposable elements and plant viroids
encodes a self-cleaving RNA.
Greider, C.,1 Blackburn, E.,2 'Cold Spring Harbor Laboratory,
Cold Spring Harbor, New York; 2Dept. of Molecular
Biology, University of California, Berkeley: Characteriza-
tion of telomerase RNP.
Bennett, J.L., Chang, D.D., Fisher, R.P., Stohl, L.L.,
Topper, J.N., Clayton D.A., Dept. of Pathology, Stanford
University School of Medicine, California: Mitochondrial
enzymes with nuclear RNA components
SESSION 2 SPLICING OF GROUP I AND GROUP II INTRONS
Chairman: C. Peebles, University of Pittsburgh
Burgin, A.B.,' Parardos, K.,2 Lane, D.J.,2 Pace, N.R.,1
'Dept. of Biology, Indiana University, Bloomington;
2Gene-Trak System, Framingham, Massachusetts:
Excision of intron-like elements from Salmonella 23S
rRNA precursors.
Shub, D.A.,' Goodrich, H.E.,1 Gott, J.M.,1 Xu, M.-Q.,'
Scarlato, V.,2 'Dept. of Biological Sciences, State
University of New York, Albany; 2Dept. of Biology,
University of California, San Francisco, and Institute of
Genetics and Biophysics, Naples, Italy: A self-splicing
group I intron in the DNA polymerase gene of the B.
subtilis bacteriophage SPO1.
Flanegan, J.B.,1 Cech, T.R.,2 'Dept. of Immunology and
Medical Microbiology, University of Florida, Gainesville;
2Dept. of Chemistry and Biochemistry, University of
Colorado, Boulder: trans-Splicing of model
oligoribonucleotide substrates by Tetrahymena ribozyme.
Kay, P.S., Menzel, P., Inoue, T., Salk Institute, La Jolla,
California: Two guanosine-binding sites in the group I
IVS RNA and their roles in the mechanism of
self-splicing.
Burke, J., Williamson, C., Desai, N., Chemistry Dept.,
Williams College, Williamstown, Massachusetts:
Compensatory mutations in P6 and P8 of self-splicing
tetrahymena pre-rRNA.
Coetzee, T.,1 '2 Salvo, J.G.,1 DiMarla, P.,1,3 Belfort, M.,1
'Wadsworth Center of Laboratories and Research, New
York State Dept. of Health, 2Albany Medical College,
3Dept. of Biology, State University of New York, College
at Fredonia: Deletion analysis and trans-splicing of the
group I td intron.
Akins, R., Majumder, A.L., Cherniack, A., Ericson, J.,
Kelley, R., Snook, A., Lambowitz, A., Depts. of
Molecular Genetics and Biochemistry, Ohio State
University, Columbus: Involvement of an aminoacyl-tRNA
synthetase in splicing of group I mitochondrial introns.
Herbert, C.J., Labouesse, M., Dujardin, G., Slonimski, P.P.,
Centre de Genetique Moleculaire du CNRS, France:
Evidence for the involvement of the mitochondrial leucyl
tRNA synthetase in yeast mitochondrial RNA splicing.
Peebles, C.L.1 Stoops, M.J.,1 Perlman, P.S.,2 'Dept. of
Biological Sciences, University of Pittsburgh,
Pennsylvania; 2Dept. of Molecular Genetics, Ohio State
University, Columbus: The 3'-terminal ribose of exon 1 is
a crucial determinant for conformational switching by
self-splicing group II introns.
Altura, R., Rymond, B., Seraphin, B., Rosbash, M., Dept. of
Biology, Brandeis University, Waltham, Massachusetts:
The 5' end of the intron suppresses hydrolysis of
group II 5' splice sites.
Perlman, P.S., Hebbar, S.K., Dietrich, R.C., Jarrell, K.A.,
Dib-Hajj, S.D., Dept. of Molecular Genetics, Ohio State
University, Columbus: Studies of the structure and func-
tion of domain 5 of a group II intron of yeast
mitochondria] DNA.
241
SESSION 3 POSTER SESSION
Abmayr, S., Reed, R., Maniatis, T., Dept. of Biochemistry
and Molecular Biology, Harvard University, Cambridge,
Massachusetts: Functional analysis of mammalian
splicing complexes.
Acheson, N.H., Lanoix, J., Dept. of Microbiology and
Immunology, McGill University, Montreal, Quebec,
Canada: A rabbit p-globin polyadenylation signal directs
efficient termination of transcription on polyomavirus
DNA.
Adami, G.,1 Nevins, J.,2 1Rockefeller University, New York,
New York; 2HHM1, Duke University, Durham, North
Carolina: Adenovirus mRNA processing-In a regulated
manner, a splice-site choice dominates over selection of
a poly(A) site located in an intron.
Apostol, B., Belford, H., Greer, C., Dept. of Biological
Chemistry, University of California, Irvine: Characteriza-
tion of pre-tRNA binding by yeast ligase.
Arrigo, S., Beemon, K., Dept. of Biology, Johns Hopkins
University, Baltimore, Maryland: Negative regulation of
RSV RNA splicing.
Augustin, S.,1 Morl, M.,2 Muller, M.W.,2 Schmelzer, C.,2
1Universitat Wien, Austria; 2Universitat Munchen, Federal
Republic of Germany: Effect of mutations at the 3' end
of group II intron bll on splicing efficiency and 3' splice-
site selection.
Banroques, J., Abelson, J., California Institute of Technology,
Pasadena, California: RNA4 protein and yeast
spliceosome.
Bartkiewicz, M., Gold H., Altman, S., Yale University,
New Haven, Connecticut: RNA subunit of RNase P from
He La cells.
Baas, P.D., Adema, G.J., Bovenberg, R.A.L., Jansz, H.S.,
University of Utrecht, The Netherlands: Processing of
CALC -I RNA in vitro.
Bewley, G.C., Cook, J.L., Dept. of Genetics, North Carolina
State University, Raleigh: Drosophila
sn-glycerol-3-phosphate dehydrogenase isozymes are
generated by alternate pathways of RNA processing,
resulting in different carboxy-terminal amino acid
sequences.
Bond, U., Steitz, J.A., Yale University Medical School,
New Haven, Connecticut: Differential effects of stress on
pre-mRNA processing in He La cells.
Branch, A.D.,1 Benenfeld, B.J.,1 Robertson, H.D.,1
Baroudy, B.M.,2 Buckler-White, A. 2 Gerin,
J.L.,2 1Rockefeller University, New York, New York;
2Georgetown University, Rockville, Maryland: A
hammerhead structure from RNA of the delta agent.
Castan-o, J.G., Universidad Autonoma de Madrid, Spain:
Purification and characterization of the 3'-pre-tRNAse
from Ehrilich ascites cells.
Chauhan, A.K., Subbarao, M.N., Miczak, A., Apirion, D.,
Dept. of Microbiology, Washington University, St. Louis,
Missouri: Cloning and sequencing the gene for a small
abundant RNA of E. coli.
Connelly, S., Manley, J.L., Dept. of Biological Sciences,
Columbia University, New York, New York: Poly(A) site-
dependent transcription termination by RNA polymerase
II-A role for promoter-proximal DNA sequences.
Conway, G., Roberts, R.J., Cold Spring Harbor Laboratory,
Cold Spring Harbor, New York: A splicing factor(s) is
associated with large RNP complexes and is released in
a soluble active form in the presence of ATP.
Conway, L., Wickens, M., Dept. of Biochemistry, University
of Wisconsin, Madison: Identification of bases and
phosphates of SV40 late pre-mRNAs that are required
for 3'-end formation in vitro.
Cooke, N.E.,1,2 Ray, J.,2'3 Estes, P.A.,2 Emery, J.G.,1,2,3
Liebhaber, S.A.,1,2,3 Depts. of 1Medicine, 2Human
Genetics, 3Howard Hughes Medical Institute, University
of Pennsylvania School of Medicine, Philadelphia: Alter-
native mRNA processing within the human growth-
hormone gene family.
Corell, R.A., Friedlander, L.H., Rice, P.W., Gross, R.N.,
Dept. of Biological Sciences and Molecular Genetics
Center, Dartmouth College, Hanover, New Hampshire:
Diffusible factors involved in RNA processing.
Craig, N.,1 Kass, 5.,2 Sollner-Webb, B.,2 1Dept. of
Biological Sciences, University of Maryland, Baltimore
County; 2Dept. of Biological Chemistry, Johns Hopkins
School of Medicine, Baltimore, Maryland: Sequences
required for processing of mouse rRNA.
Cusick, M., Abelson, J., Division of Biology, California
Institute of Technology, Pasadena: Search for yeast
hnRNPs.
Daar, 1.0., Lim, S., Maquat, L.E., Dept. of Human Genetics,
Roswell Park Memorial Institute, Buffalo, New York:
Premature translation termination mediates mammalian
mRNA degradation.
Das, G., Henning, D., Reddy, R., Baylor College of
Medicine, Houston, Texas: Involvement of components
of both RNA polymerase II and III transcription
machineries in U6 snRNA gene transcription.
Dauwalder, B., Kulp E., Institute of Zoology, University of
Zurich, Switzerland: D. melanogaster U6 snRNA
genes-Control of Drosophila U6 gene transcription is
different from that in vertebrates.
deLannoy, P., Caruthers, M.H., Dept. of Biochemistry,
University of Colorado, Boulder: Partial purification of a
factor required for 5' splice-site cleavage and 1VS-exon
formation.
de Mars, M., Sterner, D.A., Murphy, E.C., Jr., University of
Texas System Cancer Center, M.D. Anderson Hospital,
Houston: Changes in nonconserved intron sequences
alter MSV RNA splicing.
Deshler, J.0., Rossi, J.J., Dept. of Microbiology, University
of California, Los Angeles, and Beckman Research
Institute, City of Hope, Duarte: Characterizing the
heterologous splicing capabilities of two budding
yeasts-S. cerevisiae and K. lactis.
Deutscher, M.P., Marshall, G.T., Cudny, H., Dept. of
Biochemistry, University of Connecticut Health Center,
Farmington: RNase PH-A new phosphate-dependent
nuclease implicated in tRNA processing.
DeZa77o, J.D., Wilson-Gunn, S.I., Hales, K.H., Imperiale, M.J.,
Dept. of Microbiology and Immunology, University of
Michigan Medical School, Ann Arbor: Regulation of
polyadenylation within the adenovirus major late
transcription unit.
Drabkin, H.J., RajBhandary, U.L., Dept. of Biology,
T. Grodzicker, M. Green, C. Guthrie, T. Blumenthal
Massachusetts Institute of Technology, Cambridge:
Introduction of an intervening sequence into a
mammalian serine amber suppressor tRNA gene.
Erster, S.H., Finn, L.A., Helfman, D.M., Cold Spring Harbor
Laboratory, Cold Spring Harbor, New York: Alternative
3'-end processing of tropomyosin pre-mRNA in vivo.
Fabrizio, P., McPheeters, D., Abelson, J., Division of
Biology, California Institute of Technology, Pasadena: In
vitro assembly of yeast snRNPs.
Flaspohler, J.A., Milcarek, C., Dept. of Microbiology,
Biochemistry, and Molecular Biology, University of
Pittsburgh, Pennsylvania: Transcription termination in the
murine immunoglobulin y2b and y2a genes.
Francis, M.A., RajBhandary, U.L., Dept. of Biology,
Massachusetts Institute of Technology, Cambridge:
Functional expression of a mammalian RNA polymerase
III gene in yeast.
Frank D., Guthrie, C., Dept. of Biochemistry, University of
California, San Francisco: Structural analysis of yeast
snRNAs and snRNPs.
Fresco, L.D., Keene, J.D., Dept. of Microbiology and
Immunology, Duke University Medical Center, Durham,
North Carolina: Molecular analysis of the U2 snRNP uni-
que protein A'.
Freyer, G.A., O'Brien, J.P., Balogh, L.A., Kurwitz, J., Cold
Spring Harbor Laboratory, New York: Effects of
alterations in the polypyrimidine sequence of the splicing
of single- and double-intron-containing pre-mRNAs.
Gallego, M.E., Nadal-Ginard, B., Howard Hughes Medical
Institute, Dept. of Cardiology, Children's Hospital,
Harvard Medical School, Cambridge, Massachusetts:
Mutually exclusive splicing of MLC1/3 transcripts is
cis-regulated.
Genovese, C., Milcarek, C., Dept. of Microbiology,
Biochemistry, and Molecular Biology, University of
Pittsburgh, Pennsylvania: Alterations in immunoglobulin
mRNA stability during B-cell development.
Goodall, G., Wiebauer, K., Filipowicz, W., Friedrich
Miescher-lnstitut, Basel, Switzerland: Specificity of
nuclear pre-RNA splicing in plants.
Goux-Pelletan, M.S., Brody, E., Marie, J., Institut de Biologie
Physico-Chimique, Paris, France: In vitro splicing of the
chicken f3- tropomyosin pre-mRNA.
Green, C.,1 Vold, B.S.,1 Morch, M.D.,2 Joshi, R.L.,2
Haenni, A.-L.,2 1SRI International, Menlo Park,
California: 2lnstitut Jacques Monod, CNRS and
University Paris, France: Processing of the tRNA-like
structure of TYMV RNA by the catalytic RNA component
of RNase P.
Habets, W.J., Sillekens, P.T., Hoet, M.N., Beyer, R.P.,
van Venrooij, W.J., Dept. of Biochemistry, University of
Nijmegen, The Netherlands: Molecular cloning of U1
and U2 snRNP-associated proteins.
Hall, B., Milcarek, C., Dept. of Microbiology, Biochemistry,
and Molecular Biology, University of Pittsburgh,
Pennsylvania: Sequence and secondary structure of the
membrane 3' UT region of the murine immunoglobulin
y2a gene.
Hampson, R.K., Rottman, F.M., Dept. of Molecular Biology
and Microbiology, Case Western Reserve University
School of Medicine, Cleveland, Ohio: Alternative
processing of bovine growth-hormone precursor mRNA
243
is strongly influenced by sequences within
the
downstream exon.
Hanley, B.A., Egeland, D.B., Schuler, M.A.,
Depts. of Plant
Biology and Biochemistry, University of Illinois,
Urbana:
Plant introns and snRNAs.
Hanna, M., Cherry, M., Doudna, J., Green, R.,
Szostak, J.W.,
Dept. of Molecular Biology, Massachusetts General
Hospital, Boston: Mutational analysis of tetrahymena
rRNA intron core.
Hartmuth, K., Berta, A., Instltut fur Biochemie, Vienna,
Austria: Possible base-pairing interactions between
mammalian branch point sequences and U2 RNA.
Haynes, S.,1 Johnson, D.,2 Raychaudhuri, G.,3
Beyer, A.,3
1NICHD, National Institutes of Health, Bethesda,
Maryland; 2Dept. of Biological Sciences, George
Washington University, Washington, D.C.; 3Dept. of
Microbiology, University of Virginia School of Medicine,
Charlottesville: Molecular characterization of Drosophila
genes for proteins related to the mammalian hnRNP Al
protein.
Hebbar, S.K., Perlman, P.S., Dept. of Molecular Genetics,
Ohio State University, Columbus: Auto-catalytic reactions
of a maturase encoding group II intron.
Henchcliffe, C., Paolella, G., Barone, M.V., Baralle, F.E., Sir
William Dunn School of Pathology, University of Oxford,
England: An investigation of cis- and trans-acting
elements involved in alternative splicing of the primary
transcript of the human fibronectin gene.
Hernandez, N., Lucito, R., Cold Spring Harbor Laboratory,
Cold Spring Harbor, New York: Promoter sequences
required for initiation and 3'-end formation of the human
U2 snRNA.
Herrick, D., Jacobson, A., Department of Molecular
Genetics and Microbiology, University of Massachusetts
Medical School, Worcester: Use of chimeric mRNAs to
study the structural determinants of mRNA stability in
yeast.
Hirsh, D.I., Bektesh, S.L., Van Doren, K., Synergen, Inc.,
Dept. of Developmental Biology, Boulder, Colorado:
Presence of the 22-nucleotide C. elegans spliced leader
in mRNAs of other nematodes.
Ho, C.K., Vijayraghavan, U., Abelson, J., Division of Biology,
California Institute of Technology, Pasadena: A yeast
mutant that accumulates pre-tRNA splicing "2/3"
intermediates.
Hwang, S.-P.L., Shelness, G.S., Binder, R., Eisenberg, M.,
Williams, D.L., Dept. of Pharmacological Sciences, State
University of New York, Stony Brook: Secondary
structure of apolipoprotein II mRNA. Evidence for base
pairing between the 3'-noncoding region and the coding
region near the termination codon.
Inoue, K., Ohno, M., Sakamoto, H., Shimura, Y., Dept. of
Biophysics, Faculty of Science, Kyoto University, Japan:
Effect of the cap structure on pre-mRNA in Xenopus
oocytes.
Jarrell, K.A., Dietrich, R.C., Hebbar, S.K., Perlman, P.S.,
Dept. of Molecular Genetics, Ohio State University,
Columbus: trans-Splicing experiments with a group II
intron reveal an essential function for intron domain 5.
Jones, M.H., Guthrie, C., University of California, San
Francisco: Biochemical and genetic analysis of yeast
Sm snRNPs.
Joyce, G.F., Inoue, T., Nucleotide Chemistry Laboratory,
Salk Institute of Biological Studies, La Jolla, California:
Deletion of nonconserved portions of a self-splicing
group I intron using a novel in vitro mutagenesis
technique.
Kaufer, N.F., Gatermann, K., Rosenberg, G., Hoffmann, A.,
Dept. of Bioscience and Biotechnology, Drexel
University, Philadelphia, Pennsylvania: Features and
"make up" of introns in the fission yeast S. pombe.
Kedes, D.H., Steitz, J.A., Dept. of Molecular Biophysics and
Biochemistry, Yale University, New Haven, Connecticut:
In vivo versus in vitro 5' splice-site selection in the
mouse immunoglobulin x light-chain transcript-Why the
difference?
Kessler, M., Resnekov, 0., Ben-Asher, E., Aloni, Y.,
Weizmann Institute of Science, Rehovot, Israel: A novel
transcription elongation block is active within the late
leader sequences of SV40.
Kessler, M., Bengal, E., Aloni, J., Weizmann Institute of
Science, Rehovot, Israel: In vitro structural analysis of a
eukaryotic RNA polymerase II termination signal.
Kirsebom, L.A., Baer, M., Altman, S., Yale University, New
Haven, Connecticut: Kinetic studies of the RNase P
reaction using mutants of both the substrate and the
enzyme.
Kiss, T., Jakab, G., Antal, M., Palk Z., Hegyi, H., Kiss, M.,
Solymosy, F., Institute of Plant Physiology, Biological
Research Center, Hungarian Academy of Science,
Szeged: Plant snRNAs. U4 RNA is present in plants-
Primary and possible secondary structure as well as
base pairing with plant U6 RNA.
Kleinschmidt, A.M., Patton, J.R., Pederson, T., Worcester
Foundation for Experimental Biology, Shrewsbury,
Massachusetts: In vitro assembly of the U2 snRNP
particle.
Kloetzel, P.M., Haass, C., ZMBH, Molekulare Genetik,
Heidelberg, Federal Republic of Germany: The small
heat-shock proteins of D. me/anogaster form globular
cytoplasmic 16S RNP particles-Molecular analysis of
the protein components and cDNA cloning of the RNA
component.
Knaack, D., Breitbart, R., Nadal-Ginard, B., Howard Hughes
Medical Institute, Harvard Medical School, Boston,
Massachusetts: Identification of an intron sequence with
developmentally regulated effects on the splicing of
muscle-specific exons.
Kohrer, K., Low, A., Domdey, H., Genzentrum der Ludwig-
Maximilians-Universitat Munchen, Federal Republic of
Germany: Dependence of yeast pre-mRNA splicing and
polyadenylation from transcription.
Konarska, M.M., Sharp, P.A., Center for Cancer Research
and Dept. of Biology, Massachusetts Institute of
Technology, Cambridge: Associations of snRNPs in the
formation of pseudospliceosomes.
Koster, J.G.,1 Hanover, J.A.,2 Zasloff, M.,1 1NICHHD,
2NIDDKD, National Institutes of Health, Bethesda,
Maryland: Inhibition of tRNA nuclear transport by the lec-
tin wheat-germ agglutinin.
Kreivi, J.-P., Svensson, C., Larsson, S., Akusjarvi, G., Dept.
of Microbial Genetics, Karolinska Instituet, Stockholm,
Sweden: Regulation of adenovirus-2 Ll pre-mRNA
splicing.
Krol, A.,1 Carbon, P.,1 Murgo, S.,1 Lescure, A.,1 Dathan, N.,2
Kazmaier, M. 2 Parry, H., 2 Tebb, G.,2 Mattaj, I.W., 2
1IBMC, Strasbourg, France; 2EMBL, Heidelberg, Federal
Republic of Germany: Expression of Xenopus U6 snRNA
genes.
Kwakman, J.H.J.M., Pel, H.J., Grivell, L.A., Dept. of
Molecular Cell Biology, University of Amsterdam, The
Netherlands: Determination of the secondary structure of
a group II intron by chemical modification.
Lang, K.M., Keller, W., Dept. of Cell Biology, Biocenter of
the University, Basel, Switzerland: Interaction of splicing
SESSION 4 PRE-mRNA SPLICING MECHANISMS
Chairman: A. Weiner, Yale University School of Medicine
Siliciano, P.G., Guthrie, C., Dept. of Biochemistry and
Biophysics, University of California, San Francisco: Base
pairing between yeast U1 and the 5' splice site dictates
cleavage efficiency but not fidelity.
Seraphin, B., Kretzner, L., Rosbash, M., Dept. of Biology,
Brandeis University, Waltham, Massachusetts: Role of
U1 snRNA during splicing in yeast.
Nelson, K.K., Zamore, P.D., Ruskin, B., Green, M.R., Dept.
of Biochemistry and Molecular Biology, Harvard
University, Cambridge, Massachusetts: Mechanistic
aspects of U2 snRNP binding.
Zhuang, Y., Weiner, A.M., Dept. of Molecular Biophysics
and Biochemistry, Yale University, New Haven,
Connecticut: Sequence specificity of branch-site selection
in mammalian cells.
Reed, R., Maniatis, T., Dept. of Biochemistry and Molecular
Biology, Harvard University, Cambridge, Massachusetts:
The branchpoint sequence plays a role in 3' splice-site
selection in vitro.
Lotan, A.,1 Sperling, J.,2 Sperling, R.,1 1Dept. of Genetics,
Hebrew University of Jerusalem, 2Dept. of Organic
Chemistry, Weizmann Institute of Science, Rehovot,
Israel: Localization of a base-paired region of U2 snRNA
with pre-mRNA in an in-vitro-splicing complex by UV-
induced psoralen-mediated cross-linking.
Garcia-Blanco, M.A., Konarska, M.M., Sharp, P.A., Center
components with pre-mRNA substrates-Investigations
with modification/interference techniques.
Lassman, C., Milcarek, C., Dept. of Microbiology, Bio-
chemistry, and Molecular Biology, University of
Pittsburgh, Pennsylvania: Regulation of immunoglobulin
y2b mRNA processing.
Lavery, D., Chen-Kiang, S., Immunobiology Center and
Dept. of Microbiology, Mt. Sinai Medical School, New
York, New York: Lymphoid-cell-specific regulation of
nuclear-cytoplasmic mRNA transport.
for Cancer Research, Dept. of Biology, Massachusetts
Institute of Technology, Cambridge: Two proteins in
He La cell nuclear extracts interact specifically with
pre-mRNAs.
Kramer, A., Frick, M., Utans, U., Keller, W., Dept. of Cell
Biology, Biocenter of the University, Basel, Switzerland:
Analysis of protein factors from He La cells involved in
the assembly of splicing complexes with nuclear
pre-mRNA.
Sawa, H., Ohno, M., Sakamoto, H., Shimura, Y., Dept. of
Biophysics, Faculty of Science, Kyoto University, Japan:
Requirement of ATP in the second step of the pre-mRNA
splicing reaction.
Gutman, D., Goswami, P., Goldenberg, C.J., Dept. of
Microbiology and Immunology, University of Miami
School of Medicine, Florida: Purification and
characterization of an RNA helicase involved in
pre-mRNA splicing.
Zapp, M.L., Berget, S.M., Dept. of Biochemistry, Baylor
College of Medicine, Houston, Texas: Factors required
for recognition of 5' splice junctions.
Zeit lin, S., Wilson, R.C., Parent, A., Efstratiadis, A., Dept. of
Genetics and Development, Columbia University, New
York, New York: In vivo or in vitro assembled self-splicing
and complementable complexes.
SESSION 5 SPLICEOSOME ASSEMBLY AND TRANS-SPLICING
Chairman: P. Sharp, Massachusetts Institute of Technology
Michaeli, S., Watkins, K.P., Agabian, N., Intercampus
Program, Molecular Parasitology, University of California,
San Francisco: SL RNP-A unique small ribonucleo-
protein particle in Trypanosomes.
Bruzik, J.P.,1 Van Doren, K.,2 Hirsh, D.,2 Steitz, J.A.,1
1Dept. of Molecular Biophysics and Biochemistry, Yale
University, New Haven, Connecticut; 2Synergen, Inc.,
Boulder, Colorado: trans-Spliced leader RNAs exist as
covalently linked exon-snRNPs incorporated into Sm
particles.
Thomas, J., Conrad, R., Blumenthal, T., Dept. of Biology,
Indiana University, Bloomington: C. elegans snRNAs-
The trans-spliced leader precursor is bound to Sm
antigen and may have a TMG cap.
Osheim, Y.N., Amero, S.A., Beyer, A.L., Dept. of
Microbiology, UniversIty of Virginia, Charlottesville:
Visualizing the splicing process.
Jamieson, D., Beggs, J., Dept. of Molecular Biology,
University of Edinburgh, Scotland: Identification and
cloning of the sspl gene whose product suppresses the
defect of the rna8 -1 mutant of S. cerevisiae.
Brow, D.A., Guthrie, C., Dept. of Biochemistry and Biophysics,
University of California, San Francisco: Conserved
features of the synthesis and structure of U6 snRNA.
Bindereif, A., Pikielny, C.W., Green, M.R., Dept. of Bio-
chemistry and Molecular Biology, Harvard University,
Cambridge, Massachusetts: In vitro reconstitution of
functional snRNPs and mufti -snRNP complexes.
245
E Brody, J. Abelson, N. Pace
Lassota, P., Pruzan, R., Belgado, N., Hurwitz, J., Memorial
Sloan-Kettering Cancer Center, New York, New York:
Pre-spliceosome formation in vitro using purified U2
RNA.
Legrain, P., Seraphin, B., Fromherz, S., Rosbash, M., Dept.
of Biology, Brandeis University, Waltham, Massachusetts:
Yeast pre-mRNA is committed to the spliceosome
pathway before formation of U2 snRNP-containing
complexes.
SESSION 6 POSTER SESSION
Layden, R., Eisen, H., Fred Hutchinson Cancer Research
Center, Seattle, Washington: Does trans-splicing in
trypanosomes require base pairing between the two
spliced RNAs?
Lee, S.,1 Murthy, 5.,2 Trimble, J.,2 Desrosiers, R.C.,2
Steitz, J.A.,1 1Howard Hughes Medical Instituet, Dept.
of Molecular Biophysics and Biochemistry, Yale
University School of Medicine, New Haven, Connecticut;
2New England Regional Primate Research Center,
Harvard Medical School, Cambridge, Massachusetts: A
virus encodes four small U RNAs.
Legrain, P., Rosbash, M., Dept. of Biology, Brandeis
University, Waltham, Massachusetts: Splicing and
nuclear-cytoplasmic transport.
Liao, X., Brennwald, P., Wise, J.A., Dept. of Biochemistry,
University of Illinois, Urbana: Lethal point mutations in S.
pombe 7SL RNA.
Lim, S.,1 Cheng, J.,1 Mullins, J.J.,2 Gross, K.W.,2
Maguart, L.E.,1 Depts. of 1Human Genetics, 2Molecular
and Cellular Biology, Roswell Park Memorial Institute,
Ruby, S.W., Goelz, S., Abelson, J.N., Division of Biology,
California Institute of Technology, Pasadena: Yeast U1
snRNP binding is required for other snRNPs to bind dur-
ing in vitro splicing.
Padgett, R.A., Wang, X., Dept. of Biochemistry, University of
Texas Southwestern Medical Center, Dallas: Chemical
footprinting of splicing factors on pre-mRNA.
Buffalo, New York: Tissue specificity of mRNA
degradation.
Liu, T.-J.,1 Levine, B.J.,2 Skoultchi, A.I.,2 Marzluff, W.F.,2
1Dept. of Chemistry, Florida State University,
Tallahassee; 2Albert Einstein College of Medicine, Bronx,
New York: Efficiency of 3'-end formation contributes to
the steady-state level of histone mRNAs.
Lo, P., Mancebo, R., Pep ling, M., Mount, S.M., Dept. of
Biological Sciences, Columbia University, New York,
New York: Genes for U1 RNA and the U1 snRNP
"70K" protein in D. melanogaster.
Lobo, S., Hernandez, N., Cold Spring Harbor Laboratory,
Cold Spring Harbor, New York: A protein factor that
interacts with the proximal promoter element of a
polymerase II and a polymerase III snRNA gene.
MacDonald, C.C., Williams, D.L., Dept. of Pharmacological
Sciences, State University of New York, Stony Brook:
Isolation of proteins associated with the apolipoprotein II
mRNA.
Maddock, J.R., Lunz, R.L., Woolford, J.L., Carnegie Mellon
University, Pittsburgh, Pennsylvania: Interacting gene
products required for pre-mRNA processing.
Mans, R., van Belkum, A., Verlaan, P., Pley, C., Bosch, L.,
Dept. of Biochemistry, Leiden University, The
Netherlands: Site-directed mutagenesis of the cloned
3'-terminal tRNA-like structure of TYMV RNA.
Marciniak, R., Sharp, P., Dept. of Biology, Massachusetts
Institute of Technology, Cambridge: Studies of alternative
splicing of the L1 region of adenovirus type 2.
Maroney, P.A.,1 Hannon, G.,1 Branch, S.,2 Robertson, H.D.,2
Nilsen, T.W.,1 1Dept. of Molecular Biology and
Microbiology, Case Western Reserve University, School
of Medicine, Cleveland, Ohio; 2Rockefeller University,
New York, New York: Accurate processing of human
pre-rRNA in vitro.
McAllister, G., Roby-Shemkovitz, A.J., Amara, S.G.,
Lerner, M.R., Section of Molecular Neurobiology, Yale
University School of Medicine, New Haven, Connecticut:
Molecular cloning on N-A tissue-specific snRNP-
associated polypeptide.
Mellits, K.H., Mathews, M.B., Cold Spring Harbor
Laboratory, Cold Spring Harbor, New York: Structure-
function relationships in adenovirus VA RNA,.
Miczak, A., Apirion, D., Dept. of Microbiology, Washington
University, St. Louis, Missouri: Expression of the RNase
E gene in plasmids.
Montzka, K.A., Steitz, J.A., Dept. of Molecular Biophysics
and Biochemistry, Yale University, New Haven,
Connecticut: New low-abundance snRNPs-U11,
U12... .
Muller, M.W.,1 Schweywn, R.J. , 2 Schmelzer, C.,1
1Universitat Munchen, Federal Republic of
2Universitat Wien, Austria: Selection of cryptic splice sites
in self-splicing group II intron RNAs.
Munroe, S.H., Cold Spring Harbor Laboratory, Cold Spring
Harbor, New York: Antisense RNA complementary to 3'
exon sequences inhibits splicing of pre-mRNA.
Nilsen, T.W., Takacs, A., Denker, J., Perrine, K.,
Maroney, P.A., Dept. of Molecular Biology and
Microbiology, Case Western Reserve University, School
of Medicine, Cleveland, Ohio: A 22-nucleotide spliced
leader sequence in the human parasitic nematode
Brugia malayi is identical to the trans-spliced leader exon
in C. elegans.
Noble, J.C.S., Prives, C., Manley, J.L., Columbia University,
New York, New York: Role of the multiple branch-site
region in splicing of SV40 early pre-mRNA.
Nordstrom, J.L.,1,2 Chuang, K.C.,1 Prowdrill, T.F.,2 1Dept.
of Biological Sciences, Fordham University, Bronx, New
York; 2Dept. of Biochemistry and Biophysics, Texas A&M
University, College Station: Processing of transcripts
when polyadenylation and splicing signals are mutually
exclusive.
Norton, P.A., Hynes, R.O., Center for Cancer Research and
Dept. of Biology, Massachusetts Institute of Technology,
Cambridge: Splicing of fibronectin in vitro.
O'Connor, J.P., Peebles, C.L., Dept. of Biological Sciences,
University of Pittsburgh, Pennsylvania: A new yeast
mutant that affects tRNA splicing.
Offen, D.,1 Ast, G.,1 Sperling, R.,2 Sperling, J.,
1 1Dept. of
Organic Chemistry, Weizman Institute of Science,
Rehovot, 2Dept. of Genetics, Hebrew University of
Jerusalem, Israel: Monoclonal antibodies against 200S
nuclear RNP particles.
Offen, D.,1 Mendlovic, 5.,2 Sperling, R.,3 Sperling, J.,1
Mozes, E.,2 Depts. of 'Organic Chemistry, 2Chemical
Immunology, Weizmann Institute of Science, Rehovot,
3Dept. of Genetics, Hebrew University of Jerusalem,
Israel: Monoclonal anti-La antibody derived from a
mouse with experimental SLE is similar to human anti-La
antibodies.
Ohno, M., Kataoka, N., Shimura, Y., Dept. of Biophysics,
Faculty of Science, Kyoto University, Japan: A nuclear
cap-binding protein and pre-mRNA splicing.
Patterson, R.J., Werner, E.A., Dept. of Microbiology and
Public Health, Michigan State University, East Lansing:
Heat shock induces altered nuclear compartmentalization
and transport of non-heat-shock RNAs.
Phizicky, E.M.,1,2 Consaul, S.A.,1 Abelson, J.,2 1Dept. of
Biochemistry, University of Rochester Medical School,
New York; 2Division of Biology, California Institute of
Technology, Pasadena: Yeast strains that conditionally
lack functional tRNA ligase accumulate tRNA half-
molecules under nonpermissive conditions.
Platt, T., Butler, J.S., Baker, S.M., Ruohola, H., Hazen, J.,
University of Rochester Medical School, New York:
Orientation-dependent function of an 82-bp CYC1 DNA
fragment in directing mRNA 3'-end formation in yeast.
Potashkin, J., Li, R., Frendewey, D., Cold Spring Harbor
Laboratory, Cold Spring Harbor, New York: Pre-mRNA
splicing mutants of S. pombe.
Query, C.C.,1 Bentley, R.C.,2 Keene, J.D.,1 Depts. of
1Microbiology and Immunology, 2Pathology, Duke
University Medical Center, Durham, North Carolina:
RNA-binding properties of the U1 snRNP 70K protein.
Quirk, S.M.,1 Bell-Pedersen, D.,1 Tomaschewski, J.,2
Ruger, W.,2 Belfort, M.,1 1New York State Dept. of
Health, Wadsworth Laboratories, Albany; 2Arbeitsgruppe
Molekulare Genetik, Ruhr-Universitat Bochum, Federal
Republic of Germany: Inconsistent distribution of introns
in the T-even phages indicates recent genetic
exchanges.
Ratnasabapathy, R., Williams, D.L., Dept. of
Pharmacological Sciences, State University of New York,
Stony Brook: Interaction of apolipoprotein II mRNA with
cytoplasmic mRNA-binding proteins.
Reed, R.,1 Griffith, J.D.,2 Maniatis, T.,1 1Dept. of
Biochemistry and Molecular Biology, Harvard University,
Cambridge, Massachusetts; 2Lineberger Cancer
Research Institute and Dept. of Microbiology and
Immunology, University of North Carolina Medical
School, Chapel Hill: Purification and visualization of
native spliceosomes.
Reich, C., Pace, N.R., Dept. of Biology, Indiana University,
Bloomington: Influence of 3'-CCA content on precursor
tRNA cleavage by the B. subtilis ribonuclease P.
Reilly, J.D.,1 Melhem, R.F.,1 Kopp, D.,1 Edmonds, M.,1
Munns, T.,2 1Dept. of Biological Sciences, University of
Pittsburgh, Pennsylvania; 2Dept. of Rheumatology,
Washington University Medical School, St. Louis,
Missouri: Antibodies specific for the branch consensus
sequence A[2'p5'G]3'p5'C.
Rio, D.C., Whitehead Institute for Biomedical Research and
Dept. of Biology, Massachusetts Institute of Technology,
247
Cambridge: Accurate and efficient pre-mRNA
splicing in
Drosophila cell-free extracts.
Rokeach, L.A., Jannatipour, M., Hoch, S.O., Agouron
Institute, La Jolla, California: Primary structure
of the
autoantigen associated with the Ro-RNP.
Rossi, J.J., Felder, E., Deshler, J., Dept. of Molecular
Genetics, Beckman Research Institute of the
City of
Hope, Duarte, California: Generation of alternatively
spliced transcripts from the S. cerevisiae actin
pre-mRNA.
Ryner, L.C., Takagaki, Y., Manley, J.L., Dept.
of Biological
Sciences, Columbia University, New York, New
York:
Sequence requirements for cleavage and polyadenyla-
tion in fractionated extracts.
Samuels, M., Keyes, L., Schedl, P., Cline, T., Dept. of
Biology, Princeton University, New Jersey: Analysis of
the expression pattern of the Drosophila sex determina-
tion gene, sex-lethal.
Sapolsky, R.J., Davis, R.W., Stanford University School of
Medicine, California: Deletion analysis of the 3' end of
the GAL7 gene-DNA fragments that protect ARS
function from transcriptional interference in yeast.
Schappert, K.T., Friesen, J.D., Dept. of Medical Genetics,
University of Toronto, Canada: Characterization of
RNA11 -A yeast gene involved in mRNA processing in
yeast.
Schamperli, D., Lascher, B., Meier, V., Soldati, D., Stauber, C.,
Institut far Molekularbiologie II, Universitat Zurich,
Switzerland: Regulation of mouse histone gene
expression by RNA 3' processing-Characterization of
U7 snRNA.
Shukla, R., Zwierzynski, T., Kole, R., Dept. of Pharmacology
and Lineberger Cancer Research, University of North
Carolina, Chapel Hill: Inactivation of a splicing factor by
heat shock of He La cells.
Shumard, C.M., Eichler, D.C., Dept. of Biochemistry,
University of South Florida College of Medicine, Tampa:
Involvement of a nucleolar endoribonuclease in an early
cleavage event of precursor rRNA processing.
Smith, H.C., Harris, S.G., Dept. of Pathology, University of
Rochester, New York: Organization of Sm antigens B',
B, D, and U1 snRNP-specific 63-kD revealed by thiol
reversible chemical cross-linking.
Smith, J.B., Dinter-Gottlieb, G., Dept. of Bioscience and
Biotechnology, Drexel University, Philadelphia,
Pennsylvania: Detection of viroid-binding proteins in
uninfected tomato plants.
Solymosy, F., Kiss, T., Institute of Plant Physiology, Biological
Research Center, Hungarian Academy of Science, Szeg-
ed: Structure of plant U snRNA-An overview with
special reference to functional aspects.
Spann, P.,1 Cahana, N.,1 Sperling, J.,2 Sperling, R.,1 1Dept.
of Genetics, Hebrew University of Jerusalem, 2Dept. of
Organic Chemistry, Weizmann Institute of Science,
Rehovot, Israel: The effect of Mg + + ions on the
association of U snRNPs with large 200S nuclear RNP
complexes.
Srivastava, R.A.K., Miczak, A., Apirion, D., Dept. of Micro-
biology, Washington University, St. Louis, Missouri:
RNaseJ-A new RNA processing enzyme from E. coli.
Stanford, D.R., Perry, C.A., Patton, J.P., Fautsch, M.P.,
Wieben, E.D., Dept. of Biochemistry and Molecular
248
Biology, Mayo Foundation, Rochester, Maine: Structure
and function of the human snRNP E protein.
Stover, C.B., Uhlenbeck, 0.C., Dept. of Chemistry and
Biochemistry, University of Colorado, Boulder: Kinetic
effects of conserved tRNA nucleotide mutations on
RNase P cleavage.
Surowy, C.S., van Santen, V.L., Wixted, S.M., Spritz, R.A.
Dept. of Medical Genetics, University of Wisconsin,
Madison: The human U1-70K snRNP protein-RNA
binding and immunological studies.
Swanson, M.S., Piriol-Roma, S., Dreyfuss, G., Dept. of
Biochemistry, Molecular Biology and Cell Biology,
Northwestern University, Evanston, Illinois: Novel
proteins of heterogeneous nuclear ribonucleoprotein
particles-Identification, molecular cloning, and
characterization.
Swartwout, S.G.,1 Kinniburgh, A.J.,1,2 Depts. of 1Human
Genetics, 2Hematological Oncology, Roswell Park
Memorial Institute, Buffalo, New York: Alternate pathways
of c-myc RNA turnover in growing and differentiating
cells.
Tanner, N.K.,1 Hanna, M.M.,2 Abelson, J.,1 'Division of
Biology, California Institute of Technology, Pasadena;
2Dept. of Biological Chemistry, University of California,
Irvine: Cross-linking yeast tRNA ligase to bromouridine-
and thiouridine-incorporated precursor tRNA.
Teare, J., Wollenzien, P., Dept. of Biochemistry, St. Louis
University Medical Center, Missouri: Analysis of the
secondary structures of human and rabbit /3- globin pre-
mRNA by psoralen cross-linking.
to Heesen, S.,1 Melchers, K.,1 Werr, H.,2 Henrich, B.,2
Schafer, K.P.,1 1Byk Gulden Pharmaceuticals, Molecular
Biology, Konstanz, 2Ruhr-Universitat Bochum, Federal
Republic of Germany: Gene families for hnRNP core
proteins Al, A2, and C3-Is hnRNP protein Al express-
ed from an activated retroposon?
Tazi, J., Temsamani, J., Alibert, C., Rhead, W., Cathala, G.,
Brunel, C., Jeanteur, P., Laboratoire de Biochimie, et
Laboratoire de Biologie Moleculare, USTL, Montpellier,
France: U5 snRNP is involved early in mammalian
pre-mRNA splicing.
Thomas, J., Zucker-Aprison, E., Blumenthal, T., Dept. of
Biology, Indiana University, Bloomington: C. elegans
snRNAs and snRNA genes.
Tollervey, D.,1 Tessars, G.,2 Luhrmann, R.,1 1 Institut
Pasteur, Paris, France; 2Max-Plank-Institut fur Molekulare
Genetik, Berlin, Federal Republic of Germany: Structure
of yeast snRNPs.
Topper, J.N., Clayton, D.A., Dept. of Pathology, Stanford
University School of Medicine, California: Cleavage of a
nucleus-encoded RNA component of a vertebrate
mitoc'hondrial RNA-processing enzyme.
Tyc, K., Steitz, J.A., Howard Hughes Medical Institute, Dept.
of Molecular Biophysics and Biochemistry, Yale
University, New Haven, Connecticut: Chemical
modification studies of the U2 snRNA in splicing
complexes.
Uzan, M., Favre, R., Lobo, C.D.S., Brody, E., IBCP, Paris,
France: A nuclease that cuts specifically in the ribosome-
binding site of some T4 mRNAs.
Vankan, P., Waibel, F., Edoh, D., Filipowicz, W., Friedrich
Miescher Institut, Basel, Switzerland: Structure and
expression of plant U2, U5, and U6 snRNA genes.
Vattay, A., Noll, G., Hart, R., Dept. of Biological Sciences,
Rutgers University, Newark, New Jersey: Putative He La
cell nuclear factors recognizing poly(A)-site sequences.
Vijayraghavan, U., Abelson, J., Division of Biology,
California Institute of Technology, Pasadena:
Temperature-sensitive splicing mutants in yeast.
Wang, S., Hopper, A.K., Dept. of Biological Chemistry,
M.S. Hershey Medical Center, Pennsylvania State
University, Hershey; Isolation of a yeast gene involved
in species-specific pre-tRNA splicing.
Wang, M.J., Ory, G., Oommen, A., Gegenheimer, P.,
Depts. of Biochemistry and Botany and Molecular
Genetics Program, University of Kansas, Lawrence:
Inhibition of RNA processing by micrococcal nuclease
results from binding of EGTA-inactivated nuclease to
substrate RNA.
Ware, V.C., Dept. of Biology and Center for Molecular
Bioscience and Biotechnology, Lehigh University,
Bethlehem, Pennsylvania: rRNA processing-Structure
of the gap region in domain IV of T. thermophila
26S rRNA.
Welch, A.R., Dinter-Gottlieb, G., Dept. of Bioscience and
Biotechnology, Drexel University, Philadelphia,
Pennsylvania: Although not phylogenetically conserved
in all group I introns, P5C appears to be necessary for
self-splicing of the Tetrahymena intron.
Willis, I., Li, R., So II, D., Dept. of Molecular Biophysics and
Biochemistry, Yale University, New Haven, Connecticut:
Multiple extragenic mutations restore phenotypic
expression of a mutant nonsense suppressor.
Wurtz, T., Lonnroth, A., Kirov, N., Ovchinnikov, L.,
Daneholt, B., Dept. of Molecular Genetics, Karolinska
Instituet, Stockholm, Sweden: Isolation and partial
characterization of specific pre-mRNP particles.
Xu, Q., Abelson, J., Division of Biology, California Institute of
Technology, Pasadena: Structural and functional analysis
of the active domains of yeast tRNA ligase.
Zarkower, D., Wickens, M., Dept. of Biochemistry, University
of Wisconsin, Madison: Specific precleavage and
postcleavage complexes involved in the formation of
SV40 late mRNA 3' termini in vitro.
Zassenhaus, P., Dept. of Microbiology, St. Louis University
Medical Center, St. Louis, Missouri: An ATP-dependent
5' exoribonuclease from yeast mitochondria.
Zaug, A.J., Grosshans, C., Cech, T.R., Dept. of Chemistry
and Biochemistry, University of Colorado, Boulder:
Sequence-specific endoribonuclease activity of the
Tetrahymena ribozyme-Enhanced cleavage of certain
oligonucleotide substrates that form mismatched
ribozyme-substrate complexes.
Zhang, J., Deutscher, M.P., Dept. of Biochemistry,
University of Connecticut Health Center, Farmington:
E. coil RNase D-Sequencing and characterization of
the md structural gene.
Zieve, G.W., Sauterer, R.A., Feeney, R.J., Dept. of
Anatomical Sciences and Program in Cellular and
Developmental Biology, State University of New York,
Stony Brook: snRNP particles assemble in the cytoplasm
from newly synthesized snRNA and stored pools of
partially assembled proteins with at least three different
kinetic components.
Zwieb, C., European Molecular Biology Laboratory,
Heidelberg, Federal Republic of Germany: Toward the
three-dimensional structure of 7SL RNA-Functional
implications.
SESSION 7 snRNP AND HNRNP STRUCTURE AND SYNTHESIS
Chairman: D. Clayton, Stanford University Medical School
Luhrmann, R., Bach, M., Heyer, A., Kastner, B.,
Winkelmann, G., Max-Planck-Institut fur Molekulare
Genetik, Berlin, Federal Republic of Germany: The major
UsnRNPs from He La Cells-Heterogeneity of protein
composition, immunoelectron microscopic investigation,
and contribution of individual snRNPs to splicing as
investigated by a complementation assay.
Krainer, A.R., Kozak, D., Cold Spring Harbor Laboratory,
Cold Spring Harbor, New York: Purification of active
mammalian m3G snRNPs.
Pan, Z., Prives, C., Columbia University, New York, New
York: Assembly of functional U1 and U2 human-
amphibian hybrid snRNPs in X. laevis oocytes.
Hamm, J., Mattaj, I.W., EMBL, Heidelberg, Federal
Republic of Germany: Identification of protein-binding
sites on U1 snRNA by in vitro assembly of RNPs.
Carbon, P.,1 Westhof, E.,1 Ebel, J.P.,1 Bach, M.,2
Luhrmann, R.,2 Krol, A.,1 1 IBMC, Strasbourg, France;
2MPI, Berlin, Federal Republic of Germany: Three-
dimensional model of U1 snRNA.
Petersen-Bjorn, S., Friesen, J.D., Dept. of Medical Genetics,
University of Toronto, Canada: Analysis of the roles
of
RNA4 and ORF2 in yeast mRNA splicing.
Lund, E., Dahlberg, J.E., Dept. of Physiological Chemistry,
University of Wisconsin, Madison: Efficient and accurate
transcription of exogenous U1 RNA genes in isolated
nuclei of X. laevis oocytes.
Shuster, E.O., Guthrie, C., University of California, San
Francisco: Yeast U2 has two functionally important
domains separated by a large nonessential region.
Frendewey, D., Li, R., Potashkin, J., Cold Spring Harbor
Laboratory, New York: Isolation of a mutant defective in
U2 RNA sysnthesis from S. pombe.
Swanson, M.S., Dreyfuss, G., Dept. of Biochemistry,
Molecular Biology and Cell Biology, Northwestern
University, Evanston, Illinois: Specific binding and
ATP-dependent complex formation of hnRNP proteins at
the 3' end of introns.
Barnett, S.F., Friedman, D.L., LeStourgeon, W.M., Dept. of
Molecular Biology, Vanderbilt University, Nashville,
Tennessee: The C proteins of core 40S hnRNP particles
exist as four tetramers of 3C1-1C2 with a Stokes' radius
of 6.2 nm and an RNA-binding potential of 115
nucleotides per tetramer.
249
SESSION 8 ALTERNATIVE PROCESSING PATHWAYS
Chairman: A. Beyer, University of Virginia
Ge, H., Fu, X.-Y., Manley, J.L., Dept. of Biological Sciences,
Columbia University, New York, New York: A varient U5
found in human 293 cells but not He La cells may
influence alternative splicing of SV40 early pre-mRNA.
Smith, C.W.J., Gooding, C., Nadal-Ginard, B., Dept. of
Cardiology, Children's Hospital, Howard Hughes Medical
Institute, Boston, Massachusetts: Mechanism of
alternative splicing in a a-tropomyosin-Mutually
exclusive splicing is enforced by an abnormally positioned
lariat branch point distance from the acceptor.
Helfman, D.M., Ricci, W.M., Cold Spring Harbor Laboratory,
Cold Spring Harbor, New York: Studies of alternative
RNA splicing of tropomyosin pre-mRNAs in vitro.
Cooper, T.A., Cardone, M.H., Ordahl, C.P., Dept. of
Anatomy, University of California, San Francisco:
cis requirements for alternative splicing.
Eng, F.J., Johnson, S.P., Warner, J.R., Depts. of Cell
Biology and Biochemistry, Albert Einstein College of
Medicine, Bronx, New York: Mechanism of the
autogenous regulation of mRNA splicing by a yeast
ribosomal protein.
Bingham, P., Chou, T.-B., Mims, I., Zachar, Z., Dept. of
Biochemistry, State University of New York, Stony Brook:
SESSION 9 RNA TRANSPORT AND TURNOVER
Analysis of autoregulation of a regulatory gene at the
level of splicing.
Bell, L., Maine, E., Cline, T., Schedl, P., Dept. of Biology,
Princeton University, New Jersey: Sex-specific splicing of
a Drosophila sex-determination gene, sex-lethal, that
shows sequence similarity of RNA-binding proteins.
Brady, H., Wold, W., Institute of Molecular Virology,
St. Louis University School of Medicine, Missouri:
Competition between splicing and polyadenylation
determines which adenovirus region E3 mRNAs are
synthesized.
Rivkin, E.,1 Galli, G.,1 Tucker, P.W.,2 Nevins, JR.,3
1Howard Hughes Medical Institute, Rockefeller University,
New York, New York; 2Dept. of Microbiology, University
of Texas, Southwestern Medical Center, Dallas; 3Howard
Hughes Medical Institute, Duke University Medical
Center, Durham, North Carolina: Efficiency of poly(A)-site
utilization, dictated by downstream sequence elements,
determines immunoglobulin I.4-gene control.
Peterson, M.L., Perry, R.P., Institute for Cancer Research,
Philadelphia, Pennsylvania: On the developmentally
regulated processing of immunoglobulin mRNA.
Chairman: D. Cleveland, Johns Hopkins University School of Medicine
Aebi, M.1 Vijayraghavan, U.,1 Jacobson, A.,2 Abelson, J.,1
1Division of Biology, California Institute of Technology,
Pasadena; 2University of Massachusetts Medical School,
Worcester: A search for mutants of S. cerevisiae
defective in transport of mRNA from the nucleus to the
cytoplasm.
Hopper, A.K., Traglia, H.M., Dept. of Biological Chemistry,
M.S. Hershey Medical Center, Pennsylvania State
University, Hershey: Intracellular location of the yeast
RNA1 protein.
von Gabain, A., Dept. of Bacteriology, Karolinska Institute,
Stockholm, Sweden: The growth-dependent stability of
E. co/i ompA mRNA is regulated by a site-specific
endonuclease.
Yen, T.J., Cleveland, D.W., Dept. of Biological Chemistry,
Johns Hopkins University School of Medicine, Baltimore,
Maryland: Autoregulated degradion of (3 tubulin mRNA
requires its presence on polysomes and is achieved
through the recognition of nascent n-terminus of (3 tubulin.
Casey, J.L., Hentze, M.W., Koeller, D.M., Caughman, S.W.,
Rouault, T.A., Klausner, R.D., Harford, J.B., NICHD,
National Institutes of Health, Bethesda, Maryland: Similar
SESSION 10 3'-END FORMATION
Chairman: J. Manley, Columbia University
Takagaki, Y., Ryner, L.C., Manley, J.L., Dept. of Biological
Sciences, Columbia University, New York, New York:
250
iron-responsive RNA elements are implicated in the
control of transferrin receptor mRNA levels and ferritin
mRNA translation.
Tatro, T.A., Zhang, Y., Schneider, R.J., Dept. of
Biochemistry and Kaplan Cancer Center, New York
University Medical Center, New York: Targeted
degradation of RNAs by an AU-rich sequence is
independent of translation, splicing, and polyadenylation.
Brewer, G., Ross, J., McArdle Laboratory for Cancer
Research and Dept. of Pathology, University of
Wisconsin, Madison: The c-myc mRNA decay rate is
accelerated by labile cytosolic factor(s) in a cell-free
mRNA decay system.
Binder, R., Hwang, S.-P.L., MacDonald, C.C., Williams, D.L.,
Dept. of Pharmacological Sciences, State University of New
York, Stony Brook: Degradation of the estrogen-induced
mRNA for chick apolipoprotein II occurs via cleavage at
AAUs with loop structures of the 3'-noncoding region.
Munroe, D., Jacobson, A., Dept. of Molecular Genetics and
Microbiology, University of Massachusetts Medical
School, Worcester: Direct evidence for translational role
for the poly(A) tract of mRNA.
Separation and further purification of a poly(A)
polymerase and a cleavage-specificity factor required for
pre-mRNA polyadenylation.
McDevitt, M.A., Gilmartin, G.M., Lakota, J., Nevins, J.R.,
Howard Hughes Medical Institute, Duke University
Medical Center, Durham, North Carolina: Identification of
multiple factors involved in poly(A)-site formation.
Virtanen, A.,1 Gil, A.,2 Sharp, P.A.,2 1Dept. of Medical
Genetics, Uppsala University, Sweden; 2Center for
Cancer Research, Massachusetts Institute of Technology,
Cambridge: Characterization of factors responsible for
cleavage and polyadenylation of pre-mRNA in He La
nuclear extract.
Clements, J.B., Simpson, S., McLauchlan, J., MRC Virology
Unity, University of Glasgow, Scotland: Temporal
regulation of HSV poly (A)- site selection.
Moore, C., Chen, J., Whoriskey, J., Dept. of Molecular
Biology and Microbiology, Tufts Medical School, Boston,
Massachusetts: Two proteins cross-linked to RNA
containing the adenovirus L3 polyadenylation site require
the AAUAAA sequence for binding.
Wilusz, J., Shenk, T., Dept. of Molecular Biology, Princeton
University, New Jersey: The downstream element of the
polyadenylation sibnal is required for efficient cross-linking
RNA Tumor Viruses
of hnRNP C proteins to polyadenylation substrate RNAs.
Wickens, M., Bardwell, V., Conway, L., Fox, C., Ogg, S.,
Sheets, M., Wig ley, P., Zarkower, D., Dept. of
Biochemistry, University of Wisconsin, Madison:
Formation of SV40 late pre-mRNA 3' termini in vitro-
Complexes and critical features of the substrate.
Rose, S.D., Berget, S.M., Baylor College of Medicine,
Houston, Texas: Evidence for classes of polyadenylation
sites.
Marzluff, W.F.,1 Pandey, N.,2 1 Dept. of Chemistry, 2lnstitute
of Molecular Biophysics, Florida State University,
tion of 3' ends of histone mRNAs.
Proudfoot, N.J., Levett, N.C., Briggs, D., Sir William Dunn
School of Pathology, University of Oxford, England: A-
rich sequences in RNA polymerase II termination.
Mowry, K.L., Oh, R., Steitz, J.A., Howard Hughes Medical
Institute, Dept. of Molecular Biophysics and
Biochemistry, Yale University School of Medicine, New
Haven, Connecticut: The mammalian U7 snRNP and at
least one additional factor are required for 3'-end
processing of mammalian histone pre-RNAs in vitro.
May 17-May 22
ARRANGED BY
Stephen Goff, Columbia University
Naomi Rosenberg, Tufts University Medical School
363 participants
The 1988 RNA Tumor Virus meeting brought together several
hundred
virologists, biochemists, geneticists, and clinicians to discuss progress
in the field
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of retroviruses. This year's meeting continued the trends of
recent years in
emphasis of two major areas: biochemical analysis of retroviral
replication, on the
one hand, and analysis of viral pathogenesis, on the other.
Important progress
was reported on the identification of the murine viral receptor; on the mechanism
of integration of the proviral DNA, facilitated by the development of an in vitro
recombination system; on the identification of "hot spots" in the cellular genome
for retroviral integration; on the formation and translation of viral mRNAs; and on
the assembly of virion particles, especially the selective encapsidation
of genomic
viral RNA. The interactions of the viruses with cellular oncogenes-both
insertional activation and transduction-remained significant fields of study.
A large portion of the meeting was devoted to the biology of the human and
simian retroviruses. Major debates centered around the mechanisms of regulation
of expression of the viral gene products, under the control of (at a minimum) the
tat and rev proteins. The identification of new gene products, perhaps with
regulatory functions, encoded by selected isolates of the HIV family was
reported. The rapid mutability of the viral genome continues to be documented,
foreboding difficulties in preparation of vaccines. Specific alterations (truncations)
of the SIV env gene that arise spontaneously were found to be essential for
replication of the virus in culture; the complete gene was essential for full
pathogenicity in animals.
M. Linial, G.S. Martin
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LoSardo, J., Dept. of Genetics, Albert Einstein College of
Medicine, Bronx, New York: Identification of cell-type-
specificity-determining elements in MLV LTRs.
Dutta, A., Dorai, T., Hanafusa, H., Rockefeller University,
New York, New York: The putative trans-activator in the
gag region of RSV is not required for transformation of
primary CEFs.
Katz, R.A., Kotler, M., Skalka, A.M., Fox Chase Cancer
Center, Institute for Cancer Research, Philadelphia,
Pennsylvania: Genetic selection strategy for identification
of sequences required for regulated ASV splicing.
Stoltzfus, C.M., Berberich, S.L., Fogarty, S.J., Dept. of
Microbiology, University of Iowa, Iowa City: Deletions in
the RSV v-src intron affect spliced to unspliced RNA
levels-Correlation with infectivity.
Arrigo, S., Beemon, K., Dept. of Biology, Johns Hopkins
University, Baltimore, Maryland: Negative regulation of
RSV RNA splicing.
Feng, Y.X.,1 Hatfield, D.,2 Rein, A.,3 Levin, J.G.,1 1NICHD,
2LEC, NCI, National Institutes of Health, 3NCI-Frederick
Cancer Research Facility, Frederick, Maryland: Analysis
of tRNA involved in suppression of the MLV amber
codon at the gag-pol junction.
Derse, D., NCI-Frederick Cancer Research Facility,
Frederick, Maryland: cis- and trans-Acting regulation of
BLV mRNA 3'-end formation.
Swain, A., Coffin, J.M., Dept. of Molecular Biology and
Microbiology, Tufts University School of Medicine,
Boston, Massachusetts: Correct polyadenylation is not
required for retroviral replication.
SESSION 3 POSTER SESSION: Receptors, Viral Genes, and
Expression
Basu, S., Varmus, H.E., Dept. of Microbiology and
Immunology, University of California, San Francisco:
Studies on the Mo-MLV integrase produced in yeast.
Blair, D.G., Dunn, K.J., O'Hara, B.M., NCI-Frederick Cancer
Research Facility, Frederick, Maryland; Leder le
Laboratories, Pearl River, New York: Glycosylation
inhibition afters retroviral receptor specificity on mouse
cells.
Sommerfelt, M.A.,1 Williams, B.P.,2 Goodfellow, P.N.,2
Weiss, R.A.,1 1 Institute of Cancer Research, 2lmperial
Cancer Research Fund, London, England: Receptors for
retroviruses on human cells.
Goodrich, D., Duesberg, P., Dept. of Molecular Biology,
University of California, Berkeley: Retroviruses use RNA
template switching for homologous, but not for
nonhomologous, recombination.
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Posters
Pryciak, P.M., Varmus, H.E., Depts. of Biochemistry and
Biophysics, and Microbiology and Immunology, Universi-
ty of California, San Francisco: In vitro dissection of the
mechanism of MLV replicative restriction by the mouse
Fv-1 locus.
Chalker, D.L., Haywood, L.J., Sandmeyer, S.B., Dept. of
Microbiology and Molecular Genetics, University of
California, Irvine: Position-specific transposition of a yeast
retrotransposon, Ty3.
Haywood, L., Chalker, D., Sandmeyer, S., University of
California, Irvine: The yeast retrotransposon, Ty3, is
homologous to animal retroviruses.
Youngren, S.D., Garfinkel, D.J., NCI-Frederick Cancer
Research Facility, Frederick, Maryland: Organization of
the TyB gene from the S. cerevisiae retrotransposon
Tyl.
McClure, M.A., Johnson, M.S., Feng, D.-F., Doolittle, R.F.,
Dept. of Chemistry and Center for Molecular Genetics,
University of California, San Diego: Sequence
comparisons of retroviral proteins-Relative rates of
change, recombination, and general phylogeny.
Moustakas, A., Hackett, P.B., Dept. of Genetics and Cell
Biology, University of Minnesota, St. Paul: Modification of
the first and second open reading frames on RSV RNA
affects viral propagation.
Shoji, A., Park, H.T., Kaji, A., Dept. of Microbiology, University
of Pennsylvania School of Medicine, Philadelphia:
Unusual properties of RSV particles produced at early
period postinfection-Presence of viral DNA and
reduced amount of env protein.
Pryciak, P.M., Jacks, T.E., Varmus, H.E., Depts. of
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Biochemistry and Biophysics, and Microbiology and
Immunology, University of California, San Francisco:
Mutations in the site of ribosomal frameshifting in RSV
and their effects on viral replication.
Felsenstein, K.M., Goff, S.P., Dept. of Biochemistry, Columbia
University, College of Physicians & Surgeons, New York,
New York: RNA sequence requirements for pol gene
expression via translational readthrough of the gag
terminator codon in Mo-MLV.
Donehower, L.A., Dept. of Virology and Epidemiology,
Houston, Texas: Analysis of linker insertion mutants in
the integrase-encoding region of Mo-MLV.
Mumm, S., Grandgenett, D., St. Louis University, Institute
for Molecular Virology, Missouri: Synthesis of avian
retrovirus pp32 protein by in vitro translation-purification
and mapping of DNA-binding domains.
Karnitz, L., Ip, T., Chalk ley, R., Dept. of Molecular Physiology
and Biophysics, Vanderbilt University, Nashville,
Tennessee: Chromatin structure of the 5' end of the RSV
provirus in BHK cells.
Speck, N., Renjifo, B., Golemis, E., Hartley, J., Hopkins, N.,
Center for Cancer Research, Massachusetts Institute of
Technology, Cambridge, and NCI, National Institutes of
Health, Bethesda, Maryland: Functional contribution of
enhancer-binding nuclear factors to the transcriptional
activity of the Mo-MLV enhancer.
Shimkus, M., Boulden, A., Sealy, L., Dept. of Molecular
Physiology and Biophysics, Vanderbilt University,
Nashville, Tennessee: trans-Acting factors that interact
with the RSV LTR enhancer.
Kitado, H., Fan, H., Dept. of Molecular Biology and
Biochemistry, University of California, Irvine: Chromatin
structure of chimeric Mo-MLV proviruses containing
pX-responsive sequences from HTLV-II.
Mondal, D., Prakash, 0., Laboratory of Molecular Oncology,
Alton Ochsner Medical Foundation, New Orleans,
Louisiana: Regulation of MMTV LTR-directed gene
expression by phorbol esters.
Gowland, P., Diggelmann, H., Buetti, E., Swiss Institute for
Experimental Cancer Research, Epalinges, Switzerland:
Mutations in the hormone regulatory element of MMTV
differentially affect the response to progestins and
androgens as compared to glucocorticoids.
Golemis, E.,1 Li, Y.,2 Hartley, J.W.,3 Hopkins, N.,1 1Center
for Cancer Research, Massachusetts Institute of
Technology, Cambridge; 2New England Regional
Primate Center, Harvard Medical School, Southboro,
Massachusetts; 3NCI, National Institutes of Health,
Bethesda, Maryland: Disease specificity of MLVs-
Interactions between discrete segments within the
enhancer are involved in targeting.
Theunissen, H.J.M., Paardekooper, M., Michalides, R.J.A.M.,
Nusse, R., Dept. of Molecular Biology, Antoni van
Leeuwenhoekhuis, Netherlands Cancer Institute,
Amsterdam: TPA-inducible cell-type-specific expression
of MMTV variants.
van Klaveren, P., Kneppers, A.L.J., Bentvelzun, P., Dept. of
Retrovirology, Radiobiological Institute TNO, Rijswijk, The
Netherlands: trans-Activating potential of the LTR of the
MMTV.
Dorn, P.L.,1 Derse, D.,2 1NCI and Dept. of Zoology,
University of Maryland, College Park; 2NCI-Frederick
Cancer Research Facility, Frederick, cis- and
trans-Acting regulation of gene expression of EIAV.
Crowell, R.C.,1 Wolfes, H.,2 Cooper, G.M.,2 Kiessling, A.A.,1
1Dept. of Obstetrics, Gynecology, and Reproductive
Biology, 2Dana-Farber Cancer Institute, Harvard Medical
School, Boston, Massachusetts: The epididymis is a
preferred site of synthesis of a unique retroviral
transcript.
SESSION 4 REGULATION: TAT AND ART
Tupper, J., Diem, K., Yoshimura, F., Dept. of Bio Structure,
University of Washington, Seattle: Differences in protein-
DNA complexes generated by LTR sequences of MLVs
with different pathogenicities.
Falzon, M., Kuff, E.L., NCI, National Institutes of Health,
Bethesda, Maryland: Characterization of nuclear protein-
binding domains within the mouse intracisternal
A-particle LTR.
Villar, C.J., Kozak, C.A., NIAID, National Institutes of Health,
Bethesda, Maryland: Transcriptional activity of the
MCF-related proviruses of Mus spretus and their
potential for recombination.
Brack-Werner, R.,1 Barton, D.E.,4 Werner, T. 2
Foellmer, B.E.,4 Leib-Mosch, C.,3 Francke, U.,4 Ertle, V.,1
Hehlmann, R.,3 1Abt. f. Molekulare Zellpatholgie,
2lnstitut f. Saeugetiergenetik, Neuherberg, 3Medizinische
Poliklinik der Universitaet Muenchen, Munich, Federal
Republic of Germany; 4Dept. of Human Genetics, Yale
University School of Medicine, New Haven, Connecticut:
A human endogenous LTR-like sequence is located on
chromosome 18021.
Fredholm, M.,1,2 Policastro, P.F.,1 Wilson, M.C.,1 1Dept. of
Molecular Biology, Research Institute of Scripps Clinic,
La Jolla, California; 2Dept. of Animal Genetics, Royal
Veterinary and Agricultural University, Copenhagen,
Denmark: Recombination and transposition of murine
endogenous retroviral sequences.
Boone, L.R.,1 Glover, P.L.,1 Innes, C.L.,1 Niver, L.A.,1
Bondurant, M.C.,2 Yang, W.K.,3 1National Institute of
Environmental Health Sciences, Research Triangle Park,
North Carolina; 2Veterans Administration Medical Center,
Nashville, 3Oak Ridge National Laboratory, Tennessee:
Analysis of Fv-1 N- and B-tropic-specific sequences in
MLV and related endogenous proviral genomes.
Olsen, H.S., Lovmand, S., Baekgard, A., Dai, H.Y.,
Jorgensen, P., Kjeldgaard, N.O., Pedersen, F.S., Dept.
of Molecular Biology, University of Aarhus, Denmark:
Transcriptional control of Akv and related MLVs-Role of
nuclear- factor -I -like DNA-binding activity.
Chairmen: W. Haseltine, Dana Farber Cancer Institute, Harvard Medical School
P. Jolicoeur, Clinical Research Institute of Montreal
Dokhelar, M.C., Sodroski, J., Haseltine, W., Dana-Farber
Cancer Institute, Boston, Massachusetts: HTLV-I p27
protein regulates gag-env and tat expression.
Tan, T.-H., Roeder, R.G., Rockeller University, New York,
New York: Identification and purification of nuclear
factors interacting with HTLV-I tat-l-responsive element
within the HTLV-I LTR.
Ruben, S.,1 Poteat, H.,2 Tan, T.H.,3 Hurst, H.,4
Hazeltine, W.,2 Roeder, R.,3 Jones, N.,4 Rosen, C.,1
1Roche Institute of Molecular Biology, Nutley, New
Jersey; 2Dana-Farber Cancer Institute, Boston,
Massachusetts; 3Rockefeller University, New York, New
York; 4lmperial Cancer Research Fund, London,
England: Identification and characterization of
transcription factors required for regulation of viral and
cellular gene expression by the HTLV-I tax protein.
Chen, I.S.Y., Rosenblatt, J., Lugo, J., Williams, J., Depts. of
Medicine and Microbiology and Immunology, University
of California School of Medicine, Los Angeles:
Regulation of HTLV gene expression.
lkawa, Y.,1 Katoh, 1.,1 Shoji, A.,1 Yoshinaka, y.,2 1Tsukuba
Life Science Center, Riken, 2Japan lmmunoresearch
Laboratories, Takasaki: BLV tat protein trans-activates
heterologous promoters with cAMP-responsive elements.
Seiki, M., Inoue, J., Hidaka, M., Yoshida, M., Dept. of Viral
Oncology, Cancer Institute, Tokyo, Japan: A unique
posttranscriptional mechanism controls viral mRNA levels
and replication of HTLV-I.
Williams, J.L., Chen, I.S.Y., Depts. of Medicine and Micro-
biology and Immunology, University of California School
of Medicine, Los Angeles: Studies of heterologous
promoter trans-activation by the HTLV-II x protein.
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Ohta, M., Akagi, T., Nyunoya, H., Tanaka, H., Okamoto, T.,
Shimotohno, K., Division of Virology, National Cancer
Center Research Institute, Tokyo, Japan: The rex gene
products of HTLV-II may be involved in stabilization of
the unspliced viral RNAs.
Ruben, 5.,1 Perkins, A.,1 Purcell, R.,2 Rosen, C.,1 1Dept.
of Molecular Oncology, Roche Institute of Molecular
Biology, 2Dept. of Pritein Chemistry, Roche Research
Center, Nutley, New Jersey: Mutational analysis of the
HIV trans-acting regulatory proteins tat and art.
Kao, S.-Y., Selby, M.J., Peter lin, B.M., Howard Hughes
Medical Institute, Dept. of Medicine, University of
California, San Francisco: Transcriptional elongation
effect of HIV-1 by tat gene product.
Dayton, A.I., Terwilliger, E.,1 Potz, J., Rosen, C.,2
Kowalski, M., Haseltine, W.A.,1 1Dana-Farber Cancer
Institute, Boston, Massachusetts; 2Dept. of Molecular
Oncology, Roche Institute of Molecular Biology, Nutley,
New Jersey: On the nature of ART/CAR-The second
trans-activation axis of HIV-1.
Ahmad, N., Mervis, R.J., Venkatesan, S., NIAID, National
Institutes of Health, Bethesda, Maryland: The B(3')-ORF
product of HIV suppresses transcription from HIV LTR
containing the negative regulatory element.
SESSION 5 RNA PACKAGING, VIRAL VECTORS, AND GENE TRANSFER
Chairmen: M. Linial, Fred Hutchinson Cancer Research Center
H. Hanafusa, Rockefeller University
Cobrinik, D., Leis, J., Dept. of Biochemistry, Case Western
Reserve University School of Medicine, Cleveland, Ohio:
A retroviral RNA secondary structure near the primer-
binding site is required for efficient priming of reverse
transcriptase.
Malone, R.,1 Feigner, P.,2 Verma, I.M.,1 1Salk Institute and
Dept. of Biology, University of California, San Diego, La
Jolla, 'Syntex Corporation, Palo Alto: A novel approach
to study packaging of retroviral RNA by RNA
transfection.
Danos, 0., Mulligan, R.C., Whitehead Institute for Biomedical
Research and Dept. of Biology, Massachusetts Institute
of Technology, Cambridge: Safe and efficient generation
of recombinant retroviruses with amphotropic and
ecotropic host range.
Markowitz, D., Goff, S., Bank, A., Dept. of Genetics and
Development, Biochemistry and Molecular Biophysics,
and Medicine, Columbia University, College of
Physicians & Surgeons, New York, New York:
Construction of a safe and efficient amphotropic
retrovirus-packaging cell line.
Shackleford, G., Varmus, H., Dept. of Microbiology and
Immunology, University of California, San Francisco:
SESSION 6 POSTER SESSION: Regulation, Expression, and
Ratner, L., Niederman, T., Dept. of Medicine, Washington
University, St. Louis, Missouri: Analysis of the functions
of the HIV-1 R and F gene products.
Viglianti, G.A., Mullins, J.I., Dept. of Cancer Biology, Harvard
School of Public Health, Boston, Massachusetts: SIV and
HIV -1 tat have different requirements for activity.
Bache ler, L., Strehl, L., Ferguson, B., Neubauer, R.,
Eustice, D., Dept. of Medical Products, E.I. du Pont de
Nemours & Co., Inc., Wilmington, Delaware:
Heterologous gene expression under HIV LTR/tat
control.
Ahmad, N., Mervis, R.J., Lillehof, E.P., and Venkatesan, S.,
NIAID, National Institutes of Health, Bethesda, Maryland:
art/trs protein of HIV is essential for splicing and/or
transport of HIV transcripts containing env sequences.
Jeang, K.-T.,1 Shank, P.,2 Rabson, A.,3 Kumar, A.,4
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Construction of a fully clonable provirus that produces
infectious, tumorigenic MMTV and derivation of an
MMTV vector.
Dornburg, R., Temin, H.M., McArdle Laboratory for Cancer
Research, University of Wisconsin, Madison: A retroviral
vector system to study formation of cDNA genes.
Aronoff, R.,1 Adam, M.,1 Katz, R.,2 Miller, D.,1 Linial, M.,1
1Fred Hutchinson Cancer Research Center, Seattle,
Washington; 2lnstitute for Cancer Research, Philadelphia,
Pennsylvania: Development and analysis of retrofection
in avian and mammalian cell lines.
von Ruden, T.,1 Gilboa, E.,2 1 EMBL, Heidelberg, Federal
Republic of Germany; 2Memorial Sloan-Kettering Cancer
Center, New York, New York: Inhibition of HTLV-I
replication in primary human T cells expressing
antisense RNA.
Lobel, L.I., Schwartzberg, P., Parker, R., Dept. of
Biochemistry, Columbia University, College of Physicians
& Surgeons, New York, New York: Construction of
retroviral vectors for the isolation of constitutive or
inducible promoters of a Mud-/ac-like vector for murine
cells.
Gene Transfer
1Laboratory of Molecular Virology, 2Division of Biology
and Medicine, Brown University, 3Laboratory of
Molecular Microbiology, 4NIAID, Dept. of Biochemistry,
George Washington University, Washington, D.C.: Ex-
pression of HIV trans-activator protein in baculovirus
vector system.
Pavlakis, EN., Felber, B.K., Cladaras, M., Cladaras, C.,
Wright, C.M., NCI-Frederick Cancer Research Facility,
Frederick, Maryland: Feedback regulation of HIV -1 gene
expression by trs.
Cann, A., Koyanagi, Y., Zack, J., Chen, I.S.Y., Depts. of
Medicine and Microbiology and Immunology, University
of California School of Medicine, Los Angeles:
Regulation of HIV gene expression in primary isolates.
Cochrane, A.,1 Terwilliger, E.,2 Hazeltine, W.,2 Rosen, C.,1
1Dept. of Molecular Oncology, Roche Institute of
Molecular Biology, Nutley, New Jersey; 2Dana-Farber
Cancer Institute, Boston, Massachusetts: Localization of
intragenic cis-acting repressive and art-responsive
sequences within the HIV genome.
Garcia, J.A., Harrich, D., Wu, F., Jackson, D., Gaynor, R.B.,
Dept. of Medicine, University of California School of
Medicine, Los Angeles: Characterization of DNA-binding
proteins and regulatory sequences involved in HIV
transcriptional regulation.
Weighous, T.F.,1 Tomich, C.-S.C., 2 Tarp ley, W.G.,1 'Cancer
and Infectious Diseases Research, 2Molecular Biology
Research, Upjohn Company, Kalamazoo, Michigan:
Synthesis at high levels in E. coil of a soluble, truncated
HIV trans-activator.
Radonovich, M., Jeang, K.-T., Rasheed, S., Zhou, J.-T.,
NCI, National Institutes of Health, Bethesda, Maryland:
Activation of the HTLV-I LTR by phorbol ester.
Inoue, J., Seiki, M., Fujisawa, J., Yoshida, M., Dept. of Viral
Oncology, Cancer Institute, Tokyo, Japan: Further
studies on trans-activation of IL-2 receptor (Tac antigen)
gene expression by p4Otax of HTLV-1.
Gore, 1.,1 Hui, H.,1 Wong-Staal, F.,2 Gallo, R.C.,2
Shaw, G.M.,1 Hahn, B.H.,1 1Dept. of Medicine,
University of Alabama, Birmingham; 2NCI, National
Institutes of Health, Bethesda, Maryland: Molecular
characterization of a variant of HTLV-I with sequence
homology with normal human DNA.
Lagarias, D., Radke, K., Dept. of Avian Sciences, University
of California, Davis: Transcriptional activation of BLV in
blood cells from infected animals.
Krump-Konvalinkova, V.,1 Gilboa, E.,2 1Radiobiological
Institute TNO, Rijswijk, The Netherlands; 2Memorial
Sloan-Kettering Cancer Center, New York, New York:
Killer vectors-Retroviral vectors inhibiting the growth of
HTLV-I trans-activation protein producing cells.
Bovenhoff, M.E., Visser, T.P., de Groene, E.M.,
Dorssers, L.C.J., Valerio, D., Wagemaker, G., Dept. of
Radiobiology, Erasmus University and Radiobiological
Institute TNO, Rijswijk, The Netherlands: Friend-virus-
derived retroviral vectors for gene transfer into
hematopoietic stem cells.
Noel, G.,1 Zillinger, L.,1 Laliberte, F.,1 Crine, P.,1 Boileau, G.,1
Rassart, E.,2 1E34. de biochimie, Universite de Montreal,
2Dep. Sciences biologiques, Universite du Quebec,
Montreal, Canada: Expression and processing of
pro-opiomelanocortin in neural cell lines using a retroviral
vector.
Bradac, J.A., Hughes, S.H., NCI-Frederick Cancer Research
Facility, Frederick, Maryland: Replication enhancement of
SESSION 7 VIRAL PROTEINS
Chairmen: V. Vogt, Cornell University
J. Coffin, Tufts University
Wills, J.W., Weldon, R.A., Jr., Craven, R.C., Achacoso, J.A.,
Dept. of Biochemistry and Molecular Biology, Louisiana
State University Medical School, Shreveport: Creation of
novel myristic addition sites on the RSV gag gene
product and their expression in mammalian cells.
Rhee, S.S., Hunter, E., Dept. of Microbiology, University of
avian retroviral vectors containing the polymerase gene
derived from the Bryan high-titer strain of RSV.
Hunt, L.A.,1 Brown, D.W.,2 Robinson, H.L.,2 Naeve, C.W.,3
Webster, R.G.,3 1University of Louisville School of
Medicine, Kentucky; 2University of Massachusetts
Medical Center, Worcester; 3St. Jude Children's
Research Hosptial, Memphis, Tennessee: An avian
leukosis virus vector expressing H7 hemagglutinin
protects chickens against lethal influenza infections.
Hantzopolous, P., Bordignon, C., Smith, C.A., Yu, S.F.,
Ungers, G.E., O'Reilly, R., Gilboa, E., Memorial
Sloan-Kettering Cancer Center, New York, New York:
Retroviral vector-mediated expression of adenosine
deaminase in long-term bone marrow cultures from
patients affected by the ADA-deficient variant of severe
combined immunodeficiency.
Evrard, C., Galiana, E., Rouget, P., Laboratoire de
Biochimie Cellulaire, College de France, Paris:
Establishment of permanent and genetically marked
neural cell lines after oncogene transfection or retroviral
vector transduction.
Morgenstern, J.P., Land, H., Imperial Cancer Research
Fund, London, England: An advanced retrovirus-based
gene-transfer system for mammalian cells.
Young, J.A.T., Bates, P., Varmus, H.E., Dept. of Microbiology
and Immunology, University of California, San Francisco:
An attempt to alter retroviral tropism specifically using
egf-envelope chimeras.
Alford, R.L.,1 MacGregor, G.R.,2 Moore, K.A. 2
Fletcher, F.A.,2 Hawkins, D.,3 Caskey, C.T.,1,2,3
Belmont, J.W.,2,3 1Dept. of Biochemistry, 2lnstitute for
Molecular Genetics, Baylor College of Medicine,
3Howard Hughes Medical Institute, Houston, Texas:
Long-term expression of human adenosine deaminase in
murine hematopoietic cells by retroviral vector-mediated
gene transfer.
Kerner, N., Decaux, J.F., Kahn, A., Weber-Benarous, A.,
INSERM, Paris, France: Expression and regulation of a
hepatic gene transferred into primary culture of adult rat
hepatocytes using a retroviral vector.
Scadden, D., Cunningham, J., Howard Hughes Medical
Institute and Dept. of Medicine, Brigham and Women's
Hospital, Boston, Massachusetts: Identification of a
defective MCF RNA efficiently packaged into
recombinant retroviruses.
Murphy, J.E., Kalnik, S.T., Goff, S.P., Dept. of Biochemistry,
Columbia University, College of Physicians & Surgeons,
New York, New York: Analysis of cis-acting sequences
in the 5'-noncoding regions of Mo-MLV.
Alabama, Birmingham: Mutagenic analysis of the
membrane-binding protein, p10, of MPMV.
Jentoft, J., Fu, X.-D., Smith, L., Johnson, M., Leis, J., Dept.
of Biochemistry, Case Western Reserve University,
School of Medicine, Cleveland, Ohio: Conserved Cys
and His residues of avian retrovirus nucleocapsid protein
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are essential for viral replication but do not form
Zn-binding fingers.
Meric, C., Fisher, J., Goff, S.P., Dept. of Biochemistry,
Columbia University, College of Physicians & Surgeons,
New York, New York: Site-directed mutagenesis of the
nucleocapsid p10 of Mo-MLV.
Gorelick, R.J., Henderson, L.E., Rein, A., NCI-Frederick
Cancer Research Facility, Frederick, Maryland: Point
mutations preventing encapsidation of Mo-MLV RNA-
Evidence for role of "finger-like" sequence in recognition
of genomic RNA.
Darlix, J.L., Prats, A.C., Constantin, S., Bieth, E., Gabus, C.,
Centre de Recherche de Biochimie et Genetique
Cellulaires, CNRS, Toulouse, France: Small finger protein
of avian and murine retroviruses causes two RNA
conformational changes required for the production of
infectious viral particles.
Vogt, V.M., Schatz, G., Putterman, D., Section of Biochemistry,
Cornell University, Ithaca, New York: Viral protease and
gag protein cleavage in ASV and ALV.
SESSION 8 ONCOGENES
Chairmen: G.S. Martin, University of California, Berkeley
N. Teich, Imperial Cancer Research Fund
Engelman, A., Rosenberg, N., Dept. of Molecular Biology
and Microbiology, Tufts University School of Medicine,
Boston, Massachusetts: Ab-MLV mutants temperature-
sensitive for transformation are defective in kinase
activity.
Franz, W.M., Wang, J.Y.J., Dept. of Biology, University of
California, San Diego, La Jolla: Deletion of the tyrosine
kinase regulatory domain of the c-abl protein activates its
oncogenic potential.
Poirier, Y., Jolicoeur, P., Clinical Research Institute of
Loeb, D.,1 Hutchison, C.,1 Stamper, S.,1 Edgell,
O'Bryan, J.,2 Everitt, L.,2 Swanstrom, R.,2 Depts. of
1Microbiology, 2Biochemistry, University of North
Carolina, Chapel Hill: Genetic analysis of the HIV-1
protease.
Vicenzi, E., Obata, M., Garon, C., Khan, A.S., NIAID,
National Institutes of Health, Bethesda, Maryland:
Isolation and characterization of MLV-related "solo" pol
genes.
Dong, Y.-Y., Dubay, J.W., Perez, L.G., Hunter, E., Dept. of
Microbiology, University of Alabama, Birmingham:
Mutations in the proteolytic cleavage site of the RSV
envelope glycoprotein.
Einfeld, D., Hunter, E., Dept. of Microbiology, University of
Alabama, Birmingham: The RSV glycoprotein complex is
an oligomeric structure.
Tsai, W.-P., Oroszlan, S., NCI-Frederick Cancer Research
Facility, Frederick, Maryland: Identification of novel
glycosylation pathways and characterization of an Endo-
H-resistant env precursor polyprotein in avian REV.
Montreal, Canada: Difference in helper-virus
requirements between Abelson-induced pre-B- and T-cell
lymphomas.
Green, P.L., Kaehler, D.A., Bennett, L.M., Risser, R.,
McArdle Laboratory for Cancer Research, University of
Wisconsin, Madison: Clonal selection and progression in
Ab-MLV tumorigenesis.
Hoffmann, F.M., Henkemeyer, M.J., Bennett, R.L., Risser, R.,
McArdle Laboratory for Cancer Research, University of
Wisconsin, Madison: The Abelson tyrosine kinase of
Drosophila-Fly/mammalian chimeric genes function in
transformation of mouse cells and in the terminal dif-
ferentiation of neural cells of Drosophila.
De Clue, J.E., Martin, G.S., University of California, Berkeley:
Linker insertion mutagenesis of the v-src gene -Isolation
of host- and temperature-dependent mutants.
Fuhrmann, U., Ness, S., Beug, H., Differentiation Programme,
European Molecular Biology Laboratory, Heidelberg,
Federal Republic of Germany: Oncogenic potential of
the v-fms oncogene in the chicken hematopoietic
system.
Lipsick, J., Garcia, A., Grasser, F., Ibanez, C., Lane, T.,
Stober-Grasser, U., Veteran's Administration Medical
Center and Dept. of Pathology, University of California,
San Diego, La Jolla: Molecular genetics of the v-myb of
AMV.
Neuberg, M.,1 Lucibello, F.C.,1 Hunter, J.B.,1 Jenuwein, T.,1
Wallich, R.,1 Schuermann, M.,1 Stein, B.,2 Schonthal,
A.,2 Herrlich, P.,2 Muller, R.,1 1European Molecular
Biology Laboratory, Heidelberg, 2lnstitut fur Genetik and
Toxikologie Kernforschungszentrum Karlsruhe, Federal
Republic of Germany: trans-Activation of gene expression
by fos proteins-Involvement of a binding site for the
transcription factor AP-1.
Judelson, C., Boucher, P., Privalsky, M., Depts. of
Bacteriology and Biochemistry and Biophysics,
University of California, Davis: Determinants of the AEV
genome involved in erythroid transformation-Dissection
of the v-erb A and v-erb B oncogenes.
Bar-Sagi, D.,1 Cockcroft, 5.,2 1Cold Spring Harbor
Laboratory, New York; 2Dept. of Experimental Pathology,
University College London, England: H-ras proteins can
stimulate polyphosphoinositide phosphodiesterase
activity in HL-60 membranes.
SESSION 9 POSTER SESSION: Viral Proteins, Pathogenesis, and Oncogenesis
Prats, A.C., De Billy, G., Darlix, J.L., Labo-Tetro, Centre de
Recherche de Biochimie et de Genetique Cellulaires,
CNRS, France: Translation initiation of the novel CUG
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SV40, Polyoma, and Adenoviruses
August 10-August 14
ARRANGED BY
Terri Grodzicker, Cold Spring Harbor Laboratory
Michael Botchan, University of California, Berkeley
393 participants
The Tumor Virus meeting on SV40, polyoma and adenoviruses, which has been
held for 15 years, continues to bring together a large group of scientists to
discuss their latest findings. This year's meeting was attended by more than 400
scientists who use the small DNA tumor viruses as model systems to analyze
mechanisms of eukaryotic transcription, replication, RNA processing, and
transformation.
Much excitement at this year's meeting focused on mechanisms of
transformation and the finding that the adenovirus E1A proteins, SV40 large
T antigen, and the human papillomavirus type-16 E7 protein all bind to the
product of the retinoblastoma gene, a protein whose inactivation is involved in
tumor growth. Much research continues to focus on the purification and analysis
of cellular transcription factors that bind to viral promoters and enhancers and
the cloning of the genes that encode these factors; on viral proteins such as the
adenovirus E1A proteins that interact with and/or affect the activity of transcription
factors; and on the use of in vitro systems to analyze the role of purified viral and
cellular proteinson viral DNA replication. Talks were also given on splicing,
transport, and stability of viral mRNAs; translational control; the role of protein
modifications and different domains on the function of transcription factors and
transforming proteins; the interaction of viral transforming proteins with additional
cellular proteins such as p53 and tyrosine kinase; and the role of different viral
proteins in the host's immune response.
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Interaction of infection-induced factors with sequences
within the first intron on the adenovirus MLP results in
elevated accumulation of RNA synthesized from the MLP
in late adenovirus-infected cells.
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SESSION 10 POST-TRANSCRIPTIONAL REGULATION
Chairman: C. Prives, Columbia University
Huang, M., Gorman, C., Dept. of Cell Genetics, Genentech,
South San Francisco, California: Splicing contributes to
the stability and/or transport of mRNA in 293 cells.
Ryu, W.-S., Mertz, J.E., McArdle Laboratory for Cancer
Research, University of Wisconsin, Madison: Transcripts
synthesized from cDNA mutants of SV40 late mRNA are
defective in both stability in the nucleus and transport to
the cytoplasm.
Hyde-DeRuyscher, R., Carmichael, G., Dept. of Microbiology,
University of Connecticut Health Center, Farmington: An
unusual mechanism for the temporal regulation of
polyomavirus gene expression.
Kessler, M., Resnekov, 0., Bengal, E., Aloni, Y., Weizmann
Institute of Science, Rehovot, Israel: In vitro structural
analyses of the SV40 attenuation signal.
Larsson, S., Akusjarvi, G., Dept. of Microbial Genetics,
Karolinska Institute, Stockholm, Sweden: Activation of the
adenovirus major late transcription unit-Accumulation of
late mRNA is controlled at multiple levels.
Mellits, K.H., Kostura, M., Mathews, M.B., Cold Spring
Harbor Laboratory, Cold Spring Harbor, New York:
Structure and function of adenovirus VA RNA,.
Furtado, M.R.,1 Subramanian, S.,1 Bhat, R.A.,1 Safer, B. 2
Thimmappaya, B.,1 1Dept. of Microbiology and
Immunology, Northwestern University Medical School,
Chicago, Illinois; 2NHLB Institute, National Institutes of
Health, Bethesda, Maryland: Adenovirus VA, RNA and
translation control-Structure rather than the sequence
per se may be critical for its function.
Slavicek, J.M.,1 Jones, N.,2 Richter, J.D.,1 1Worcester
Foundation for Experimental Biology, Shrewsbury,
Massachusetts; 2lmperial Cancer Research Fund,
London, England: Rapid turnover of adenovirus E1A is
determined through a cotranslational mechanism that
requires an amino-terminal domain.
Lavery, D., Leu, M.-H., Chen-Kiang, S., Immunobiology
Center and Dept. of Microbiology, Mt. Sinai School of
Medicine, New York, New York: Enhancement of T-cell-
specific block of adenoviral mRNA transport in the
absence of E1 B.
SESSION 11 TRANSFORMATION AND VIRUSHOST CELL INTERACTIONS
Chairman: Y. Gluzman, Leder le Laboratories
Kaplan, P.,1 Small, M.B.,2 Li, G.,1 Orlian, M.,1 Pardinas,
Resnick-Silverman, L.,1 Zainul, B.,1 Jha, K.K.,1 Ozer,
H.L.,1 iDept. of Biological Sciences, Hunter College,
City University of New York, New York; 2G.S. Hooper
Foundation, Dept. of Microbiology and Immunology,
University of California Medical Center, San Francisco:
Role of SV40 T antigen in immortalization of human
fibroblasts.
Westphal, K.-H., Kolbeck, C., Mitreiter, R., Laboratorium kir
molekulare Biologie, Genzentrum, Martinsried, Federal
Republic of Germany: Expression of SV40 T antigen in
human embryonic cells in human malignant melanoma
and normalized derivatives.
Butel, J.S.,1 Slagle, B.L.,1 Sepulveda, A.,2 Clift, S.M.,3
Shen, R.-F.,3 De Mayo, J.L.,3 Finegold, M.J. 2
Woo, S.L.C.,3 Depts. of 1Virology, 2Pathology, 3Cell
Biology, Baylor College of Medicine, Houston, Texas:
Multiple tumors induced in transgenic mice by the
expression of SV40 large T antigen controlled by the
regulatory elements of the human alpha-antitrypsin gene.
Dubensky, T.W., Freund, R., Dawe, C.J., Benjamin, T.L.,
Dept. of Pathology, Harvard Medical School, Boston,
Massachusetts: Polyomavirus tumor induction in mice-
Influences of viral replication on tumor profiles.
Yamashita, T., Kato, H., Fujinaga, K., Dept. of Molecular
Biology, Cancer Research Institute, Sapporo Medical
College, Japan: Collaborative transformation of rat cells
by Ad12 E1A and v-abl oncogenes.
Subramanian, T., Chinnadurai, G., Institute for Molecular
Virology, St. Louis University Medical Center, Missouri:
Suppression of T24 ras oncogene-mediated
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tumorigenesis by an Ad2 E1A protein region.
Ginsberg, H.S.,1 Beauchamp, U.,1 Wold, W.S., 2
Chanock, R.M.,3 Pernis, B.,1 Prince, G.,3 1Columbia
University, New York, New York; 2lnstitute for Molecular
Virology, St. Louis University, Missouri; 3NIAID, National
Institutes of Health, Bethesda, Maryland: Function of
adenovirus E3 in pathogenesis.
Gooding, L.R.,1 Tollefson, A.E. , 2 Elmore, L.,1 Horton, T.,1
Duerksen-Hughes, P.,1 Wold, W.S.M.,2 1Dept. of
Microbiology, Emory University School of Medicine,
Atlanta, Georgia; 2lnstitute for Molecular Virology, St.
Louis University Medical Center, Missouri: The 14.7K
protein encoded in region E3 of adenovirus is a
conditional inhibitor of TNF-mediated cytolysis.
Cook, J.,1 May, D.,1 Wilson, B.,1 Chen, M.-J.,2
Shalloway, D.,3 Walker, T.,1 1National Jewish Center for
Immunology and Respiratory Medicine, Denver,
Colorado; 2Smith Kline and French Laboratories, King of
Prussia, Pennsylvania; 3Pennsylvania State University,
University Park: E1A gene expression in transformed
cells induces cytolytic susceptibility by TNF-dependent
and -independent mechanisms.
Atwood, W.J., Norkin, L.C., Dept. of Microbiology, University
of Massachusetts, Amherst: Interaction of SV40 with class
I MHC antigens on rhesus monkey kidney cells.
Tevethia, S.,1 Tanaka, Y.,1 Anderson, R.,2 Maloy, L.,2 1Dept.
of Microbiology, Penn State College of Medicine, Hershey,
Pennsylvania; 2NIAID, National Institutes of Health, Bethesda,
Maryland: Synthetic peptides as probes for the localization
of SV40 T antigen epitopes recognized by cytotoxic lym-
phocyte clones.
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The 1988 meeting on Molecular Genetics of Bacteria and Phages attracted over
300 scientists, including many young investigators in the field. Topics discussed
at the meeting included DNA replication, recombination, various aspects of
transcriptional control, RNA processing, and membrane proteins. The common
thread throughout the meeting was again the mechanism by which protein-DNA
interactions influence processes such as DNA replication, DNA partitioning, site-
specific recombination, and regulation of gene expression. Of particular interest
was the role that proteins such as IHF and FIS play as accessory factors in many
of these processes. Exciting advances were reported in the understanding of the
molecular mechanisms of signal transduction in E. coli by the regulatory pairs of
proteins EnvZ/OmpR, NtrB/NtrC, and CheA/CheY, which function through protein
phosphorylation to regulate important cellular processes. At least two of these
systems were shown to exhibit crosstalk, sharing a common transphosphorylation
step. It was evident that molecular techniques are now being applied to a wider
range of microorganisms than ever before. Impressive advances were reported in
the understanding of gene regulation relating to pathogenesis in organisms such
as Vibrio cholerae and Bordetella pertussis. The quality of presentations at the
meeting was of uniformly high quality.
SESSION 1 DNA REPLICATION
Wickner, S., Hoskins, J., Chattoraj, D., Mc Kenney, K., NCI,
National Institutes of Health, Bethesda, Maryland:
Replication of mini-P1 plasmid DNA in vitro.
Pal, S.K., Dasgupta, S., Chattoraj, D.K., NCI, National
Institutes of Health, Bethesda, Maryland: P1 plasmid
replication-Control by steric hindrance.
Davis, M., Martin, K., Austin, S., NCI-Frederick Cancer
Research Facility, Frederick, Maryland: A host factor that
binds to the partition site of the P1 plasmid.
Martin, K., Davis, M., Fernandez, L., Austin, S., NCI-
Frederick Cancer Research Facility, Frederick, Maryland:
Mutagenesis of the P1 plasmid-partition site.
Novick, R.P. lordanescu, S., Projan, S.J., Edelman, I.,
Public Health Research Institute, New York, New York:
pT181 replication is regulated by countertranscript-
induced transcriptional attenuation.
Pelletier, A.J., Hill, T.M., Kuempel, P.L., Dept. of Molecular,
Cellular, and Developmental Biology, University of
Colorado, Boulder: Studies in a plasmid system of
termination sites that inhibit DNA replication in E. coll.
Lin, G., Gruidl, M., Luder, A., Mosig, G., Dept. of
Molecular Biology, Vanderbilt University, Nashville,
Tennessee: Novel intermediates in phage T4 DNA
replication.
Andrake, M.,1 Hsu, T.,1 Guild, N.,2 Dawson, M.,1 Gold, L.,2
Karam, J.,1 1Dept. of Biochemistry and Molecular
Biology, Medical University of South Carolina,
Charleston; 2Dept. of Molecular, Cellular, and
Developmental Biology, University of Colorado, Boulder:
Control of T4 DNA polymerase biosynthesis.
Polayes, D.A., Martin-Moe, S.A., Ruscitti, T.M., Linn, S.M.,
Dept. of Biochemistry, University of California, Berkeley:
Transcriptional control of the polA gene in E. coll.
Imamoto, F., Kano, Y., Wada, M., Kohno, K., Goshima, N.,
Tsukuba Life Science Center, Riken, Japan: Genetic
characterization and transcriptional regulation of the hup
genes encoding histone-like protein HU of E. coll.
Di Laurenzio, L., Frost, L., Finlay, B., Paranchych, W., Dept.
of Biochemistry, University of Alberta, Edmonton,
Canada: Interaction of the mating signal protein, TraMp,
with the origin of transfer of the conjugative plasmid
pED208.
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SESSION 2 RECOMBINATION
Hughes, R., Hatfull, G., Sanderson, M., Freemont, P.,
Rice, P., Goldman, A., Steitz, T., Grindley, N., Dept. of
Molecular Biophysics and Biochemistry, Yale University,
New Haven, Connecticut: Recombinationally deficient
mutants of the yd resolvase that are deficient in
protein/protein interactions in the yd resolvasome.
Lee, E., Gardner, J., Dept. of Microbiology, University of
Illinois, Urbana: Genetic analysis of A integrase arm-type
binding-site interactions.
Ball, C.A.,1 Saccone, G.D.,2 Johnson, R.C.,12 1Molecular
Biology Institute, 2Dept. of Biological Chemistry,
University of California, Los Angeles: Genetic analysis of
SESSION 3 POSTER SESSION
Alifano, P., Nappo, A.G., Bruni, C.B., Carlomagno, M.S.,
Dept. of Biology, University of Naples, Italy: Polar effects
of nonsense mutations within a cistron.
Anderson, R., Young, K.D., Dept. of Microbiology and
Immunology, University of North Dakota School of
Medicine, Grand Forks: At low, noninducing
temperature, grpE and/or dnaK mutations affect lysis of
E. coil by 4X174.
Balke, V., Nagaraja, V., Wall, L., Hattman, S., Dept. of
Biology, University of Rochester, New York: Mutation
and footprinting analysis of the phage Mu mom operon.
Barras, F.,1 Marinus, M.G.,2 1LCB, CNRS, Marseille, France;
2Dept. of Pharmacology, University of Massachusetts
Medical School, Worcester: Arrangement and evolution
of Dam methylation sites (GATC) in the E. coil
chromosome.
Blyn, L., Low, D., Dept. of Pathology, University of Utah,
Salt Lake City: Analysis of a novel phase-variation switch
the operon encoding Fis-In vivo function of Fis in
Hin-mediated DNA inversion and A excision.
Ramaiah, N.,1 Yagil, E.,2 Kislev, N.,1 Do lev, S.,2
Weisberg, R.,1 1NCI, National Institutes of Health,
Bethesda, Maryland; 2Tel Aviv University, Israel:
Localization of the determinants of specificity of
site-specific recombination.
Shapiro, J.A.,1 Higgins, N.P.,2 1Dept. of Biochemistry and
Molecular Biology, University of Chicago, Illinois; 2Dept.
of Biochemistry, University of Alabama Medical School,
Birmingham: Mud lac replication/transposition and lacZ
expression in E. coli colonies.
Schumann, W., Apfel, C., Mummenthey, K., Kirschner, P.,
Lehrstuhl far Genetik, Universiat Bayreuther, Federal
Republic of Germany: Identification of two functions
involved in the regulation of the transposition functions of
phage Mu.
Sonti, R.V., Keating, D.H., Roth, J.R., Dept. of Biology,
University of Utah, Salt Lake City: Rec-dependent
transposition of Mud phages of transducing fragments is
due to increased transposition in recA1 and in recBC1
strains.
Sandler, S.J., Clark, A.J., Dept. of Molecular Biology,
University of California, Berkeley: Factors influencing
inhibition of overexpression of the recF gene of E. coli
K-12.
Poteete, A.R., Volkert, M.R., Dept. of Molecular Genetics
and Microbiology, University of Massachusetts,
Worcester: Activation of RecF-dependent recombination
in E. coli by bacteriophage A- and p22-encoded
functions.
Kobayashi, I., Takahashi, N., Dept. of Infectious Diseases
Research, National Children's Research Center and
Hospital, Tokyo, Japan: Double-strand gap repair by
E. coli and A.
Brusca, J.S., Chastain, C.J., Hale, M.A., Carrasco, C.,
Golden, J.W., Dept. of Biology, Texas A&M University,
College Station: Expression of the xisA gene of
Anabaena 7120 causes excision of the nifD element in
vegetative cells.
in uropathogenic E. coli.
Bukau, B., Walker, G.C., Dept. of Biology, Massachusetts
Institute of Technology, Cambridge: Deletion of the dnaK
heat-shock gene of E. coli causes defects in
chromosome distribution and plasmid maintenance.
Calendar, R.,1 Erickson, J.W.,2 Hailing, C.,1 Nolte, A.,1
1Dept. of Molecular Biology, University of California,
Berkeley; 2Dept. of Bacteriology, University of Wisconsin,
Madison: Deletion and insertion mutations in the rpoH
gene of E. coil that produce functional a32.
Carlson, N.,1 Little, J.,1 Oberto, J.,2 Weisberg, R.,2 1Dept.
of Biochemistry, University of Arizona, Tucson; 2NCI,
National Institutes of Health, Bethesda, Maryland:
Characterization of specific DNA binding and RecA-
mediated cleavage of the putative cl repressor from the
A-related phage, HK022.
Carty, M., Menzel, R., E.I. du Pont de Nemours, Experimental
Station, Wilmington, Delaware: Relaxation (novobiocin)
activation of the gyrA promoter in an S-30 in vitro
transcription-translation system-Evidence for regulatory
factors.
Chandran, U., Hendrix, R., Dept. of Biological Sciences,
University of Pittsburgh, Pennsylvania: Translation control
of the bacteriophage A tail gene H.
Chen, S.-M., Takiff, H., Patterson, T., Court, D., NCI-Frederick
Cancer Research Facility, Frederick, Maryland:
Biochemical properties of the RNase III and ERA
proteins; products of the E. coil RNase III operon.
Chon, Y., Gayda, R., Dept. of Microbiology, Louisiana State
University and Agricultural Center, Baton Rouge:
Localization of FtsA protein near the membrane
septation sites in E. colt K-12.
Dailey, S.H., Finkelstein, M., Dept. of Molecular Biology,
Biotechnology Division, Schering Corporation,
Bloomfield, New Jersey: Plasmid stability in E. coli-
A comparison of E. colt 294 and W3110.
Davagnino, J., Yorgey, P., Kolter, R., Harvard Medical
School, Boston, Massachusetts: Production of a small
unstable protein-toxin involves the action of three
regulatory proteins that afford protection from
proteolysis.
de la Cruz, N.B., Krebs, M.P., Reznikoff, W.S., Dept. of
Biochemistry, University of Wisconsin, Madison: Partial
purification and binding studies on the Tn5 transposase.
De Long, A.,1 Syvanen, M.,2 1Dept. of Microbiology and
Molecular Genetics, Harvard Medical School, Boston,
Massachusetts; 2Dept. of Medical Microbiology and
Immunology, University of California, Davis:
Characterization of two Tn5 mutants with trans-dominant
defects in inhibition of transposition.
Demirjian, D., Pagratis, N., Casadaban, M., Dept. of
Molecular Genetics and Cell Biology, University of
Chicago, Illinois: Thermo-p-galactosidase-A new
assayable marker.
Diaz, D.L.,1 Rabin, B.A.,1 Williams, K.R.,2 Chase, J.W.,1
1Dept. of Molecular Biology, Albert Einstein College of
Medicine, Bronx, New York; 2Dept. of Molecular
Biophysics and Biochemistry, Yale University School of
Medicine, New Haven, Connecticut: Structure and
expression of the E. coli xseB gene, coding for the f3
subunit of exonuclease VII.
Dila, D., Raleigh, E.A., New England Biolabs, Beverly,
Massachusetts: Genetic dissection of the methylcytosine-
specific restriction system mcrB of E. colt K-12.
Driks, A.,1 Greene, R.,2 Schoenlein, P.,3 Ely, B.,3
Shapiro, L.,2 De Rosier, D.,1 1Graduate Program in
Biology, Brandeis University, Waltham, Massachusetts;
2Dept. of Microbiology, Columbia University, New York,
New York; 3Dept. of Biology, University of South
SESSION 4 DNA MODIFICATION-ACTION OF IHF
Heitman, J., Rockefeller University, New York, New York:
Substrate recognition by the EcoRI endonuclease.
Kelleher, J.E., Daniel, A.S., Murray, N.E., Dept. of
Molecular Biology, Edinburgh, Scotland: Defining
structural domains of the EcoK methylase.
Sutherland, E., Raleigh, E.A., New England Biolabs,
Beverly, Massachusetts: In vitro restriction of
Carolina, Columbia: Construction of the flagellum of C.
crescentus.
Dul, E., Shatzman, A.R., Smith Kline and French Laboratories,
King of Prussia, Pennsylvania: An unidentified A function
is required for expression of gene products encoded on
plasmids containing a PL transcription unit during SOS-
mediated induction.
Eraso, J., Weinstock, G., Dept. of Biochemistry and
Molecular Biology, University of Texas Medical School,
Houston: Isolation of regulatory mutations in the cea
gene.
Erickson, B.D., Burgess, R.R., McArdle Laboratory for
Cancer Research, University of Wisconsin, Madison:
RNA processing in the rpsU-dnaG-rpoD operon of
E. colt.
Escalante-Semerena, J.C.,1 Roth, J.R.,2 1Dept. of
Biochemistry, University of Wisconsin, Madison; 2Dept.
of Biology, University of Utah, Salt Lake City: cobA, a
new genetic locus of S. typhimurium involved in B12
biosynthesis.
Ferrell, R., McIntosh, M., Dept. of Microbiology, University
of Missouri School of Medicine, Columbia: Distribution of
a repeated genetic element in porcine mycoplasmas
suggests an extrachromosomal origin.
Frazier, M.W., Mosig, G., Dept. of Molecular Biology,
Vanderbilt University, Nashville: A new phage T4 gene
that prevents T4 late transcription in an E. colt mutant
with a defective heat-shock 032 factor.
Ganjam, K.,1 Tuckman, M.,1 Jacobs, W., Jr.,1 Smith, C.,2
Bloom, B.,1 1Dept. of Microbiology and Immunology,
Albert Einstein College of Medicine, Bronx, 2Dept. of
Human Genetics, Columbia University College of Physi-
cians and Surgeons, New York, New York: Construction
of physical maps of mycobacterial genomes.
Goodman, E.M.,1 Greenebaum, B.,1 Marron, M.T.,2
1Biomedical Research Institute, University of Wisconsin,
Parkside; 2Office of Navy Research, Arlington, Virginia:
Electromagnetic field effects on E. coll.
Greenberg, J.T., Monach, P., Demple, B., Dept. of
Biochemistry and Molecular Biology, Harvard University,
Cambridge, Massachusetts: Overlapping and distinct
responses in E. coli to oxidative stresses generated by
H202 or redox-cycling agents.
Grossman, T.H., Silverman, P.M., Dept. of Molecular Biology,
Albert Einstein College of Medicine, Bronx, New York:
Inducible synthesis of functional F-pili in E. colt K-12.
Guo, H.-C., Roberts, J.W., Section of Biochemistry, Molecular
and Cell Biology, Cornell University, Ithaca, New York:
Point mutational analysis of transcriptional pausing and
initiation at the phage 82 late gene promoter.
5-methylcytosine-modified DNA by the mcrB system of
E. coil K-12.
Miner, Z., Schlagman, S., Hattman, S., Dept. of Biology,
University of Rochester, New York: Single-amino-acid
changes that alter the sequence specificity of the T4
(Dam) DNA-adenine methyltransferase.
Wu, T.-H., Marinus, M.G., Dept. of Pharamacology,
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M. Igo, K. Csonka
University of Massachusetts Medical School, Worcester:
Spontaneous mutation and GATC sites in E. coli.
Bhagwat, Sohail, Lieb, M.,4 1Dept. of
Chemistry, Wayne State University, Detroit, Michigan;
2Co Id Spring Harbor Laboratory, Cold Spring Harbor,
New York; 3University of the Punjab, Lahore, Pakistan;
4University of Southern California School of Medicine,
Los Angeles: A new gene involved in mismatch
correction in E. coli.
Kosturko, L.D.,1 Daub, E.,2 Murialdo, H.,2 1Dept. of
Molecular Biology and Biochemistry, Wesleyan
University, 2Dept. of Medical Genetics, University of
Toronto, Canada: Biochemistry of IHF/DNA interactions
in A DNA packaging.
Makris, J.C., Nordmann, P.L., Reznikoff, W.S., Dept. of
Biochemistry, University of Wisconsin, Madison: 1. IHF is
required for stimulation of IS50 transposition in a dam'
SESSION 5 MEMBRANE PROTEINS
Boyd, D.,1 Lee, C.A.,2 Manoil, C.,3 Beckwith, J.,1 1Harvard
Medical School, Cambridge, Massachusetts; 2Stanford
University Medical School, California; 3University of
Washington, Seattle: Determinants of membrane protein
topology.
Gannon, P.,1 Kumamoto, C.,12 Depts. of 1Physiology,
2Molecular Biology and Microbiology, Tufts University
School of Medicine, Boston, Massachusetts: seoC,
dependent export of maltose-binding protein requires a
portion of the mature sequence.
Greenwood, J., Rowitch, D.H., Perham, R.N., Dept. of
Biochemistry, University of Cambridge, England:
Expression and site-directed mutagenesis of
host. 2. Inversion of the transposase gene with respect
to the /S50 ends affects the level of transposition.
Greenstein, D., Horiuchi, K., Rockefeller University, New
York, New York: Integration host factor interacts with the
DNA replication enhancer of the filamentous phage fl.
van Rijn, P.A., Goosen, N., van de Putte, P., Dept. of
Molecular Genetics, Leiden University, The Netherlands:
Regulation of Mu transcription by IHF.
Kur, J., Hasan, N., Podhajska, A.J., Szybalski, W., McArdle
Laboratory for Cancer Research, University of
Wisconsin, Madison: In vitro transcription from the b2-att
and PR promoter regions of coliphage A -Repression
by the E. coli integration host factor.
Tsui, P., Stevenson, B., Freundlich, M., Dept. of Biochemistry,
State University of New York, Stony Brook: Specific
binding of IHF to i/v promoter regions and effects on
ilvBN attenuation.
bacteriophage Pf1 coat protein gene in E. coli-
Membrane insertion and processing.
Ball, T., Wasmuth, C., Benedik, M., Dept. of Biology, Texas
A&M University, College Station: Regulation and
excretion of S. marcescens nuclease.
Jakes, K.S.,1 Davis, N.G.,2 1Rockefeller University, New
York, New York; 2lnstitute for Molecular Biology,
University of Oregon, Eugene: A hybrid toxin from
phage f1 attachment protein and colicin E3 has altered
cell receptor specificity.
Slauch, J.M., Silhavy, T.J., Dept. of Biology, Princeton
University, New Jersey: The switch from OmpF to OmpC
synthesis in E. coli.
Igo, M., Dept. of Molecular Biology, Princeton University,
New Jersey: EnvZ, a regulatory protein involved in porin
fluctuation, can be phosphorylated.
Misra, R., Benson, S.A., Dept. of Molecular Biology,
Princeton University, New Jersey: Identification and
characterization of a new porin protein, OmpG, of
E. coli K-12.
Jacoby, G.H., Leidenix, M., Young, K.D., Dept. of
Microbiology and Immunology, University of North
Dakota School of Medicine, Grand Forks: Diverse
SESSION 6 POSTER SESSION
Hamilton, E.P., Lee, N.L., Dept. of Biological Sciences,
University of California, Santa Barbara: Fucose-induced
binding of a mutant AraC protein to aral2 activates the
araBAD operon promoter.
Heltzel, A., Totis, P., Summers, A.O., Dept. of Microbiology,
University of Georgia, Athens: In vivo analysis of
transcription initiation at the mer promoter of Tn21.
Hupp, T.R., Kaguni, J.M., Dept. of Biochemistry, Michigan
State University, East Lansing, Michigan: Biochemical
characterization of the E. coli DnaA5 protein.
Hwa, V., Salyers, A.A., Dept. of Microbiology, University of
Illinois, Champaign-Urbana: Characterization and
regulation of chondroitin sulfate utilization in Bacteroides.
Javad, T., Musso, R.E., Dept. of Biology, University of
South Carolina, Columbia: Demonstration of the genes
encoded by the insertion sequence IS2 using lacZ
fusions.
Kang, P.J., Craig, Dept. of Physiological Chemistry,
University of Wisconsin, Madison: Cloning and
identification of a new E. coli gene that suppresses the
temperature-sensitive growth of a dnaK deletion mutant
strain.
Kantorow, M., Mc Kenney, K., Dept. of Genetics, George
Washington University, and National Bureau of
Standards, Gaithersburg, Maryland: Efficient site-directed
mutagenesis and protein domain mapping using gene
fusions.
Keller, J., Gerber, R., Del Tito, B.J., Sharr, D., Arcuri, E.J.,
Dept. of Biological Process Sciences, Smith Kline and
French Laboratories, King of Prussia, Pennsylvania:
Effect of mutations altering SOS regulation on nalidixic
acid induction of heterologous protein synthesis in E.
coli.
Kiino, D.R.,1 Wilt, K.,1 Rothman-Denes, L.B.,1'2 Depts. of
1Molecular Genetics and Cell Biology, 2Biochemistry and
Molecular Biology, University of Chicago, Illinois: At least
four genes are involved in coliphage N4 adsorption.
Kim, J., Zwieb, C., Wu, C., Adhya, S., National Cancer
Institute, NIH, Bethesda, Maryland: DNA bending by
cAMP receptor protein; use of a DNA bending vector.
Lau, P.C.K., Condie, J.A., Biotechnology Research Institute,
National Research Council of Canada, Montreal,
Quebec: Colicin E9 plasmid contains an insertion
sequence with features similar to those of the
degenerate transposon, IS 101.
Lazarus, A., Warren, F., Zabriskie, D., Shatzman, A., Smith
Kline and French Laboratories, King of Prussia,
Pennsylvania: Rate of thermal induction affects
fractionation techniques reveal an unequal distribution of
E. coli penicillin-binding proteins among inner-membrane
vesicles.
Gottesman, S., Clark, W., Maurizi, M., NCI, National
Institutes of Health, Bethesda, Maryland: Genetics of
proteolysis in E. coif -The Clp ATP-dependent protease.
Di Rita, V.J., Miller, V.L., Mekalanos, J.J., Dept. of Microbiology
and Molecular Genetics, Harvard Medical School,
Boston, Massachusetts: Molecular basis of coordinate
gene expression in V. cholerae.
production of heterologous gene products from PL
vectors in E. coli.
Lim, D.F., Kuempel, P.L., Dept. of Molecular, Cellular, and
Developmental Biology, University of Colorado, Boulder:
Deletion of dif, a cis-acting locus in the terminal region of
the E. coli chromosome, induces SOS.
Liu, L., Berg, C.M., Dept. of Molecular and Cell Biology,
University of Connecticut, Storrs: Mutagenization of
dimeric plasmids.
L6bner-Olesen, A.,1 Skarstad, K.,2 Hansen, F.G.,1
von Meyenburg, K.,1 Boye, E.,2 1Dept. of Microbiology,
Technical University of Denmark, Copenhagen; 2Dept. of
Biophysics, Norwegian Radium Hospital, Os low, Norway:
The DNAA protein level determines the initiation mass of
E. coli K-12.
McGovern, K., Beckwith, J., Dept. of Microbiology and
Molecular Genetics, Harvard University School of
Medicine, Boston, Massachusetts: Study of membrane
localization of MaIF, an integral membrane protein of E.
coli.
Mecsas, J., Cowing, D.W., Gross, C.A., Dept. of Bacteriology,
University of Wisconsin, Madison: Hydroxyl radical
footprinting of E032 promoter complexes at the groE
promoter at different temperatures.
Michel, B., Zinder, N.D., Rockefeller University, New York,
New York: Fl gene II protein translational repression by
gene V protein.
Miller, J., Roy, C., Reiman, D., Falkow, S., Dept. of
Microbiology and Immunology, Stanford University,
California: Analysis of B. pertussis virulence gene
expression in E. coli.
Minnich, S.A.,1 Ohta, N.,2 Newton, A.,2 1Dept. of Biology,
Tulane University, New Orleans, Louisiana; 2Dept. of
Molecular Biology, Princeton University, New Jersey:
Flagellin gene regulation in C. crescentus.
Miura-Masuda, A., Ikeda, H., Institute of Medical Science,
University of Tokyo, Japan: Participation of DNA gyrase
of E. coli in formation of spontaneous deletion in vivo.
Mullin, D.A.,1 Van Way, S.M.,1 Newton, A.,2 1Dept. of
Biology, Tu lane University, New Orleans, Louisiana;
2Dept. of Molecular Biology, Princeton University, New
Jersey: Analysis of the C. crescentus fla0 promoter using
site-specific mutagenesis.
Musso, R., Hodam, T., Wilson, L., Dept. of Biology, University
of South Carolina, Columbia: Tn5-derived kanamycin
resistance cassettes for delivery of in-phase, frameshift,
and translation termination mutations.
Ninfa, A.J., Mullin, D.A., Ramakrishnan, G., Newton, A.,
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Dept. of Molecular Biology, Princeton University, New
Jersey: E. coli 054 RNA polymerase recognizes C.
crescentus flaN and flaK flagellar gene promoters in
vitro.
Numrych, T., Gardner, J., Dept. of Microbiology, University
of Illinois, Urbana: Analysis of integration and excision of
bacteriophage A through mutagenesis of the Int arm-type
binding sites.
Oeschger, M., Donze, D., Leitz, L., Dept. of Microbiology,
Immunology, and Parasitology, Louisiana State
University Medical Center, New Orleans: Antitermination
regulation of RNA polymerase genes in E. coll.
Osuna, R., Schwacha, A., Bender, R.A., Dept. of Biology,
SESSION 7 TRANSCRIPTIONAL REGULATORY PROTEINS
Bushman, F.D., Ptashne, M., Dept. of Biochemistry and
Molecular Biology, Harvard University, Cambridge,
Massachusetts: Amino acid sequence requirements for
transcriptional activation and DNA binding by A
repressor.
Orosz, L., Dallmann, G., Papp, P., Marincs, F., Dept. of
Genetics, Attila Jdzsef University, Szeged, Hungary: On
the specificity of 16-3 repressor.
Takeda, Y.,1 Sarai, A.,2 Hausheer, F.H.,1 1NCI-Frederick
Cancer Research Facility, Frederick, 2NCI, National
Institutes of Health, Bethesda, Maryland: Recognition of
the operator DNA sequence by Cro repressor.
Thliveris, A.T., Mount, D.W., University of Arizona, Tucson:
Genetic analysis of the DNA-binding domain of LexA
protein of E. coll.
Astromoff, A., Ptashne, M., Dept. of Biochemistry and
Molecular Biology, Harvard University, Cambridge,
Massachusetts: A Repressor cooperativity at a
distance-Roles of operator sequence and protein
flexibility.
Kim, J., Garges, S., Adhya, S., National Cancer Institute,
NIH, Bethesda, Maryland: Mutation-induced allosteric
changes in CRP.
SESSION 8 SIGMA FACTORS AND GLOBAL REGULATION
Lesley, S.A., Burgess, R.A., McArdle Laboratory for Cancer
Research, University of Wisconsin, Madison: Identification
of a region in 070 required for binding to core RNA
polymerase.
Erickson, J.W., Gross, C.A., Dept. of Bacteriology, University
of Wisconsin, Madison: Identification of a novel E. coli o
factor involved in high-temperature gene expression.
Kalman, S., Duncan, M.L., Thomas, S.M., Price, C.W., University
of California, Davis: Regulation of the sigB gene encoding
an alternative a factor of B. subtilis RNA polymerase.
Daniels, D., Dept. of Cellular and Developmental Biology,
Harvard University, Cambridge, Massachusetts:
"Loss-
of-specificity" mutation in an RNA polymerase a factor
defines a contact site with the 10 region of a cognate
promoter.
Jaacks, K.J., Grossman, A.D., Dept. of Biology, Massachusetts
Institute of Technology, Cambridge: Identification and
characterization of genes controlled by spoOH (sigma-H)
in B. subtilis.
University of Michigan, Ann Arbor: Deletion analysis
of
the hutUH operon regulatory region in K. aerogenes.
Plumbridge, J., IBPC, Paris, France: Structure and regulation
of the nag regulon of E. coll.
Post le, K., Dept. of Microbiology, Washington State
University, Pullman: Transcriptional regulation of the
E. coli tonB gene.
Pruss, G.J., Dept. of Biology, University of South Carolina,
Columbia: Divergent transcription units, translation, and
plasmid DNA supercoiling.
Ramakrishnan, G., Newton, A., Dept. of Molecular Biology,
Princeton University, New Jersey: Developmental
regulation of flagellar genes in C. crescentus.
Su, W.,1 Adhya, S.,2 Echols, H.,1 1Dept. of Molecular
Biology, University of California, Berkeley; 2NCI, National
Institutes of Health, Bethesda, Maryland: Formation of a
DNA-wound nucleoprotein structure by RNA polymerase
and Crp-cAMP at the P1 promoter of the gal operon.
Hendrickson, W., Flaherty, C., Yin, L., Molz, L., Dept. of
Microbiology and Immunology, Penn State University,
Hershey Medical Center, Pennsylvania: Regulation of the
E. coli araFG promoter.
Yin, L., Hendrickson, W., Dept. of Microbiology and
Immunology, Penn State University, Hershey Medical
Center, Pennsylvania: Structure of the AraC protein-
binding site.
Menon, K., Lee, N.L., Dept. of Biological Sciences,
University of California, Santa Barbara: Activation of ara
operons by truncated AraC proteins does not require
inducer-Arabinose unmasks, rather than generates, a
transcriptional activator.
Lee, N.L., Francklyn, C., Hamilton, E., Dept. of Biological
Sciences, University of California, Santa Barbara:
Activation of the araBAD operon promoter by AraC
protein-Cooperative binding of araC to arali and aral2
sites.
Cutting, S., The Biological Laboratories, Harvard University,
Cambridge, Massachusetts: Coupling of late gene
transcription to morphogenesis during sporulation in B.
subtilis.
Keener, J., Popham, D.L., Kustu, S., Dept. of Microbiology
and Immunology, University of California, Berkeley: Role
of NTRC in initiation of transcription by 054 holoenzyme
and comparison with other prokaryotic regulatory
systems.
Ninfa, A.J.,1 Ninfa, E.G.,1 Lupas, A.N.,1 Stock, A.M.,1
Magasanik, B.,2 Stock, J.B.,1 1Dept. of Molecular
Biology, Princeton University, New Jersey; 2Dept. of
Biology, Massachusetts Institute of Technology, Cam-
bridge: Crosstalk between bacterial chemotaxis signal
transduction proteins and the regulators of transcription
of the Ntr regulon-Evidence that nitrogen assimilation
and chemotaxis are controlled by a common
phosphotransfer mechanism.
Best, E.A., Bender, R.A., Depts. of Microbiology and
Biology, University of Michigan, Ann Arbor: Nac-The
"additional factor" required for Ntr control of but in
Salmonella.
Wilmes, M.R., Wanner, B.L., Dept. of Biological Sciences,
Purdue University, West Lafayette, Indiana: Does
"crosstalk" control the phosphate regulon in phoR
mutants?
SESSION 9 POSTER SESSION
Rampersaud, A., Inouye, M., Dept. of Biochemistry,
Robert Wood Johnson Medical School, University of
Medicine and Dentistry of New Jersey, Piscataway:
Involvement of specific base pairs within the ompF and
ompC promoter regions for DNA binding and
transcriptional activation by the OmpR protein.
Rangwala, S.H., Fuchs, R.L., Drahos, D.J., Olins, P.O.,
Monsanto Company, St. Louis, Missouri: Use of the
E. coli recA promoter for inducible expression in other
gram-negative bacteria.
Ringquist, S.,1 Smith, C.L.,2 Depts. of 1Genetics and
Development, 2Psychology and Microbiology, Columbia
University, New York, New York: In vivo footprinting of
the E. coli chromosome.
Ruckman, J.,1 Hall, D.H.,2 Parma, D.,1 Gold, L.,1 1Dept.
of Molecular, Cellular, and Developmental Biology,
University of Colorado, Boulder; 2School of Applied
Biology, Georgia Institute of Technology, Atlanta: A virus-
encoded gene product is involved in specific nucleolytic
cleavage of some T4 mRNAs.
Ryncarz, A.J., Lammers, P.J., Dept. of Chemistry and the
Plant Genetic Engineering Laboratory, New Mexico State
University, Las Cruces: A small inversion element resides
within the 11-kb excision element that interrupts the nifD
gene of Anabaena 7120.
Sampson, B.A., Misra, R., Benson, S.A., Dept. of Molecular
Biology, Princeton University, New Jersey: Identification
of a new gene of E. coli K-12 involved in outer mem-
brane permeability.
Saporito, S.M.,1 Smith-White, B.J.,2 Cunningham, R.P.,1
1State University of New York, Albany; 2Upjohn
Company, Kalamazoo, Michigan: Nucleotide sequence
of the gene encoding exonuclease III of E. coli.
Schulz, V., Reznikoff, W.S., Dept. of Biochemistry,
University of Wisconsin, Madison: In vitro secondary-
structure analysis of mRNA from lacZ translation initiation
mutants.
Schwartz, E., We lz, C., Rak, B., Institut kir Biologie III,
Universitat Freiburg, Federal Republic of Germany: High-
efficiency natural frameshifting in a new insertion element
of E. coil K-12.
Schwedock, J., Fisher, R., Long, S., Dept. of Biological
Sciences, Stanford University, California: Molecular and
genetic studies of Rhizobium meliloti modulation genes.
Segall, A., Menzel, R., E.I. du Pont de Nemours, Experimental
Station, Wilmington, Delaware: Regulation of DNA
super-coiling-Insertion mutants that suppress double
mutants defective in gyrase and topoisomerase I.
Semerjian, A.V., Fenton, A.C., Poteete, A.R., Dept. of
Molecular Genetics and Microbiology, University of
Massachusetts, Worcester: Identification of two phage
Connell, N., Genii loud, 0., Seikhaus, D., Kolter, R., Dept. of
Microbiology and Molecular Genetics, Harvard Medical
School, Boston, Massachusetts: Point and deletion muta-
tions that define an E. coli promoter regulated by growth
phase.
A. Wright, A. Das
P22 genes involved in recombination.
Shiba, K., Hama, C., Moriwaki, H., Asano, K., Mizobuchi, K.,
Dept. of Biophysics and Biochemistry, Faculty of
Science, University of Tokyo, Japan: Studies on genes
involved in replication and incompatibility of the Col lb
plasmid.
Singer, M., Gross, C., Dept. of Bacteriology, University of
Wisconsin, Madison: A comprehensive mapping kit for
E. coll.
Smith, K.A., Anderson, K.A., Salyers, A.A., Dept. of
Microbiology, University of Illinois, Urbana: Characterization
of a pullulanase and the starch utilization system of
Bacteroides thetaiotaomicron.
Smith, L.D.,1 Bertrand, K.P.,2 1Dept. of Molecular Biology,
Scripps Clinic and Research Foundation, La Jolla,
California; 1Biochemistry/Biophysics Program,
Washington State University, Pullman: Mutations in the
Tn10 tet repressor that interfere with induction-Location
of the tetracycline-binding domain.
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Snapper, S.B., Pane, L., Bloom, B.R., Jacobs, W.R., Jr.,
Albert Einstein College of Medicine, Bronx, New York:
Expression of a selectable marker gene in mycobacteria
using a temperate shuttle phasmid.
Speer, B.S., Salyers, A.A., University of Illinois, Urbana:
Characterization of a gene that codes for a tetracycline-
modifying enzyme.
Stout, V., Gottesman, S., NCI, National Institutes of Health,
Bethesda, Maryland: Regulation of capsule synthesis by
RcsA and RcsC.
Sznyter, L.A., Brooks, J.E., New England Biolabs, Beverly,
Massachusetts: Cloning and characterization of the Eagl
restriction-modification system.
Tilly, K., NCI, National Institutes of Health, Bethesda,
Maryland: Participation of DnaJ protein in P1 plasmid
maintenance.
Tuohy, T.:1'2 O'Connor, M., 23 Falahee, 11,2'3 Hughes, D.,1
Gesteland, R.,2 Atkins, J.,2.3 Thompson, 5.,1 1Dept. of
Genetics, Trinity College, Dublin, Ireland; 2Howard
Hughes Medical Institute and Dept. of Human Genetics,
University of Utah, Salt Lake City; 3Dept. of
Biochemistry, University College Cork, Ireland:
Frameshift suppressors in E. coli and
S. typhimurium.
Valenzuela, D., Ptashne, M., Dept. of Biochemistry and
Molecular Biology, Harvard University, Cambridge,
Massachusetts: Cooperativity "at a distance" by the P22
and 434 bacteriophage repressors.
Venkatesan, M.M., Buysse, J.M., Mills, J., Kopecko, D.J.,
Dept. of Bacterial Immunology, Walter Reed Army
Institute of Research, Washington, D.C.: Characterization
of ipaBCDA genes of S. flexneri associated with
epithelial cell invasion and mapping of a regulatory
element.
Vargas, R., Menzel, R., E.I. du Pont de Nemours,
Experimental Station, Wilmington, Delaware: Sequences
3' to the start of transcription affect DNA relaxation
(coumermycin) activation of gene expression-lacZ
fusions behave differently than galK fusions.
Wanner, B.L., Boline, J.A., Metcalf, W., Dept. of Biological
Sciences, Purdue University, West Lafayette, Indiana:
Methane biogenesis from methylphosphonate by a
cryptic gene(s) in E. coif K-12.
Watson, N., Palsrok, K., Olson, E., Dept. of Molecular
Biology Research, Upjohn Company, Kalamazoo,
Michigan: Mapping and characterization of plasmid
mutations that increase bovine growth hormone gene
expression in E. coli.
Wild, J., Gross, C.A., Dept. of Bacteriology, University of
Wisconsin, Madison: E. coil mutants exhibiting increased
synthesis of heat-shock proteins.
Xu, H., Dingwall, A., Bryan, R., Loewy, Z., Shapiro, L.,
Dept. of Microbiology, Columbia University, New York,
New York: Temporal control of the fla gene network in
Caulobacter-Positive and negative regulation.
Yajnik, V., Almond, N., Godson, G.N., New York University
Medical Center, New York, New York: Antitermination in
the E. coil rpsU-dnaG-rpoD operon.
Yamamoto, K.,1 Takahashi, N.,2 Yoshikura, H.,1
Kobayashi, I.,2 1Dept. of Bacteriology, Faculty of
Medicine, University of Tokyo, 2National Children's
Medical Research Center, Japan: Plasmid homologous
recombination-Origins of gene-conversion-type
products in different pathways.
Yano, R., Yura, T., Institute for Virus Research, Kyoto
University, Japan: E. coli mutations (suhD) causing
reduced synthesis of ribosomal protein S15 can
suppress an opal rpoH mutation.
SESSION 10 PHAGE REGULATION-OTHER
TRANSCRIPTION SYSTEMS
Keener, J.,1 Kustu, S.,1 Hailing, C. 2 Dale, E. 2 Morrison, T.,2
Van Bokkelen, G. 2 Calendar, R. 2 Gebhardt, K.,3
Lindqvist, B.H.,3 Depts. of 1Microbiology, 2Molecular
Biology, University of California, Berkeley; 3Dept. of
Biology, University of Oslo, Norway: trans-Activation by
satellite phage P4.
Lee, T.-C., Christie, G.E., Dept. of Microbiology and
Immunology, Virginia Commonwealth University,
Richmond: Purification and characterization of the
bacteriophage P2 ogr gene product.
Margolin, W., Howe, M.M., Dept. of Microbiology and
Immunology, University of Tennessee, Memphis: In vitro
activation of transcription from a bacteriophage Mu late
promoter by Mu C protein.
Baek, N.-Y.,1 Lindberg, G.K.,2 Rothman-Denes, L.C.,1'2
Depts. of 1Molecular Genetics and Cell Biology,
2Biochemistry and Molecular Biology, University of
Chicago, Illinois: Regulation of N4 late transcription.
Glucksmann, A.,1 Nichols, K.,1 Rothman-Denes, L.B.,1'2
Depts. of 1Molecular Genetics and Cell Biology,
2Biochemistry and Molecular Biology, University of
Chicago, Illinois: N4 virion RNA polymerase-promoter
interaction.
Deno, G., Schilke, B., Maloy, S., Dept. of Microbiology,
University of Illinois, Urbana: Regulation of praline
utilization by S. typhimurium-Expression of the put
operon in vitro.
Hsu, L.M.,1 Stellwagen, A.E.,1 Giannini, J.K.,1
Hattingh, S.E.,1 Leung, C.,1 Crosthwaite, J.C.,2 1Program
in Biochemistry, Mount Holyoke College, South Hadley,
Massachusetts; 2Dept. of Chemistry, University of North
Carolina, Charlotte: Flanking sequence requirements of
the E. coli argT promoter-A functional determination.
Menzel, R., E.I. du Pont de Nemours, Experimental Station,
Wilmington, Delaware: Suppression of the temperature-
sensitive character of a gyrB-defective strain by
mutations affecting transcription.
SESSION 11 SPECIAL SESSION
Ruvolo, P.P.,1 Williams, K.R.,2 Chase, J.W.,1 1Dept. of
Molecular Biology, Albert Einstein College of Medicine,
Bronx, New York; 2Dept. of Molecular Biophysics and
Biochemistry, Yale University School of Medicine, New
Haven, Connecticut: Biochemical and genetic
characterization of conjugative plasmid SSBs from E.
coli.
Panayotatos, N.,1 Fontaine, A.,2 Backman, S.,1 1Michigan
Biotechnology Institute, Lansing; 2lnstitut Pasteur, Paris,
France: A hybrid nuclease probe of DNA structure.
Koalick, E., Ronecker, H.J., Schnetz, K., Schwartz, E., Rak, B.,
Institut fur Biologie, Universitat Schanzlestr., Freiburg,
Federal Republic of Germany: Analysis of mutations
activating the cryptic bgl operon.
Gentry, D.R., Burgess, R.R., McArdle Laboratory for Cancer
Research, University of Wisconsin, Madison: The gene
encoding thew subunit of RNA polymerase, rpoZ, is in
the same operon as spoT.
Zhou, Y.N., Gross, C.A., Dept. of Bacteriology, University of
Wisconsin, Madison: Examination of the heat-shock
response in E. coli cells containing mutations affecting
o70 and 032 reveals a translational regulatory mechanism.
Schaefer, M.R.,1 Golden, S.S.,2 Depts. of 1Biochemistry,
2Biology, Texas A&M University, College Station:
Differential regulation of the psbA multigene family in the
cyanobacterium Synechococcus sp. strain PCC 7942.
French, S.L., Miller, 01., Jr., Dept. of Biology, University of
Virginia, Charlottesville: Transcriptional mapping of the E.
coli chromosome by electron microscopy-rmC to rrnE.
Arica, B.,1 Gross, R.,1 Stibitz, S.,2 Falkow, S.,3 Rappuoli, R.,1
1Sc lavo Research Center, Siena, Italy; 2Food and Drug
Administration, Bethesda, Maryland; 3Dept. of Medical
Microbiology, University of Stanford, California: Regulation
of the virulence factors in Bordetella spp.
Tartaglia, L.A., Storz, G., Jacobson, F.S., Ames, B.N., Dept.
of Biochemistry, University of California, Berkeley:
Regulation of a bacterial response to oxidative stress.
Denoya, C., Breidt, F., Dubnau, D., Dept. of Microbiology,
Public Health Research Institute, New York, New York:
Inducible and constitutive expression of erythromycin
resistance mediated by erm determinants-Regulatory
mechanisms involved.
King, J., Villafane, R., Fane, B., Haase-Pettingell, C., Dept.
of Biology, Massachusetts Institute of Technology,
Cambridge: Second-site suppressors of temperature-
sensitive folding mutants in P22-infected Salmonella.
Mojumdar, M., Berget, B., Dept. of Biological Sciences,
Carneigie Mellon University, Pittsburgh, Pennsylvania:
Structural and functional roles of cysteine residues in the
bacteriophage P22 tail protein.
Barto lome, B., Jubete, Y., Fernandez-Moreno, M.,
Diaz-Aroca, E., Zabala, J.C., de la Cruz, F., Dept. de
Biologie Molecular, Universidad de Cantabria,
Santander, Spain: Genetic analysis of the transcriptional
organization of the hemolysin genes of E. coli.
Cross, M., Koronakis, V., Hughes, C., Dept. of Pathology,
Cambridge University, England: Transcript anti-
termination dictates activation of E. coli hemolysin
secretion genes.
Ishihama, A., Fujita, N., Ueshima, R., Nakayama, M.,
Kajitani, M., Dept. of Molecular Genetics, National
Institute of Genetics, Shizuoka, Japan: Strengths and
regulations of E. coli promoters.
SESSION 12 TRANSCRIPTION TERMINATION AND ANTITERMINATION
Hart, C.M., Roberts, J.W., Section of Biochemistry, Molecular
and Cell Biology, Cornell University, Ithaca, New York:
Characterizing upstream sequence requirements for
p-dependent transcription termination.
Alifano, P.,1 Nappo, A.G.,1 Ciampi, M.S.,2 1Dept. of
Biology, University of Naples, 2lnstitute of Genetics,
University of Bari, Italy: Analysis of the rho-dependent
transcription termination site responsible for polarity in
the hisG gene of S. typhimurium.
Sparkowski, J., Das, A., Dept. of Microbiology, University of
Connecticut, Farmington: Interaction of RNA polymerase
with termination and antitermination factors-A recessive
lethal, dominant suppressor mutation defining a critical
site in the f3 subunit.
Court, D., Patterson, T., Wig le, T., NCI-Frederick Cancer
Research Facility, Frederick, Maryland: Transcription
antitermination at tR1 mediated by
A function.
Oberto, J., Cam, K., Gottesman, M.E., Weisberg, R.A., NCI,
National Institutes of Health, Bethesda, Maryland, and
Columbia University Medical School, New York, New
York: Unusual regulation of expression of genes in the
PL operon of lambdoid phage HK022.
Barik, S., Ghosh, B., Gradzielska, E., Lazinski, D., Whalen, W.,
Das, A., Dept. of Microbiology, University of
Connecticut, Farmington: Biochemical and genetic
dissection of a transcription antitermination apparatus.
Yarnell, W.S., Roberts, J.W., Dept. of Biochemistry, Cornell
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D. Wulff, A. Poteete, G. Gussin, R. Calendar
University, Ithaca, New York: Q-Mediated antitermination
of artificially paused complexes.
Kao, C., Bergs land, K., Snyder, L., Dept. of Microbiology,
Michigan State University, East Lansing: The gol site of
T4 bacteriophage-Antitermination with a difference?
Zhou, Y., McAllister, W.T., Dept. of Microbiology and
Immunology, State University of New York Health
Science Center Brooklyn: Termination of transcription by
bacteriophage T7 RNA polymerase.
Linderoth, N.A., Calendar, R., Dept. of Molecular Biology,
SESSION 13 POSTTRANSCRIPTIONAL EVENTS
Sarkar, N., Popowski, J., Shen, P., Taljanidisz, J., Karnik, P.,
Boston Biomedical Research Institute and Dept. of
Biological Chemistry and Molecular Pharmacology,
Harvard Medical School, Massachusetts: 3'-Terminal
polyadenylation of mRNA in prokaryotes.
Goodrich, H.A.,1 Gott, J.M.,1 Xu, M-.0.,1 Scarlato,
Shub, D.A.,1 1Dept. of Biological Sciences, State
University of New York, Albany; 2Dept. of Biology,
University of California, San Diego, La Jolla; 3lnstitute of
Genetics and Biophysics, Naples, Italy: A self-splicing
group I intron in the DNA polymerase gene of the B.
subtilis bacteriophage spot .
Zeeh, A., Shub, D.A., Dept. of Biological Sciences, State
University of New York, Albany: The product of the
spliced phage T4 sunY gene is a processed protein.
Vogel, G., Toussaint, A., Higgins, P., Dept. of Biochemistry,
University of Alabama, Birmingham Laboratory of
Genetics, Free University of Brussels, Belgium:
Regulation of Mu repressor.
Kameyama, L.,12 Court, D.,2 Guarneros, G.,1 1Dept. of
Genetics and Molecular Biology, CINVESTAV-IPN,
Mexico City, Mexico; 2NIC-Frederick Cancer Research
Facility, Frederick, Maryland: Positive regulation of
A N gene expression by RNase III.
Krinke, L., Wulff, D.L., Dept. of Biological Sciences, State
University of New York, Albany: OOP RNA initiates
c11-0 mRNA degradation through an RNase-Ill-
dependent mechanism.
University of California, Berkeley: Cloning of the phage
P4 psu gene and demonstration of polarity suppression
activity.
Schnetz, K., Rak, B., Institut fur Biologie III, Universitat
Schanzlestr., Freiburg, Federal Republic of Germany:
Regulation of the f3- glucoside (bgl) operon of E. coli.
Houman, F., Lopilato, J., Amster-Choder, 0., Wright, A.,
Dept. of Molecular Biology, Tufts Medical School,
Boston, Massachusetts: Antitermination in the bgl operon
of E. coli K-12.
Bardwell, J.C.A., Takiff, H., Chen, S.-M., Court, D., NCI-
Frederick Cancer Research Facility, Frederick, Maryland:
Regulation of the me operon.
Lee, S., Frost, L., Yanchar, N., Paranchych, W., Dept. of
Biochemistry, University of Alberta, Edmonton, Canada:
Regulation of the transfer operon of F plasmid by the
FinOP system -FinO prevents degradation of the FinP
antisense RNA.
Kornitzer, D., Altuvia, S., Teff, D., Oppenheim, A.B., Dept. of
Molecular Genetics, Hebrew University-Hadassah
Medical School, Jerusalem, Israel: A unique A clIl mRNA
structure is essential for the binding of mRNA to
ribosomes.
Engelberg-Kulka, H., Miller, C., Benhar, I., Dept. of Molecular
Biology, Hebrew University, Hadassah Medical School,
Jerusalem, Israel: Translational error as a regulatory
mechanism of gene expression-Natural frameshift
suppression of the trpR gene.
Webster, K.R., Spicer, E.K., Yale University School of
Medicine, New Haven, Connecticut: In vitro studies of
T4 RegA protein-RNA interactions.
Carpousis, A.J.,1 Mudd, E.A.,1 Prentki, P.,1 Be lin, D.,2
Krisch, H.M.,1 Depts. of 1Molecular Biology, 2Pathology,
University of Geneva, Switzerland: Maintenance of the
capacity to make T4 single-stranded DNA-binding
protein throughout infection by multiple promoters and
mRNA processing.
Mouse Molecular Genetics
August 24-August 25
ARRANGED BY
Douglas Hanahan, Cold Spring Harbor Laboratory
Richard Palmiter, University of Washington, Seattle
Erwin Wagner, Institute of Molecular Pathology, Vienna
368 participants
The excitement in Mouse Molecular Genetics has been increasing dramatically in
the last few years, and the August 1988 meeting at Cold Spring Harbor
Laboratory revealed both the recent accomplishments and the promise of this
blossoming field. The accelerating pace and new approaches for isolating
developmentally interesting genes provide the grist, whereas transgenesis, the
process of introducing foreign genes into the germ line of animals, provides the
means of exploring their regulation and function. Techniques for identifying the
cis-acting elements necessary for appropriate expression are well established;
nevertheless, new levels of regulation are still being discovered and some of the
elements lie long distances away from the genes they control. Once the
cis-acting control elements are in hand, it is possible to use them to overexpress
a particular gene in cells where it is normally expressed, or decrease its
expression by using antisense constructs. It is also possible to use them to direct
the expression of heterologous structural genes to specific cell types. Modifying
gene expression in these ways often has profound effects on cell function and
ultimately may affect the physiology of the animal, in some cases, mimicking
human diseases. Applications of these techniques for studying complex diseases
such as cancer or cellular interactions such as those that occur in the immune
system were particularly evident at this meeting.
Improved methods of visualizing natural gene products, and for tagging cells
with genetic markers, are revealing the complexity of gene expression patterns
during development. By using retroviral vectors or by making chimeric mice, it is
now possible to begin mapping cell lineages, an approach that may be
especially rewarding in deciphering how the nervous system develops. Other
genetic tricks allow the deletion of specific cell lineages by selective expression
of
toxins.
Introduction of foreign genes into the germ line of mice often produces new
mutations that may have novel effects on development. As a consequence of the
chromosomal tagging by the transgene, it is sometimes possible to isolate the
flanking sequences and ultimately identify the gene that was disrupted. In a few,
particularly gratifying cases, these new mutations map to the same locus as
spontaneous or induced mutations that were identified previously.
Gene targeting, by homologous recombination or gene conversion,
finally
seems within reach and will add an essential tool to the currently
available
genetic approaches. Novel selection strategies for minimizing
the number of
nonhomologous integrants in embryonal stem cells as well as powerful screening
approaches that allow one to identify the appropriate
clones are in hand, and we
can expect to soon learn the consequences of making gene
disruptions in a
variety of developmentally interesting genes.
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This meeting clearly demonstrated that mouse molecular
genetics has come of
age, and we can anticipate a wealth of new information in the next few years
that
should provide invaluable insights into the developmental and physiological
controls that operate in mammals.
This meeting was supported in part by funds from the National Science
Foundation and the National Institute of Child Health and Human Development, a
division of the National Institutes of Health.
M. Rassoulzadegan, H. Westphal, L. Pozzi
SESSION 1 GENE REGULATION
Chairman: R. Palmiter, University of Washington, Seattle
Hammer, R.E.,1 Swift, G.H.,2 Kruse, F.,2 MacDonald, R.J.,2
1Howard Hughes Medical Institute, Dept. of Cell Biology,
2Dept. of Biochemistry, University of Texas Southwestern
Medical Center, Dallas: Differential requirements for
cell-specific enhancer domains in transfected cells and
transgenic mice.
Grosschedl, R., Travis, A., Marx, M., Dept. of Microbiology
and Immunology, University of California, San Francisco:
Developmental regulation of immunoglobulin heavy-chain
gene transcription in transgenic mice.
Grosveld, F., National Institute for Medical Research,
London, England:Position-independent high-level
expression of the human fl-globin gene in transgenic
mice.
Behringer, R.,1 Ryan, 1.,2 Palmiter, R.,3 Brinster, R.,1
Townes, T.,2 1School of Veterinary Medicine, University
of Pennsylvania, Philadelphia; 2Dept. of Biochemistry,
University of Alabama, Birmingham; 3Howard Hughes
Medical Institute, University of Washington, Seattle:
Regulation of the (3- globin gene cluster during erythroid
development in transgenic mice.
Johnson, J.E.,1 Wilkie, T.M.,1 Gartside, C.L.,2 Wold, B.J.,1
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Eye Institute, University of California, Los Angeles: Lens-
specific expression of recombinant ricin induces
developmental defects in the eyes of transgenic mice.
Rassoulzadegan, M., Leopold, P., Vail ly, J., Blangy, A.,
Cuzin, F., INSET, Universite de Nice, France: Episomal
elements in transgenic mice.
Corden, J.L.,1 Bartolomei, M.S.,1 Overbeek, P.,2 1Howard
Hughes Medical Institute and Dept. of Molecular Biology
and Genetics, Johns Hopkins University School of
Medicine, Maryland; 2Howard Hughes Medical Institute
and Dept. of Cell Biology, Baylor College of Medicine,
Houston, Texas: Transgenic a-amanitin-resistant mice.
Byrne, G.W,1 O'Hare, P.,2 Utset, M.,1 Rudd le, F.H.,1
1Dept. of Biology, Yale University, New Haven,
Connecticut; 2Marie Curie Research Institute, London,
England: Multiplex gene regulation for the analysis of
gene function in transgenic mice.
Rosenberg, M.P., Felder, B.K., Walton, E.M., Swing, D.A.,
Grammatikakis, N., Pavlakis, G.N., Jenkins, N.A.,
Copeland, N.G., NCI-Frederick Cancer Research Facility,
Frederick, Maryland: Molecular mechanisms of HTLV
trans-activator gene action in transgenic mice.
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Intermediates in Genetic Recombination
August 31-September 4
ARRANGED BY
Amar Klar, Cold Spring Harbor Laboratory
Raju Kucherlapati, University of Illinois
Charles Radding, Yale University
Jeffrey Strathern, NCI-Frederick Cancer Research Facility
313 participants
The meeting on Intermediates in Genetic Recombination attracted about 400
people and nearly 250 abstracts, divided into eight sessions. As implied in the
title, the focus of the meeting was to understand the strand mechanics and the
enzymatic functions involved in recombination. This question has been
approached by a variety of mechanisms ranging from the classic genetic
approach of monitoring the endproducts to determine the constraints placed on
the intermediates to the physical techniques designed to capture transition states
in the process. The eight sessions reflected this broad spectrum. Site-specific
Recombination was chaired by David Sherrat. By changing the bases at the
target sites, the sequence requirements for several systems have been defined.
More importantly, some of these defective sites allow partial reactions to occur
and hence trap intermediates for further analysis. Similar progress has been
made in determining the essential parts of the enzymes involved in these
processes. The session was noteworthy both for the recurrent themes and for the
well-defined differences between the systems presented. The session on
Retrotransposons, chaired by Steve Goff, focused on the integration step. This
process is site-specific on the transposon but has little or no target specificity.
The session on Biophysical Aspects of Recombination, chaired by Steve West,
was dedicated to Dr. Paul Howard-Flanders. Most of the talks dealt with the
characterization of E. coli proteins and DNA-protein complexes involved in
homologous DNA recombination. Bill Holloman chaired the session on
Enzymology of Recombination. This session continued the discussion of proteins,
from several organisms, involved in strand exchange reactions and in the
resolution of Holliday junctions. The systems that recognize and repair
mismatched bases was the topic of a session chaired by Paul Modrich. These
systems have been defined both genetically and biochemically. The talks
included descriptions of a multiplicity of systems with specificity for different
mismatches and the well-characterized methyl-directed mismatch repair system of
E. coll. Homologous recombination between exogenously added DNA and the
chromosomes of higher eukaryotic is becoming experimentally more accessible
as a tool for making specific gene replacements. The session chaired by Nat
Sternberg included several demonstrations of this technique as well as
descriptions of homologous recombination events between chromosomal
sequences. Homologous recombination in budding and fission yeast was
covered in the session chaired by Tom Petes. This session included discussions
of the nature of initiating events, the roles of gene products involved in
recombination, and the physical demonstration of recombination intermediates.The final session was chaired by Susumu Tonegawa and dealt with the use of
recombination as a means of gene activation. Examples presented included the
mating-type switching in yeast and the rearrangement of the genes for the
immunoglobin proteins. The meeting provided an excellent opportunity for
scientific exchange between experimentalists with different approaches. Those
that work on substantially different systems often find inspiration both from the
generalities that emerge and from the well-characterized distinctions.
This meeting was supported in part by the National Science Foundation.
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SESSION 1 SITE-SPECIFIC RECOMBINATION
Chairman: D. Sherratt, University of Glasgow
Bruist, M.F., Nash, H.A., Laboratory of Molecular Biology,
National Institute of Mental Health, Bethesda, Maryland:
A kinetic study of A site-specific recognition.
Nunes-Duby, S.E., Landy, A., Division of Biology and
Medicine, Brown University, Providence, Rhode Island: A
half attachment sites can serve as substrates for
recombination and for an integrase-mediated ligation
reaction.
Weinberg, R.L., Haskins, W.P., Cozzarelli, N.R., Dept. of
Molecular Biology, University of California, Berkeley:
Topological tests of the mechanisms of integration and
excision by bacteriophage A.
Ramaiah, N.,1 Yagil, E.,2 Kislev, N.,1 Do lev, S.,2
Weisberg, R.,1 1NCI, National Institutes of Health,
Bethesda, Maryland; 2Tel Aviv University, Israel:
Localization of the determinants of specificity of site-
specific recombination.
Parsons, R.L., Evans, B.R., Crain, K., Jayaram, M., Dept. of
Molecular Biology, Research Institute of Scripps Clinic,
La Jolla, California: Intermediates in recombination
revealed by step-arrest mutants of Flp.
Umlaut, S., Qian, X.-H., Cox, M.M., Program of
Biochemistry and Molecular Biology and Dept. of
Biochemistry, University of Wisconsin, Madison:
Mechanisms of site-specific recombination of the yeast
plasmid-Studies of the role of DNA structure and
cooperative binding of FLP protein.
Abremski, K., Wierzbicki, A., Hoess, R., Dept. of Central
Research and Development, E.I. du Pont de Nemours &
Co., Wilmington, Delaware: Studies on recombination
intermediates generated during Cre-/ox site-specific
recombination.
Hatfull, G., Hughes, R., Sanderson, M., Freemont, P., Rice, P.,
Goldman, A., Steitz, T., Grindley, N., Dept. of Molecular
Biophysics and Biochemistry, Yale University, New
Haven, Connecticut: A structure-function analysis of the
site-specific recombinase, resolvase, encoded by
transposon yd.
Bednarz, A.L., Stark, W.M., Boocock, M.R., Sherratt, D.J.,
Institute of Genetics, University of Glasgow, Scotland:
Polarity of the Tn3 res and the directionality of strand
exchange.
Kanaar, R.,1 van de Putte, P.,1 Cozzarelli, N.R.,2 2Dept. of
Biochemistry, University of Leiden, The Netherlands;
2Dept. of Molecular Biology, University of California,
Berkeley: Gin-mediated recombination of catenated and
A. Klar, N. Symonds
knotted DNA substrates-Implications for synaptic
complex formation.
Glasgow, A.C., Simon, M.I., Division of Biology, California
Institute of Technology, Pasadena: Protein-DNA
interactions and altered DNA structures in the Salmonella
DNA inversion system.
Johnson, R.C.,1 Ball, C.A.,1 Bruist, M.F.,2 1Dept. of
Biological Chemistry, and the Molecular Biology Institute,
University of California, Los Angeles; 2Division of
Biology, California Institute of Technology, Pasadena:
Mechanism of strand exchange in Hin-mediated site-
specific DNA inversion.
Benjamin, H., Kleckner, N., Dept. of Biochemistry and
Molecular Biology, Harvard University, Cambridge,
Massachusetts: Characterization of a complete
intramolecular transposition reaction mediated by Tn/O
transposase.
Leung, P.C., Nallur, G.N., Hershey, R.M., Dept. of Molecular
Biology, Research Institute of Scipps Clinic, La Jolla,
California: Structure-function relationships in phage Mu
transposase.
Adzuma, K., Mizuuchi, K., NIDDK, National Institutes of
Health, Bethesda, Maryland: Action of Mu B ATPase in
the Mu DNA strand-transfer reaction.
Bainton, R.J., Craig, N.L., Dept. of Microbiology and
Immunology and Hooper Foundation, University of
California, San Francisco: In vitro transposition of Tn7.
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SESSION 2 RETROTRANSPOSITION
Chairman: S. Goff, Columbia University
Fujiwara, T., Craigie, R., NIDDK, National Institutes of Health,
Bethesda, Maryland: Integration of exogenously added
retroviral DNA in a cell-free reaction.
Bowerman, B., Brown, P.O., Bishop, M., Varmus, H.E.,
University of California, San Francisco: Biochemical and
structural characterization of the nucleoprotein complex
active in the integration of retroviral DNA.
Roth, M., Schwartzberg, P., Tanese, N., Goff, S.P., Dept. of
Biochemistry and Molecular Biophysics, Columbia
University College of Physicians & Surgeons, New York,
New York: Characterization of mutants of the integration
protein of Mo-MLV.
SESSION 3 BIOPHYSICAL: ASPECTS OF RECOMBINATION
Chairman: P. Howard-Flanders, Yale University
Bujalowski, W., Lohman, T.M., Dept. of Biochemistry and
Biophysics, Texas A&M University, College Station:
Negative cooperativity among single-stranded DNA-
binding sites within individual E. coli SSB tetramers.
Kodadek, T., Stemke, K., Gan, D., Maine, R., Dept. of
Chemistry and Clayton Foundation Biomedical Institute,
University of Texas, Austin: The bacteriophage T4 UvsY
protein-The first well-characterized accessory factor for
homologous strand exchange.
Thaler, D.S., Sampson, E., Siddiqi, I., Rosenberg, S.M.,
Stahl, M.M., Stahl, F.W., Institute of Molecular Biology,
University of Oregon, Eugene: RecBC$ recombination of
bacteriophage A.
Lovett, S.T., Griffin IV, T.J., Kolodner, R.D., Dana-Farber
Cancer Institute, Boston, Massachusetts: Purification and
characterization of the RecF and RecJ proteins of
E. coll.
Lindsley, J.E., Pugh, B.F., Kim, J.-I., Schutte, B.C., Cox, M.M.,
Dept. of Biochemistry, University of Wisconsin, Madison:
Association and dissociation of RecA protein with duplex
DNA.
Rao, B.J., Jwang, B., Flory, J., Radding, C.M., Dept. of
Human Genetics, Yale University School of Medicine,
SESSION 4 ENZYMOLOGY OF RECOMBINATION
Chairman: B. Holloman, Cornell University Medical School
Kawasaki, K.,1 Arai, N.,2 Natori, M.,2 Shibata, T.,1
1Laboratory of Microbiology, RIKEN Institute, Saitama,
2Co liege of Agricultural and Veterinary Medicine, Nihon
University, Tokyo, Japan: Homologous pairing and
strand exchange promoted by proteins from fission
yeast.
Sena, E.,1 Fishel, R.,2 Zarling, D.,1 1Dept. of Molecular
Biology, SRI International, Menlo Park, California; 2NCI-
Frederick Cancer Research Facility, Frederick, Maryland:
Z -DNA affinity chromatography selects for yeast strand-
transfer activity.
Levine, K., Steiner, B., Linial, M., Fred Hutchinson Cancer
Research Center, Seattle, Washington: Molecular
analysis of processed pseudogenes formed via
retrofection.
Eichinger, D., Boeke, J., Dept. of Molecular Biology and
Genetics, Johns Hopkins University School of Medicine,
Baltimore, Maryland: Cell-free transposition of the yeast
transposable element Tyl.
Weinstock, K., Mastrangelo, M., Shafer, B., Garfinkel, D.,
Strathern, J., NCI-Frederick Cancer Research Facility,
BRI-Basic Research Program, Frederick, Maryland:
Insertions of Ty multimers at HMLa.
New Haven, Connecticut: Defining the E. coil RecA-SSB
strand-exchange machine-A reconstitution study.
Thresher, R., Griffith, J., Lineberger Cancer Research Center,
University of North Carolina, Chapel Hill: Ethidium
bromide and acridine orange cause RecA protein to
form active complexes with duplex DNA.
Egelman, E.H., Yu, X., Dept. of Molecular Biophysics and
Biochemistry, Yale University, New Haven, Connecticut:
Structure and dynamics of the E. coil RecA protein-
Conformational changes and enzymatic function.
Conley, E.C., West, S.C., Imperial Cancer Research Fund,
Clare Hall Laboratories, South Mimms, England: RecA
protein promotes homologous pairing between regions
of duplex DNA.
Duckett, D.R.,1 Murchie, A.I.H.,1 Dickmann, S.,2
von Kitzing, E.,2 Kemper, B.,3 Lilley, D.M.J.,1 1Dept. of
Biochemistry, University of Dundee, Scotland;
2Max-Planck-Institut far Biophysikalischeme, Gottingen,
Federal Republic of Germany; 3lnstitut fur Genetik,
Universitat zu Ko In, Cologne, Federal Republic of
Germany: The structure of the Holliday
junction, and its resolution.
Sander, M., Lowenhaupt, K., Rich, A., Dept. of Biology,
Massachusetts Institute of Technology, Cambridge:
Properties of a D. melanogaster strand-transfer activity.
Heyer, W.-D., Kolodner, R.D., Dana-Farber Cancer Institute
and Dept. of Biological Chemistry and Molecular
Pharmacology, Harvard Medical School, Boston,
Massachusetts: Purification and characterization of a
single-stranded DNA-binding protein from S. cerevisiae
that stimulates the cognate mitotic strand-exchange
protein.
Ganea, D.,1 Frey, S.,1 Boudos, C.,1 Moore, P.,2
A. Skala, C. Radding
Kucherlapati, R.,1 Depts. of 1Genetics, 2Microbiology
and Immunology, University of Illinois, Chicago:
Characterization of a human DNA-strand transferase.
Moore, S.P., Harris, C.J., Fishel, R., NCI-Frederick Cancer
Research Facility, Frederick, Maryland: The human
recombination strand-transfer process-Purification and
characterization of the protein(s).
Hsieh, P., Camerini-Otero, C.S., Mills, F., Camerini-Otero, R.D.,
NIDDK, National Institutes of Health, Bethesda,
Maryland: Recombinases can form DNA joint molecules
in the absence of strand displacement.
Dykstra, C., Clark, A., Sugino, A., National Institute of
Environmental Health Sciences, Research Triangle Park,
North Carolina: Identification of a gene encoding a
meiotically inducible DNA-strand-transfer activity from S.
cerevisiae.
West, S.C., Parsons, C.A., Picks ley, S.M., Imperial Cancer
Research Fund, Clare Hall Laboratories, South Mimms,
England: Resolution of recombination intermediates in
vitro-Studies with model Holliday junctions.
Kemper, B.,1 Kleff, 5.,2 Jensch, F.,1 Pottmeyer, 5.,1
Seeman, N.,3 Solaro, P.,1 lInstitut fOr Genetik, Köln,
Federal Republic of Germany; 2Dept. of Biochemistry,
State University of New York, Stony Brook; 3State
University of New York, Albany: Resolution of
recombinational intermediates by X-solvases,
endonuclease VII from phage T4 and endonuclease Y3
SESSION 5 MISMATCH REPAIR
Chairman: P. Modrich, Duke University
Au, K.,1 Clark, S.,1 Grilley, M.,1 Lahue, R.,1 Su, S.-S,1
Thresher, R.,2 Welsh, K.,1 Griffith, J.,2 Modrich,
from yeast S. cerevisiae.
Mueller, J.E.,1 Kemper, B.,2 Cunningham, R.P.,1
Kallenbach, N.R.,3 Seeman, N.C.,1'3 1Dept. of Biology,
State University of New York, Albany; 2lnstitute of
Genetics, University of Cologne, Federal Republic of
Germany; 3Dept. of Chemistry, New York University,
New York: Cleavage preferences of T4 endonuclease VII
for Holliday crossover analogs correlate with structural
results in solution.
Kleff, S.,1 Kemper, B.,2 Sternglanz, R.,1 1Dept. of
Biochemistry, State University of New York, Stony Brook;
2lnstitute of Genetics, Cologne, Federal Republic of
Germany: Identification of a yeast mutant deficient in an
endonuclease that cleaves Holliday junctions.
Holbeck, S.L.,1 Taylor, A.F.,1 Braedt, F.,1 Smith, G.R.,1,2
1Fred Hutchinson Cancer Research Center, 2Dept. of
Pathology, University of Washington, Seattle: Physical
analysis of RecBCD enzyme action.
Kulkarni, S.K., Thaler, D.S., Shurvinton, C.E., Stahl, F.W.,
Institute of Molecular Biology, University of Oregon,
Eugene: Stimulation of recombination by a palindrome
on bacteriophage A in a recD mutant.
Lu, B.C., Sakaguchi, K., Dept. of Molecular Biology and
Genetics, University of Guelph, Ontario, Canada:
Meiosis-specific deoxynucleases from the synchronous
meiotic system of Coprinus cinereus.
p.,1 iDept. of Biochemistry, Duke University Medical
Center, 2Lineberger Cancer Research Center, University
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of North Carolina, Chapel Hill: Enzymology of methyl-
directed DNA mismatch correction.
Claverys, J.-P., Mejean, V., Prudhomme, M., Centre de
Recherche de Biochimie et de Genetique Cellulaires du
CNRS, Universite Paul Sabatier, Toulouse, France: DNA
mismatch repair during transformation in S. pneumoniae.
Kramer, B., Kramer, W., Williamson, M.S., Fogel, S., Dept.
of Genetics, University of California, Berkeley: DNA
mismatch repair in S. cerevisiae-Analysis of substrate
SESSION 6 RECOMBINATION IN HIGHER EUKARYOTES
Chairman: N. Sternberg, E.I. du Pont de Nemours & Co.
Campbell, C., Keown, W., Lowe, L., Kucherlapati, R., Dept.
of Genetics, University of Illinois College of Medicine,
Chicago: Gene modification by synthetic oligonucleotides
in human cells.
Lin, F.-L.M., Sperle, K., Sternberg, N., Dept. of Central
Research and Development, E.I. du Pont de Nemours &
Co., Inc., Experimental Station, Wilmington, Delaware:
Repair of double-stranded DNA breaks with a
homolgous DNA fragment in gene transfer of mouse L
cells.
Hu, W.S.,1 Rio, D.,2 Tjian, R.,2 Shen, C.-K.J.,1 1Dept. of
Genetics, University of California, Davis; 2Dept. of
Biochemistry, University of California, Berkeley: cis-
Controlling elements and trans-acting factor(s) of a
homologous DNA recombination system in primate cells.
Colinas, R.J.,1 Condit, R.C.,2 Pao letti, E.,3 lAlbany Medical
College, 2State University of New York, Buffalo, 3New
York State Dept. of Health, Wadsworth Center for Labs
and Research, Albany: Homologous recombination in
vaccinia-infected cells requires a functional DNA
polymerase.
Jasin, M., Berg, P., Dept. of Biochemistry, Stanford
University School of Medicine, California: Selected
homologous integrations in mammalian cells without
target gene selection.
SESSION 7 HOMOLOGOUS RECOMBINATION
Chairman: T. Petes, University of Chicago
Sun, H., Treco, D., Schultes, N., Szostak, J.W., Dept. of
Molecular Biology, Massachusetts General Hospital,
Boston: Double-strand breaks at an initiation site for
meiotic recombination.
Cao, L., Alani, E., Kleckner, N., Dept. of Biochemistry and
Molecular Biology, Harvard University, Cambridge,
Massachusetts: Identification of a possible intermediate
in meiotic chromosome synapsis and homologous
recombination-A meiosis-specific, RAD50,
SPO/ /-dependent DNA signal present between
premeiotic DNA synthesis and maximal level of a
heteroallelic recombinant.
Nag, D., Detloff, P., White, M., Petes, T.D., Dept. of
Molecular Genetics and Cell Biology, University of
Chicago, Illinois: Non-Mendelian meiotic segregation at
the HIS4 locus of yeast.
Lichten, M.,1 Nicolas, A.,2 Schultes, N.P.,3 Treco, D.,3
specificity and the effect of the pms mutations.
Hare, J.T., Taylor, J.H., Institute of Molecular Biophysics,
Florida State University, Tallahassee: Bias in the selection
of template strand in mismatch repair of vertebrate
cells.
J.,2 1MRC Radiobiology Unit, Harwell,
h Miescher Institute, Basel,
Brown, lTa.nCd.;,12FJriireicdnriyc,
Switzerland: Repair of mismatched bases in simian and
human cells.
Scheerer, J., Adair, G., University of Texas M.D. Anderson
Cancer Center, Smithville: Targeted correction of an
APRT deletion mutation by homologous recombination
with a fragment of the APRT gene.
Baker, M.D., Pennell, N., Bosnoyan, L., Shulman, M.J.,
Depts. of Immunology and Medical Genetics, University
of Toronto, Canada: Homologous recombination of
transferred and chromosomal immunoglobulin genes -
Toward a mammalian lac operon.
Groden, J.,1 Nakamura, Y.,2 White, R.,2 German, J.,1
1Cornell University Graduate School of Medical Sciences,
New York, New York; 2University of Utah Medical
Center, Salt Lake City: Homologous recombination in
proliferating human cells.
Sauer, B., Henderson, N., Dept. of Central Research and
Development, E.I. du Pont de Nemours and Co., Ex-
perimental Station, Wilmington, Delaware: Cre-mediated
site-specific recombination in mammalian cells.
Heartlein, M.W.,1 Latt, S.A.,1'2 1Division of Genetics,
Children's Hospital, Howard Hughes Medical Institute,
Depts. of Pediatrics, 2Genetics, Harvard Medical School,
Boston, Massachusetts: Inverted duplication within and
adjacent to heterologous selectable DNA is associated
with DNA
amplification in CHO cells.
Szortak, J.W.,3 Haber, J.E.,4 1NCI, National Institutes of
Health, Bethesda, Maryland; 2University Paris, Orsay,
France; 3Dept. of Molecular Biology, Massachusetts
General Hospital, Boston; 4Rosenstiel Center, Brandeis
University, Waltham, Massachusetts: Detection of
heteroduplex DNA molecules among the products of
yeast meiosis.
Rothstein, R., Rashba, E., Stollman, N., Ronne, H., Dept. of
Genetics and Development, Columbia University College
of Physicians & Surgeons, New York, New York: A
genetic system to detect unselected mitotic recombina-
tion events between marked direct repeats.
Higgins, D., McGill, C., Strathern, J., NCI-Frederick Cancer
Research Facility, Frederick, Maryland: Recombinogenic
nature of DNA lesions generated in vitro.
Klar, A.J.S., NCI-Frederick Cancer Research Facility,
Frederick, Maryland: A cold spot of mitotic and meiotic
recombination in fission yeast inhibits meiotic recombina-
tion in flanking intervals.
Voelkel-Meiman, K., Xie, K., Roeder, S., Dept. of Biology,
Yale University, New Haven, Connecticut: Studies on the
mechanism of HOT/-promoted recombination events.
Hayden, M., Byers, B., Dept. of Genetics, University of
Washington, Seattle: How much homology is needed for
meiotic recombination?
Schuchert, P., Langsford, M., Grimm, C., Kaeslin, E.,
Koh li, J., Institute of General Microbiology, Bern,
Switzerland: Analysis of recombination initiation in fission
yeast.
Kramer, K.M., Haber, J.E., Brandeis University, Rosenstiel
Research Center, Waltham, Massachusetts: Healing of
double-strand breaks by de novo telomere formation.
Brunier, D.,1 Peeters, B.,2 Ehrlich, S.D.,1 "'Institut des
Biotechnologies, INRS, Jouy en Josas, France; 2Dept. of
SESSION 8 GENE ACTIVATION BY RECOMBINATION
Chairman: S. Tonegawa, Massachusetts Institute of
Technology
Klar, A.J.S., Cafferkey, R., NCI-Frederick Cancer Research
Facility, Frederick, Maryland: The developmental fate of
fission yeast cells is determined by the pattern of in-
heritance of parental and grandparental DNA strands.
Stavnezer, J., Nietupski, J., Lin, Y.-C., Radcliffe, G.,
Severinson, E., University of Massachusetts Medical
School, Worcester: Immunoglobulin heavy-chain
switching may be directed by prior induction of
transcripts from constant-region genes.
Li, M., Halligan, B., Morzycka-Wroblewska, E., Desiderio, S.,
Howard Hughes Medical Institute and Dept. of Molecular
Biology and Genetics, Johns Hopkins University School
of Medicine, Baltimore, Maryland: Identification and
characterization of a protein that specifically binds the
POSTER SESSION I
Site-specific Recombination
Hoess, R., Wierzbicki, A., Abremski, K., Dept. of Central
Research and Development, E.I. du Pont de Nemours &
Co., Inc., Wilmington, Delaware: Isolation of intermediates
in the Cre-/ox recombination pathway.
Sternberg, N., Dept. of Central Research and Development,
Dept. of E.I. du Pont de Nemours and Co., Inc.,
Wilmington, Delaware: A new P1 site-specific recombina-
tion cloning system that permits the efficient isolation,
amplification, and recovery of big DNA inserts.
Goodman, S.T., Yang, C.-C., Nash, H.A., NCI, National
Institute of Mental Health, Bethesda, Maryland: IHF-DNA
interactions-A binding and bending analysis.
Kitts, P.A., Nash, H.A., Laboratory of Molecular Biology,
National Institute of Mental Health, Bethesda, Maryland:
Bacteriophage A site-specific recombination proceeds
with a defined order of strand exchanges.
Amin, A.A., Sadowski, P.D., Dept. of Medical Genetics,
University of Toronto, Ontario, Canada: Regions of the
Genetics, University of Groningen, The Netherlands:
Mechanisms of recombination between short
homologous sequences.
Christman, M.F.,1 Dietrich, F.S.,1 Fink, G.R.,1.2 1Whitehead
Institute for Biomedical Research, Cambridge Center,
2Dept. of Biology, Massachusetts Institute of Technology,
Cambridge: Mitotic recombination in the rDNA of S.
cerevisiae is strongly suppressed through the combined
action of DNA topoisomerases I and II.
Keil, R.L., McWilliams, A.D., Pindowski, C.L., Dept. of
Biological Chemistry, Hershey Medical Center, Hershey,
Pennsylvania: Mutations affecting rDNA recombination in
S. cerevisiae.
Aguilera, A., Klein, H.L., Dept. of Biochemistry, New York
University Medical Center, New York: Genetic and
molecular analysis of recombination events enhanced by
the hyper recombination mutant hprl
nonamer recombinational signals of immunoglobulin
genes.
Lieber, M.R.,1 Hesse, J.E.,1 Lewis, 5.,1 Bosma, G.C.,2
Mizuuchi, K.,1 Bosma, M.J.,2 Gellert, M.,1 1NIDDK,
National Institutes of Health, Bethesda, Maryland;
2lnstitute for Cancer Research, Fox Chase Cancer
Center, Philadelphia, Pennsylvania: Severe combined
immune deficiency (scid) mutation in mice-Joining of
signal sequences but not coding segments in V(D)J
recombination.
McCormack, W.T., Tjoelker, L., Carlson, L.M., Petryniak, B.,
Thompson, C.B., Howard Hughes Medical Institute,
University of Michigan, Ann Arbor: IgA V-J gene rear-
rangement in chicken bursal lymphocytes.
D. Sherratt
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FLP protein required for site-specific DNA recognition.
Schwartz, C.J.E., Sadowski, P.D., Dept. of Medical Genetics,
University of Toronto, Ontario, Canada: The FLP
recombinase of 21.4 circle of S. cerevisiae bends its DNA
target.
Meyer-Leon, L., Huang, L.-C., Umlauf, S.W., Cox, M.M.,
Inman, R.B., Program in Cellular and Molecular Biology
and Dept. of Biochemistry, University of Wisconsin,
Madison: Intermediates and by-products in the FLP
protein site-specific recombination reaction.
Musso, R.E., Black, T.A., Dept. of Biology, University of
South Carolina, Columbia: IS2-encoded factors mediate
excision of the bacterial insertion sequence IS2.
Waddell, C.S., Craig, N.L., Dept. of Biochemistry and
Biophysics and the Hooper Foundation, University of
California, San Francisco: Recognition of att Tn7 target
sequences by a Tn7-dependent DNA-binding activity.
Nissley, D., Fennewald, M., Dept. of Microbiology and
Immunology, University of Health Sciences, Chicago
Medical School, Illinois: Regions of the Tn3 inverted
repeat involved in transposase binding.
Huisman, 0., Signon, L., Morisato, D., Kleckner, N., Dept.
of Biochemistry and Molecular Biology, Harvard Univer-
sity, Cambridge, Massachusetts: Analysis of the ends of
the transposon Tn10.
Benjamin, H., Kleckner, N., Dept. of Biochemistry and
Molecular Biology, Harvard University, Cambridge,
Massachusetts: Characterization of a complete
intramolecular transposition reaction mediated by Tn/O
transposase.
Derbyshire, K.M., Kramer, M., Grindley, N.D.F., Dept. of
Molecular Biophysics and Biochemistry, Yale University,
New Haven, Connecticut: Analysis of the cis-action of
the 1S903 transposase.
Leung, P.C.,1 Teplow, D.B.,2 Harshey, R.M.,1 1Dept. of
Molecular Biology, Research Institute of Scripps Clinic,
La Jolla, 2Division of Biology, California Institute of
Technology, Pasadena: Mu B-ATP-binding, hydrolysis,
and role in formation of the transposition intermediate.
Mizuuchi, M., Mizuuchi, K., NIDDK, National Institutes of
Health, Bethesda, Maryland: Cloning and expression of
partial polypeptides of the Mu A protein.
Abraham, Z., Symonds, N., School of Biological Sciences,
University of Sussex, England: In vitro studies with the
GAM protein of phage Mu.
Haffter, P., Bickle, T.A., Biocenter, Basal, Switzerland:
Analysis of the topological specificity of the DNA
invertase cin and the Tn3 resolvase.
Gonzalez, T.N.,1 Kanaar, R.,2 Boles, T.C.,1 Dungan, J.,1
van de Putte, P.,2 Cozzarelli, N.R.,1 1Dept. of Molecular
Biology, University of California, Berkeley; 2Dept. of
Biochemistry, State University of Leiden, The
Netherlands: Synapsis of the recombination sites and the
recombinational enhancer in the Mu Gin-DNA system.
Dungan, J.M., Cozzarelli, N.R., Dept. of Molecular Biology,
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The Molecular Diagnostics of Human Cancer
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Mark E. Furth, Regeneron, New York
M.F. Greaves, Institute of Cancer Research, London
232 participants
The 1988 Cancer Cells meeting, The Molecular
Diagnostics of Human Cancer",
focused on the medical implications of recent
discoveries concerning the genetic
basis of neoplastic disease. This international meeting brought
together more than
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232 scientists and physicians who share overlapping interests in fundamental
cancer biology and in the potential clinical ramifications of the detection of
specific molecular abnormalities in cancer cells. The active participation of
individuals with complementary expertise in basic and clinical research proved
stimulating and productive, and the focus on studies directly concerning human
disease marked a new venture in the Laboratory's series of Cancer Cells
meetings. This theme was highlighted in six "clinical overviews" designed to help
educate molecular biologists in medical aspects of cancer, as well as to define
areas in which improved diagnostic assays might have significant clinical impact.
The program of research talks centered principally on the role of oncogenes and
their protein products in human tumors and emphasized the utility of activated
oncogenes as cancer markers. The oncogene proteins serve a wide variety of
regulatory functions and include nuclear proteins involved in the control of DNA
replication and gene expression, growth factors and their cell-surface receptors,
and elements of signal transduction pathways, such as protein kinases and
GTP-binding proteins. Assays either for the overproduction of particular
oncogene proteins, often associated with gene amplification, or for qualitative
iabnormalities in oncogenes and their protein products have proven valuable in
the specific diagnosis and/or prediction of prognosis of certain human cancers.
Perhaps more importantly, insights into the genetic basis of cancer may guide
the development of improved forms of therapy. The program included sessions
on nuclear oncogene proteins, growth factors, growth factor receptors, and the
products of the ras, arc, and raf oncogenes. Other sessions focused on
chromosomal rearrangements known or likely to be associated with oncogene
activation, such as the "Philadelphia chromosome," characteristic of chronic
myelogenous leukemia, in which a translocation activates the abl gene. The
meeting provided an exceptionally good forum for the critical discussion of very
recent data on the prognostic implications of particular oncogene alterations in a
number of cancers, notably pediatric tumors such as neuroblastoma, the
myelogenous leukemias, and carcinomas of the colon, bladder, pancreas, and
breast. Other timely presentations focused on the importance of gene loss in
some of the major human cancers and on the identification and potential function
of "anti-oncogenes." Additional sessions concerned several topics closely related
to the main subject of the meeting, including the genetic basis for the resistance
of tumor cells to chemotherapeutic drugs and the role of DNA tumor virus
oncogenes in some human cancers.
This meeting was funded in part by the National Cancer Institute, a division of
the National Institutes of Health.
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The annual meeting on Modern Approaches to New Vaccines, held in
September 1988, maintained the level of excellence established during the
preceding five conferences. Attendance was 15% greater than that of the
previous year. There was also a significant increase in the number of high-quality
abstracts. As a consequence, we arranged for additional papers to be presented
at the meeting by scheduling additional 5-minute talks. Nevertheless, enthusiasm
remained high and audience participation during the discussion periods was both
spirited and extensive.
The program included sessions on Immunology, Parasitology, and
Bacteriology, three sessions on Virology, and three sessions on AIDS. More than
70 posters were also on display at the Poster session.
This meeting was supported in part by the Rockefeller Foundation.
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This meeting was the first to focus on all aspects of ribosome synthesis, from
transcription of ribosomal RNA and protein genes to the assembly of ribosomes.
Another hallmark of the meeting was bringing together researchers working on
both prokaryotic and eukaryotic organisms. This is a particularly useful strategy in
the study of ribosomes, an organelle that exhibits so many features conserved
throughout evolution.
The meeting was dedicated to Professor Ole Maalbe, one of the founding
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fathers of the study of the regulation of ribosome synthesis. The scientific
program offered about 225 reports, of which 77 were given with slides and the
remainder with posters. These presentations demonstrated how far we have
come in elucidating intricate molecular details of some regulatory mechanisms,
and yet how far we must go before even the most important regulatory circuits
are fully understood. In some areas, such as the regulation of rRNA and
ribosomal protein synthesis in bacteria and yeast, at least some of the major
regulatory pathways have been identified, and the focus is now on understanding
the interactions of the regulators affecting transcription and translation. In other
areas, like the eukaryotic RNA polymerases and perhaps in particular ribosome
assembly, many participating components have yet to be identified and
investigated.
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Co., Inc., Mettler Instrument Corporation, Milli Gen, Promega Corp., United States
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Grants were also received from the National Institute of General Medical Sciences
and the National Institute of Child Health and Human Development, divisions of
the National Institutes of Health.
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University of Texas Medical School, Houston:
Polypeptide composition and peptide map analysis of
stringently purified RNA polymerase I.
Rozen, F.,1 Pelletier, J.,1 Nielsen, P.J.,2 Sonenberg, N.,1
1Dept. of Biochemistry, McGill University, Montreal,
Canada; 2Max-Planck-Institut fOr Immunobiologie,
Freiburg, Federal Republic of Germany: Mutagenesis
studies of the ATP-binding site of mouse eukaryotic
initiation factor-4A.
Rudner, R., Widom, R.L., Jarvis, E.D., White, A., Hunter
College, City University of New York, New York:
Heterogeneity of rRNA operons in
B. subtilis.
Ryan, K., Henderson, S., Sollner -Webb, B., Dept. of
Biological Chemistry, Johns Hopkins University School of
Medicine, Baltimore, Maryland: The promoter-proximal
rDNA terminator augments initiation by preventing
disruption of the stable transcription complex caused by
polymerase read-in.
Said, B., Cole, J.R., Nomura, M., Dept. of Biological
Chemistry, University of California, Irvine: Mutational
analysis of the L1-binding site of 23S rRNA.
Sanchez, M.E.,1 Amils, R.,1 Londei, P.,2 1Centro de Biologia
Molecular, CSIC, Madrid, Spain; 2Dpt. Biopatologie
Umana, Universita di Roma, Italy: In vitro total
reconstitution of active large ribosomal subunits of a
halophilic archaebacterium.
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Sandbaken, M.G., Culbertson, M.R., Laboratories of Molecular
Biology and Genetics, University of Wisconsin, Madison:
Mutations in elongation factor EF-1 a affect the frequency
of frameshifting and amino acid misincorporation in S.
cerevisiae.
Scheibe, U.,1 Federn, H.,2 Wagner, R.,2 1Freie Universitat
Berlin, 2Universitat Dusseldorf, Federal Republic of
Germany: Characterization of the ORF I region in the
rrnb operon from E. coll. A new overlapping gene.
Scheinman, A., Shankweiler, G.W., Lake, J.A., Molecular
Biology Institute and Dept. of Biology, University of
California, Los Angeles: Reconstitution of structurally
intact small ribosomal subunits from in-vitro-transcribed
rRNA containing an insert.
Schnare, M.N.,1 Cook, J.R.,2 Gray, M.W.,1 1Dept. of
Biochemistry, Dalhousie University, Halifax, Nova Scotia,
Canada; 2Dept. of Zoology, University of Maine, Orono:
Nuclear genes encoding discontinuous large subunit
rRNAs in C. fasciculata and E. gracilis.
Scholl, R.L., Kim, Y., Dept. of Molecular Genetics, Ohio
State University, Columbus: Isolation, characterization,
and expression of ribosomal protein genes in A.
thaliana.
Seyer, P., Li, Y.F., Massenet, 0., Dorne, A.M., Mache, R.,
CNRS, Universite J. Fourier, Grenoble, France:
Comparison of the evolution of the chloroplast ribosomal
protein rp/21 gene in a chloroplast genome
(M. po/ymorpha) and in a nuclear genome (S. oleracea).
Shazand, K.,1 Tucker, J.,2 Chiang, R. 2 Grunberg-
J.,2 Leighton, T.,2 11BPC.Manago, M.,1 Rabinowitz,
Paris, France; 2University of California, Berkeley: Isolation
and genetic characterization of the B. subtilis gene
encoding protein synthesis initiation factor 2 (infB).
Shen, P., Zengel, J.M., Lindahl, L., Dept. of Biology,
University of Rochester, New York: Secondary structure
and autogenous control of the E. coli S10 ribosomal
protein operon.
Srivastava, A.K.,1 Slrdeshmukh, R. 2 Schlessinger, D.,1
1Dept. of Microbiology and Immunology, Washington
University School of Medicine, St. Louis, Missouri;
2CCMB, Hyderabad, India: Pathways of E. coli rRNA
maturation and the link to ribosome function.
Stebbins-Boaz, B., Gerbi, S.A., Division of Biology and
Medicine, Brown University, Providence, Rhode Island:
The peptidyl transferase center in eukaryotic ribosomes-
Determination of its rRNA secondary structure in X. laevis.
Szopa, J., Rose, K.M., Dept. of Pharmacology, University of
Texas Medical School, Houston: Separation of RNA
polymerase I activities capable of specific and
nonspecific transcription.
Tapprich, W.E., Dahlberg, A.E., Brown University, Providence,
Rhode Island: Regions of rRNA involved in the initiation
and elongation cycles of protein synthesis.
Tate, W.P., Williams, J.M., Brown, C.M., Trotman, C.N.A.,
Dept. of Biochemistry, University of Otago, Dunedin,
New Zealand: Frameshifting in release factor-2 mRNA
can occur on eukaryotic ribosomes in the absence of
the upstream rRNA/mRNA interaction.
Thomas, C.L., Zimmermann, R.A., University of
Massachusetts, Amherst: Lethal mutations within the
decoding site of E. coli 16S rRNA-Growth rate
impairment, lethality, and intragenic suppression.
Thompson, M., Gantt, J.S., Dept. of Botany, University of
Minnesota, St. Paul: Amino acid sequence comparisons
of A. thaliana ribosomal proteins CS17 and S11 and the
nucleotide sequence of the CS17 gene.
Timofeeva, M.,1 Sedman, J.,3 Shostak, N.,1 Felgengauer, P.,2
Luchina, N.,1 "V. Engelhardt Institute of Molecular
Biology, 2N. Koltsov Institute of Developmental Biology,
Academy of Sciences, Moscow, Union of Soviet
Socialists Republic; 3Estonian Biocentre, Estonian
Academy of Sciences, Tartu: Structural and functional
analysis of loach 5S rRNA genes in embryogenesis.
Toone, W.M., Friesen, J.D., Dept. of Medical Genetics,
University of Toronto, Ontario, Canada: Isolation and
characterization of conditional lethal mutants of E. col'
that are resistant to the amino acid analog
3-amino-1,2,4-triazole.
Triman, K.,1 Becker, E.,1 Dammel, C.,1 Douthwaite, 5.,2
Katz, J.,1 Mori, H.,1 Yapijakis, C.,1 Yoast, S.,1 Noller,
H.,1 1Thimann Laboratories, University of California,
Santa Cruz; 2Dept. of Molecular Biology, Odense
University, Denmark: Isolation of rRNA mutants in E. coli.
Tsay, Y.F., Paulovich, A.G., Woolford, J.L., Dept. of
Biological Sciences, Carnegie Mellon University,
Pittsburgh, Pennsylvania: Structural and functional
similarities between ribosomal proteins from yeast,
bacteria, archaebacteria, plants, and animals.
Tsurugi, K., Mitsui, K., Dept. of Biochemistry, Yamanashi
Medical College, Japan: Structures and metabolism of
acidic ribosomal proteins in yeast S. cerevisiae.
van der Sande, C.A.F.M., van Heerikhuizen, H., Klootwijk, J.,
Planta, R.J., Biochemisch Laboratorium, Vrije
Universiteit, Amsterdam, The Netherlands: 3'-end
formation of the rRNA precursor in yeast.
van Knippenberg, P.H.,1 van Gemen, B.,1 Suvorov,
'Dept. of Biochemistry, Leiden University, The
Netherlands; 2lnstitute of Experimental Medicine,
Leningrad, Union of Soviet Socialists Republic:
Dimethylation of adenosines in rRNA. Function and
genetics.
Vester, B., Garrett, R.A., Institute of Chemistry, Aarhus,
Denmark: Importance of individual conserved
nucleotides in the peptidyl transfer region of E. coli 23S
rRNA.
Wada, A., Dept. of Physics, Faculty of Science, Kyoto
University, Japan: Detection of new ribosomal proteins in
E. coli and changes in the copy numbers of growth-
phase transition.
Ware, V.C., Dept. of Biology and Center for Molecular
Bioscience and Biotechnology, Lehigh University,
Bethlehem, Pennsylvania: Interaction of yeast ribosomal
protein L25 with Tetrahymena 26S rRNA at the "gap"
region of domain IV.
R. Perry, M. Pau le
Weitzmann, C.,1 Negre, D.,1 van Knippenberg, P.H.,2
Ofengand, J.,1 1Roche Institute of Molecular Biology,
Roche Research Center, Nutley, New Jersey; 2Dept. of
Biochemistry, University of Leiden, The Netherlands: In
vitro methylation of 30S ribosomes lacking all methylated
nucleotides.
Wejksnora, P., Bacsi, S., Dumenco, V., Dept. of Biological
Sciences, University of Wisconsin, Milwaukee: Upstream
repeats in Chinese hamster may direct initiation of rRNA
transcription at the correct promoter site.
Wittekind, M.,1 Dodd, J.,1 Kolb, J.,1 Buhler, J. -M.,2
Sentenac, A.,2 Nomura, M.,1 1Dept. of Biological
Chemistry, University of California, Irvine; 2Service de
Biochimie, Centre d'Etudes Nucleaire de Sac lay, Cedex,
France: Studies on RNA polymerase and ribosome
synthesis in S. cerevisiae.
Wright, J.J., Hayward, R.S., Dept. of Molecular Biology,
University of Edinburgh, Scotland: Hypersymmetry in-
creases the efficiency of a trancriptional terminator, as
well as conferring bidirectionality.
Yamagishi, M., Nomura, M., Dept. of Biological Chemistry,
University of California, Irvine: Synthesis of rRNA and
ribosomal proteins in S. pombe.
Zacharias, M.,1 &ginger, H.U.,1 Wagner, R.,2 1Max-Planck-
Institut fOr Molekulare Genetik, Abt. Wittmann, Berlin,
'Institut fur Physikalische Biologie, UniversItat DOsseldorf,
Federal Republic of Germany: Characterization of an E.
coli rrnB-P2-promoter mutation and a putative
internal promoter.
Zhou, D.X., Bisanz-Seyer, C., tvlache, R., CNRS, Universite
Joseph, Fourier, Grenoble, France: Presence of a large
pool of one ribosomal protein in the stroma of
chloroplast that is homologous to one domain of the E.
coli S1 ribosomal protein.
Workshop: Transcription by RNA Polymerase I
SESSION 7 SYNTHESIS OF PROTEINS AND FACTORS: PROKARYOTES
Chairman: M. Nomura, University of California, Irvine
Mattheakis, L., Vu, L., Nomura, M., Dept. of Biological
Chemistry, University of California, Irvine: Retroregulation
of the synthesis of ribosomal proteins L14, L24, and S12
by feedback repressor ribosomal proteins in E. coli.
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J. Warner, W. Merrick
Climie, S., Scime, A., Harrington, T., Friesen, J.D., Dept. of
Medical Genetics, University of Toronto and Hospital for
Sick Children, Ontario, Canada: Genetic and structural
studies of the mRNA target site and the regulator protein
in the rpIJL operon of E. coli.
Zengel, J.M., Archer, R.H., Lindahl, L., Dept. of Biology,
University of Rochester, New York: Attenuation control of
the E. coli S10 ribosomal protein operon.
Lindahl, L., Archer, R.H., McCormick, J.R., Zengel, J.M.,
Dept. of Biology, University of Rochester, New York:
Translational coupling in the E. coli S10 ribosomal
protein operon.
Moine, H., Romby, P., Ebel, J.P., Ehresmann, B.,
Ehresmann, C., Institut de Biologie Moleculaire et
Cellulaire, CNRS, Strasbourg, France: mRNA structure
and gene regulation at the translational level in E. coli-
The case of threonine:tRNATh1 ligase.
Springer, M., Graffe, M., Dondon, J., Grunberg-Manago, M.,
IBPC, Paris, France: A specific link between translational
repression and informational suppression in E. coli.
Draper, D.E., Tang, C.K., Dept. of Chemistry, Johns Hopkins
University, Baltimore, Maryland: A pseudoknot structure
in the a mRNA is required for translational repression
by S4.
Bosch, L., Vijgenboom, E., van Delft, J.H.M., Nilsson, L.,
Dept. of Biochemistry, Leiden University, The
Netherlands: Elongation factor EF-Tu binds to the
upstream activator region of the tRNA-tufB operon.
Wikstrom, P.M., Bystrom, A.S., Bjork, G.R., Dept. of
Microbiology, University of Umeg, Sweden:
Nonautogenous and discoordinate translational control of
the trmD operon of E. coli.
Rasmussen, M.D., Pedersen, S., University Institute of
Microbiology, Copenhagen, Denmark: Regulation of the
rpsA gene in E. coli.
SESSION 8 RIBOSOMES FROM TWO GENOMES: ORGANELLAR RIBOSOMES
Chairman: R. Butow, University of Texas Southwestern Medical Center
O'Brien, T., Dens low, N., Piatyszek, M., Graak, H., Bryant, M.,
Gil levet, P., Dept. of Biochemistry and Molecular
Biology, University of Florida, Gainesville: Synthesis,
assembly, and organization of proteins in bovine
mitochondrial ribosomes.
Bolotin-Fukuhara, M., Daignan-Fornier, B., Laboratoire de
Genetique Moleculaire, Orsay, France: Mutational
analysis of structure-function relationship in the large
rRNA of yeast mitochondria.
Johnson, S., Dang, H., Ellis, S., Dept. of Biochemistry,
University of Louisville, Kentucky: Import of mitochondrial
ribosomal proteins into yeast mitochondria.
Fearon, K., Partaledis, J., Mason, T., Dept. of Biochemistry
and Program in Molecular and Cellular Biology,
University of Massachusetts, Amherst: Structure and
regulation of nuclear genes in S. cerevisiae that specify
mitochondria] ribosomal proteins.
Harris, E.H., Liu, X.-Q., Boynton, J.E., Gillham, N.W.,
Depts. of Botany and Zoology, Duke University,
SESSION 9 RIBOSOME ASSEMBLY AND THE NUCLEOLUS
Chairman: D. Schlessinger, Washington University
Functional Organization of the Nucleolus
Scheer, U., Dabauvalle, M.-C., Institute of Zoology, University
of WOrzburg, Federal Republic of Germany: Functional
organization of the nucleolus.
Amalric, F., Belenguer, P., Bouche, G., Bourbon, H.,
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Durham, North Carolina: Involvement of chloroplast
genes in biogenesis of chloroplast ribosomes in C.
reinhardtii.
Romby, P.,1 Westhof, E.,1 Mache, R.,2 Ebel, J.P.,1
Ehresmann, C.,1 Ehresmann, B.,1 1 Institut de Biologie
Moleculaire et Cellulaire, CNRS, Strasbourg; 2Laboratoire
de Biologie Vegeta le, University de Grenoble, France:
RNA structure and protein recognition. II. Chloroplastic
5S rRNA from spinach and interaction with protein L12.
Gray, M.W.,1 Boer, P.H.,1 Boulanger, J.,2 Heinonen, T.Y.K.,1
Lemieux, C.,2 Schnare, M.N.,1 Turmel, M.,2 1Dept. of
Biochemistry, Dalhousie University, Halifax, Nova Scotia;
2Dept. de biochimie, University Laval, Quebec, Canada:
Discontinuous rRNAs in mitochondria and chloroplasts.
Butow, R.A., Dept. of Biochemistry, University of Texas
Southwestern Medical Center, Dallas: Interactions
between mitochondria and the nucleus in yeast-
Influence of the mitochondrial genotype on novel
transcription of the nuclear rDNA repeat.
Bugler, B., Caizergues-Ferrer, M., Erard, M., Ghisolfi, L.,
Lapeyre, B., Centre de Biochimie et Genetique
Cellulaires, CNRS, Toulouse, France: Role of nucleolin in
expression and packaging of pre-rRNA.
Schmidt-Zachmann, M.S., Peters, J.M., Franke, W.W., Institute
of Cell and Tumor Biology, German Cancer Research
Center, Heidelberg, Federal Republic of Germany:
Protein N038/B23-Molecular characterization of a major
nucleolus-associated member of the nucleoplasmin
family.
Assembly Interactions
Gregory, R.J., King, S.R., Wower, I., Zimmermann, R.A.,
University of Massachusetts, Amherst: Structural and
regulatory properties of S8-RNA interactions in E. coli.
Nishi, K.,1 Morel-Deville, F.,2 Hershey, J.W.B.,2 Leighton, T.,3
Schnier, J.,3 1Max-Planck-Institut fir Molekulare Genetik,
Abt. Wittmann, Berlin, Federal Republic of Germany;
2Dept. of Biological Chemistry, University of California,
Davis; 3Dept. of Microbiology and Immunology,
University of California, Berkeley: Identification of an
EIF-4A-like protein involved in ribosomal 50S subunit
assembly in E. co/i.
Hadjiolov, A.A.,1 Dabeva, M.D.,1 Hadjiolova, K.V.,1
Dimova, R.N.,2 Gajdardjieva, K.C.,1 1 Institute of Cell
Biology and Morphology, 2Regeneration Research
Laboratory, Bulgarian Academy of Science, Sofia:
Ribosome assembly and processing in rat hepatocytes
upon D-galactosamine transcription block.
Sequence Requirements for Processing
Musters, W., Klootwijk, J., Planta, R.J., Biochemisch
Laboratorium, Vrije Universiteit, Amsterdam, The
Netherlands: Mutational analysis of yeast rDNA.
Kass, 5.,1 Craig, N.,2 Sollner-Webb, B.,1 1Dept. of Biological
Chemistry, Johns Hopkins School of Medicine, 2Dept. of
Biological Science, University of Maryland, Baltimore:
Sequences required for processing of mouse rRNA.
Eichler, D.C., Shumard, C.M., Dept. of Biochemistry, University
of South Florida College of Medicine, Tampa: Limited
cleavages of mouse pre-rRNA by a nucleolar
endoribonuclease include the early +650 processing
site.
Maroney, P.A.,1 Hannon, G.,1 Branch, A.,2 Robertson, H.D.,2
Nilsen, T.W.,1 1Dept. of Molecular Biology and
Microbiology, Case Western Reserve University School
of Medicine, Cleveland, Ohio; 2Rockefeller University,
New York, New York: Accurate processing of human
pre-rRNA in vitro.
Intracellular Transport
Underwood, M., Bataille, N., Fried, H., Dept. of Biochemistry,
University of North Carolina, Chapel Hill: Intracellular
trafficking of ribosomal components.
Khanna-Gupta, A., Ware, V.C., Dept. of Biology and Center
for Molecular Bioscience and Biotechnology, Lehigh
University, Bethelehem, Pennsylvania: Inhibition of
ribosome nucleocytoplasmic transport using a synthetic
DNA oligomer complementary to a conserved region in
eukaryotic 28S rRNA.
Allison, L.A., Bakken, A.H., Dept. of Zoology, University of
Washington, Seattle: Nucleocytoplasmic transport of
stored 5S RNA during ribosome biogenesis in X. laevis
oocytes.
D. Schlessinger, L. Lindahl
SESSION 10 RIBOSOMES AND DEVELOPMENT
Chairman: F. Amaldi, University de Roma "Tor Vergata"
McCutchan, T.F., Waters, A.P., NIAID, National Institutes of
Health, Bethesda, Maryland: Plasmodium species have
stage-dependent ribosomes.
Mariottini, P., Bagni, C., Amaldi, F., Dipt. di Biologia,
University di Roma, Italy: The 5'-untranslated region is
involved in the translational control of mRNA for
ribosomal protein S19 in Xenopus development.
Wormington, M., Keiper, B., O'Keefe, R., Varnum, S.,
Rosenstiel Center, Brandeis University, Waltham,
Massachusetts: Translational control of ribosomal protein
synthesis during oocyte maturation and the early
development of X. laevis.
Steel, L.F., Jacobson, A., Dept. of Molecular Genetics and
Microbiology, University of Massachusetts Medical
School, Worcester: Posttranscriptional regulation of
ribosomal protein gene expression during Dictyostelium
development.
Patel, R., Tamate, H., Hongo, S., Riedl, A., Jacobs-Lorena, M.,
Dept. of Genetics, Case Western Reserve University,
Cleveland, Ohio: Regulation of ribosomal protein mRNA
translation during early development of Drosophila.
Pellegrini, M., Vallett, S.M., Weber, H.W., Dept. of Molecular
Biology, University of Southern California, Los Angeles:
Changes in rRNA synthesis in mitotic and nonmitotic
Drosophila cells.
Bowman, L.H., Sun, C., Hammond, M.L., Dept. of Biology,
University of South Carolina, Columbia: In vitro and in
vivo studies of mouse ribosomal protein mRNA
translation.
Thompson, E.A., Mahajan, P.B., Dept. of Human Biological
Chemistry and Genetics, University of Texas Medical
Branch, Galveston: Hormonal regulation of transcription
of rDNA.
Webb, M.L., Cavender, J.F., Jacob, S.T., Dept. of
Pharmacology and Cell and Molecular Biology Center,
Pennsylvania State University College of Medicine,
Hershey: Regulation of ribosomal gene transcription by
glucocorticoids.
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Cell and Molecular Neurobiology of Aplysia
September 28-October 2
ARRANGED BY
Hersch M. Gerschenfeld, Ecole Norma le SupOrieure
Leonard Kaczmarek, Yale University Medical School
Eric Kandel, Columbia University College of Physicians & Surgeons
Richard Scheller, Stanford University
Felix Strumwasser, Marine Biological Laboratory
111 participants
The first Cold Spring Harbor Laboratory meeting on Cell and Molecular
Neurobiology of Aplysia featured presentations by an international group of
speakers on a wide variety of topics, in which Aplysia has proven capable of
providing new and general insights into neuroscience. These included (1) the use
of giant growth cones of identified cells to study the dynamics of growth cone
motility and intracellular organelle rearrangement using video-enhanced
microscopy; (2) imaging of intracellular Ca" fluxes in response to neuronal
stimulation; (3) mechanisms for second messenger control of ion channel
function and transmitter and hormone release; (4) molecular and cellular
control of peptide production and processing; (5) analyses of complex
neural circuitry and the control of animal behavior; (6) molecular studies
of circadian rhythms; (7) cellular and molecular mechanisms for learning,
and memory; and (8) neural development. It was exciting to hear
presentations of such a high level, on a wide variety of topics within the
context of a single organism, and in a small, intimate setting.
The meeting was funded in part by the National Science Foundation.
Welcoming Remarks: Eric R. Kandel
G. Cottrell, E. Roubos, J. Joosse
SESSION 1 CELL IMAGING AND NEURONAL GROWTH
Chairman: S.J. Smith, Yale School of Medicine
Goldberg, D.J., Burmeister, D.W., Dept. of Pharmacology
and Center for Neurobiology and Behavior, Columbia
University, New York, New York: How axons grow-
Insights from high-resolution video microscopic
observations of Aplysia growth cones.
Forscher, P., Smith, S.J., Howard Hughes Medical Institute,
Yale School of Medicine, New Haven, Connecticut:
Dynamic actin-microtubule interactions in regulation of
neuronal growth cone structure and function.
Smith, S.J., Forscher, P., Howard Hughes Medical Institute,
and Section of Molecular Neurobiology, Yale University
School of Medicine, New Haven, Connecticut: Actions of
cAMP on microtubules and actin filaments in growth
SESSION 2 POSTER SESSION
Single Channels and Channel Modulation
Smit, A.B., Geraerts, W.P.M., Dept. of Biology, Vrije
Universiteit, Amsterdam, The Netherlands: Organization
and expression of an insulin-related peptide gene family
in growth-controlling neurons of L. stagnalis.
Kits, K.S., Lodder, J.C., Dept. of Biology, Vrije Universiteit,
Amsterdam, The Netherlands: Modulation of Ca currents
in growth hormone cells producing insulin-like peptides
in L. stagnalis.
Keicher, E., Nicaise, G., Laboratoire de Cytologie
Experimentale, Universite de Nice, France: Granule-
containing glial cells in Aplysia-Are they involved in
calcium regulation of the perineuronal extracellular
spaces?
Brezina, V., Howard Hughes Medical Institute, Center for
Neurobiology and Behavior, Columbia University, New
York, New York: Toluene, benzene, and other
hydrophobic solvents activate "S"(-like) K current in
Aplysia neurons.
Peptides, Small Molecule Transmitters,
and Synaptic Transmission
Berry, R.W., Dept. of Cell Biology and Anatomy, North-
western University, Chicago, Illinois: Regulation of
pro-ELH biosynthesis requires RNA synthesis.
Loechner, K., Azhderian, E., Kaczmarek, L.K., Dept. of
Pharmacology, Yale University School of Medicine, New
Haven, Connecticut: Release and action of autoactive
peptides in bag cell neurons.
Roubos, E.W. van Heumen, W.R.A., Slootstra, J., Dept. of
Biology Vrije Universiteit, Amsterdam, The Netherlands:
Cellular dynamics of peptides controlling egg-laying
behavior and growth in the snail L. stagnalis.
Linacre, A.M.T., Kellett, E., Burke, J.F., Benjamin, P.R.,
University of Sussex School of Biology, Falmer, Brighton,
England: Structure of a gene encoding FMRF amide-like
peptides in L. stagnalis.
Miller, M.W., Cropper, E.C., Alevizos, A., Tenenbaum, R.,
Kupfermann, I., Weiss, K.R., Center for Neurobiology
cones of cultured bag cell neurons of Aplysia.
Guthrie, P.C., Kater, S.B., Dept. of Anatomy and
Neurobiology, Colorado State University, Fort Collins:
Control of growth cone behavior by classic integrative
mechanisms-Neurotransmitters, electrical activity, and,
ultimately, intracellular calcium.
Connor, J.A., AT&T Bell Laboratories, Murray Hill, New
Jersey: Digital imaging of regional calcium changes in
isolated Aplysia neurons.
Schacher, S., Center for Neurobiology and Behavior,
Columbia University College of Physicians & Surgeons,
New York, New York: Synapse formation and synapse
specificity.
and Behavior, Columbia University, New York, New
York: Distribution of buccalin-like immunoreactivity in the
central nervous system and peripheral tissues of Aplysia.
Cropper, E.C., Tenenbaum, R., VIlim, F.S., Kupfermann, I.,
Weiss, K.R., Center for Neurology and Behavior,
Columbia University, New York, New York:
Parabuccalin-A novel neuropeptide localized to
cholinergic buccal motor neurons B15 and B16 of
Aplysia.
Hooper, S.L., Weiss, K.R., Kupfermann, I., Center for
Neurobiology and Behavior, Columbia Univeisity, New
York, New York: Gut stimulation evokes a slow IPSP in
histaminergic neuron C2, mediated by CCK-gastrin-like
immunoreactive buccal neuron, B18.
Shapiro, E.,1 Kretz, R.,2 1Howard Hughes Medical Institute,
Center for Neurobiology and Behavior, New York, New
York; 2Dept. of Anatomy and Special Embryology,
University of Fribourg, Switzerland: Effects of membrane
potential and activity pattern on presynaptic function.
Poulain, B., Fossier, P., Baux, G., Tauc, L., Laboratoire de
Neurobiologie Cellulaire et Moleculaire, CNRS, France:
Evidence for a modulation of acetylcholine release by
autoreceptors at a central synapse of Aplysia.
Poulain, B.,1 Tauc, L.,1 Maisey, E.A.,2 Wadsworth, J.D.F.,2
Dolly, J.0.,2 ' Laboratoire de Neurobiologie Cellulaire et
Moleculaire, CNRS, France; 2Dept. of Biochemistry,
Imperial College, London, England: Aplysia as model for
the study of the mechanism of inhibition of cholinergic
transmission by botulinum neurotoxin.
Hellmich, M.R.,1 Navarro, J.V.,2 Strumwasser, F.,1 'Marine
Biological Laboratory, Woods Hole, 2Dept. of Physiology,
Boston University School of Medicine, Massachusetts:
Bacteria-toxin-catalyzed ADP-ribosylation of membrane
and soluble components in tissues of A. californica.
Fredman, S.M.,1 Rieke, G.A.,2
Depts. of 1Physiology,
2Anatomy, Meharry Medical College, Nashville,
Tennessee: Behavioral, physiological, and
morphological
effects of kainic acid in Aplysia.
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SESSION 3 SINGLE CHANNELS AND CHANNEL MODULATION
Chairman: H. Gerschenfeld, Ecole Norma le Superieure
Gerschenfeld, H.M., Hammond, C., Harris-Warrick, R.,
Paupardin-Tritsch, D., Laboratoire de Neurobiologie,
Ecole Norma le Superieure, Paris, France: Recent studies
on the neurotransmitter-induced regulation of voltage-
dependent Ca current in snail neurons.
Volterra, A., Buttner, N., Siegelbaum, S.A., Center for
Neurobiology and Behavior, Howard Hughes Medical
Institute, Dept. of Pharmacology, Columbia University
College of Physicians & Surgeons, New York, New York:
Role of two G proteins in the up- and down-modulation
of the S K+ channel.
Brezina, V., Howard Hughes Medical Institute, Center for
Neurobiology and Behavior, Columbia University, New
York, New York: Aplysia neurons possess a family of
G-protein-linked neurotransmitter receptors mediating
both activation of "S"(-like) K current and suppression of
Ca current.
Kehoe, J.S., Laboratoire de Neurobiologie, Ecole Normale
Superieure, Paris, France: cAMP-mediated synaptic
responses in the medial neurons of A. californica.
Kaczmarek, L.M., Depts. of Pharmacology and Molecular
and Cellular Physiology, Yale University School of
Medicine, New Haven, Connecticut: Regulation of
excitability in peptide-secreting bag cell neurons of
Aplysia.
Levitan, I.B., Carrow, G.M., Lin, S., Dept. of Biochemistry,
Brandeis University, Waltham, Massachusetts: Specificity
and plasticity of synaptic connections between cultured
Aplysia neurons.
SESSION 4 PEPTIDES, SMALL MOLECULE TRANSMITTERS, AND SYNAPTIC TRANSMISSION
Chairman: R. Scheller, Stanford University
Fossier, P., Baux, G., Tauc, L., Laboratoire de Neurobiologie
Cellulaire et Moleculaire, CNRS, Paris, France: G
proteins control quantal evoked acetylcholine release at
a neuro-neuronal synapse in Aplysia.
Cottrell, G.A., Dept. of Biology and Preclinical Medicine,
University of St. Andrews, Fife, Scotland: Multiple
selective actions of molluscan peptides of the
FMRFamide-series (FM/LRFamide and XDPFLRFamide)
and their biological significance.
Joosse, J., Dept. of Biology, Vrije Universiteit, Amsterdam,
The Netherlands: Central and peripheral expression of
genes coding for (neuro-)peptides involved in control
systems of reproduction, growth, energy metabolism,
and ionic regulation.
Scheller, R., Fisher, J., Sossin, W., Newcomb, R., Dept. of
Biological Sciences, Stanford University, California:
SESSION 5 POSTER SESSION
Circadian Rhythms
Khalsa, S.B.S., Block, G.D., Dept. of Biology, University of
Virginia, Charlottesville: Role of calcium in phase shifting
the ocular circadian pacemaker of the opisthobranch
Bulla.
Ralph, M.R., Block, G.D., Dept. of Biology, University of
Virginia, Charlottesville: cAMP and intracellular calcium
regulation of circadian rhythms in Bulla.
Strack, S.,1 Jack let, J.,1 Siwicki, K. 2 Roshbash, M.,1
Hall, J.,2 1Dept. of Biology and Neurobiology Research
Center, State University of New York, Albany; 2Dept. of
Biology, Brandeis University, Waltham, Massachusetts:
Immunological evidence for a protein in the nervous
system of Aplysia and Bulla similar to the period protein
in Drosophila.
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Proteolytic processing and packaging of peptides from
the Aplysia egg-laying hormone precursor.
Blankenship, J.E., Nagle, G., Painter, S., Kruger, T.,
Choate, J., Shope, S., Marine Biomedical Institute,
Galveston, Texas: Roles of identified peptides in Aplysia
reproduction.
Mayeri, E., Jansen, R., Brown, R.O., Dept. of Physiology,
University of California, San Francisco: Diversity in the
sets of currents modulated by egg-laying hormone and
bag cell peptide in various target neurons of Aplysia.
Lloyd, P.E., Pearson, W.L., Connolly, C.M., Dept. of
Pharmacology and Physiological Science and
Communication on Neurobiology, University of Chicago,
Illinois: Pedal peptide-A major peptide transmitter in
Aplysia.
Neural Circuitry and Behavior
Koester, J., Center for Neurobiology and Behavior, New
York State Psychiatric Institute and Columbia University,
New York, New York: Modulation of Aplysia renal pore
activity by L10, the LUQ cells, and an unidentified
peripheral motor neuron.
Alevizos, A.,1'2 Weiss, K.R.,1 Koester, J.,1 1Center for
Neurobiology and Behavior, New York State Psychiatric
Institute, 2Dept. of Physiology and Cellular Biophysics,
Columbia University, New York, New York: Modulation
of respiratory pumping by cell R15.
Teyke, T., Weiss, K.R., Kupfermann, I., Center for Neurobiology
and Behavior, Columbia University, New York, New
York: Kinetics of the head-turning response of Aplysia.
Rosen, S.C., Miller, M.W., Weiss, K.R., Kupfermann, I.,
F. Strumwasser, B. Rothman, D. Glick
Center for Neurobiology and Behavior, Columbia
University, New York, New York: Neural control of the
initiation and maintenance of biting behavior in Ap/ysia.
Ter Maat, A., Ferguson, G.P., Pinsker, H.M., Marine
Biomedical Institute, University of Texas, Galveston:
Aplysia egg-laying behaviors-Neuronal and hormonal
control in intact and freely behaving animals.
Ter Maat, A., Ferguson, G.P., Jansen, R.F., Pieneman, A.W.,
Dept. of Biology, Free University, Amsterdam, The
Netherlands: Egg-laying behaviors in L. stagnalis.
Lukowiak, K., Higgins, A., Cawthorpe, D.R.L.,
Martinez-Padron, M., Neuroscience Research Group,
Faculty of Medicine, University of Calgary, Alberta,
Canada: Adaptive gill behaviors in Aplysia-Peptidergic
modulation.
Leonard, J.L., Dept. of Zoology, University of Oklahoma,
Norman: Six identified motor neurons in search of a
function.
Fiore, L., Geppetti, L., Universita de Pisa, Italy: Cross-
correlation-based evaluations of bidirectional impulse
transmission in Aplysia cerebrobuccal connective.
Koike, H., Umitsu, Y., Matsumoto, H., Dept. of
Neurophysiology, Tokyo Metropolitan Institute for
Neurosciences, Japan: A nerve-contractor motoneuron
in Ap/ysia.
Learning
Cook, D.G., Kuenzi, F.M., Carew, T.J., Depts. of Biology
and Psychology, Yale University, New Haven,
Connecticut: Operant conditioning of identified muscles
and motor neurons in Aplysia.
Cleary, L.J.,i Hammer, Byrne, J.H.,1 'Dept. of
Neurobiology and Anatomy, University of Texas Medical
School, Houston; 2lnstitut fur Neurobiologie, Frei
Universitat, Berlin, Federal Republic of Germany:
Serotonin broadens action potentials in both somata and
axons of pleural sensory neurons in Aplysia.
Marcus, E.A., Wright, W.G., Carew, T.J., Depts. of Biology
and Psychology, Yale University, New Haven,
Connecticut: Behavioral and cellular dissociation of multi-
ple components of nonassociative learning in Aplysia.
Sweatt, J.D., Kandel, E.R., Columbia University College of
Physicians & Surgeons and Howard Hughes Medical
Institute, New York, New York: Serotonin (5-HT) causes
a persistent increase in protein phosphorylation that is
transcription-dependent--A molecular mechanism
contributing to long-term sensitization in Aplysia sensory
neurons.
,1'2 Sweatt, J.D., 1'2 1ColumbiaWager-Smith, K.,1 Kandel, E.R.
University, 2Howard Hughes Medical Institute, New York,
New York: Subcellular location and partial amino acid
sequence of proteins that are phosphorylated in Aplysia
sensory neurons in response to serotonin.
Barzilai, A., Kennedy, T.E., Sweatt, J.D., Kandel, E.R.,
Columbia University College of Physicians & Surgeons
and Howard Hughes Medical Institute, New York, New
York: Serotonin (5-HT) induces changes in protein
synthesis during the acquisition phase of long-term
facilitation in the sensory neurons of Aplysia.
Kennedy, T.E., Kandel, E.R., Knapp, M., Sweatt, J.D.,
Columbia University College of Physicians & Surgeons
and Howard Hughes Medical Institute, New York, New
York: Characterization of a protein whose net rate of
synthesis increases in association with long-term
sensitization in Aplysia.
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Zhao, B.,1 Dugan, D.,1'2 Kandel, R.E.,1.2 Knapp, M.,1
Columbia University College of Physicians & Surgeons,
2Howard Hughes Medical Institute, New York, New York:
Molecular cloning of highly abundant polyadenylated
RNAs from Aplysia nervous system.
Baxter, D.A., Buonomano, D., Corcos, S., Patel, S.,
Byrne, J.H., Dept. of Neurobiology and Anatomy,
University of Texas Medical School, Houston: Small
networks of adaptive elements that reflect the properties
of neurons in Aplysia exhibit higher-order features of
classic conditioning.
Development of Synaptic Plasticity and Learning
Buriani, A., Savage, M.J., Goldberg, D.J., Dept. of
Pharmacology and Center for Neurobiology and
SESSION 6 CIRCADIAN RHYTHM
Chairman: F. Strumwasser, Marine Biological Laboratory
Strumwasser, F., Marine Biological Laboratory, Woods Hole,
Massachusetts: Two model neuropeptidergic systems
controlling different behaviors in Aplysia.
Jack let, J.,1 Siwicki, K.,2 Rosbash, M.,2 Hall, J.,2 1Dept. of
Biology and Neurobiology Research Center, State
University of New York, Albany; 2Dept. of Biology,
Brandeis University, Waltham, Massachusetts: Circadian
pacemaker neurons in Aplysia and Bulla eyes-
Membrane properties and period-like protein
SESSION 7 NEURAL CIRCUITRY AND BEHAVIOR
Chairman: J. Koester, Columbia University
Koester, J.,1 Alevizos, A. ,1'2 Weiss, K.R.,1 1Center for
Neurobiology and Behavior, New York State Psychiatric
Institute, 2Dept. of Physiology and Cellular Biophysics,
Columbia University, New York, New York: Generation
and modulation of respiratory pumping.
Getting, P.A., Frost, W.N., Dept. of Physiology and
Biophysics, University of Iowa, Iowa City: "Self-tuning"
within a neural circuit-Are neural networks dynamically
organized?
Gardner, D., Dept. of Physiology, Cornell University Medical
College, New York, New York: Synaptic variability in S-
and 4-cell neural networks.
Spira, M.E., Segev, I., Werman, R., Yarom, Y., Dept. of
Neurobiology, Hebrew University, Jerusalem, Israel:
Experimental and theoretical analysis of the electrotonic
SESSION 8 LEARNING
Chairman: J. Byrne, University of Texas, Houston
bailey, C.H., Chen, M., Center for Neurobiology and
Behavior, Columbia University College of Physicians &
Surgeons and New York State Psychiatric Institute, New
York: Morphological basis of long-term memory in
Aplysia.
Byrne, J.H., Scholz, K.P., Eskin, A., Dept. of Neurobiology
348
Behavior, Columbia University, New York, New York:
Axotomy induces early changes in the incorporation of
[35S]methionine into proteins in the nucleus of the
Aplysia neuron R2.
Glanzman, Schacher, 5.,2 Kandel, 'Howard
Hughes Medical Institute, 2Columbia University College
of Physicians & Surgeons, New York, New York:
Morphology of Aplysia sensory neurons in dissociated
cell culture alone and with target motor neurons-
Correlates of synaptic specificity and evidence for synap-
tic competition.
Peretz, B., Dept. of Physiology and Biophysics, University of
Kentucky Medical Center, Lexington: Age effects on
long-term neuron function and its behavioral expressions
in adult Aplysia.
immunoreactivity.
Block, G.D., Khalsa, S.B.S., Ralph, M.R., McMahon, D.G.,
Dept. of Biology, University of Virginia, Charlottesville:
Cellular analysis of phase and period regulation of a
molluscan ocular circadian pacemaker.
Eskin, A., Yeung, S.J., Raju, U., Dept. of Biology, University
of Houston, Texas: Identification of components of
circadian timers in the eye of Aplysia.
structure of cultured Aplysia neurons.
Cohen, L., Hoepp, H.-P., Wu, J.-Y., Xiao, C., Zecevic, D.,
London, J., Dept. of Physiology, Yale University School
of Medicine, New Haven, Connecticut: Optical
measurement of neuron activity during the gill withdrawal
reflex in Aplysia.
Kirk, M.D., Plummer, M.R., Cirenza, P.F., Rathouz, M.M.,
Church, P.J., Dept. of Biology, Boston University,
Massachusetts: Premotor neurons B41 and B42 of the
buccal ganglia-Morphology, bursting properties,
synaptic connections, and responses to SCPB.
Kupfermann, I., Cropper, B.C., Rosen, S.C., Weiss, K.R.,
Center for Neurobiology and Behavior, Columbia
University, New York, New York: Control and modulation
of feeding behavior in Aplysia.
and Anatomy, University of Texas Medical School,
Houston; Dept. of Biology, University of Houston, Texas:
Steps toward an understanding of the biochemical and
biophysical basis of long-term sensitization.
Kandel, E.R., Barzilai, A., Kennedy, T., Sweatt, D., Columbia
University College of Physicians & Surgeons, New York,
New York: Molecular similarities and differences between
long-term and short-term memory for sensitization-
Transcriptional function for modulatory transmitters
important for learning.
Schwartz, J.H., Howard Hughes Medical Institute, Columbia
University College of Physicians & Surgeons, New York,
New York: Multiple second-messenger systems modulate
facilatory and inhibitory processes in Aplysia sensory
neurons.
Abrams, T.W., Goldsmith, B., Bolton, M., Dept. of Biology
and Institute of Neurological Sciences, University of
Pennsylvania, Philadelphia: Studies of additional
mechanisms of stimulus convergence during activity-
dependent facilitation in Aplysia sensory neurons.
Walters, E.T., Dept. of Physiology and Cell Biology,
University of Texas Medical School, Houston: Functional
significance of distributed cellular memory in circuits
controlling defensive behavior of Aplysia.
Crow, T., Forrester, J., Dept. of Neurobiology and Anatomy,
University of Texas Medical School, Houston: Possible
role for protein kinase C in light-5-HT-induced
enhancement of generator potentials in Hermissenda B
photoreceptors.
SESSION 9 DEVELOPMENT OF SYNAPTIC PLASTICITY AND LEARNING
Chairman: T.J. Carew, Yale University
Carew, T.J., Depts. of Psychology and Biology, Yale
University, New Haven, Connecticut: Developmental
emergence of different forms of learning in Aplysia.
Sharma, J.S., Wiederhold, M.L., Division of
Otorhinolaryngology, University of Texas Health Science
Center, San Antonio: Development of the statocyst in
Aplysia.
Bidwell, J.P., Howard Hughes Medical Institute, Woods
Hole, Massachusetts: Artificial seawater and A.
californica.
Chiel, H.J.,1 Tank, D.W.,2 1Dept. of Biology, Case Western
Reserve University, Cleveland, Ohio; 2Dept. of Molecular
Biophysics Research, AT&T Bell Laboratories, Murray
Hill, New Jersey: Analysis of presynaptic inhibition using
Aplysia neurons in culture.
Zucker, R.S., Dept. of Physiology/Anatomy, University of
California, Berkeley: Calcium-activated currents in
Aplysia neurons studied with "caged calcium" chelators.
DesGroseillers, L., Dept. of Biochemistry, University of
Montreal, Canada: Molecular cloning of the genes
encoding a LUQ-specific neuropeptide and a neutral
endopeptidase-like enzyme.
E. Kandel, D. Gardner
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BANBURY CENTER
DIRECTOR'S REPORT
Sixteen meetings, with over 500 participants, were held at the Banbury Center in
1988. The topics reflect the increasing diversity of Banbury Center meetings, with
subjects drawn from research in "basic" science, biotechnology, human diseases,
and the neurosciences.
HIV and AIDS
Discussions of AIDS featured strongly during the year. Research on the human
immunodeficiency virus (HIV), the causative agent of AIDS, has shown that
complex interactions between virus and host-cell factors govern expression of HIV
genes. Controversial data have been accumulating about these interactions, and
the Control of HIV Gene Expression meeting was one of the highlights of the
Banbury year. Needless to say, the meeting did not resolve all of the issues, but at
least the relevant parties met and an attempt was made to untangle the confusion
of the names of the HIV genes. This came to fruition later in the year with the
publication in Nature of a proposal for a standardized nomenclature.
Molecular Genetics and Human Inherited Diseases
Two meetings dealt with the molecular biology and genetics of human disorders.
The Genetic Approaches in Schizophrenia meeting was particularly exciting as it
brought together expert geneticists and psychiatrists who have been studying the
genetics of schizophrenia. The aim of the meeting was to determine if the
armamentarium of molecular genetics that has been applied so successfully in
other human inherited disorders can be applied to schizophrenia. However, it
became clear during the course of the meeting that so little is known about the
underlying biology of schizophrenia, and its definitive diagnosis is so difficult, that
more patient and family studies are required.
The Molecular Biology of Alzheimer's Disease meeting showed that research
on this disease is at a more satisfactory stage. This meeting included a remarkable
group of studies ranging from neuroanatomical genetics, through protein
chemistry, to molecular genetics. In a particularly exciting session, it was shown
that p-amyloid protein is not a constituent of the paired helical
filaments that
accumulate in the tangles and plaques that are characteristic of Alzheimer's
disease. In addition to evaluating data, meeting participants
discussed the ethics
of performing early autopsies to obtain brain samples from patients.
The
overwhelming consensus of the participants was that these
procedures are ethical
and provide invaluable data.
Technical Developments in Molecular Biology
The Banbury Center is noted for meetings dealing with
the technical aspects of
molecular biology, and another meeting in the Viral Vectors "series"
was held in
March. Not suprisingly, the topic of retroviruses as vectors
dominated the meeting,
but there were presentations dealing with small DNA viruses
such as bovine
Papillomavirus and vectors for expression such as the insect
baculoviruses.
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During the past two years, a new technique called the
polyrTierase chain
reaction (PCR) has been sweeping through molecular biology laboratories. The
technique enables very large quantities of specific
DNA sequences to be
generated from very small starting amounts of DNA. Perkin-Elmer Cetus
sponsored the Polymerase Chain Reaction meeting,
which brought a group of
the world's leading exponents of the technique to the Banbury Center to discuss
the latest, novel uses of the technique. PCR applications
are very diverse and it
became clear during the meeting that they are limited only by the ingenuity of the
research scientist!
Another meeting dealing with the molecular biology techniques was that on
DNA Technology and Forensic Science. Participants included forensic scientists,
population geneticists, representatives of law enforcement agencies, prosecution
and defense attorneys, ethicists, and civil libertarians. There were many energetic
exchanges on the whole range of problems inherent in the introduction of DNA
evidence into the legal system. The meeting set out these issues in a clear and
forthright way for further debate in the legal and forensic communities.
Linkage analysis using restriction-fragment-length polymorphisms (RFLPs) has
revolutionized human genetics, and the meeting on Molecular Markers and Their
Application to Problems in Plant Genetics showed that RFLPs are likely to have a
similar impact in plant genetics. Detailed RFLP maps are being prepared for a
number of agriculturally important crops, and RFLPs linked with quantitative trait
loci should improve the efficiency of breeding programs.
Topics in Basic Research
Ubiquitin is a small, highly conserved protein that, as its name implies, seems to
take part in many processes in the cell. The Ubiquitin System was the subject of
a meeting in Spring 1988, at which the molecular genetics of ubiquitin and its
structure were discussed, as well as its role in protein degradation.
One of the most popular meetings of the year was Cell Cycle Control in
Eukaryotes. An interesting feature of this meeting was the wide range of
organisms that has been selected for study of cell-cycle control. The techniques of
modern molecular biology provide tools for getting to the basic features of cell-
cycle control, for example, by selecting genes that are activated or proteins that
are synthesized when cells are stimulated to enter mitosis.
Sloan Foundation Workshops
The Workshops for science journalists and Congressional staff workers continue to
be very successful in introducing the two groups to important scientific issues. The
AIDS Update for the Congressional staff was, not surprisingly, very popular. The
speakers included the leading people in the field, covering the molecular biology
of the human immunodeficiency virus, epidemiology, and drug treatments. One of
the highlights of the meeting was a discussion of the social impact of AIDS.
The continuing interest of the Press in molecular biology, especially in relation to
human health, was evident from the 20 journalists who came to the workshop on
the Impact of DNA Technology in Medicine in March. The topics of the meeting
included DNA diagnosis, gene therapy, and AIDS. At least three of the journalists
wrote stories using the meeting as background, including a front-page story in the
Wall Street Journal.
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The Baring Brothers/CSHL Conference
For the third year, the Banbury Center was host to a meeting for senior business
executives, this year organized in conjunction with Baring Brothers. The meeting
attracted a record number of participants, including executives from companies in
our Corporate Sponsor Program. The subject was Manipulating the Immune
Response. Once again an outstanding group of scientists came, and they covered
such topics as cytokines, catalytic antibodies, and scid mice for analysis of
immune function. One afternoon was spent in the DNA Learning Center, where a
group of industry's leaders enthusiasically tackled an experiment.
Other Meetings
We have continued to make the Center available to other groups when appropri-
ate. The deans of the Associated Medical Schools of New York came for a study
weekend, reviewing once more the problems they face operating
in a city like
ew York. In April, the Klingenstein Fund held a review of the neuroscience
research supported by the Fund. In May, the Cold Spring Harbor
School District
brought parent leaders to the Banbury Center to discuss AIDS education.
This
fascinating meeting provided a perspective on AIDS that was very
different from
Perspectives provided by the technical meeting on HIV gene
expression. Here. a
small community was trying to come to grips with the complex
and diverse
the
of society to this disease. We have also continued
to host seminars for
e local community of Lloyd Harbor. These are presentations by
members of
nonprofit organizations in the village. The 1988-1989 meetings
season began in
October, when I spoke on genes and cancer, and in December,
Don Nilson of
Friends World College spoke on differences between
American and Japanese
cultures.
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Funding
The Corporate Sponsor Program once again underpinned the meetings program,
providing funding for five meetings, and support for the meeting on Cytoskeletal
Proteins in Tumor Diagnosis came from the James McDonnell Foundation. In
addition, companies and federal sources provided $120,000 in contributions for
the support of other meetings. Particularly noteworthy was the meeting on
Polymerase Chain Reaction, sponsored entirely by Perkin-Elmer Cetus. A number
of companies, including five Japanese companies, underwrote the costs of
another very successful Therapeutic Peptides meeting. As a result, we were very
pleased to welcome a larger than usual number of Japanese scientists to the
meeting. This proved to be one of the special features of this meeting, and I hope
that we will be able to increase Japanese participation in other meetings. However,
this cannot be done without support because of the high costs of travel between
Japan and the United States.
A number of plant biotechnology companies contributed to the cost of the plant
molecular markers meeting, and many of these companies have expressed an
interest in supporting a similar meeting in 1989. Five biotechnology companies
helped to underwrite the meeting on the Control of Gene Expression in HIV, and
the success of the meeting was instrumental in obtaining a contract from the
National Institute for Allergic and Infectious Diseases to hold two meetings on
HIV/AIDS in 1989. I hope that this will be extended for a three-year period. Three
companies applying "DNA fingerprinting," together with one of the National
Institutes, contributed to the DNA Technology and Forensic Science meeting.
Unusually for Cold Spring Harbor Laboratory, this was not one of the National
Institutes of Health, but the National Institute of Justice!
Full details Banbury Center meetings are listed under "Grants
Contributions' I am very encouraged by the positive responses of companies to
requests for support for meetings, although my goal is to try to obtain some
longer-term funding for meetings in specific areas. These responses show that we
are holding meetings that deal with exciting scientific research and that also have
wider implications for society.
Funding for Congressional and Science Journalist Workshops
The Sloan Foundation began to support the Banbury Center program as long ago
as August 1978. That the Foundation has given us funding for ten consecutive
years is an indication of the success and importance of this workshop series. The
present grant will fund two further meetings to be held in 1989, but I am very
pleased to report that the Sloan Foundation has approved a further three years of
funding for this program. One feature that we are going to introduce into the next
series of meetings is a laboratory session at the DNA Learning Center. We hope
that doing even a simple experiment using restriction endonucleases and running
gels will give the participants a better appreciation of molecular biology research.
Banbury Center Publications
These publications are now the responsibility of Cold Spring Harbor Laboratory
Press, but I want to mention that a more flexible policy regarding the style of
books has been implemented and their publication has been speeded up.
Meetings may be published in the Current Communications in Molecular Biology
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series, the Banbury Report series, or as individual volumes. The Control of Gene
Expression in HIV meeting was the first to be published as a special volume, and
it appeared within five months of the meeting. We expect the books based on the
Polymerase Chain Reaction and the DNA Technology and Forensic Science
meetings to be firsts in their fields.
The Banbury Center Logo
To make the activities of the Center known more widely, we have designed a logo,
a stylized view of the Conference Center, that will appear on the title page of our
publications.
A Banbury Center Meeting
Looking Forward to 1989
I remarked in last year's Annual Report that the Banbury Center program would
become more diverse and deal with an increasing number of topics in the areas
of biotechnology, human diseases, and the social impact of modern biology. This
change in emphasis was evident in the 1988 program and will continue in 1989.
There will be meetings dealing with "basic" research (recessive oncogenes; early
development in Drosophila and mouse; molecular biology and evolution), environ-
mental issues (germ-line mutations), biotechnology (genetic engineering of
livestock), and social issues (alcoholism; scientific misconduct).
Robertson House provides
housing and dining
accommodations at
Banbury Center
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Conclusion
I have been at the Banbury Center for just over one your, and I am finding it to be
as enjoyable and fascinating as I had expected. I was enthusiastic about the aims
of the Banbury Center before I arrived, and my experience with the variety of
topics and the enthusiasm of participants demonstrates that the Banbury Center is
a unique resource for exchanging scientific information. Bea Toliver, the Center's
administrative assistant, together with Barbara Fischer and Eleanor Sidorenko, and
Katya Davey at Robertson House, worked hard, often under considerable
pressure, to ensure that our program was implemented smoothly. All the
indications are that 1989 at the Banbury Center will be as successful, exciting,
and innovative as 1988.
Jan Witkowski
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MEETINGS
Congressional Workshop on AIDS
January 28-January 30
ARRANGED BY
J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
SESSION 1
J.D. Watson, Cold Spring Harbor Laboratory, New York:
Introduction.
I. Chen, University of California, Los Angeles: Molecular
biology of HIV.
H. Jaffe, Centers for Disease Control, Atlanta, Georgia:
Epidemiology of AIDS.
A. Stanley, Los Alamos National Laboratory, New Mexico:
The future of the AIDS epidemic-Computer modeling.
SESSION 2
G.B. Scott, University of Miami School of Medicine, Florida:
Pediatric aspects of HIV infections.
S. Broder, National Cancer Institute, Bethesda, Maryland:
Combating HIV. I. Drug therapy.
J. Petricciani, U.S. Public Health Service, Washington, D.C.:
Combating HIV. II. Vaccines.
SESSION 3
R. Stall, Rutgers University, New Brunswick, New Jersey:
Combating HIV. III. Education and behavior.
M. F. Silverman, American Foundation for Research on
AIDS, Los Angeles, California: Social aspects of the AIDS
epidemic.
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The Control of HIV Gene Expression
February 28-March 2
ARRANGED BY
R. Franza, Cold Spring Harbor Laboratory, New York
B.R. Cullen, Duke University Medical Center, Durham, North Carolina
F. Wong-Staal, National Cancer Institute, Bethesda, Maryland
SESSION 1: HIV TRANS-ACTING ELEMENTS
F Wong-Staal, National Cancer Institute, Bethesda,
Maryland: Mutagenesis of the tat and trs genes of an
infectious HIV genome.
G.N. Pavlakis, NCI-Frederick Cancer Research Facility,
Maryland: HIV regulation by viral trans-activators.
C.A. Rosen, Roche Institute of Molecular Biology, Nutley,
New Jersey: Regulation of HIV gene expression by the
art protein.
S. Venkatesan, National Institutes of Health, Rockville,
Maryland: Properties of tat and 3' orf mutants of HIV.
D. Capon, Genentech, Inc., South San Francisco, California:
Regulation of HIV gene expression by the HIV-1 tat gene
product.
B.R. Cullen, Duke University Medical Center, Durham, North
Carolina: HIV tat gene function.
B.M. Peter lin, University of California, San Francisco: HIV-1
activation and trans-activation by the tat gene product.
A.P. Rice, Cold Spring Harbor Laboratory, New York: The
use of adenovirus vectors to analyze HIV gene
expression.
M. Rosenberg, Smith Kline & French Laboratories, King of
Prussia, Pennsylvania: HIV trans-activation phenomenon
and protease function.
E Holland, Stanford University School of Medicine,
California: Mutations in the tar region of HIV-1.
L. Montagnier, Institut Pasteur, Paris, France: Diversity and
gene function of the human immunodeficiency viruses.
M. Emerman, Institut Pasteur, Paris, France: HIV-2 tat.
W. Haseltine, Dana-Farber Cancer Institute, Cambridge,
Massachusetts: Regulation of replication of HIV-1.
R. Gallo, L. Montagnier J. Brady J. Clements
G. Pavlakis, B. Felber
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B. Franza, T Curran
SESSION 2: CELLULAR FACTORS INVOLVED IN RETROVIRAL GENE EXPRESSION
PA. Baeuerle, Whitehead Institute for Biomedical Research,
Bethesda, Maryland: Characterization of HIV-1 enhancer-
Cambridge, Massachusetts: Activation of NF-x13. binding proteins.
R. Franza, Cold Spring Harbor Laboratory, New York: Study R.G. Roeder, Rockefeller
University, New. York: Eukaryotic
of cellular proteins that interact with the HIV long terminal
repeat.
transcription factors and mechanisms.
J. Kadonaga, University of California, Berkeley: Promoter-
T. Curran, Roche Institute of Molecular Biology, Nutley, New
selective activation of transcription by Sp1.
Jersey: fos and gene regulation.
H.E. Varmus, University of California, San Francisco: Signals
WC Greene, Duke University Medical Center, Durham,
for the expression of the HIV pol gene by ribosomal
North Carolina: HIV-1 and T-cell activation.
K.A. Jones, Salk Institute, San Diego, California: Analysis of J.D.
Mosca, Johns Hopkins Oncology Center, Baltimore,
the cellular transcription complex at the HIV promoters.
Maryland: Herpesvirus trans-activation-Role of HIV-1 tat
M.A. Norcross, U.S. Food and Drug Administration,
in RNA stability.
SESSION 3: REGULATION OF GENE EXPRESSION IN RELATED
RETROVIRUSES
BY. Chen, University of California, Los Angeles: Pathogene-
J.E. Clements, Johns Hopkins Hospital,
Baltimore, Maryland:
trans-Activation of visna virus-A neurotropic lentivirus of
sis of HTLV/H IV.
J. Brady, National Institutes of Health, Bethesda, Maryland:
HTLV-I gene regulation.
sheep.
F. Wong-Staal, National Cancer Institute,
Bethesda,
Maryland: Meeting summary.
B. Felber, NCI-Frederick Cancer Research Facility, Maryland:
Regulation of viral and cellular promoters by the
transcriptional activator of HTLV-I.
361
Journalists' Workshop on "The Impact of DNA Technology
in Medicine"
March 6-March 8
ARRANGED BY
J.A. Witkowski, Banbury Center Cold Spring Harbor Laboratory, New York
SESSION 1: THE "NEW" GENETICS
J.A. Witkowski, Banbury Center, Cold Spring Harbor
Laboratory, New York: Introduction.
P Ward, Institute for Molecular Genetics, Baylor College of
Medicine, Houston, Texas: Duchenne muscular
dystrophy- DNA diagnosis in practice.
SESSION 2: GENE THERAPY AND DNA DIAGNOSIS
F Led ley, Howard Hughes Medical Institute, Baylor College
of Medicine, Houston, Texas: Gene therapy-Reality and
future promise.
J. Sninsky, Cetus Corporation, Emeryville, California: DNA
SESSION 3: SOCIAL AND ETHICAL CONSEQUENCES
R. Myers, Boston University Medical Center, Massachusetts:
DNA diagnosis in Huntington's chorea.
J. Gitschier, Howard Hughes Medical Institute, University of
California, San Francisco: Hemophilia-State-of-the-art
DNA diagnosis.
M. Furth, Oncogene Science Inc., Manhasset, New York:
Cancer diagnosis.
probes in the diagnosis of acquired diseases.
D.J. Green, Cellmark Diagnostics, Germantown, Maryland:
DNA "fingerprinting"-What it is and what it does.
L. Andrews, American Bar Foundation, Chicago, Illinois:
Genetic testing-Protecting the individual.
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Viral Vectors
March 13-March 16
ARRANGED BY
Y. Gluzman, Leder le Laboratories, Pearl River; New York
S.H. Hughes, NCI-Frederick Cancer Research Facility, Maryland
SESSION 1
B. Moss, National Institutes of Health, Bethesda, Maryland:
Vaccinia virus and vaccinia virus/baceriophage T7 hybrid
vectors.
B. Roizman, University of Chicago, Illinois: Genetic engineer-
ing of herpes simplex viruses for use as vaccines and
vectors.
L. Post, Upjohn Company, Kalamazoo, Michigan: Pseudo-
rabies virus-A possible vector for vaccines in livestock
animals.
E.S. Mocarski, Stanford University School of Medicine,
California: Recombinant cytomegalovirus-based
expression vectors.
B. Mason, Wyeth Laboratories, Inc., Philadelphia, Pennsylva-
nia: Recombinant adenovirus as a vaccine.
K.L. Berkner, ZymoGenetics, Seattle, Washington: Efficiency
of translation of polycistronic messages in uninfected and
adenovirus-infected cells.
SESSION 2
E.A. Dzierzak, Whitehead Institute for Biomedical Research,
Cambridge, Massachusetts: In vivo expression of a
normal cellular human /3-globin gene transduced via
retroviral infection of murine bone marrow.
E. Gilboa, Memorial Sloan-Kettering Cancer Center, New
York, New York: Retroviral gene transfer-Applications to
human therapy.
A.D. Miller; Fred Hutchinson Cancer Research Center,
SESSION 3
D. Di Maio, Yale University School of Medicine, New Haven,
Connecticut: Bovine papilloma genetics-Implications
for
vector design.
S. Goodbdurn, Imperial Cancer Research Fund Laboratories,
London, England: Use of a bovine papillomavirus vector
Seattle, Washington: Retrovirus-mediated gene transfer
into skin fibroblasts.
J. Ellis, Mt. Sinai Hospital Research Institute, Toronto,
Canada: Gene targeting with retroviral vectors.
R. Cone, Cold Spring Harbor Laboratory,
New York:
Establishment of differentiated cell lines using retroviral
vectors.
to study gene expression.
W. Hammerschmidt,
McArdle Laboratory for Cancer
Research, Madison,
Wisconsin: Viral vectors derived from
Epstein-Barr virus.
R.F. Margolskee, Roche Institute of
Molecular Biology,
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Nutley, New Jersey: Epstein-Barr virus shuttle vectors for
stable episomal replication of cDNA expression libraries
in human cells.
M. Manos, Cetus Corporation, Emeryville, California: Use of
an SV40/adenovirus recombinant in an inducible
mammalian expression system.
SESSION 4
S.H. Hughes, NCI-Frederick Cancer Research Facility,
Maryland: Retroviral vectors and adaptors.
J.M. Coffin, Tufts University School of Medicine, Boston,
Massachusetts: Effect of antisense RNA on retrovirus
replication.
M. Linial, Fred Hutchinson Cancer Research Center, Seattle,
Washington: Retrofection-Reverse transcription and
integration of nonretroviral RNAs after viral infection.
SESSION 5
P Ahlquist, University of Wisconsin, Madison: Plant RNA
virus gene expression vectors.
D.M. Bisaro, Ohio State University, Columbus: Genetic
analysis of tomato golden mosaic virus.
J. Futterer, Friedrich-Miescher-lnstitut, Basel, Switzerland:
Transient expression from CaMV signals in plant
protoplasts.
S. Schlesinger, Washington University School of Medicine,
St. Louis, Missouri: Development of Sindbis virus and
Cell Cycle Control in Eukaryotes
R. Kaufman, Genetics Institute, Cambridge, Massachusetts:
The role of eIF -2 a phosphorylation in translational control
in transfected and adenovirus-infected cells.
N. Muzyczka, State University of New York, Stony Brook: The
genetics of adeno-associated virus.
R. Dornburg, University of Wisconsin, Madison: A retroviral
vector system to study the formation of cDNA genes.
A.J. Kingsman, University of Oxford, England: Exploitation of
a retrotransposon to produce polyvalent particulate
proteins.
H. Piwnica-Worms, Dana-Farber Cancer Institute, Boston,
Massachusetts: Interactions between 60 c - s rs and the
middle T antigen of polyomavirus in insect cells.
defective-interfering RNAs as expression vectors.
M.D. Summers, Texas A&M University, College Station:
Baculovirus-directed foreign gene expression.
N.C. Jones, Imperial Cancer Research Fund Laboratories,
London, England: Overproduction of E1A, human EGF
receptor, and protein kinase proteins in the baculovirus
expression system - Functional characterization of purified
proteins.
March 20-March 23
ARRANGED BY
D. Beach, Cold Spring Harbor Laboratory, New York
C. Basilico, New York University Medical Center, New York
J. Newport, University of California, San Diego, La Jolla
SESSION 1
S. Reed, Research Institute of Scripps Clinic, La Jolla.
California: Control of cell division in S. cerevisiae.
F. Cross, Fred Hutchinson Cancer Research Center. Seattle.
Washington: Size control in S. cerevisiae.
K. Matsumoto, DNA Research Institute, Palo Alto. California:
Cell cycle control within the GI phase of S. cerevisiae.
C. Basilico, New York University Medical Center, New York:
Cloning of cell cycle genes.
SESSION 2
H.L. Ozer, Hunter College, CUNY, New York, New York:
Studies with mammalian cell mutants temperature-
sensitive for cell and viral DNA synthesis.
B. Stillman, Cold Spring Harbor Laboratory, New York:
Cellular proteins required for multiple stages of DNA
replication.
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N. Heintz, Rockefeller University. New York, New York:
Factors controlling histone gene expression during the
cell cycle.
J. Roberts, Fred Hutchinson Cancer Research Center,
Seattle, Washington: Regulation of DNA replication.
T. Roberts, Dana-Farber Cancer Institute, Boston,
Massachusetts: Oncogenes and signal transduction.
W. Earnshaw, Johns Hopkins University School of Medicine,
Baltimore. Maryland: Synthesis, stability, and modification
of DNA topoisomerase II across the eukaryotic cell cycle.
R. Laskey, CRC Molecular Embryology Group, Cambridge,
England: Control of DNA replication in Xenopus egg
extracts.
D.M. Glover, Imperial College of Science and Technology,
London, England: Mitosis in Drosophila.
P O'Farrell, University of California, San Francisco: Program-
ming spatial patterns of gene expression and cell division
times in early Drosophila embryos.
SESSION 3
D. Beach, Cold Spring Harbor Laboratory, New York: Control
of mitosis by the cdc2 protein kinase in fission yeast and
human cells.
N.R. Morris, UMDNJ-Robert Wood Johnson Medical School,
Piscataway, New Jersey: Regulation of mitosis in
Aspergillus nidulans.
L.H. Hartwell, University of Washington, Seattle: RAD9
controls the G2 transition in S. cerevisiae.
T Hunt, University of Cambridge, England: Role of cyclin
synthesis and destruction in meiotic and mitotic cell
cycles in eggs and oocytes.
Session 4
J.S. Hyams, University College, London, England: The fission
yeast cytoskeleton and cell-cycle control.
B. Byers, University of Washington, Seattle: Regulation of the
spindle pole body in budding yeast.
M. Yanagida, Kyoto University, Japan: Genetic control of
mitotic anaphase-Association and dissociation of sister
chromatids in cell cycle.
W.Z. Cande, University of California, Berkeley, California:
Regulation of anaphase spindle elongation in vitro.
D. Vandre, Southern Methodist University, Dallas, Texas:
Phosphorylation state of microtubule organizing
centers-Regulation of activity during mitosis.
K. Hennessy, Massachusetts Institute of Technology,
Cambridge, Massachusetts: Characterization of new cell
cycle mutants.
S. Jentsch, Massachusetts Institute of Technology.
Cambridge, Massachusetts: Ubiquitin-ligation system of
S. cerevisiae.
C.D. Stiles, Dana-Farber Cancer Institute, Boston,
Massachusetts: The role of PDGF-inducible genes in the
T Nishimoto, Kyushu University, Maidashi, Fukuoka, Japan:
Identification of human RCCI protein and the possible
involvement of ubiquitin for onset of chromosome
condensation.
J. Ruderman, Duke University, Durham, North Carolina:
Mitotic cyclins and the cell cycle in early embryos.
W. Dunphy, University of California, San Diego: A yeast cdc
gene product regulates mitotic conversion in Xenopus
egg extracts.
J.L. Ma Iler, University of Colorado School of Medicine,
Denver: Purification and characterization of maturation-
promoting factor from Xenopus eggs.
D. Chelsky, E.I. duPont de Nemours & Company, Wilming-
ton, Delaware: Lamin B methylation and assembly.
mitogenic response of fibroblast cells.
D. Nathans, Johns Hopkins University School of Medicine,
Baltimore, Maryland: The genomic response to growth
factors.
R. Franza, Cold Spring Harbor Laboratory, New
York: Fos
complex interacts with control elements that contain an
AP1 site.
R Bravo, European Molecular Biology Laboratory,
Heidelberg, Federal Republic of Germany: Complexity of
the genetic early response to growth factors in mouse
fibroblasts.
R. Baserga, Temple University School of Medicine,
Philadel-
phia, Pennsylvania: Expression of growth-regulated
genes.
E. Harlow, Cold Spring Harbor Laboratory,
New York: Protein
complexes between dominant and recessive
oncoproteins.
E. Ziff, New York University Medical
Center, New York: Gene
regulation by growth factors and oncogenes.
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The Ubiquitin System
March 27-March 30
ARRANGED BY
M.J. Schlesinger, Washington University School of Medicine, St. Louis, Missouri
A. Hershko, Technion-lsrael Institute of Technology, Haifa, Israel
SESSION 1: STRUCTURE, CHEMISTRY, BIOSYNTHESIS OF UBIQUITIN
Chairperson: I.A. Rose, Fox Chase Cancer Center, Philadelphia, Pennsylvania
W.J. Cook, University of Alabama, Birmingham: Crystal
structure of ubiquitin.
D. Ecker, Smith Kline & French Laboratories, King of Prussia,
Pennsylvania: Structures and functional activities of site-
specific mutants of ubiquitin.
N. Agell, Washington University School of Medicine,
St. Louis, Missouri: In vitro biosynthesis of ubiquitin-
containing proteins.
V.A. Fried, St. Jude Children's Research Hospital, Memphis,
Tennessee: The intrinsic proteolytic activity of ubiquitin.
T.R. Butt, Smith Kline & French Laboratories, King of
Prussia, Pennsylvania: In vivo and in vitro activities of
"engineered" ubiquitin conjugates.
K.D. Wilkinson, Emory University, Atlanta, Georgia: Structure
and enzymology of ubiquitin-dependent systems.
SESSION 2: UBIQUITIN AND PROTEIN TURNOVER
Chairperson: M. Rechsteiner, University of Utah School of Medicine, Salt Lake City
A. Hershko, Technion-Israel Institute of Technology, Haifa:
Selectivity of ubiquitin protein ligase system.
A. Ciechanover, Technion-Israel Institute of Technology, Haifa:
Role of arginyl-tRNA-protein transferase in recognition of
substrates of the ubiquitin system.
A. Varshaysky, Massachusetts Institute of Technology,
Cambridge: The degradation signal in a short-lived
protein.
I.A. Rose, Fox Chase Cancer Center, Philadelphia, Pennsyl-
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vania: Role of ubiquitin hydrolases in protein breakdown.
D.K. Gonda, Massachusetts Institute of Technology,
Cambridge, Massachusetts: The N-end rule in a
mammalian cell-free system.
V. Chau, Wayne State University School of Medicine, Detroit,
Michigan: Is polyubiquitin the recognition signal?
C.M. Pickart, State University of New York, Buffalo:
Mechanisms of inhibition by arsenite of ubiquitin-
dependent proteolysis.
SESSION 3: UBIQUITIN GENES AND EXPRESSION
Chairperson: M.J. Schlesinger, Washington University School of Medicine, St. Louis, Missouri
D. Finley, Massachusetts Institute of Technology, Cambridge:
Functional analysis of the yeast ubiquitin genes.
RI Baker, John Curtin School of Medical Research,
Canberra, Australia: Structure and expression of the
human ubiquitin gene family.
P.K. Lund, University of North Carolina, Chapel Hill:
Expression of human ubiquitin genes.
H.L. Ennis, Roche Institute of Molecular Biology, Nutley,
New Jersey: Structure of Dictyostelium discoideum
ubiquitin genes and their regulation during development.
A. Muller-Taubenberger, Max-Planck-Institute for Biochemistry,
Martinsried, Federal Republic of Germany: Extended
ubiquitin in Dictyostelium.
K. Gausing, University of Aarhus, Denmark: Structure and
expression of ubiquitin genes in plants.
J.T. Lis, Cornell University, Ithaca, New York: Characterization
of ubiquitin gene structure and expression in Drosophila.
SESSION 4: UBIQUITIN IN CELLULAR STRUCTURES
Chairperson: A. Varshaysky, Massachusetts Institute of Technology, Cambridge
W.M. Bonner, National Cancer Institute, Bethesda, Maryland:
Metabolism of ubiquitinated histone 2A.
J.R. Davie, University of Manitoba, Winnipeg, Canada:
Ubiquitinated histones-H2B is preferentially located in
transcriptionally active chromatin.
A.L. Haas, Medical College of Wisconsin, Milwaukee:
Ubiquitin pools in skeletal muscle.
E. Fryberg, Johns Hopkins University, Baltimore, Maryland:
An actin-ubiquitin conjugate in insect flight muscle.
M. van de Rijn, Stanford University School of Medicine,
California: Biosynthesis of Mel-14.
SESSION 5: PROTEOLYSIS
Chairperson: A. Ciechanover, Technion-lsrael Institute of Technology, Haifa
R.D. Vierstra, University of Wisconsin, Madison: Ubiquitin
proteolytic pathway in higher plants.
M. Rechsteiner, University of Utah School of Medicine, Salt
Lake City: Ubiquitin/ATP-dependent proteases.
R.G. Kulka, Hebrew University of Jerusalem, Israel: Ubiquitin
conjugation patterns in ubiquitin system mutants.
A.L. Goldberg, Harvard Medical School, Boston,
Massachusetts: ATP-dependent proteases.
J.F. Dice, Tufts University School of Medicine, Boston,
Massachusetts: Lysosomal pathways of protein
degradation.
G.N. De Martino, University of Texas, Dallas: Ubiquitin-
mediated and ubiquitin-independent pathways of intracel-
lular proteolysis.
M.R. Maurizi, National Cancer Institute, Bethesda, Maryland:
Regulatory functions of ATP-dependent proteases in
E. coli.
Genetic Approaches to Schizophrenia
April 17-April 20
ARRANGED BY
L. Delisi, State University of New York, Stony Brook
F. Henn, State University of New York, Stony Brook
D. Housman, Massachusetts Institute of Technology.
Cambridge
H. Pardes, New York State Psychiatric Institute,
New York
SESSION 1: CLINICAL ISSUES RELEVANT TO THE GENETICS
OF SCHIZOPHRENIA
Chairperson: H. Pardes, New York State Psychiatric Institute,
New York
clinical nature of the disease process-Problems of
diagnosis and heterogeneity.
Discussion
J.D. Watson, Cold Spring Harbor Laboratory, New York:
Introduction.
F. Henn, State University of New York. Stony Brook: The
SESSION 2: CLINICAL GENETICS OF SCHIZOPHRENIA
Chairperson: H. Pardes, New York State Psychiatric Institute.
New York
component in schizophrenia?
DiscussionKendler, Medical College of Virginia, Virginia
Commonwealth University, Richmond: Is there a genetic
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SESSION 3: REVIEW OF CURRENT FAMILY AND RFLP STUDIES
Chairperson: F. Henn, State University of New York, Stony Brook
T Bishop, University of Utah, Salt Lake City: Applying schizophrenia-What is needed.
molecular genetic strategies to the study of Discussion
SESSION 4: IS A MOLECULAR GENETICS OF SCHIZOPHRENIA POSSIBLE?
Chairperson: F.S. Collins, University of Michigan Medical School, Ann Arbor
Overviews: (1) from a psychiatrist; (2) from a linkage Discussion
expert; (3) from a molecular biologist.
SESSION 5: WHAT ARE THE BIOLOGICAL PHENOTYPES OF SCHIZOPHRENIA?
Overviews on various topics in neuroanatomy and Discussion
neurochemistry.
The Molecular Biology of Alzheimer's Disease
April 24-April 27
ARRANGED BY
C.F. Finch, University of Southern California, Los Angeles
P. Davies, Albert Einstein College of Medicine, Bronx, New York
SESSION 1: NEUROCHEMISTRY AND NEUROANATOMY
D.M. Bowen, Institute of Neurology, London, England:
Absence of both hypometabolism and widespread loss of
pyramidal neurones antemortem?
P. Davies, Albert Einstein College of Medicine, Bronx, New
York: Further studies of A68.
C.E. Finch, University of Southern California, Los Angeles:
Cloning for mRNAs that have regionally selective
alterations in Alzheimer's disease.
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F. Hefti, University of Miami, Florida: Nerve growth factor
reestablishes several cholinergic pathways-Implications
for Alzheimer's disease.
R. Reeves, Johns Hopkins University School of Medicine,
Baltimore, Maryland: An animal model for studies of
Down's syndrome and Alzheimer's disease.
S I Rapoport, National Institute on Aging, Bethesda,
Maryland: Is Alzheimer's a phylogenetic disease?
P.D. Coleman, University of Rochester Medical Center, New
York: Growth-associated protein (GAP-43) in Alzheimer's
disease.
EH. Gage, University of California, San Diego: Effects of
NGF on cholinergic neurons in the central nervous
system.
PL. McGee( University of British Columbia, Vancouver,
Canada: Immune system response in Alzheimer's
disease.
J. Rogers, Institute for Biogerontology Research, Sun City,
Arizona: Neuroimmunology of Alzheimer's disease.
G.A. Higgins, University of Rochester Medical Center, New
York: In situ hybridization of amyloid-g-protein mRNA
transcripts in the hippocampal formation in Alzheimer's
disease.
C.A. Miller, University of Southern California School of
Medicine, Los Angeles: Neuronal specificity in
Alzheimer's disease.
J.H. Morrison, Research Institute of Scripps Clinic, La Jolla,
California: The cellular, laminar, and regional distribution
of neurofilament protein and amyloid -p- protein mRNA in
neocortex- Implications for Alzheimer's disease
pathology.
D.L. Price, Johns Hopkins University School of Medicine,
Baltimore, Maryland: Alzheimer's disease and animal
models.
SESSION 2: MOLECULAR BIOLOGY OF PLAQUES AND TANGLES
K. Beyreuther, University of Heidelberg, Federal Republic of
Germany: Alzheimer's disease and the amyloid gene
product.
K. Goldgaber, National Institute of Neurological and
Communicative Disorders and Stroke, Bethesda,
Maryland: The amyloid -/3- protein precursor gene encodes
a family of secreted polyprotein-A hypothesis.
S.A. Johnson, University of Southern California, Los Angeles:
/3- Amyloid gene expression and cellular localization in
Alzheimer's disease brain.
C.L. Masters, University of Heidelberg, Federal Republic of
Germany: Molecular basis of amyloidosis in Alzheimer's
disease.
B. Muller-Hill, Institut fur Genetik der Universitat, Ko In,
Federal Republic of Germany: precursor of
Alzheimer's disease A4 protein.
R.L. Neve, The Children's Hospital, Boston, Massachusetts:
SESSION 3: GENETICS
A.D. Roses, Duke University Medical Center, Durham, North
Carolina: Linkage in late-onset Alzheimer's disease.
PH. St. George-Hyslop, Massachusetts General Hospital,
Boston: Molecular genetics of sporadic and familial
Alzheimer's disease.
T.D. Bird, Seattle VA Medical Center, Washington: The clinical
and neuropathological spectrum of familial Alzheimer's
disease in 24 kindreds.
G.D. Schellenberg, University of Washington School of
Expression of Alzheimer amyloid precursor messenger
RNAs in the developing adult brain.
D.J. Selkoe, Harvard Medical School, Brigham and Women's
Hospital, Boston, Massachusetts: g-Amyloid precursor
proteins-Regional CNS processing and comparison of
PHF-related proteins.
R. Tanzi, Massachusetts General Hospital, Boston: Molecular
genetics analysis of the APP gene.
H.M. Wisniewski, Institute for Basic Research in Develop-
mental Disabilities, Staten Island, New York: (3- Peptide
precursor protein producing and processing cells.
A. Klug, C.M. Wischik, and Michael Goedert, MRC
Laboratory of Molecular Biology, Cambridge, England:
Structure and biochemistry of the Alzheimer tangle.
G. Dean, University of Cincinnati College of Medicine, Ohio:
Untangling the insoluble-A characterization of
Alzheimer's paired helical filaments.
Medicine: Evidence for phenotypic heterogeneity in
familial Alzheimer's disease.
R.C. Mohs, Veterans Administration Medical Center, Bronx,
New York: Familial aggregation of Alzheimer's disease-
Implications for genetic models.
S.B. Prusiner, University of California, San Francisco, School
of Medicine: The formation of brain amyloids; molecular
genetics of neurodegeneration-The prion model.
Refining Ocular Motor Models through Simulation-Workshop on
Computational Neuroscience
July 5-July 9
ARRANGED BY
L. Optican, National Eye Institute, Bethesda, Maryland
S. Hockfield, Yale University, New Haven, Connecticut
SESSION 1: COMPUTER SYSTEMS
L. Optican, National Eye Institute, Bethesda, Maryland
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SESSION 2: EYE PLANT
H.P. Goldstein, Wills Eye Hospital, Philadelphia, Pennsylvania J.D. Ender le, North Dakota State University, Fargo
SESSION 3: VOR
T. Raphan, Brooklyn College, New York
H.L. Galiana, McGill University, Montreal, Quebec, Canada
SESSION 4: SACCADES
A.J. van Opstal, University of Nijmegen, The Netherlands
K. Hepp, Eidgenovvische Techn Hock, Zurich, Switzerland
C.A. Scudder, Washington University School of Medicine,
St. Louis, Missouri
P Inchingolo, University of Trieste, Italy
T.C. Hain, Johns Hopkins Hospital, Baltimore, Maryland
D. Tweed, The University of Western Ontario, London,
Canada
S. Grossberg, Boston University, Massachusetts
D.L. Sparks, University of Alabama, Birmingham
D.M. Waitzman, National Eye Institute, Bethesda, Maryland
SESSION 5: PURSUIT
S.G. Lisberger, University of California School of Medicine,
San Francisco
D.A. Robinson, Johns Hopkins University, Baltimore,
Maryland
R. Krauzlis, University of California School of Medicine,
San Francisco
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J.R. Carl, National Eye Institute, Bethesda, Maryland
E.L. Keller, Smith-Kettlewell Institute for Visual Science,
San Francisco, California
R.H. Wurtz, National Eye Institute, Bethesda, Maryland
L.E. Mays, University of Alabama, Birmingham
F.A. Miles, National Eye Institute, Bethesda, Maryland
Cytoskeletal Proteins in Tumor Diagnosis
October 6-October 9
ARRANGED BY
M. Osborn, Max-Planck-Institute for Biophysical Chemistry, Goettingen, Federal Republic of Germany
K. Weber, Max-Planck-Institute for Biophysical Chemistry, Goettingen, Federal Republic of Germany
SESSION 1: NEURAL AND NEUROENDOCRINE MARKERS
Chairperson: M. Osborn, Max-Planck-Institute for Biophysical Chemistry, Goettingen, Federal Republic of Germany
N.J. Cowan, New York University, New York: Regulation of
expression of the genes encoding neurofilament and glial
filament proteins.
L.A. Sternberger, University of Maryland, Baltimore:
Neurofilament phosphorylation- Reactive and
degenerative.
J.O. Trojanowski, University of Pennsylvania, Philadelphia:
Diagnostic problems in neuropathology-An overview of
recent efforts to address diagnostic and prognostic
problems with monoclonal antibodies to neurofilarnents.
M.L. Shelanski, Columbia University College of Physicians &
Surgeons, New York, New York: Peripherin and other
markers of neural differentiation.
V.E. Gould, Rush-Presbyterian-St. Luke's Medical Center,
Chicago, Illinois: Neuroendocrine and nerve sheath
tumors.
A.F. Gazdar, Naval Hospital, Bethesda, Maryland:
Differentiation and molecular biology of lung cancer.
SESSION 2: DIFFERENTIATION MARKERS IN THE MESENCHYME AND ITS TUMORS
Chairperson: G. Gabbiani, University of Geneva, Switzerland
M. Altmannsberger, University of Giessen, Federal Republic
of Germany: Distinction of small round-cell tumors of
children with special emphasis on neuroblastomas and
rhabdomyosarcomas.
G. Gabbiani, of Geneva, Switzerland: Actin
isoform identification in the diagnosis of soft tissue tumors
and of nonmalignant smooth muscle proliferation.
A.M. Gown, University of Washington, Seattle: Anti-actin
antibodies-Use in diagnosis.
D. Helfman, Cold Spring Harbor Laboratory, New York:
Regulation of expression of marker molecules of
myogenesis.
J.S. Morrow, Yale University, New Haven, Connecticut:
Spectrins and the cortical cytoskeleton-Tissue specificity.
K. Gaffer, John Radcliffe Hospital, Oxford, England: Value of
cytoskeletal markers in diagnosis of lymphomas and
other tumors.
A.M. Vogel, St. Louis University, Missouri: Melanocyte-
specific cytoplasmic antigens.
C.C. Kumar, Schering Corporation, Bloomfield, New Jersey:
Regulation of smooth-muscle-specific myosin light-chain-2
isoforms by oncogenes and by tumor-promoting agents.
SESSION 3: DIFFERENTIATION MARKERS: SWITCHES DURING DEVELOPMENT
AND USES IN CYTOLOGY
AND IN TUMOR DIAGNOSIS
Chairperson: L.A. Sternberger, University of Maryland, Baltimore
I. Virtanen, University of Helsinki, Finland: Changes of
expression of intermediate filaments during development
and in culture.
I. Damjanov, Jefferson Medical College, Philadelphia.
Pennsylvania: Cytoskeletal and lectin markers of
embryonal carcinomas and teratocarcinomas.
D Louvard, Pasteur
Institut, Paris. France: The use of villin
for histopathological and serological diagnosis of
digestive tumors.
L.G. Koss, Montefiore Medical Center and Albert Einstein
College of Medicine, Bronx, New York: Diagnostic
cytology and cell markers-Some practical
considerations.
M. Osborn, Max-Planck-Institute for Biophysical Chemistry,
Goettingen, Federal Republic of Germany: IF typing in
cytology.
B. Cunningham, Rockefeller University, New York, New York:
Cell adhesion molecules.
P Cowin, New York University, New York: Molecular markers
of adhering junctions.
SESSION 4: EPITHELIA AND CARCINOMAS I
Chairperson: T.T. Sun, New York University, New York
W.W. Franke, German Cancer Research Center Heidelberg,
Federal Republic of Germany: Molecular biological and
histological aspects of expression of cytokeratins and
desmosomal proteins.
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B. Lane, Imperial Cancer Research Fund, Herts, England:
Differential expression of keratins as seen by monoclonal
antibodies.
J.G. Rheinwald, Dana-Farber Cancer Institute, Boston,
Massachusetts: Keratin 19 expression as a marker of
premalignancy in oral epithelium.
R. Moll, University of Mainz, Germany: Cytoskeletal markers
in the classification of carcinomas and their metastases.
R.B. Nagle, University of Arizona, Tucson: The study of
intermediate filaments as an adjuvant to pathological
diagnosis.
H. Battifora, City of Hope National Medical Center, Duarte,
California: Fixatives and proteases, their effect in the
demonstration of intermediate filaments by
immunohistochemistry.
M. Miettinen, University of Helsinki, Finland: Intermediate
filaments in sarcomas-New findings suggest complex
patterns of expression.
SESSION 5: EPITHELIA AND CARCINOMAS II
Chairperson: W.W. Franke, German Cancer Research Center,
E.V. Fuchs, University of Chicago, Illinois: Regulation of
keratin gene expression in human epithelial cells.
T.T. Sun, New York University, New York: Pathways of
keratinocyte differentiation.
S.P. Banks-Schlegel, National Heart, Lung and Blood
Institute, Bethesda, Maryland: Keratin proteins and
involucrin-Diagnostic aids in neoplasis.
H. Kahn, Women's College Hospital, Toronto, Canada:
Keratin patterns in epithelial tumors.
D.R. Roop, National Institutes of Health, Bethesda,
Maryland: The use of monospecific keratin antisera to
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Heidelberg, Federal Republic of Germany
monitor different stages of carcinogenesis.
F Ramaekers, University Hospital, Nijmegen, The
Netherlands: The use of monoclonal antibodies to
cytokeratins in the characterization of epithelial lesions
with special emphasis on their application in flow
cytometry.
G. Riethmuller, University of Munich, Federal Republic of
Germany: Oncogene expression and tumorigenesis of
early disseminated cancer cells from human bone
marrow- Identification of single tumor cells with anti-
cytokeratin antibodies.
The Pancreatic /3 Cell: Development, Cell and Molecular Biology,
and lmmunopathology
October 16-October 19
ARRANGED BY
G. Cahill, Howard Hughes Medical Institute, Bethesda, Maryland
D. Hanahan, Cold Spring Harbor Laboratory, New York
H.O. McDevitt, Stanford University School of Medicine, California
SESSION 1: BIOLOGY AND MOLECULAR BIOLOGY OF THE (3 CELL
Chairperson: G. Cahill, Howard Hughes Medical Institute, Bethesda, Maryland
D. Steiner, University of Chicago, Illinois: Cellular and
molecular biology of the f3 cell.
W. Rutter, University of California, San Francisco: Insulin
genes and receptors.
R. Stein, Vanderbilt University, Nashville, Tennessee: Insulin
gene regulation-The role of positive and negative
transcription factors in pancreatic (3-cell-specific
expression.
M.J. Tsai, Baylor College of Medicine, Houston, Texas:
Regulation of the rat insulin II gene expression-cis- and
trans-acting factors.
G.I. Bell, University of Chicago, Illinois: Characterization of
proteins expressed in the (3 cell-A molecular analysis.
G. Teitelman, New York Hospital-Cornell University Medical
Center, New York: Expression of neural antigens by
pancreatic [3 cells-Developmental implications.
SESSION 2: INSULIN-DEPENDENT DIABETES
Chairperson: J. Kapp ler, University of Colorado Health Science Center, Denver
G. Cahill, Howard Hughes Medical Institute, Bethesda,
Maryland, and Ronald Kahn, Jos lin Diabetes Center,
Boston, Massachusetts: The nature of diabetes and its
physiologic defects.
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S. Baekkeskov, Hagedorn University, Gentofte, Denmark:
Characterization of the 64K autoantigen in diabetes.
H.O. McDevitt, Stanford University School of Medicine,
California: Role of class II MHC molecules in type I
diabetes.
E.H. Leiter, The Jackson Laboratory, Bar Harbor, Maine:
SESSION 3: IMMUNOLOGICAL TOLERANCE
Chairperson: N.A. Mitchison, University of London, England
N.A. Mitchison, University of London, England: General
perspectives on tolerance.
J. Kapp ler, University of Colorado Health Science Center,
Denver: Shaping of the T-cell repertoire by tolerance.
J. Sprent, Scripps Clinic, La Jolla, California: T-cell selection
in the thymus.
D. Hanahan, Cold Spring Harbor Laboratory, New York:
SESSION 4: AUTOIMMUNITY
Genetic control of interferon-y-induced class -I -like genes
in NOD islets and macrophages.
A. Like, University of Massachusetts Medical School,
Worcester: Reconstitution studies in the BB/Wor model of
spontaneous autoimmune diabetes.
Tolerance or autoimmunity to a transgenic /3-cell antigen.
D. Lo, University of Pennsylvania School of Veterinary
Medicine, Philadelphia: Transgenic mice with specific
expression of class II MHC on 13 cells-Antigen-
presenting function and tolerance induction.
General discussion: Mechanisms of tolerance.
Chairperson: R Marrack, Howard Hughes Medical Institute Research Laboratories, Denver Colorado
N. Sarvetnick, Genentech, Inc., South San Francisco, Califor-
nia: Interferon-y-induced diabetes in transgenic mice.
J. Sambrook, University of Texas Southwestern Medical
Center, Dallas: Expression of a foreign antigen, influenza
virus hemagglutinin, on the surfaces of pancreatic /3 cells
in transgenic mice-A model for autoimmune diabetes.
SESSION 5: TRANSGENIC DIABETES/HORMONE SECRETION
J.F. Bach, Institut National de la Sante et de la Recherche
Medicale, Paris, France: MHC-based immunomanipula-
tion of anti-p-cell autoimmunity in NOD mice.
C.A. Janeway, Jr., Yale University School of Medicine, New
Haven, Connecticut: Approaches to the analysis of
autoantigens.
Chairperson: H.O. McDevitt, Stanford University School of Medicine, California
L. Harrison, Walter & Eliza Hall Institute of Medical
Research, Melbourne, Australia: Mechanisms of 13-cell
destruction in type I diabetes-Immune and nonimmune.
D. Mathis, Institut de Chimie Biologique, Faculte de
Medecine, Strasbourg, France: Expression of MHC class
II molecules on [3 cells is not a sufficient condition for
insulin-dependent diabetes.
N. Sarvetnick, Genentech, Inc., South San Francisco, Califor-
nia: EM analysis of class II expression in /3 cells of
transgenic mice.
S. Efrat, Cold Spring Harbor Laboratory, New York: A new
model for diabetes in transgenic mice.
P Epstein, Baylor College of Medicine, Houston, Texas:
Overexpression of calmodulin in cells of transgenic
mice.
R. Kelly, University of California, San Francisco: Hormone
secretion of endocrine cells.
L. Villa-Komaroff, The Children's Hospital, Boston,
Massachusetts: Mutations of insulin, effects on process-
ing and secretion.
Therapeutic Peptides and Proteins: Formulation, Delivery,and Targeting
October 23-October 26
ARRANGED BY
D.T. Liu, U.S. Food and Drug Adminstration, Bethesda, Maryland
D. Marshak, Cold Spring Harbor Laboratory, New York
SESSION 1: FORMULATIONS
Chairperson: Z. Shaked, CODON, South San Francisco, California
Z. Shaked, CODON, South San Francisco, California:
Formulation of pharmaceutical proteins.
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A.P. MacKenzie, University of Washington, Seattle: Freeze-
drying of peptide and protein-containing sytems.
R. Pearlman, Genentech, Inc., South San Francisco, Califor-
nia: Formulation strategies for recombinant proteins-
Growth hormone and tissue-type plasminogen activator.
SESSION 2: ROUTES FOR DELIVERY
Chairperson: S.S. Davis, University of Nottingham, England
S.S. Davis, University of Nottingham, England: Oral adminis-
tration of peptides.
S. Muranishi, Kyoto Pharmaceutical University, Japan:
Biopharmaceutical aspects of enhanced-transmembrane
delivery of peptides and proteins.
S. Hershenson, Cetus Corporation, Emeryville, California:
Formulation of interferon-p-scr17 (BetascronTm), a
hydrophobic protein, using a nonionic surfactant.
L. Ilium, University of Nottingham, England: Nasal delivery
of peptides and proteins.
J.P. Longenecker, California Biotechnology Inc., Mountain
View, California: Nasal delivery of proteins for systemic
use.
SESSION 3: PHARMACOKINETICS
Chairperson: L.Z. Benet, University of California, San Francisco
L.Z. Benet, University of California, San Francisco:
Pharmacokinetics of peptides and proteins-Boundaries
of formulation, delivery, and targeting.
S. Poole, National Institute for Biological Standards and
Control, Herts, England: Pharmacokinetics and tissue
targeting.
M.J. Browne, Beecham Pharmaceuticals Research Division,
Surrey, England: Slow in vivo clearance of novel tissue-
type plasminogen activator species and hybrid enzymes.
A.M. Breckenridge, University of Liverpool, England:
Therapeutic peptides-A clinical pharmacologist's views.
SESSION 4: REGULATORY ASPECTS I
Chairperson: D.T. Liu, U.S. Food and Drug Administration,
Bethesda, Maryland
S. Sobel, Center for Drug Evaluation and Research, U.S.
Hayakawa, National Institute of Hygienic Sciences, Tokyo,
Food and Drug Administration, Rockville, Maryland: U.S.
Japan: Preclinical study groups for biotechnology drugs
as an aid in the development of regulatory policies.
perspectives on drug regulation.
SESSION 5: BRAIN PEPTIDES
Chairperson: N. Sherwood, University of Victoria,
British Columbia, Canada
L L Rubin, Athena Neurosciences, Inc., San Carlos, Califor-
J.E. Rivier, Salk Institute, La Jolla, California:
Pharmacology
nia: Cell biology of the blood-brain barrier.
of selected hypothalamic releasing factors.
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N. Sherwood, University of Victoria, British Columbia,
Canada: Formulation and delivery of gonadotrophin-
releasing hormones and their analogs for control of
reproduction in fish.
SESSION 6: CONTROLLED DELIVERY
Chairperson: R. Langer, Massachusetts Institute of Technology, Cambridge
L. Huang, University of Tennessee, Knoxville: Liposomal
delivery of proteins and peptides.
H. Okada, Takeda Chemical Industries, Ltd., Osaka, Japan:
One-month release injectable microspheres of leuprolide
acetate.
R. Langer, Massachusetts Institute of Technology,
Cambridge: Controlled polymeric delivery systems for
small molecules and polypeptides.
SESSION 7: GLYCOPROTEINS
Chairperson: D.R. Bangham, National Institute for Biological Standards and Control, Herts, England
J.U. Baenziger, Washington University, St. Louis, Missouri: J.R. Rasmussen, Genzyme Corporation, Boston,
Structure and function of glycoprotein hormone Massachusetts: Targeting of glucocerebrosidase to
oligosaccharides. macrophages.
H. Kinoshita, Chugai Pharmaceutical Co., Ltd., Tokyo,
Japan: Pharmacokinetics of recombinant erythropoietin in
rats.
SESSION 8: CELLULAR APPROACHES
Chairperson: D.R. Marshak, Cold Spring Harbor Laboratory, New York
D.B. Glass, Emory University, Atlanta, Georgia: Potent,
selective peptide inhibitors of cAMP-dependent protein
kinase-Structure-function and biostability studies.
J.A. Thompson, National Heart, Lung and Blood Institute,
Bethesda, Maryland: Implantable bioreactors-Modern
concepts of gene therapy.
SESSION 9: REGULATORY ASPECTS II
J.R. Murphy, Boston University Medical Center,
Massachusetts: Diphtheria-toxin-related growth-factor
fusion genes-Model systems for target-cell-receptor-
specific toxins.
P.W. Trown, XOMA Corp., Berkeley, California:
Immunotoxins-Chemistry, biology, and clinical efficacy.
Chairperson: D.T. Liu, U.S. Food and Drug Administration, Bethesda, Maryland
E. Esber, Center for Biologics Evaluation and Research, U.S.
Food and Drug Administration, Bethesda, Maryland: U.S.
perspectives on evaluation of therapeutic biological
products.
SESSION 10: CYTOKINES
Chairperson:
G. Tosato, U.S. Food and Drug Administration, Bethesda,
Maryland: Interferon-p-2/B-cell-stimulating factor 2,
interleukin 6-A novel cytokine that regulates B- and
T-cell growth.
D.L. Urdal, Immunex Corporation, Seattle, Washington:
Hematopoietic growth factors-From cloning to clinic.
M. Masui, Otsuka Pharmaceutical Co., Ltd., Rockville,
Maryland: Heterogeneity of recombinant products.
Human interleukin-la and -1/3.
S.L. Jeffcoate, National Institute for Biological Standards and
Control, Herts, England: The European approach to the
regulation of therapeutic proteins produced by the new
biotechnologies.
N. Katre, Cetus Corporation, Emeryville, California: Chemical
modification of interleukin-2-A potent drug-delivery
system.
M.J. Hawkins, National Cancer Institute, Bethesda,
Maryland: Ex vivo activation of leukocytes.
D.R. Bangham, National Institute for Biological Standards
and Control, Herts, England: Summary and thoughts for
the future.
Development and Application of Molecular Markers to Problems in
Plant Genetics
November 1-November 4
ARRANGED BY
B. Burr, Brookhaven National Laboratory, Upton, New York
T. Helentjaris, Native Plants, Inc., Salt Lake City, Utah
S. Tanks ley, Cornell University, Ithaca, New York
SESSION 1: SUMMARY OF MAIZE EFFORTS
B. Bun; Brookhaven National Laboratory, Upton, New York:
Introduction.
M.G. Murray, Agrigenetics Corporation, Madison, Wisconsin:
General considerations on building an RFLP linkage map
with specific reference to maize.
B. Burt; Brookhaven National Laboratory, Upton, New York:
The application of recombinant inbred lines in the
analysis of linkage of RFLP loci and their relationship to
traits of interest.
D.A. Hoisington, University of Missouri, Columbia: Correla-
tion of RFLP work with existing maps and coordination of
multiple group efforts.
G.E. Hart, Texas A&M University, College Station: Use of
existing genetic tools in wheat as they might be applied
to RFLP analysis.
P.J. Sharp, Institute of Plant Science Research, Cambridge,
England: Construction of RFLP maps in wheat and other
related species.
R.C. Shoemaker, Iowa State University, Ames: RFLP analysis
in soybean and the special problems using self-pollinated
species.
SESSION 2
N. Young, Cornell University, Ithaca, New York: The applica-
tion of RFLPs to studies in plant evolution-The rice and
Solanaceae synteny stories.
M.K. Slocum, Native Plants, Inc., Salt Lake City, Utah: The
genomic structure of related brassica species and
subspecies studied by RFLP analysis.
E. Meyerowitz, California Institute of Technology,
Pasadena:
An RFLP map for Arabidopsis and its genetic
applications.
Open discussion: Summaries of other mapping efforts.
Moderator: T. Helentjaris, Native Plants, Inc., Salt Lake
City, Utah
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SESSION 3
R.W. Michelmore, University of California, Davis: Use of an
RFLP map for lettuce in the analysis of host-parasite
interactions.
M.T. Clegg, University of California, Riverside: Studies of
genetic variation between plants by sequence and RFLP
analysis.
Roundtable: The use of RFLPs in the study of evolution and
systematics, with reference to both research and practical
applications.
Moderator: J. Doebley, University of Minnesota, St. Paul
J. F. Wendel and M. Lee, Iowa State University, Ames
SESSION 4: RFLPS AND THE ANALYSIS OF QUANTITATIVE TRAIT LOCI (QTL)
J. Romero-Severson, Agrigenetics Corporation, Madison,
Wisconsin: Use of RFLPs for analysis of quantitative trait
loci in maize-General considerations and potential
impact on crop improvement.
C.W. Stuber, North Carolina State University, Raleigh:
Comparative studies using both RFLPs and isozymes as
molecular markers to analyze multigenic traits in maize.
J. Nienhuis, Native Plants, Inc., Salt Lake City, Utah: The use
of RFLPs to analyze multigenic traits in tomato-The
simultaneous selection of contrasting traits.
SESSION 5
D.S. Robertson, Iowa State University, Ames: Understanding
the relationship between qualitative and quantitative
genetics.
B. Haughe, Massachusetts General Hospital, Boston:
Physical mapping in Arabidopsis and possible applica-
tions of this approach.
E. Lander, Whitehead Institute for Biomedical Research,
Cambridge, Massachusetts: Mapping QTLs with
RFLPs-Mathematical theory and experimental results.
Roundtable: Theoretical considerations for the application of
RFLPs to QTL analysis.
Moderator: N. Cowen, United Agriseeds, Inc.,
Champaign, Illinois
J.S. Beckman, The Volcani Center, Bet Dagan, Israel;
M. Edwards, The Pillsbury Company, LeSueur, Minnesota
M. Wu, Los Alamos National Laboratory, New Mexico: In situ
hybridization to physically map cloned probes in plant
chromosomes-Physical-recombination map
relationships.
T. Helentjaris, Native Plants, Inc., Salt Lake City, Utah: Future
directions for both the technology and its applications.
DNA Technology and Forensic Science
November 28-December 1
ARRANGED BY
J. Ballantyne, Office of the Medical Examiner, Suffolk County, Hauppauge, New York
G.F. Sensabaugh, University of California, Berkeley
J.A. Witkowski, Banbury Center, Cold Spring Harbor Laboratory, New York
SESSION 1: FORENSIC USE OF GENETIC INFORMATION-LEGAL AND SOCIAL ISSUES
Chairperson: A.G. Motulsky, University of Washington School of Medicine, Seattle
G.F. Sensabaugh, University of California, Berkeley:
Introduction.
J.L. Peterson, University of Illinois at Chicago: Biological
evidence and its impact on judicial decision making.
A.G. Motulsky, University of Washington School of Medicine,
Seattle: Genetics and society.
D. Nelkin, New York University, New York: Society's use of
data.
A. Westin, Columbia University, New York, New York:
General aspects of privacy.
P Reilly, Shriver Center for Mental Retardation, Waltham,
Massachusetts: Regulation of access to genetic data.
SESSION 2: BASIC ISSUES-LEGAL AND SCIENTIFIC
Chairperson: G.F. Sensabaugh, University of California, Berkeley
P Neufeld, New York, New York: The Frye test and the
admissibility of scientific evidence.
R.P. Harmon, Alameda County District Attorney's Office,
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Oakland, California: The Frye test-Considerations for
DNA fingerprinting.
M. Katzer, Office of the District Attorney, County of Albany,
New York: Review of present cases.
C.T. Caskey, Baylor College of Medicine, Houston, Texas:
A critical evaluation of the laboratory techniques.
E.S. Lander, Whitehead Institute for Biomedical Research,
Cambridge, Massachusetts: The requirements for
population studies.
E. Lander, R. Roberts, P Neufeld B. Budowle, R. Harmon
D. Werrett, A, Jeffreys T. Caskey, J. Bashinski
SESSION 3: TRANSFER OF DNA TECHNOLOGY TO THE FORENSIC
LABORATORY
Chairperson: J.W. Hicks, FBI Laboratory Division, Washington, D.C.
J.S. Bashinski, Oakland Police Department Crime Lab,
California: Laboratory accreditation, training, and certifi-
cation of staff in the forensic context.
M.L. Baird, Lifecodes Corporation, Valhalla, New York:
Quality control and quality assurance.
ET Blake, Forensic Science Associates, Richmond, Califor-
nia: DNA analysis and its integration into traditional
forensic serology.
Discussion: Practical experiences of the transfer of DNA
technology to the forensic laboratory.
Discussants:
J.W. Hicks, FBI Laboratory Division, Washington, D.C.
J. Ballantyne, Office of the Medical Examiner, Suffolk
County, Hauppauge, New York
H. Lee, Connecticut State Police Forensic Science
Laboratory, Meriden
W.C. Stuber, Metro-Dade Police Department Crime
Laboratory, Miami, Florida
B.D. Gaudette, Royal Canadian Mounted Police
Central
Forensic Laboratory, Ottawa, Ontario
D. Werrett, Home Office Research Establishment, Reading,
England
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SESSION 4: ADVANCED DNA TECHNIQUES WITH APPLICATION IN THE FORENSIC LABORATORY
Chairperson: C.T. Caskey, Baylor College of Medicine, Houston, Texas
S. Odelberg, University of Utah School of Medicine, Salt
Lake City: Tandem ly repeated DNA and its applications
in forensic biology.
D.D. Garner, Cellmark Diagnostics, Germantown, Maryland:
Current case experience with single-locus hypervariable
probes.
R. Higuchi, Cetus Corporation, Emeryville, California:
Applications of the polymerase chain reaction in forensic
science.
A.J. Jeffreys, University of Leicester, England: Minisatellite
probes and the polymerase chain reaction.
G.L. Trainor, DuPont Company, Wilmington, Delaware:
Fluorescence detection nucleic acid analysis.
M. Hunkapiller, Applied Biosystems, Inc., Foster City, Califor-
nia: Detection systems for DNA sequencing and specific
nucleotide sequences.
SESSION 5: ESTABLISHMENT MAINTENANCE, AND REGULATION OF DATABASES
Chairperson: R. Roberts, Cold Spring Harbor Laboratory,
S.D. Rose, Collaborative Research, Inc., Bedford,
Massachusetts: Standardization of systems- Essential or
desirable?
E.A. Rathbun, FBI National Crime Information Center,
Washington D.C.: The NCIC experience.
K.K. Kidd, Yale University School of Medicine, New Haven,
The Polymerase Chain Reaction
New York
Connecticut: The human gene-mapping database.
T.G. Marr, Los Alamos National Laboratory, New Mexico: An
analysis system and database for gel images.
D. Boggs, U.S. Court of Appeals, Louisville, Kentucky:
Summary.
December 11-December 14
ARRANGED BY
H.A. Erlich, Cetus Corporation, Emeryville, California
R. Gibbs, Baylor College of Medicine, Houston, Texas
H.H. Kazazian, Jr., Johns Hopkins Hospital, Baltimore, Maryland
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SESSION 1: BASIC TOPICS
Chairperson: T.A. Kunkel, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina
TA. Kunkel, National Institute of Environmental Health
Sciences, Research Triangle Park, North Carolina: DNA
polymerase fidelity.
D. Gelfand, Cetus Corporation, Emeryville, California:
Enzymes in PCR.
P Keohavong, Massachusetts Institute of Technology,
Cambridge: Fidelity of DNA amplification in vitro.
R.K. Saiki, Cetus Corporation, Emeryville, California:
Optimization of PCR.
SESSION 2: HUMAN GENETIC DISEASE MUTATIONS
M.S. Lee, University of Texas, Houston: Detection of
chromosomal translocations by sequence amplification.
M. Perucho, California Institute of Biological Research,
La Jolla: Application of PCR to the diagnostic detection
of mutant ras oncogenes in human tumors by the
RNase-A mismatch-cleavage method.
D. Goldgaber, State University of New York, Stony Brook:
Problems with fidelity of Taq polymerase in searching for
mutation in the human PRP gene.
Chairperson: 0. Smithies, University of North Carolina, Chapel Hill
H.H. Kazazian, Jr., Johns Hopkins Hospital, Baltimore,
Maryland: Use of PCR in clinical diagnosis of genetic
disease.
S.L.C. Woo, Howard Hughes Medical Institute, Baylor
College of Medicine, Houston, Texas: Mutations in
phenylketonuria.
D. Valle, Johns Hopkins Hospital, Baltimore, Maryland:
Mutation detection and structure-function studies at the
ornithine aminotransferase locus.
K. Tindall, National Institute of Environmental Health
Sciences, Research Triangle Park, North Carolina:
Molecular analysis of mutations at gpt locus in Chinese
hamster ovary cells.
R. Williamson, St. Mary's Hospital Medical School, London,
England: Application of PCR to cystic fibrosis-Prenatal
diagnosis and carrier testing.
R. Gibbs, Baylor College of Medicine, Houston, Texas: HPRT
mutations and competitive oligonucleotide priming.
A.A. van Zeeland, State University of Leiden, The
Netherlands: Sequence determination of point mutations
at the HPRT locus in mammalian cells using HPRT cDNA
prepared from total cellular RNA.
D. Ginsburg, Howard Hughes Medical Institute, University of
Michigan Medical School, Ann Arbor: Human von
Willebrand's disease-Analysis of platelet mRNA by PCR.
SESSION 3: ANALYSIS OF HIGHLY POLYMORPHIC REGIONS
Chairperson: R. Williamson, St. Mary's Hospital Medical School, London, England
J.A. Todd, John Radcliffe Hospital, Oxford, England: Cloning
immune response genes.
G.F. Sensabaugh, University of California, Berkeley: PCR
applications in forensic science.
A.F. Markham, ICI Diagnostics, Norwich, Cheshire, England:
H.A. Erlich, Cetus Corporation, Emeryville, California: HLA
class II polymorphisms-Detection and evaluation.
J. Weber, Marshfield Medical Research Foundation,
Wisconsin: Length polymorphisms in abundant
(dC-dA),(dG-dT), repeats.
N. Arnheim, H. Kazazian
S. Woo, O. Smithies
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Specificity and reproducibility of the PCR.
R.M. Myers, University of California, San Francisco: PCR
and denaturing gradient gels.
T Kunkel, H. Erlich
L.S. Lerman, Massachusetts Institute of Technology,
Cambridge: Analysis of single -base changes in the
human genome.
SESSION 4: DETECTION OF RARE SEQUENCES
Chairperson: K.B. Mullis, XYTRONYX, Inc.,
San Diego, California
J.J. Sninsky, Cetus Corporation, Emeryville, California: HIV.
B.J. Poiesz, State University of New York Health Science
Center, Syracuse: The use of PCR in the detection,
quantification, and characterization of human retroviruses.
G. Schochetman, Centers for Disease Control, Atlanta,
Georgia: HIV detection.
T.R. Broker, University of Rochester School of Medicine, New
York: Synthesis of human papillomavirus cDNAs by PCR
amplification.
N. Arnheim, University of Southern California, Los Angeles:
Single-cell templates/gene mapping.
0. Smithies, University of North Carolina at Chapel Hill: Use
of PCR for detection of targeted gene modifications.
J.S. Chamberlain, Baylor College of Medicine, Houston,
Texas: Multiplex PCR for DMD diagnosis.
SESSION 5: ALTERNATIVES, AUTOMATION, AND THE FUTURE
Chairperson: R.M. Myers, University of California, San Francisco
H. Lehrach, Imperial Cancer Research Fund Laboratories, P.J. de Jong, Lawrence Livermore National Laboratory,
London, England: Approaches to a large-scale analysis California: In vitro mutagenesis via PCR.
of mammalian genomes. R.B. Wallace, Beckman Research Institute of the City of
McBride, Applied Biosystems, Inc., Foster City, Califor- Hope, Duarte, California: Alternative to PCR.
nia: Thermal cycling and automated fluorescent DNA K.B. Mullis, XYTRONYX, Inc., San Diego, California:
sequencing. Variations on the polymerase chain reaction.
R.K. Wilson, California Institute of Technology, Pasadena:
Rapid analysis of T-cell-receptor gene structure and
expression.
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DNA LEARNING CENTER
David A. Mick los, Director
Mark V. Bloom, Assistant Director
This Annual Report marks the emergence of the DNA Learning Center (DNALC)
as a new operating unit of Cold Spring Harbor Laboratory. Like its sister Banbury
Center, founded in 1976, the DNALC has a separate operating budget and
advisory board. The DNALC extends the traditional postgraduate education and
research mission of Cold Spring Harbor Laboratory to the college, precollege, and
public levels. The DNALC collaborates extensively with the Public Affairs
Department and Banbury Center, which have overlapping roles in interpreting
science and interacting with segments of the public.
The DNALC is the culmination of the DNA Literacy Program, which was initiated
5 years ago as the nation's first laboratory-based program to retrain precollege
teachers in molecular genetics. At that time, many felt that we were a little mad to
think that widespread public understanding of one molecule (DNA) could be so
important. In fact, our first attempt for federal grant support of this program met
with failure.
The dedication of the Learning Center on September 18th, 1988 marked the
coming of age of that "crazy" idea. Opening-day tours of the facility were attended
by 800 students, teachers, friends, and employees of Cold Spring Harbor
Laboratory. A standing-room-only crowd of 400 packed Grace Auditorium for the
dedication ceremony, at which Dr. Robert Pollock, Dean of Columbia College,
delivered the keynote address, "Reading DNA:' Backed by the prestige of Cold
Spring Harbor Laboratory, the event sent a clear message that there is now room
in the world for at least one institution devoted entirely to biotechnology education.
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Cold Spring Harbor
Laboratory Director James
D. Watson with Robert
Pollock, Dean of Columbia
College, who delivered the
keynote address at the
Learning Center dedication
on September 18, 1989.
Huntington Town Supervisor
Toni Rettaliata (above) also
spoke.
Scientists have already begun to write the history of discovery that has led us
into the biotechnology era. Most of us cannot participate in discovery; however,
each of us can help write the history of the first society to dwell in the gene age.
Only through widespread education can we ensure a society that shepherds the
benevolent use of genetic technology for the good of all its citizens.
Cold Spring Harbor Laboratory has provided for the world a model of what a
research institute should be-a quiet place where people can solve the problems
of biology. Similarly, we hope that the DNALC will provide a model of how a
science education institute can help solve the problems of scientific illiteracy. Now,
by our example, we must show the world that there is need for other DNA
education units as well. To the extent that we prove that the general public is
eager and able to learn about biotechnology, we also provide models of informal
science education for other institutions to follow.
The Human Genome Project
Written in the approximately 100,000 human genes is the molecular code-script
that, to a large extent, determines the life and health of each individual. This entire
complement of genetic instructions encoding human life is called the human
genome.
During the last 15 years, biologists have gained the extraordinary ability to
dissect precisely the molecules of DNA that comprise the human genome. The
molecular dissection of the fundamental units of heredity has added rich detail to
our understanding of how human life develops and changes-from fertilized egg
to adulthood. It has also enabled scientists to pinpoint changes in the DNA
molecule that predispose one to illnesses such as cancer, muscular dystrophy,
Alzheimer's disease, and manic depression.
Until recently, the molecular exploration of the human genome has proceeded
in a relatively uncoordinated fashion, with many scientific teams working indepen-
dently on one or several genes of interest. The information so gathered can be
likened to the individual squares of a patchwork quilt, each with its own story to
tell. The inauguration of the Human Genome Project in 1988 marked the
beginning of a national commitment to knit the patches of genetic research into a
cohesive whole. Its goal is to determine the sequence of the estimated 3 billion
bits of molecular information-the arrangement of nucleotide rungs of the DNA
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The Search for Life exhibit
includes a multi-projector
slide show and a genetic
code game. (Photo by
Edward McCain.)
ladder-that constitute the entire code-script of human life. The Human Genome
Office, within the National Institutes of Health, now coordinates the
collection, storage, and dissemination of research data collected by thousands of
scientists throughout the country.
Possession of an increasingly complete code-script of hereditary information will
bring numerous benefits to man- and womankind. Gene-mapping techniques
have
already made possible accurate DNA diagnosis of a number of debilitating
illnesses. By pushing back the threshold of early disease detection,
DNA
diagnosis should increase therapy options and play a positive
role in personal
health management. Increased knowledge of the molecular basis of disease
should lead to therapies that treat the cause, rather than the
symptoms, of illness.
Similar techniques are now used to produce DNA
fingerprints, which are gaining
acceptance as the most definitive evidence of identity in rape, murder,
and
paternity cases.
The day is not far off when medical doctors may maintain personal
genetic
profiles of their patients, and DNA fingerprints may replace thumb-
and
fingerprints on file with law enforcement agencies. Guidelines
concerning access
to and use of this information must be rigorously enforced
to ensure protection of
individual privacy rights.
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Barbara McClintock
previewed The Search
for Life exhibit.
Building DNA Literacy
Biology, and with it, our society, has truly stepped into a new era. It is clear that
the science of DNA will increasingly generate important public policy issues. If we
indeed believe in the Madisonian concept of an informed citizenry that participates
in public decision making, then DNA literacy can no longer be considered an
esoteric pursuit.
As applications of DNA science leave the laboratories, trained personnel from
nearly every segment of society must interface with this new technology. Young
people entering the medical, agricultural, manufacturing, and even legal
professions will be expected to have a basic command of DNA science. Within the
scientific community, there is concern that shortages of researchers and
technicians will retard the growth of biotechnology and limit its full potential.
The nation's schools are the logical place to begin building a DNA literate
public. Unfortunately, biology curricula have evolved over the years by simply
cramming in more and more facts. Survey data show, for example, that the vast
majority of high school biology teachers spend most of class time lecturing from
textbooks. Yet even the textbooks they teach from are typically 5 to 10 years out of
date! Thus, at a time when scientists are embarking upon the most ambitious
project in the history of biology, students are required to memorize terms and
definitions of observational biology, a historical science of little relevance to current
research or society.
Survey data also tell us that the majority of elementary school students are
enthusiastic about science; however, student interest in science decreases dramati-
cally through the junior and senior high school years. This suggests that young
people are not turned off to science itself, but to the manner in which it is taught.
Children start their lives as natural scientists. Turning over a rock is an expression
of a seemingly innate curiosity about the living world. Rather than building upon
this natural interest, formal science education effectively squelches young people's
interest in science.
Experience-based learning-like the child's rock-turning inquiry-has long been
touted as the means to increase student interest and comprehension of science.
However, fewer and fewer biology students are given the opportunity for any sort
of meaningful laboratory experience, let alone "advanced" experiments with DNA.
It is a sad fact that biology education has changed little from the days of our
grandparents. Hands-on laboratories are the exception; rote memorization is the
norm.
The excitement of the Human Genome Project offers an important opportunity
to reorganize public biology education. Now is the time to sweep clean the granny
closet of biology education to make room for the excitement of modern biology-
to replace recitation of facts with frequent laboratory investigation. It is time to let
the awesome beauty of the DNA molecule integrate biological phenomena for
young people as it has for the last two generations of scientists.
Laboratory Field Trips to the Bio2000 Teaching Laboratory
We live in an age when young people are buffeted by all manner of distractions
that keep them from pondering the mystery of life. Students socialized to be
fascinated by money, and what it can buy, have little time for physics or
metaphysics. However, in working directly with DNA, the molecule of life, we may
have the last decent chance to interest young people in the intellectual pleasure
and social relevancy of that wonderful mystery. Thus, as plans were made for
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renovation of the Learning Center, priority was given to creating a teaching facility
where hands-on laboratory experiences could be offered to the public. Designed
to accommodate 24 participants, the Bio2000 Laboratory was conceived as a
model teaching facility of the 21st century. Anticipating that we could never service
all the people interested in doing a DNA manipulation lab, we had a glass
window-wall installed between the Bio2000 Laboratory and the adjacent "observa-
tion room:' We hope soon to add a closed-circuit television system, with monitors
in both the laboratory and observation room, that will enable lab participants and
observers to have a close-up view of the instructor's demonstrations.
In developing a laboratory field trip program, our aim was to put modern DNA
technology within the reach of precollege science students and teachers. Lab
experience gives the student a working knowledge of the possibilities and
limitations of DNA technology, which is the basis for rational evaluation of the
social and personal implications of biotechnology. Practical experience with DNA
techniques, which until recently have been the sole province of researchers,
reinforces that student experiments have current relevance and are "real science':
For the motivated student, a DNA lab experience encourages information-seeking
behavior, such as independent reading and research. The laboratory field trip also
affords instructors a "micro-teaching" experience, giving them a nonthreatening
exposure to DNA lab technology. Observing the Learning Center staff interact with
their own students provides convincing proof that it is indeed possible for real
students to perform DNA experiments.
The laboratory field trip program was initiated in spring of 1988, following
completion of the Bio2000 Laboratory. The program was an immediate success;
every lab space has been continuously booked since that time, with a standing
waiting list of 30 schools. Two laboratories are currently offered:
Bacterial Transformation. This experiment illustrates the direct link between an
organism's genetic complement (genotype) and its observable characteristics
(phenotype). Students introduce a new gene into the bacterium Escherichia coli,
giving it the ability to grow in the presence of the antibiotic ampicillin. Teachers
take culture plates back to their schools for incubation and discussion of results.
The Bio2000 Laboratory,
under renovation below, is
visited by 2,800 students
each year, including these
from Hillcrest High School in
Jamaica, Queens. (Photo by
Mort Kelman.)
DNA Restriction Analysis. This experiment demonstrates that DNA can be
precisely manipulated and that it behaves as predicted by the structure discovered
by Watson and Crick in 1953. Students use restriction enzymes to cut purified
DNA, and the resulting fragments are separated according to size using gel
electrophoresis. Students take home Polaroid snapshots of their results.
In an era when fewer teachers have the time or equipment to offer meaningful
lab experiences, the laboratory field trip program is a model for a cost-effective
means to provide pooled laboratory resources to a local region. The Bio2000
Laboratory has functioned at full capacity since the day it opened, serving 2800
students (160 classes) in its first year of operation. A DNA teaching lab like ours
can be equipped for $10,000-20,000, and a field trip program can be operated at
a cost of $30,000-50,000 per year (exclusive of utilities and facility overhead). By
making routine the performance of several lab experiences, museums, regional
science centers, vocational technology centers, and "magnet" schools can at once
take up the slack in laboratory teaching and help to train teachers for independent
instruction.
DNA Laboratories Come of Age
Over the years, we have fought the contention of many educators that DNA
manipulation labs are too esoteric, too expensive, or too difficult for the high
school setting. There is now growing conviction that such laboratories are, in fact,
essential to a general biology education. This sentiment has been legitimized by
the Educational Testing Service, which will recommend teaching bacterial transfor-
mation and DNA restriction analysis labs in the 1989-1990 Advanced Placement
(AP) syllabus. These labs will likely become compulsory for AP students in
1993-1994.
As early as 1985, we were training local Long Island teachers to perform these
experiments in the high school classroom. So, foresighted Long Island teachers
will have been doing these labs as much as a decade before the majority of
American biology teachers. Surely the students of these teachers have been
similarly ahead of their college-bound peers.
Our experience with rural schools in Alabama and public schools in New York
City indicates that DNA laboratories need not be confined to gifted high school
students. Labs are perhaps even more important to the nongifted student, for
whom involvement of several senses increases chances for internalization of the
biological concepts. These students may possess greater manual dexterity, and
achieve comparable or better results, than their academically gifted peers.
Success with a laboratory manipulation may provide a handle with which the
nongifted student can pull a theoretical concept into his or her realm of
experience.
In spring 1989, we conducted a learning experiment that supports our
contention that there is no intrinsic reason why young people should not be given
the opportunity to try their hands at DNA manipulation labs. Eighteen gifted fifth
and sixth graders from local school districts were invited into the Bio2000 for a
Saturday laboratory program called "Fun with DNA." During two introductory
sessions, the youngsters observed and categorized Drosophila mutations,
analyzed inheritance of kernel characteristics in corn, used classmates' trait data
for a ministudy on population genetics, constructed models of DNA molecules,
and learned to handle sophisticated micropipets. In the final session, the students
successfully performed the DNA restriction analysis described above.
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We found that the students' grasp of concepts was comparable to or better than
that of many of the high school students we have taught. Working with these
eager and inquisitive young scientists was at once invigorating and saddening:
invigorating, because it showed us the full measure of childhood thirst for
understanding of the natural world, and saddening, because we can only wonder
in how precious few of these the spark of science will be kept alive through the
remainder of their precollege schooling.
Vector DNA Science Workshops
The silver Vector vans that crisscross the country during the summer to give in-
service training to high school and college instructors have become the identifying
emblem of the DNA Literacy Program. Our successful DNA Science Workshop
arose from a collaboration with eight neighboring school districts on Long
Island-the Cold Spring Harbor Curriculum Study. These schools were used as a
proving ground to develop a laboratory curriculum that illustrates the basic
techniques of molecular genetics. Using equipment identical to that found in
research laboratories, participants performed nine experiments that culminate in
the production and analysis of recombinant-DNA molecules. The laboratory
protocols were initially tested in spring 1985, and during that summer, the first
training workshop was offered to introduce local high school
teachers to the
curriculum.
Enthusiasm from participants and interest from numerous educators around the
country suggested the desirability of making the workshop available to teachers
nationwide. Through a grant from Citibank, N.A., the first Vector
van was
purchased and equipped. In summers 1985 and 1986, a total of
266 educators
attended eight workshops.
Receipt in 1987 of major 3-year grants from the National Science Foundation
and the Josiah Macy, Jr. Foundation lent legitimacy to the proposition
that it is
indeed possible to "backpack" a DNA laboratory to
essentially anywhere in the
nation. These grants provide key support for our teaching staff, as
well as stipend
and travel expenses for workshop participants. They also
allowed us to initiate a
program of weekend follow-ups during the fall and winter to
keep up the interest of
participants and introduce teaching innovations.
Recognizing the educational value of this workshop
experience, the State
University of New York at Stony Brook agreed to offer a
credit option to Vector
workshop participants nationwide. Teachers who complete
both a workshop and
follow-up are eligible for three graduate credits from
the Continuing Education
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"Fun with DNA" marked our
first venture into primary
science education. These
gifted 5th and 6th graders
were the youngest group of
students ever to perform a
restriction analysis. The
National Science Foundation
has challenged science edu-
cators to focus attention on
improving grade school
science.
Senior Staff Scientist Ed
Harlow gave a student
lecture on "Recessive On-
cogenes," focusing on
the childhood cancer,
retinoblastoma.
Department. A workshop has been held at the Stony Brook campus each summer
since 1987, sponsored by the University's Center for Biotechnology.
Demand for courses in 1987 was great enough to justify the purchase of a
second Vector van that enables two workshops to be taught simultaneously in
different parts of the country. In summer 1987, 307 educators attended 14
workshops around the country. Two additional workshops were conducted for
technicians and researchers at the Cleveland Clinic. Nearly 250 teachers were
instructed by us at 13 sites in 1988.
The Evaluation Program
Through fall 1989, we have instructed nearly 1100 high school and college instruc-
tors in DNA The majority of these individuals completed both
a pre-survey at the beginning of the workshop and a post-survey at the end of
their week-long training experience. In fall 1988, we began a mail survey to follow
up on all teachers who had completed the workshop prior to 1988. The response
of our "alumni" was overwhelming; 90% returned completed surveys. The good
response was in large part due to adhering strictly to a detailed formatting
guideline and to a series of follow-up mailings extending over 2 months.
We have just begun the arduous task of entering this mass of data for computer
analysis. The amount of information is staggering-each case may have up to 280
bits of data. Furthermore, the amount of data increases each year, as we add new
cases and follow up on a new class of "alumni." The total number of cases will
increase by nearly one third in winter 1989, when we add some 300 teachers who
have independently taught our workshop in collaborative programs in North
Carolina, California, and Wisconsin.
By the end of 1989, we will have comparable data on nearly 1600 teachers who
have taken the DNA Science Workshop over the last 5 years. Taken together,
these data represent a substantial sampling of lead biology teachers nationwide
and perhaps the most ambitious long-term study of high school biology teachers
ever undertaken. From their responses, we hope to determine the characteristics
of the "pioneer" teachers who will spearhead biotechnological literacy. We are
especially interested in learning how lead teachers seek information and overcome
constraints in converting positive attitudes about molecular biology into innovative
teaching behavior.
Our data represent a treasure to be used and shared by opinion researchers
and educators nationwide. However, we have only begun to scratch the surface of
this load of data; layer after layer of insights remain to be revealed. Currently, we
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do not have sufficient staff time to do justice to the task. We do, however, have the
nucleus of a strong evaluation team to carry on this and other educational
research. Dave Mick los combines the perspective of a communication researcher
with past experience in opinion research with a major public relations firm. John
Kruper, who is using part of the survey data as the basis of his doctoral disserta-
tion at the University of Illinois at Chicago, brings an educational perspective. We
now need to locate specific funding to develop a full-time evaluation unit that
focuses on the interface of biotechnology and society.
Initiating a Collegiate Vector Program
Our experience over the past 4 years has strengthened our conviction that the
DNA Science Workshop is equally valuable to college teaching faculty who have
little or no practical experience in molecular genetic analysis. In 1986 and 1987, a
total of 28 college faculty teachers participated in our program. Follow-up survey
data, collected in 1988, indicate that they were excited about their experience, and
most have already begun to implement laboratories from the workshop into their
teaching.
Our first workshop geared specifically to college teachers was held at Bethany
College in West Virginia in June, 1989. This workshop was supported by a grant
from the National Science Foundation to Bethany College and was attended by
faculty members from a consortium of eight small colleges from West Virginia,
Ohio, and Pennsylvania. Positive feedback from this workshop reinforced our belief
that the information needs of college instructors are not far different from those of
the high-caliber AP teachers we have regularly encountered. We envision the
Bethany workshop as a model for a nationwide series of workshops patterned
after our successful high school program.
Colleges and universities provide infrastructures conducive to implementing
experiments introduced during the DNA Science Workshop. The entire course
can serve as the core of a sophomore-level molecular biology course, or individual
experiments can be integrated at various levels into the biology curricula, including
courses on general biology, cell biology, microbiology, genetics, and biochemistry.
Costs to equip and supply a DNA teaching laboratory are well within the means of
most college biology departments.
Two-day workshops at regional meetings of the American Society of Microbiol-
ogy (ASM) provide another means for introducing our hands-on approach to
college educators nationwide. The success of workshops held in Seattle, Washing-
ton and Valley Forge, Pennsylvania in 1988 prompted us to expand our
collabora-
tion to five sites in 1989-East Lansing, Michigan; Louisville,
Kentucky; Denver,
Colorado; Houston, Texas; and Minneapolis, Minnesota.
Educational Collaborations
The Curriculum Study has grown to include 20 Long Island school
districts, which
receive numerous benefits, including lectures by scientists, reduced
admission to
Learning Center programs, teacher in-service workshops,
and equipment
purchase options. Curriculum Study teachers gain an insider's
view of current
biological research and of the future of modern biology teaching.
As the Curricu-
lum Study continues to grow, we strive to provide a
support system for pioneer
teachers on Long Island, who are retooling biology
education for the next century.
Through our collaboration with the Josiah Macy, Jr.
Foundation, we have
extended our teacher-training and student programs to
Macy-sponsored schools in
inner-city New York and New Haven, Connecticut,
as well as in rural Alabama
and
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Arizona. In summer 1988, minority/rural students and teacher chaperones
representing each of the Macy-sponsored programs convened for a 2-week
workshop at Tuba City, Arizona, within the Navajo Indian Reservation. The first
week of the workshop provided a microteaching experience, where students and
their instructors learned DNA manipulation techniques in preparation for
implementing specialized laboratory courses at their home schools. During the
second week, the focus expanded to natural history, geology, and cultural
anthropology. In addition to tours of the natural wonders of the Grand Canyon and
Monument Valley, and ancient Indian ruins at Wapatki National Monument and
Canyon de Chelly, the students also experienced Native American culture first-
hand during a 2-day "live-in" with Navajo families. In summer 1989, the format was
repeated, this time relying on the cultural offerings of New York, including the
Metropolitan Museum, Bronx Zoo, Museum of Natural History, Broadway, and the
New York Mets.
Another ongoing collaboration is with the Macy BioPrep program at the
University of Alabama, at Tuscaloosa, where a DNA Science Workshop has been
held each year since 1987. With our assistance, the BioPrep staff has outfitted their
own Vector van, which carries DNA restriction and bacterial transformation
experiments to schools in rural Alabama. Since spring of 1988, the mobile
laboratory has visited 39 schools, where BioPrep teachers have instructed 1300
students.
Through our collaboration with the Macy BioPrep Program, we continue to
explore creative means to advance biology instruction in the many resource-poor
schools in rural America. Beginning in summer 1989, we will provide laboratory
instruction over the TI-IN United Star Network. This partnership between public
education institutions and private enterprise uses satellite technology to bring live
instructional programs to 750 schools in 32 states. The initial three-part broadcast
on bacterial transformation, described above, should give AP teachers nationwide
the confidence to rapidly introduce this experience into their laboratory program.
In several states, educational consortia have adopted our workshop as a
mechanism for introducing teachers to the techniques of DNA manipulation. In
many other locations, aspects of our workshop are being implemented one step at
a time, as equipment and supplies become available.
The 1986 workshop held at the University of California at Davis prompted the
creation of a state-supported instructional program. With funding from the National
Science Foundation, a mentor/teacher program was established at San Francisco
State University to give high school teachers training in recombinant DNA
techniques and access to working researchers who serve as their mentors. Our
workshop is taught at three locations in northern California each year, and they
In addition to students, DNA
analysis labs are offered to
special interest groups.
Assistant Director Mark
Bloom interprets a DNA
gel with seniors from
Farmingdale University.
have also "cloned" our Vector van approach to teaching. A minivan supplied by
Genentech, Inc.-dubbed Helix I-carries equipment to participating schools,
where teachers and some 600 students have performed DNA experiments.
A 1987 workshop, conducted in cooperation with the North Carolina Biotechnol-
ogy Center, provided the initial impetus for what has become the nation's most
extensive state-supported program in molecular biology education. Lead teachers,
selected from throughout North Carolina, were trained at the 1987 workshop and
then returned to their regions to assist local scientists in conducting eight local
workshops in summer 1988 that reached an additional 172 teachers. The program
also makes available, on a rotating basis, 24 equipment sets to help teachers
begin to implement DNA laboratories. In 1988, some 100 schools, representing
nearly a third of the schools in the state, used an equipment set. One small
measure of the program's success is the case of Celeste Posey, a senior at the
North Carolina School of Science and Mathematics, who, working under the
mentorship of a teacher trained at the 1987 workshop, took fifth place in the 1989
Westinghouse Talent Search.
Another ongoing collaboration is with the Institute for Genetics Education at the
University of Wisconsin-Madison, where the DNA Science Workshop is one of
several modules devoted to the study of genetics and its ethical implications.
Reception of the workshop in 1988 was so enthusiastic that it has become a
standard part of the Institute's summer program.
Materials Development
Our goal has been to modify current research protocols to minimize expense while
maximizing safety and reproducibility in the teaching laboratory. However, we strive
to maintain the integrity of research methods so that novices need not relearn
techniques as they progress to advanced lab work or to a research setting.
Experiments are not reduced to the "add A to B" mentality that pervades some
laboratory experiences and effectively obscures the process of science. For
example, we have learned that having controls performed by every lab team is
essential to student interpretation and to sorting out anomalies that invariably arise.
The success of our DNA Science protocols lies in their extensive testing and
refinement over a long period of time. A deceptively large amount of fine
adjustment is required to effectively transfer research techniques into the
classroom. Thus, research biologists may encounter difficulties when they attempt
to transfer their own protocols and reagents into the teaching
laboratory. Molecular
biology professors who run training workshops for the North
Carolina program
have been impressed by the consistent results obtained
with the DNA Science
protocols.
In our quest to make the DNA Science course as nearly foolproof as
possible,
we have gone as far as to develop new plasmids-named simply
pAMP and
PKAN. Restriction digests of these plasmids yield restriction fragments
of markedly
different sizes, making gel interpretation straightforward.
They are highly amplified
in E. coil, giving consistent yields in minipreparations.
These are, to our
knowledge, the only DNA molecules specifically
engineered for educational
Purposes. Many teachers have indicated that time for setup
and preparation is
now the most serious constraint to teaching DNA laboratories.
Their
H
need for one-
stop shopping" and quality-assured reagents led us to
collaborate with the
Carolina Biological Supply Company, which distributes all
reagents and equipment
necessary to perform the experiments in our
lab/text. A range of product options
is offered-from bulk reagents, to multi-use reagent systems,
to throwaway kits.
395
Eye-catching banners
crafted by Jan Eisenman of
Laurel Hollow.
Executives from biotechnol-
ogy and health care com-
panies, pictured here with
Banbury Center Director
Jan Witkowski (second
from left), performed a
lab as part of the Baring
Brothers conference on
immunology.
We regularly test lab equipment to assess appropriateness for student use, and
we are collaborating with suppliers to design and adapt equipment to meet the
cost and safety requirements of the education marketplace. For example, we
helped to test the first ultraviolet transilluminator designed with student use in
mind. Our collaboration with Carolina Biological has resulted in the production of
low-cost electrophoresis equipment. A colony transformation kit developed at the
DNA Learning Center is proving to be very popular among high school biology
teachers and should make it easier for large numbers of AP teachers to perform
this recommended experiment.
We plan to develop a second set of laboratory exercises that articulate with and
build upon those introduced during the DNA Science Workshop. These
experiments will be published in a second edition of our DNA Science lab/text
planned for publication in 1991. Envisioned as the basis for a second-level course,
the new protocols will introduce three powerful techniques of molecular biology-
Southern hybridization, DNA sequencing, and polymerase chain reaction (PCR). In
each case, we will collaborate with a corporate partner that has specific expertise
in the technology and work with them to optimize research-grade kits.
In spring 1989, we began a collaboration with United States Biochemical
Corporation and Perkin-Elmer Cetus to develop PCR for educational purposes. Of
great interest is a kit that would allow students to amplify a segment of their own
DNA. We regard this as an ideal "entry level" experience in DNA manipulation,
combining the involvement of an individually performed experiment with the
economy of an instructor demonstration. Although students prepare their own
DNA, student samples are run together in separate lanes of an agarose gel. Thus,
one or at most two gels would be necessary for an entire class.
We also recently joined with the National Air and Space Administration (NASA)
on a unique project that combines the latest in space and biotechnology. The
SEEDS Project-for Space Exposed Experiment Developed for Students-began
in 1984, when 12.5 million tomato seeds were delivered into low Earth orbit by the
Space Shuttle. The flight seeds will be retrieved in 1989 and, together with
ground-based control seeds, will be distributed to more than 50,000 classrooms
nationwide in the spring of 1990. Students in grades 5 through 12 will have the
opportunity to design, execute, and interpret their own experiments using these
unusual specimens. Our participation will include training a team of NASA
education specialists in PCR and gel electrophoresis so that they can train
teachers to analyze the DNA from their "space seeds" to look for cosmic-ray-
induced mutations.
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Exhibit Development
In preparation for our museum/teaching function, more than $400,000 was
expended in 1987-1988 to entirely revamp the heating, air conditioning, and
electrical systems of our 1925 schoolhouse; to renovate laboratory, exhibit, and
office space; and to upgrade parking. A world-class museum program was
inaugurated with the installation of The Search for Life: Genetic Technology in
the 20th Century, on loan from the National Museum of American History of the
Smithsonian Institution. We now face the challenge of designing and executing
new exhibits, revolving around the Human Genome Project, that must be readied
to replace the Smithsonian exhibit.
The establishment of the Exploring the Human Genome exhibit at the DNA
Learning Center will mark one of the first major efforts to spark public imagination
about this important endeavor. Cold Spring Harbor Laboratory is an especially
fitting host for such an exhibit. The Laboratory's director, James Watson, was the
codiscoverer of the structure of DNA and is associate director of the National
Institutes of Health in charge of the Human Genome Project.
Exploring the Human Genome Exhibit
Our exhibit will approach the genome project from the standpoint of potential
gains in understanding the genetic basis of human disease. Although there are
more than 3000 known inherited diseases of humans, the causative gene has
been identified for only a fraction of these. Mapping disease genes to their exact
locations on the chromosomes will facilitate diagnosis, and determining the
genetic instructions they encode should lead to improved therapies. The exhibit
will focus on several genetic diseases, including thalassemia, sickle cell
anemia, muscular dystrophy, Burkitt's lymphoma, familial colon cancer, retino-
blastoma, Alzheimer's disease, manic depression, and Huntington's disease-
which illustrate different molecular mechanisms of disease. This case study
approach will allow the visitor to learn about both genetic disease and methods
of molecular genetic analysis.
Installation of the The
Search for Life exhibit
required major renovation of
our building, which was built
in 1925 as the grade school
of Cold Spring Harbor
Village.
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DNA Detective/DNA Diagnosis
The natural variability of human life-eye color, hair color, body features, and
physical and mental abilities-is determined by genetic instructions encoded in
DNA molecules that make up the chromosomes of our cells. Thus, it is not
surprising that biologists have identified specific chromosomal regions where the
chemical structure of the DNA molecule varies from person to person. Such
variable regions are called DNA polymorphisms-for "many forms': Like physical
traits, DNA polymorphisms are passed on from parent to child in a Mendelian
fashion. The ultimate expression of individual identity, DNA polymorphisms are
now revolutionizing forensic medical science, paternity determination, and disease
diagnosis.
The DNA Detective/DNA Diagnosis exhibit and the DNA manipulation laborato-
ries are the first elements of a coordinated interpretive program on the Human
Genome Project that captures the importance and excitement of human molecular
genetics. The exhibit, which emphasizes the interaction of science and society, is
situated adjacent to the Bio2000 Laboratory, where hands-on experiments
emphasize the methods of science.
The exhibit consists of five Formica-laminated modules-two video modules and
three case modules. The video modules, each containing a television monitor,
confront visitors as they enter the exhibit area. A short video cycles continuously
on each monitor, presenting the scientific basis of DNA polymorphisms and the
steps involved in making a DNA fingerprint.
Each case module consists of three back-lit visual displays that highlight an
actual case study involving DNA fingerprinting. Using a montage of photographs
and newspaper reports, the first display presents the facts of the case and sets the
stage for the DNA fingerprint data. The second display is composed of tempered
glass panels with the stylized DNA fingerprints of individuals involved in the case.
The observer slides the panels to juxtapose fingerprints: A match results in an
obvious color and pattern change of the overlapping "bar codes':
We intend to develop new cases throughout the year, rotating them into the
exhibit on a regular basis. The serialization of cases and the ease of exchanging
case materials between one or more modules make it cost effective to create a
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rotating "gallery" of DNA fingerprint cases. The Technology Center in Silicon Valley,
San Jose, California, plans to install a unit for its opening in 1990, and several
other museums have expressed serious interest. The initial cases illustrate various
applications of DNA fingerprinting and historical precedents in law, medicine, and
society:
Ghana Immigration Case (1985). In this case, DNA fingerprints were used to
prove the family relationship between an English woman and her child, who
wished to emigrate from Ghana. This was the first use of DNA fingerprints in a
court of law. Original case materials were provided by Alec Jeffreys, University of
Leicester.
Murder at Rodman Dam (1988). DNA fingerprints were used to help convict the
suspect in a double murder/rape case. This was the first case involving DNA
fingerprint evidence in which the death penalty was handed down. Original case
materials were provided by Cellmark Diagnostics and the Florida State Attorney's
Office.
DNA Diagnosis of Muscular Dystrophy (1988). This case shows one of the first
uses of DNA fingerprints in family genetic medicine. The inheritance of a DNA
polymorphism, linked to a causative gene for muscular dystrophy, is traced from
"carrier" mother to affected son.
Exploring the Uses of Multimedia
In the last several decades, we have witnessed the virtual perfection of several
audiovisual technologies: television, video, computers, and random-access laser
discs. Taken alone, none has lived up to its potential as a teaching tool. This is
because each learning exercise is only as good as its creator. To the extent that
the producer's or programmer's conceptual framework for linking ideas overlaps
that of the learner, the presentation will be more or less successful.
Recently, computer researchers have begun to explore methods to link these
computo-audiovisual technologies into a flexible system that potentially allows
individuals to structure their own learning experience. Multimedia can essentially
be thought of as an extension of "windows" technology that allows one to access
and display information, from several different sources,
simultaneously on a single
screen.
The multimedia network consists of an array of stored audiovisual
and textual
information-an information field-and a set of computer-encoded decision
points
at intersections of pathways through that field. A command issued at a
decision
point (by keyboard or mouse) allows one to select a pathway and to rapidly
access information stored at addresses along that pathway.
Textual information is
retrieved from storage in the computer's random-access
memory, and audiovisual
information is retrieved from an optical laser disc. The information
is presented on
a high-resolution television monitor.
The open-endedness of the learning experience
increases with the number and
connectivity of decision points. By choosing their own pathways
to explore the
information field, individuals may structure the learning experience
according to
their own p references of information use. Thus, it is
plausible that the pathway
individuals take through an information field in some way
mirrors the cognitive
structure they use to make sense of the world.
For example, some people
may
prefer an analytic pathway, where one begins with
general information and
progresses to specific information. Others may prefer
a synthetic pathway,
beginning with specific information and progressing to
the more general.
DNA Detective/DNA
Diagnosis is the first major
exhibit designed by the staff
of the DNA Learning Center.
(Photos by Mort Kelman.)
The combination of multimedia with parallel distributed processing (PDP) offers
even more tantalizing prospects for education. There has been initial success in
creating PDP systems that function in a manner analogous to the human nervous
system. These simple neural networks can "learn" to identify patterns of input
information, for example, words and shapes.
If a person's choices at various decision points in a multimedia information field
are input into a neural network, could it then use these choices as feedback to
predict the person's best learning path through that field? After extrapolating a
Feedback Predicted Learning Path, could the neural network then direct the
multimedia computer to structure (edit) the available information into a personal-
ized learning experience that might even be more effective than one selected by
the individual? This is possible, considering that without foreknowledge of every bit
of stored information and its access points, individuals must wind their way
through the information field. In this sense, periodic input to the neural network
would produce a Feedback Corrected Learning Path that would, at the least,
straighten out some bends and avoid dead ends.
As yet, multimedia systems are not being widely used in educational or museum
settings. This is partly due to the fact that every system is essentially custom-made,
and development costs are not trivial. Therefore, we hope to set up a facility like
the Apple Multimedia Lab in San Francisco to explore the uses of computer/video
disc interfacing in science education. The insights we gain and the programs we
develop will serve as models for other science educators. In conjunction with a
multimedia laboratory, we hope to set up a student laboratory with 10-15 student
stations. Here, students would work with computer programs for DNA sequence
analysis and molecular modeling to perform simulations of laboratory procedures
and to participate in the testing and development of multimedia productions.
Staff
In June 1988, Mark Bloom was promoted to Assistant Director of the DNA
Learning Center in recognition of his dedication to the program. Mark remains
primarily responsible for the smooth running of our laboratory teaching programs.
including the Vector workshops and the Bio2000 Laboratory. Greg Freyer,
currently an assistant professor at Columbia University College of Physicians &
Surgeons, continues to supply the specially designed DNA molecules used in our
workshops and, together with Mark, conducts research to translate the techniques
of molecular biology to the teaching environment.
We were fortunate to obtain the services of John Le Guyader as our new
education manager. John comes to us from the Woodmere Academy, where he
taught advanced placement biology. He has research experience at the State
University of New York at Stony Brook and is an adjunct professor at Dowling
College. Arriving in November, John quickly assumed the burden of instructing
our daily lab class visits. His background and enthusiasm make him an ideal
manager of our Bio2000 teaching laboratory and strengthen our understanding of
the problems facing today's biology educators. The teaching load was also
lightened by the arrival of part-time volunteer Kelly Flynn. She is a perfect addition
to our teaching staff, with a degree in biology from Cornell University and
experience in the laboratory of Amar Klar, a former CSHL staff scientist.
In January 1989, Susan Zehl left the Laboratory's Public Affairs Department tojoin our permanent staff as designer. Sue came to Cold Spring Harbor Laboratory
in 1985 as a photographic intern for Public Affairs and began a full-time position
as photographer/artist following her graduation from The Cooper Union in 1986.
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While a member of the Public Affairs Department, Sue played an important part in
the development of the DNA Literacy Program. She has already launched us into
the age of computer-aided design, using our Sun computer and plotter to
generate exhibit concepts and artwork for our textbook, DNA Science: A First
Course in Recombinant-DNA Technology.
Interns, ranging from high school juniors to graduate students, provide critical
assistance to our teaching staff. Deserving special mention are John Kruper and
Jeff Mondschein. John, who is completing his doctorate in science education at
the University of Illinois at Chicago, has had primary responsibility for our
evaluation program, which tracks the many hundreds of teachers who have partici-
pated in Vector workshops over the years. Jeff, who is currently in the pre-med
program at New York University, was the first DNA gypsy, traveling coast-to-coast
with the first Vector tour in 1986. He was joined in summer 1988 by Ken
La Montagne, a native of Williston Park, presently a senior at James Madison
University in Virginia. Lab aides Steve Malloy and Chris Inzarillo, both juniors at
Cold Spring Harbor High School, have been key to the smooth functioning of the
Bio2000 Laboratory.
In summer 1988, we bid farewell to Ellen Gene Skaggs, who departed to Israel
with her husband Jesse. Seemingly possessed of two sets of arms, she with calm
Precision administered the Curriculum Study and Vector workshop
programs at a
time when they were cottage industries of the Public
Affairs and Development
Department. She, more than anyone else, is responsible
for building the "family"
feeling that has made our small group so productive. We miss
her every day.
Anne Zollo, gamely stepped in to fill Ellen's shoes and has managed
to clear up
the residual confusion left from having moved our office
quarters too many times
in a single year. She contributes greatly to the smooth operation
of the Learning
Center-juggling travel schedules, appointments, and reservations
and maintaining
daily contact with educators nationwide.
The opening of the DNA Learning Center to the general public
also required
organizing a group of volunteers to administer our museum
program. Besieged by
new responsibilities, we gratefully accepted the help of Anne
Meier and Sandy
Ordway to solicit and coordinate the participation of
volunteers. With their help
and that of the other volunteers, the DNA Learning Center
is growing. striving to
reach its potential as an "exploratorium of DNA."
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DNA Learning Center staff
and associates (left to right)
John LeGuyader, David
Mick los, Greg Freyer, Susan
Zehl, John Kruper, and
Mark Bloom.
Volunteer directors Sandy
Ordway and Anne Meier in
the bookstore, which was
renovated with funds
provided by the Banbury
Fund of Lloyd Harbor.
PUBLICATIONS
Kwong, A., J. Kruper, and N. Frenkel. 1988. Herpes simplex virus
host shutoff function. J. Virol. 62: 912.
Mick los, D. 1988. The first hundred years: A history of man and
science at Cold Spring Harbor. (Video) Cold Spring Harbor
Laboratory, New York.
Micklos, D. 1988. Making the American public DNA literate. In
Proceedings of Biotech USA, 5th Annual Conference, San
Francisco, California.
Micklos, D. and M. Bloom. 1988. DNA transformation of
Escherichia coll. Carol. Tips 51.
Micklos, D. and M. Bloom. 1988. A laboratory introduction to DNA
restriction analysis. In Proceedings of the Association for
Biology Laboratory Education, 9th Annual Meeting,
Minneapolis.
Preiss, J., D. Cress, J. Hutny, M. Morrell, M. Bloom, T Okita, and
J. Anderson. 1988. Regulation of starch synthesis: Biochem-
ical and genetic studies, Biocatalysis in agricultural biotech-
nology. ACS Symp. Ser. 39.
Curriculum Study Membership 1988-89
Cold Spring Harbor Central School District
Commack Union Free School District
East Williston Union Free School District
Great Neck Public Schools
Half Hollow Hill Central School District
Harborfields Central School District
Herricks Union Free School District
Huntington Union Free School District
Jericho Union Free School District
Lawrence Public Schools
In Press, Submitted, and In Preparation
Kruper, J. 1989. The computer in the biotechnology classroom.
Biotechnology Education (Submitted.)
Micklos, D. and M. Bloom. 1989, DNA restriction analysis. Carol.
Tips 53.
Micklos, D. and G. Freyer 1989. DNA science: A first course
in recombinant DNA technology. Cold Spring Harbor
Laboratory Press, New York. (In press.)
Micklos, D. and G. Freyer 1989. A laboratory introduction to DNA
restriction analysis. Biotechnology Education (in press).
Locust Valley Central School District
Manhasset Public Schools
Northport-East Northport Union Free School District
North Shore Central School District
Oyster Bay-East Norwich Central School District
Plainview-Old Bethpage Central School District
Portledge School
Port Washington Union Free School District
Sachem Central School District at Holbrook
Syosset Central School District
VECTOR WORKSHOP SITES 1985-89
ALABAMA University of Alabama, Tuscaloosa
ARIZONA Tuba City High School
CALIFORNIA University of California, Davis
CONNECTICUT Choate Rosemary Hall, Wallingford
FLORIDA University of Florida, Gainesville
GEORGIA Fernbank, Inc., Atlanta
ILLINOIS Argonne National Laboratory, Chicago
Wheaton College*
INDIANA Butler University, Indianapolis
IOWA Drake University, Des Moines
KENTUCKY Murray State University
MANITOBA Red River Community College, Winnipeg
MARYLAND Annapolis Senior High School
McDonogh School, Baltimore
MASSACHUSETTS Beverly High School
Dover-Sherborn High School
Randolph High School, Boston
Winsor School, Boston
MICHIGAN Michigan State University, East Lansing*
Troy High School
MINNESOTA University of Minnesota, Minneapolis*
MISSOURI Washington University, St. Louis
NEW HAMPSHIRE St. Paul's School, Concord
NEW YORK Albany High School
Bronx High School of Science
Cold Spring Harbor High School
DNA Learning Center
Huntington High School
Irvington High School
State University, Purchase
State University, Stony Brook
NORTH CAROLINA
Wheatley School, Old Westbury
OHIO
North Carolina School of Science, Durham
PENNSYLVANIA
Cleveland Clinic
Duquesne University, Pittsburgh
Germantown Academy, Philadelphia
SOUTH CAROLINA
Gwenyde Mercy College, King
of Prussia*
Medical University of South Carolina,
Charleston
TEXAS
University of South Carolina, Columbia
VERMONT
University of Houston*
VIRGINIA
Champlain Valley Union High
School
WASHINGTON
Jefferson School of Science,
Alexandria
WEST VIRGINIA
Department of Public Health, Seattle*
WISCONSIN
Bethany College
Marquette University,
Milwaukee
University of Wisconsin, Madison
*Two-day workshop, all others five days.
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1988
1986
1987
1989
1989
1986, 1987
1988
1987
1987
1988
1989
1989
1988
1986
1989
1988
1987
1989
1989
1989
1989
1986, 1987
1987
1987
1985, 1987
1988 (3), 1989
1986
1986
1989
1987, 1988, 1989
1985
1987
1987
1988
1988
1988
1988
1988
1989
1989
1987
1988
1989
1986, 1987
1988, 1989



Postgraduate Courses
The summer program of Postgraduate Courses at Cold Spring Harbor Laboratoryis aimed at meeting the special need for training in interdisciplinary subjects that
are either so new or so specialized that they are not adequately treated by
universities. Our aim is to provide intensive study in the most recent developments
and techniques in these subjects and to prepare students to enter directly into
research in a particular area. To ensure up-to-date coverage of current research
work, we bring together a workshop staff from many laboratories around the world
and supplement this staff with a series of seminar speakers.
Molecular Approaches to Ion Channel Function and Expression
June 3-June 23
INSTRUCTORS
Snutch, Terry, Ph.D., California Institute of Technology, Pasadena
White, Michael, Ph.D., University of Pennsylvania, Philadelphia
ASSISTANT
Stevens, Meg, B.A., Yale University Medical School, New Haven, Connecticut
The technologies of molecular biology and patch-clamping have provided major
revisions and novel approaches for the examination of many neurobiological
problems. Applications of these methods to the study of ion channels were taught
in this intensive laboratory/lecture course. Students concentrated initially on the
basic aspects of these approaches and then proceeded to more integrated
studies. Patch Clamping: cell-attached, excised patch, and whole-cell recording;
design and implementation of recording equipment; theory and analysis of ionic
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currents. Ion Channel Expression: mRNA isolation and handling; Xenopus oocytes
as an expression system; characterization of newly expressed channels in oocytes
using voltage and patch-clamp methods; monitoring changes in channel
expression in PC12 and BC3H1 cells after differentiation using electrophysiology
and Northern blot analysis. There were opportunities during the final week of the
course for students to undertake special projects of their own design using the
methods taught in the course.
PARTICIPANTS
Brink, Deidre, M.S., University of Oregon, Eugene
Brody, David, M.D., Stanford University, California
Cifuentes, Fredy, M.S., Universidad de Chile, Santiago
Huang, Chi-ming, Ph.D., University of Missouri, Kansas City
Korpi, Esa, Ph.D., Alko, Ltd., Helsinki, Finland
MacKinnon, Roderick, M.D., Brandeis University, Waltham,
Massachusetts
SEMINARS
Margiotta, J., University of California, San Diego. Regulation
of neuronal nicotinic acetylcholine receptors.
Willard, A., University of North Carolina. Ionic currents in
mesenteric neurons.
Beam, K., Colorado State University. Molecular and develop-
mental studies of muscle Ca' channels.
Levinson, S.R., University of Colorado. Role of nonprotein
domains in channel biology.
Raby, Wilfrid, Ph.D., Montreal General Hospital, Quebec,
Canada
Russek, Shelley, B.A., Leder le Laboratories, Pearl River
New York
Soravia, Emilia, M.D., National Institutes of Health, Bethesda,
Maryland
Stengl, Monika, M.S., University of Arizona, Tempe
Horn, R., Roche Institute of Molecular Biology. Perforated
patch recording.
Claudio, T., Yale University. Stable transfection of acetylcho-
line receptors in mammalian cell lines.
Sahley, C., Yale University. Behavioral and cellular analysis of
learning or What are all those channels for?
Stevens, C.F., Yale University. What's so exciting about
glutamate receptors?
Molecular Embryology of the Mouse
June 3-June 23
INSTRUCTORS
Beddington, Rosa, Ph.D., ICRF, Oxford, England
Robertson, Liz, Ph.D., Columbia University, New York, New York
CO-INSTRUCTORS
Lovell-Badge, Robin, Ph.D., National Institute for Medical Research, London, England
McMahon, Andy, Ph.D., Roche Institute of Molecular Biology, Nutley, New Jersey
ASSISTANTS
Cooke, Lesley, University of Cambridge, England
McMahon, Jill, M.A., Roche Institute of Molecular Biology, Nutley, New Jersey
This course was designed for molecular biologists, biochemists, and cell biologists
interested in applying their expertise to the study of mouse embryonic develop-
ment. Lecture and laboratory components of the course emphasized both the
practical aspects of working with mouse embryos and the conceptual basis of
current embryonic research. The following procedures and their potential applica-
tions were described: isolation and culture of preimplantation and postimplantation
embryos; embryo transfer; establishment, culture, and manipulation of embryo-
derived stem cell lines; germ layer separation; chimera formation; nuclear
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transplantation; microinjection of DNA into eggs; retroviral infection of embryos;in situ hybridization; immunofluorescence and immunoperoxidase techniques.
PARTICIPANTS
Bucan, Maja, Ph.D., Imperial Cancer Research Fund,
London, England
Cheah, Kathryn, Ph.D., Hong Kong University
Downs, Karen, Ph.D., University of California, San Francisco
Hardeman, Edna, Ph.D., Childrens Research Foundation,
Camperdown, Australia
Harris, Thomas, M.S., Albert Einstein College, Bronx,
New York
Johnson, Gary, Ph.D., University of Massachusetts, Amherst
Lee, Se-Jin, B.A., Johns Hopkins University, Baltimore,
Maryland
SEMINARS
Avner, P., Pasteur Institute. Genetic resources.
Hogan, B., Vanderbilt University. Extraembryonic membranes
and extracellular molecules.
Rudd le, F., Yale University. Mouse homeobox genes.
Wassarman, P, Roche Institute of Molecular Biology.
Fertilization.
Mintz, B., Fox Chase Center. Development of the pigmentary
system.
Jaenisch, R., Whitehead Institute. Retroviruses and
development.
Bradley, A., Baylor College. Genetic manipulation of
embryonic stem cells.
Papaioannou, G., Tufts University. Developmental mutants.
Williams, D., Children's Hospital, Boston. Hematopoietic stem
cells.
Clark, S., Genetics Institute. Hematopoietic growth factors.
Petersen, A., Ludwig Institute. Development of the peripheral
nervous system.
Lendahl, Urban, Ph.D., Massachusetts Institute of Technol-
ogy, Cambridge
Norton, Pamela, Ph.D., Massachusetts Institute of Technol-
ogy, Cambridge
Pey, Roxana, M.S., University of Chile, Santiago
Sandhu, Faheem, B.A., University of Rochester, New York
Stewart, A. Francis, Ph.D., German Cancer Research Center,
Heidelberg
Sutton, Paul, B.A., University of Illinois, Urbana
White law, Emma, Ph.D., University of Oxford, England
Sapienza, C., Ludwig Institute. Imprinting and its
implications.
Cepko, C., Harvard Medical School. Retroviral analysis of
neural lineages.
Calof, A., Tufts University. Early development of the central
nervous system.
Rossant, J., Mt. Sinai Hospital. Chimaeras in development.
Costantini, F, Columbia University. Analysis of globin genes
using transgenic mice.
Hanahan, D., Cold Spring Harbor Laboratory. Transgenics
and oncogenesis.
Struhl, G., Columbia University. Drosophila development.
Chalfie, M., Columbia University. C. elegans development.
Jeffreys, B., University of Texas, Austin. Ascidian
development.
Klar, A., Cold Spring Harbor Laboratory. Imprinting in yeast.
Solter, D., Wistar Institute. Nuclear transplantation and
imprinting.
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Advanced Bacterial Genetics
June 3-June 23
INSTRUCTORS
Berget, Peter, Ph.D., Carnegie Mellon University, Pittsburgh, Pennsylvania
Maurer, Russ, Ph.D., Case Western Reserve University, Cleveland, Ohio
Weinstock, George, Ph.D., University of Texas School of Medicine, Houston
ASSISTANTS
Barrett, B. Kyle, B.S., Carnegie Mellon University, Pittsburgh, Pennsylvania
Cardaman, Richard, B.S., Case Western Reserve University, Cleveland, Ohio
Heath, Joe Don, B.S., University of Texas School of Medicine, Houston
This laboratory course demonstrated genetic approaches that can be used to
analyze biological processes and their regulation, as well as detailed
structure/function relationships of genes. Techniques that were covered included
isolation, complementation, and mapping of mutations; use of transposable
genetic elements; construction of gene fusions; cloning and manipulation of DNA;
and DNA sequencing. The course consisted of a set of experiments incorporating
most of these techniques, supplemented with lectures and discussions. The aim
was to develop in students the ability to design a successful genetic approach to
any biological problem.
PARTICIPANTS
Brun, Yves, M.S., University Laval, Quebec, Canada
Caces, Maria Luz, M.S., University of Hawaii, Honolulu
Damon, Inger, B.A., University of Connecticut, Farmington
Dicker, Ira, Ph.D., E.I. du Pont de Nemours & Company,
Wilmington, Delaware
Hitchcock, Penny, M.S., University of Tennessee, Memphis
Jenal, Urs, B.S., ETH, Zurich, Switzerland
Kaempf, Charlotte, Ph.D., Cornell University, Ithaca,
New York
Khosla, Chaitan, B.S., California Institute of Technology,
Pasadena
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Krishnan, B. Rajendra, Ph.D., Carleton University, Ottawa,
Canada
Libby, Stephen, Ph.D., Kansas State University, Manhattan,
Kansas
Lobo, Denise, M.S., Institut de Biologie, Paris, France
Muir, Susie, Ph.D., Research Institute of Scripps Clinic,
La Jolla, California
Pierce, Margaret, Ph.D., Oklahoma State University, Stillwater
Puziss, John, B.S., University of North Carolina, Chapel Hill
Radstrom, Peter, M.S., Biomedical Center, Uppsala, Sweden
Zeef, Leo, B.S., Leiden University, The Netherlands
SEMINARS
Ausubel, F, Harvard Medical School. Regulation of nitrogen
fixation gene expression in Rhizobium and its relation to
general models of signal transduction in prokaryotes.
Malloy, S., University of Illinois. Genetic analysis of protein
structure and function-Mutations that define the active
site of proline permease of Salmonella.
Shapiro, L., Columbia University College of Physicians &
Surgeons. Temporal and spatial regulation of gene
expression during Caulobacter development.
McClelland, M., University of Chicago. Enzymology for
pulse-field mapping of bacterial genomes.
Schuman, H., Columbia University. Genetics of Legionella
pathogenicity.
Molecular Neurobiology of Human Disease
June 5-June 15
INSTRUCTORS
Black, Ira B., M.D., Cornell University Medical Center, New York, New York
Breakefield, Xandra 0., Ph.D., E.K. Shriver Center and Harvard Medical School, Boston,
Massachusetts
Gusella, James, F., Ph.D., Massachusetts General Hospital and Harvard Medical School,
Boston
This intensive seminar course explored the molecular and cellular basis of
abnormal neural function. It focused on basic scientific studies that have provided
insight into the etiology and pathogenesis of neurologic and psychiatirc diseases.
Emphasis was also placed on new techniques in neuroscience and molecular
genetics that should provide additional insights. Topics included Molecular
pathology of neurotransmitter derangement; Developmental plasticity and choice
of neurotransmitter phenotype; Synthesis and regulation of neuropeptides; Cellular
events in neural regeneration and brain transplantation; Neural pathways involved
iin pain syndromes; Genetic linkage analysis using DNA polymorphisms; Defects in
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DNA repair; Activation of one genes and genetic homozygosity in neural tumors;
Mutations causing the Lesch-Nyhan syndrome and possible means of gene
therapy; Biochemistry of the lipidoses; Autoimmune diseases; Brain imaging and
metabolism; Epilepsy and seizure disorders; Cell death in degenerative disorders;
Viral infections of the nervous system; Experimental models of learning and
memory.
PARTICIPANTS
Alsobrook, John, M.S., Yale University, New Haven,
Connecticut
Borasio, Gian, M.D., Max-Planck-Institut, Martinsried, Federal
Republic of Germany
Chirwa, Sanika, M.S., University of British Columbia,
Vancouver
Cohen, Maurice, Ph.D., Abbott Laboratories, Abbott Park,
Illinois
Ezzedine, Dia la, M.S., E.K. Shriver Center, Boston,
Massachusetts
Fischer Walter, B.S., University of Lund, Sweden
Freimer, Nelson, M.D., Columbia University, New York,
New York
Gardella, Joseph, B.S., State University of New York, Stony
Brook
Giuffra, Luis, M.D., Yale University, New Haven, Connecticut
Godbout, Martin, Ph.D., Scripps Clinic and Research
Foundation, La Jolla, California
Gomez, Maria del Filar, M.D., Boston University,
Massachusetts
Hemperly, John, Ph.D., Becton Dickinson and Co., Research
Triangle Park, North Carolina
SEMINARS
Rossant, J., Mt. Sinai Hospital. Creating animal models
using embryonic cells.
Evans, G., Salk Institute. Transgenics-Cell ablation studies.
Sanes, J., Washington University. Retrovirus-Cell lineage
studies.
Coleman, D., Columbia University College of Physicians &
Surgeons. Biogenesis of myelin membrane.
Milner, R., Salk Institute. Genetic defects in myelin.
Lee, W.H., University of California, San Diego. Retino-
blastoma gene and protein.
Mechler, B., Johannes Guttenburg University. Drosophila
cancer gene.
Anderson, R., Massachusetts Institute of Technology. Visual
cortex and modeling.
Roses, A., Duke University Medical Center. Myotonic
dystrophy.
Ray, P, Hospital for Sick Children. Duchenne's muscular
dystrophy.
Gravel, R., Hospital for Sick Children. Genetic defects in
lysosomal enzymes.
Woo, S., Baylor College of Medicine. Molecular basis and
population genetics of PKU.
McNamara, J.0., Duke University Medical Center. Epilepsy.
Dingledine, R., University of North Carolina. NMDA
receptors.
Uhl, G., National Institute of Drug Abuse. Receptor distribu-
tion in brain.
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Hingorani, Vijay, Ph.D.. University of Illinois, Chicago
Lock, Christopher, B.S., Imperial Cancer Research Fund,
London, England
Melmer, Georg, Ph.D., Hospital for Sick Children, Toronto,
Canada
Nagy, Thomas, B.S., University of Calgary, British Columbia
Pollack, Nancy, M.S., Emory University, Atlanta, Georgia
Qiu, Feihua, M.D., Memorial Sloan-Kettering Cancer Center,
New York, New York
Raymond, Vincent, Ph.D., Salk Institute, San Diego,
California
Rubin, Michael, Ph.D Columbia University, New York, New
York
Saraiva, Maria, Ph.D., Universidade Do Porto, Portugal
Wang, Samuel, B.S. Stanford University, Pacific Grove,
California
Watson, Bracie, M.S., Howard University, Washington, D.C.
Welch, Mary, Ph.D., Boehringer Mannheim Corp.,
Indianapolis, Indiana
Price, R., Memorial Sloan-Kettering Cancer Center. AIDS in
CNS.
Wexler, N., Columbia University. Molecular and human
aspects of Huntington's disease.
Schwarcz, R., Maryland Psychiatric Research Center. Cell
death in Huntington's disease.
Aguayo, A., Montreal General Hospital. Regeneration in the
adult mammalian CNS.
Rakic, P, Yale University School of Medicine. Cell migration
and the Hiroshima blast.
Fields, B., Harvard Medical School. Molecular basis of
neurotropism.
Stevens, J., University of California, Los Angeles. Herpesvi-
rus pathogenesis of latency.
Davies, P, Albert Einstein College of Medicine. Alzheimer's
disease protein.
Gurney, M., University of Chicago. Neuroleukin.
Chao, M., Cornell Medical School. Growth factors.
Mc Geer, P, University of British Columbia.
Neuroimmunology.
Gage, F., University of California School of Medicine,
La Jolla. Brain transplantation.
Raichle, M.E., Washington University School of Medicine.
PET
Filipek, P, Massachusetts General Hospital. MRI-based
morphometric analyses.
Developmental Neurobiology
June 17-July 1
INSTRUCTORS
Goodman, Corey, Ph.D., University of California, Berkeley
Patterson, Paul, Ph.D., California Institute of Technology, Pasadena
The aim of this lecture course was to review established principles and recent
advances in developmental neurobiology. Major topics considered were prolifera-
tion, migration, and aggregation of nerve cells; factors influencing the differentia-
tion of neurons; trophic interactions in neural development; patterns, gradients and
compartments; genetic programs for development; the guidance of axons
to
targets; and the formation of synaptic connections. Particular emphasis was
given
to synapse formation and to mechanisms underlying the specificity of
this process.
Finally, the operation of developmental principles was
examined in the context of
the mammalian visual system and in the development of learning and
behavior.
PARTICIPANTS
Baron, Margaret, Ph.D., Harvard University, Cambridge,
Massachusetts
Basler Konrad, B.S., University of Zurich, Switzerland
Dudek, Serena, B.S., Brown University, Providence, Rhode
Island
Grenningloh, GE:brie le, Ph.D., University of Heidelberg,
Federal Republic of Germany
Harel, Adrian, M.S., Weizmann Institute, Rehovot, Israel
Hart, Anne, B.S., University of California, Los Angeles
Hill, Caryl, Ph.D., Australian National University, Canberra
Hopkins, Nancy, Ph.D., Massachusetts Institute of
Technology, Cambridge
Howard, Kenneth, Ph.D., Columbia University. New York,
New York
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Hynes, Mary, Ph.D., Columbia University, New York,
New York
Kalb, Robert, M.D., Yale University, New Haven, Connecticut
Lugo, Ana, B.S., University of Puerto Rico, Rio Piedras
Moore, Robert, B.S., National Institute for Medical Research,
London, England
Mundy, Nicholas, M.A., University College London, England
Nawa, Hiroyuki, Ph.D., California Institute of Technology,
Pasadena
Pickford, Lesley, B.S., Stanford University, California
Placzek, Marysia, Ph.D., Columbia University, New York,
New York
SEMINARS
Shatz, C., Stanford Medical School. Neurogenesis, migration,
and synaptogenesis in the mammalian visual system.
Cepko, C., Harvard Medical School. Retroviruses and
lineage in the CNS.
Hatten, M.E., Columbia University Medical School. Migration
in the embryonic CNS.
Raft, M., University College London. Glial lineages in the
CNS.
Rubin, G., University of California, Berkeley. Development of
the Drosophila eye.
Chalfie, M., Columbia University. Neural development in the
nematode.
Anderson, D., California Institute of Technology. Neural crest
differentiation.
.
Intracellular mechanisms of trophic factors.
Landmesser, L., University of Connecticut. Axon guidance in
vertebrates.
Neurobiology of Drosophila
Rovelli, Giorgio, M.S., Friedrich Miescher Institute, Basel,
Switzerland
Sabry, James, M.D., California Institute of Technology,
Pasadena
Tonegawa, Susumu, Ph.D., Massachusetts Institute of
Technology, Cambridge
Viereck, Christopher, M.S., Friedrich Miescher Institute,
Basel, Switzerland
Wilson, Stephen W., Ph.D., University of Michigan, Ann
Arbor
Rutishauser, U., Case Western Reserve University. Adhesion
molecules in the nervous system.
Jessell, T., Columbia University Medical School. Mechanisms
of specificity in the embryonic spinal cord.
Fraser, S., University of California, Irvine. Development of
retinotectal specificity.
Bonhoeffer, F., Max-Planck-Institut, Tubingen. Surface
molecules and retinotectal connections.
Sanes, J., Washington University Medical School. Develop-
ment of the neuro-muscular junction.
Purves, D., Washington University Medical School. Synaptic
specificity and rearrangement in the PNS.
Kandel, E., Columbia University Medical School. Learning
and plasticity of connections in invertebrates.
Nottebohm, F., Rockefeller University. Learning and plasticity
in the bird song system.
June 26-July 16
INSTRUCTORS
Bate, Michael, Ph.D., University of Cambridge, England
Campos-Ortega, Jose, M.D., Ph.D., University of Cologne, Federal Republic of Germany
Palka, John, Ph.D., University of Washington, Seattle
ASSISTANTS
Brand, Michael, M.S., University of Cologne, Federal Republic of Germany
Hannaford, Susanah, B.S., University of Washington, Seattle
This laboratory/lecture course provided an introduction to current research in
neuronal function and development in Drosophila. It was intended for researchers
at all levels who may want to use Drosophila as an experimental system for
studying neurobiology, taking advantage of the genetic and molecular techniques
that are so highly developed for this organism. The course included a crash
course on Drosophila genetics and other techniques that make Drosophila
research distinctive, such as cytogenetics and DNA transformation. The main
emphasis, however, was on studies of the nervous system.
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The course covered basic electrophysiological techniques, as applied to
mutants with altered ion channels or sensory physiology. It also included mutant
analysis of complex behaviors, such as courtship, circadian rhythms, learning, and
memory. In the developmental section, processes of neurogenesis, including
determination and pathway formation, were examined. The course familiarized
students with various preparations, including the embryonic nervous system,
imaginal discs, and adult nervous system. It also reviewed the different
approaches being used in attempts to unravel the molecular basis of neural
development.
PARTICIPANTS
Awad, Timothy A., B.S., University of Washington, Seattle
Bay lies, Mary K., B.A., Rockefeller University, New York,
New York
Bonini, Nancy, Ph.D., University of Wisconsin, Madison
Delgado, Ricardo, B.S., Universidad de Chile, Santiago
Malsch, Paul L., M.S., Kansas State University, Manhattan
Pflugfelder, Gert, Ph.D., Universitat WOrzburg, Federal
Republic of Germany
SEMINARS
Aldrich, R., Stanford University. on channels in Drosophila.
Elkins, T, University of California, Berkeley. Adhesion
molecules.
Rutledge, Barbara J., Ph.D., Harvard University, Cambridge,
Massachusetts
Steele, Fintan R., M.A., University of Notre Dame, Indiana
Ungar, Anne R., B.A., Northwestern University, Evanston,
Illinois
White, Kristin, Ph.D., Massachusetts Institute of Technology,
Cambridge
Fischbach, K.-F., University of Freiburg. Brain anatomy and
mutants.
Ganetzky, B., University of Wisconsin. Drosophila genetics.
Hall, J., Brandeis University. Behavior and its genetic
analysis.
Hartenstein, V., University of California, San Diego.
Neurogenesis.
Hartley, D., Yale University. Molecular biology of neurogenic
mutants.
Hoy, R., Cornell University. Behavior and evolution.
Orr-Weaver T, Massachusetts Institute of Technology. Germ
line transformation.
Ready, D., Purdue University. Eye morphogenesis.
Rubin, G. M., University of California, Berkeley. How to clone
interesting genes.
Technau, G., University of Cologne. Cell transplantation.
Timpe, L., University of California, San Francisco. Cellular
neurophysiology.
Truman, J.W., University of Washington. Postembryonic
neurogenesis.
Molecular and Developmental Biology of Plants
June 26-July 16
INSTRUCTORS
Maliga, Pal, Ph.D., Advanced Genetic Sciences, Oakland, California
Messing, Joachim, Ph.D., Waksman Institute, Rutgers University, Piscataway, New Jersey
Sussex, Ian, Ph.D., Yale University, New Haven, Connecticut
ASSISTANTS
Cruz-Alvarez, Marilyn, Ph.D., Waksman Institute, Rutgers University, Piscataway, New Jersey
Elliston, Keith, B.S., Waksman Institute, Rutgers University, Piscataway, New Jersey
Harper, Elizabeth, B.S., Advanced Genetic Sciences, Oakland, California
McGonigle, Bryan, Yale University, New Haven, Connecticut
Miller, Ellen, M.S., Yale University, New Haven, Connecticut
This course provided an intensive overview of current topics and techniques in
plant biology, with emphasis on molecular and developmental biology and
genetics. It was designed for scientists with a working knowledge of molecular
techniques who are either working with plant systems or wish to. The course
consisted of a rigorous lecture series, a hands-on laboratory, and informal
discussions. Different guest speakers provided both an in-depth discussion of their
work and an overview of their specialty, as well as informal discussions after their
seminars. The laboratory covered established and novel techniques in plant
biology, including plant structure and development, nucleic acid manipulations,
gene transfer techniques, tissue and cell culture techniques, photosynthesis, and
genetics and cytogenetics of maize.
PARTICIPANTS
Benvenuto, Eugenio, Ph.D., ENEA, Rome, Italy
De Verna, Joseph, Ph.D., Campbell Institute, Davis, California
Gallagher, Jane, Ph.D., City College of New York, New York
Graner, Andreas, Ph.D., Institut fur Resistenzgenetik.
Gruenbach, Federal Republic of Germany
Handley, Levis, Ph.D., Westvaco Corp.. Summerville, South
Carolina
Irish, Vivian, Ph.D., Yale University, New Haven, Connecticut
Johnson, Sheila, B.S., University of California, Davis
Kreiberg, Jette, Ph.D., Aarhus University, Denmark
Mahoney, Deborah, B.A., Princeton University, New Jersey
Moneger, Francoise, M.S., Universite Joseph Fourier,
Grenoble, France
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Paul, Cynthia, Ph.D., Rockefeller University, New York.
New York
Pecker, Iris, M.S., Hebrew University, Jerusalem
Sadosky. Alesia. B.S., Pennsylvania State University,
University Park
Shiraishi, Hideaki. Ph.D.. National Institute, Okazaki, Japan
Vioque, Agustin, Ph.D., Universidad Autonoma, Madrid,
Spain
Waibel, Franz. Ph.D., Friedrich Miescher Institute, Basel,
Switzerland
SEMINARS
Horsch, R., Monsanto Co. Transformation systems for plants.
Mottinger, J., Rhode Island University. Classical and
molecular methods for mapping genes to chromosomes.
Nelson, T, Yale University. C3 and C4 photosynthesis gene
expression.
Tobin, E., University of California, Los Angeles. Light
regulation of photosynthesis genes.
Quatrano, R., E.I. du Pont de Nemours & Company. Polarity
induction in Fucus zygotes.
Gruissem, W., University of California, Berkeley. Fruit
ripening molecular biology.
Levings III, C., North Carolina State University. Mitochondrial
genomes and male sterility.
Poethig, S., University of Pennsylvania, Genetic and clonal
analysis of corn.
Theologis, S., Plant Gene Expression Center. Hormone-
regulated gene expression.
Chum ley, F and B. Sheperd, E.I. du Pont de Nemours &
Company. Rice blast disease-Biology and molecular
biology.
Meyerowitz, E., California Institute of Technology.
Arabidopsis- Genes, genome organization, mutants.
Rogers, S., Monsanto Co. Molecular biology of the gemini
viruses.
Bernatzky, R., University of Massachusetts. Restriction
fragment length polymorphism mapping in plants.
Klein, E., Plant Gene Expression Center. Transformation with
the particle gun.
Whalen, M., University of California, Berkeley. Interactions of
plants with their pathogenic bacteria.
Gillham, N., Duke University. Chlamydomonas chloroplast
genetics and transformation.
Crouch, M., Indiana University. Developmental biology of
pollen.
Meinke, D., Oklahoma State University. Developmental
biology and genetic analysis in Arabidopsis.
Dellaporta, S., Yale University. Genetic and molecular
analysis of the R locus in maize.
Molecular Cloning of Eukaryotic Genes
June 26-July 16
INSTRUCTORS
Alt, Fred, Ph.D., Columbia University, New York, New York
Roberts, Thomas, Ph.D., Dana Farber Cancer Institute, Boston,
Massachusetts
Yancopoulos, G., M.D., Ph.D., Columbia University, New
York, New York
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ASSISTANTS
Ma, Avaril, M.D., Columbia University, New York, New York
Morgan, William, B.S., Dana Farber Cancer Institute, Boston, Massachusetts
Oltz, Eugene, Ph.D., Columbia University, New York, New York
This laboratory and lecture course covered the principles of recombinant DNA
technology and the application of these procedures to the study of eukaryotic
genes. The isolation and characterization of lymphocyte specific genes were
emphasized. Among the topics covered were the construction of cDNA libraries in
plasmid or bacteriophage A vectors, construction of bacteriophage A and cosmid
libraries of high-molecular-weight eukaryotic DNA, screening DNA libraries with
gene-specific hybridization probes, purification and characterization of recombinant
clones using restriction endonuclease and blot hybridization analyses, and
reintroduction and expression of cloned genes in heterologous systems. Strategies
for isolating genes that encode rare mRNA sequences were discussed. Guest
lecturers discussed the application of molecular cloning procedures to the study of
specific eukaryotic gene systems.
PARTICIPANTS
Albino, Tony, Ph.D., Memorial Sloan-Kettering Cancer Center,
New York, New York
Biddle, Fred, Ph.D., Alberta Children's Research Center,
Canada
Bierer, Barbara, M.D., Dana Farber Cancer Institute, Boston,
Massachusetts
Brannon, Patsy, Ph.D., University of Arizona, Tempe
Cheng, Hazel, Ph.D., University of Toronto, Ontario, Canada
Coffey, Robert, M.D., Vanderbilt University, Nashville,
Tennessee
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Dahl, Karen, M.D., Yale University Medical School. New
Haven, Connecticut
Fletcher, Jacqueline, Ph.D., Oklahoma State University,
Stillwater
Gahl, William, Ph.D., National Institutes of Health, Bethesda,
Maryland
Gil ly, William, Ph.D Stanford University, Pacific Grove,
California
Johnson, Thomas, Ph.D., University of California, Irvine
Kornecki, Elizabeth, Ph.D., University of Vermont, Burlington
Larsson, Catharina, M.D., Karolinska Hospital, Stockholm,
Sweden
Simpson, Paul, M.D., VA Hospital, San Francisco, California
SEMINARS
Aruffo, S., Massachusetts General Hospital. Techniques for
cloning mammalian cell surface proteins.
Ferrier, P and K. Blackwell, Columbia University. Gene
transfer-Techniques to study Ig gene recombination.
Harlow, E., Cold Spring Harbor Laboratory. E1A complexes
with the retinoblastoma protein.
McKnight, S., Carnegie Institution. Purification and cloning of
mammalian transcription factors.
Hood, L., California Institute of Technology. /g gene
superfamily-New advances in molecular genetic
technologies.
Cantor, C. and C. Smith, Columbia University. Large-scale
genome mapping.
Goff, S., Columbia University. Retroviral genetics.
Hanahan, D., Cold Spring Harbor Laboratory. Transgenic
systems as models for oncogenesis.
Wig ler, M., Cold Spring Harbor Laboratory. Oncogenes/
signal transduction.
Kellems, R., Baylor College of Medicine. Molecular genetics
of ADA.
Tucker P., Southwestern Medical Center. Control of Ig gene
expression.
Stevenson, Mary, Ph.D., Montreal General Hospital, Canada
Stutman, Osias, M.D., Memorial Sloan-Kettering Cancer
Center, New York, New York
Sakano, H., University of California, Berkeley. Purification of
proteins involved in Ig recombination.
Mulligan, R., Whitehead Institute. The Complete Angeler.
Shapiro, L., Columbia University. Control of bacterial gene
expression.
Okayama, H., National Institutes of Health. Expression
cloning.
Gitsier, J., University of California, San Francisco. PCR and
molecular genetics.
Tsukamoto, A., University of California, San Francisco. Int-1
tumorigenesis in transgenic mice.
Weissman, I., Stanford University. Molecular genetics of a
reconstructed immune system.
Dixon, R., Merck, Sharp and Dohme. Site-directed
mutagenesis- Beta -adrenergic receptor.
Kucherlapati, R., University of Illinois. Reverse genetics.
Piwnica-Worms, H., Dana Farber Cancer Institute. Baculovi-
rus as a tool to study oncogene function.
Robertson, L., Columbia University. Reverse genetics-Part II.
Computational Neuroscience: Motor Control
July 11-July 24
INSTRUCTORS
Atkeson, Chris, Ph.D., Massachusetts Institute of Technology, Cambridge
Bizzi, Emilio, Ph.D., Massachusetts Institute of Technology, Cambridge
ASSISTANT
McIntyre, Joe, B.S., Massachusetts Institute of Technology, Cambridge
This intensive laboratory/lecture course examined computational approaches in
the
control, with the theme that understanding of the computational
problems,
e constraints on solutions to these problems, and the range of possible
solutions
can help guide research in neuroscience.
The most prominent successes of information-processing
approaches have
tOome in areas where strong inputs from neurobiological, behavioral,
and computa-
tional approaches interact. The goals of this course were to expose students
to
areas where interdisciplinary approaches have been important and to
help
students integrate computational approaches into their own research.
The course
included a computer-based laboratory so that students could actively explore
computational issues, as well as interact with prominent
research workers in the
field.
The course focused on computational approaches to
the study
taken
f motor control
and their interactions with motor control neuroscience.
Examples w
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single- and multi-articular arm movements; body posture and locomotion; hand
control; oculomotor control; and "simpler" nervous systems. Areas addressed were
movement planning, kinematics, dynamics, control, actuation, and sensing.
PARTICIPANTS
Amos, Therese, B.S., University of Minnesota, Minneapolis
Bracewell, Robert, B.A., Massachusetts Institute of Technol-
ogy, Cambridge
Bronte-Stewart, Helen, M.S., University of Pennsylvania,
Philadelphia
Carter, Randy, M.S., Case Western Reserve University,
Cleveland, Ohio
Colgate, James, M.S., Massachusetts Institute of Technology,
Cambridge
Connor, Nadine, M.A., Speech Motor Control Labs, Madison,
Wisconsin
Cooper, Scott, B.A., Columbia University, New York, New
York
Gnadt, James, Ph.D., University of Alabama, Birmingham
Gourdon, Antoine, B.S., CNRS, Paris, France
SEMINARS
Sparks, D., University of Alabama. Role of the superior
colliculus and other brainstem areas in the control of
saccadic eye movements.
Wurtz, R., National Eye Institute. Physiology of the pursuit
system.
Hogan, N., Massachusetts Institute of Technology. Using
optimal control theory to model behavior- Minimum jerk
movements.
Flash, T., Weizmann Institute of Science. Multijoint minimum
jerk movements.
Hogan, N., Massachusetts Institute of Technology.
Impedance control.
Haggard, Patrick, B.A., Haskins Laboratories, New Haven,
Connecticut
He, Jiping, M.S., University of Maryland, College Park
Henis, Ealan, M.S., Weizmann Institute, Rehovot, Israel
Hoff, Bruce, M.S., University of Southern California, Los
Angeles
Jacobs, Robert, M.S., University of Massachusetts, Amherst
Kent, Linda, B.S., Drexel University, Philadelphia,
Pennsylvania
Shen, Liming, B.S., University of Minneapolis, Minnesota
Thompson, Clay, M.S., Massachusetts Institute of Technol-
ogy, Cambridge
Vetter, Monica, B.S., University of California, San Francisco
Watanabe, Takashi, B.S., University of Rochester, New York
Mussa- Ivaldi, F, Massachusetts Institute of Technology.
Multijoint arm studies.
Flash, T., Weizmann Institute of Science. Multijoint
simulations.
Kalaska, J., University of Montreal. Neural representations for
motor control.
Humphrey, D., Emory University Medical School. Central
control of voluntary arm and hand movements.
Hollerbach, J., Massachusetts Institute of Technology.
General tactile sensing issues, robot sensors.
Johnson, K., Johns Hopkins University. Mechanoreceptive
transduction in the hand.
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Hollerbach, J., Massachusetts Institute of Technology.
General hand control issues, robot hands.
Johansson, R., University of Umea. Utilization of tactile input
in the control of grip.
Jordan, M., Massachusetts Institute of Technology. Introduc-
tion to connectionism.
Yeast Genetics
Raibert, M., Massachusetts Institute of Technology.
Dynamics of running in robots.
Loeb, G. Queens University. Models of the cat hindlimb.
July 18-August 7
INSTRUCTORS
Hieter, Phil, Ph.D., Johns Hopkins University, Baltimore, Maryland
Rose, Mark, Ph.D., Princeton University, New Jersey
Winston, Fred, Ph.D., Harvard University, Cambridge, Massachusetts
ASSISTANTS
Gerring, Saundra, B.S., Johns Hopkins University, Baltimore, Maryland
Malone, Elizabeth, B.A., Harvard University, Cambridge, Massachusetts
Val len, Liz, M.A., Princeton University, New Jersey
The major laboratory techniques used in the genetic analysis of yeast were
studied, including the isolation and characterization of mutants, tetrad analysis,
complementation, and mitotic recombination. Micromanipulation used in tetrad
analysis was carried out by all students. Molecular genetic techniques, including
yeast transformation, gene replacement, analysis of gene fusions, and
electrophoretic separation of chromosomes, were applied to the analysis of yeast
421
DNA. Indirect immunofluorescence experiments were done to identify the nucleus,
microtubules, and other cellular components. Lectures on fundamental aspects of
yeast genetics were presented along with seminars given by outside speakers on
topics of current interest.
PARTICIPANTS
Armstrong, John, Ph.D., Imperial Cancer Research Fund,
London, England
Cardenas, Maria, Ph.D., Texas College, Fort Worth
Chan, Yuen-Ling, Ph.D., University of Chicago, Illinois
Halula, Madelon, Ph.D., Medical College of Virginia,
Richmond
Heitman, Joseph, M.S., Rockefeller University, New York,
New York
Hyman, Linda, Ph.D., Tufts University, Boston,
Massachusetts
Klis, Frans, Ph.D., University of Amsterdam, The Netherlands
Lahue, Robert, Ph.D., Duke University, Durham, North
Carolina
SEMINARS
Sternglanz, R., State University of New York, Stony Brook.
DNA topoisomerases and their roles in DNA replication
and transcription.
Kurjan, J., Columbia University. Cell-cell interaction involved
in yeast mating.
Klar, A., Cold Spring Harbor Laboratory. Yeast mating-type
interconversion.
Carlson, M., Columbia University. Glucose repression in
yeast.
Guarente, L., Massachusetts Institute of Technology. DNA
binding and transcriptional activation by three yeast
activators: HAP1, HAP2, and HAP3.
Wig ler, M., Cold Spring Harbor Laboratory. RAS control
pathways in yeast.
Hinnebusch, A., National Institutes of Health. Translational
control of transcriptional activator GCN4.
Stevens, T., University of Oregon. Genetic approaches to
vacuole protein sorting.
Prat, Annik, Ph.D., CNRS, Gif-sur-Yvette, France
Riggs, Daniel, Ph.D., University of California, San Diego
Ruusala, Tarmo, Ph.D., Yale University, New Haven,
Connecticut
Sperry, Ann, Ph.D., University of Texas, Dallas
Springer, Mathias, Ph.D., Institut de Biologie, Paris, France
Tibbetts, Michael, B.S., Wesleyan University, Middletown,
Connecticut
Weil, Peter, Ph.D., Vanderbilt University, Nashville, Tennessee
Zimarino, Vincenzo, M.D National Cancer Institute,
Bethesda, Maryland
Petes, T., University of Chicago. Meiotic recombination in
yeast.
Fink, G., Whitehead Institute. Regulation of amino acid
biosynthesis in yeast.
Sherman, F.. University of Rochester. Posttranslational
modification of cytochrome c.
Broach, J., Princeton University. Once more around the
2-micron circle.
Beach, D., Cold Spring Harbor Laboratory. Cell-cycle
regulation in yeast.
Fox, T., Cornell University. Translational control of yeast
mitochondrial genes.
Douglas, M., University of Texas Health Science Center.
Organization of the yeast nuclear pore complex.
Botstein, D., Genentech, Inc. Genetics of the yeast
cytoskeleton.
Molecular Probes of the Nervous System
July 19-August 8
INSTRUCTORS
Carlson, Steve, Ph.D., University of Washington, Seattle
Evans, Christopher, Ph.D., Stanford University, California
Levitt, Pat, Ph.D., Medical College of Pennsylvania, Philadelphia
GUEST INSTRUCTORS
Lagenaur, Carl, Ph.D., University of Pittsburgh, Pennsylvania
Pintar, John, Ph.D., Columbia University, New York, New York
ASSISTANT
Prouty, Steven, M.S Medical College of Pennsylvania, Philadelphia
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This course was designed for cell, molecular, and neurobiologists who are
interested in understanding the power and pitfalls of antibodies and nucleotide
probes as biochemical and anatomical reagents. A series of evening lectures
addressed basic and advanced immunology concepts and the use of molecular
probes to investigate current issues in neurobiology. The primary emphasis of the
course was to acquire practical laboratory experience through daily exercises
using an extensive number of techniques, including generation and characteriza-
tion of monoclonal antibodies to synthetic peptides and complex neural antigens,
immunocytochemistry, in situ hybridization, immunoassays (ELISA and RIA), affinity
chromatography, and Western blotting. Approaches that combine the use of
molecular probes were highlighted by performing expression library screening and
exercises employing double-labeling strategies. Biological assays in tissue culture
were designed to demonstrate functional relevance of specific molecules.
Computer-aided data analysis of protein and nucleotide sequences also was
introduced.
PARTICIPANTS
Abosch, Aviva, B.A., University of Pittsburgh, Pennsylvania
Allendoerfer, Karen, B.A., Stanford University, California
Brady, Linda, Ph.D., National Institutes of Mental Health,
Bethesda, Maryland
Carpenter, Melissa, B.S., University of California, Irvine
Carrithers, Michael, B.S., University of Illinois, Urbana
Goldman, Steven, Ph.D., Cornell University Medical College,
New York, New York
SEMINARS
Fleischman, J., Washington University School of Medicine.
Immunoglobulins and the Ig super family.
Roulet, D., Massachusetts Institute of Technology. T-cell
development and function.
Kearney, J., University of Alabama. B-cell development,
function, and the network theory.
Lagenaur, C., University of Pittsburgh School of Medicine.
Cell-surface interactions in neural development.
Granger, Ellen, Ph.D., Florida State University, Tallahassee
Keller, Flavio, M.D., University of Zurich, Switzerland
Mallat, Michel, Ph.D., INSERM, Paris, France
Mandell, James, B.A., Cornell University Medical College,
New York, New York
Soghomonian, Jean, Ph.D., University of Montreal, Quebec,
Canada
Trainer, Vera, M.S., University of Miami, Florida
Alt, F, Columbia University. Immunoglobulin gene
rearrangements.
Sharff, M., Albert Einstein College of Medicine. Somatic
mutations and the antibody repertoire.
Cohen, S., Hahnemann University School of Medicine.
Interleukins and growth factors of the immune system.
Schwartz, M., Weizmann Institute.
Molecular aspects of
nerve regeneration.
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Hockfield, S., Yale University School of Medicine. Molecular
aspects of synapse formation and brain organization.
Kaufman, D., University of California, Los Angeles. Molecular
cloning of neural genes.
Lindstrom, J., Salk Institute. Molecular organization of the
acetylcholine receptor.
Pintar, J., Columbia University College of Physicians &
Surgeons. Molecular aspects of pituitary development.
Advanced Molecular Cloning and Expression of Eukaryotic Genes
July 19-August 8
INSTRUCTORS
Botchan, Michael, Ph.D., University of California, Berkeley
Myers, Richard, Ph.D., University of California, San Francisco
Rio, Don, Ph.D., Whitehead Institute, Cambridge, Massachusetts
ASSISTANTS
Brodsky, Michael, B.A., University of California, San Francisco
Kaufman, Paul, B.A., Whitehead Institute, Cambridge, Massachusetts
Robbins, Alan, B.A., E I du Pont de Nemours & Co., Wilmington, Delaware
The focus of this course was on how to manipulate cloned eukaryote genes to
probe questions on expression, structure, and function. Students created and
screened both genomic and cDNA libraries from various organisms with
established, as well as experimental, protocols. A variety of transfection techniques
were used to introduce cloned DNA molecules that had been manipulated in vitro
into Drosophila and vertebrate cells in culture. As a model system for this
approach, we examined cis- and trans-acting components involved in the
regulation of eukaryote gene expression. Mutants were generated by a variety of
methods, including oligo-directed and random mutagenesis procedures. New
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methods for generating and physically isolating
mutant DNAs, as well as standardDNA sequencing techniques, were employed. Physical
methods for screening
mutant genes in cellular genomic DNA were also discussed and demonstrated.
Guest lecturers included speakers who discussed present problems in eukaryote
molecular biology, as well as technical approaches to their solutions.
PARTICIPANTS
Agrwal, Neera, B.S., Michigan State University. East Lansing
Aladjem, Mirit, B.S., Tel Aviv University, Israel
Boris, Kathleen, M.S., George Washington University,
Washington, D.C.
Giallongo, Agata, Ph.D., Istituto di Biologia dello Sviluppo,
Palermo, Italy
Griswold-Prenner, Irene, B.A., University of California Medical
Center, Los Angeles
Kagnoff, Martin, M.D., University of California, San Diego
Lasmoles, Frangoise, Ph.D., INSEAM, Paris, France
Leask, Andrew, B.S., University of Chicago, Illinois
SEMINARS
Sharp, P., Massachusetts Institute of Technology. Structure of
the transcriptional complex.
Guarante, L., Massachusetts Institute of Technology.
Transcriptional regulatory elements in yeast.
Mulligan, R., Massachusetts Institute of Technology. Gene
transfer systems.
Spradling, A., Carnegie Institution of Washington. Genetic
methods for studying meiosis in Drosophila.
Tjian, R., University Berkeley. Structure of
transcriptional factors in metazoans.
Lee, Brendan, B.S., State University of New York, Brooklyn
Lo, Donald, B.S., Yale University, New Haven, Connecticut
Powers, Maureen, B.S., University of California, Davis
Ratanavongsiri, Jitra, M.S., University of Alberta, Edmonton,
Canada
Sorrentino, Rosa, Ph.D., Universita di Roma, Italy
Teitz, Tal, M.S., Tel Aviv University, Ramat Aviv, Israel
Wefald, Franklin, M.D., Duke University, Durham, North
Carolina
Williams, Lewis, Ph.D., University of California, San Francisco
Chan, M., Cornell Medical College. Receptors in eukaryotic
cells.
Maniatis, T., Harvard University. Organization and control of
gene expression at the interferon locus.
Evans, R., Salk Institute. Steroid receptors.
Ptashne, M., Harvard University. Theoretical notions
regarding transcriptional regulation in eukaryon.
Molecular Biology of the Nervous System
July 26-August 8
INSTRUCTORS
Evans, Ron, Ph.D., Salk Institute, La Jolla, California
McKay, Ron, Ph.D., Massachusetts Institute of Technology, Cambridge
Reichardt, Louis, Ph.D., University of California, San Francisco
Zipursky, Larry, Ph.D., University of California, Los Angeles
This lecture course was designed for neuroscientists who wish to understand
the
concepts and methods of molecular biology and their application to problems in
neuroscience. The participants were drawn from a wide range of backgrounds.
The methods of recombinant DNA technology were introduced
in a series of
lectures. These were followed by lectures from visiting
faculty. The lectures
covered a variety of topics to give an overview of the molecular mechanisms
underlying the development and function of the nervous system.
PARTICIPANTS
Baron, Miron, M.D., New York State Psychiatric Institute,
New York
Blackshear Ann, Ph.D., Tennessee State University, Nashville
Bulleit, Robert, Ph.D., California Institute of Technology,
Pasadena
Buonamici, Matilde, Ph.D., Farmitalia Carlo Erba, Nerviano,
Italy
Farkash, Yigal, M.S., Hebrew University, Jerusalem, Israel
Friedman, Beth, Ph.D., Yale University, New Haven,
Connecticut
425
Gavras, Haralambos, M.D., Boston University, Massachusetts
Gladstein, Laura, B.A., University of Pittsburgh, Pennsylvania
Gullapalli, Sharada, Ph.D., Indian Institute of Science,
Bangalore, India
Hamilton, Bryan, M.S., University of Wisconsin, Madison
Hayes, Tim, M.S., Massachusetts Institute of Technology,
Cambridge
Liu, Shumo, M.S., Massachusetts Institute of Technology,
Cambridge
SEMINARS
Green, M., Harvard University. Transcription and RNA
processing in eukaryotes.
Myers, R., University of California, San Francisco. Long-
range structure of the genome.
Smith, J., National Institute of Medical Research, London.
Early steps in amphibian development.
Kater, S., Colorado State University. Regulating growth cone
function.
Reese, T, National Institutes of Health. How axons work.
Mitchison, T, University of California, San Francisco. Cell
biology of neurite extension.
Chikaraishi, D., Tufts University. Molecular biology of
catecholamine biosynthesis.
Kenyon, C., University of California, San Francisco. Molecular
genetics of nematode development.
Staunton, D., Center for Blood Research, Boston. Cell-
surface receptors in immune function.
Jesse!, T, Columbia University. Axon guidance in the
mammalian spinal cord.
Bastiani, M., University of Utah. Axon guidance in the insect
nervous system.
Marcom, Kelly, B.S., Baylor College of Medicine, Houston,
Texas
Matteoni, Rafaele, Ph.D., Center of Molecular Biology, Rome,
Italy
Smith, Martin, Ph.D., Upjohn Co., Kalamazoo, Michigan
Taplitz, Susan, Ph.D., California Institute of Technology,
Pasadena
Wang, Yonping, M.S., University of Rhode Island, Kingston
Curran, T., Roche Institute. Transcriptional regulation in the
nervous system by the fos/jun complex.
Sweatt, D., Columbia University. Mechanisms regulating
synaptic strength.
Schwarz, T, University of California, San Francisco.
Molecular biology of voltage-regulated channels.
Reed, R., Johns Hopkins University. Molecular biology of
olfaction in mammals.
Patrick, J., Salk Institute. Molecular biology of the acetylcho-
line receptor.
Zucker, C., University of California, San Diego. Visual
transduction in the insect eye.
Kennedy, M., California Institute of Technology. Biochemistry
of phosphokinases and synaptic function in the mammal.
Madison, D., Yale University. Physiology of long-term potenti-
ation in the mammalian hippocampus.
Andersen, R., Massachusetts Institute of Technology.
Network analysis of mammalian cortical function.
Molecular Cloning of Neural Genes
August 10-August 30
INSTRUCTORS
Eberwine, Jim, Ph.D., Stanford University, California
Evinger, Marian, Ph.D., Cornell University School of Medicine, New York, New York
Schachter, Beth, Ph.D., Mt. Sinai Medical Center, New York, New York
ASSISTANTS
Fox, Susan, Ph.D., New York University Medical School, New York
Inman, Irene, M.S., Stanford University, California
This intensive laboratory/lecture course was intended to provide scientists with a
basic knowledge of the use of the techniques of molecular biology in examining
questions of neurobiological significance. Particular emphasis was placed on using
and discussing methods for circumventing the special problems posed in the
study of the nervous system; for example, examination of low abundance mRNAs
in extremely heterogeneous cell populations.
The laboratory work included mRNA quantitation methods (Si assay, etc.),
preparation of hybridization probes, library construction (plasmid, Agt11 and 1ST
procedure), plaque and colony screening techniques (probe hybridization,
antibody interaction, and activity assays), DNA sequencing, eukaryotic cell
transfection, in situ hybridization, and in situ transcription. The lecture series, by
invited speakers, focused on how molecular biology techniques can be used to
supplement more standard neurobiological tools in examining the nervous system.
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PARTICIPANTS
Carbonetto, Salvatore, Ph.D Montreal General Hospital,
Canada
Chang, Alice, Ph.D., Indiana University, Indianapolis
Dame, Margaret, Ph.D., Abbott Laboratories, Abbott Park,
Illinois
Denburg, Jeffrey, Ph.D., University of Iowa, Iowa City
El-Fakahany, Esam, Ph.D., University of Maryland, Baltimore
Henderson, Christopher, Ph.D., INSERM, Montpellier, France
Jen, Joanna, B.S., Yale University, New Haven, Connecticut
Maycox, Peter, Ph.D., Max-Planck-Institute, Martinsried,
Federal Republic of Germany
McNamara, James, M.D., VA Hospital, Durham, North
Carolina
SEMINARS
Sudhof, T., Southwestern Medical College, Dallas. Molecular
structure of synaptic vesicle proteins.
Hahn, B., University of Colorado Medical Center. Gene
expression in the mammalian brain-Developmental and
evolutionary perspectives.
Curran T. and D. Cohen, Roche Institute of Molecular
Biology. Fos on the brain.
Goodman, R., Tufts University. Tissue-specific and -regulated
expression of somatostatin.
Claudio, T., Yale University. Gene transfer techniques.
Roberts, J., Mt. Sinai School of Medicine. Regulation of
neuroendocrine gene expression.
Macromolecular Crystallography
Nelson, James, Ph.D McGill University, Montreal, Quebec,
Canada
Philipson, Kenneth, Ph.D., University of California School of
Medicine, Los Angeles
Sobel, Andre, Ph.D., INSERM, Paris, France
Stretton, Antony, Ph.D., University of Wisconsin, Madison
Suen, Chen-Shian, B.S., Mt. Sinai Medical Center, New York,
New York
Turetsky, Dorothy, B.S University of California, San
Francisco
Yool, Andrea, Ph.D., Research Institute of Scripps Clinic,
La Jolla, California
Chao, M., Cornell University Medical College. Functional
expression of the NGF receptor.
Breakefield, X., E. K. Shriver Center, Boston. Molecular
biological approaches to understanding human
neurologic diseases.
Ramachandran, J., Neurex Corp. Structural basis and
functional diversity of muscarinic acetylcholine receptor
subtypes.
Neve, R., Children's Hospital, Boston. Human genes for
GAP-43 and the Alzheimer amyloid precursor protein-
Genetic and neurobiological studies.
October 6-October 19
INSTRUCTORS
Deisenhofer, Johann, Ph.D.*, University of Texas Southwestern Medical School, Dallas
Jones, Alwyn T., Ph.D., University of Uppsala, Sweden
McPherson, Alexander, Ph.D., University of California, Riverside
Pflugrath, James, Ph.D., Cold Spring Harbor Laboratory, New York
Remington, S.J., Ph.D., University of Oregon, Eugene
* 1988 Nobel Laureate in Chemistry.
Crystallography and X-ray diffraction yield a wealth of structural information
unobtainable through other methods. This intensive laboratory/computational
course focused on the major techniques used to determine the three-dimensional
structures of macromolecules. It was designed for scientists with a working
knowledge of protein structure and function, but who were new to macromolecular
crystallography. Topics that were covered included protein purification, crystalliza-
tion, crystal characterization, data collection (film and area detector methods), data
reduction, anomalous dispersion, phase determination, molecular replacement
and averaging, electron density interpretation, structure refinement, molecular
graphics, and molecular dynamics. Participants learned through extensive hands-
on experiments, informal discussions, and lectures on current applications of these
and related procedures given by outside speakers.
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PARTICIPANTS
Chandrasegaran, Srinivasan, Ph.D., Johns Hopkins
University, Baltimore, Maryland
Chen, Ying, B.S., Cornell University, Ithaca, New York
Clarke, Frank, Ph.D., Ciba-Geigy Corporation, Summit,
New Jersey
Coghlan, Vincent, B.S., University of California, Irvine
Eggleston, Drake, Ph.D., Smith Kline & French Laboratories,
King of Prussia, Pennsylvania
Forest, Katrina, B.S., Princeton University, New Jersey
Gajhede, Michael, M.D., Copenhagen University, Denmark
Knighton, Daniel, B.S., University of California, San Diego
Lyon, Mary, Ph.D., Scripps Clinic and Research Foundation,
La Jolla, California
Nol let, Kenneth, B.A., Mayo Foundation, Rochester,
Minnesota
SEMINARS
Reeke, G., Rockefeller University. Data scaling and
merging/ROCKS.
Sweet, R., Brookhaven National Laboratory. X-ray sources
and optics.
Bricogne, G., L.U.R.E., Orsay. The Fourier transform.
. The phase problem.
Hendrickson, W., Columbia University. Phasing with
anomalous dispersion.
Palenik, Gus, Ph.D., University of Florida, Gainesville
Ramakrishnan, Venki, Ph.D., Brookhaven National
Laboratory, Upton, New York
Schuller, David, B.A., Washington University Medical School,
St. Louis, Missouri
Shen, Betty, Ph.D., Argonne National Laboratory, Argonne,
Illinois
Swepston, Paul, Ph.D., Molecular Structure Corporation,
College Station, Texas
Takeda, Yoshinori, Ph.D., NCI-Frederick Cancer Research
Facility, Maryland
Twigg, Pamela, M.S., University of Alabama, Huntsville
Wardell, Mark, Ph.D., University of California, San Francisco
Saper, M., Harvard University. Molecular averaging.
Fitzgerald, F!, Merck Sharp & Dohme Research Laborato-
ries. Molecular replacement.
Hendrickson, W., Columbia University. Crystallographic
refinement.
Brunger, A., Yale University. Molecular dynamics.
Seminars
Cold Spring Harbor Seminars were initiated to provide a semiformal avenue
for
communication between the various research groups at the Laboratory. They are
particularly useful for research personnel who have joined the Laboratory during
the summer. The seminars also afford a necessary opportunity for the graduate
students and postgraduate staff to develop their skills in defending, organizing,
and presenting their research. In addition to those listed below, seminars were
given by many others involved in research at this Laboratory.
1988
January
Jinez Morata, Universidad Autonima de Madrid. Spain:
Further explorations of the bithorax complex of
Drosophila.
Mike Mulligan, Stanford University, California: Transcription,
initiation, and RNA processing in maize mitochondria.
W.M. Marzluff, University of Florida, Gainesville: Multiple
regulatory steps in histone mRNA metabolism.
Meinrad Buss linger, Genentech Inc., South San Francisco.
California: CCAAT displacement protein and the
regulation of human globin gene expression.
Lindsay Williams, EMBL, Heidelberg. Federal Republic of
Germany: Effects of polyomavirus middle T oncogene on
embryonic stem cells and chimeric mice.
Patricia Smith Church land, University of California, San
Diego: The mind as a neurobiological machine.
Gilbert Jay, NCI. National Institutes of Health. Bethesda.
Maryland: Viral oncogenes in transgenic mice- Model for
study of human cancers.
February
Sara Lavi, University of Tel Aviv. Israel: Carcinogen-induced
over-replication of SV40 in Chinese hamster cells in vivo
and in vitro.
Martyn Goulding. University of Auckland. New Zealand:
Cyclic AMP induces stable expression of c-fos in a mast
cell line.
Nicole Le Douarin, Institute d'Embryologie College de
France, Nogent-sur-marne, France: Differentiation of the
peripheral nervous system from the neural crest-Cell
determination and influence of environmental factors.
Masataka Nakamura, Institute for Virus Research. Kyoto
University, Japan: Regulation of the promoter activity of
human T-cell leukemia virus type I.
Bill Reznikoff, University of Wisconsin, Madison: The
regulation of Tn5 transposition.
Amalendra Kumar New York University Medical Center. New
York: Domain structure and RNA binding properties of
some hnRNA proteins.
Gottfried Schatz, Biocenter, Basel, Switzerland: Protein
unfolding and protein translocation across membranes.
Ann Wrinkler, University of Missouri, Columbia: Selective
recognition of higher-order snRNP complexes by
monoclonal antibodies.
Peter Peterson, Iowa State University, Ames: Structure and
function of the En transposable element system in maize.
Sung-Hou Kim, University of California. Berkeley: Three-
dimensional structure of human ras oncoprotein and its
biochemical implications.
March
Helen Brady. St. Louis University Medical Center. Missouri:
Alternative pre-mRNA processing in region E3 of
adenovirus- Evidence for competition between splicing
and polyadenylation reactions.
Judy Fox. Rockefeller University. New York, New York: GPI-
PLCs- Possible role in signal transduction.
David W. Marshak, University of Texas Medical School,
Houston: Function of neuropeptides in the vertebrate
retina.
Shamshad Cockcroft. University College. London. England:
G proteins. inositol lipid signaling pathway. and
exocytosis.
Arpad Parducz. Hungarian Academy of Science. Szeged.
Hungary: Fine structural changes in synapses during the
transmission of a single nerve impulse.
Tom Moss. Laval University. Quebec. Canada: Multiple
mechanisms of ribosomal transcription enhancement.
Tony Pryor. CSIRO. Canberra. Australia: Genetic approaches
to cloning and fine structure of a gene for rust resistance
in maize.
Michele Sawadogo. Rockefeller University. New York. New
York: Interaction of transcription factors and RNA
polymerase II with the adenovirus major late promoter.
M. Yanagida. Kyoto University. Japan: New nuclear proteins
implicated in chromosome organization and separation in
fission yeast.
Graham Tebb. EMBL. Heidelberg. Federal Republic of
Germany: Transcription of Xenopus UsnRNA genes.
Roger Brent. Harvard Medical School. Cambridge.
Massachusetts: Studying higher eukaryotic regulatory
proteins with transcription regulation in yeast.
April
Peter Fantes. University of Edinburgh. Scotland:
Chromosome function in yeast and mammalian cells.
Ed Chang. Public Health Research Institute. New York. New
York: Expression of heterologous genes in Bacillus.
Grant McFadden, University of Alberta, Edmonton, Canada:
Biology and replication of Shope fibroma virus.
Ingrid Grummt, University of Wurzburg, Federal Republic of
Germany: cis-Acting elements and trans-acting factors
involved in initiation and termination of mouse rDNA
transcription.
Kevin Brady, Indiana University, Bloomington: Chemical,
environmental, and phytopathogen stress-induced genes
in tobacco.
Nat Heintz, Rockefeller University, New York, New York:
Factors regulating histone gene expression during a cell
cycle.
Gary Ruvkun, Harvard University, Cambridge,
Massachusetts: Temporal control of the C. elegans cell
lineage by lin-14.
May
0. Prem Das, Waksman Institute, Piscataway, New Jersey: A
novel recombinational event at a storage protein locus in
maize.
Jeffrey A. Kazzaz, Case Western Reserve University,
Cleveland, Ohio: Tissue specificity of myosin heavy chain
transcripts and isoforms in Drosophila melanogaster.
Tom Dutchman, University of Wisconsin, Madison: Targeted
gene modifications in embryonic stem cells.
Robert Martienssen, University of California, Berkeley: A
nuclear gene in maize involved in photosynthetic
membrane organization and its regulation by Robertson's
mutator.
Francis Barany, Cornell University Medical College, New
York, New York: How Taql restriction endonuclease
recognizes its cognate sequence.
Christolph Mueller, Stanford University, California: Molecular
mechanism of cell-mediated cytotoxicity in vivo.
Peter Hornbeck, National Institutes of Health, Bethesda,
Maryland: Signal transduction in lymphocytes.
June
Eric Richards, Harvard Medical School, Boston,
Massachusetts: Isolation of a telomere from Arabidopsis.
Jeffrey W. Kelly, Rockefeller University, New York, New York:
Design and chemical synthesis of the lambda Cro
repressor.
M, Gerry Neuffer, University of Missouri, Columbia: Orange
pericarp in maize; filial expression in a maternal tissue.
July
Brian Hauge, Massachusetts General Hospital, Boston:
Progress toward a physical map of the Arabidopsis
genome.
Brian Gavin, Yale University School of Medicine, New Haven.
Connecticut: A GC-box-binding protein mediates
transcriptional control of the minute virus of mice P4
promoter in human and murine nuclear extracts.
Hans-Georg Simon, Max-Planck-Institute for Immunobiology,
Freiburg, Federal Republic of Germany: T-cell-specific
serine proteinase-cDNA cloning and expression of
the
gene in T lymphocytes.
Edgar Serf ling, University of WUrzburg, Federal Republic of
Germany: Functional analysis of the mouse interleukin
enhancer.
August
Robin Al !shire, MRC, London, England: From fission yeast
chromosomes to human telomeres.
Ueli Grossniklaus, Biocenter, Basel, Switzerland: Enhancer
traps in Drosophila.
Aneel Aggarwall, Harvard University, Cambridge,
Massachusetts: Structure of the 434 repressor-operator
complex at 2.5-angstrom resolution.
David A. Christopher, University of Arizona, Tucson:
Organization and expression of ribosomal protein genes
on the Euglena chloroplast genome-The presence of
novel chloroplast introns.
Walter Keller, Biozentrum, Basel, Switzerland: Processing
(splicing and 3' end formation) of nuclear mRNA
precursors in vitro.
John Leavitt, Institute for Medical Research, San Jose,
California: Use of protein profiling for molecular diagnosis
of disease.
Rodrigo Bravo, EMBL, Heidelberg, Federal Republic of
Germany: Identification of genes induced by growth
factors in mouse fibroblasts.
September
William Phares, University of California, Berkeley: Transduc-
tion of proto-src sequences in tissue culture by
transformation-defective RSV with an internal src deletion.
Stan Brown, Fred Hutchinson Cancer Research Center,
Seattle, Washington: Suppressor analysis of 4.5S RNA of
E. coli.
October
Nava Segev, Genentech, Inc., South San Francisco, Califor-
nia: The small yeast GTP-binding protein, YPT1, is
associated with secretion.
Ann Tsukamoto, University of California, San Francisco:
The
int-1 proto-oncogene in transgenic mice induces
mammary gland abnormalities and tumorigenesis.
Per Nielsen, Odense University, Denmark: Optimization of
plasma desorption mass spectrometry-Application to
protein structure.
Bengt Westermark, University of Uppsala, Sweden:
Differences in transforming activities and biological
functions of the various isoforms of PDGF.
Jeffrey Way, Columbia University, New York, New York:
Mec-3-A homeobox-containing gene that controls
neuronal development in C. elegans.
November
Rick Thompson, National Institutes of Health,
Bethesda,
Maryland: Application of an in vitro basement membrane
invasion assay to the study of human breast cancer and
Kaposi's sarcoma.
Dirk Bohmann, University of California,
Berkeley: AP-1-A
family of jun-related transcription factors.
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Alexei Ryazanov, Institute of Protein Research, Pushchino,
USSR: Phosphorylation of elongation factor 2 and its role
in the regulation of protein synthesis.
Sam Benchimol, Ontario Cancer Institute, Toronto, Canada:
Inactivation of the cellular p53 gene is associated with
Friend-virus-induced erythroleukemia.
James Lillie, Harvard University, Cambridge, Massachusetts:
Transcription activation by adenovirus E1A protein.
Henry Sadowski, University of Rochester Medical Center,
New York: Growth-factor-induced phosphorylation in
Swiss 3T3 cells.
December
Lucio Miele, National Institutes of Health, Bethesda,
Maryland: Phospholipase A2 inhibitory peptides from the
region of highest similarity between uteroglobin and
lipocortin.
John Cairns, Harvard Medical School, Boston,
Massachusetts: Spontaneous mutation.
Michael Finney, Massachusetts General Hospital, Boston:
unc-86, a C. elegans neural developmental gene, is
homologous to mammalian transcription factors.
Uli Schibler, University of Geneva, Switzerland: A biochemi-
cal approach to tissue-specific gene expression.
Richard Gibbs and Jeff Chamberlain, Baylor College of
Medicine, Houston, Texas: The polymerase chain
reaction - Recent developments and application.
Undergraduate Research
An important aspect of the summer program at the Laboratory is the participation
of college undergraduate students in active research projects under the super-
vision of full-time laboratory staff members. The program was initiated in 1959.
Since that year, 301 students have completed the course, and many have gone on
to creative careers in biological science.
The objectives of the program are to provide (1) a greater understanding of the
fundamental principles of biology, (2) an increased awareness of major problem
areas under investigation, (3) a better understanding of the physical and intellec-
tual tools for modern research and the pertinence of this information to future
training, and (4) a personal acquaintance with research, research workers, and
centers for study.
The following students, selected from well over 100 applicants, took part in the
program, which was supported by the Alfred P Sloan Foundation, Burroughs
Wellcome Fund, and Cold Spring Harbor Laboratory Funds.
Jennifer Brown, Yale University
Research Advisor: Kim Arndt
Cloning a transcription factor of the yeast HIS4 gene by
expression library screening.
Franco Carlotti, University of Cambridge
Research Advisor: Andrew Rice
Human immunodeficiency virus tat protein function.
Emily Chan, Harvard University/Radcliff College
Research Advisor: Richard Roberts
mRNA splicing extracts from mammalian tissues.
Emad Gharavi, City College of New York
Research Advisor Michael Mathews
Cloning of PCNA by screening rat and human genomic
libraries in bacteriophage A and isolation of genomic
DNA fragments.
Lisa Gloss, Michigan State University
Research Advisor: Robert Franza
Expression of three eukaryotic nuclear proteins.
Daniel Grief, Stanford University
Research Advisor: John Anderson
Purification of the myc oncoprotein.
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Ulrich Grossniklaus, University of Basel
Research Advisor: Nouria Hernandez
trans-Activation of the human U2 small nuclear RNA
promoter.
Beth Hance, Moravian College
Research Advisor: Elizabeth Moran
Activation of cellular gene expression by the adenovirus E1A
gene produCts.
Junjiro Horiuchi, Stanford University
Research Advisors: Bruce Stillman and Toshiki Tsurimoto
Isolation of putative human chromosomal origins of DNA
replication.
Seth Karp, Harvard University
Research Advisor: David Beach
Cell-cycle regulation.
Chris Leptak, Yale University
Research Advisor: David Frendewey
S. pombe mRNA splicing in vitro.
Brandon Lloyd, Grinnell College
Research Advisor: Venkatesan Sundaresan
Cell-cycle control in S. cerevisiae.
Melissa Macias, University of Texas
Research Advisor: James Pflugrath
Purification of pl3sucl.
Sharon Perez, Wellesley College
Research Advisor: Michael Gilman
Transcriptional activation of the c-fos gene.
Mia Schmiedeskamp, University of Michigan
Research Advisor: Daniel Marshak
Determination of S100B levels in chick embryo cerebral
cortex at successive stages in development.
Ann Schroeder, University of California, Davis
Research Advisor: David Spector
DHFR mRNA localization in mammalian nuclei.
Tanya Whitfield, Cambridge University
Research Advisor: Winship Herr
HIV-1 tat/tar interaction.
Albert Yan, Princeton University
Research Advisor: David Helfman
Rat tropomyosin gene control.
Nature Study Program
The Nature Study Program gives elementary and secondary school students the
opportunity to acquire a greater knowledge and understanding of their environ-
ment. Through a series of specialized field courses, students can engage in such
introductory programs as Nature Detectives, Seashore Life, and Pebble Pups, as
well as more advanced programs such as Marine Biology and Nature
Photography.
During the summer of 1989 a total of 480 students participated in the Nature
Study Program. Most classes were held outdoors, when weather permitted, or at
the Uplands Farm Nature Preserve, the headquarters of the Long Island Chapter
of the Nature Conservancy. The Laboratory has equipped and maintains
classrooms/laboratories as well as a darkroom at Uplands Farm. This facility is
used as a base for the student's exploration of the local environment. Field classes
are held on Laboratory grounds, St. John's Preserve, Fire Island National
Seashore, Caumsett State Park, the Cold Spring Harbor Fish Hatchery, and the
Muttontown Preserve, as well as other local preserves and sanctuaries. Students in
Marine Biology participated in a whale watch aboard the Finback II, operated by
the Okeanos Ocean Research Foundation Inc. Hampton Bays, New York.
In addition to the four-week courses, a series of one-day marine biology
workshops was offered to students. Studies on the marine ecology of L.I. Sound
were conducted aboard Little Jenny, a restored 19th century vessel based in
Huntington. Students were able to study the Sound chemically, physically, and
biologically using the ship's instrumentation. The three-day Adventure Education
class took students on an 18 mile bike hike to Caumsett State Park, a 12-mile
canoe trip on the Nissequogue River, and a day of sailing on Little Jenny.
PROGRAM DIRECTOR
William M. Payoski, M.A., Adjunct Professor,
Nassau Community College
INSTRUCTORS
Ruth Burgess, B.A., Cold Spring Harbor Nursery School
James Dunleavy, B.A., science teacher, St. Anthony's High School
Cheryl Littman, B.A., science teacher, Northport School District
Noah Newman, B.A., science teacher candidate
Linda Payoski, B.A., science teacher, Uniondale High School
Marjorie Pizza, B.A., science teacher, Glen Cove School District
COURSES
Nature Bugs
Nature Detectives
Advanced Nature Study
Introduction to Ecology
Frogs, Flippers, and Fins
Pebble Pups
Bird Study
Fresh Water Life
Seashore Life
Marine Biology
Nature Photography
Adventure Education
Marine Biology Workshops
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FINANCIAL STATEMENT
BALANCE SHEET
year ended December 31, 1988
4. with comparative figures for year ended December 31, 1987
,.,
oo
ASSETS
Operating Funds
Endowment &
Similar Funds
Land, Building, &
Equipment Funds
Total All Funds
Unrestricted Restricted 1988 1987
Cash and cash equivalents $4,499,218 $372,408 $382,094 $9,406,587 $14,660,307 $12,797,099
Marketable securities - 2,676,487 152,875 2,829,362 1,948,138
Accounts receivable:
Publications (less allowance for doubtful accounts
of $24,000 in 1988 and $21,000 in 1987) 230,056 - - 230,056 218,831
Other 158,657 - 158,657 84,563
Grants receivable 853,813 - 853,813 1,559,866
Accrued interest receivable 153,443 - - 79,083 232,526 268,592
Publications inventory 602,807 - - 602,807 425,832
Other assets, principally prepaid expenses 603,653 - - 603,653 349,536
Contract deposit - - 161,143 161,143 161,143
Investment in employee residences - - 747,156 747,156 938,221
Land, buildings and equipment:
Land and improvements 2,579,440 2,579,440 2,233,486
Buildings - - 21,614,551 21,614,551 20,518,291
Furniture, fixtures and equipment - 1,736,200 1,736,200 1,417,131
Laboratory equipment - - 4,550,493 4,550,493 4,318,510
Library books and periodicals - 365,630 365,630 365,630
- - 30,846,314 30,846,314 28,853,048
Less accumulated depreciation and amortization - - 9,774,795 9,774,795 8,490,284
Land, buildings and equipment, net - - 21,071,519 21,071,519 20,362,764
Construction in progress - 2,774,090 2,774,090 348,688
Total assets $6,247,834 $1,226,221 $3,058,581 $34,392,453 $44,925,089 $39,463,273
LIABILITIES AND FUND BALANCES
Operating Funds Endowment &
Similar Funds
Land, Building, &
Equipment Funds
Total All Funds
Unrestricted Restricted 1988 1987
Liabilities:
Accounts payable and accrued expenses $1,343,374 $17,478 $481,296 $1,842,148 $1,863,227
Note payable to Robertson Maintenance Fund - - 670,000 670,000
Loan payable - 4,000,000 4,000,000 6,500,000
Deferred revenue 548,806 1,208,743 - 1,757,549 1,977,048
Total liabilities 1,892,180 1,226,221 5,151,296 8,269,697 10,340,275
Fund balances:
Unrestricted 4,355,654 - - - 4,355,654 4,300,665
Endowment and similar funds - 3,058,581 3,058,581 1,937,311
Land, building and equipment:
Expended - - 20,434,689 20,434,689 18,111,309
Unexpended-Donor restricted - 7,958,695 7,958,695 3,787,934
Unexpended-Board authorized - - - 847,773 847,773 985,779
Total fund balances 4,355,654 3,058,581 29,241,157 36,655,392 29,122,998
Total liabilities and fund balances $6,247,834 $1,226,221 $3,058,581 $34,392,453 $44,925,089 $39,463,273
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CO
STATEMENT OF SUPPORT, REVENUE, AND EXPENSES
AND CHANGES IN FUND BALANCES
year ended December 31, 1988
with comparative figures for year ended December 31, 1987
Operating Funds
Endowment &
Similar Funds
Land, Building, &
Equipment Funds
Total All Funds
Unrestricted Restricted 1988 1987
Support and Revenue:
Public support-contributions and grants $638,659 $3,270,742 $1,010,449 $6,001,669 $10,921,519 $8,677,267
Government grant awards 8,102,876 - 8,102,876 6,861,271
Indirect cost allowances 5,643,433 - - 5,643,433 4,544,846
6,282,092 11,373,618 1,010,449 6,001,669 24,667,828 20,083,384
Other revenue:
Program fees 956,795 - - - 956,795 793,476
Rental income 89,658 89,658 86,501
Publications 1,640,491 - - 1,640,491 1,646,913
Dining services 1,118,037 - - 1,118,037 990,389
Rooms and apartments 544,753 - - 544,753 420,387
Distribution from Robertson Maintenance and
Research Funds 130,000 800,000 - - 930,000 925,000
Investment income 212,056 178,650 730,777 1,121,483 2,027,134
Miscellaneous 258,248 - - 138,205 396,453 70,844
Total other revenue 4,950,038 800,000 178,650 868,982 6,797,670 6,960,644
Total support ani revenue 11,232,130 12,173,618 1,189,099 6,870,651 31,465,498 27,044,028
Expenses:
Program services:
Research - 9,138,957 - - 9,138,957 8,008,814
Summer programs 549,632 1,872,226 - 2,421,858 2,278,121
Publications 1,719,187 - 1,719,187 1,449,178
Banbury Center conferences 5,574 515,529 - - 521,103 386,922
DNA Learning Center programs 4,901 358,438 - - 363,339 211,738
Total program services 2,279,294 11,885,150 14,164,444 12,334,773
Supporting services:
Direct research support 485,915 - - 485,915 504,153
Library 339,915 - - - 339,915 287,905
Operation and maintenance of plant 3,259,354 - - 3,259,354 2,945,532
General and administrative 2,890,857 - - - 2,890,857 2,017,976
Dining services 1,167,405 - - - 1,167,405 1,034,927
Interest - - 339,055 339,055 423,154
Total supporting services 8,143,446 - - 339,055 8,482,501 7,213,647
Depreciation - - - 1,286,159 1,286,159 1,126,349
Total expenses 10,422,740 11,885,150 - 1,625,214 23,933,104 20,674,769
Excess of support and revenue over expenses 809,390 288,468 1,189,099 5,245,437 7,532,394 6,369,259
Other changes in fund balances:
Transfer to unexpended plant funds (754,401) (95,000) - 849,401 - -
Capital expenditures - (261,297) 261,297 -
Transfer to restricted funds
- 67,829 (67,829)
Net increase in fund balance 54,989 - 1,121,270 6,356,135 7,532,394 6,369,259
Fund balance at beginning of year 4,300,665 - 1,937,311 22,885,022 29,122,998 22,753,739
Fund balance at end of year $4,355,654 $3,058,581 $29,241,157 $36,655,392 $29,122,998
NOTE: Copies of our complete, audited financial statements, certified by the independent auditing firm
of Peat, Marwick, Main & Co., are available upon request from the Comptroller, Cold Spring Harbor
Laboratory.
Endowments and
Similar Funds 3.5%
COLD SPRING HARBOR LABORATORY
SOURCES OF REVENUE
YEAR ENDED DECEMBER 31, 1988
Federal Grants and Contracts
41.1%
Auxiliary Activitic
13.8%
Foundation and Private
Contributions and Grants 31.5% Interest andMiscellaneous 4.3%
Corporate Contributions:
and Grants 5.8%
FINANCIAL SUPPORT
OF THE LABORATORY

SOURCES OF SUPPORT
Cold Spring Harbor Laboratory is a nonprofit research and educational institution
chartered by the University of the State of New York. Less than half of its annual
support is derived from Federal grants and contracts. Contributions from the
private sector are tax exempt under the provisions of Section 501(c)(3) of the
Internal Revenue Code. In addition, the Laboratory has been designated a "public
charity" and, therefore, may receive funds resulting from the termination of "private"
foundations.
Over the years, the Laboratory has won a reputation for innovative research
and high-level science education. By training young scientists in the latest
experimental techniques, it has helped spur the development of many research
fields, including tumor virology, cancer genes, gene regulation, movable genetic
elements, yeast genetics, and molecular neurobiology. However, the continued
development of new research programs and training courses requires substantial
support from private sources.
Because its endowment is small, because government support is highly
competitive and the uses of research grants are restricted, the Laboratory
depends upon annual contributions from the private sector; foundations, corpora-
tions and individuals for its central institutional needs.
The Second Century Campaign seeks to raise $44M in capital funds by
December 1991 for construction of new facilities, renovation of existing facilities,
and for staff and student endowment. This is the Laboratory's first public capital
campaign and it marks its Centennial.
METHODS OF CONTRIBUTING TO COLD SPRING HARBOR LABORATORY
Gifts of money can be made directly to Cold Spring Harbor Laboratory.
Securities You can generally deduct the full amount of the gift on your
income tax return,
and, of course, you need pay no capital gains tax on the stock's appreciation.
We recommend any of the following methods:
(1) Have your broker sell the stock and remit the proceeds to Cold Spring Harbor
Laboratory.
(2) Deliver the stock certificates to your broker with instructions to him to
open an account
for Cold Spring Harbor Laboratory and hold the securities in
that account pending
instructions from Cold Spring Harbor Laboratory.
(3) Send the unendorsed stock certificates directly to the Laboratory:
Comptroller, Cold
Spring Harbor Laboratory, Cold Spring Harbor, New York 11724.
In a separate
envelope send an executed stock power.
Pooled Income Funds Combine gifts from a number of donors in a
pool for attractive
investment and tax purposes.
Appreciated real estate or personal property
Sizable tax benefits can result from
such
donations; the Laboratory can use some in its program
and can sell others.
e insurance and charitable remainder trusts can be
structured to suit the donor's
pecific desires as to extent, timing, and tax needs.
Bequests Most wills probably need to be updated.
Designating Cold Spring Harbor
Labo-
ratory as beneficiary ensures that a bequest will be utilized
as specified for continuing
good.
Conversion of private foundation to "public" status on
termination
This may be one
by creating a separate fund within Cold Spring Harbor
Laboratory
whereby the assets
d
of
the private foundation are accounted for as a separate fund
and used for the purposes
"supporting
by the donor. Alternatively, the private
foundation can be established
as a
rti  organization of Cold Spring Harbor Laboratory."
For additional information, please contact the
Director of Development,
Cold Spring Harbor
Laboratory, Box 100, Cold Spring Harbor, N.Y.
11724, or call 516-367-8840.
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GRANTS
January 1, 1988-December 31, 1988
COLD SPRING HARBOR LABORATORY
Grantor Program/Principal Investigator Duration of Grant Total Award
FEDERAL GRANTS
NATIONAL INSTITUTES OF HEALTH
Program Projects Cancer Research Center, Dr. Mathews
Cancer Center Support, Dr. Watson
HIV Program Project, Dr. Watson
Oncogene Program Project, Dr. Wig ler
1/87-12/91
7/87-6/90
9/88-8/91
3/88-2/93
$16,787,416
5,346,907
3,672,816*
4,869,923 *
Research Support Dr. Arndt 4/88-3/93 1,288,964 *
Dr. Beach 12/84-1/93 1,481,482
Dr. Beach 9/86-8/89 578,929
Dr. Beach 7/88-6/93 1,064,173*
Dr. L. Field 4/87-3/92 568,521
Dr. Feramisco 4/85-3/88
535,534
Dr. Franza 9/85-11/88
522,439
Dr. Frendeway 4/87-3/92
775,814
Dr. Futcher
4/88-3/93 1,115,434*
Dr. Garrels
1/85-12/89 2,028,833
Dr. Gilman
9/87-8/92 608,291
Dr. Hanahan
8/87-7/88 312,634
Dr. Helfman
9/85-12/88 616,510
Dr. Hernandez
7/87-6/92 1,293,754
Dr. Klar/Futcher
Dr. Moran
Dr. Peterson
Dr. Pflugrath
7/81-6/90
3/88-2/93
4/88-3/93
4/88-3/91
9/87-8/90
2,411,676
547,214*
704,475*
573,503 *
528,037
Dr. Rice 9/86-8/88 216,446
Dr. Roberts 7/88-6/93 1,598,876*
Dr. Roberts 9/88-8/91 446,241 *
Dr. Roberts 7/83-6/92 1,869,678
Dr. Stillman 4/87-3/88 117,413
Dr. Watson 4/88-3/89 121,971 *
Dr. Watson 4/84-11/88 676,359
Dr. Welch 7/85-6/92 8,426,929
Dr. Wig ler 9/85-8/88 545,752
Dr. Zoller
2/88-2/89 189, 000 *
Equipment Support Dr. Marshak 6/87-5/88
38,991 *
Dr. Roberts 6/88-5/89
27,331 *
Dr. Roberts 2/87-2/88
165,000*
Dr. Spector
New Grants Awarded in 1988 447
Grantor Program/Principal Investigator Duration of Grant Total Award
Fellowships Dr. Cheley
Dr. J. Field
10/86-3/88
10/86-9/89
37,494
63,996
Dr. Kessler 8/88-7/91 93,996*
Dr. McLeod 2/85-1/88 63,996
Dr. Meyertons 5/88-4/91 63,996*
Dr. Morris 11/86-10/89 82,008
Dr. Munroe 10/87-4/88 28,000
Dr. Potashkin 10/85-9/88 64,886
Dr. Stern 11/88-11/91 63,996*
Training Support Institutional, Dr. Grodzicker 7/78-8/89 1,291,646
Course Support Advanced Bacterial Genetics, Dr. Grodzicker 5/80-4/93 559,540
Cancer Research Center Workshops,
Dr. Grodzicker 1/83-3/92 1,010,057
Neruobiology Short Term Training,
Dr. Hockfield 5/82-4/90 723,939
Neurobiology Short Term Training,
Dr. Hockfield 6/79-3/89 922,887
Meeting Support C. elegans 1987 & 1989 61,874
RNA Processing 1988-1991 9,500
Symposium 1988 27,774*
Cancer Cell Meeting 1988 5,000*
Conference on Mouse Molecular Genetics 1988 16,000*
Ribosome Synthesis 1988 3,000*
NATIONAL SCIENCE FOUNDATION
Research Support Dr. Herr 6/88-5/91 240,000*
Dr. Klar 8/86-7/88 220,000
Dr. Marshak 7/87-12/90 190,000
Dr. Roberts 1/83-5/90 640,000
Dr. Roberts 2/87-1/89 359,262
Dr. Roberts 8/87-1/90 43,106
Dr. Sundaresan 5/87-10/90 270,000
Dr. Zoller 8/88-1/92 285,000*
Equipment Support Dr. Spector 3/87-2/89 95,000*
Training Support Undergraduate Research Program, Dr. Herr 6/87-5/88 32,000
Course Support Plant Molecular Biology, Dr. Grodzicker 8/86-1/90 137,490
Meeting Support C. elegans 1987-1989 22,819
Ribosome Synthesis Conference 1988 8,000*
Symposium 1988 5,000*
RNA Processing Conference 4/88-3/91 30,000*
Chlamydomonas Conference 1988 5,000*
Conference on Mouse Molecular Genetics 1988 13,875*
Molecular Neurobiology of Aplysia Conference 1988 13,000"
Intermidiates in Genetic Recombination
Conference 1988 4,000*
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Grantor
DEPARTMENT OF ENERGY
Meeting Support
OFFICE OF NAVAL RESEARCH
Course Support
Program/Principal Investigator
Chlamydomonas Conference
Symposium
Computational Eye Movement Workshop
Duration of Grant
1988
1988
7/88-6/91
Total Award
3,000*
9,000*
62,125 *
NONFEDERAL GRANTS
Research Support
Aaron Diamond Foundation
American Boremene, Inc.
(Subcontract)
American Cancer Society
Amersham International
Am FAR
Howard Hughes Medical Institute
J.N. Pew Jr. Charitable Trust
Juvenile Diabetes Foundation
LIBA
Muscular Dystrophy Association
Me Ilam Family Foundation
Monsanto Company
New England Biolabs
Pfizer, Inc.
Pioneer Hi-Bred International Inc.
Rita Allen Foundation
Scripps Clinic
Equipment Support
Fellowships
American Cancer Society
Bristol-Myers Company
Bioseeds International
Cancer Research Institute
Dr. Anderson
Drs. Feramisco,
Bar-Sagi
Dr. Hanahan
Dr. Moran
Dr. Spector
Drs. Stillman, Gluzman,
Welch-Institutional Award
Dr. Gilman-Institutional Award
Dr. Wig ler
Dr. Wig ler, Professorship
Dr. Harlow
Dr. Franza
Neurobiology Support
Dr. Watson
Dr. Hanahan
Dr. Hernandez
Dr. Spector
Dr. Frendewey
Dr. Peterson
Dr. Feramisco
Dr. Helfman
Dr. Mathews
Dr. Franza
Cooperative Research
Dr. Roberts
Dr. Wig ler
Cooperative Research
Dr. Herr
Dr. Hanahan (subcontract)
Fannie E. Rippel Foundation
Dr. Conway
Dr. Ryan
Fellowship Support
Plant Fellowship Support
Dr. Young
Dr. Sturm
Dr. Efrat
12/88-11/89
9/87-3/88
7/87-6/89
1/88-12/90
7/87-6/89
7/82-6/88
7/88-6/90
4/87-3/89
1986-2012
11/86-10/91
12/87-11/88
1987-1990
4/87-4/90
9/86-9/88
7/87-6/88
4/87-3/88
4/88-3/89
4/88-3/89
1/87-1/88
7/86-6/89
1/87-6/90
12/88-11/89
10/84-9/90
1988
1985-1990
8/85-4/91
9/85-8/90
1/86-9/88
3/87-12/88
10/88-9/91
7/88-6/90
6/86-5/91
7/88-6/89
8/85-7/88
9/86-8/89
9/86-1/89
200,000"
16,498
160,000
90,500*
162,000
220,000
80,000*
20,000
1,333,333
799,635
78,000
1,000,000
260,000
66,000
20,000
27,000
25,000*
25,000*
50,764
94,500
100,718
50,000*
2,089,200
15,000*
500,000
2,500,000
150,000
356,806
125,000
63,000"
90,000 *
500,000
25,000*
73,500
79,500
62,313
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Grantor Program/Principal Investigator Duration of Grant Total Award
Damon Runyon-Walter
Winchell Cancer Fund
Esther and Joseph A. Klingenstein
Fund, Inc.
Juvenile Diabetes Foundation
International
LIBA
Life Science Research Foundation
Medical Research Council
of Canada
Merck Sharp & Dohme
Research Laboratories
Muscular Dystrophy Association
NYS Health Research Council
Oncogene Science Fellowship
Fund
Weizmann Institute of Science
Training Support
Alfred P. Sloan Foundation
Burroughs Wellcome Foundation
Grass Foundation
Lucille P. Markey Charitable Trust
Robert H.P. Olney
Memorial Fund
Course Support
Alfred P. Sloan Fund
Amersham International plc
Howard Hughes Medical Institute
Ester and Joseph A. Klingenstein
Foundation
Meeting Support
Accurate Chemical and
Scientific Support
Amoco Corporation
Beckman Instruments
Bio-Rad Lab Inc.
Chisso Corporation
Clontech Laboratories Inc.
E I DuPont de Nemours,
& Company
Foundation for Microbiology
International Society for
Plant Molecular Biology
Lucille P. Markey Charitable Trust
Merck & Co., Inc.
Mettler Instrument Corp.
Milligen
Nestle, S.A.
U.S. Biochemical Corp.
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Dr. Michaeli
Dr. D. Roberts
Dr. Marshak
Dr. Grant
Eight Fellowships
Dr. Colicelli
Dr. Mizzen
Graduate Student Support
Dr. Lees-Miller
Dr. Bautch
Dr. Watson
Dr. Gerst
Undergraduate Research Program
Undergraduate Research Program
Neurobiology Scholarship Support
Scholarship Support
Undergraduate Research
Computational Neuroscience Course
Advances in Molecular Cloning and
Expression of Eukaryotic Gene Courses
Neurobiology Courses
Neurobiology Support
Ribosome Conference
Chlamydomonas Conference
Ribosome Conference
Liver Gene Expression Conference
Liver Gene Expression Conference
Liver Gene Expression Conference
Liver Gene Expression Conference
Ribosome Conference
Liver Gene Expression Conference
Chlamydomonas Conference
Chlamydomonas Conference
53rd Symposium: Molecular Biology
of Signal Transduction
Ribosome Conference
Ribosome Conference
Ribosome Conference
Liver Gene Expression Conference
Liver Gene Expression Conference
3/87-2/90 69,000
9/88-3/90 36,250"
7/87-6/90 100,000
7/87-6/89 51,000
1987-1989 200,000
9/86-8/89 105,000
6/87-5/88 38,052
12/88-11/90 30,000
7/88-6/89 23,000
9/86-8/88 39,000
1987-1989 25,000
9/88-8/89 28,500*
1985-1988 74,000
1987-1988 16,560
1980-1988 141,670
1985-1989 250,000
1988 2,443*
1986-1989 140,000
1988 2,500*
1987-1990 1,000,000
1982-1988 300,000
1988
1988
1988
1989
1989
1989
1989
1988
1989
1988
1988
1988
1988
1988
1988
1989
1989
175*
1,000"
175*
500
500
1,000
500
300*
300
2,500*
1,500*
15,000*
500*
200*
200*
1,000
175
Grantor Program/Principal Investigator Duration of Grant Total Award
Monsanto Company Chlamydomonas Conference 1988 3,000 *
Nippon Zeon Co., Ltd. Chlamydomonas Conference 1988 1,000*
Promega Biotech Ribosome Conference 1988 200 *
Rockefeller Foundation Vaccines Conference 1986-1990 45,000
United States Biochemical
Corporation Ribosome Conference 1988 175*
Worthington Biochemical
Corporation Ribosome Conference 1988
250*
VWR Scientific-Rochester Ribosome Conference 1988
175*
Zoecon Research Inst./Sandoz
Crop Protection Corp. Chamydomonas Conference 1988
1,000*
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DNA LEARNING CENTER
Grantor Program Duration of Grant Total Award
FEDERAL GRANTS
NATIONAL SCIENCE FOUNDATION
STATE GRANTS
Teacher Enhancement Program 6/87-11/90 415,928
New York State Legislature The Search for Life 1988 74,595*
NONFEDERAL GRANTS
Boehringer Mannheim Biochemicals Core Support 1988 $ 2,000*
Brinkmann Instruments, Inc. Core Support 1988 10,000*
Harweb Foundation Core Support 1988 1,500*
J.M. Foundation Core Support 1988 25,000*
Richard Lounsbery Foundation Core Support 1988 30,000*
Josiah Macy, Jr. Foundation Core Support 7/87-6/90 490,850
The Banbury Fund Renovation 1988-1989 56,200*
Center for Biotechnology, SUNY
Stony Brook Vector Workshop 1988 10,550 *
Fotodyne Inc. Vector Workshop 1988 4,000*
Samual Freeman Charitable Trust Vector Workshop 1988 10,000*
Cold Spring Harbor Curriculum Study 1988 500"
Commack School District Curriculum Study 1988 500*
East Williston School District Curriculum Study 1988 500"
Great Neck School District Curriculum Study 1988 500*
Harborfields School District Curriculum Study 1988 3,000*
Herricks School District Curriculum Study 1988 500"
Huntington School District Curriculum Study 1988 500*
Jericho School District Curriculum Study 1988 500*
Lawrence School District Curriculum Study 1988 500*
Locust Valley School District Curriculum Study 1988 1,500*
Manhasset School District Curriculum Study 1988 500*
Northport-East Northport School District Curriculum Study 1988 500*
North Shore School District Curriculum Study 1988 500*
Oyster Bay-East Norwich School District Curriculum Study 1988 500*
Plainview-Old Bethpage School District Curriculum Study 1988 500*
Port ledge School Curriculum Study 1988 500*
Port Washington School District Curriculum Study 1988 500*
Sachem School District Curriculum Study 1988 500*
Syosset School District Curriculum Study 1988 500*
Aboffs Inc. The Search for Life Exhibit 1988 50*Agway Petroleum Corporation The Search for Life Exhibit 1988 200*Amity Westchester The Search for Life Exhibit 1988 100*Andrew Goetzs Sons, Inc. The Search for Life Exhibit 1988 100*Apple Bank The Search for Life Exhibit 1988 150*Automatic Data Processing The Search for Life Exhibit 1988 1,000*Badge Agency, Inc. The Search for Life Exhibit 1988 1,000*Barek-Karpel Industries, Inc. The Search for Life Exhibit 1988 100*
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Grantor Program Duration of Grant Total Award
Bethesda Research Laboratories Life
Technologies, Inc.
Blackman General Offices
Brinkmann Instruments, Inc.
BRL Life Technologies
Brunswick Appraisal Corp.
Budget Instant Print
Dale Carnegie & Associates, Inc.
C.N.D. Supply Corp.
Damson Oil Corporation
Dunkin Donuts, Inc.
Fairchild Weston System, Inc.
Grumman Corporation
Harris Trust
Hickey's Carting, Inc.
Huntington Business Products
Huntington Market, Inc.
I. Janvey & Sons, Inc.
Jeffs Seafood
Kollmorgen Corporation
Limco Manufacturing Corp.
Meenan Oil Company, Inc.
Meyer, Suozzi, English & Klein
Miller, Anderson & Sherrerd
New York Telephone
Northville Industries Corp.
Official Offset Corp.
Pall Corporation
Peat Marwick
The Roslyn Savings Bank
Servo Corporation of America
Spinnaker Travel, Ltd.
The Stebbins Fund
James F. Straub, Inc.
Tambrands, Inc.
Thermo Electron
The Tiles Investment Company
Vecco Instruments
W.A. Baum Company
Wentworth Films, Inc.
Winston Foundation
Individual Contributors
Mr. and Mrs. G. Morgan Browne
Bernadette Castro
Mr. Peter 0. Crisp
Katya Davey
Eleanor Greenan
Mrs. Sinclair Hatch
Phyllis Satz
Cynthia R. Stebbins
Mr. Byam K. Stevens, Jr.
Joseph A. Suozzi, Esq.
Mr. and Mrs. Walter C. Teagle, III
Mr. and Mrs. Richard Wesley
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The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
Search for Life Exhibit
Search for Life Exhibit
Search for Life Exhibit
Search for Life Exhibit
Search for Life Exhibit
Search for Life Exhibit
Search for Life Exhibit
Search for Life Exhibit
Search for Life Exhibit
Thhee Search for Life Exhibit
Search for Life Exhibit
The Search for Life Exhibit
The Search for Life Exhibit
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1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
1988
10,000*
200*
1,000*
10,000 *
150*
200*
100*
1, 000 *
1,000*
1,000*
1,000"
10,000*
90*
1,000*
100*
1,000*
250*
300*
1,000*
1,000*
1,500*
1,000*
5,000*
1,000*
1,000*
2,500*
5,000*
1,000*
1,000*
1,000*
1,000*
500*
500*
5,000*
1,000*
1,000*
1,000 "
150*
100*
5,000*
8,105*
BANBURY CENTER
Grantor Program/Principal Investigator Duration of Grant Total Award
FEDERAL GRANTS
Meeting Support
U.S. Department of Agriculture
U.S. Department of Justice
RFLPs and the Molecular
Biology of Plants Conference
DNA Technology and Forensic
Science Conference
9/88-8/89
10/88-9/89
3,000*
5,000*
NONFEDERAL SUPPORT
Meeting Support
Agrigenetics Corp. Molecular Biology of Plants Conference 1988 1,000*
Alfred P. Sloan Foundation Journalists and Congressional Workshops 1985-1989 162,000
Bionetics Research Control of HIV Expression 1988 3,000*
Biotech Research
Laboratories, Inc. Control of HIV Expression 1988 3,000*
Calgene RFLPs and the Molecular 1988 1,000*
Biology of Plants Conference
California Biotechnology Therapeutics Peptides
and Proteins Conference
1988 3,000*
Chugai Pharmaceutical Co., Ltd. Therapeutics Peptides
and Proteins Conference
1988 5,000*
Collaborative Research, Inc. DNA Technology and Forensic 1988 5,000"
Science Conference
Hoffmann-La Roche, Inc. Control of HIV Expression 1988 2,000*
ICI Americas Inc. DNA Technology and Forensic 1988 5,000"
Science Conference
ICI Seeds RFLPs and the Molecular 1988 2,000*
Biology of Plants Conference
Kabivitrum Therapeutic Peptides
and Proteins Conference
1988 3,000"
Lifecodes Corporation DNA Technology and Forensic 1988 5,000*
Science Conference
Merck Sharp & Dohme Control of HIV Expression Conference 1988 7,500*
Research Laboratories
Molecular Device Corp. Therapeutic Peptides and 1988 500*
Proteins Conference
Otsuka Pharmaceutical Therapeutic Peptides and 1988 1,500*Research Center Protein Conference
The Plant Cell Research RFLPs and the Molecular 1988 5,000*Institute, Inc. Biology of Plants Conference
Perkin Cetus Elmer Polymerase Chain Reaction 1988 35,000*Repligen Corporation Control of HIV Expression Conference 1988 3,000*Sumito Pharmaceutical Therapeutic Peptides and 1988 5,000*Research Center Proteins Conference
Sungene Technologies
Corporation
RFLPs and the Molecular Biology
of Plants Conference
1988 1,000*
Takeda Chemical Therapeutic Peptides and 1988 5,000*Industries Ltd. Proteins Conference
Toyobo New York Inc. Therapeutic Peptides and 1988 5,000 *
Proteins Conference
Yamanouchi Pharmaceutical Therapeutic Peptides and 1988 5,000*Co., Ltd. Proteins Conference
* New Grants Awarded in 1988
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ANNUAL CONTRIBUTIONS
Unrestricted
Long Island Biological Association (LIBA)
The Long Island Biological Association is the oldest supporting organization for Cold Spring
Harbor Laboratory. Over the years a most unique and productive partnership has developed
wherein LIBA has become our "Friends of the Laboratory" and accounts for the largest
amount of unrestricted annual giving for the Laboratory. (The detailed report of their activities
appears later in this Annual Report.)
Memorial Gifts
Mr and Mrs. Cliff Bates
Ms. Helen Bilbrey
Mr. David C. Clark
Mr. Laurence M. Clum
Mrs. John L. Davenport
Mr. and Mrs. Raymond C. Doop
Mr and Mrs. James J. Feeney
Mrs. Pearl S. Fisher
Ms. Helena Gaviola
Dr and Mrs. Richard L. Golden
In memory of
.
. .
Nelson Appet
Irene Bal
Marguerite Bhend
Mrs. C. Buckley, Jr.
John L. Davenport
Thomas Donahue
Pat Famighetti
Mr. and Mrs. Gerald Griffin
J.W. Hirschfeld Agency, Inc.
Mr. and Mrs. Dennis R. Holland
Mr. and Mrs. Andrew Hulko
Interboro Institute
Mr. and Mrs. Marc W. Jensen
Mrs. Mary Kelly
Mr. and Mrs. Richard E. Leckerling
Ms. Mary T. Maher
Mr. and Mrs. E. Mahoney
Joseph Ferrante
Richard Hathorn
Helen Leckerling
Jean Leckerling
Evelyn M. Levin
Barbara A. Mahoney
Jim Maxfield
Participating Institutions
Albert Einstein College of Medicine
Columbia University
Massachusetts Institute of Technology
Memorial Sloan-Kettering Cancer Center
New York University Medical Center
Princeton University
Rockefeller University
State University of New York, Stony Brook
Mr. and Mrs. Harold T. McGrath
Mr. and Mrs. Glenn W. Mullen
Mr. and Mrs. John E. Nelson
Mr and Mrs. John A. Pieper
Mr and Mrs. Bernard Silverwater
Mr and Mrs. Henry E. Spire
Mr. and Mrs. Henry H. Spire
Dr and Mrs. James D. Watson
Mr and Mrs. George Weber
Michael O'Grady
Stephanie Pall
Mrs. Jerald Rose
Robert Simkins
Alfred Wheeler
Posy White
Frank Zizza
Restricted
Corporate Sponsor Program
Cold Spring Harbor Laboratory is renowned throughout the scientific world as a
meeting place offering the most comprehensive series of conferences on
molecular biology available anywhere. Access to current research presented at
these high-level professional meetings is an important resource for the biotechnol-
ogy industry.
The annual $15,000 membership commitment from each Corporate Sponsor
has enabled the Laboratory to significantly expand this role as a clearinghouse for
biotechnical information. In 1988, more than 4000 scientists from around the world
attended conferences and advanced training courses at Cold Spring Harbor
Laboratory and Banbury Center.
The Corporate Sponsor Program supports a series of Special Banbury
Conferences that focuses on basic research as well as emerging areas of research
germane to industrial biotechnology. These high-level meetings are the basis for
the Laboratory's popular book series Current Communications in Molecular
Biology. Topics of 1988 conferences were "Ubiquitin," "Viral Vectors': "Cell-Cycle
Control': "Cytoskeletal Proteins in Tumor Diagnosis': and "Molecular Markers in
Problems of Plant Genetics':
Benefits to Sponsor companies include waiver of all fees for six representatives
at Cold Spring Harbor meetings and special Banbury conferences; gratis Cold
Spring Harbor and Banbury publications, including the journal Genes & Develop-
ment; and recognition in meeting abstracts and publications.
Since 1984, more than 30 companies have participated in the Corporate
Sponsor Program. The membership renewal rate is 90%. The 1988 members of
the Corporate Sponsor Program-world leaders in the application of biotechnology
to health care, agriculture, and manufacturing-were:
Abbott Laboratories
American Cyanamid Company
Amersham International plc
AMGen Inc.
Applied Biosystems, Inc.
Becton Dickinson and Company
Boehringer Mannheim
Bristol-Myers Company
Cetus Corporation
Ciba-Geigy Corporation
Diagnostic Products Corporation
E.I. du Pont de Nemours
& Company
Eastman Kodak Company
Genentech, Inc.
Genetics Institute
Hoffman-La Roche Inc.
Johnson & Johnson
Life Technologies, Inc.
Eli Lilly and Company
Millipore Corporation
Monsanto Company
Oncogene Science, Inc.
Pall Corporation
Pfizer Inc.
Pharmacia Inc.
Schering-Plough Corporation
Smith Kline & French Laboratories
Tambrands Inc.
The Upjohn Company
The Wellcome Research Laboratories,
Burroughs Wellcome Co.
Wyeth Laboratories
Summary of Annual Contributions
Unrestricted Annual Contributions
CSHL (LIBA) Associates (1/1/88-12/31/88) $189,541
LIBA Members (1/1/88-12/31/88) 40,322
General 1,445
Memorials 8,122
Corporations 15,000
Foundations 5,000
Participating Institutions 8,000
Restricted Annual Contributions
Corporate Sponsor Program
DNA Learning Center
Airs lie Fund
Dorcas Cummings Fund
Olney Fund
Prentis Memorial
Robertson House
Total Annual Contributions
$465,000
159,615
1,606
2,525
2,646
821
5,000
$267,430
637 213
$904,643
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Second Century Campaign
January 1, 1988-December 31, 1988
Unrestricted Contributions
Anonymous
Mrs. Donald Arthur, Jr.
Mr. and Mrs. Allen L. Boorstein
Mr. G. Morgan Browne
Mr. and Mrs. Samuel R. Callaway
Dr. Bayard Clarkson
Mr. and Mrs. Miner D. Crary, Jr.
Mr. Robert L. Cummings
Mr. and Mrs. Roderick H. Cushman
Mr. George W. Cutting, Jr.
Mr. and Mrs. Norris Darrell, Jr.
Mr. William Everdell
Mr. and Mrs. Henry U. Harris, Jr.
Mr. and Mrs. Sinclair Hatch
Restricted Contributions
Total $1,013,000
Mr. and Mrs. Townsend J. Knight
Mr. and Mrs. George N. Lindsay
Mr. David L. Luke, Ill
Miller Richard, Inc.
Mr. and Mrs. F. Warren Moore
Dr. David B. Pall
Mrs. H. Irving Pratt
William and Maude Pritchard Charitable Trust
Mr. and Mrs. John R. Reese
Mr. and Mrs. Harvey E. Sampson
Mr. George F. Sprague, Jr.
Mr. Jonathan R. Warner
Mr. Taggart Whipple
ENDOWMENT $4,820,000
Oliver and Lorraine Grace Director's Chair
Doubleday Professorship for Advanced Cancer Research
Anonymous Professorship in Molecular Neuroscience
PROGRAM 2,000,000
Howard Hughes Medical Institute
FACILITIES DEVELOPMENT 19,580,000
Cancer Biology
Neuroscience Center/Lodge
Arnold and Mabel Beckman Foundation
Dolan Family Foundation
Samuel Freeman Charitable Trust
Lita Annenberg Hazen Trust
Howard Hughes Medical Institute
Esther A. and Joseph Klingenstein Fund, Inc.
Litchfield Charitable Trust
W.M. Keck Foundation
James S. McDonnell Foundation
Individual Contributors
Structural Biology
Lucille P. Markey Charitable Trust
Page Laboratory of Plant Genetics
Charles E. Culpepper Foundation
Ira W. De Camp Foundation
Morgan Guaranty Trust Company of New York
National Science Foundation
William and Maude Pritchard Charitable Trust
Individual Contributors
GUEST FACILITIES
10 Guest Houses
Alumni Cabin Contributors
Dr. Herbert Boyer
Mrs. George G. Montgomery, Jr.
New England Biological Laboratories
Dr. Mark Ptashne
Visiting Scientist Guest House
Russell and Janet Doubleday Fund
1,041,000
DNA LEARNING CENTER 151,000
Banbury Fund #1
Banbury Fund #2
Brinkmann Foundation
Mr. and Mrs. Henry U. Harris, Jr.
New York State
Total Second Century Campaign Contributions $28,605,000
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Alumni Cabin Contributors
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Dr.
Fred Ausubel
Richard Axel
Ronald Bauer le
Gunter Blobel
Robert M. Blumenthal
Thomas Blumenthal
Walter F Bodmer
Jeremy Bruen
Keith Burridge
Charles R. Cantor
Mario Capecchi
Germaine Chipault
James Crow
and Mrs. James Darnell
Julian Davies
Hajo Deulis
Kurt Drickamer
Sarah C.R. Elgin
Sharyn A. Endow
Lynn W. Enquist
Ronald M. Evans
Georg Fey
John Fiddes
Richard A. Firtel
Beth Friedman
C.R. Fuerst
Walter Gehring
William M. Gelbart
Martin Gellert
Nicholas W. Gillham
Thomas R. Gingeras
Since the first Symposium on
Quantitative Biology in 1933, Cold Spring Harbor
Laboratory has been a major site for discussion of serious science. Each year,
visiting scientists from all over the
world remember a time when the entire
molecular biology community could be
comfortably seated in Vannevar Bush Hall.
The spectacular growth of molecular
biology research worldwide is reflected in
attendance at Cold Spring Harbor meetings. Over the last six years, the number of
meeting participants has increased 57% to a record 4000 scientists in 1988.
The caliber of science discussed at Cold Spring Harbor has remained
consistently excellent; however, facilities once considered rustic have become
inadequate. As part of a program to update our guest facilities prior to the
Laboratory's Centennial in 1990, meetings attendees, course instructors, and
former staff personnel were asked to recall how their careers had benefitted from
the Cold Spring Harbor experience and to contribute to the Alumni Cabin
Campaign. Alumni Cabin is one of ten eight-person cabins being constructed in a
lovely wooded area overlooking Laboratory grounds. In late 1987, ground was
broken for six of the new cabins which will be completed in 1989 in time for the
April meetings. In generous response to three annual Alumni Cabin appeals, 325
biologists from around the world had contributed over $55,000 by the end of 1988
.Cold Spring Harbor Laboratory Alumni continue to make donations, and we hope
that the goal of $100,000 can be achieved in 1989.
The following individuals contributed to Alumni Cabin in 1988:
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Dr. Howard Green
Dr. Maurice Green
Dr. Francois Gros
Dr. Christine Guthrie
Dr. H.T. Hanafusa
Dr. Lawrence E. Hightower
Dr. Bernhard Hirt
Dr. Susan Hockfield
Dr. David Hogness
Dr. Nancy Hopkins
Dr. Tony Hunter
Dr. Jerard Hurwitz
Dr. Richard Hynes
Dr. Yuriko Kataoka
Dr. Tohru Kataoka
Dr. Daniel Koshland
Dr. Samuel Latt
Dr. Michael J. Lenardo
Dr. John Lewis
Dr. Jim Jung-Ching Lin
Dr. Janet I. Macinnes
Dr. Fumio Matsumura
Dr. I. George Miller, Jr.
Dr. Jeffrey Miller
Dr. Gisela Mosig
Dr. Frederick C. Neidhardt
New England Bio-Labs
Dr. Masayasu Nomura
Dr. Richard P. Novick
Dr. Stephen Oroszlan
Dr. Paul H. Patterson
Dr. Manuel Perucho
Dr. Peter Philippssen
Dr. Anthony R. Poteete
Dr. Dale Purves
Dr. Charles M. Radding
Dr. Martin Raff
Dr. Charles C. Richardson
Dr. Rex G. Risser
Dr. Gordon Sato
Dr. Miyo Sato
Dr. Walter Schaffner
Dr. Milton Schlesinger
Dr. Sondra Schlesinger
Dr. Walter Scott
Dr. Charles J. Sherr
Dr. Maxime Singer
Dr. Cassandra L. Smith
Dr. Davor Solter
Dr. A.R. Srinivasan
Dr. David Stacy
Dr. Charles D. Stiles
Dr. Howard M. Temin
Dr. Charles Thomas
Dr. Jeremy Thorner
Dr. G.P. Tocchini Valentine
Dr. James C. Wang
Dr. David Ward
Dr. Peter C. Wensink
Dr. Heiner Westphal
Dr. Masao Yamada
Dr. Keith R. Yamamoto


THE LONG ISLAND BIOLOGICAL ASSOCIATION (LIBA)
and Its Relation to the Cold Spring Harbor Laboratory
Biological research at Cold Spring Harbor began in 1890 when the Brooklyn
Institute of Arts and Sciences was looking for a place to set up a summer
laboratory as the headquarters of its Department of Zoology. Representatives of
the Institute were invited by Eugene S. Blackford, at that time the Fish
Commissioner of the State of New York, to inspect a site on Bungtown Road
across Northern Boulevard (25A) from the Fish Hatchery. The site was found to be
ideal, and so the original Laboratory was organized with Mr. Blackford as
president of the Board of Trustees. The land was leased from Mr. John D. Jones,
whose family since 1819 had operated various industries including shipbuilding,
coopering, and textile manufacture (later whaling, also) at the head of Cold Spring
Harbor. Bungtown Road, which runs through the Lab property, got its name from
the factory that specialized in making bungs-or stoppers-for barrels.
In 1892, the Laboratory's land was leased for a dollar a year from the Wawepex
Society, which Mr. Jones had organized as a corporation for holding real estate
and for investing funds for the propagation of fishes and for scientific research. In
1904 the Wawepex Society leased additional land to the Carnegie Institution of
Washington, which wanted to locate a Department of Experimental Evolution in the
Cold Spring Harbor area. Charles B. Davenport, who had been directing the
Laboratory since 1896, assumed the additional duties of director of the Carnegie
Institution's experimental station. Until 1934, Mr. Davenport lived in the large
Victorian house that still stands at the corner of Bungtown Road and 25A. Built in
1882 by John D. Jones, the house was renovated and repainted in its original
colors in 1979-80, when it was renamed Davenport House. Since 1934 it has
served as a dormitory for Laboratory scientists.
The Long Island Biological Association was established in 1924 when the
Brooklyn Institute decided to discontinue its research at Cold Spring Harbor and
offered its laboratory to two universities. Fortunately, a local group of interested
neighbors decided to assume responsibility for the Lab, and thus LIBA came into
being. For 38 years LIBA actually operated the Laboratory in conjunction with the
Carnegie Institution, but in 1962 it seemed advisable for the Laboratory to be
reorganized as an independent unit. Therefore, the property on which it now
stands was conveyed to it by LIBA, which, however, still retains reversionary
rights.
Today LIBA is one of twelve institutions participating in the support of
the
Laboratory, each institution being represented on the Laboratory's Board of
Trustees.
LIBA has become an expanding group of "Friends of the
Laboratory" who help
support it through annual contributions.
A large part of the Laboratory's resources is obtained from
governmental,
corporate, and foundation sources as a result of grant applications
which are
submitted by the individual scientists. Years ago, 85% of the funding
came from
governmental agencies, but presently less than 50% comes
from these sources.
Therefore the scientists must rely on an assortment of
foundations, corporations,
and individuals for an increasing share of their support.
The researchers compete
for grants in their specific areas of study. If an award is made, a
portion of the
Membership in LIBA requires a minimum annual contribution (tax
deductible) of $25 to the Cold Spring Harbor Laboratory.
Further information can be obtained from the Long Island Biological
Association, Box 100, Cold Spring Harbor, N.Y. 11724, or
by telephoning the Laboratory at (516) 36A8840.
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award is returned to the Laboratory in the form of indirect costs for overhead. It is
important to remember that these grants are highly competitive, and even if a
grant is given an outstanding score by scientific peers, the funding may not be
available.
LIBA sponsors the Laboratory's Annual Giving Program, which is its largest
source of unrestricted annual gifts. These gifts enable the Laboratory to respond
quickly to urgent or unexpected needs. Also, primarily through LIBA Fellowships
and funds to start up new laboratories, LIBA helps ensure that the Cold Spring
Harbor Laboratory continues to attract the best and brightest young scientists.
The affairs of LIBA are handled by a board of 28 directors who are elected to
office by the membership at an annual meeting. LIBA members are invited to
bring their friends to lectures and open houses at the Laboratory.
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Officers
Mr. George W. Cutting, Jr., Chairman
Mrs. George N. Lindsay, Vice-Chairman
Mr. James A. Eisenman, Treasurer
Mrs. John P. Campbell, Secretary
Mr. G. Morgan Browne, Asst. Secretary/Treasurer
Directors
Mrs. Donald Arthur
Mrs. Allen L. Boorstein
Mr. Lionel Chaikin
Mr. Arthur M. Crocker
Mr. Lawrence L. Davis
Mr. Joseph P. Downer
Dr. Lester Dubnick
Mrs. Duncan Elder
Mrs. Henry U. Harris, Jr.
Mrs. Sinclair Hatch
Mr. Gordon E. Lamb
Mrs. Walter C. Meier
Mr. Arthur C. Merrill
Dr. Larry Nathanson
Mr. William F. Payson
Mr. Edward Pulling
Mr. John R. Reese
Mr. Douglas E. Rogers
Mr. Byam K. Stevens, Jr.
Mrs. Stanley S. Trotman, Jr.
Mrs. Philip R. von Stade
Dr. James D. Watson
Mrs. Bradford Weekes, Ill
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CHAIRMAN'S REPORT
The interrelationship of the Long Island Biological Association with the Cold Spring
Harbor Laboratory is developing into a unique partnership wherein members of
LIBA are becoming the sponsors of the Annual Giving Program at Cold Spring
Harbor, and at the same time, the members are receiving more and more
opportunities to expand their understanding of molecular biology.
LIBA's Role
The Annual Giving effort results this year were most encouraging. Total contribu-
tions were $261,525 versus $182,195 last year a 44% gain. The Cold Spring
Harbor Associate Program, established for those who contribute $1,000 or more,
was a major factor in this success.
This success has enabled the Laboratory to fund LIBA Fellowships for Drs.
Joseph Colasanti, Bernard Ducommun, Ann Sutton, and Peter Yaciuk. In addition,
the New Investigator Start-up Fund awarded grants to Drs. Dave Frendewey and
Tom Peterson. And finally, the Laboratory was given the resources to fund
unexpected requirements of their scientific programs.
Programs for LIBA Members
During the year, LIBA continued its efforts to increase the understanding of
molecular biology throughout its membership. Besides Dr. Church land's talk titled
"The Brain: as a Neurological Machine" at the Annual Meeting, Dr. Eric Kandel, a
trustee of the Laboratory and Chief of Psychology at Columbia Presbyterian
Hospital, addressed the Dorcas Cummings Memorial Lecture in May on "The
Dr, Patriciatric Church land chatting with George W. Cutting prior to
her talk at the LIBA Annual
Meeting.
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Long and Short of Long-term
Memory." Dr. Kandel, who attended the Cold Spring
Harbor Symposium on Quantitative Biology which was conducted at that time on
"The Molecular Biology of Signal Transduction",
put forth some insights on
functions of the brain. The programs of Dr. Kandel and Dr. Church land gave the
LIBA membrship its first glimpse of the world of neurobiology. This will become an
increasingly important field of study at Cold Spring Harbor as the development of
a Neuroscience Center emerges.
Additional learning opportunities were arranged for Cold Spring Harbor
Laboratory Associates, including the first "hands-on" laboratory workshop for
members at the DNA Learning Center. In addition, there was a series of five
lectures from January to May by Laboratory scientists Drs. Dan Marshak, Rich
Roberts, Mike Gilman, Jim Pflugrath, and Barbara McClintock. Their talks covered
a broad spectrum of fields in molecular biology and were enthusiastically received
by the participants. These scientists deserve our very special thanks, as the
preparation of a talk for the "lay" community to understand is no easy task in the
highly technical field of molecular biology.
Following the Dorcas Cummings Lecture, nearly 180 Symposium speakers and
Laboratory scientists were entertained at 21 dinner parties in the surrounding
community. The parties were a great success and this year's hosts and hostesses
have our special thanks. They were:
Mrs. Donald Arthur
Mr. & Mrs. William Braden
Mr. & Mrs. John P Cleary
Mr. & Mrs. Miner D. Crary
Mr. & Mrs. Robert L. Cummings
Mr. & Mrs. George W. Cutting
Mr. & Mrs. Joseph P Downer
Mrs. Carol DuBois
Mr. & Mrs. William Everdell
Mrs. Peter Fisher
Mr. & Mrs. Oliver R. Grace
Mr. & Mrs. Sinclair Hatch
Mr. & Mrs. Thomas L. Higginson
Mrs. Ruth Bennett Jordan
Mrs. Carol Hill Lamb
Mr. & Mrs. Gordon E. Lamb
Captain & Mrs. Vladimir Littauer
Dr. & Mrs. Walter C. Meier
Mr & Mrs. F Warren Moore
DE & Mrs. Larry Nathanson
Dr. & Mrs. David B. Pall
Mr. & Mrs. Franz Schneider
Mr & Mrs. Byam K. Stevens, Jr
Mr. & Mrs. John C. Stevenson
Mr & Mrs. Norman Stewart
Mr & Mrs. Martin B. Travis
Mr & Mrs. Robert P Walton
Mr & Mrs. Richard J. Weghorn
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Changes in LIBA Directors
At the Annual Meeting special recognition was given to: Jeanne Ball, Mary Crary,
Joan Hutchins, Sam Callaway, Rod Cushman, Charles Dolan, George Hossfeld,
Jr, and Harvey Sampson, all of whom retired as directors after loyal and effective
service.
Elected to replace them were: Jane Boorstein, Susie Trotman, Marjorie von
Stade, Joe Downer, Les Dubnick, Gordon Lamb, Larry Nathanson, and Doug
Rogers.
Laboratory Highlights
In the fifteen years since recombinant DNA techniques were developed, the
number of scientists working in the field has expanded from a few hundred to
almost 100,000. The pace of discovery has been expanding rapidly and whole
new methods of investigation have been uncovered. Under the leadership of Dr.
James D. Watson, the Cold Spring Harbor Laboratory is renowned as a world
center for the exchange of ideas, through its meetings programs and through the
basic research of its staff of more than 110 scientists. No LIBA report could be
complete without a brief summary of some of the highlights of the year on the
Laboratory campus.
Banbury Center Programs
Beginning to the east of the harbor, the Banbury Center, under the able leadership
of Dr. Jan Witkowski, has conducted several outstanding programs, including an
important meeting on gene expression in the AIDS virus, and congres-
sional workshops, and a seminar on the human brain for corporate executives.
The interaction between LIBA and the Laboratory was evident as Dr. Patricia
Church land, the closing speaker at the seminar on the brain, returned to Cold
Spring Harbor to deliver a talk to LIBA membership at the Annual Meeting in
January.
DNA Learning Center
1988 saw the establishment of the DNA Learning Center in the former
administra-
tion building of the Cold Spring Harbor School District. In March,
DNA Workshops
were held for the first time in the refurbished building. Here, high school
and
college instructors can learn the latest developments in molecular
biology,
enabling them to bring this technology to their students.
Workshops are now run
daily for students from the surrounding metropolitan area.
Of further note, the DNA Learning Center received a one-year
loan of an exhibit
from the Smithsonian Institution in Washington titled "The Search
for Life: Genetic
Technology in the Twentieth Century:' This exhibit calls on LIBA
members for
another supporting activity-staffing for the exhibit.
Page Laboratory Opened
In October, the Laboratory saw the completion of a three -year
capital program in
plant biology with the dedication of the Arthur W. and Walter
H. Page Laboratory.
This 6,500-square-foot facility provides the Uplands Farm Field
Station with much
needed laboratory space and meeting rooms.
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Dr. Ed Harlow and a
participant in the Under-
graduate Research Program
examine test results.
Construction was begun on six guest houses, each with four double rooms, to
replace the rustic cabins which have
served the Laboratory for nearly 50 years.
These will be ready for occupancy
when the meetings season begins in the
Spring.
Research Highlights
The science undertaken at the Laboratory
continues on the highest level. The five-
year DNA Tumor Virus Project grant from the National Cancer Institute was
renewed for the fourth time since its inception in 1972 under Dr. Mike Mathews'
supervision. Equally important was the NCI award of a large core grant for the
Lab's activities as a specialized cancer center under the coordinating efforts of Dr.
Rich Roberts. These two grants total $6 million of support for the cancer research
effort.
Highlighting the research successes at Cold Spring Harbor this past year was
the disclosure by Dr. Ed Harlow and his staff that a cancer-causing gene (an
oncogene) found in a virus apparently acts by blocking the action of a second
gene that seems to protect against cancer. This discovery sheds important new
light on a mechanism that makes an ordinary cell suddenly erupt into uncontrolled
growth, forming a cancer, and will have great impact on the cancer research field.
The Future
The success of LIBAs sponsorship of the Annual Giving Program at the
Laboratory is dependent on the members' continuing efforts to introduce their
friends to the excitement at the Laboratory, as their contributions will play an
important part in the support of science at Cold Spring Harbor. They too will enjoy
being a part of the Laboratory team and LIBA will continue to keep its
membership apprised of discoveries in the fast-growing field of molecular biology.
George W. Cutting, Jr., Chairman
Members of LIBA (October 1, 1987-September 30, 1988)
COLD SPRING HARBOR LABORATORY ASSOCIATES*
Anonymous
Mr. Amyas Ames
Are II Foundation
Mrs. Donald Arthur
& Mrs. Allen L. Boorstein
Dr. David Botstein
Mrs. Leonie T. Brigham
Mrs. Harry Brooks
Mr & Mrs. G. Morgan Browne
Mr. & Mrs. John P Campbell
Centerbrook Architects
Mr & Mrs. Lionel Chaikin
Mr. David C. Clark
Dr. & Mrs. Bayard D. Clarkson
Mrs. Robert L. Clarkson
Mr. Henry Clay
Mr. James W. Cleary
Mr. & Mrs. John P Cleary
Mr & Mrs. Gregory S. Coleman
Mrs. John K. Colgate
Mr. & Mrs. Arthur Crocker
Mr. Robert L. Cummings
Ms. Lucy Cutting
Mr. & Mrs. George W. Cutting, Jr.
Mr. Norris Darrell, Jr.
Mr & Mrs. Donald L. Deming
Mr. & Mrs. Charles F. Dolan
Mr & Mrs. Joseph P Downer
Dr & Mrs. Lester Dubnick
Mr. & Mrs. James A. Eisenman
Mr & Mrs. Duncan Elder
Mr. & Mrs. William Everdell
Mr. John R. Fell, Jr.
Mr & Mrs. Robert B. Gardner Jr.
Mr. & Mrs. Charles S. Gay
Mr. & Mrs. Robert A. Gay
Mr. & Mrs. Joseph Gerrity
MEMBERS**
Mr. & Mrs. Thomas H. Ackerman
Mrs. Stirling S. Adams
Mrs. Charles E. Ames
Mrs. Hoyt Ammidon
Mr. & Mrs. Robert W. Anthony
Mr. & Mrs. Silas Reed Anthony
Mr. & Mrs. Martin S. Arbonies
Mr. & Mrs. J.S. Armentrout, Jr.
Mrs. Robert W. Ayer
Dr. & Mrs. Alfred A. Azzoni
Mr. & Mrs. Henry D. Babcock, Jr.
Mrs. Gilbert A. Ball
*Contributors of $1000.00 or more
**Contributors of $25.00-999.00
Mr. & Mrs. Allen Goldring
Mr. & Mrs. Oliver R. Grace
Mr. & Mrs. Oliver R. Grace, Jr.
Mr. & Mrs. Edward Greenberg
Rev. Linda Peyton Hancock
Mr & Mrs. Henry U. Harris, Jr
Miss Maxine Harrison
Harweb Foundation
Mrs. Sinclair Hatch
Mr. Sinclair Hatch
Dr. & Mrs. Alfred D. Hershey
Mr & Mrs. Thomas L. Higginson
Mr. & Mrs. Charles J. Hubbard
Mr. & Mrs. Waldo Hutchins
Mrs. Warren C. Hutchins
Mr. & Mrs. Nicholas L. lhasz
Dr. & Mrs. Leonard Jasen
Mr. & Mrs. Francis S. Kinney
Mr. Townsend J. Knight
Mr. & Mrs. Gordon Lamb
Dr. Laurie J. Landeau
Mr. & Mrs. Henry C. Lee
Mrs. John H. Leib
Dr. Robert V. Lewis
Mr. & Mrs. George N. Lindsay
Mr. & Mrs. Robert V. Lindsay
Capt. & Mrs. Vladimir S. Littauer
Mr. & Mrs. John H. Livingston
Mr. & Mrs. David L. Luke, Ill
Ms. Martha Makanna
Mr. Robert R. Maxfield
Mr. & Mrs. Gerald M. Mayer Jr
Miss Diana Mcllvaine
Dr. & Mrs. Walter C. Meier
Mr. Arthur C. Merrill
Miller-Richard, Inc.
Dr. Peter Model
Mrs. William N. Bannard
Mr. & Mrs. George Barclay
Dr. & Mrs. Henry H. Bard
Mr. & Mrs. John S. Barker
Mr. & Mrs. Stephen A. Barre
Mr. Edmund Bartlett
Mr. & Mrs. Cliff Bates
Dr & Mrs. Neil J. Battinelli
Mr & Mrs. Sherburn M. Becker
Dr & Mrs. John Bell-Thomson
Mrs. Elena Benson
Mr. Paul Berg
Mr & Mrs. George G. Montgomery, Jr.
Mr & Mrs. F. Warren Moore
Dr. & Mrs. Larry Nathanson
Mrs. John Nields
Mr. & Mrs. George D. O'Neill
Mr & Mrs. Walter H. Page
Dr & Mrs. David B. Pall
Mr & Mrs. Nicholas R. Parks
Mr & Mrs. William Parsons, Jr
Mr & Mrs. Fremont C. Peck
Mrs. Claire Platkin
Mrs. Francis T.P. Plimpton
Mr & Mrs. Martin Pollak
Mrs. H. Irving Pratt
Mr & Mrs. Richardson Pratt, Jr.
Mr Edward Pulling
Mrs. Seena H. Purdy
Mr & Mrs. John R. Reese
Mr & Mrs. Willis L.M. Reese
Mr & Mrs. William S. Robertson
Miss Elizabeth Roosevelt
Mr Robert Sabin
Mr & Mrs. Harvey E. Sampson
Mr & Mrs. Peter G. Schiff
Mr & Mrs. Franz Schneider
Seth Sprague Educational and
Charitable Foundation
Mr & Mrs. James F. Stebbins
Mr & Mrs. Byam K. Stevens, Jr
Mr & Mrs. Richard M. Sykes
Mrs. David S. Taylor
Mrs. Robert W. Tilney, Jr
Mr & Mrs. Martin Victor
Mr & Mrs. Philip R. von Stade
Mrs. George G. Walker
Dr. & Mrs. James D. Watson
Mr & Mrs. Taggart Whipple
Mr & Mrs. Loren C. Berry
Mr & Mrs. Nicholas Biddle, Jr
Mrs. William Binnian
Mr F Roberts Blair
Ms. Mary Lenore Blair
Ms. Margery Blumenthal
Mr & Mrs. Elito J. Bongarzone
Dr. Jonathan M. Borkum
Mr & Mrs. Murray Borson
Mr & Mrs. William Braden
Mr & Mrs. Thomas A. Bradley, Jr.
Dr & Mrs. Arik Brissenden
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Dr. Thomas Broker
Mr. & Mrs. F. Sedgwick Browne
Mr. & Mrs. Franklin Bruder
Mr. Julian G. Buckley
Mr & Mrs. Robert M. Bunnell
Mr. & Mrs. Samuel R. Callaway
Mr. & Mrs. Anthony Cambria
Mr. & Mrs. Ward C. Campbell
Mr. & Mrs. Robert A. Carlson
Ms. Bernadette Castro
Mr. & Mrs. Gilbert W. Chapman, Jr.
Mr. & Mrs. Harry G. Charlston
Mr. & Mrs. Paul J. Chase
Mrs. Helen B. Chenery
Mr. & Mrs. Anwar Chitayat
Mr. Jan S. Chock
Dr. Louise Chow
Ms. Sue Ellen Christensen
Mr. Lawrence M. Clum
Drs. Peter & Joan Cohn
Mrs. C. Payson Coleman
Mr. & Mrs. John H. Coleman
Mr. & Mrs. Francis X. Coleman, Jr.
Mr & Mrs. Emilio G. Collado
Mr. Bradley Collins
Ms. Kim M. Collins
Mr. & Mrs. Patrick Collins
Mr. & Mrs. Kingsley Colton
Mrs. Ralph C. Colyer
Dr. & Mrs. Joseph B. Conolly, Jr.
Mrs. Crispin Cooke
Mr. & Mrs. Robert Cooper
Mrs. Ann B. Copeland
Mrs. Howard Corning, Jr.
Mr. & Mrs. Charles Craig
Mr. & Mrs. Miner D. Crary, Jr.
Mrs. Ralph Crews
Mr. & Mrs. Henry B. Cross
Mr. & Mrs. Howard W. Crusey
CSS Pederson Krag Center
Mr. Robert L. Cummings III
Mr. Richard T. Cunniff
Mr. & Mrs. Roderick H. Cushman
Dr. & Mrs. Paul Cushman, Jr.
Mr. & Mrs. A. Neville Cutting
Mrs. Howard H. Dana
Mr. & Mrs. A. George Dartt
Mrs. Katya Davey
Mr. & Mrs. Lawrence L. Davis
Mrs. F. Trubee Davison
Mr. & Mrs. Raymond deClairville
Mr. & Mrs. Louis D. Delalio
Mr. & Mrs. William R. Dens low, Jr.
Mrs. Douglas C. Despard, Jr.
Mr. & Mrs. Joseph C. Dey
Ms. Carolyn C. Dilworth
Mr. E. Richard Droesch
Mrs. Eugene Dubois
Dr. & Mrs. John L. Duffy
Mr. & Mrs. Anthony D. Duke, Jr.
Mr. & Mrs. Edgar P Dunlaevy
Mr. & Mrs. William T. Dunn, Jr
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Dr. & Mrs. Gerard L. Eastman
Dr. & Mrs. James D. Ebert
Mrs. Fred J. Eissler
Mr & Mrs. Ashton G. Eldredge
Mr. Martin Elias
Mr. & Mrs. John J. Evans
Mr. & Mrs. Raymond Z. Fahs
Mr. & Mrs. Joel M. Fairman
Mr. & Mrs. Harold L. Fates
Mr & Mrs. George S. Franklin, Jr.
Mr. & Mrs. Jack B. Friedman
Mr. & Mrs. Stephen D. Fuller
Mr & Mrs. H. Gaiss
Mr. & Mrs. D. Kent Gale
Mr. & Mrs. Clarence E. Galston
Mr. & Mrs. John W. Galston
Dr. & Mrs. Aaron Ganz
Mrs. James E. Gardner Jr.
Mrs. Louis F Geissler
Mr. & Mrs. Martin Gellert
Mr. Elbridge T Gerry, Jr.
Mrs. Vera C. Gibbons
Mr. Harry Giffords
Mr & Mrs. Stephen E. Gilhuley
Mr. & Mrs. Robert Gilmor, Jr.
Dr. & Mrs. H. Bentley Glass
Mrs. J. Wooderson Glenn
Mr. & Mrs. Bernard J. Gloisten
Mr. & Mrs. Edward R. Godfrey, Jr.
Mr. Stanley F. Gordon
Mr & Mrs. Kilbourn Gordon, Jr.
Mrs. Henry W. Grabowski
Mr. & Mrs. Austen T. Gray
Mr. & Mrs. Craig P Greason
Mr. Edward R. Greeff
Mr. & Mrs. Alfred T Gregory
Dr. & Mrs. Donald S. Gromisch
Mr. Irving Haber
Mr. & Mrs. George J. Haberer
Mr. & Mrs. John W.B. Hadley
Mr. & Mrs. Lawrence J. Hahn
Dr. Seymour Halpern
Mr. & Mrs. Gordon Hargraves
Mr. & Mrs. Gerald W. Hart
Dr. & Mrs. Chester Hartenstein
Mr & Mrs. Philip E. Hartmann
Mr & Mrs. Rolf D. Hartmann
Mr & Mrs. Horace Havemeyer, Jr.
Mr Ralph F. Hayden
Mr. & Mrs. Thomas M. Hearn
Mr. Huy ler C. Held
Mr. & Mrs. James E. Hellier
Dr. & Mrs. William Heroy
Mrs. Charles L. Hewitt
Mr. & Mrs. Charles A. Hickmann
Mr. Albert P Hildebrandt
Mrs. Albert L. Hoffman
Mr. & Mrs. Charles R. Holcomb
Mr. & Mrs. Dennis R. Holland
Mr. & Mrs. George J. Hossfeld
Mr. & Mrs. George J. Hossfeld, Jr.
Mr. George H. Howard
Mr. & Mrs. George H. Howard III
Dr. E. John Hughes
Mr & Mrs. Philip G. Hull
Mrs. John S. Humes
Mr & Mrs. Robert Hutchings
Mr. & Mrs. Judson A.V. Hyatt
Mrs. David Ingraham
Mr. & Mrs. Frederic B. Ingraham
Interboro Institute
Mr. & Mrs. Fred Irwin
Mrs. Richard M. Jackson
Mr & Mrs. Valdemar F Jacobsen
Mr. Irving D. Jakobson
Mr. & Mrs. Robert D. Jay
Mrs. B. Brewster Jennings
Mr. & Mrs. Hugh G. Johnson
Mr. & Mrs. Laurence S. Johnson
Dr. Gail & Mr. E. William Jones
Mrs. Ruth B. Jordan
Mr. & Mrs. John Juda, Jr.
Mr. & Mrs. Howard L. Kane
Mr. & Mrs. Morris I. Karpen
Dr. & Mrs. Francis C. Keil
Mr. Francis E. Kelly, Jr
Mrs. Walter A. Kernan
Mrs. Louise M. King
Mr. & Mrs. Jeffrey Klein
Mr. & Mrs. Walter R. Klein
Mr. & Mrs. John Klingenstein
Mrs. Robert P Koenig
Mr & Mrs. Jack Kolodny
Mr & Mrs. Edward W. Kozlik
Dr. Marcia J. Kramer
Mr. & Mrs. Paul Kramer
Dr. Rakesh Kumar
Mr. & Mrs. Mort Kunst ler
Mr. & Mrs. Edward M. Lamont
Dr. & Mrs. Ralph Landau
Mr. & Mrs. Charles L. Lassen
Mrs. Leslie S. Learned
Mrs. Randall J. LeBoeuf
Mr & Mrs. Richard E. Leckerling
Rev. & Mrs. T. Carleton Lee
Dr. & Mrs. Monroe L. Levin
Mrs. Elizabeth A. Lindsay
Mr. George Lindsay, Jr.
Dr. & Mrs. L. Lippert
Mr. & Mrs. Robert F Little
Mr. Angus C. Littlejohn
Mr. & Mrs. Candido V. Llovera
Mr. & Mrs. Alan J. Long
Mrs. Wladimir Z. Lotowycz
Mr. Henry Luce III
Mr. & Mrs. Richard H. MacDougall
Mr. & Mrs. John F MacKay
Mr. & Mrs. Malcolm MacKay
Dr. & Mrs. James N. Macri
Mr. & Mrs. Vincent J. Macri
Mrs. Henry R. Macy
Mr. & Mrs. William E. Mahoney
Mrs. Mary Anne Mann
Mr. & Mrs. John Mariani
Mrs. Lawrence M. Marks
Mr & Mrs. John Maroney
Mrs. John B. Marsh
Dr. Daniel R. Marshak
Mr & Mrs. William H. Mathers
Mrs. Dorothea S. Mathews
Mr & Mrs. Konrad H. Matthaei
Dr. Ernst Mayr
Mr & Mrs. Edward F McCann II
Dr. & Mrs. Robert L. McCollom
Mr. & Mrs. Victor C. McCuaig, Jr
Mr & Mrs. James A. McCurdy II
Mr & Mrs. Victor King McElheny
Mr & Mrs. James McEnerney, Jr
Mr & Mrs. Harold T. McGrath
Mr & Mrs. Angus P. McIntyre
Mr & Mrs. Randall P. McIntyre
Ms. Leila Laughlin McKnight
Mr & Mrs. Robert M. McLane
Mr & Mrs. Lawrence M. Mead, Jr
Mr & Mrs. Robert G. Merrill
Ms. Nancy Metz
Mrs. Frances Meurer
Mrs. Charles G. Meyer
Mr. & Mrs. George S. Meyer
Dr & Mrs. Leo M. Meyer
Mr. Richard W. Meyer
Mr. & Mrs. William H. Miller
Mrs. Newton Millham
Mr. Keith M. Moffat
Mrs. F Franklin Moon
Mr. & Mrs. James D. Mooney, Jr
Mr. & Mrs. Richard K. Moore
Mr. George Morgese
Dorothy C. Morrell
Mr & Mrs. Duncan C. Morrell
Mr & Mrs. Grinnell Morris
Mr. Frederick R. Moseley, Jr
Mr & Mrs. Brent M. Mowery, Jr
Mr & Mrs. Glenn W. Mullen
Mr. Gardner M. Mundy
Mr & Mrs. Francis W. Murray III
Mr & Mrs. Rem V. Myers
Mr & Mrs. F. Barry Nelson
Dr Franklin Nelson
Mr & Mrs. Richard Neuendorffer
Mr & Mrs. John S. Nichols
Mr & Mrs. Adams H. Nickerson
Mrs. Jeanne S. Niven
Mr & Mrs. Albert C. Nolte, Jr
Mr & Mrs. Charles P. Noyes
Mr & Mrs. David C. Noyes
NY Community Trust
Mr & Mrs. Richard B. Opsahl
Dr & Mrs. Craig B. Ordway
Mrs. William H. Osborn
Mr & Mrs. Robert J. Osterhus
Dr & Mrs. David A. Page
Mr & Mrs. John H. Page
Mr & Mrs. Arthur W. Page, Jr.
Mr & Mrs. Fred W. Pain
Mr & Mrs. Samuel D. Parkinson
Mr & Mrs. Joseph M. Parriott
Mr. William Parsons, Sr
Mr & Mrs. William H. Peck, Jr
Mr & Mrs. Donald R. Peirce
Mr & Mrs. Peter J. Pell
Mr & Mrs. John M. Perkins
Ms. Joan M. Pesek
Dr & Mrs. Lee W. Petersen
Mrs. Susan R. Peterson
Mr & Mrs. Howard Phipps, Jr
Mr. Whitney D. Pidot
Mr & Mrs. John A. Pieper
Mrs. Richard N. Pierson
Mr & Mrs. Robert A. Pilkington
Mrs. James J. Pirtle, Jr.
Mr & Mrs. Collier Platt
Mr & Mrs. Graham L. Platt
Mr. Henry Platt
Hon. & Mrs. Thomas Platt
Mr & Mrs. William Porter
Mr & Mrs. Joseph D. Posillico, Jr
Mr & Mrs. Edward Everett Post
Mrs. William S. Post
Mrs. Helen W. Powers
Mr. & Mrs. Richard M. Powers
Mr & Mrs. William M. Preston
Mr. Thomas L. Pulling
Mr & Mrs. Preston V Pumphrey
Mr & Mrs. Tarrant Putnam
Mr & Mrs. James T Pyle
Mr. William Rand
Mrs. Joan R. Read
Mr. Arthur G. Reid
Dr & Mrs. Robert M. Reiss
Mr. Bernard J. Reverdin
Mr & Mrs. Harold Van B. Richard
Dr. Frederic M. Richards
Mr & Mrs. John T Ricks
Mr & Mrs. George H. Roberts
Mr & Mrs. Douglas E. Rogers
Mr & Mrs. Samuel B. Rogers
Mrs. Quentin Roosevelt
Mrs. Donald W. Rose
Mrs. Arthur W. Rossiter, Jr
Mr & Mrs. Richard G. Roth
Mr. & Mrs. Walter N. Rothschild,
Jr.
Mr & Mrs. Donal H. Russell
Dr. Claire A. Ryan
Mrs. Harold P. Salembier
Mr & Mrs. Bernard Salzberg
Mr & Mrs. John K. Sands
Mr Carl Schlanger
Dr. Carl J. Schmidlapp
Dr & Mrs. Irving M. Schneider
Mr & Mrs. Henry Schniewind
Mr & Mrs. Hermann G. Schwab
Mr & Mrs. David R. Schwarz
Mr & Mrs. Enrique F. Senior
Mr. & Mrs. Frederick E. Seymour
Mr & Mrs. Marvin J. Sharfin
Mr & Mrs. Amos B. Sharretts
Dr & Mrs. Edward M. Shepard
Col. & Mrs. Robert E. Sheridan
Dr. & Mrs. Walter Shropshire, Jr
Mr. & Mrs. Robert P. Sibert
Mr & Mrs. Paul W. Siegert
Dr. & Mrs. Paul Siminoff
ME William C. Simpson
Mr & Mrs. James C. Skiff
Mr. & Mrs. Rowland G. Skinner
Mr. Richard Slade
Mr. Alexander B. Slater
Mr & Mrs. H. Turner Slocum
Dr & Mrs. Robert Smirnow
Mr & Mrs. Brant R. Smith
Mr & Mrs. William S. Smoot
Mr & Mrs. Sedgwick Snedeker
Mr & Mrs. James Sommermeyer
Dr. Keld Sorensen
Mr. & Mrs. David H. Stein
Mr & Mrs. John C. Stevenson
Mr & Mrs. Norman W. Stewart
Mr. Dudley W. Stoddard
Mr & Mrs. Richard Storrs
Mr. & Mrs. Joseph S. Stout
Mrs. Joseph S. Stout, Jr
Dr & Mrs. Sidney Strickland
Mr. & Mrs. James E. Swiggett
Mr & Mrs. Robert L. Swiggett
Dr & Mrs. Basil Tangredi
Mr. & Mrs. Benjamin N. Taylor
Mr. John W. Taylor
Mr. Dudley B. Tenney
Mr & Mrs. Daniel G. Tenney, Jr
Mr & Mrs. Seth A. Thayer
Mr & Mrs. Edward M. Thomas
Mr & Mrs. Evan W. Thomas II
Mr & Mrs. William J. Thompson
Mrs. Denyse D. Thors
Mr & Mrs. Warren I. Titus, Jr
Mr & Mrs. Alexander C. Tomlinson
Mr & Mrs. George I. Toumanoff
Mr & Mrs. Martin B. Travis, Jr
Mr & Mrs. Stanley S. Trotman
Mr & Mrs. Anthony M. Trotter
Mr & Mrs. Godfrey G. Truslow
Mrs. Ernest T. Turner
Mr & Mrs. Cornelius M. Ulman
Mr & Mrs. Stephen Van R. Ulman
Dr & Mrs. Thornton Vandersall
Mr & Mrs. Herbert A. Vitriol
Mr & Mrs. Joseph C. Viviani
Mr. Eric A. Von Raits
Mr. & Mrs. Eugene D. Wadsworth
Mr & Mrs. Colton P. Wagner
Mr. Sherwood Waldron
Mr & Mrs. R. W. Walker
Mr & Mrs. Robert P. Walton
Mr & Mrs. Charles W.B. Wardell, Jr
Mr & Mrs. David E. Warden
Mrs. Ethelbert Warfield
Mr & Mrs. Bradford A. Warner
Mr & Mrs. Harold L. Warner, Jr
Mr & Mrs. Morris Wasser
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Mrs. Bradford G. Weekes
Mr & Mrs. Bradford G. Weekes III
Mr. Townsend U. Weekes
Mr. John C. Weghorn
& Mrs. Richard J. Weghorn
Mr. & Mrs. L. Brandeis Wehle, Jr.
Mr & Mrs. H.L. Christian Wenk
Dr. & Mrs. Charles A. Werner
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